Drug;Gene;Genotype;Alleles;Outcome;Variation;Effect
NIFEDIPINE;CYP3A4;CYP3A4*1, CYP3A4*17;*17;OTHER, LADME_PK;DECREASED_METABOLISM;
SITAGLIPTIN;DPP4;rs2909451;TT;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
SITAGLIPTIN;KCNJ11;rs2285676;GG;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
WARFARIN;CYP2C9;CYP2C9*11;*11/*11;DOSAGE;DECREASED_DOSE;
SITAGLIPTIN;KCNQ1;rs163184;GG;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*18;*1/*18;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
SITAGLIPTIN;DPP4;rs4664443;GG;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
CODEINE;CYP2D6;CYP2D6*1xN;*1xN;LADME_PK;INCREASED_METABOLISM;
SITAGLIPTIN;CYP2C9;rs1799853;TT;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
SITAGLIPTIN;GLP1R;rs3765467;AG;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
IVACAFTOR / LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
FLUOXETINE;CYP2C19;CYP2C19;intermediate_metabolizer;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;CYP2C19;CYP2C19;ultrarapid_metabolizer;EFFICACY;DECREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
SITAGLIPTIN;GLP1R;rs6923761;AA;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
CODEINE;CYP2D6;CYP2D6*2, CYP2D6*2xN;*2/*2xN;LADME_PK;INCREASED_METABOLISM;
EXENATIDE, LIRAGLUTIDE;GLP1R;rs3765467;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
IVACAFTOR / LUMACAFTOR;CFTR;rs113993960;del;EFFICACY;RESPONSE;
CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;CYP2C19;CYP2C19;poor_metabolizer;EFFICACY;DECREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;GLP1R;rs6923761;A;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
EXENATIDE;TCF7L2;rs7903146;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
RIFAPENTINE;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;CYP2B6;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
LANSOPRAZOLE;CYP2C19;CYP2C19*1;*1/*1;LADME_PK;DECREASED_EXPOSURE;OTHER:HISTORY_OF_GASTRIC_BYPASS_SURGERY
ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;ARRB1;rs140226575;A;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
EFAVIRENZ;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
PROPAFENONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:CARDIAC_RHYTHM_DISEASE
PROPAFENONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;EFFICACY;INCREASED_RESPONSE;DISEASE:CARDIAC_RHYTHM_DISEASE
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4, CYP2D6*6;*4/*6;LADME_PK;DECREASED_METABOLISM;
NEVIRAPINE;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;ARRB1;rs78979036;A;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
METHADONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*2xN;*1/*2xN + *2/*2xN;EFFICACY;INCREASED_RESPONSE;OTHER:OPIOID-RELATED_DISORDERS
LURBINECTEDIN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*1;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;ARRB1;rs78052828;T;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
METHYLMERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:INFLAMMATORY_BOWEL_DISEASES
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ALBIGLUTIDE, DULAGLUTIDE, GLP-1 RECEPTOR AGONISTS;ARRB1;rs58428187;C;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*36;*10/*36;DOSAGE;INCREASED_DOSE;OTHER:BREAST_NEOPLASMS
RALOXIFENE 6-GLUCURONIDE, RALOXIFENE-4â€²-GLUCURONIDE;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OSTEOPOROSIS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION,_DISEASE:HIV_INFECTIOUS_DISEASE
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*17;*1/*4 + *1/*5 + *1/*9 + *1/*10 + *4/*10 + *5/*10 + *10/*10 + *10/*17;LADME_PK;DECREASED_CLEARANCE;
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;CYP1A2*35;*35;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
VENLAFAXINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_EXPOSURE;OTHER:LACTATION
LURBINECTEDIN;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME_PK;INCREASED_CLEARANCE;OTHER:NEOPLASMS
LURBINECTEDIN;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:NEOPLASMS
LEFLUNOMIDE;PON1;rs705379;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;DOSAGE;DECREASED_DOSE;DISEASE:COLORECTAL_NEOPLASMS
LETROZOLE;CYP2A6;rs56113850;T;;INCREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
TRAMADOL;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_EXPOSURE;
(S)-METHADONE;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7;*6/*6;LADME_PK;INCREASED_CONCENTRATIONS;
ANTIEPILEPTICS;SCN1A;rs2298771;C;EFFICACY;INCREASED_RESISTANCE;OTHER:EPILEPSY
ANTIEPILEPTICS;SCN1A;rs10167228;T;EFFICACY;INCREASED_RESISTANCE;OTHER:EPILEPSY
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*10;*3/*4 + *4/*4;LADME_PK;DECREASED_CONCENTRATIONS;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;DOSAGE;DECREASED_DOSE;
CODEINE;CYP2D6;CYP2D6*2, CYP2D6*2xN;*2/*2xN;LADME_PK;INCREASED_METABOLISM;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*5;*1/*5;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*11;*1/*11;DOSAGE;DECREASED_DOSE;
METHADONE;;low activity;;LADME_PK;INCREASED_TROUGH CONCENTRATION;
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;LADME_PK;DECREASED_METABOLISM;OTHER:NEOPLASMS
BILIRUBIN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;OTHER;INCREASED_;DISEASE:NEOPLASMS
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME_PK;DECREASED_METABOLISM;OTHER:NEOPLASMS
CARVEDILOL;UGT1A1;UGT1A1*1, UGT1A1*28;*28;LADME_PK;INCREASED_METABOLISM;OTHER:ANGINA_PECTORIS
LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;
ACENOCOUMAROL;VKORC1;rs9934438;A;DOSAGE;DOSE;OTHER:A_STABLE_MAINTENANCE_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3 + *1/*3;DOSAGE;DECREASED_DOSE;
LIRAGLUTIDE;CNR1;rs1049353;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2,_OTHER:OBESITY
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;DECREASED_CONCENTRATIONS;
FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;rs104894542;C;DOSAGE;INCREASED_DOSE;
CLONIDINE;ADRA2C;rs11269124;GGGGAGCTTTCCCAGAGACCC/del + del/del;EFFICACY;INCREASED_RESPONSE;DISEASE:LIVER_CIRRHOSIS
SIMVASTATIN ACID;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:CARDIOVASCULAR_DISEASE,_OTHER:DYSLIPIDAEMIA
SIMVASTATIN ACID;SLCO1B1;rs2306283;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:CARDIOVASCULAR_DISEASE,_OTHER:DYSLIPIDAEMIA
DEXTROMETHORPHAN;CYP2D6;CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5;*4/*2xN;LADME_PK;INCREASED_METABOLISM;OTHER:HYPERCHOLESTEROLEMIA
ASPIRIN;P2RY1;rs1371097;T;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:STROKE
ASPIRIN;ABCB1;rs1045642;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:STROKE
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*28;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:COLONIC_NEOPLASMS
DEXTROMETHORPHAN;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM;
SIROLIMUS;CYP3A4;CYP3A4*8, CYP3A4*20;*8/*20;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SEIZURES,_OTHER:INTESTINAL_DISEASES,_OTHER:CONGENITAL_ABNORMALITIES
DEXTROMETHORPHAN;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM;
RIBAVIRIN, SOFOSBUVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
RIFAMPIN;SLCO1B1;rs4149032;TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TUBERCULOSIS
MODAFINIL;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;OTHER:METHAMPHETAMINE_DEPENDENCE
ISONIAZID;;rs1495741;AA;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TUBERCULOSIS
VALSARTAN;AGT;rs699;GG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:HYPERTENSION
NALTREXONE;OPRM1;rs1799971;G;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ALCOHOL_ABUSE
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;INCREASED_RESPONSE;
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;INCREASED_RESPONSE;
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;INCREASED_RESPONSE;
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
ELEXACAFTOR;CFTR;CFTR deficiency;;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:CYSTIC_FIBROSIS
REMIFENTANIL;ADRA2A;rs1800544;CG + GG;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
WARFARIN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;DOSAGE;INCREASED_DOSE;OTHER:THROMBOEMBOLISM
REMIFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
ELIGLUSTAT;CYP2D6;CYP2D6;ultrarapid_metabolizer;DOSAGE;INCREASED_DOSE;OTHER:GAUCHER_DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE;OTHER:LIVER_TRANSPLANTATION
POSACONAZOLE, TACROLIMUS;ABCB1;rs1045642;GG;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*6;*6;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
LACOSAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
TACROLIMUS;CYP3A5;CYP3A5*3;*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*7;*7;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_DOSE;DISEASE:ORGAN_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:ULCERATIVE_COLITIS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;CONCENTRATIONS;
COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*10;*4/*4 + *4/*10;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2;*1/*2 + *2/*2;DOSAGE;DECREASED_DOSE;DISEASE:TOBACCO_USE_DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*60;*28/*28 + *1/*60 + *60/*60;DOSAGE;DECREASED_DOSE;OTHER:NEOPLASMS
MOXIFLOXACIN;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36, UGT1A1*37;*1/*36;LADME_PK;DECREASED_CLEARANCE;DISEASE:TUBERCULOSIS
DEXTROMETHORPHAN;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM;OTHER:BREAST_NEOPLASMS
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*46;*46/*46;LADME_PK;INCREASED_CLEARANCE;
BUPRENORPHINE;SLC39A10;rs149319538;C;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:OPIOID-RELATED_DISORDERS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE, LADME_PK;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2/*2;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:HEART_DISEASES
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;DISEASE:VENOUS_THROMBOEMBOLISM
SIMVASTATIN, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE, LADME_PK;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE, LADME_PK;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*4;*4;LADME_PK;DECREASED_METABOLISM;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE, LADME_PK;DOSE;
LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12;*1/*1;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*46;*1/*46 + *1/*46 + *46/*46;LADME_PK;INCREASED_CLEARANCE;
WARFARIN;CYP4F2;CYP4F2*3;*3;DOSAGE;DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT,_OTHER:ATRIAL_FIBRILLATION,_OTHER:STROKE,_OTHER:PULMONARY_EMBOLISM,_OTHER:VENOUS_THROMBOSIS
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT,_OTHER:ATRIAL_FIBRILLATION,_OTHER:STROKE,_OTHER:PULMONARY_EMBOLISM,_OTHER:VENOUS_THROMBOSIS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;
ARIPIPRAZOLE;DRD2;rs1799732;G/del;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOAFFECTIVE_DISORDER
RIVAROXABAN;ABCB1;rs4148738;CC;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
RIVAROXABAN;ABCB1;rs1128503;AA;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
METHOTREXATE;TYMS;rs2853542;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*33, TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;ATIC;rs4673993;TT;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
FLUOXETINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_RESPONSE;EFFICACY:MAJOR_DEPRESSIVE_DISORDER
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *4/*3 + *5/*5 + *6/*6;EFFICACY;INCREASED_DISCONTINUATION;OTHER:SCHIZOPHRENIA,_OTHER:SCHIZOAFFECTIVE_DISORDER,_OTHER:BIPOLAR_DISORDER,_OTHER:DEPRESSIVE_DISORDER
SN-38;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28, UGT1A1*60;*6/*60 + *6/*28;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
TAMOXIFEN;CYP2D6;rs16947;A;EFFICACY, TOXICITY;INCREASED_DISCONTINUATION;OTHER:BREAST_NEOPLASMS
DIHYDROPYRIDINE DERIVATIVES;NUMA1;rs10898815;AA + AG;OTHER;INCREASED_DISCONTINUATION;
TAMOXIFEN;ABCC2;rs3740065;G;EFFICACY, TOXICITY;INCREASED_DISCONTINUATION;OTHER:BREAST_NEOPLASMS
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;DOSAGE;DECREASED_DOSE;
HYDRALAZINE;NAT2;NAT2;rapid_acetylator;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER:HYPERTENSION
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:GASTROESOPHAGEAL_REFLUX
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_METABOLISM;DISEASE:HEART_TRANSPLANTATION
LANSOPRAZOLE;CYP2C19;CYP2C19;poor_metabolizer;LADME_PK;DECREASED_CLEARANCE;OTHER:GASTROESOPHAGEAL_REFLUX
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *1/*2 + *1/*3 + *2/*17;LADME_PK;DECREASED_METABOLISM;DISEASE:FUNGAL_INFECTIOUS_DISEASE
SULFONAMIDES, UREA DERIVATIVES;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2  + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
CORTICOSTEROIDS;NR3C1;rs10482634;GG;EFFICACY;INCREASED_RESISTANCE;OTHER:NEPHROTIC_SYNDROME
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*10, CYP2C9*11;*11 + *2 + *3 + *5 + *6;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_DOSE;DISEASE:HEART_TRANSPLANTATION
VALPROIC ACID;UGT1A6;rs6759892;TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:EPILEPSY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
METHYLPHENIDATE;SYT1;rs2251214;AA + AG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
VORICONAZOLE;CYP2C19;CYP2C19*17;*17/*17;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:SEVERE_COMBINED_IMMUNODEFICIENCY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HYPERTENSION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
CHOP, RITUXIMAB;CBR3;rs8133052;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER:NON-HODGKIN_LYMPHOMA
CHOP, RITUXIMAB;ABCC2;rs8187710;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER:NON-HODGKIN_LYMPHOMA
N-DESMETHYLTAMOXIFEN;SEPTIN3;rs11914200;AG;LADME_PK;DECREASED_METABOLISM;
FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:NEOPLASMS,_DISEASE:PAIN
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs34130495;A;EFFICACY, LADME_PK;DECREASED_RESPONSE;
N-DESMETHYLTAMOXIFEN;SREBF2;rs133290;AC;LADME_PK;DECREASED_METABOLISM;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;DISEASE:VENOUS_THROMBOEMBOLISM
N-DESMETHYLTAMOXIFEN;TCF20;rs5751251;GG;LADME_PK;INCREASED_METABOLISM;
N-DESMETHYLTAMOXIFEN;SREBF2;rs2267439;TT;LADME_PK;INCREASED_METABOLISM;
N-DESMETHYLTAMOXIFEN;SREBF2;rs9607850;TT;LADME_PK;INCREASED_METABOLISM;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE, LADME_PK;DECREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
N-DESMETHYLTAMOXIFEN;CENPM, SMIM45;rs8140869;AG;LADME_PK;DECREASED_METABOLISM;
RIBAVIRIN, SOFOSBUVIR;IFNL4;rs11322783;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
VARENICLINE;CYP2A6;CYP2A6 high activity;;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*24;*2/*24;DOSAGE;DECREASED_CLEARANCE;OTHER:CARDIOMYOPATHIES
ETOPOSIDE;;rs446112;AA;OTHER;INCREASED_RESISTANCE;
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_EXPOSURE;OTHER:DIABETES_MELLITUS,_OTHER:HYPERCHOLESTEROLEMIA
FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;CYP2D6;CYP2D6*2;*2/*2;LADME_PK;INCREASED_CLEARANCE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
OPIOIDS;CYP2D6;CYP2D6 poor and ultrarapid metabolizers;;EFFICACY;DECREASED_RESPONSE;DISEASE:PAIN
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*24;*2/*24;DOSAGE;DECREASED_DOSE;OTHER:CARDIOMYOPATHIES
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:PANIC_DISORDER
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;
AFATINIB;EGFR;rs28929495;GG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA
HYDROMORPHONE;CYP2D6;CYP2D6*5, CYP2D6*17;*5/*17;LADME_PK;DECREASED_CONCENTRATIONS;
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
3-AMINOISOBUTYRATE;DPYD;rs3918290;TT;LADME_PK;DECREASED_CONCENTRATIONS;
HYDRALAZINE;NAT2;NAT2;rapid_acetylator;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER:HYPERTENSION
MEXILETINE;CYP2D6;CYP2D6*41;*41;EFFICACY;DECREASED_RESPONSE;OTHER:MYOTONIC_DYSTROPHY,_OTHER:NONDYSTROPHIC_MYOTONIA
HYDROCODONE, TRAMADOL;CYP2D6;CYP2D6*5, CYP2D6*17;*5/*17;EFFICACY;DECREASED_RESPONSE;
3-AMINOISOBUTYRATE;UPB1;rs143493067;AA;LADME_PK;DECREASED_CONCENTRATIONS;
3-AMINOISOBUTYRATE;AGXT2;rs114286107;TT;LADME_PK;INCREASED_CONCENTRATIONS;
FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:PAIN,_POSTOPERATIVE
URACIL;DPYD;rs3918290;TT;LADME_PK;INCREASED_CONCENTRATIONS;
2-AMINOHEPTANOATE, 2-AMINOOCTANOIC ACID, 2-HYDROXYLAURATE;ACAD11;rs41272317;AA;LADME_PK;INCREASED_CONCENTRATIONS;
CYSTEINE-S-SULFATE, L-ORNITHINE;NPC2;rs140130028;TT;LADME_PK;INCREASED_CONCENTRATIONS;
HYDRALAZINE;NAT2;NAT2;slow_acetylator;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
5,6-DIHYDROTHYMINE;UPB1;rs143493067;AA;LADME_PK;INCREASED_CONCENTRATIONS;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HYPERTENSION
10-MONOHYDROXY OXCARBAZEPINE;ABCC2;rs2273697;G;LADME_PK;INCREASED_CLEARANCE;OTHER:EPILEPSY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;
RIVAROXABAN;CYP3A5;rs776746;TT;TOXICITY;DECREASED_CONCENTRATIONS;OTHER:VENOUS_THROMBOEMBOLISM
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
CYTARABINE;SLC29A1;rs2396243;T;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ACUTE_MYELOID_LEUKEMIA
CYTARABINE;NME4;rs5841;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ACUTE_MYELOID_LEUKEMIA
PRAZIQUANTEL;CYP1A2;CYP1A2*1, CYP1A2*30;*1/*30 + *30/*30;LADME_PK;INCREASED_METABOLISM;OTHER:SCHISTOSOMIASIS
PRAZIQUANTEL;CYP2C9;CYP2C9*1, CYP2C9*9;*1/*9 + *9/*9;LADME_PK;INCREASED_METABOLISM;OTHER:SCHISTOSOMIASIS
CYTARABINE;CDA;rs10916819;AG + GG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ACUTE_MYELOID_LEUKEMIA
CYTARABINE;CMPK1;rs17103168;AG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ACUTE_MYELOID_LEUKEMIA
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CYTARABINE;CTPS1;rs12067645;A;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ACUTE_MYELOID_LEUKEMIA
CYTARABINE;RRM1;rs11030918;CC;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ACUTE_MYELOID_LEUKEMIA
CYTARABINE;DCK;rs4643786;C;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ACUTE_MYELOID_LEUKEMIA
CYTARABINE;RRM2;rs1138729;AG + GG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ACUTE_MYELOID_LEUKEMIA
CYTARABINE;CMPK1;rs1044457;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ACUTE_MYELOID_LEUKEMIA
CYTARABINE;SLC28A3;rs17343066;AA;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ACUTE_MYELOID_LEUKEMIA
ARIPIPRAZOLE;CYP2D6;rs1065852;AA + AG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:TIC_DISORDERS
ARIPIPRAZOLE;CYP2D6;rs1080989;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:TIC_DISORDERS
QUINAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;
ARIPIPRAZOLE;CYP2D6;rs1080989;CT + TT;EFFICACY;DECREASED_CLEARANCE;OTHER:TIC_DISORDERS
CYCLOPHOSPHAMIDE;CYP3A4;rs2740574;CC + CT;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:B-CELL_CHRONIC_LYMPHOCYTIC_LEUKEMIA
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*1, CYP3A5*3;*3;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:B-CELL_CHRONIC_LYMPHOCYTIC_LEUKEMIA
WARFARIN;CYP2C9;rs72558189;A;DOSAGE;DOSE;
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
WARFARIN;CYP2C9;rs28371686;C;DOSAGE;DOSE;
WARFARIN;CYP2C9;rs1057910;A;DOSAGE;DOSE;
WARFARIN;CYP4F2;rs2108622;C;DOSAGE;DOSE;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
TACROLIMUS;UGT1A4;rs2011425;TT;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A4;rs35599367;GG;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_EXPOSURE;OTHER:DIABETES_MELLITUS,_OTHER:HYPERCHOLESTEROLEMIA
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*22;DOSAGE;DECREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2/*3;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*28;*28;LADME_PK;INCREASED_EXPOSURE;DISEASE:HIV_INFECTIOUS_DISEASE
ALOGLIPTIN;PNPLA3;rs738409;CG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2,_OTHER:FATTY_LIVER_DISEASE,_OTHER:BODY_WEIGHT_CHANGES
AMLODIPINE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:HYPERTENSION
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;CTT/del;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
SERTRALINE;DRD3;rs167770;AG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:OBSESSIVE-COMPULSIVE_DISORDER
SERTRALINE;DRD3;rs11721264;AG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:OBSESSIVE-COMPULSIVE_DISORDER
ILOPERIDONE, ILOPERIDONE METABOLITE P88;CYP2D6;rs1065852;AA;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;DECREASED_RESPONSE;
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*4;*1/*4;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
VALPROIC ACID;CACNA1H;rs3751664;T;EFFICACY;INCREASED_RESISTANCE;OTHER:EPILEPSY
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
PENICILLIN G;IFNG;rs1861494;CC;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:SYPHILIS
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;
PENICILLIN G;IFNG;rs2430561;TT;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:SYPHILIS
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
IMIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN;*1/*1xN + *1/*2xN;DOSAGE;INCREASED_DOSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ISONIAZID;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7;*6/*6 + *6/*7 + *7/*7;LADME_PK;DECREASED_METABOLISM;OTHER:TUBERCULOSIS
SIMVASTATIN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HYPERCHOLESTEROLEMIA
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele) + HTTLPR long form (L allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE, LADME_PK;DECREASED_METABOLISM;DISEASE:LIVER_TRANSPLANTATION
IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;DECREASED_METABOLISM;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5;*3 + *5 + *2 + *1;DOSAGE;DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE;
VENETOCLAX;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:ACUTE_MYELOID_LEUKEMIA
CLOZAPINE;NFIB;rs28379954;CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:SCHIZOPHRENIA
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A4;rs2740574;TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;INCREASED_METABOLISM;DISEASE:GASTROESOPHAGEAL_REFLUX
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME_PK;INCREASED_METABOLISM;DISEASE:GASTROESOPHAGEAL_REFLUX
METHYLPHENIDATE;SLC6A2;rs998424;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;DECREASED_METABOLISM;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:LUPUS_NEPHRITIS
LITHIUM;;rs7405404;T;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
NICOTINE;CYP2A6;rs28399454;CT + TT;LADME_PK;DECREASED_METABOLISM;
3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2 + *2/*2;DOSAGE;DECREASED_DOSE;
EFAVIRENZ;CYP2B6;rs28399499;C;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs35167514;del;EFFICACY, LADME_PK;DECREASED_RESPONSE;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;
FENTANYL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;DOSAGE;INCREASED_DOSE;OTHER:GASTROINTESTINAL_NEOPLASMS,_OTHER:PAIN,_POSTOPERATIVE
VARENICLINE;HYKK;rs7164594;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
SIROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
VORICONAZOLE;CYP2C19;CYP2C19*17;*17/*17;EFFICACY;DECREASED_RESPONSE;DISEASE:FUNGAL_INFECTIOUS_DISEASE
4-HYDROXYTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*4 + *3/*5;LADME_PK;DECREASED_METABOLISM;
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5;*1/*1;LADME_PK;INCREASED_METABOLISM;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
VENLAFAXINE;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*5;LADME_PK;DECREASED_METABOLISM;
ENALAPRIL, LOSARTAN;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_DISEASE
VENLAFAXINE;CYP2C19;CYP2C19*2;*2/*2;LADME_PK;DECREASED_METABOLISM;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
BENAZEPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
BUPROPION;CYP2B6;rs8109525;GG;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5;*1/*1;DOSAGE;INCREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:NEPHROTIC_SYNDROME
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*41;*10/*10 + *10/*41 + *1/*5 + *2/*5 + *5/*10;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
MESALAZINE, THIOGUANINE;NAT1;NAT1*3, NAT1*4, NAT1*10;*10;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ULCERATIVE_COLITIS,_DISEASE:CROHN_DISEASE,_DISEASE:INFLAMMATORY_BOWEL_DISEASES
PIOGLITAZONE;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;INCREASED_METABOLISM;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:ULCERATIVE_COLITIS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:ORGAN_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:ORGAN_TRANSPLANTATION
EXEMESTANE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
WARFARIN;CYP4F2;CYP4F2*1, CYP4F2*3;*3;DOSAGE;INCREASED_DOSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_METABOLISM;DISEASE:HEART_TRANSPLANTATION
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4 + *5;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14;*4 + *5 + *10 +*14;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
METOPROLOL;CYP2D6;CYP2D6*4;*4;DOSAGE;DECREASED_DOSE;DISEASE:HEART_FAILURE
CETUXIMAB;VEGFA;rs144854329;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME_PK;DECREASED_METABOLISM;OTHER:NEOPLASMS
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:RHEUMATOID_ARTHRITIS,_DISEASE:ULCERATIVE_COLITIS
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;INCREASED_TROUGH CONCENTRATION;DISEASE:ULCERATIVE_COLITIS
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME_PK;DECREASED_CLEARANCE;OTHER:NEOPLASMS
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*6;*1/*6;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;DOSAGE;INCREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE;DISEASE:STROKE
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*3/*4 + *4/*4 + *4/*5;LADME_PK;DECREASED_METABOLISM;
LETROZOLE;;rs7937;C;;INCREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY
PROPOFOL;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*1 + *1/*2;LADME_PK;DECREASED_CONCENTRATIONS;
WARFARIN;VKORC1;rs104894540;G;DOSAGE;INCREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;CLEARANCE;DISEASE:HEART_DISEASES
CODEINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;DECREASED_RESPONSE;OTHER:PAIN
LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
NOROXYCODONE, OXYCODONE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME_PK;INCREASED_CONCENTRATIONS;
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, PAROXETINE, SERTRALINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
DISULFIRAM;SLC6A3;rs28363170;GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT/GGGGGCCCTGCATGCGTCCTGGGGTAGTACACGCTCCAGT;EFFICACY;INCREASED_RESPONSE;OTHER:COCAINE_DEPENDENCE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;DOSAGE;INCREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY
BENAZEPRIL, PERINDOPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*4/*4;LADME_PK;DECREASED_CLEARANCE;DISEASE:PSYCHOTIC_DISORDER
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;DOSAGE;DECREASED_DOSE;
THIOGUANINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:CROHN_DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_CLEARANCE;OTHER:HUMAN_LIVER_MICROSOMES
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;DISEASE:ULCERATIVE_COLITIS
PROGUANIL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME_PK;DECREASED_METABOLISM;DISEASE:MALARIA
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CITALOPRAM;CYP2C19;CYP2C19*17;*17/*17;EFFICACY;DECREASED_RESPONSE;DISEASE:OBSESSIVE-COMPULSIVE_DISORDER
N-DESMETHYLCLOZAPINE;CYP2C19;CYP2C19*1, CYP2C19*17;*17;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:SCHIZOAFFECTIVE_DISORDER,_DISEASE:SCHIZOPHRENIA
CLOZAPINE;CYP2C19;CYP2C19*17;*17/*17;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOAFFECTIVE_DISORDER,_DISEASE:SCHIZOPHRENIA
WARFARIN;VKORC1;rs104894541;C;DOSAGE;INCREASED_DOSE;
EFAVIRENZ;CYP2B6;rs36118214;GG;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;rs104894539;A;DOSAGE;INCREASED_DOSE;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;DECREASED_METABOLISM;DISEASE:NON-HODGKIN_LYMPHOMA
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*30;*1/*30;LADME_PK;DECREASED_METABOLISM;DISEASE:NON-HODGKIN_LYMPHOMA
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*29;*1/*29;LADME_PK;DECREASED_METABOLISM;DISEASE:NON-HODGKIN_LYMPHOMA
LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
CYCLOPHOSPHAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME_PK;DECREASED_METABOLISM;DISEASE:NON-HODGKIN_LYMPHOMA
QUINAPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
CYCLOPHOSPHAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-HODGKIN_LYMPHOMA
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION,_DISEASE:VENOUS_THROMBOEMBOLISM
TESTOSTERONE;UGT1A4;UGT1A4*1a, UGT1A4*3a;*3a;EFFICACY, LADME_PK;INCREASED_CLEARANCE;
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-HODGKIN_LYMPHOMA
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;DECREASED_METABOLISM;OTHER:HYPERTENSION
ACENOCOUMAROL;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE;
LAMOTRIGINE;UGT1A4;UGT1A4*1a, UGT1A4*2, UGT1A4*3a;*2 + *3a;EFFICACY, LADME_PK;DECREASED_CLEARANCE;
CURCUMIN, IVACAFTOR;CFTR;rs77010898;AA + AG;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MENTAL_DISORDERS
3-HYDROXYCOTININE;CYP2A6;CYP2A6*1, CYP2A6*12;*1/*12;LADME_PK;DECREASED_CONCENTRATIONS;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;DECREASED_METABOLISM;DISEASE:MENTAL_DISORDERS
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:LIVER_TRANSPLANTATION
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;DOSAGE, LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*45, CYP2D6*46;*9 + *29 + *45 + *46 + *17 + *10;TOXICITY, LADME_PK;DECREASED_METABOLISM;DISEASE:HYPERTENSION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_RESISTANCE;OTHER:CORONARY_DISEASE
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *17/*2 + *17/*3 + *2/*2 + *2/*3 + *3/*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;DOSAGE, LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
METHOTREXATE;HLA-G;rs371194629;del/del;EFFICACY;INCREASED_RESPONSE;EFFICACY:RHEUMATOID_ARTHRITIS
METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*4 + *3 + *5  + *6;TOXICITY, LADME_PK;DECREASED_METABOLISM;DISEASE:HYPERTENSION
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
ESOMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*17;EFFICACY;DECREASED_RESPONSE;OTHER:EOSINOPHILIC_ESOPHAGITIS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;DOSAGE, LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:NEOPLASMS
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6/*6 + *28/*28 + *6/*28;DOSAGE;DECREASED_DOSE;DISEASE:NEOPLASMS
CAPTOPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;
IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME_PK;INCREASED_METABOLISM;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;DOSAGE;DECREASED_DOSE;
LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:HYPERTENSION
CHIGLITAZAR;PPARA;rs1800234;CC + CT;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
LAMOTRIGINE;UGT1A4;UGT1A4*1a, UGT1A4*1b;*1b;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:EPILEPSY
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*5 + *10;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3 + *4;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*1/*4 + *3/*4;LADME_PK;DECREASED_METABOLISM;OTHER:SCHIZOPHRENIA
AZATHIOPRINE, MERCAPTOPURINE;TPMT;TPMT low activity;;LADME_PK;DECREASED_METABOLISM;
O-DESMETHYLTRAMADOL;SLC22A1;SLC22A1 deficiency;;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:PAIN
MERCAPTOPURINE;TPMT;TPMT intermediate activity;;EFFICACY;INCREASED_RESPONSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
FENTANYL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
SULFASALAZINE;NAT2;NAT2;slow_acetylator;OTHER;INCREASED_DISCONTINUATION;DISEASE:RHEUMATOID_ARTHRITIS
FENTANYL;CYP3A4;rs2242480;T/T;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:PAIN,_POSTOPERATIVE
ETHANOL;OPRM1;rs1799971;G;DOSAGE;INCREASED_DOSE;
SUFENTANIL;CYP3A4;rs2242480;T/T;EFFICACY;INCREASED_RESPONSE;OTHER:PAIN,_POSTOPERATIVE
SUFENTANIL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
SUFENTANIL;CYP3A4;rs2242480;T/T;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:PAIN
TACROLIMUS;CYP3A4;rs2242480;C/C;OTHER, LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
FENTANYL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
SUFENTANIL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
FENTANYL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
BETA BLOCKING AGENTS;GRK5;rs4752292;T;EFFICACY;DECREASED_RESPONSE;OTHER:CORONARY_ARTERY_DISEASE
INTERFERON BETA-1A;HLA-B;HLA-B*15:01;*15:01;EFFICACY;DECREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DOSE;DISEASE:HEART_DISEASES
RUBELLA VACCINES;HLA-B;HLA-B*35:03;*35:03;EFFICACY;INCREASED_RESPONSE;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;HLA-B;HLA-B*38:01;*38:01;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);OPRM1;rs671531;GG;EFFICACY;DECREASED_RESPONSE;OTHER:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*18;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*18;*18/*18;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
USTEKINUMAB;HLA-C;HLA-C*06:02;*06:02;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
METHOTREXATE;HLA-C;HLA-C*06:02;*06:02;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
FENTANYL;CYP3A4;CYP3A4*1, CYP3A4*18;*18/*18;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
RUBELLA VACCINES;HLA-C;HLA-C*15:02;*15:02;EFFICACY;INCREASED_RESPONSE;
PEGINTERFERON ALFA-2B, RIBAVIRIN;HLA-C;HLA-C*01:02, HLA-C*02:02, HLA-C*03:02, HLA-C*04:01, HLA-C*05:01, HLA-C*06:02, HLA-C*07:01, HLA-C*08:01, HLA-C*12:02, HLA-C*14:02, HLA-C*15:02, HLA-C*16:01, HLA-C*17:01;*02:02 + *04:01 + *05:01 + *06:02 + *15:02 + *17:01;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
MEASLES VACCINES;HLA-DQA1;HLA-DQA1*01:04;*01:04;EFFICACY;INCREASED_RESPONSE;
MEASLES VACCINES;HLA-DRB1;HLA-DRB1*01:01;*01:01;EFFICACY;RESPONSE;
CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*1;LADME_PK;INCREASED_CONCENTRATIONS;
INTERFERON BETA-1A;HLA-DRB1;HLA-DRB1*04:01;*04:01;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;HLA-DRB1;HLA-DRB1*04:01;*04:01;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
HEPATITIS VACCINES;HLA-DRB1;HLA-DRB1*07:01;*07:01;EFFICACY;DECREASED_RESPONSE;
INFLUENZA VACCINES;HLA-DRB1;HLA-DRB1*07:01;*07:01;EFFICACY;DECREASED_RESPONSE;
MEASLES VACCINES;HLA-DRB1;HLA-DRB1*08:01;*08:01;EFFICACY;RESPONSE;
INFLUENZA VACCINES;HLA-DRB1;HLA-DRB1*13:01;*13:01;EFFICACY;INCREASED_RESPONSE;
TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3 + *3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
METHOTREXATE;GGH;rs11545078;AA + AG;TOXICITY;INCREASED_DISCONTINUATION;SIDE_EFFECT:RHEUMATOID_ARTHRITIS
IBUPROFEN;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3;DOSAGE;DECREASED_DOSE;
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7, CYP2B6*18;*1/*6 + *1/*18 + *6/*6 + *6/*18;LADME_PK;DECREASED_METABOLISM;OTHER:OPIOID-RELATED_DISORDERS
DISULFIRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele) / HTTLPR short form (S allele) + HTTLPR short form (S allele) / L allele-rs25531C + L allele-rs25531C / L allele-rs25531C;EFFICACY;INCREASED_RESPONSE;OTHER:COCAINE_DEPENDENCE
SERTRALINE;CYP2B6;CYP2B6*1, CYP2B6*4;*1/*4 + *4/*4;LADME_PK;DECREASED_CONCENTRATIONS;
SERTRALINE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*9;*6 + *9;LADME_PK;INCREASED_CONCENTRATIONS;
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;DECREASED_CONCENTRATIONS;
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4;*2 + *3 + *4;LADME_PK;INCREASED_CONCENTRATIONS;
SERTRALINE;CYP2B6;CYP2B6*1, CYP2B6*9;*9/*9;LADME_PK;INCREASED_HALF_LIFE TIME;
PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*1/*15;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERCHOLESTEROLEMIA
RIFAMPIN, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*11;*2 + *3 + *11;EFFICACY;INCREASED_RESPONSE;OTHER:TUBERCULOSIS
ACYCLOVIR;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5;*2/*2 +*2/*3 +*3/*3 + *5/*5;EFFICACY;INCREASED_RESPONSE;
TACROLIMUS;ABCB1;rs1045642;GG;LADME_PK;INCREASED_METABOLISM;DISEASE:LIVER_TRANSPLANTATION
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
FLUVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*14;*14;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;
METHADONE;CYP2B6;CYP2B6*6;*6/*6;TOXICITY;DECREASED_METABOLISM;OTHER:PAIN,_POSTOPERATIVE,_OTHER:SCOLIOSIS
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*31, SLCO1B1*37;*31;LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*20, SLCO1B1*37;*20;LADME_PK;INCREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CONJUGATED ESTROGENS;SLCO1B1;rs4149056;TT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:MENOPAUSE
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*23, SLCO1B1*37;*23;LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ACENOCOUMAROL;CYP2C18;rs1998591;GG;DOSAGE;INCREASED_DOSE;
ACENOCOUMAROL;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_RESISTANCE;OTHER:STROKE
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*15;LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ATORVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*15;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HYPERCHOLESTEROLEMIA
ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*14, SLCO1B1*15, SLCO1B1*37;*15/*15 + *1/*15 + *15/*37 + *14/*37;LADME_PK;INCREASED_CONCENTRATIONS;
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;DECREASED_CONCENTRATIONS;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_STEADY_STATE CONCENTRATION;OTHER:TRANSPLANTATION
3,4-DEHYDROCILOSTAZOL;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:CEREBRAL_INFARCTION
BETA BLOCKING AGENTS;ADRA2C;rs61767072;del;EFFICACY;INCREASED_RESPONSE;OTHER:CARDIOMYOPATHY,_DILATED
ARIPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*3 + *4 + *4xN + *5 + *6 + *10 + *41;LADME_PK;INCREASED_CONCENTRATIONS;
ATOMOXETINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
DOCETAXEL, THALIDOMIDE;SULT1C4;rs1402467;G;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
ATOMOXETINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;DOSAGE;DECREASED_DOSE;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
ATOMOXETINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
AMITRIPTYLINE, CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;OTHER;INCREASED_DISCONTINUATION;OTHER:BIPOLAR_DISORDER
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;*1/*2 + *1/*3 + *1/*5 + *1/*6;DOSAGE;DECREASED_DOSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
BREXPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*2;*2;LADME_PK;DECREASED_METABOLISM;
BREXPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*14, CYP2D6*17, CYP2D6*29, CYP2D6*41;*9 +*10 + *14 + *17 + *29 + *41;LADME_PK;DECREASED_METABOLISM;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
N-DESMETHYLTRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*1/*5 + *1/*10 + *2/*5 + *2/*10 + *5/*10 + *10/*10;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HEAD_AND_NECK_NEOPLASMS
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;
VENLAFAXINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
VENLAFAXINE;SLC6A4;SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;EFFICACY;INCREASED_RESPONSE;OTHER:ANXIETY_DISORDERS
VENLAFAXINE;SLC6A4;SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;EFFICACY;DECREASED_RESPONSE;OTHER:DEPRESSION
METHOTREXATE;ABCC2;rs717620;CT + TT;TOXICITY;DECREASED_DISCONTINUATION;SIDE_EFFECT:RHEUMATOID_ARTHRITIS
KETOROLAC;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;INCREASED_RESPONSE;OTHER:PAIN,_POSTOPERATIVE
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4;EFFICACY;DECREASED_RESPONSE;OTHER:PAIN,_POSTOPERATIVE
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC1;rs3212948;C;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;OTHER:PANIC_DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
ENDOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*22/*22;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*22;DOSAGE;DECREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
MIDAZOLAM;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_CLEARANCE;OTHER:NEOPLASMS
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*17, CYP2D6*29;*17/*29 + *17/*17;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
LIRAGLUTIDE;GLP1R;rs10305420;TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME_PK;DECREASED_METABOLISM;
N-DESMETHYLTAMOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;DECREASED_METABOLISM;
TAMOXIFEN;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME_PK;DECREASED_METABOLISM;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
OXYCODONE;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;LADME_PK;DECREASED_METABOLISM;
OXYCODONE;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;LADME_PK;DECREASED_METABOLISM;
OXYCODONE;CYP3A4;CYP3A4*1, CYP3A4*22;*22;LADME_PK;DECREASED_METABOLISM;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE;OTHER:LUNG_TRANSPLANTATION
BEVACIZUMAB, CYCLOPHOSPHAMIDE;CXCL8;rs4073;AA + AT;EFFICACY;DECREASED_RESPONSE;DISEASE:OVARIAN_NEOPLASMS
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*4;*4/*4;LADME_PK;DECREASED_METABOLISM;
DULOXETINE;CYP2D6;CYP2D6*4;*4/*4;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEPRESSIVE_DISORDER
N-DESMETHYLCLOZAPINE;CYP3A4;CYP3A4 low activity;;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
DIHYDROPYRIDINE DERIVATIVES;CYP3A5;rs776746;TT;OTHER;INCREASED_DISCONTINUATION;
DESVENLAFAXINE;CYP2D6;CYP2D6*4;*4/*4;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:DEPRESSIVE_DISORDER
N-DESMETHYLCLOZAPINE;CYP1A2;CYP1A2 low activity;;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
DESVENLAFAXINE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:DEPRESSIVE_DISORDER
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*9, CYP2A6*17, CYP2A6*35;*1/*35 + *9/*35 + *17/*35;LADME_PK;DECREASED_METABOLISM;
DISULFIRAM;ALDH2;ALDH2 deficiency;;EFFICACY;INCREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*46;*1/*46 + *46/*46;LADME_PK;INCREASED_METABOLISM;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28, CYP2A6*35;*1/*2 + *1/*4 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME_PK;DECREASED_METABOLISM;
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
NICOTINE;CYP2A6;rs137904044;A;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*35;*35/*35;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;rs571335587;A;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;rs28399454;T;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;rs140471703;T;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;rs199515342;A;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;rs61605570;T;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;rs768416963;T;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;rs1302192284;C;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;rs111869995;A;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;rs200554095;A;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;rs772964366;G;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;rs145308399;T;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;rs758479488;T;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;rs145157460;T;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;rs148693084;G;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;rs1303839356;T;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;rs374515279;T;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;rs777098658;G;LADME_PK;DECREASED_METABOLISM;
WARFARIN;VKORC1;rs11150606;C;DOSAGE;DECREASED_DOSE;
NICOTINE;CYP2A6;rs5031016;G;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*14, CYP2A6*38, CYP2A6*46;*1 + *46 + *9 + *14 + *38;LADME_PK;INCREASED_METABOLISM;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*9, CYP2A6*12, CYP2A6*38, CYP2A6*46;*1 + *9 + *12 + *38;LADME_PK;DECREASED_METABOLISM;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;
OXALIPLATIN;MTHFR;rs1801131;GG + GT;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
ALPRAZOLAM;CYP3A4;CYP3A4 low activity;;EFFICACY;INCREASED_RESPONSE;OTHER:ALCOHOL_ABUSE,_OTHER:ANXIETY_DISORDERS
TACROLIMUS;CYP3A4;rs2242480;C/C;LADME_PK;DECREASED_METABOLISM;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A4;rs2242480;C/C;LADME_PK;DECREASED_METABOLISM;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A4;rs2242480;C/T + T/T;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;rs2242480;C/C;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
FENTANYL;CYP3A4;rs2242480;T/T;DOSAGE;DECREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
ENDOXIFEN;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5 intermediate metabolizer and normal metabolizer;;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
CLOZAPINE;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:SCHIZOPHRENIA
DOLUTEGRAVIR;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTIONS_AND_DRUG-ELUTING_STENTS
(S)-METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*7, CYP2B6*9, CYP2B6*18;*6 + *7 + *9 + *18;LADME_PK;DECREASED_CLEARANCE;OTHER:SCOLIOSIS
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7;*4/*4 + *4/*7;OTHER, LADME_PK;DECREASED_METABOLISM;
HYDRALAZINE;NAT2;NAT2;rapid_acetylator;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER:HYPERTENSION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*13;*1/*13;DOSAGE;DECREASED_DOSE;OTHER:ATRIAL_FIBRILLATION
L-METHYLFOLATE;MTHFR;rs1801133;AG;EFFICACY;INCREASED_RESPONSE;OTHER:BIPOLAR_DISORDER,_OTHER:DEPRESSION,_OTHER:OBSESSIVE-COMPULSIVE_DISORDER
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA,_OTHER:LYMPHOMA,_OTHER:ACUTE_MYELOID_LEUKEMIA
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HYPERTENSION
VENLAFAXINE;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;DECREASED_METABOLISM;OTHER:ELDERLY_ADULT
ESCITALOPRAM;CYP2C19;CYP2C19;intermediate_metabolizer;LADME_PK;DECREASED_METABOLISM;OTHER:ELDERLY_ADULT
SOMATROPIN RECOMBINANT;COL1A1;rs1800012;AA;DOSAGE;DECREASED_DOSE;OTHER:GROWTH_HORMONE_DEFICIENCY
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10, CYP2A6*11, CYP2A6*13, CYP2A6*15, CYP2A6*17, CYP2A6*19, CYP2A6*20;*2 + *4 + *7 + *9 + *10 + *11 + *13 + *15 + *17 + *19 + *20;LADME_PK;DECREASED_METABOLISM;
TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*11;*11/*4;LADME_PK;DECREASED_METABOLISM;OTHER:STOMACH_NEOPLASMS
LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*35;*1/*17 + *20/*23 + *9/*9 + *1/*4 + *1/*2 + *17/*17 + *17/*35 + *2/*9 + *9/*12 + *1/*9 + *1/*12;LADME_PK;DECREASED_CLEARANCE;DISEASE:BREAST_NEOPLASMS
L-METHYLFOLATE;MTHFR;rs1801131;GT;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*46;*1/*46;LADME_PK;INCREASED_CLEARANCE;
COUMARIN;CYP2A6;CYP2A6*5, CYP2A6*47;*5/*47;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28, CYP2A6*35, CYP2A6*46;*1/*2 + *1/*4 + *1/*9 + *1/*12 + *1/*17 + *1/*20 + *1/*23 + *1/*24 + *1/*25 + *1/*26 + *1/*27  + *1/*28 + *1/*35 + *9/*9 + *17/*17 + *20/*20 + *35/*35;LADME_PK;DECREASED_METABOLISM;
VITAMIN B-COMPLEX, INCL. COMBINATIONS;MTHFR;rs1801133;A;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED_DOSE;
VITAMIN B-COMPLEX, INCL. COMBINATIONS;MTHFR;rs1801131;G;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;rs9923231;G;DOSAGE;DOSE;DISEASE:HEART_DISEASES
ATOMOXETINE;SLC6A2;rs12708954;A;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
CYCLOSPORINE, TACROLIMUS;CYP3A4;rs2740574;C;LADME_PK;DECREASED_CONCENTRATIONS;SIDE_EFFECT:KIDNEY_TRANSPLANTATION
MERCAPTOPURINE;NUDT15;rs746071566;del;DOSAGE, TOXICITY;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;
RIZATRIPTAN;DRD2;rs6275;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER:MIGRAINE_WITHOUT_AURA
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;rs1799853;C;DOSAGE;DOSE;
WARFARIN;VKORC1;rs61162043;G;DOSAGE;INCREASED_DOSE;
SULFONAMIDES, UREA DERIVATIVES;CYP2C9;rs1057910;CC;EFFICACY;INCREASED_RESPONSE;
NICOTINE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
RISPERIDONE;DRD3;rs6280;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTISM
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;
SIROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;DECREASED_CONCENTRATIONS;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*3;DOSAGE;DECREASED_DOSE;
CYSTEAMINE;CFTR;rs113993960;CTT/del + del/del;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;DISEASE:PANIC_DISORDER
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2/*2;DOSAGE;DECREASED_DOSE;
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HYPERTENSION
FLUOROURACIL;DPYD;DPYD deficiency;;LADME_PK;DECREASED_METABOLISM;DISEASE:BREAST_NEOPLASMS
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;DOSAGE;DECREASED_DOSE;DISEASE:TRANSPLANTATION
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;EFFICACY;DECREASED_RESPONSE;DISEASE:MYOCARDIAL_INFARCTION
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;DECREASED_METABOLISM;OTHER:HYPERTENSION
CODEINE;CYP2D6;CYP2D6*17;*17;LADME_PK;DECREASED_METABOLISM;DISEASE:ANEMIA,_SICKLE_CELL
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;DOSAGE;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *1/*2 + *17/*17;DOSAGE;DOSE;DISEASE:CYSTIC_FIBROSIS,_DISEASE:LUNG_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE, EFFICACY;DECREASED_DOSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ARIPIPRAZOLE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;*4 + *5 + *6;LADME_PK;DECREASED_METABOLISM;
RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;DISEASE:GASTROESOPHAGEAL_REFLUX
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17 + *1/*2;DOSAGE;DOSE;DISEASE:CYSTIC_FIBROSIS,_DISEASE:LUNG_TRANSPLANTATION
PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*1 + *1/*17;LADME_PK;INCREASED_METABOLISM;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;DOSAGE;DECREASED_DOSE;
ANTHRACYCLINES AND RELATED SUBSTANCES, CAPECITABINE, CYCLOPHOSPHAMIDE, FLUOROURACIL, TAXANES;GSTM1;GSTM1 non-null, GSTM1 null;;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;DISEASE:GASTROESOPHAGEAL_REFLUX
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE;
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;INCREASED_METABOLISM;DISEASE:GASTROESOPHAGEAL_REFLUX
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME_PK;INCREASED_METABOLISM;DISEASE:GASTROESOPHAGEAL_REFLUX
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME_PK;DECREASED_CLEARANCE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
MIANSERIN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*1/*10 + *5/*10;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:DEPRESSION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
SALVIANOLIC ACID B;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE;OTHER:CORONARY_DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
VALPROIC ACID;UGT1A6;UGT1A6*1a, UGT1A6*2a, UGT1A6*3a, UGT1A6*4a, UGT1A6*8;*1a;LADME_PK;METABOLISM;DISEASE:EPILEPSY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:MYASTHENIA_GRAVIS
VALPROIC ACID;UGT1A6;UGT1A6*1a, UGT1A6*2a, UGT1A6*3a, UGT1A6*4a, UGT1A6*8;*1a;DOSAGE;DECREASED_DOSE;DISEASE:EPILEPSY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*8;*8/*8;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*1;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
CAPECITABINE, FLUOROURACIL;DPYD;rs55886062;C;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
SIROLIMUS, TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;DOSAGE;DECREASED_DOSE;DISEASE:DEPRESSION
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*18;*18;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;EFFICACY;DECREASED_RESPONSE;DISEASE:FUNGAL_INFECTIOUS_DISEASE
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *3/*3 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*41;LADME_PK;DECREASED_METABOLISM;
VORICONAZOLE;CYP2C19;CYP2C19*17;*17/*17;EFFICACY;DECREASED_RESPONSE;DISEASE:FUNGAL_INFECTIOUS_DISEASE
ENDOXIFEN;CYP2D6;CYP2D6 normal metabolizer and ultrarapid metabolizer;;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
IMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:LOW_BACK_PAIN,_DISEASE:OSTEOARTHRITIS
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
ISONIAZID;NAT2;NAT2;slow_acetylator;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:TUBERCULOSIS
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;DOSAGE;DECREASED_DOSE;DISEASE:COLORECTAL_NEOPLASMS
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;DOSAGE;DECREASED_DOSE;DISEASE:COLORECTAL_NEOPLASMS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:FUNGAL_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2;LADME_PK;DECREASED_METABOLISM;
CORTICOSTEROIDS;NR1I2;rs3842689;del/del;EFFICACY;INCREASED_RESISTANCE;
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;DOSAGE;DECREASED_DOSE;DISEASE:COLORECTAL_NEOPLASMS
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:FUNGAL_INFECTIOUS_DISEASE
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*26;*26;LADME_PK;DECREASED_METABOLISM;
IRBESARTAN;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;DECREASED_EXPOSURE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4;*2 + *3 + *4;LADME_PK;INCREASED_EXPOSURE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
SIPOGLITAZAR;UGT2B15;UGT2B15*1, UGT2B15*2;*2/*2;EFFICACY, LADME_PK;INCREASED_RESPONSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
SERTRALINE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*9;*6/*9 + *1/*6 + *6/*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
CLOMIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:DEPRESSION
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10 + *1/*10;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:BREAST_NEOPLASMS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_RESISTANCE;DISEASE:STROKE
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
NORTRIPTYLINE;CYP2D6;CYP2D6*1xN, CYP2D6*2;*2/*1xN;LADME_PK;INCREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;DISEASE:CEREBRAL_SINOVENOUS_THROMBOSIS
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*26;*1/*26 + *6/*6 + *6/*26;DOSAGE;DECREASED_DOSE;DISEASE:HIV_INFECTIOUS_DISEASE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;DISEASE:CEREBRAL_SINOVENOUS_THROMBOSIS
NORTRIPTYLINE;CYP2D6;CYP2D6*1xN, CYP2D6*2;*2/*1xN;DOSAGE, EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1;*1;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
CLOPIDOGREL, PRASUGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1 + *1/*2 + *1/*3;EFFICACY;RESPONSE;DISEASE:MYOCARDIAL_INFARCTION
CLOPIDOGREL;CYP2C19;CYP2C19*2, CYP2C19*3, CYP2C19*17;*2 + *3 + *17;DOSAGE;DOSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
CLOMIPRAMINE;CYP2D6;CYP2D6*1xN, CYP2D6*2;*2/*1xN;DOSAGE, EFFICACY;DECREASED_RESPONSE;DISEASE:AGORAPHOBIA
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;DECREASED_METABOLISM;
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;LADME_PK;INCREASED_METABOLISM;
NICOTINE;CYP2A6;CYP2A6*4, CYP2A6*9, CYP2A6*17, CYP2A6*26;*4/*17 + *9/*26;LADME_PK;DECREASED_METABOLISM;
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;DECREASED_METABOLISM;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_RESISTANCE;DISEASE:STROKE
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*41;*3/*4 + *4/*4;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*4/*4 + *3/*4 + *4/*5 + *4/*6;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
MORPHINE;SLC22A1;rs72552763;GAT/del + del/del;LADME_PK;DECREASED_CLEARANCE;
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*17, CYP2D6*41;*4/*41 + *4/*10 + *4/*17 + *5/*41;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*1/*4 + *2/*4 + *1/*5 + *1/*3 + *2/*5 + *1/*6 + *2/*3 + *2/*6;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
IMATINIB;GSTT1;GSTT1 non-null, GSTT1 null;null/null;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
GLUCOCORTICOIDS;HSD3B1;rs1047303;AA + AC;EFFICACY;INCREASED_RESISTANCE;OTHER:ASTHMA
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4xN, CYP2D6*12, CYP2D6*29, CYP2D6*84;*12/*84 + *4xN/*29;LADME_PK;DECREASED_METABOLISM;
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;DECREASED_METABOLISM;
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;LADME_PK;INCREASED_METABOLISM;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME_PK;DECREASED_METABOLISM;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*17/*17;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:FUNGAL_INFECTIOUS_DISEASE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*1 + *1/*17;LADME_PK;INCREASED_METABOLISM;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;*3/*9 + *4/*4 + *4/*5 + *4/*10 + *4/*41 + *5/*17 + *5/*41 + *41/*41;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
SIMVASTATIN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;CONCENTRATIONS;
MORPHINE;SLC22A1;rs72552763;del/del;LADME_PK;DECREASED_CLEARANCE;OTHER:ADENOTONSILLECTOMY
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*5, SLCO1B1*37;*5;LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME_PK;DECREASED_METABOLISM;DISEASE:ACUTE_CORONARY_SYNDROME
FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;DISEASE:MOOD_DISORDER
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
SILDENAFIL;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEART_FAILURE
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28 + *1/*28;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;LADME_PK;METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs55918055;C;EFFICACY, LADME_PK;DECREASED_RESPONSE;
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;EFFICACY;INCREASED_RESPONSE;DISEASE:RECTAL_NEOPLASMS
BILIRUBIN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:NEOPLASMS
METHADONE;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;LADME_PK;INCREASED_CONCENTRATIONS;
BILIRUBIN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:NEOPLASMS
METHADONE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS;
METHADONE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;INCREASED_CONCENTRATIONS;
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*14, SLCO1B1*37;*14;LADME_PK;INCREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;CYP2C9;CYP2C9*1;*1/*1;DOSAGE, LADME_PK;INCREASED_DOSE;
SN-38;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6 + *1/*6;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1;LADME_PK;INCREASED_CLEARANCE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*1;LADME_PK;INCREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;*3/*9 + *4/*17 +  *4/*41 + *4/*10;DOSAGE;DECREASED_DOSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PACLITAXEL;CYP2C8;CYP2C8*3;*3;LADME_PK;DECREASED_EXPOSURE;DISEASE:BREAST_NEOPLASMS
PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;DECREASED_CLEARANCE;
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME_PK;METABOLISM;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
GLATIRAMER ACETATE;CCR5;rs333;del;EFFICACY;DECREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3, CYP2C9*13, CYP2C9*16, CYP2C9*60;*1/*13 + *1/*16 + *1/*60;DOSAGE;DECREASED_DOSE;OTHER:ATRIAL_FIBRILLATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*1;LADME_PK;DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*3A/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;DISEASE:CROHN_DISEASE
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A;*3A/*3A;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;DISEASE:CROHN_DISEASE
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE;
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*9;*2 + *3 + *8 + *9;LADME_PK;DECREASED_METABOLISM;DISEASE:ASTHMA
GLIPIZIDE;TCF7L2;rs7903146;T;EFFICACY;INCREASED_RESPONSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;DISEASE:CAROTID_ARTERY_DISEASES
CLOPIDOGREL;SLC14A2;rs12456693;T;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_B_VIRUS_INFECTION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*1;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
CISPLATIN, FLUOROURACIL;TPMT;TPMT*3C;*3C;EFFICACY;DECREASED_RESPONSE;DISEASE:HEAD_AND_NECK_NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
CAVOSONSTAT;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
BUPROPION;CYP2B6;CYP2B6*6;*6;LADME_PK;DECREASED_METABOLISM;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2;LADME_PK;DECREASED_METABOLISM;DISEASE:CORONARY_ARTERY_DISEASE
RISPERIDONE;CYP2D6;CYP2D6*5, CYP2D6*10;*10 + *5;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:SCHIZOPHRENIA
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2 + *3;LADME_PK;INCREASED_TROUGH CONCENTRATION;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
NEVIRAPINE;NR1I2;rs3842689;GAGAAG/del + del/del;DOSAGE, LADME_PK;INCREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
IVACAFTOR / LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:FUNGAL_INFECTIOUS_DISEASE
MIDAZOLAM;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
SN-38;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6 + *28;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:COLORECTAL_NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;DOSAGE;DECREASED_DOSE;DISEASE:TRANSPLANTATION
IVACAFTOR / LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*5;*5;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_METABOLISM;DISEASE:ULCERATIVE_COLITIS
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:FUNGAL_INFECTIOUS_DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;*1/*2 + *1/*8 + *2/*2 + *2/*3;LADME_PK;DECREASED_METABOLISM;DISEASE:CORONARY_ARTERY_DISEASE
MEASLES VACCINES;HLA-B;HLA-B*51:01;*51:01;EFFICACY;DECREASED_RESPONSE;
BUCINDOLOL;ADRA2C;rs61767072;GGGGCGGGGCCG/GGGGCGGGGCCG;EFFICACY;INCREASED_RESPONSE;DISEASE:HEART_FAILURE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;DOSAGE;DECREASED_DOSE;DISEASE:PSYCHOTIC_DISORDER
MEASLES VACCINES;HLA-B;HLA-B*07:02;*07:02;EFFICACY;INCREASED_RESPONSE;
MEASLES VACCINES;HLA-B;HLA-B*13:01;*13:01;EFFICACY;DECREASED_RESPONSE;
MEASLES VACCINES;HLA-B;HLA-B*08:01;*08:01;EFFICACY;DECREASED_RESPONSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*3;DOSAGE;DECREASED_DOSE;
INFLUENZA VACCINES;HLA-DQB1;HLA-DQB1*03:03;*03:03;EFFICACY;DECREASED_RESPONSE;
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1 + *1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
MEASLES VACCINES;HLA-DQA1;HLA-DQA1*02:01;*02:01;EFFICACY;DECREASED_RESPONSE;
MEASLES VACCINES;HLA-DRB1;HLA-DRB1*03:01;*03:01;EFFICACY;DECREASED_RESPONSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*20;*1/*20;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
FLUOROURACIL;DPYD;DPYD;poor_metabolizer;DOSAGE;DECREASED_DOSE;DISEASE:COLORECTAL_NEOPLASMS,_DISEASE:GASTROINTESTINAL_NEOPLASMS,_DISEASE:RECTAL_NEOPLASMS
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE;OTHER:HEART_TRANSPLANTATION
CISPLATIN, FLUOROURACIL;TPMT;TPMT*3B;*3B;EFFICACY;DECREASED_RESPONSE;DISEASE:HEAD_AND_NECK_NEOPLASMS
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER:HEART_TRANSPLANTATION
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_METABOLISM;DISEASE:ULCERATIVE_COLITIS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10;*4/*5 + *4/*4;LADME_PK;DECREASED_METABOLISM;
SIROLIMUS, TEMSIROLIMUS;ABCB1;rs1128503;GG;LADME_PK;DECREASED_EXPOSURE;DISEASE:URINARY_BLADDER_NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE;OTHER:LUNG_TRANSPLANTATION
AMITRIPTYLINE;CYP2D6;CYP2D6*4;*4/*4;LADME_PK;INCREASED_CONCENTRATIONS;
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1 + *1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*59;*1/*59;DOSAGE;DECREASED_DOSE;
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME_PK;INCREASED_CONCENTRATIONS;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *3/*3 + *2/*3;DOSAGE;DECREASED_DOSE;
GRANISETRON;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE;
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*40;*40;EFFICACY;DECREASED_RESPONSE;DISEASE:ANEMIA,_SICKLE_CELL
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*17;*17;EFFICACY;DECREASED_RESPONSE;DISEASE:ANEMIA,_SICKLE_CELL
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;OTHER;INCREASED_DISCONTINUATION;DISEASE:RHEUMATOID_ARTHRITIS
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*6;*6;EFFICACY;DECREASED_RESPONSE;DISEASE:ANEMIA,_SICKLE_CELL
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;EFFICACY;DECREASED_RESPONSE;DISEASE:ANEMIA,_SICKLE_CELL
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE;DISEASE:STROKE
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*5;*5;EFFICACY;DECREASED_RESPONSE;DISEASE:ANEMIA,_SICKLE_CELL
GRANISETRON;CYP1A1;CYP1A1*1, CYP1A1*2A;*2A;LADME_PK;INCREASED_CLEARANCE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:RHEUMATOID_ARTHRITIS
CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;DECREASED_METABOLISM;DISEASE:MENTAL_DISORDERS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
HMG COA REDUCTASE INHIBITORS;UGT1A1;UGT1A1*28;*28;TOXICITY;DECREASED_DISCONTINUATION;DISEASE:HYPERLIPIDEMIAS
ROCURONIUM;SLCO1A2;rs7967354;CC;DOSAGE;DECREASED_DOSE;
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *2/*3;DOSAGE;DECREASED_DOSE;
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3 + *4 + *5 + *6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MENTAL_DISORDERS
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MENTAL_DISORDERS
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*11;*11;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:HIV_INFECTIOUS_DISEASE,_DISEASE:TUBERCULOSIS
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs12208357;T;EFFICACY, LADME_PK;DECREASED_RESPONSE;
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:HIV_INFECTIOUS_DISEASE,_DISEASE:TUBERCULOSIS
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*3 + *2;DOSAGE;DECREASED_DOSE;
CAPECITABINE, FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/CCGCGC(CACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE;DISEASE:RECTAL_NEOPLASMS
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;DECREASED_METABOLISM;DISEASE:MENTAL_DISORDERS
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;DECREASED_CLEARANCE;
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
CARVEDILOL;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*10;*3/*10 + *4/*4;DOSAGE;INCREASED_DOSE;DISEASE:HEART_FAILURE
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3 + *1/*3;DOSAGE;DECREASED_DOSE;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *3/*3 + *2/*3;DOSAGE;DECREASED_DOSE;
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*58;*58;DOSAGE;DECREASED_DOSE;
VORICONAZOLE;CYP3A4;CYP3A4*1, CYP3A4*22;*22;LADME_PK;INCREASED_EXPOSURE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;DOSAGE;INCREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;EFFICACY;INCREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;DECREASED_METABOLISM;DISEASE:MENTAL_DISORDERS
IMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3 + *2/*2;DOSAGE;DECREASED_DOSE;
VARENICLINE;CYP2A6;CYP2A6 normal metabolizer;;EFFICACY;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
AZATHIOPRINE;GSTM1;GSTM1 non-null, GSTM1 null;;LADME_PK;INCREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *3/*3 + *2/*3;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*12;*1/*12;DOSAGE;DECREASED_DOSE;
RALOXIFENE;UGT1A8;UGT1A8*1a, UGT1A8*2, UGT1A8*3;*1a/*3;LADME_PK;INCREASED_METABOLISM;
PHENAZEPAM;CYP2C19;CYP2C19*1, CYP2C19*17;*17;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ALCOHOL_ABUSE,_OTHER:ANXIETY_DISORDERS
DAUNORUBICIN;G6PD;G6PD Mediterranean, Dallas, Panama, Sassari, Cagliari, Birmingham;Mediterranean, Dallas, Panama' Sassari, Cagliari, Birmingham;LADME_PK;DECREASED_METABOLISM;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*5, CYP2C9*6, CYP2C9*11;*5 + *6 + *11;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
DOLUTEGRAVIR;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28, UGT1A1*36, UGT1A1*37;*28/*28 + *28/*37 + *1/*6 + *1/*28 + *1/*37 + *28/*36 + *36/*37;LADME_PK;DECREASED_CLEARANCE;
NICOTINE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;DECREASED_METABOLISM;
MERCAPTOPURINE;TPMT;TPMT*3A, TPMT*3C;*3A/*3C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
DIMETHYL FUMARATE;GSTP1;rs1695;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
MERCAPTOPURINE;TPMT;TPMT*3A;*3A/*3A;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*1/*3 + *1/*4 + *1/*5;LADME_PK;DECREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_METABOLISM;DISEASE:ULCERATIVE_COLITIS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;OTHER;INCREASED_DISCONTINUATION;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*8, CYP2C9*11;*2 + *3 + *5 + *8 + *11;DOSAGE;DECREASED_DOSE;
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6;ultrarapid_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:LOW_BACK_PAIN,_DISEASE:OSTEOARTHRITIS
TOREMIFENE;CYP2D6;CYP2D6*10;*10;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BREAST_NEOPLASMS
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*4/*41 + *5/*6;EFFICACY;DECREASED_RESPONSE;DISEASE:MALARIA
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;DECREASED_RESPONSE;
TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;DECREASED_METABOLISM;DISEASE:BREAST_NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;EFFICACY;INCREASED_RESPONSE;
ANTIEMETICS AND ANTINAUSEANTS;SLC22A1;rs34059508;A;EFFICACY, LADME_PK;DECREASED_RESPONSE;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;OTHER;INCREASED_RESISTANCE;DISEASE:CORONARY_ARTERY_DISEASE
CAPECITABINE, FLUOROURACIL;TYMP;rs11479;AA + AG;DOSAGE;DOSE;DISEASE:COLORECTAL_NEOPLASMS
USTEKINUMAB;HLA-C;HLA-C*06:02;*06:02;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE;DISEASE:ATRIAL_FIBRILLATION,_DISEASE:PULMONARY_EMBOLISM,_DISEASE:STROKE,_DISEASE:VENOUS_THROMBOSIS
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE;
DOXEPIN;CYP2D6;CYP2D6*3, CYP2D6*4;*3/*4;LADME_PK;DECREASED_METABOLISM;
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
PHENYTOIN;CYP2C19;CYP2C19*2, CYP2C19*3;*2 + *3;DOSAGE;DOSE;DISEASE:EPILEPSY
CLOZAPINE;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele)/L allele-rs25531C;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
PHENYTOIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE;DISEASE:EPILEPSY
ANTIPSYCHOTICS, HALOPERIDOL, OLANZAPINE, RISPERIDONE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
FOLIC ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;DECREASED_METABOLISM;DISEASE:CORONARY_ARTERY_DISEASE
FLUVASTATIN;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
ONDANSETRON;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME_PK;INCREASED_METABOLISM;
INTERFERON ALFA-2A, RECOMBINANT, RIBAVIRIN;HLA-B;HLA-B*44:02;*44:02;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
ONDANSETRON, TROPISETRON;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;EFFICACY;DECREASED_RESPONSE;DISEASE:NEOPLASMS
CYCLOSPORINE, TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
PRAVASTATIN;ACE;rs1799752;del/del;EFFICACY;RESPONSE;OTHER:NON-HYPERCHOLESTEROLAEMIC_PATIENTS_SCHEDULED_FOR_ANGIOPLASTY
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*6;*1/*2 + *1/*3 + *1/*4 + *1/*6;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*18;*1/*18;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*9;*1/*9;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
FLUOXETINE, SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;DOSAGE;DOSE;DISEASE:COLORECTAL_NEOPLASMS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3 + *1/*2 + *1/*3 + *2/*17;EFFICACY;DECREASED_RESPONSE;
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
(S)-METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
METOPROLOL;ADRA2C;rs61767072;del;EFFICACY;INCREASED_RESPONSE;DISEASE:HEART_FAILURE
ENDOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
IMATINIB;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:GASTROINTESTINAL_STROMAL_TUMORS
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AT;DOSAGE;DOSE;DISEASE:COLORECTAL_NEOPLASMS
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;DECREASED_METABOLISM;
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*3/*3 + *6/*6 + *7/*7 + *3/*6 + *3/*7 + *6/*7;LADME_PK;DECREASED_METABOLISM;OTHER:LUNG_TRANSPLANTATION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
GEFITINIB;EGFR;rs121434568;GT;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
VINCRISTINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_METABOLISM;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ENDOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;*9/*4;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;*1/*4 + *1/*5 + *1/*6;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*41;*9/*41 + *10/*10 + *41/*41;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*9, CYP2D6*10, CYP2D6*41;*1/*9 + *1/*10 + *1/*41;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*81;*1/*81;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
CAPECITABINE, FLUOROURACIL;DPYD;rs75017182;CG;DOSAGE;DOSE;DISEASE:COLORECTAL_NEOPLASMS
SIROLIMUS, TEMSIROLIMUS;NR1I2;rs6785049;GG;LADME_PK;INCREASED_EXPOSURE;DISEASE:URINARY_BLADDER_NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:LAPAROSCOPIC_SLEEVE_GASTRECTOMY
TACROLIMUS;;rs4646458;G;DOSAGE;DOSE;DISEASE:KIDNEY_TRANSPLANTATION
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;DOSAGE;DECREASED_DOSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ROCURONIUM;IAPP, SLCO1A2;rs11045995;CC;DOSAGE;DECREASED_DOSE;
MEASLES VACCINES;HLA-B;HLA-B*44:02;*44:02;EFFICACY;RESPONSE;
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3 + *4 + *5 + *6;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
NORTRIPTYLINE;CYP2D6;CYP2D6*1xN, CYP2D6*2;*2/*1xN;LADME_PK;INCREASED_DOSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:LAPAROSCOPIC_SLEEVE_GASTRECTOMY
METOPROLOL;CYP2D6;rs5030655;del/del;EFFICACY;INCREASED_RESPONSE;
AMOXICILLIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;RESPONSE;
AMOXICILLIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3;*2/*3;TOXICITY;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5;*1/*2 + *1/*3 + *1/*5;TOXICITY;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ESTRONE SULFATE;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*5;LADME_PK;INCREASED_;OTHER:BREAST_NEOPLASMS
HMG COA REDUCTASE INHIBITORS;CXCL5;rs352046;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
AMOXICILLIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE, LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;DISEASE:VENOUS_THROMBOEMBOLISM
DEBRISOQUINE;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*15;*4/*5 + *4/*15 + *4/*6 + *3/*4 + *4/*4 + *3/*5;LADME_PK;DECREASED_METABOLISM;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:LEUKEMIA
DEXTROMETHORPHAN;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*15;*4/*5 + *4/*15 + *4/*6 + *3/*4 + *4/*4 + *3/*5;LADME_PK;DECREASED_METABOLISM;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;DOSAGE;DECREASED_DOSE;
ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36;*28/*28;TOXICITY;INCREASED_DISCONTINUATION;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*5, CYP2C9*6, CYP2C9*11;*2 + *6 + *5 + *11;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*5, CYP2C9*6, CYP2C9*8, CYP2C9*9, CYP2C9*11;*2 + *6 + *5 + *11;DOSAGE;DECREASED_DOSE;
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;
CYCLOSPORINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME_PK;DECREASED_CONCENTRATIONS;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DOSE;
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*6, CYP2D6*8;*4 + *6 + *8;LADME_PK;DECREASED_CONCENTRATIONS;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DOSE;
METFORMIN;CSMD1;rs2954625;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_DISCONTINUATION;OTHER:HIV_INFECTIOUS_DISEASE
ESTRONE;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*5/*5;EFFICACY;INCREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE;
VORICONAZOLE;ABCB1;rs1045642;AA;LADME_PK;DECREASED_TROUGH CONCENTRATION;
MERCAPTOPURINE;NT5C2;rs72846714;AA + AG;LADME_PK;DECREASED_METABOLISM;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*2;*2/*2;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:SCHIZOPHRENIA
CYCLOSPORINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;UGT1A1*60;*60;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*8;*1/*8 + *8/*8;LADME_PK;DECREASED_CLEARANCE;
WARFARIN;VKORC1;rs7294;T;DOSAGE;INCREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE;
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29 + *2xN/*4;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C;*2 + *3A + *3B + *3C;DOSAGE;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
SERTRALINE;CYP2C18;rs11188059;GG;LADME_PK;DECREASED_CONCENTRATIONS;
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*4 + *7 + *9;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
DONEPEZIL;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*4 + *4/*5;LADME_PK;DECREASED_CLEARANCE;DISEASE:ALZHEIMER_DISEASE
DEBRISOQUINE;CYP2D6;CYP2D6*4, CYP2D6*17;*4/*17;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;CYP2A6 high activity;;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
FENTANYL;CYP2D6;CYP2D6*1, CYP2D6*29;*29;LADME_PK;DECREASED_CLEARANCE;OTHER:BURNS
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41;*1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *9/*5 + *2/*41 + *1/*41 + *35/*41 + *1/*10 + *2/*10 + *35/*10;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4xN, CYP2D6*56;*4xN/*56;LADME_PK;DECREASED_METABOLISM;
LEVONORGESTREL;CYP2B6;rs3745274;GT + TT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ADALIMUMAB;;rs9828223;T;EFFICACY;DECREASED_RESPONSE;OTHER:CROHN_DISEASE
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_RESPONSE;OTHER:COLORECTAL_NEOPLASMS
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PROGESTERONE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*17;LADME_PK;INCREASED_EXPOSURE;
TACROLIMUS;CYP3A5;CYP3A5*3, CYP3A5*6, CYP3A5*7;*3 + *6 + *7;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
DONEPEZIL;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN + *1xN/*1xN;LADME_PK;INCREASED_CLEARANCE;DISEASE:ALZHEIMER_DISEASE
CYCLOPHOSPHAMIDE, FLUDARABINE;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;EFFICACY;DECREASED_RESPONSE;DISEASE:B-CELL_CHRONIC_LYMPHOCYTIC_LEUKEMIA
LEVONORGESTREL;CYP2B6;rs4803419;CT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
MERCAPTOPURINE;TPMT;TPMT;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;
ATORVASTATIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;DECREASED_CLEARANCE;
SORAFENIB;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME_PK;INCREASED_EXPOSURE;DISEASE:NEOPLASMS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B;*1/*3A;DOSAGE, TOXICITY;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME_PK;DECREASED_DOSE;DISEASE:EPILEPSY
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME_PK;METABOLISM;DISEASE:EPILEPSY
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*2;LADME_PK;DECREASED_CLEARANCE;DISEASE:GASTROESOPHAGEAL_REFLUX
ATENOLOL, ENALAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESISTANCE;DISEASE:KIDNEY_DISORDER
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;INCREASED_CONCENTRATIONS;
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*3C + *1/*2 + *1/*3A;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME_PK;METABOLISM;DISEASE:EPILEPSY
BREXPIPRAZOLE;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;DECREASED_METABOLISM;OTHER:SCHIZOPHRENIA
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESISTANCE;DISEASE:EPILEPSY
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
LOPINAVIR;CYP3A4;CYP3A4*1, CYP3A4*22;*22/*22;LADME_PK;DECREASED_CLEARANCE;OTHER:HIV_INFECTIOUS_DISEASE
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME_PK;METABOLISM;DISEASE:EPILEPSY
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME_PK;METABOLISM;DISEASE:EPILEPSY
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*9;*4/*9 + *9/*9;LADME_PK;DECREASED_METABOLISM;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE;
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;METABOLISM;DISEASE:EPILEPSY
EFAVIRENZ;ABCB1;rs3842;C;LADME_PK;METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;METABOLISM;DISEASE:EPILEPSY
CITALOPRAM, FLUOXETINE;SERPINE1;rs2227631;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PHENYTOIN;CYP2C9;rs12782374;AG;OTHER, LADME_PK;INCREASED_METABOLISM;
PHENYTOIN;CYP2C9;rs71486745;GT/del + del/del;DOSAGE, LADME_PK;DECREASED_DOSE;DISEASE:EPILEPSY
ATENOLOL, HYDROCHLOROTHIAZIDE, METOPROLOL;SLC25A31;rs201279313;TTA/del;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME_PK;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
CAPTOPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28;DOSAGE;DECREASED_DOSE;OTHER:ADENOCARCINOMA,_OTHER:GASTROINTESTINAL_NEOPLASMS
TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;*1/*1;LADME_PK;INCREASED_METABOLISM;DISEASE:BILIARY_TRACT_NEOPLASM
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*17;*17;EFFICACY, LADME_PK;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*1;DOSAGE;INCREASED_DOSE;
TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY, LADME_PK;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED_RESPONSE;DISEASE:HEART_FAILURE
MERCAPTOPURINE;CNNM2;rs58700372;CC + CT;LADME_PK;DECREASED_METABOLISM;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
OXYCODONE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;INCREASED_DOSE;DISEASE:NEOPLASMS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*1 + *1/*17;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:HEMATOLOGIC_DISORDER
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;LADME_PK;INCREASED_CONCENTRATIONS;
FLUOROURACIL;TYMS;rs11280056;TTAAAGTTA/del;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*41 + *1/*4 + *10/*10 + *10/*41 + *2/*4 + *41/*41;EFFICACY;DECREASED_RESPONSE;DISEASE:MALARIA
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_CONCENTRATIONS;
SERTRALINE;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE;
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*4/*41 + *5/*6;LADME_PK;DECREASED_CLEARANCE;DISEASE:MALARIA
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;DOSAGE, TOXICITY;INCREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;DOSAGE, TOXICITY;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 deficiency;;LADME_PK;DECREASED_EXPOSURE;DISEASE:PAIN
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ESOMEPRAZOLE, PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
TACROLIMUS;CYP3A7;CYP3A7*1A, CYP3A7*1C;*1A/*1A;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;
KETAMINE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;DECREASED_CLEARANCE;DISEASE:NEOPLASMS,_DISEASE:PAIN
ESOMEPRAZOLE, PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
ESOMEPRAZOLE, LANSOPRAZOLE, OMEPRAZOLE, PANTOPRAZOLE, RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;
CLOMIPRAMINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME_PK;INCREASED_METABOLISM;DISEASE:CHRONIC_GRANULOMATOUS_DISEASE
CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;T;DOSAGE;DECREASED_DOSE;
ETHANOL;DRD2;rs1800497;A;DOSAGE;INCREASED_DOSE;
VARDENAFIL;CYP3A5;rs776746;TT;OTHER, LADME_PK;INCREASED_CLEARANCE;
ETHANOL;OPRM1;rs1799971;G;DOSAGE;INCREASED_DOSE;
IMATINIB;SLC22A1;rs683369;CC;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:GASTROINTESTINAL_STROMAL_TUMORS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;INCREASED_RESISTANCE;DISEASE:GASTROESOPHAGEAL_REFLUX
CAPECITABINE, FLUOROURACIL;DPYD;rs56038477;T;DOSAGE;DECREASED_DOSE;
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESISTANCE;DISEASE:GASTROESOPHAGEAL_REFLUX
ACETAMINOPHEN;UGT1A6;UGT1A6*1a, UGT1A6*2a;*2a;LADME_PK;INCREASED_CLEARANCE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;A;DOSAGE;DECREASED_DOSE;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION,_DISEASE:ATRIAL_FLUTTER,_DISEASE:VENOUS_THROMBOSIS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
METHADONE;OPRK1;rs3802281;TT;DOSAGE;DECREASED_DOSE;OTHER:HEROIN_DEPENDENCE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;
AZATHIOPRINE;TPMT;rs1142345;CT;DOSAGE;DECREASED_DOSE;OTHER:ULCERATIVE_COLITIS,_OTHER:CROHN_DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
DEBRISOQUINE;CYP2D6;CYP2D6*17;*17/*17;LADME_PK;DECREASED_METABOLISM;
TOLTERODINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3 + *4;LADME_PK;DECREASED_METABOLISM;
CITALOPRAM, MIANSERIN, MIRTAZAPINE, NORTRIPTYLINE, PAROXETINE, VENLAFAXINE;CYP2D6;CYP2D6*1xN, CYP2D6*2xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE;DISEASE:MOOD_DISORDER
SPARTEINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*10;*10/*10 + *4/*10;LADME_PK;DECREASED_METABOLISM;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:AUTOIMMUNE_DISEASES
HYDROXYUREA;SIN3A;rs7166737;GG;EFFICACY;DECREASED_RESPONSE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:HELICOBACTER_INFECTIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;DECREASED_METABOLISM;OTHER:HYPERTENSION
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6;LADME_PK;INCREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799964;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:SPONDYLITIS,_ANKYLOSING
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;INCREASED_RESPONSE;
VENLAFAXINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM;
CAPECITABINE, RALTITREXED;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*1;DOSAGE;INCREASED_DOSE;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
VENLAFAXINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM;OTHER:ELDERLY_ADULT
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE;DISEASE:ATRIAL_FIBRILLATION,_DISEASE:VENOUS_THROMBOEMBOLISM
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;G/TT + TT/TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
VENLAFAXINE;CYP2D6;CYP2D6 normal metabolizer;;LADME_PK;DECREASED_METABOLISM;OTHER:ELDERLY_ADULT
DEBRISOQUINE, SPARTEINE;CYP2D6;CYP2D6*3, CYP2D6*4;*4/*4 + *3/*4;LADME_PK;DECREASED_METABOLISM;
ESCITALOPRAM;CYP2C19;CYP2C19 normal metabolizer;;LADME_PK;DECREASED_METABOLISM;OTHER:ELDERLY_ADULT
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;TOXICITY;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME_PK;DECREASED_CONCENTRATIONS;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;LADME_PK;INCREASED_CONCENTRATIONS;
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;DECREASED_CLEARANCE;DISEASE:LYMPHOMA,_B-CELL
SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;OTHER:POSTTRAUMATIC_STRESS_DISORDER
MIDAZOLAM;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:GASTROINTESTINAL_NEOPLASMS
BUPROPION;HTR2A;rs2770296;CC;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
CAPECITABINE, FLUOROURACIL;HLA-G;rs371194629;ATTTGTTCATGCCT/ATTTGTTCATGCCT + ATTTGTTCATGCCT/del;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
VORICONAZOLE;CYP2C19;CYP2C19;ultrarapid_metabolizer;LADME_PK;DECREASED_CONCENTRATIONS;
VORICONAZOLE;CYP2C19;CYP2C19;poor_metabolizer;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:FUNGAL_INFECTIOUS_DISEASE
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;DECREASED_METABOLISM;OTHER:NEOPLASMS
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;DECREASED_METABOLISM;OTHER:NEOPLASMS
PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:MYOCARDIAL_INFARCTION
FLUVOXAMINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*3 + *3/*3;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
DONEPEZIL;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM;DISEASE:ALZHEIMER_DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
FLUOXETINE;ABCB1;rs2032582;A;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4/*4 + *4/*5;LADME_PK;DECREASED_CONCENTRATIONS;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_EXPOSURE;OTHER:KIDNEY_TRANSPLANTATION
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
COLCHICINE;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*1;EFFICACY;INCREASED_RESPONSE;DISEASE:FAMILIAL_MEDITERRANEAN_FEVER
FLUOXETINE, SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*1/*4 + *4/*4 + *4/*7 + *4/*9;LADME_PK;DECREASED_METABOLISM;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
AZATHIOPRINE;GSTM1;GSTM1 non-null, GSTM1 null;;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ULCERATIVE_COLITIS,_OTHER:CROHN_DISEASE
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10;*4/*10 + *5/*10;LADME_PK;DECREASED_METABOLISM;
OXYCODONE;CYP2D6;CYP2D6*4;*4;LADME_PK;INCREASED_CONCENTRATIONS;
NILOTINIB;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*27, UGT1A1*28;*6/*6 + *6/*28;DOSAGE;DECREASED_DOSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *1/*5 + *2/*5;DOSAGE;DECREASED_DOSE;
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;DECREASED_CLEARANCE;DISEASE:OPIOID-RELATED_DISORDERS
BUPROPION;DBH;rs2873804;CC;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:RHEUMATOID_ARTHRITIS,_DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_RESPONSE;DISEASE:NEOPLASM_OF_ESOPHAGUS,_DISEASE:STOMACH_NEOPLASMS
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;DECREASED_METABOLISM;OTHER:HYPERTENSION
PACLITAXEL, PLATINUM COMPOUNDS;GSTM1;GSTM1 non-null, GSTM1 null;non-null;EFFICACY;DECREASED_RESPONSE;DISEASE:OVARIAN_NEOPLASMS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3, CYP2C9*13;*3/*13;DOSAGE;DECREASED_DOSE;
BLEOMYCIN, DACARBAZINE, DOXORUBICIN, VINBLASTINE;GSTM1;GSTM1 non-null, GSTM1 null;non-null/non-null;EFFICACY;INCREASED_RESPONSE;DISEASE:HODGKIN_DISEASE
METHADONE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;DECREASED_CONCENTRATIONS;
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE;
S-EDDP;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_CONCENTRATIONS;
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;DECREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ENALAPRIL, LISINOPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HYPERTENSION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
BUPROPION;SLC18A2;rs363225;CC;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
RALTEGRAVIR;UGT1A9;UGT1A9*3a;*3a;LADME_PK;INCREASED_EXPOSURE;DISEASE:HIV_INFECTIOUS_DISEASE
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*9;*1/*2 + *1/*9;LADME_PK;DECREASED_METABOLISM;
SERTRALINE;CYP2C18;rs2860840;TT;LADME_PK;DECREASED_CONCENTRATIONS;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DOSE;DISEASE:HEART_DISEASES
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;DISEASE:RHEUMATIC_HEART_DISEASE
ARIPIPRAZOLE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOAFFECTIVE_DISORDER,_DISEASE:SCHIZOPHRENIA
4-HYDROXYTAMOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*22;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
TAMOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*22;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RESPONSE;OTHER:RECTAL_NEOPLASMS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_CONCENTRATIONS;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*14;*1/*14;DOSAGE;DECREASED_DOSE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:FUNGAL_INFECTIOUS_DISEASE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:SPONDYLITIS,_ANKYLOSING
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;
ACETYLCYSTEINE;EPHX1;EPHX1;poor_metabolizer;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE
BUPROPION;SLC18A2;rs363226;GG;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;
METHOTREXATE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ISONIAZID;NAT2;NAT2*4;*4;LADME_PK;INCREASED_METABOLISM;DISEASE:TUBERCULOSIS
LEVODOPA, METHYLPHENIDATE;SLC6A3;rs3836790;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;EFFICACY;INCREASED_RESPONSE;DISEASE:PARKINSON_DISEASE
ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*29, CYP2D6*41;*4/*4xN + *4/*4;LADME_PK;DECREASED_CLEARANCE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:HEART_DISEASES
LEVODOPA;SLC6A3;rs3836790;ACATACACACTCAGACACACATACCATGCA/ACATACACACTCAGACACACATACCATGCA;EFFICACY;INCREASED_RESPONSE;DISEASE:PARKINSON_DISEASE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*3;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:HEART_DISEASES
FLUOROURACIL;DPYD;DPYD deficiency;;LADME_PK;CLEARANCE;DISEASE:HEAD_AND_NECK_NEOPLASMS
ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*41;*4/*4xN + *4/*4;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
BUPROPION;FKBP5;rs17614642;TT;EFFICACY;DECREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:HEART_DISEASES
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:HEART_DISEASES
INTERFERON BETA-1A;ACE;rs1799752;del/del;EFFICACY;DECREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
ETHANOL;OPRM1;rs1799971;AG;EFFICACY;INCREASED_RESPONSE;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;
WARFARIN;EPHX1;rs2260863;CG;DOSAGE;INCREASED_DOSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LUNG_TRANSPLANTATION
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;DISEASE:ESOPHAGITIS,_DISEASE:GASTROESOPHAGEAL_REFLUX
LOSARTAN;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
TACROLIMUS;CYP3A4;rs35599367;GG;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
THALIDOMIDE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;DOSAGE;INCREASED_DOSE;DISEASE:ERYTHEMA_NODOSUM,_DISEASE:LEPROSY
CARVEDILOL;CYP2D6;CYP2D6*10;*10;LADME_PK;DECREASED_METABOLISM;DISEASE:ANGINA_PECTORIS
EFAVIRENZ;CYP2B6;CYP2B6*1;*1/*1;LADME_PK;INCREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE, LADME_PK;DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;OTHER:ATRIAL_FIBRILLATION,_OTHER:PULMONARY_EMBOLISM,_OTHER:VENOUS_THROMBOSIS
WARFARIN;CYP2C9;CYP2C9*8;*8;DOSAGE, LADME_PK;DOSE;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;INCREASED_METABOLISM;DISEASE:FUNGAL_INFECTIOUS_DISEASE
DIHYDROCODEINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;DECREASED_METABOLISM;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*1 + *1/*3 + *1/*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
NICOTINE;CYP2A6;CYP2A6 low activity;;DOSAGE;DECREASED_DOSE;DISEASE:TOBACCO_USE_DISORDER
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;DECREASED_METABOLISM;DISEASE:FUNGAL_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;DOSAGE;DECREASED_DOSE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:FUNGAL_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;
IMATINIB;CYP3A5;rs776746;CC;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE:GASTROESOPHAGEAL_REFLUX
PACLITAXEL;SLCO1B1;SLCO1B1*5, SLCO1B1*15;*5 + *15;LADME_PK;INCREASED_EXPOSURE;DISEASE:BREAST_NEOPLASMS
IMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3 + *2/*2;LADME_PK;DECREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;INCREASED_METABOLISM;DISEASE:GASTROESOPHAGEAL_REFLUX
LAMOTRIGINE;UGT2B7;rs7668258;CC;DOSAGE, LADME_PK;INCREASED_CLEARANCE;
RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME_PK;INCREASED_METABOLISM;DISEASE:GASTROESOPHAGEAL_REFLUX
BUPRENORPHINE;UGT2B7;UGT2B7;*2;EFFICACY;DECREASED_RESPONSE;DISEASE:PAIN
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;DOSAGE;INCREASED_DOSE;DISEASE:FUNGAL_INFECTIOUS_DISEASE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:FUNGAL_INFECTIOUS_DISEASE
IMATINIB;ABCB1;rs1045642;AG;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:FUNGAL_INFECTIOUS_DISEASE
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME_PK;CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEPATITIS_C_VIRUS_INFECTION,_DISEASE:LYMPHOMA,_DISEASE:SHOCK,_SEPTIC
NELFINAVIR;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;DECREASED_METABOLISM;
HYDROXYBUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME_PK;DECREASED_CONCENTRATIONS;
NELFINAVIR;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:PANCREATIC_NEOPLASMS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*18, CYP2B6*22;*1/*6 + *1/*18;LADME_PK;DECREASED_METABOLISM;DISEASE:TOBACCO_USE_DISORDER
IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*18, CYP2B6*22;*6/*6 + *6/*18;LADME_PK;DECREASED_METABOLISM;DISEASE:TOBACCO_USE_DISORDER
IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;CTT/del;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
WARFARIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
WARFARIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*1 + *1/*3 + *1/*6;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ATOMOXETINE;CYP2D6;CYP2D6;poor_metabolizer;DOSAGE;DECREASED_DOSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
GEMCITABINE;CDA;rs60369023;A;OTHER, LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;ABCB1;rs1045642;GG;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:THROMBOEMBOLISM
ATAZANAVIR;NR1I2;rs2472677;TT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
IMATINIB;ABCB1;rs2032582;A;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
ANTIDEPRESSANTS;FKBP5;rs1360780;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
IMATINIB;ABCB1;rs1128503;A;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
TACROLIMUS;CYP3A5;rs776746;TT;LADME_PK;INCREASED_METABOLISM;DISEASE:LIVER_TRANSPLANTATION
ANTIDEPRESSANTS;GNB3;rs5443;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
IMATINIB;ABCB1;rs1045642;A;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
ANTIDEPRESSANTS;FKBP5;rs3800373;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;
METHADONE;OPRK1;rs963549;CC;DOSAGE;DECREASED_DOSE;OTHER:HEROIN_DEPENDENCE
ANTIPSYCHOTICS;ABCB1;rs1128503;AA;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:SCHIZOPHRENIA
IMATINIB;ABCG2;rs2231142;T;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;EFFICACY;DECREASED_RESISTANCE;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;PPARA;rs4823613;G;LADME_PK;DECREASED_METABOLISM;OTHER:KIDNEY_TRANSPLANTATION
INFLIXIMAB;SLCO1C1;rs3794271;G;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
TACROLIMUS;POR;rs1057868;T;LADME_PK;INCREASED_METABOLISM;OTHER:KIDNEY_TRANSPLANTATION
DALCETRAPIB;ADCY9;rs1967309;AA;EFFICACY;INCREASED_RESPONSE;
ANTIDEPRESSANTS;BDNF;rs6265;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
BETA BLOCKING AGENTS, FLECAINIDE;ADRB1;rs1801253;G;EFFICACY;DECREASED_RESPONSE;DISEASE:TACHYCARDIA
METHOTREXATE;ABCC2;rs717620;T;LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
RITUXIMAB;FCGR3A;rs396991;AA;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:NEUROMYELITIS_OPTICA
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*18;*18;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
DRUGS USED IN ALCOHOL DEPENDENCE;GATA4;rs13273672;CC;EFFICACY;DECREASED_CLINICAL BENEFIT;DISEASE:ALCOHOL_ABUSE
CHORIONIC GONADOTROPIN;FSHR;rs6166;CC;DOSAGE;INCREASED_DOSE;
BEPRIDIL;CYP2D6;CYP2D6*10;*10;LADME_PK;INCREASED_CLEARANCE;DISEASE:CARDIAC_RHYTHM_DISEASE
TACROLIMUS;CYP3A4;rs35599367;GG;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
NICARDIPINE, NIMODIPINE;CACNA1B;rs2739260;AG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BIPOLAR_DISORDER
CITALOPRAM, ESCITALOPRAM;GLDC;rs10975641;G;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DOSE;OTHER:A_STABLE_MAINTENANCE_DOSE
CORTISONE ACETATE;CYP3A7;CYP3A7*1A, CYP3A7*1C;*1C;DOSAGE;DECREASED_DOSE;DISEASE:ADRENAL_HYPERPLASIA,_CONGENITAL
DAUNORUBICIN;G6PD;G6PD A- 202A_376G;A-202A_376G;LADME_PK;DECREASED_METABOLISM;
TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7;*4/*4 + *4/*7 + *7/*7;LADME_PK;DECREASED_CLEARANCE;DISEASE:NEOPLASMS
EFAVIRENZ;CYP2A6;CYP2A6*2;*2;OTHER, LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE, EFFICACY;DECREASED_DOSE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE;OTHER:A_STABLE_MAINTENANCE_DOSE
METFORMIN;HNF1B;rs11868513;AA + AG;EFFICACY;INCREASED_RESPONSE;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;
ATORVASTATIN;CYP3A4;rs2242480;C/C;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
GLATIRAMER ACETATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;EFFICACY;DECREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE, LADME_PK;DECREASED_CLEARANCE;DISEASE:CARDIOVASCULAR_DISEASE
WARFARIN;CYP2C9;CYP2C9*1;*1/*1;DOSAGE, LADME_PK;INCREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*3;*3;LADME_PK;DECREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*1 + *1/*17 + *2/*17 + *3/*17;EFFICACY;INCREASED_RESPONSE;DISEASE:ANGINA_PECTORIS
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
ATORVASTATIN;CYP3A4;rs2242480;C/C;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
DIAZEPAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;OTHER, LADME_PK;DECREASED_METABOLISM;
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, INTERFERONS, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IL18;rs1946518;T;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
FLUOXETINE, PAROXETINE;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
VENLAFAXINE;CYP2D6;CYP2D6*4;*4/*4;LADME_PK;DECREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;EFFICACY;INCREASED_RESPONSE;
THIOGUANOSINE DIPHOSPHATE, THIOGUANOSINE MONOPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT;TPMT;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:INFLAMMATORY_BOWEL_DISEASES
COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*12;*12;OTHER, LADME_PK;DECREASED_METABOLISM;
VALPROIC ACID;CYP2A6;CYP2A6*1, CYP2A6*4;*4;LADME_PK;DECREASED_METABOLISM;DISEASE:EPILEPSY
TEGAFUR;CYP2A6;CYP2A6*4;*4;LADME_PK;DECREASED_METABOLISM;DISEASE:STOMACH_NEOPLASMS
TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4;*4;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*7;*1/*7;LADME_PK;DECREASED_METABOLISM;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;DOSAGE;DECREASED_DOSE;OTHER:A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_OF_BETWEEN_TWO_AND_THREE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2/*2;DOSAGE;DECREASED_DOSE;OTHER:A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_OF_BETWEEN_TWO_AND_THREE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
WARFARIN;CYP4F2;CYP4F2*1, CYP4F2*3;*3/*3;DOSAGE;INCREASED_DOSE;OTHER:A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_OF_BETWEEN_TWO_AND_THREE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*3;DOSAGE;DECREASED_DOSE;OTHER:A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_OF_BETWEEN_TWO_AND_THREE
PACLITAXEL;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
CAFFEINE;CYP2A6;CYP2A6*1, CYP2A6*7, CYP2A6*10, CYP2A6*11;*7 + *10 + *11;OTHER, LADME_PK;DECREASED_METABOLISM;
CAFFEINE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*9;*1/*4 + *1/*9 + *4/*4 + *4/*9;OTHER, LADME_PK;DECREASED_METABOLISM;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE, LADME_PK;DECREASED_DOSE;DISEASE:THROMBOEMBOLISM
TOCILIZUMAB;IL6R;rs4845625;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
ATORVASTATIN;CYP3A4;rs2242480;T/T;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:CARDIOVASCULAR_DISEASE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;OTHER, LADME_PK;DECREASED_CLEARANCE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;OTHER, LADME_PK;DECREASED_CLEARANCE;
LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*26;*1/*26;LADME_PK;METABOLISM;DISEASE:BREAST_NEOPLASMS
LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*35;*1/*35;;METABOLISM;DISEASE:BREAST_NEOPLASMS
MIRTAZAPINE;CYP2B6;CYP2B6*6;*6/*6;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
METHOTREXATE;SLC19A1;rs1051266;CT;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE, LADME_PK;DECREASED_CLEARANCE;DISEASE:CARDIOVASCULAR_DISEASE
WARFARIN;CYP2C9;CYP2C9*2;*2;LADME_PK;DECREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, INTERFERONS, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IL18;rs187238;C;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;DECREASED_METABOLISM;OTHER:HUMAN_LIVER_MICROSOMES
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*1;DOSAGE;INCREASED_DOSE;
ISONIAZID;NAT2;NAT2*4;*4/*4;LADME_PK;INCREASED_METABOLISM;DISEASE:TUBERCULOSIS
ISONIAZID;NAT2;NAT2*4;*4/*4;LADME_PK;INCREASED_METABOLISM;DISEASE:TUBERCULOSIS
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
ACENOCOUMAROL;CYP2C9;CYP2C9*1;*1/*1;DOSAGE;INCREASED_DOSE;
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME_PK;TROUGH CONCENTRATION;
LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE:KIDNEY_DISORDER
TROPISETRON;CYP2D6;CYP2D6*3;*3/*3;EFFICACY;DECREASED_METABOLISM;DISEASE:NEOPLASMS
LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2;EFFICACY;DECREASED_RESPONSE;DISEASE:KIDNEY_DISORDER
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;DECREASED_RESPONSE;DISEASE:MYOCARDIAL_ISCHEMIA
TACROLIMUS;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
METOPROLOL;CYP2D6;CYP2D6*10;*10;LADME_PK;DECREASED_CLEARANCE;
SIMVASTATIN;CYP3A4;CYP3A4*1, CYP3A4*4;*1/*4;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;LADME_PK;DECREASED_METABOLISM;
ONDANSETRON;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2xN;*1xN + *2xN;EFFICACY;DECREASED_RESPONSE;
PHENPROCOUMON;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_DOSE;
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
DEBRISOQUINE;CYP2D6;CYP2D6*2xN;*2xN;LADME_PK;INCREASED_METABOLISM;
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
CARVEDILOL;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;LADME_PK;DECREASED_CLEARANCE;DISEASE:HEART_DISEASES
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:GASTROESOPHAGEAL_REFLUX
CARVEDILOL;CYP2D6;CYP2D6*4, CYP2D6*5, CYP2D6*6;*4/*5 + *4/*6;DOSAGE;INCREASED_DOSE;DISEASE:HEART_FAILURE
CLOPIDOGREL;CYP2C19;CYP2C19*1;*1/*1;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
OMEPRAZOLE, PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
CARVEDILOL;CYP2D6;CYP2D6*10;*10/*10;LADME_PK;DECREASED_CLEARANCE;DISEASE:HEART_DISEASES
CARVEDILOL;CYP2D6;CYP2D6*1, CYP2D6*5;*1/*5;LADME_PK;DECREASED_CLEARANCE;DISEASE:HEART_DISEASES
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*3;*3;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
FLUOXETINE;CYP2D6;rs3892097;CC;EFFICACY;INCREASED_RESPONSE;EFFICACY:ALCOHOL_ABUSE,_EFFICACY:MAJOR_DEPRESSIVE_DISORDER
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
SUFENTANIL;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
METFORMIN;;rs6719578;CG;EFFICACY;INCREASED_RESPONSE;
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;EFFICACY, LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
AMITRIPTYLINE;CYP2D6;CYP2D6*4;*4/*4;TOXICITY, LADME_PK;DECREASED_CLEARANCE;OTHER:ONE_SUICIDE_CASE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
METHOTREXATE;ATIC;rs4673993;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCER
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
CLOPIDOGREL;CYP2C19;CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE;DISEASE:CARDIOVASCULAR_DISEASE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;DECREASED_METABOLISM;
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *2/*3;DOSAGE;DECREASED_DOSE;
HYDROMORPHONE, KETOROLAC, MORPHINE, OPIOIDS, OXYCODONE;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;DECREASED_RESPONSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE;
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*22;*1/*22;LADME_PK;INCREASED_METABOLISM;
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;DECREASED_METABOLISM;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_DOSE;
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;CYP2C9*1;*1/*1;DOSAGE, LADME_PK;INCREASED_DOSE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2;DOSAGE;DECREASED_DOSE;DISEASE:CYSTIC_FIBROSIS,_DISEASE:LUNG_TRANSPLANTATION
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE:PANIC_DISORDER
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;
FLUOXETINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
HYDRALAZINE;NAT2;NAT2;slow_acetylator;LADME_PK;DECREASED_METABOLISM;OTHER:HYPERTENSION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY, TOXICITY;DECREASED_RESPONSE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;HLA-A;HLA-A*01:01;*01:01;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
CITALOPRAM, FLUOXETINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
ACENOCOUMAROL;VKORC1;rs104894542;AC + CC;DOSAGE;INCREASED_DOSE;
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;
MEPHENYTOIN;CYP2C19;rs28399504;G;LADME_PK;DECREASED_METABOLISM;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*5;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3 + *3/*3 + *2/*2;DOSAGE;DECREASED_DOSE;
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:EPILEPSY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2 + *2/*2;DOSAGE;DECREASED_DOSE;
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;
LAMIVUDINE, NEVIRAPINE, STAVUDINE;HLA-B;HLA-B*40:01;*40:01;EFFICACY;RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *3/*3;DOSAGE;DECREASED_DOSE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;INCREASED_CONCENTRATIONS;
BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*60;*1/*60 + *60/*60;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:NEOPLASMS
BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*60;*1/*60 + *60/*60;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10;*2/*2 + *2/*10 + *1/*3 + *1/*4 + *2/*4 + *5/*10 + *4/*4 + *3/*4;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
BOCEPREVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*11;*2 + *3 + *5 + *6 + *11;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;
ACENOCOUMAROL, PHENPROCOUMON;CYP2C19;CYP2C19*2, CYP2C19*3;*2 + *3;DOSAGE;DOSE;
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DOSE;DISEASE:STROKE
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DOSE;
COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*6;*6;LADME_PK;DECREASED_METABOLISM;
ECULIZUMAB;C5;rs56040400;CT;EFFICACY;DECREASED_RESPONSE;OTHER:PAROXYSMAL_NOCTURNAL_HEMOGLOBINURIA
DEFERASIROX;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ANEMIA
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DOSE;
CLOPIDOGREL, PRASUGREL, TICAGRELOR;CYP2C19;rs4244285;A;EFFICACY;RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
WARFARIN;CYP2C9;rs9332131;A;DOSAGE;DOSE;
WARFARIN;CYP2C9;rs28371685;C;DOSAGE;DOSE;
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;EFFICACY;INCREASED_RESISTANCE;DISEASE:ACUTE_CORONARY_SYNDROME,_DISEASE:STROKE
VALPROIC ACID;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;DOSAGE;DECREASED_DOSE;DISEASE:BIPOLAR_DISORDER,_DISEASE:PSYCHOTIC_DISORDER
WARFARIN;POR;rs41301394;CT + TT;DOSAGE;INCREASED_DOSE;
METHADONE;DRD2;rs6275;AA + AG;;INCREASED_DOSE;OTHER:TREATMENT_FOR_HEROIN_ADDICTION
CARBOPLATIN, PACLITAXEL;GSTP1;rs1695;G;TOXICITY;DECREASED_RESPONSE;OTHER:OVARIAN_NEOPLASMS
VORICONAZOLE;CYP2C19;CYP2C19;ultrarapid_metabolizer;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:FUNGAL_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;DOSAGE;DECREASED_DOSE;DISEASE:COLORECTAL_NEOPLASMS
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;DECREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*1;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
CISPLATIN;MIR335;rs3807348;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER:MESOTHELIOMA
HYDROCODONE;CYP2D6;CYP2D6*2, CYP2D6*41;*2/*41;LADME_PK;INCREASED_CONCENTRATIONS;
CYCLOPHOSPHAMIDE, DOXORUBICIN;ALDH1A1;rs6151031;CTGGTGAGGAGAGAACC/del;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
BUPRENORPHINE, METHADONE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
DESVENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;VKORC1 low activity;;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE;DECREASED_DOSE;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2 + *2/*17;EFFICACY;DECREASED_RESPONSE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17;LADME_PK;DECREASED_METABOLISM;DISEASE:FUNGAL_INFECTIOUS_DISEASE
CLOMIPRAMINE;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*5;LADME_PK;DECREASED_METABOLISM;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:LIVER_TRANSPLANTATION
CLOZAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;DOSAGE;DECREASED_CONCENTRATIONS;DISEASE:SCHIZOAFFECTIVE_DISORDER,_DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;OTHER:HEART_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;DECREASED_TROUGH CONCENTRATION;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
SIROLIMUS, TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:HEART_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:ULCERATIVE_COLITIS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
CARBAMAZEPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:EPILEPSY
FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:NEOPLASMS,_DISEASE:PAIN
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE;DISEASE:PAIN,_POSTOPERATIVE
MIDAZOLAM;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_METABOLISM;DISEASE:NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_METABOLISM;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
CYCLOSPORINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
FENTANYL;CYP2D6;CYP2D6*1, CYP2D6*9;*9;LADME_PK;DECREASED_CLEARANCE;OTHER:BURNS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
SIMVASTATIN;F3;rs3917643;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:MYOCARDIAL_ISCHEMIA
IVACAFTOR / LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
FLUVASTATIN;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
IVACAFTOR;CFTR;rs113993960;CTT/del;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
ENALAPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del + del/del;EFFICACY;INCREASED_RESPONSE;DISEASE:ARTERIOSCLEROSIS
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
IMATINIB;CYP3A5;rs776746;C;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;DOSAGE;DECREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
FENTANYL, MEPERIDINE, MIDAZOLAM;CYP3A5;CYP3A5;poor_metabolizer;LADME_PK;DECREASED_DOSE;OTHER:SEDATION
FENTANYL, MEPERIDINE, MIDAZOLAM;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;LADME_PK;DECREASED_DOSE;OTHER:SEDATION
FENTANYL, MEPERIDINE, MIDAZOLAM;UGT1A1;UGT1A1;poor_metabolizer;LADME_PK;DECREASED_DOSE;OTHER:SEDATION
BELZUTIFAN;UGT2B17;UGT2B17;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:VON_HIPPEL-LINDAU_DISEASE,_OTHER:RENAL_CELL_CARCINOMA
BELZUTIFAN;CYP2C19;CYP2C19;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:VON_HIPPEL-LINDAU_DISEASE,_OTHER:RENAL_CELL_CARCINOMA
TACROLIMUS;CYP3A4;rs35599367;AG;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:PAIN
4-HYDROXYTAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
TAMSULOSIN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;*1/*4 + *4/*10;EFFICACY;INCREASED_CLINICAL BENEFIT;
IMATINIB;CYP3A4;rs2242480;C;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
FULVESTRANT;CYP2C9;CYP2C9;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS,_OTHER:METASTATIC_NEOPLASM
ANASTROZOLE;CYP2C9;CYP2C9;intermediate_metabolizer;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS,_OTHER:METASTATIC_NEOPLASM
ANASTROZOLE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS,_OTHER:METASTATIC_NEOPLASM
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_DOSE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LEUKEMIA
ABATACEPT;HLA-DRB1;HLA-DRB1*04:05;*04:05;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
ETANERCEPT;SLCO1C1;rs3794271;G;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
APATINIB;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_CLEARANCE;OTHER:NEOPLASMS
ESCITALOPRAM;CYP2C19;CYP2C19;rapid_metabolizer;LADME_PK;INCREASED_CLEARANCE;
ESCITALOPRAM;CYP2C19;CYP2C19;poor_metabolizer;LADME_PK;DECREASED_CLEARANCE;
SERTRALINE;CYP2C19;CYP2C19;poor_metabolizer;LADME_PK;DECREASED_CLEARANCE;
DULOXETINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;
AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;VDR;rs7975232;A;EFFICACY;INCREASED_RESPONSE;OTHER:HELICOBACTER_INFECTIONS
AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;VDR;rs2228570;A;EFFICACY;INCREASED_RESPONSE;OTHER:HELICOBACTER_INFECTIONS
BUPROPION, NALTREXONE;ANKK1, DRD2;rs1800497;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER:OBESITY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE;OTHER:HEART_TRANSPLANTATION
RISPERIDONE;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:AUTISM_SPECTRUM_DISORDER
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*1;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
DOCETAXEL, THALIDOMIDE;PPARD;rs6922548;G;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
SN-38;UGT1A1;UGT1A1*1, UGT1A1*6;*6;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:RECTAL_NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1;*1;LADME_PK;INCREASED_TIME TO RESPONSE;OTHER:KIDNEY_TRANSPLANTATION
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:PAIN,_POSTOPERATIVE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
NALDEMEDINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:NEOPLASMS,_OTHER:PAIN,_OTHER:CONSTIPATION
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*41, CYP2D6*65;*10/*10 + *10/*65 + *10/*41;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
DOCETAXEL, THALIDOMIDE;PPARD;rs7769719;G;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;TT;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;NEDD4;rs2288344;G;DOSAGE;INCREASED_DOSE;
QUETIAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;DECREASED_CLEARANCE;OTHER:BIPOLAR_DISORDER
TACROLIMUS;CYP3A5;rs776746;TT;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;DDHD1;rs17126068;G;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;CYP3A5;intermediate_metabolizer;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LUNG_TRANSPLANTATION
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
DESVENLAFAXINE, VENLAFAXINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_EXPOSURE;OTHER:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;rs776746;CT;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
SALBUTAMOL;;rs7903366;T;EFFICACY;DECREASED_RESPONSE;OTHER:ASTHMA
PRAZIQUANTEL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3;LADME_PK;INCREASED_EXPOSURE;OTHER:SCHISTOSOMIASIS
LOSARTAN;CYP2C9;rs1057910;C;LADME_PK;DECREASED_METABOLISM;PK:NO_DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY;DECREASED_RESPONSE;DISEASE:STROKE
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME_PK;INCREASED_EXPOSURE;DISEASE:BIPOLAR_DISORDER,_DISEASE:DEPRESSION,_DISEASE:PSYCHOTIC_DISORDER,_DISEASE:SUBSTANCE-RELATED_DISORDERS
ISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;LADME_PK;DECREASED_METABOLISM;DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS
ISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *6/*6 + *6/*7 + *7/*7;LADME_PK;DECREASED_METABOLISM;DISEASE:TUBERCULOSIS
SALBUTAMOL;;rs7081864;A;EFFICACY;DECREASED_RESPONSE;OTHER:ASTHMA
SULFINPYRAZONE;UGT1A9;rs72551330;T;LADME_PK;INCREASED_METABOLISM;
SULFAMETHOXAZOLE;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*4/*4;LADME_PK;INCREASED_METABOLISM;OTHER:KIDNEY_TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;rs1051792;AA;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:SPONDYLARTHROPATHIES
WARFARIN;VKORC1;rs9923231;GG;DOSAGE;INCREASED_DOSE;OTHER:ATRIAL_FIBRILLATION,_OTHER:PULMONARY_EMBOLISM,_OTHER:VENOUS_THROMBOSIS
METHADONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*2xN;*1/*2xN + *2/*2xN;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:OPIOID-RELATED_DISORDERS
LITHIUM;GSK3B;rs6438552;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
TACROLIMUS;ABCB1;rs1045642;AA;DOSAGE;DECREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
LITHIUM;NR1D1, THRA;rs2071427;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
TACROLIMUS;CYP3A5;CYP3A5 poor metabolizers;;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
MORPHINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME_PK;DECREASED_EXPOSURE;
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ARIPIPRAZOLE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:PSYCHOTIC_DISORDER
ATOMOXETINE;CYP2C19;CYP2C19 poor metabolizers;;LADME_PK;INCREASED_CONCENTRATIONS;
CAFFEINE;NAT2;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*16;*4/*5 + *1/*16 + *4/*6 + *4/*7;LADME_PK;INCREASED_METABOLISM;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:HEART_TRANSPLANTATION
ISONIAZID;NAT2;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G, NAT2*39;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME_PK;DECREASED_CLEARANCE;DISEASE:TUBERCULOSIS
TACROLIMUS;ABCB1;rs1045642;GG;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
INFLIXIMAB;HLA-DQA1;HLA-DQA1*05;*05;EFFICACY;INCREASED_DISCONTINUATION;EFFICACY:CROHN_DISEASE
TACROLIMUS;ABCB1;rs1045642;AA;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
ENZYME INHIBITORS;CYP19A1;rs700518;CC;OTHER;RESPONSE;DISEASE:BREAST_NEOPLASMS
TACROLIMUS;ABCB1;rs1128503;AA;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
CORTICOSTEROIDS;FCER2;rs28364072;G;DOSAGE;INCREASED_DOSE;DISEASE:ASTHMA
TACROLIMUS;ABCB1;rs2032582;AA;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
ISONIAZID;NAT2;NAT2*1, NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *6 + *7 + *14;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;ABCB1;rs1045642;AG + GG;LADME_PK;INCREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
HYDRALAZINE;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*4/*16 + *4/*6 + *4/*7;LADME_PK;INCREASED_METABOLISM;OTHER:HYPERTENSION,_OTHER:PREGNANCY
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4, CYP2D6*59;*4/*59;LADME_PK;DECREASED_METABOLISM;
HALOPERIDOL;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:PSYCHOTIC_DISORDER
ESCITALOPRAM;;rs12154537;G;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
MORPHINE;ABCB1;rs1128503;AG + GG;LADME_PK;DECREASED_CONCENTRATIONS;
ISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16, NAT2*19;*4/*4;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:TUBERCULOSIS
DOCETAXEL;SLCO1B3;rs11045585;G;OTHER, LADME_PK;DECREASED_CLEARANCE;DISEASE:NASOPHARYNGEAL_NEOPLASMS
DOCETAXEL;SLCO1B3;rs7311358;A;OTHER, LADME_PK;DECREASED_CLEARANCE;DISEASE:NASOPHARYNGEAL_NEOPLASMS
DOCETAXEL;SLCO1B3;rs4149118;G;OTHER, LADME_PK;DECREASED_CLEARANCE;DISEASE:NASOPHARYNGEAL_NEOPLASMS
CAFFEINE;NAT2;NAT2*5, NAT2*6, NAT2*7, NAT2*16, NAT2*34;*16/*5 + *5/*5 + *5/*6 + *5/*34 + *5/*7 + *6/*6 + *6/*7;LADME_PK;DECREASED_METABOLISM;
ISONIAZID;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*7G;*5/*7 + *5/*5 + *5/*6 + *5/*6J + *5/*7G + *6/*7;LADME_PK;DECREASED_METABOLISM;DISEASE:TUBERCULOSIS
WARFARIN;VKORC1;rs9934438;A;DOSAGE, LADME_PK;DECREASED_DOSE;
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:HEART_TRANSPLANTATION
MIDAZOLAM;VDR;rs1544410;C;LADME_PK;INCREASED_CLEARANCE;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;KLRC4;rs1154831;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SPONDYLARTHROPATHIES
TACROLIMUS;CYP3A5;CYP3A5*1;*1;DOSAGE;INCREASED_DOSE;OTHER:LUNG_TRANSPLANTATION
ESCITALOPRAM;CYP2C19;CYP2C19;intermediate_metabolizer;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:DEPRESSION,_OTHER:ANXIETY_DISORDERS
METHADONE;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;EFFICACY;DECREASED_RESPONSE;OTHER:HEROIN_DEPENDENCE
FLUOXETINE;CYP2D6;CYP2D6;ultrarapid_metabolizer;EFFICACY;DECREASED_CLINICAL BENEFIT;EFFICACY:MAJOR_DEPRESSIVE_DISORDER,_EFFICACY:OBSESSIVE-COMPULSIVE_DISORDER
HYDRALAZINE;NAT2;NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *7/*6;EFFICACY;INCREASED_RESPONSE;OTHER:RESISTANT_HYPERTENSION
ISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TUBERCULOSIS
ACETYLISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16/*14 + *16/*16 + *16/*6 + *16/*7 + *6/*14 + *6/*6 + *6/*7;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:TUBERCULOSIS
ACETAMINOPHEN;CYP2D6;CYP2D6*10;*10;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PATENT_DUCTUS_ARTERIOSUS
BUPROPION;CYP2B6;CYP2B6*6;*6;LADME_PK;INCREASED_EXPOSURE;OTHER:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;rs7294;T;DOSAGE, LADME_PK;INCREASED_DOSE;
PARAMETHOXYMETHAMPHETAMINE;CYP2D6;CYP2D6 normal metabolizer genotype;;LADME_PK;INCREASED_METABOLISM;DISEASE:SUBSTANCE-RELATED_DISORDERS
VORICONAZOLE;CYP2C19;CYP2C19 intermediate metabolizers;*1/*2 + *1/*3 + *2/*17;LADME_PK;INCREASED_CONCENTRATIONS;
MARAVIROC;CYP3A5;CYP3A5 intermediate metabolizers;;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;DECREASED_RESPONSE;
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:FUNGAL_INFECTIOUS_DISEASE
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17;LADME_PK;INCREASED_EXPOSURE;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
NORTRIPTYLINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;LADME_PK;INCREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
HALOPERIDOL, OLANZAPINE, PERPHENAZINE, QUETIAPINE, RISPERIDONE;DRD2;rs1799978;C;EFFICACY;INCREASED_RESISTANCE;OTHER:SCHIZOPHRENIA
MARAVIROC;CYP3A5;CYP3A5 poor metabolizers;;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;LADME_PK;DECREASED_EXPOSURE;
TACROLIMUS;CYP3A5;CYP3A5 intermediate metabolizer and normal metabolizer;;DOSAGE, LADME_PK;INCREASED_TIME TO RESPONSE;OTHER:KIDNEY_TRANSPLANTATION
RISPERIDONE;CYP2D6;CYP2D6;ultrarapid_metabolizer;LADME_PK;INCREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
RISPERIDONE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
NORTRIPTYLINE;CYP2D6;CYP2D6 intermediate metabolizers;;LADME_PK;DECREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
IMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;DOSAGE;DECREASED_DOSE;DISEASE:DIABETIC_NEUROPATHIES
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
HYDROCODONE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM;
ATOMOXETINE;CYP2C19;CYP2C19 poor metabolizers;;LADME_PK;DECREASED_CLEARANCE;
IMIPRAMINE;CYP2C19;CYP2C19 poor metabolizers;;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:PSYCHOTIC_DISORDER
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*8, CYP2C19*17;*1/*2 + *1/*8 + *2/*2;EFFICACY, LADME_PK;DECREASED_METABOLISM;DISEASE:CORONARY_ARTERY_DISEASE
TAMOXIFEN;CYP2D6;CYP2D6 intermediate metabolizers;;LADME_PK;INCREASED_DOSE;DISEASE:BREAST_NEOPLASMS
PROPAFENONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*36;*1/*5 + *2/*36 + *5/*10 + *5/*5;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TACHYCARDIA
IMIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5;*4/*4 + *4/*5;DOSAGE;DECREASED_DOSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME_PK;DECREASED_EXPOSURE;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*8, CYP2C19*17;*1/*2 + *1/*8 + *2/*2;EFFICACY, LADME_PK;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
METHAMPHETAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*18, CYP2D6*36;*4/*10 + *5/*10 + *5/*14 + *10/*10 + *10/*18 + *10/*36;LADME_PK;INCREASED_CONCENTRATIONS;
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME_PK;INCREASED_EXPOSURE;OTHER:PSYCHOTIC_DISORDER,_OTHER:SCHIZOPHRENIA
NORTRIPTYLINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;DOSAGE, EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
DESVENLAFAXINE;CYP2D6;CYP2D6*99;*99;LADME_PK;DECREASED_CONCENTRATIONS;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4, CYP2D6*4x2, CYP2D6*36;*4/*36 + *4x2/*36;LADME_PK;DECREASED_METABOLISM;
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*5/*10 + *4/*10 + *10/*10 + *10/*41;LADME_PK;DECREASED_METABOLISM;
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME_PK;DECREASED_METABOLISM;
METHADONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*2xN;*1/*2xN + *2/*2xN;DOSAGE;INCREASED_DOSE;OTHER:OPIOID-RELATED_DISORDERS
VENLAFAXINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;EFFICACY;INCREASED_RESPONSE;
DESIPRAMINE, IMIPRAMINE;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*4 + *4/*5;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TRANS 4-HYDROXYPRAZIQUANTEL;CYP2J2;rs890293;AA + AC;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHISTOSOMIASIS
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME_PK;DECREASED_METABOLISM;
PERPHENAZINE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME_PK;INCREASED_CONCENTRATIONS;
TACROLIMUS;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 +*2/*3;DOSAGE, LADME_PK;DECREASED_DOSE;OTHER:HEART_TRANSPLANTATION
VORTIOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;TOXICITY;INCREASED_DISCONTINUATION;
DEBRISOQUINE;CYP2D6;CYP2D6*4, CYP2D6*38;*4/*38;LADME_PK;DECREASED_METABOLISM;
NORTRIPTYLINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
FENTANYL;;poor metabolizers;;LADME_PK;DECREASED_METABOLISM;DISEASE:PAIN
ESCITALOPRAM;CYP2C19;CYP2C19 ultrarapid metabolizer phenotype;;LADME_PK;INCREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
NORTRIPTYLINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizers;;LADME_PK;DECREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ETHANOL;OPRM1;rs2075572;G;EFFICACY;INCREASED_RESPONSE;
PROTON PUMP INHIBITORS;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HELICOBACTER_INFECTIONS
DEXAMETHASONE;CHRM3;rs2165870;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING
METOPROLOL;CYP2D6;CYP2D6 poor metabolizers;;DOSAGE;DECREASED_DOSE;
ETHANOL;OPRM1;rs548646;T;EFFICACY;INCREASED_RESPONSE;
GLICLAZIDE;KCNQ1;rs2237892;T;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4, CYP2D6*31;*4/*31;LADME_PK;DECREASED_METABOLISM;
NORTRIPTYLINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;LADME_PK;INCREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
NICOTINE;DRD2;rs1799732;G/del + del/del;EFFICACY;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
LINAGLIPTIN;TCF7L2;rs7903146;CC + CT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
DEXTROMETHORPHAN;CYP2D6;CYP2D6*5, CYP2D6*13;*5/*13;LADME_PK;DECREASED_METABOLISM;
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizer phenotype;;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_CLEARANCE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ETHANOL;OPRM1;rs681243;T;EFFICACY;INCREASED_RESPONSE;
DEXTROMETHORPHAN;CYP2D6;CYP2D6 normal metabolizer genotype;;LADME_PK;INCREASED_METABOLISM;
AMOXICILLIN, CLARITHROMYCIN, ESOMEPRAZOLE;CYP2C19;CYP2C19 normal metabolizer genotype;;EFFICACY;DECREASED_RESPONSE;DISEASE:GASTRITIS
ESCITALOPRAM;CYP2C19;CYP2C19 poor metabolizers;;LADME_PK;DECREASED_METABOLISM;
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizers;;EFFICACY;DECREASED_RESPONSE;EFFICACY:MAJOR_DEPRESSIVE_DISORDER
BUPROPION;COMT;rs4680;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
ARIPIPRAZOLE;CYP2D6;CYP2D6 intermediate metabolizer phenotype;;LADME_PK;DECREASED_METABOLISM;
CODEINE, FENTANYL, HYDROCODONE, HYDROMORPHONE, METHADONE, MORPHINE, OXYCODONE, TRAMADOL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY;DECREASED_RESPONSE;OTHER:NEOPLASMS,_OTHER:PAIN
TRIMIPRAMINE;CYP2C19;CYP2C19 poor metabolizers;;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_METABOLISM;OTHER:MAJOR_DEPRESSIVE_DISORDER
ETHANOL;OPRM1;rs1461773;A;EFFICACY;INCREASED_RESPONSE;
3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*10, CYP2D6*41;*4/*4 + *3/*5;EFFICACY;INCREASED_RESPONSE;
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ETHANOL;OPRM1;rs3778148;T;EFFICACY;INCREASED_RESPONSE;
AMOXICILLIN, CLARITHROMYCIN, LANSOPRAZOLE;CYP2C19;CYP2C19 normal metabolizer genotype;;EFFICACY;DECREASED_CLINICAL BENEFIT;EFFICACY:HELICOBACTER_INFECTIONS
AMOXICILLIN, CLARITHROMYCIN, OMEPRAZOLE;CYP2C19;CYP2C19 normal metabolizer genotype;;EFFICACY;DECREASED_CLINICAL BENEFIT;EFFICACY:HELICOBACTER_INFECTIONS
MIDAZOLAM;VDR;rs4516035;T;LADME_PK;INCREASED_CLEARANCE;
DESIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;DOSAGE;DECREASED_DOSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
AMITRIPTYLINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED_RESPONSE;OTHER:PHANTOM_LIMB_SYNDROME
TRAMADOL;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;INCREASED_RESPONSE;OTHER:PHANTOM_LIMB_SYNDROME
MORPHINE;COMT;rs4680;A;EFFICACY;INCREASED_RESPONSE;DISEASE:LOW_BACK_PAIN
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers;;EFFICACY;INCREASED_RESPONSE;
ANTIDEPRESSANTS;FKBP5;rs3800373;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
VENLAFAXINE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME_PK;DECREASED_CLEARANCE;
DESIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;LADME_PK;INCREASED_TROUGH CONCENTRATION;
TRIMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_METABOLISM;DISEASE:SCHIZOPHRENIA
OPIOIDS;COMT;rs4680;GG;DOSAGE;INCREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
ATENOLOL, METOPROLOL;ADRB2;rs1042714;CC;EFFICACY;INCREASED_RESPONSE;OTHER:TACHYCARDIA
GLICLAZIDE;KCNQ1;rs2237895;C;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
WARFARIN;CYP2C9;CYP2C9 normal metabolizers;;DOSAGE;INCREASED_DOSE;
SOLANIDINE;CYP2D6;CYP2D6 poor metabolizer genotype;;LADME_PK;DECREASED_METABOLISM;OTHER:DEPRESSION
FLECAINIDE;CYP2D6;CYP2D6 normal metabolizer genotype;;LADME_PK;CONCENTRATIONS;DISEASE:TACHYCARDIA,_SUPRAVENTRICULAR
NOROXYCODONE, OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:NEOPLASMS,_OTHER:PAIN
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED_RESPONSE;OTHER:NEOPLASMS,_OTHER:PAIN
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizers;*2/*2 + *2/*3 + *3/*3;LADME_PK;DECREASED_METABOLISM;DISEASE:FUNGAL_INFECTIOUS_DISEASE
VORICONAZOLE;CYP2C19;CYP2C19*2;*2/*2;LADME_PK;INCREASED_CONCENTRATIONS;
PIMOZIDE;CYP2D6;CYP2D6 poor metabolizers;;DOSAGE;DECREASED_DOSE;
PERPHENAZINE;CYP2D6;CYP2D6 normal metabolizer genotype;;LADME_PK;INCREASED_CLEARANCE;
BUPROPION;CYP2C19;CYP2C19*2, CYP2C19*3, CYP2C19*17;*2 + *3;LADME_PK;DECREASED_METABOLISM;DISEASE:PREGNANCY
(R)-METHADONE, (S)-METHADONE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*1/*1xN;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:HEROIN_DEPENDENCE
METHADONE;OPRM1;rs1799971;AA;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:OPIOID-RELATED_DISORDERS
ARSENIC COMPOUNDS;CBS;rs4920037;AA + AG;TOXICITY, LADME_PK;INCREASED_METABOLISM;
(R)-METHADONE, (S)-METHADONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3/*4 + *4/*4 + *4/*6;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HEROIN_DEPENDENCE
VORICONAZOLE;CYP2C19;CYP2C19*2;*2/*2;LADME_PK;INCREASED_CONCENTRATIONS;
MORPHINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
CODEINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_METABOLISM;
O-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:NEOPLASMS,_OTHER:PAIN
(S)-METHADONE;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
WARFARIN;VKORC1;rs9934438;GG;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;INCREASED_CLINICAL BENEFIT;
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6, CYP2D6*9;*4/*4;LADME_PK;DECREASED_METABOLISM;
METHOTREXATE;FOXP3;rs3761548;G;OTHER;DECREASED_RESPONSE;DISEASE:PSORIASIS
ATENOLOL, METOPROLOL;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RESPONSE;OTHER:TACHYCARDIA
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:FUNGAL_INFECTIOUS_DISEASE
N-DESMETHYLTRAMADOL;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:NEOPLASMS,_OTHER:PAIN
4-HYDROXYTAMOXIFEN, ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
GEMCITABINE;NT5C2;rs11598702;TT;LADME_PK;DECREASED_CLEARANCE;
GEMCITABINE;CDA;rs1048977;TT;LADME_PK;DECREASED_METABOLISM;
VORICONAZOLE;CYP2C19;CYP2C19*17;*17/*17;LADME_PK;DECREASED_CONCENTRATIONS;
METHADONE;ABCB1;rs1045642;AG;LADME_PK;DECREASED_CONCENTRATIONS;
CLOMIPRAMINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
OXYMORPHONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*17, CYP2D6*41;*1/*1 + *1/*9 + *2/*9 + *1/*2 + *2/*2;LADME_PK;INCREASED_EXPOSURE;
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CTRB1, CTRB2;rs7202877;GG + GT;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
LANSOPRAZOLE, OMEPRAZOLE;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HELICOBACTER_INFECTIONS
SERTRALINE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*9;*6/*6 + *6/*9;LADME_PK;INCREASED_CONCENTRATIONS;
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;*3 + *4 + *5 + *6 + *9 + *10 + *17 + *29 + *41;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ARSENIC COMPOUNDS;CBS;rs234709;CT + TT;TOXICITY, LADME_PK;INCREASED_METABOLISM;
3-HYDROXYCOTININE, 3-HYDROXYCOTININE GLUCURONIDE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*9, CYP2A6*10;*1 + *2;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TOBACCO_USE_DISORDER
RISPERIDONE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;LADME_PK;INCREASED_CLEARANCE;DISEASE:PSYCHOTIC_DISORDER
RISPERIDONE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_METABOLISM;
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;VDR;rs2239179;C;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41;*1/*1 + *2/*2 + *1/*2;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
AMITRIPTYLINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_METABOLISM;DISEASE:DEPRESSION
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;VDR;rs1540339;C;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
ENDOXIFEN;CYP2C9;CYP2C9 poor metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS;
CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:HEMATOLOGIC_DISORDER,_DISEASE:INFECTIOUS_DISEASE
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
IMIPRAMINE;CYP2C19;CYP2C19 poor metabolizers;;LADME_PK;DECREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DEBRISOQUINE;CYP2D6;CYP2D6*21, CYP2D6*36xN;*21/*36xN;LADME_PK;DECREASED_METABOLISM;
GEMIGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;GLP1R;rs3765467;AA + AG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
METHADONE;ABCB1;rs1045642;AA;LADME_PK;INCREASED_CONCENTRATIONS;
FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*3 + *1/*6 + *3/*3 + *3/*6 + *6/*6;LADME_PK;DECREASED_CLEARANCE;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
NORQUETIAPINE;CYP2D6;CYP2D6 poor metabolizer and intermediate metabolizer genotypes;;LADME_PK;INCREASED_EXPOSURE;
CODEINE;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;INCREASED_RESPONSE;OTHER:PAIN
VORICONAZOLE;CYP2C19;CYP2C19 intermediate metabolizers;*1/*2 + *1/*3;LADME_PK;DECREASED_METABOLISM;DISEASE:FUNGAL_INFECTIOUS_DISEASE
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *3/*3 + *2/*3;LADME_PK;INCREASED_EXPOSURE;
INDOMETHACIN;CYP2C9;rs2153628;G;EFFICACY;INCREASED_RESPONSE;
GEMCITABINE;CDA;rs2072671;AA;LADME_PK;DECREASED_METABOLISM;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
TACROLIMUS;CYP3A5;CYP3A5 poor metabolizer genotype;;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
VENLAFAXINE;SLC6A4;rs25531;TT;EFFICACY;INCREASED_CLINICAL BENEFIT;DISEASE:ANXIETY_DISORDERS
ENDOXIFEN;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ENDOXIFEN;CYP2D6;CYP2D6 intermediate metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
TRAMADOL;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;LADME_PK;INCREASED_METABOLISM;
CODEINE;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;INCREASED_RESPONSE;OTHER:PAIN
MARAVIROC;CYP3A5;CYP3A5 poor metabolizers;;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
VENLAFAXINE;GABRQ;rs3810651;AA + AT;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METOPROLOL;CYP2D6;CYP2D6 normal metabolizers;;LADME_PK;INCREASED_CLEARANCE;OTHER:PREGNANCY
CYTARABINE, IDARUBICIN;DCK;rs80143932;G;EFFICACY;INCREASED_RESPONSE;DISEASE:ACUTE_MYELOID_LEUKEMIA
CLOMIPRAMINE;CYP1A2;rs762551;AA;EFFICACY;INCREASED_DOSE;DISEASE:DEPRESSION
FENTANYL, HYDROMORPHONE, OPIOIDS, OXYCODONE, TRAMADOL;CYP2D6;CYP2D6;ultrarapid_metabolizer;DOSAGE;INCREASED_DOSE;OTHER:SURGERY
CLOZAPINE, N-DESMETHYLCLOZAPINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
IBOGAINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_CLEARANCE;OTHER:OPIOID-RELATED_DISORDERS
ATOMOXETINE;CYP2D6;CYP2D6*10;*10/*10;LADME_PK;INCREASED_EXPOSURE;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
ATOMOXETINE;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
AMPHETAMINE, LISDEXAMFETAMINE;CYP2D6;CYP2D6;poor_metabolizer;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;GRIA3;rs502434;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*41;*41;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*55;*55;LADME_PK;DECREASED_METABOLISM;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*39;*39;LADME_PK;DECREASED_METABOLISM;
ISONIAZID;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TUBERCULOSIS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_EXPOSURE;OTHER:KIDNEY_TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-DQA1;HLA-DQA1*05;*05;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:INFLAMMATORY_BOWEL_DISEASES,_OTHER:INFLAMMATION
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;DOSAGE, EFFICACY;DOSE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME_PK;DECREASED_CONCENTRATIONS;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;GRIA3;rs3761554;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CALU;rs339097;G;DOSAGE;INCREASED_DOSE;
ISONIAZID;NAT2;NAT2;intermediate_acetylator;LADME_PK;INCREASED_CLEARANCE;OTHER:TUBERCULOSIS
OPIOIDS;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE;OTHER:PAIN
DIHYDROARTEMISININ;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*18;*6/*6 + *18/*18 + *1/*6;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:MALARIA,_FALCIPARUM
DESBUTYL LUMEFANTRINE;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*3;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:MALARIA,_FALCIPARUM
SERTRALINE;CYP2D6;CYP2D6*1, CYP2D6*2;*2;LADME_PK;DECREASED_CLEARANCE;OTHER:SUBSTANCE-RELATED_DISORDERS,_OTHER:MAJOR_DEPRESSIVE_DISORDER,_OTHER:ANXIETY_DISORDERS,_OTHER:BORDERLINE_PERSONALITY_DISORDER
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2 + *2/*17;LADME_PK;DECREASED_CLEARANCE;OTHER:SUBSTANCE-RELATED_DISORDERS,_OTHER:MAJOR_DEPRESSIVE_DISORDER,_OTHER:ANXIETY_DISORDERS,_OTHER:BORDERLINE_PERSONALITY_DISORDER
TACROLIMUS;ABCC2;rs3740066;TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
LEVONORGESTREL;CYP2B6;CYP2B6;poor_metabolizer;LADME_PK;INCREASED_CLEARANCE;OTHER:HIV_INFECTIOUS_DISEASE
SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;GRIA3;rs3761555;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;NKX2-6;rs310279;AG + GG;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
CYTARABINE, IDARUBICIN;DCK;rs2306744;T;EFFICACY;INCREASED_RESPONSE;DISEASE:ACUTE_MYELOID_LEUKEMIA
VENLAFAXINE;HTR2A;rs7997012;AG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT;DISEASE:ANXIETY_DISORDERS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:THERAPEUTIC_DRUG_MONITORING_ANALYSES
ANTIEPILEPTICS;;rs16935279;CC + CT;LADME_PK;DECREASED_METABOLISM;DISEASE:BIPOLAR_DISORDER,_DISEASE:PSYCHOTIC_DISORDER
FOLLITROPIN BETA, UROFOLLITROPIN;FSHR;rs6166;CC + CT;DOSAGE;INCREASED_DOSE;
PAROXETINE;CYP2D6;CYP2D6;ultrarapid_metabolizer;LADME_PK;DECREASED_STEADY_STATE CONCENTRATION;OTHER:MAJOR_DEPRESSIVE_DISORDER,_OTHER:ANXIETY_DISORDERS,_OTHER:PANIC_DISORDER
PAROXETINE;CYP2D6;CYP2D6;ultrarapid_metabolizer;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
CLOMIPRAMINE;CYP2D6;CYP2D6*1xN, CYP2D6*2;*2/*1xN;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:AGORAPHOBIA
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
CLOMIPRAMINE;CYP2D6;CYP2D6*4, CYP2D6*6;*4/*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;INCREASED_CLEARANCE;
ATORVASTATIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4, CYP2C19*8, CYP2C19*11;*2 + *4 + *8;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CARDIOVASCULAR_DISEASE
CISPLATIN, IRINOTECAN;UBE2I;rs9597;CG;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
WARFARIN;FRAS1;rs4386623;AA + AG;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:GASTROESOPHAGEAL_REFLUX
WARFARIN;FAM201A;rs1890109;AG + GG;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
VALPROIC ACID;SCN1A;rs3812718;T;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCER
PANTOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCER
CAPECITABINE;DPYD;rs1801159;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:GASTROESOPHAGEAL_CANCER
NICOTINE;DRD2;rs6277;A;EFFICACY;INCREASED_RESPONSE;
CAPTOPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESISTANCE;DISEASE:DIABETES_MELLITUS
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:THROMBOEMBOLISM
BUPROPION;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR short form (S allele) + HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
ETHANOL;OPRM1;rs648007;A;EFFICACY;INCREASED_RESPONSE;
MIDAZOLAM;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
CLOZAPINE;NFIB;rs28379954;CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:TOBACCO_USE_DISORDER
ETHANOL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;INCREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*41;*4/*41 + *5/*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MALARIA
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;
NICOTINE;UGT2B10;rs61750900;T;OTHER, LADME_PK;DECREASED_METABOLISM;
NICOTINE;CHRNA7;rs2337980;CC;EFFICACY;INCREASED_RESPONSE;
BUPROPION;DRD2;rs1799732;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_DOSE;
CLOZAPINE;CYP1A1;rs2472297;CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:TOBACCO_USE_DISORDER
SIMVASTATIN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;CONCENTRATIONS;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:FUNGAL_INFECTIOUS_DISEASE
QUETIAPINE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:PSYCHOTIC_DISORDER
WARFARIN;EPHX1;rs1131873;A;DOSAGE;DECREASED_DOSE;
CLOZAPINE;CYP1A1;rs2472297;CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;
METFORMIN;SLC2A2;rs8192675;C;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
WARFARIN;CYP2C9;rs28371686;G;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM;DISEASE:CONNECTIVE_TISSUE_DISEASES
WARFARIN;CYP2C9;rs28371685;T;DOSAGE;DECREASED_DOSE;
DULOXETINE;CYP2D6;rs3892097;CC;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ALCOHOL_ABUSE,_OTHER:DEPRESSIVE_DISORDER
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:NEOPLASMS
WARFARIN;CYP2C9;rs9332131;del;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS;
CLOZAPINE;NFIB;rs28379954;CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;
HYDROXYUREA;BCL11A;rs4671393;A;EFFICACY;INCREASED_RESPONSE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
WARFARIN;CYP2C9;rs7900194;A;DOSAGE;DECREASED_DOSE;
ROSIGLITAZONE;CYP2C8;CYP2C8*1, CYP2C8*3;*3;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
BETA BLOCKING AGENTS;KL;rs36217263;A/del + del/del;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6 + *1/*6;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *1/*2 + *1/*3;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:FUNGAL_INFECTIOUS_DISEASE
GEMCITABINE;RRM1;rs12806698;AC;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
FLUOXETINE, SERTRALINE;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
BUPROPION;ACE;rs8075924;TT;EFFICACY;DECREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_METABOLISM;OTHER:KIDNEY_TRANSPLANTATION
SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
SUNITINIB;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;DECREASED_CLEARANCE;
HYDROXYCHLOROQUINE;CYP3A4;rs3735451;CC;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:RHEUMATOID_ARTHRITIS,_OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS
FLUOROURACIL;XRCC1;rs25487;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:RECTAL_NEOPLASMS
MIRTAZAPINE;CYP2B6;CYP2B6*6;*6/*6;LADME_PK;INCREASED_METABOLISM;DISEASE:DEPRESSION
CLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
GEMCITABINE;RRM1;rs11030918;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
TACROLIMUS;ABCB1;rs1045642;AG + GG;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;LADME_PK;DECREASED_CLEARANCE;
RISPERIDONE;CYP2D6;CYP2D6 intermediate metabolizer phenotype;;LADME_PK;DECREASED_METABOLISM;
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;DOSAGE, EFFICACY;DECREASED_RESPONSE;OTHER:PERCUTANEOUS_CORONARY_INTERVENTION
PACLITAXEL;CYP2C8;rs11572080;T;OTHER, LADME_PK;DECREASED_METABOLISM;
PACLITAXEL;CYP2C8;rs10509681;C;OTHER, LADME_PK;DECREASED_METABOLISM;
CYCLOSPORINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;DECREASED_CONCENTRATIONS;
CYCLOSPORINE;CYP3A4;rs35599367;A;LADME_PK;DECREASED_METABOLISM;OTHER:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*10;*1/*1 + *10/*10 + *1/*4 + *1/*10;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ANXIETY_DISORDERS,_OTHER:DEPRESSION,_OTHER:MAJOR_DEPRESSIVE_DISORDER
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;DECREASED_METABOLISM;DISEASE:CHRONIC_KIDNEY_FAILURE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;INCREASED_METABOLISM;OTHER:PATIENTS_WITH_DECREASED_CONCENTRATIONS_OF_VORICONAZOLE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
DOCETAXEL, THALIDOMIDE;PPARD;rs3734254;T;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
ATENOLOL, METOPROLOL;OR10P1;rs17117817;G;LADME_PD;DECREASED_RESPONSE;OTHER:HYPERTENSION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;DOSAGE;DECREASED_DOSE;
CARBOPLATIN, GEMCITABINE;RRM1;rs12806698;AC;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
METFORMIN;C11orf65;rs11212617;C;EFFICACY;INCREASED_CLINICAL BENEFIT;DISEASE:DIABETES_MELLITUS_TYPE2
ABATACEPT;HLA-DRB1;HLA-DRB1*04:01, HLA-DRB1*04:04, HLA-DRB1*04:05, HLA-DRB1*04:10, HLA-DRB1*10:01;*04:01 + *04:04 + *04:05 + *04:10 + *10:01;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
METHADONE;;rs17180299;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
WARFARIN;CALU;rs339097;G;DOSAGE;INCREASED_DOSE;
VINCRISTINE;;rs1247117;G;LADME_PD;INCREASED_RESISTANCE;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
ATENOLOL, METOPROLOL;SNX9;rs2364349;A;LADME_PD;DECREASED_RESPONSE;OTHER:HYPERTENSION
TACROLIMUS;;rs11265572;GT + TT;LADME_PK;DECREASED_METABOLISM;DISEASE:LIVER_TRANSPLANTATION
WARFARIN;STX4;rs10871454;T;DOSAGE;DECREASED_DOSE;
SIROLIMUS, TEMSIROLIMUS;CYP3A5;rs776746;CT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:URINARY_BLADDER_NEOPLASMS
PERAMPANEL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
VORICONAZOLE;CYP2C19;CYP2C19*17;*17;LADME_PK;DECREASED_CONCENTRATIONS;
ENALAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
URACIL;DPYD;DPYD c.295_298delTCAT (*7), DPYD Reference;c.295_298delTCAT (*7);LADME_PK;INCREASED_CONCENTRATIONS;
URACIL;DPYD;DPYD c.2846A>T, DPYD Reference;c.2846A>T;LADME_PK;INCREASED_CONCENTRATIONS;
URACIL;DPYD;DPYD c.1679T>G (*13), DPYD Reference;c.1679T>G (*13);LADME_PK;INCREASED_CONCENTRATIONS;
URACIL;DPYD;DPYD c.1905+1G>A (*2A), DPYD Reference;c.1905+1G>A (*2A);LADME_PK;INCREASED_CONCENTRATIONS;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*29, CYP2D6*35, CYP2D6*41;*1/*29 + *1/*41 + *2/*41 + *35/*41 + *1/*4 + *1/*5 + *2/*4 + *1/*3 + *35/*4 + *1/*6 + *35/*5 + *2/*9 + *1/*10 + *2/*10 + *35/*10;LADME_PK;DECREASED_METABOLISM;DISEASE:BREAST_NEOPLASMS
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41;*4/*4 + *41/*4 + *41/*3 + *10/*4 + *9/*41 + *17/*41 + *41/*41 + *9/*5 + *1/*29;LADME_PK;DECREASED_METABOLISM;DISEASE:BREAST_NEOPLASMS
ATORVASTATIN;CYP3A5;CYP3A5*3;*3/*3;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10 + *1/*10;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ESCITALOPRAM;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;
ESCITALOPRAM;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2 + *1/*2;TOXICITY, LADME_PK;DECREASED_METABOLISM;SIDE_EFFECT:POSTMORTEM_TOXICOLOGY_CASES
EFAVIRENZ;CYP2B6;CYP2B6;poor_metabolizer;LADME_PK;INCREASED_EXPOSURE;
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;HLA-A*03:01;*03:01;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-A;HLA-A*23:17;*23:17;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
BCR-ABL TYROSINE KINASE INHIBITORS;HLA-B;HLA-B*57:03;*57:03;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*7;*1/*1 + *1/*3;LADME_PK;INCREASED_CLEARANCE;OTHER:KIDNEY_TRANSPLANTATION
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41;*2 + *9 + *10 + *35 + *41;LADME_PK;DECREASED_CLEARANCE;
ANTIDEPRESSANTS;CYP2C19;CYP2C19;poor_metabolizer;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
SUMATRIPTAN;SLC22A1;rs1349294037;TAAGTTGT/TAAGTTGT;OTHER;INCREASED_CONCENTRATIONS;
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*18;*6 + *18;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:OPIOID-RELATED_DISORDERS
LAMOTRIGINE;UGT1A4;UGT1A4*3b;*3b;EFFICACY;DECREASED_CLINICAL BENEFIT;
DOCETAXEL, THALIDOMIDE;PPARD;rs2016520;C;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
TACROLIMUS;CYP3A5;CYP3A5*1;*1/*1;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
INFLIXIMAB;HLA-DQA1;HLA-DQA1*05;*05;EFFICACY;DECREASED_RESPONSE;OTHER:CROHN_DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4, CYP2C19*17;*2 + *4;EFFICACY;DECREASED_RESPONSE;
DOCETAXEL, THALIDOMIDE;CHST3;rs1871450;A;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
WARFARIN;VKORC1;rs9923231;T;DOSAGE, LADME_PK;DECREASED_DOSE;
PROPOFOL;CYP2B6;CYP2B6*1, CYP2B6*6;*6;TOXICITY;DECREASED_RESPONSE;OTHER:BRAIN_INJURY
TILDRAKIZUMAB;PDE4D;rs10556657;CT/CT;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
BUPRENORPHINE, DIHYDROCODEINE, FENTANYL, HYDROMORPHONE, METHADONE, MORPHINE, OXYCODONE, PIRITRAMIDE, TILIDINE, TRAMADOL;ABCB1;rs1045642;A;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;DOSAGE;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
TACROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;DECREASED_CLEARANCE;OTHER:KIDNEY_TRANSPLANTATION
SIROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
DOCETAXEL, THALIDOMIDE;PPARD;rs1883322;C;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
PHENYTOIN;CYP2C19;CYP2C19;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;
VALPROIC ACID;CYP2C19;CYP2C19;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;
CARBAMAZEPINE;CYP3A5;CYP3A5;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;
VALPROIC ACID;CYP2C9;CYP2C9;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;
VALPROIC ACID;UGT1A6;UGT1A6*1a, UGT1A6*2a;*2a;LADME_PK;DECREASED_CONCENTRATIONS;
PHENYTOIN;CYP2C9;CYP2C9;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:COLORECTAL_NEOPLASMS,_OTHER:METASTATIC_NEOPLASM
DOCETAXEL, THALIDOMIDE;CHST3;rs12418;A;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*60;*28 + *60;DOSAGE;DECREASED_DOSE;OTHER:COLORECTAL_NEOPLASMS
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28 + *1/*28;DOSAGE;DECREASED_DOSE;OTHER:COLORECTAL_NEOPLASMS,_OTHER:METASTATIC_NEOPLASM
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;LADME_PK;INCREASED_METABOLISM;OTHER:PEPTIC_ULCER_DISEASE,_OTHER:GASTROESOPHAGEAL_REFLUX,_OTHER:ESOPHAGITIS
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*8;*1/*8;LADME_PK;DECREASED_METABOLISM;
ABROCITINIB;CYP2C19;CYP2C19;poor_metabolizer;LADME_PK;INCREASED_EXPOSURE;
WARFARIN;CYP2C9;CYP2C9*1;*1/*1;DOSAGE;INCREASED_DOSE;
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*8;*2 + *3 + *8;DOSAGE;DECREASED_DOSE;
OPIOIDS;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE;OTHER:CAESARIAN_SECTION,_OTHER:PAIN
DULOXETINE;DRD3;rs963468;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:ANXIETY_DISORDERS
SIMVASTATIN;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;LADME_PK;INCREASED_EXPOSURE;
METFORMIN;C11orf65;rs11212617;C;EFFICACY;INCREASED_CLINICAL BENEFIT;DISEASE:DIABETES_MELLITUS_TYPE2
CYCLOSPORINE;CYP3A5;rs776746;CC;DOSAGE, LADME_PK;DECREASED_DOSE;
EFAVIRENZ, NEVIRAPINE;NR1I3;rs2307424;AA + AG;EFFICACY;INCREASED_RESPONSE;EFFICACY:HIV_INFECTIOUS_DISEASE
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*1 + *1/*2;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:HEMATOLOGIC_NEOPLASMS,_OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
ARIPIPRAZOLE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;INCREASED_CONCENTRATIONS;
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;
PIMOZIDE;CYP3A4;CYP3A4*1, CYP3A4*22;*22;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:PSYCHOTIC_DISORDER
DOCETAXEL, THALIDOMIDE;CHST3;rs4148943;C;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
RISPERIDONE;CYP2D6;CYP2D6;ultrarapid_metabolizer;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
DOCETAXEL, THALIDOMIDE;CHST3;rs4148945;C;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;CG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
GLYBURIDE;ABCB11;rs4148776;G;EFFICACY;INCREASED_RESPONSE;
IMATINIB;SLCO1B3;rs7311358;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
IMATINIB;SLCO1B3;rs4149117;GG + GT;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
PRAZIQUANTEL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *2/*2 + *1/*3 + *3/*3;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHISTOSOMIASIS
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA,_OTHER:LYMPHOMA,_OTHER:ACUTE_MYELOID_LEUKEMIA
GLYBURIDE;CHST13;rs1054097;C;EFFICACY;INCREASED_RESPONSE;
LACOSAMIDE;CYP2C19;CYP2C19 normal metabolizer;;LADME_PK;DECREASED_EXPOSURE;OTHER:EPILEPSY
LACOSAMIDE;ABCC2;rs717620;T;LADME_PK;DECREASED_EXPOSURE;OTHER:EPILEPSY
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*1/*3 + *1/*4;LADME_PK;INCREASED_CONCENTRATIONS;
ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*4/*4;LADME_PK;INCREASED_CONCENTRATIONS;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*1;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SURGERY
CLOZAPINE;CYP2D6;CYP2D6 normal metabolizer;;DOSAGE;INCREASED_DOSE;OTHER:SCHIZOPHRENIA,_OTHER:PSYCHOTIC_DISORDER
EFAVIRENZ;CYP2B6;CYP2B6;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
MERCAPTOPURINE;TPMT;TPMT deficiency;;DOSAGE;DECREASED_DOSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
THIOGUANOSINE DIPHOSPHATE, THIOGUANOSINE MONOPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*3A + *3B + *3C;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:INFLAMMATORY_BOWEL_DISEASES
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TOLTERODINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;
METOPROLOL;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM;
CLOZAPINE;ITIH3;rs2535629;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ATOMOXETINE;CYP2D6;CYP2D6;poor_metabolizer;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
EFAVIRENZ;CYP2B6;CYP2B6;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE,_DISEASE:TUBERCULOSIS
EFAVIRENZ;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE,_DISEASE:TUBERCULOSIS
COTININE;CYP2A6;CYP2A6 low activity;;LADME_PK;INCREASED_METABOLISM;OTHER:TOBACCO_USE_DISORDER
COTININE;CYP2A6;CYP2A6 low activity;;LADME_PK;INCREASED_CONCENTRATIONS;
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*4, CYP2A6*9, CYP2A6*12, CYP2A6*17, CYP2A6*20, CYP2A6*23, CYP2A6*24, CYP2A6*25, CYP2A6*26, CYP2A6*27, CYP2A6*28, CYP2A6*35;*2 + *4 + *9 + *17 + *20 + *23 + *25 + *26 + *27 + *28 + *35 + *12 + *24;LADME_PK;DECREASED_METABOLISM;
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;DECREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
DEOXY-THIOGUANOSINE TRIPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT;TPMT deficiency;;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ENDOXIFEN;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
CAFFEINE;ADORA1;rs10920573;CC;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:APNEA_OF_PREMATURITY
NORQUETIAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS;
QUETIAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_CONCENTRATIONS;
AMLODIPINE;CACNA1D;rs312481;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HYPERTENSION
PEGINTERFERON ALFA-2A;ZHX2;rs17289471;C;EFFICACY;INCREASED_RESPONSE;OTHER:HEPATITIS_B_VIRUS_INFECTION
BERBERINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM;
CLOPIDOGREL;CYP2C19;rs12248560;T;EFFICACY, OTHER;RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
RANIBIZUMAB;VEGFA;rs833069;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
TACROLIMUS;CYP3A5;rs4646449;CC;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
ONDANSETRON;CYP2D6;CYP2D6;poor_metabolizer;DOSAGE;INCREASED_DOSE;OTHER:SURGERY
IMATINIB;ABCA3;rs150929;GG + GT;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
METFORMIN;CBARP, STK11;rs2301759;TT;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
METFORMIN;SLC22A3;rs3127602;T;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
METFORMIN;PRKAA1;rs11749180;A;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
METFORMIN;SLC29A4;rs10234709;A;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
METFORMIN;PRKAG2;rs4725434;T;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
METFORMIN;SLC47A1;rs2120274;A;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
METFORMIN;STK11;rs2301759;C;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
METFORMIN;SLC47A2;rs4621031;C;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;CFTR 3849+10kbC->T;3849+10kbC->T;;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
ALECTINIB;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA
METFORMIN;TCF7L2;rs7903146;T;EFFICACY;INCREASED_RESPONSE;
METHADONE;OPRK1;rs3802279;CC;DOSAGE;DECREASED_DOSE;OTHER:HEROIN_DEPENDENCE
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
LACOSAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs41267797;AG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
N,N-DIDESMETHYLTRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*41, CYP2D6*45;*4/*6 + *4/*5;LADME_PK;INCREASED_CONCENTRATIONS;
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:IMMUNOGLOBULIN_A_VASCULITIS
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs75961395;AA;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
TOCILIZUMAB;IL6R;rs35717427;AG + GG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;ABCC2;rs17216317;CT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
TOCILIZUMAB;IL6R;rs6690230;CG + GG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
TOCILIZUMAB;IL6R;rs11265621;AA + AG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
TOCILIZUMAB;;rs10108210;AA;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
TOCILIZUMAB;CLEC2D;rs1560011;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
TOCILIZUMAB;KCNMB1;rs703505;AA + AG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:ELDERLY_ADULT,_OTHER:MAJOR_DEPRESSIVE_DISORDER
MORPHINE;CCL11;rs17809012;AA;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:NEOPLASMS,_OTHER:PAIN
MORPHINE;IL16;rs4778889;TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:NEOPLASMS,_OTHER:PAIN
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs35235578;CT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
VALPROIC ACID;SLC16A1;rs7169;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs9457841;C;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs34134157;CC;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:DEATH
TENOFOVIR;ABCC4;rs3742106;AC + CC;TOXICITY;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
ANTIDEPRESSANTS;FKBP5;rs1360780;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ACETAMINOPHEN SULFATE;CYP2E1;CYP2E1*1, CYP2E1*5B;*1/*5B;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:PATENT_DUCTUS_ARTERIOSUS,_OTHER:PREMATURE_BIRTH
FENTANYL;ABCC1;rs58572178;(A)14;LADME_PK;INCREASED_CLEARANCE;OTHER:PAIN,_OTHER:PREMATURE_BIRTH
VORICONAZOLE;CYP2C19;CYP2C19*2, CYP2C19*17;*2 + *17;DOSAGE;DOSE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
ACETAMINOPHEN;CYP1A2;rs2069514;A;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PATENT_DUCTUS_ARTERIOSUS
DOXORUBICIN;CBR1;rs20572;T;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
SUNITINIB;KDR;rs34231037;AG;EFFICACY;INCREASED_CLINICAL BENEFIT;
ANTIDEPRESSANTS;FKBP5;rs3800373;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
GLICLAZIDE, GLIMEPIRIDE, GLIPIZIDE, GLYBURIDE;KCNQ1;rs163184;GT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
ISONIAZID;NAT2;NAT2;slow_acetylator;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TUBERCULOSIS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
MORPHINE;CYP2D6;CYP2D6*10, CYP2D6*41;*41;LADME_PK;INCREASED_EXPOSURE;OTHER:PAIN,_POSTOPERATIVE
DULOXETINE;DRD3;rs324026;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE:ANXIETY_DISORDERS
CYTARABINE, DAUNORUBICIN;RAD50;rs2299014;AA + AC;EFFICACY;INCREASED_RESISTANCE;OTHER:ACUTE_MYELOID_LEUKEMIA
TENOFOVIR;ABCC4;rs1751034;TT;TOXICITY;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
DULOXETINE;DRD3;rs324023;CT;EFFICACY;DECREASED_RESPONSE;DISEASE:ANXIETY_DISORDERS
EFAVIRENZ, NEVIRAPINE;NR1I2;rs1523127;AA + AC;EFFICACY;DECREASED_RESPONSE;EFFICACY:HIV_INFECTIOUS_DISEASE
EZETIMIBE;ABCG8;ABCG8 deficiency;;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:FAMILIAL_HYPERCHOLESTEROLEMIA
EZETIMIBE;ABCG5;ABCG5 deficiency;;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:FAMILIAL_HYPERCHOLESTEROLEMIA
RABEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
DULOXETINE;DRD3;rs167770;AG;EFFICACY;DECREASED_RESPONSE;DISEASE:ANXIETY_DISORDERS
RISPERIDONE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BIPOLAR_DISORDER,_DISEASE:SCHIZOAFFECTIVE_DISORDER,_DISEASE:SCHIZOPHRENIA
TAMSULOSIN;CYP2D6;CYP2D6*10, CYP2D6*41;*10 + *41;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PROSTATIC_HYPERPLASIA
HYDROXYUREA;HBG2;rs7482144;AG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES,_OTHER:ALPHA-THALASSEMIA
HYDROXYUREA;HBG2;rs7482144;AA + AG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
HYDROXYUREA;HBG2;rs7482144;AA;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
HYDROXYUREA;BCL11A;rs766432;C;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
IMATINIB;PDGFRB;rs201866603;CT;EFFICACY;DECREASED_RESPONSE;EFFICACY:INFANTILE_MYOFIBROMATOSIS
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801133;A;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
VORTIOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*10;*4/*4 + *4/*10;LADME_PK;INCREASED_CONCENTRATIONS;
ANTIEPILEPTICS;SCN1A;rs121917953;AA + AT;EFFICACY;INCREASED_RESISTANCE;OTHER:EPILEPSY
NICOTINE;CYP2A6;rs778019189;G;LADME_PK;DECREASED_METABOLISM;
METHOTREXATE;ENG;rs1800956;G;LADME_PK;DECREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;PKD1L2;rs16954698;A;LADME_PK;DECREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4;*1/*2 + *1/*3 + *1/*4 + *2/*4 + *3/*3;DOSAGE;DECREASED_DOSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ANTIDEPRESSANTS;FKBP5;rs1360780;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY, LADME_PK;INCREASED_CONCENTRATIONS;SIDE_EFFECT:ADVERSE_EVENTS,_SIDE_EFFECT:CHOLESTASIS,_SIDE_EFFECT:THROMBOCYTOPENIA
EFAVIRENZ, NEVIRAPINE;NR1I3;rs3003596;AG + GG;EFFICACY;DECREASED_RESPONSE;EFFICACY:HIV_INFECTIOUS_DISEASE
ANTIDEPRESSANTS;FKBP5;rs4713916;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
ENDOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10;*10/*10 + *2/*10;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
ENDOXIFEN;CYP2D6;CYP2D6 normal metabolizer;;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
DEXTROMETHORPHAN;CYP2D6;CYP2D6*4;*4/*4;LADME_PK;DECREASED_METABOLISM;
CLOZAPINE;CYP2D6;rs202102799;C;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA,_OTHER:PSYCHOTIC_DISORDER
CLOZAPINE;CYP2D6;rs28371726;G;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA,_OTHER:PSYCHOTIC_DISORDER
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA,_OTHER:PSYCHOTIC_DISORDER
CLOZAPINE;DRD4;rs762502;C;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA,_OTHER:PSYCHOTIC_DISORDER
NIFEDIPINE;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:PREGNANCY
CLOZAPINE;DRD4;rs2133251840;del;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA,_OTHER:PSYCHOTIC_DISORDER
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;CYP1A2;ultrarapid_metabolizer;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA,_OTHER:PSYCHOTIC_DISORDER
EXENATIDE;SORCS1;rs1416406;GG;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
LINAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;KCNJ11;rs2285676;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
LINAGLIPTIN, SAXAGLIPTIN, SITAGLIPTIN, VILDAGLIPTIN;PRKD1;rs57803087;G;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
CLOZAPINE;CYP1A2;rs72547516;T;;DECREASED_METABOLISM;
CLOZAPINE;CYP1A2;CYP1A2*8;*8;LADME_PK;DECREASED_METABOLISM;
MIDAZOLAM;NR1I2;rs2461817;CC;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:RESPIRATORY_FAILURE_REQUIRING_ASSISTED_VENTILATION
METHADONE, R-EDDP, S-EDDP;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801131;G;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_DOSE;DISEASE:ULCERATIVE_COLITIS,_DISEASE:CROHN_DISEASE,_DISEASE:AUTOIMMUNE_HEPATITIS
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
WARFARIN;APOE;rs7412;CC;DOSAGE;INCREASED_DOSE;OTHER:ATRIAL_FIBRILLATION,_OTHER:PULMONARY_EMBOLISM,_OTHER:VENOUS_THROMBOSIS
METHACHOLINE;ADRB2;rs1042713;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
ACENOCOUMAROL;VKORC1;rs9923231;CT;DOSAGE;DECREASED_DOSE;
TEMSIROLIMUS;NR1I2;rs3814055;TT;LADME_PK;DECREASED_METABOLISM;DISEASE:URINARY_BLADDER_NEOPLASMS
TEMSIROLIMUS;ABCB1;rs2032582;CC;LADME_PK;INCREASED_METABOLISM;DISEASE:URINARY_BLADDER_NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;;rs4646457;C;DOSAGE;DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs15524;G;DOSAGE;DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;rs12333983;A;DOSAGE;DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;DISEASE:RHEUMATIC_HEART_DISEASE
FLECAINIDE;SCN4A;rs80338792;T;EFFICACY;INCREASED_RESPONSE;DISEASE:MYOTONIA
ATENOLOL, METOPROLOL;;rs294610;A;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
ATENOLOL, METOPROLOL;SLC4A1;rs45545233;CC + CT;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;rs3794271;G;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CAPECITABINE, FLUOROURACIL;DPYD;rs56038477;CT;DOSAGE;DOSE;DISEASE:COLORECTAL_NEOPLASMS
SUNITINIB;ABCB1;rs2032582;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:RENAL_CELL_CARCINOMA
FLUOROURACIL;DPYD;rs17376848;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:COLORECTAL_NEOPLASMS
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;
HYDROCHLOROTHIAZIDE;;rs11065987;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
METHADONE;ABCB1;rs1128503;AA;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
ETHANOL;OPRM1;rs553202;T;EFFICACY;INCREASED_RESPONSE;
ETHANOL;OPRM1;rs524731;A;EFFICACY;INCREASED_RESPONSE;
S-EDDP;ABCB1;rs1128503;AG;LADME_PK;INCREASED_CONCENTRATIONS;
NICOTINE;HINT1;rs3852209;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
S-EDDP;ABCB1;rs1045642;AG;LADME_PK;INCREASED_CONCENTRATIONS;
OPIOIDS;OPRM1;rs1799971;AG;EFFICACY;DECREASED_RESPONSE;DISEASE:PAIN,_POSTOPERATIVE
METHADONE;ABCB1;rs1128503;AG;LADME_PK;DECREASED_CONCENTRATIONS;
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
FLUOXETINE;CYP2D6;rs3892097;CT;EFFICACY;INCREASED_CONCENTRATIONS;EFFICACY:ALCOHOL_ABUSE,_EFFICACY:MAJOR_DEPRESSIVE_DISORDER
LEVODOPA;DBH;rs1611115;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:COCAINE_DEPENDENCE
VENLAFAXINE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
AXITINIB;OR2B11;rs35305980;A;LADME_PK;CONCENTRATIONS;DISEASE:RENAL_CELL_CARCINOMA
SULFONAMIDES, UREA DERIVATIVES;KCNJ11;rs5219;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
WARFARIN;VKORC1;rs7294;T;DOSAGE, LADME_PK;INCREASED_DOSE;
SULFONAMIDES, UREA DERIVATIVES;ABCC8;rs757110;AA + CC;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
TIPIRACIL HYDROCHLORIDE, TRIFLURIDINE;SLC29A1;rs9394992;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
ANTIDEPRESSANTS, DESIPRAMINE, FLUOXETINE;BDNF;rs61888800;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
AXITINIB;UGT1A10, UGT1A8, UGT1A9;rs3832043;del;LADME_PK;CONCENTRATIONS;DISEASE:RENAL_CELL_CARCINOMA
AXITINIB;UGT1A7;rs17868323;G;LADME_PK;CONCENTRATIONS;DISEASE:RENAL_CELL_CARCINOMA
RISPERIDONE;HTR2C;rs3813928;A;EFFICACY;DECREASED_RESPONSE;DISEASE:AUTISM
METHOTREXATE;MTRR;rs1532268;CT + TT;LADME_PK;INCREASED_EXPOSURE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
RISPERIDONE;HTR2A;rs6311;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTISM
AXITINIB;ABCB1;rs1045642;A;LADME_PK;CONCENTRATIONS;DISEASE:RENAL_CELL_CARCINOMA
AXITINIB;ABCG2;rs2231142;T;LADME_PK;CONCENTRATIONS;DISEASE:RENAL_CELL_CARCINOMA
AXITINIB;ABCB1;rs2032582;T;LADME_PK;CONCENTRATIONS;DISEASE:RENAL_CELL_CARCINOMA
VORICONAZOLE;CYP2C19;rs4244285;AA + AG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;
ERLOTINIB;EGFR;rs121434568;GT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
METHOTREXATE;ABCB1;rs1045642;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CYTARABINE;SLC29A1;rs3734703;A;EFFICACY;INCREASED_RESPONSE;DISEASE:ACUTE_MYELOID_LEUKEMIA
SUNITINIB;ABCB1;rs1045642;AA + AG;LADME_PK;INCREASED_CLEARANCE;DISEASE:RENAL_CELL_CARCINOMA,_DISEASE:METASTATIC_NEOPLASM
METHOTREXATE;SLC19A1;rs1051266;CC + TT;EFFICACY;DECREASED_RESPONSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
SN-38;UGT1A9;rs3832043;TT;DOSAGE;INCREASED_METABOLISM;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
EFAVIRENZ;CYP2B6;rs2279345;CC + CT;LADME_PK;INCREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
RISPERIDONE;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTISM
EFAVIRENZ;CYP2B6;rs2279345;CT;LADME_PK;INCREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
GLUCOCORTICOIDS;CRHR1;rs1876828;T;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
ANTIDEPRESSANTS;ERICH3;rs11580409;C;EFFICACY;INCREASED_RESPONSE;
SN-38;SLCO1B1;rs4149056;CC + CT;DOSAGE;INCREASED_DOSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
(S)-METHADONE;CYP3A4;rs2740574;CT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
VORICONAZOLE;CYP2C19;rs4986893;AA + AG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;
METHYLPHENIDATE;GRIN2B;rs2284411;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
WARFARIN;VKORC1;rs17708472;A;DOSAGE, LADME_PK;INCREASED_DOSE;
FENTANYL;CYP3A4;rs2740574;C;LADME_PK;DECREASED_CLEARANCE;OTHER:BURNS
METHOTREXATE;SLC19A1;rs1051266;TT;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
SALBUTAMOL, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;CRHR2;rs7793837;T;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;ABCA1;rs2230806;T;EFFICACY;DECREASED_RESPONSE;
SALBUTAMOL, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;CRHR2;rs7793837;T;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;CYP2D6;rs3892097;T;EFFICACY;DECREASED_RESPONSE;
NICARDIPINE, NIMODIPINE;CACNA1B;rs2739258;AG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BIPOLAR_DISORDER
METHOTREXATE;MTHFR;rs1801131;TT;EFFICACY;DECREASED_RESPONSE;OTHER:NON-HODGKIN_LYMPHOMA,_OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
IMATINIB;CYP3A5;rs776746;C;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
IMATINIB;SLC22A1;rs683369;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
SIMVASTATIN;APOA5;rs662799;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:DYSLIPIDAEMIA
IRBESARTAN;APOB;rs1367117;AG;EFFICACY, LADME_PK;RESPONSE;DISEASE:HYPERTENSION
IRBESARTAN;APOB;rs1367117;GG;EFFICACY;RESPONSE;DISEASE:HYPERTENSION
ATORVASTATIN;APOA5;rs662799;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:DYSLIPIDAEMIA
EFAVIRENZ;CYP2A6;rs28399433;C;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;INCREASED_RESPONSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
BENAZEPRIL;PRCP;rs2229437;GG + GT;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
EFAVIRENZ;UGT2B7;rs28365062;GG;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;rs28399499;C;LADME_PK;METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY, OTHER;RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
EFAVIRENZ, LAMIVUDINE, TENOFOVIR;CYP2B6;rs2279343;AG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HIV_INFECTIOUS_DISEASE
METHOTREXATE;MTHFR;rs1801131;GG;EFFICACY;INCREASED_RESPONSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CLOPIDOGREL;ABCB1;rs1045642;G;EFFICACY, OTHER;RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
QUETIAPINE, ZIPRASIDONE;RGS4;rs951439;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
MIDAZOLAM;VDR;rs11568820;CT + TT;LADME_PK;INCREASED_CLEARANCE;
METHYLDOPA;ARG2;rs3742879;G;EFFICACY;INCREASED_RESPONSE;OTHER:PREGNANCY,_OTHER:PRE-ECLAMPSIA
FLUOROURACIL;MTHFR;rs1801133;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
ARIPIPRAZOLE;ABCB1;rs1128503;AA;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:MAJOR_DEPRESSIVE_DISORDER
OMEPRAZOLE;CYP2C19;rs12248560;TT;DOSAGE, LADME_PK;INCREASED_METABOLISM;OTHER:NO_DISEASE
MEPHENYTOIN;CYP2C19;rs12248560;TT;DOSAGE, LADME_PK;INCREASED_METABOLISM;OTHER:NO_DISEASE
OMEPRAZOLE;CYP2C19;rs11188072;TT;DOSAGE, LADME_PK;INCREASED_METABOLISM;OTHER:NO_DISEASE
MEPHENYTOIN;CYP2C19;rs11188072;TT;DOSAGE, LADME_PK;INCREASED_METABOLISM;OTHER:NO_DISEASE
METHADONE;CYP2B6;rs3211371;TT;LADME_PK;INCREASED_CONCENTRATIONS;
MERCAPTOPURINE, METHOTREXATE;SLCO1B1;rs4149056;CC + CT;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
GEMCITABINE;CMPK1;rs1044457;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
DEXMEDETOMIDINE;ADRA2A;rs1800035;CG + GG;EFFICACY;DECREASED_RESPONSE;OTHER:PAIN,_POSTOPERATIVE
BUDESONIDE, FLUTICASONE / SALMETEROL, FORMOTEROL, OMALIZUMAB;IL10;rs3024498;CC + CT;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
DEXMEDETOMIDINE;ADRA2A;rs775887911;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER:PAIN,_POSTOPERATIVE
DEXMEDETOMIDINE;ADRA2A;rs201376588;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER:PAIN,_POSTOPERATIVE
GEMCITABINE;CMPK1;rs35687416;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
GEMCITABINE;DCTD;rs12507552;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
BETA BLOCKING AGENTS;;rs139945292;T;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
ROSUVASTATIN;APOA5;rs662799;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:DYSLIPIDAEMIA
GEMCITABINE;TENT4A;rs274713;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
METHOTREXATE;FPGS;rs1544105;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
GEMCITABINE;CDC5L;rs992160;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
METHOTREXATE;TYMS;rs2853539;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;APOA5;rs662799;AA;OTHER;RESPONSE;DISEASE:DYSLIPIDAEMIA
BUDESONIDE, FLUTICASONE / SALMETEROL, FORMOTEROL, OMALIZUMAB;IL17A;rs3819024;AG + GG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
GEMCITABINE;SH2D5;rs10916852;GT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
ROSUVASTATIN;CETP;rs708272;A;EFFICACY;DECREASED_RESPONSE;
ATORVASTATIN;ABCB1;rs1045642;AA;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CORONARY_ARTERY_DISEASE
ATORVASTATIN;SLCO1B1;rs2306283;AA;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CORONARY_ARTERY_DISEASE
PHENPROCOUMON;VKORC1;rs9923231;TT;DOSAGE, TOXICITY;DECREASED_DOSE;
AZATHIOPRINE;TPMT;rs1142345;CT;LADME_PK;DECREASED_METABOLISM;DISEASE:INFLAMMATORY_BOWEL_DISEASES
AZATHIOPRINE;ITPA;rs1127354;AC;LADME_PK;INCREASED_METABOLISM;DISEASE:INFLAMMATORY_BOWEL_DISEASES
BUPRENORPHINE;CYP3A4;rs2740574;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:ISCHEMIA,_DISEASE:PAIN
PERINDOPRIL;AGTR1;rs5186;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
NITRENDIPINE;AGTR1;rs5186;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
LAMOTRIGINE;HNF4A;rs2071197;AA;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:EPILEPSY
LAMOTRIGINE;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
LAMOTRIGINE;ABCG2;rs3114020;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
CYCLOSPORINE;TSPYL1;rs3828743;AG + GG;LADME_PK;INCREASED_CLEARANCE;OTHER:KIDNEY_TRANSPLANTATION
GEMCITABINE;CMPK1;rs7543016;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
GEMCITABINE;ESR2;rs944050;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
RISPERIDONE;DRD2;rs1799978;TT;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
IRINOTECAN;ABCC2;rs2273697;AA + AG;LADME_PK;INCREASED_METABOLISM;DISEASE:COLORECTAL_NEOPLASMS
RISPERIDONE;DRD2;rs1799978;T;OTHER;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
LETROZOLE;CYP19A1;rs4646;A;EFFICACY;INCREASED_CLINICAL BENEFIT;DISEASE:BREAST_NEOPLASMS
ANTIEPILEPTICS;ABCC2;rs717620;CT + TT;EFFICACY;INCREASED_RESISTANCE;DISEASE:EPILEPSY
WARFARIN;;rs12777823;A;DOSAGE;DOSE;
METHOTREXATE;SLCO1B1;rs2306283;AA + AG;LADME_PK;INCREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CONJUGATED ESTROGENS;SLCO1B1;rs4149056;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:MENOPAUSE
CISPLATIN;ERCC1;rs3212986;A;EFFICACY;DECREASED_RESPONSE;OTHER:OVARIAN_NEOPLASMS
ANTIPSYCHOTICS;ABCB1;rs1045642;GG;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;ABCB1;rs2032582;AA;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:SCHIZOPHRENIA
DIAZEPAM;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ALCOHOL_ABUSE
ALPRAZOLAM;CYP3A4;rs35599367;AG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ALCOHOL_ABUSE,_OTHER:ANXIETY_DISORDERS
DIAZEPAM;CYP2C19;rs12248560;CT + TT;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ALCOHOL_ABUSE
CLOZAPINE;POR;rs1057868;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:SCHIZOPHRENIA,_OTHER:TOBACCO_USE_DISORDER
SALBUTAMOL;IGF2R;rs8191725;AG;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
SALBUTAMOL;SLC24A4;rs77441273;AG;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
ALPRAZOLAM;CYP3A4;rs35599367;AG;EFFICACY;DECREASED_RESPONSE;OTHER:ALCOHOL_ABUSE,_OTHER:ANXIETY_DISORDERS
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;IL1B;rs16944;AG;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
LANSOPRAZOLE, OMEPRAZOLE, RABEPRAZOLE;IL1B;rs16944;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
METHOTREXATE;AHRR;rs2292596;G;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
WARFARIN;VKORC1;rs2359612;AA;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
PLATINUM COMPOUNDS;ERCC1;rs11615;AG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:OVARIAN_NEOPLASMS,_OTHER:NEOPLASM_OF_ESOPHAGUS,_OTHER:NEOPLASMS
ULINASTATIN;MMP2;rs243865;T;EFFICACY;DECREASED_RESPONSE;OTHER:PANCREATITIS
ANTIPSYCHOTICS;ABCB1;rs1128503;G;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ULINASTATIN;MMP9;rs3918242;T;EFFICACY;INCREASED_RESPONSE;OTHER:PANCREATITIS
TACROLIMUS;CYP3A4;rs35599367;AA + AG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;NR1I2;rs2276707;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ANTIPSYCHOTICS;ABCB1;rs1045642;G;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
IRINOTECAN;NR1I2;rs10934498;AA;TOXICITY, LADME_PK;DECREASED_EXPOSURE;DISEASE:COLONIC_NEOPLASMS
TACROLIMUS;IL10;rs1800896;CC;DOSAGE;DECREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
OLANZAPINE, PERPHENAZINE;RGS4;rs2842030;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
OLANZAPINE;DRD3;rs324026;C;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;ADH1A;rs6811453;A;EFFICACY;INCREASED_RESISTANCE;DISEASE:ACUTE_MYELOID_LEUKEMIA
RISPERIDONE;RGS4;rs2842030;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
MEASLES VACCINES;TLR3;rs3775291;CT;EFFICACY;DECREASED_RESPONSE;
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;ADH1A;rs1826909;T;EFFICACY;INCREASED_RESISTANCE;DISEASE:ACUTE_MYELOID_LEUKEMIA
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;
TAMOXIFEN;ABCC2;rs717620;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
SALBUTAMOL;;rs77149876;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;A;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CARBAMAZEPINE;SCN1A;rs3812718;TT;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
SALBUTAMOL;PAPPA2;rs77977790;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
NORBUPRENORPHINE;OPRD1;rs569356;GG;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:OPIOID-RELATED_DISORDERS
TACROLIMUS;CYP3A4;rs2740574;CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
SALMETEROL;ADRB2;rs1042713;G;EFFICACY;INCREASED_RESPONSE;OTHER:ASTHMA
SALBUTAMOL;;rs116551936;AG;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
SALBUTAMOL;NCOA3;rs115501901;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
LITHIUM;CACNG2;rs2284017;C;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
SALBUTAMOL;;rs74973995;AG;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
SALBUTAMOL;CRHR2;rs73294475;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
PHENPROCOUMON;CYP3A4;rs2740574;C;DOSAGE;DECREASED_DOSE;
SALBUTAMOL;ADCY9;rs144315541;AG;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
PERPHENAZINE;MCPH1;rs17570753;A;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
PERPHENAZINE;CDH13;rs2116971;G;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
PERPHENAZINE;SKOR2;rs9952628;G;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
METFORMIN;SLC47A2;rs12943590;AA;EFFICACY, LADME_PK;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
QUETIAPINE;KCNMA1;rs35793;G;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
PERPHENAZINE;MAML3;rs11100483;A;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
VALPROIC ACID;UGT2B7;rs7668258;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
METHACHOLINE;RUNX1;rs11702779;AA;OTHER;INCREASED_RESPONSE;DISEASE:ASTHMA
RISPERIDONE;LRP1B;rs874295;G;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
BEVACIZUMAB;HTRA1;rs11200638;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
RISPERIDONE;PSMD14;rs9713;A;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
RISPERIDONE;AGAP1;rs1869295;C;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
BEVACIZUMAB;ARMS2;rs10490924;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
VALPROIC ACID;APEH;rs3816877;CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
RISPERIDONE;NPAS3;rs1315115;G;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
RISPERIDONE;TMEFF2;rs3738883;G;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
METFORMIN;PCK1;rs4810083;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
ZIPRASIDONE;CDH4;rs4925300;A;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
ZIPRASIDONE;LYN;rs1546519;G;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
BEVACIZUMAB;CFH;rs800292;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
WARFARIN;CYP2C9;rs1799853;CT;DOSAGE;DECREASED_DOSE;
ZIPRASIDONE;NALCN;rs9585618;C;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
ZIPRASIDONE;CNTN4;rs17194378;A;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
OPIOIDS;COMT;rs4680;GG;DOSAGE;INCREASED_DOSE;DISEASE:NEOPLASMS,_DISEASE:PAIN
IMATINIB;SLCO1A2;rs4148978;CT + TT;TOXICITY, LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:GASTROINTESTINAL_STROMAL_TUMORS
IMATINIB;SLCO1B3;rs4149117;GG;TOXICITY, LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:GASTROINTESTINAL_STROMAL_TUMORS
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED_RESPONSE;
WARFARIN;CALU;rs2290228;AA;DOSAGE;DECREASED_DOSE;
OLANZAPINE;;rs12610827;T;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA
REMIFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER:SURGERY
FENOFIBRATE;APOB;rs676210;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
METHACHOLINE;RUNX1;rs11702779;AG + GG;OTHER;INCREASED_RESPONSE;DISEASE:ASTHMA
CITALOPRAM, FLUOXETINE;SERPINE1;rs1799889;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METHOTREXATE;MTR;rs1805087;G;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:NON-HODGKIN_LYMPHOMA,_OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CITALOPRAM, FLUOXETINE, MIRTAZAPINE, PAROXETINE, SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;FKBP5;rs4713916;A;EFFICACY;INCREASED_RESPONSE;DISEASE:MOOD_DISORDER
OLANZAPINE;CSMD1;rs17070785;A;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
OLANZAPINE;PLAGL1;rs2247408;C;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
SIROLIMUS;CYP3A5;rs15524;AA;LADME_PK;INCREASED_TROUGH CONCENTRATION;OTHER:KIDNEY_TRANSPLANTATION
OLANZAPINE;PLAGL1;rs3819811;A;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
SIROLIMUS;CYP3A5;rs4646453;CC;LADME_PK;INCREASED_TROUGH CONCENTRATION;OTHER:KIDNEY_TRANSPLANTATION
ACETAMINOPHEN;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;
OLANZAPINE;PTPRN2;rs221253;C;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
IMATINIB;SLC22A1;rs628031;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
WARFARIN;NQO1;rs1800566;AA + AG;DOSAGE;INCREASED_DOSE;
PERPHENAZINE;PRKCE;rs2278773;C;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
PERPHENAZINE;;rs11774231;C;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
HYDROCHLOROTHIAZIDE;DOT1L;rs2269879;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
PAROXETINE;ADM;rs11042725;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;
TILDRAKIZUMAB;ATG5;rs9373839;CT;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
TILDRAKIZUMAB;IL17RC;rs708567;CC;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
CITALOPRAM;BDNF;rs7124442;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ARIPIPRAZOLE;ABCB1;rs2032582;AA;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;
CLOZAPINE;OXT;rs2740204;T;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
DIAZEPAM;CYP3A4;rs35599367;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ALCOHOL_ABUSE
METHOTREXATE;MTHFR;rs1801133;G;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CROHN_DISEASE
METHOTREXATE;DHFR;rs408626;C;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CROHN_DISEASE
REPAGLINIDE;NOS1AP;rs10494366;T;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
CITALOPRAM;BDNF;rs7103411;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_RESISTANCE;DISEASE:HIV_INFECTIOUS_DISEASE
CITALOPRAM;BDNF;rs6265;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
LAMIVUDINE, LOPINAVIR, RITONAVIR, ZIDOVUDINE;ABCC1;rs212091;CC + CT;EFFICACY;INCREASED_RESISTANCE;DISEASE:HIV_INFECTIOUS_DISEASE
FLUOXETINE;BDNF;rs6265;CT;EFFICACY;INCREASED_CLINICAL BENEFIT;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TILDRAKIZUMAB;TNFAIP3;rs610604;GG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
ANTIDEPRESSANTS;ERICH3;rs11580409;CC;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
CLOPIDOGREL;CYP2C19;rs12248560;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
ARIPIPRAZOLE;ABCB1;rs1045642;AA;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;
IVACAFTOR;CFTR;rs77932196;A;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
PAROXETINE;DRD3;rs6280;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ENTACAPONE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:PARKINSON_DISEASE
CLOZAPINE;CYP2D6;rs1065852;AA;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
CLOZAPINE;CYP2D6;rs16947;GG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
ATORVASTATIN, SIMVASTATIN;ABCG8;rs11887534;CC + CG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DYSLIPIDAEMIA
IVACAFTOR;CFTR;rs121909011;C;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
IMATINIB;ULK3;rs2290573;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
CLOZAPINE;DRD1;rs265976;GT;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
INTERFERONS;STAT3;rs4796793;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:RENAL_CELL_CARCINOMA
TAMOXIFEN;SLCO2B1;rs12422149;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
ACENOCOUMAROL;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_DOSE;
WARFARIN;VKORC1;rs2359612;AA + AG;DOSAGE;DECREASED_DOSE;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
WARFARIN;VKORC1;rs8050894;CG + GG;DOSAGE;DECREASED_DOSE;
RISPERIDONE;HRH3;rs3787430;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
WARFARIN;;rs12777823;AA + AG;DOSAGE;DECREASED_DOSE;
WARFARIN;VKORC1;rs2884737;AC + CC;DOSAGE;DECREASED_DOSE;
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_DOSE;
RISPERIDONE;HRH3;rs3787429;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ACENOCOUMAROL;VKORC1;rs17708472;AA + AG;DOSAGE;INCREASED_DOSE;
ARIPIPRAZOLE;TAAR6;rs4305746;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
PEGINTERFERON ALFA-2A;IL6;rs1800795;G;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2A;IL6;rs1800796;G;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2A;IL6;rs1800797;G;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
WARFARIN;VKORC1;rs104894540;G;DOSAGE;INCREASED_DOSE;
ROSUVASTATIN;ABCG2;rs2199936;AA + AG;EFFICACY;INCREASED_RESPONSE;
WARFARIN;VKORC1;rs104894542;C;DOSAGE;INCREASED_DOSE;
ILOPERIDONE;CNTF, ZFP91-CNTF;rs1800169;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;
DISULFIRAM;OPRD1;rs678849;CC;EFFICACY;INCREASED_RESPONSE;OTHER:COCAINE_DEPENDENCE
ERYTHROPOIETIN;STIM1;rs1561876;AG + GG;EFFICACY;INCREASED_RESISTANCE;OTHER:KIDNEY_DISORDER,_OTHER:ANEMIA
LATANOPROST;PTGFR;rs3753380;CC;EFFICACY;INCREASED_RESPONSE;
RANIBIZUMAB;VEGFA;rs699947;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
FUROSEMIDE;ABCC4;rs17268282;T;EFFICACY;INCREASED_RESPONSE;DISEASE:HEART_FAILURE
METFORMIN;SLC22A1;rs622342;CC;EFFICACY;RESPONSE;OTHER:GENETIC_VARIATION_AT_RS2289669
MORPHINE;COMT;rs737866;T;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;COMT;rs2075507;G;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
ANTIEPILEPTICS;CYP1A1;rs2606345;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:EPILEPSY
MORPHINE;COMT;rs5746849;A;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;COMT, TXNRD2;rs7287550;C;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;COMT;rs6269;A;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
CARBAMAZEPINE;CYP3A4;rs2740574;TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:EPILEPSY
MORPHINE;COMT;rs740603;A;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
MORPHINE;ABCC3;rs4793665;T;LADME_PK;DECREASED_CLEARANCE;
TACROLIMUS;POR;rs1057868;T;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;CYP2D6;rs35742686;DELT/T;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
N-DESMETHYLTRAMADOL, TRAMADOL;CYP3A4;rs35599367;AG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY;DECREASED_RESPONSE;OTHER:CORONARY_ARTERY_DISEASE
CLOPIDOGREL;CYP2C19;rs4986893;AG;EFFICACY;DECREASED_RESPONSE;OTHER:CORONARY_ARTERY_DISEASE
CLOPIDOGREL;ABCC2;rs717620;CC;EFFICACY;DECREASED_RESPONSE;OTHER:CORONARY_ARTERY_DISEASE
ATAZANAVIR;SORCS2;rs73208473;A;LADME_PK;DECREASED_EXPOSURE;OTHER:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;rs104894539;A;DOSAGE;INCREASED_DOSE;
WARFARIN;VKORC1;rs104894541;C;DOSAGE;INCREASED_DOSE;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;ZNF816;rs9304742;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
CARBAMAZEPINE;UGT2B7;rs28365063;AA;LADME_PK;DECREASED_CLEARANCE;DISEASE:EPILEPSY
CARBAMAZEPINE;NR1I2;rs3814055;T;LADME_PK;DECREASED_CLEARANCE;DISEASE:EPILEPSY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PGLYRP4;rs2916205;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
METHOTREXATE;MTHFR;rs1801133;AA + AG;LADME_PK;INCREASED_EXPOSURE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
SULFONAMIDES, UREA DERIVATIVES;CYP2C9;rs1799853;TT;EFFICACY;INCREASED_RESPONSE;
SUMATRIPTAN;GNB3;rs5443;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:CLUSTER_HEADACHE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;rs2546890;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
DESETHYL HYDROXYCHLOROQUINE;CYP2D6;rs1135840;G;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS
CANNABINOIDS;TRPV1;rs8065080;CC;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PAIN
RIVAROXABAN;ABCB1;rs4728709;AA + AG;LADME_PK;INCREASED_CLEARANCE;OTHER:ATRIAL_FIBRILLATION
CANNABINOIDS;UGT2B7;rs7438135;AA;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PAIN
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CTNNA2;rs11126740;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
IMATINIB;ABCG2;rs2231142;GT;OTHER, LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
DESETHYL HYDROXYCHLOROQUINE;CYP2D6;rs1065852;AA;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS
REPAGLINIDE;KCNJ11;rs5219;T;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
TRAMADOL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER:PAIN,_POSTOPERATIVE
REPAGLINIDE;TCF7L2;rs290487;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
MORPHINE;COMT;rs4680;A;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
CARBAMAZEPINE;EPHX1;rs1051740;TT;LADME_PK;DECREASED_METABOLISM;DISEASE:EPILEPSY
MORPHINE;COMT;rs4818;C;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
ERYTHROPOIETIN;ORAI1;rs12320939;GG + GT;EFFICACY;INCREASED_RESISTANCE;OTHER:KIDNEY_DISORDER,_OTHER:ANEMIA
CARBAMAZEPINE;ABCB1;rs1128503;AA + AG;LADME_PK;INCREASED_CLEARANCE;DISEASE:EPILEPSY
MORPHINE;COMT;rs2239393;A;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
MERCAPTOPURINE;NUDT15;rs116855232;CT;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MORPHINE;ARVCF, COMT;rs165728;T;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
CARBAMAZEPINE;ABCB1;rs4148740;AG;LADME_PK;INCREASED_METABOLISM;DISEASE:EPILEPSY
CARBAMAZEPINE;ABCB1;rs4148739;TT;LADME_PK;DECREASED_METABOLISM;DISEASE:EPILEPSY
MORPHINE;ARVCF, COMT;rs174699;T;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS
ANTIPSYCHOTICS;DRD2;rs1799732;del;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
HMG COA REDUCTASE INHIBITORS;CETP;rs1532624;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CDKAL1;rs6908425;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
CARBAMAZEPINE;ABCC2;rs2273697;AA + AG;LADME_PK;INCREASED_CLEARANCE;DISEASE:EPILEPSY
HMG COA REDUCTASE INHIBITORS;SIK3;rs533556;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;HLA-C;rs12191877;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
RITODRINE;KCNMB2;rs7624046;TT;EFFICACY;DECREASED_RESPONSE;
CARBAMAZEPINE;ABCC2;rs4148386;AA + AG;LADME_PK;INCREASED_CLEARANCE;DISEASE:EPILEPSY
WARFARIN;VKORC1;rs61742245;AA + AC;DOSAGE;INCREASED_DOSE;
CARBAMAZEPINE;ABCC2;rs3740066;CT + TT;LADME_PK;DECREASED_METABOLISM;DISEASE:EPILEPSY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAP3K1;rs96844;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
RITODRINE;KCNMB2;rs9839376;CC;EFFICACY;DECREASED_RESPONSE;
WARFARIN;GGCX;rs11676382;G;DOSAGE;DECREASED_DOSE;
CARBAMAZEPINE;NR1I2;rs7643645;G;LADME_PK;INCREASED_METABOLISM;DISEASE:EPILEPSY
MORPHINE;METTL21A;rs2952768;CC;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
CARBAMAZEPINE;NR1I2;rs4688040;T;LADME_PK;INCREASED_METABOLISM;DISEASE:EPILEPSY
CANNABINOIDS;ABCB1;rs1045642;AG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PAIN
MORPHINE;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
CARBAMAZEPINE;NR1I2;rs2461817;C;LADME_PK;INCREASED_METABOLISM;DISEASE:EPILEPSY
METOPROLOL;ADRB1;rs1801252;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
WARFARIN;VKORC1;rs2884737;CC;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;SRP19;rs495794;G;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;
CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;REEP5;rs153560;G;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;rs8050894;GG;DOSAGE;DECREASED_DOSE;
CITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;REEP5;rs153549;A;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ATAZANAVIR;ABCB1;rs1045642;AA + AG;DOSAGE;DOSE;DISEASE:HIV_INFECTIOUS_DISEASE
ATAZANAVIR;SLCO1B1;rs4149056;TT;DOSAGE;DOSE;DISEASE:HIV_INFECTIOUS_DISEASE
FLUOROURACIL;DPYD;rs3918290;CT;OTHER, LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
ATAZANAVIR;NR1I2;rs2472677;TT;DOSAGE;DOSE;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;rs61742245;AC;DOSAGE;INCREASED_DOSE;OTHER:WARFARIN_MAINTENANCE_TREATMENT
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
ACENOCOUMAROL;VKORC1;rs9923231;CT;DOSAGE;DECREASED_DOSE;
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;rs2227310;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;rs4353229;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;rs12415607;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
DOCETAXEL, GEMCITABINE, PACLITAXEL, PLATINUM COMPOUNDS, VINORELBINE;CASP7;rs7921977;CT;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
OLANZAPINE;SLC26A9;rs11240594;A;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
SOLANIDINE;NFIB;rs28379954;CC + CT;LADME_PK;INCREASED_METABOLISM;
ZIPRASIDONE;EHF;rs286913;A;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CLOZAPINE;SLC6A3;rs2975226;A;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
OLANZAPINE;IL1A;rs11677416;C;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CYCLOSPORINE;POR;rs1057868;TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
CARBAMAZEPINE;EPHX1;rs1051740;C;DOSAGE, LADME_PK;INCREASED_METABOLISM;DISEASE:EPILEPSY
PIOGLITAZONE;PTPRD;rs17584499;CC;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;CC + CT;EFFICACY;INCREASED_DOSE;
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
ACAMPROSATE;GRIN2B;rs2058878;A;EFFICACY;INCREASED_RESPONSE;DISEASE:ALCOHOL_ABUSE
OLANZAPINE;ATP1A2;rs6688363;T;EFFICACY;DECREASED_RESPONSE;OTHER:SCHIZOPHRENIA
RISPERIDONE;;rs8050896;T;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
RISPERIDONE;TNFRSF11A;rs2980976;A;EFFICACY;DECREASED_RESPONSE;OTHER:SCHIZOPHRENIA
RISPERIDONE;PPA2;rs2636697;G;EFFICACY;DECREASED_RESPONSE;OTHER:SCHIZOPHRENIA
METHOTREXATE;;rs1232027;A;EFFICACY;INCREASED_RESPONSE;DISEASE:ARTHRITIS,_PSORIATIC
FENTANYL, HYDROMORPHONE, OPIOIDS, OXYCODONE, TRAMADOL;OPRM1;rs1799971;AA;DOSAGE;INCREASED_DOSE;OTHER:SURGERY
RISPERIDONE;PPA2;rs2636719;A;EFFICACY;DECREASED_RESPONSE;OTHER:SCHIZOPHRENIA
REPAGLINIDE;IGF2BP2;rs4402960;GT + TT;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
REPAGLINIDE;IGF2BP2;rs1470579;AC + CC;DOSAGE, EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
DISULFIRAM;MTHFR;rs1801133;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:COCAINE_DEPENDENCE
IVACAFTOR;CFTR;rs78655421;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ARTHRITIS,_PSORIATIC,_DISEASE:CROHN_DISEASE,_DISEASE:PSORIASIS,_DISEASE:SPONDYLITIS,_ANKYLOSING
ISONIAZID;NAT2;rs4646244;AT;TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:TUBERCULOSIS
PLATINUM COMPOUNDS;ERCC1;rs11615;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:OVARIAN_NEOPLASMS
ISONIAZID;NAT2;rs1799930;AA;TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:TUBERCULOSIS
HYDROCHLOROTHIAZIDE;BEST3;rs61747221;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
DEFERIPRONE;UGT1A6;rs2070959;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;rs396991;C;EFFICACY;INCREASED_RESPONSE;DISEASE:ARTHRITIS,_PSORIATIC,_DISEASE:CROHN_DISEASE,_DISEASE:PSORIASIS,_DISEASE:SPONDYLITIS,_ANKYLOSING
NIFEDIPINE;ADRA1A;rs1048101;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
DEFERIPRONE;UGT1A6;rs2070959;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
DEFERIPRONE;UGT1A6;rs6759892;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
PIOGLITAZONE;PPARG;rs1801282;CG;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
PACLITAXEL, PLATINUM COMPOUNDS;CASP7;rs4353229;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
OPIOIDS;TNF;rs1800629;GG;DOSAGE;INCREASED_DOSE;OTHER:NEOPLASMS,_OTHER:PAIN
CARBAMAZEPINE;SCN1A;rs3812718;CT;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
PACLITAXEL, PLATINUM COMPOUNDS;CASP7;rs2227310;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
RISPERIDONE;TJP1;rs813676;T;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
OPIOIDS;IL6;rs1800797;A;DOSAGE;DECREASED_DOSE;OTHER:NEOPLASMS,_OTHER:PAIN
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:MYOCARDIAL_INFARCTION
METHYLPHENIDATE;ADGRL3;rs734644;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
PACLITAXEL, PLATINUM COMPOUNDS;CASP7;rs1127687;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
FLUTICASONE PROPIONATE, MONTELUKAST;CA10;rs967676;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
CARBAMAZEPINE;EPHX1;rs1051740;CT;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
CARBAMAZEPINE;EPHX1;rs1051740;CC;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
GEMCITABINE, PLATINUM COMPOUNDS;CASP7;rs1127687;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
FLUTICASONE PROPIONATE, MONTELUKAST;;rs1786929;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
CYTARABINE;CDA;rs2072671;CC;TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:LYMPHOMA,_T-CELL
TACROLIMUS;ABCB1;rs2032582;AA;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
CARBAMAZEPINE;SCN1A;rs3812718;TT;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;
METHYLPHENIDATE;ADGRL3;rs1355368;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
METHYLPHENIDATE;ADGRL3;rs6813183;CC + CG;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
RISPERIDONE;;rs7395555;C;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
RANIBIZUMAB;CFH;rs1061170;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
OLANZAPINE;SPOPL;rs10170310;C;EFFICACY;DECREASED_RESPONSE;OTHER:SCHIZOPHRENIA
QUETIAPINE;PDE4D;rs17382202;T;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;DOSE;
ACENOCOUMAROL;CYP4F2;rs2108622;T;DOSAGE;DOSE;
QUETIAPINE;PDE4D;rs17742120;G;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
QUETIAPINE;PDE4D;rs2164660;A;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
ACENOCOUMAROL;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION,_DISEASE:VENOUS_THROMBOEMBOLISM
PERINDOPRIL;AGTR1;rs5182;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
RISPERIDONE;TJP1;rs711355;T;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
RISPERIDONE;TJP1;rs785423;A;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
TENOFOVIR ALAFENAMIDE;ABCB1;rs3842;CT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEPATITIS_B_VIRUS_INFECTION,_DISEASE:HIV_INFECTIOUS_DISEASE
CLOZAPINE;SLC6A4;rs25531;T;EFFICACY;RESPONSE;DISEASE:SCHIZOPHRENIA
RALOXIFENE;UGT1A8;rs1042597;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:MENOPAUSE,_DISEASE:SCHIZOPHRENIA
ACENOCOUMAROL, PHENPROCOUMON;VKORC1;rs9923231;T;DOSAGE;DOSE;
ESOMEPRAZOLE;STAT6;rs1059513;CC + CT;EFFICACY;INCREASED_RESPONSE;OTHER:EOSINOPHILIC_ESOPHAGITIS
RISPERIDONE;WBP2NL;rs5758550;A;LADME_PK;DECREASED_CLEARANCE;
PACLITAXEL, PLATINUM COMPOUNDS;CASP7;rs12415607;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
ADALIMUMAB;CD40LG;rs1126535;T;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
RALOXIFENE;ESR1;rs11543791;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:MENOPAUSE,_DISEASE:SCHIZOPHRENIA
PERINDOPRIL;AGTR1;rs275651;AA + AT;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
LITHIUM;MYO1H;rs7959663;C;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
INFLIXIMAB;FCGR2A;rs1801274;G;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
LITHIUM;EPHX2;rs59724122;T;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;GRAMD1B;rs61123830;A;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
WARFARIN;VKORC1;rs7294;T;DOSAGE;DECREASED_DOSE;
LITHIUM;;rs66486766;A;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;;rs324899;A;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;;rs1611259;T;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;;rs6942227;A;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
NEVIRAPINE;CYP2D6;rs28371706;AA + AG;DOSAGE, LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;CYP2B6;rs3745274;GT + TT;DOSAGE, LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
CATECHOLAMINES;ADRB1;rs1801253;CC;DOSAGE;DECREASED_DOSE;DISEASE:CORONARY_ARTERY_DISEASE
ACENOCOUMAROL;APOE;rs429358;CC;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION,_DISEASE:VENOUS_THROMBOEMBOLISM
PERINDOPRIL;BDKRB1;rs12050217;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
WARFARIN;VKORC1;rs17708472;A;DOSAGE;INCREASED_DOSE;
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;rs680244;C;OTHER;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;NFATC2;rs3787186;CC + CT;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3, CHRNA5;rs16969968;G;OTHER;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;rs680244;T;OTHER;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
ALLOPURINOL;ABCG2;rs2231142;T;EFFICACY;DECREASED_RESPONSE;OTHER:GOUT
LITHIUM;FAM177A1;rs79403677;T;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
CLOPIDOGREL;;rs2487032;A;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
WARFARIN;VKORC1;rs9923231;A;DOSAGE;DECREASED_DOSE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CHUK;rs11591741;G;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;
LITHIUM;ADCY1;rs1521470;A;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
WARFARIN;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE;
REPAGLINIDE;KCNQ1;rs2237892;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
LITHIUM;;rs7588746;A;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;FAM178B;rs6728642;A;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
BETA BLOCKING AGENTS;GRK5;rs2230345;AT + TT;EFFICACY;INCREASED_RESPONSE;OTHER:HEART_FAILURE
ZILEUTON;PRORP;rs12436663;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
LITHIUM;ZNF804A;rs62200793;T;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;;rs1611255;A;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;;rs209474;A;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
REPAGLINIDE;KCNQ1;rs2237895;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
LITHIUM;;rs3919583;A;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
PLATINUM COMPOUNDS;XRCC1;rs1799782;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
GLATIRAMER ACETATE;TGFB1;rs1800469;A;EFFICACY;DECREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
ANTIEPILEPTICS;ABCC2;rs3740066;CT + TT;EFFICACY;INCREASED_RESISTANCE;DISEASE:EPILEPSY
N-DESMETHYLTAMOXIFEN;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
GLUCOCORTICOIDS;GLCCI1;rs37973;G;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;
ANTIEPILEPTICS;ABCC2;rs717620;CT + TT;EFFICACY;INCREASED_RESISTANCE;DISEASE:EPILEPSY
AMLODIPINE;CYP3A4;rs2246709;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
NICOTINE;CYP2B6;rs2279343;G;LADME_PK;INCREASED_METABOLISM;DISEASE:TOBACCO_USE_DISORDER
TENELIGLIPTIN;FMO3;rs2266780;AG + GG;LADME_PK;DECREASED_CLEARANCE;
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3, CHRNA5;rs16969968;A;OTHER;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
QUETIAPINE;COMT;rs4818;C;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
HYDROCHLOROTHIAZIDE;GPR83;rs3758785;GG;EFFICACY;DECREASED_RESPONSE;EFFICACY:ESSENTIAL_HYPERTENSION
QUETIAPINE;COMT;rs5993883;T;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
TENELIGLIPTIN;FMO3;rs909530;CT + TT;LADME_PK;DECREASED_CLEARANCE;
MENOTROPINS;FSHR;rs6166;CT;;DECREASED_DOSE;
QUETIAPINE;COMT;rs6269;A;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CANDESARTAN;GPR83;rs3758785;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
TACROLIMUS;IL6;rs1800795;GG;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
TENELIGLIPTIN;FMO3;rs2266782;AG + GG;LADME_PK;DECREASED_CLEARANCE;
PACLITAXEL;ABCB1;rs2032582;CT;LADME_PK;INCREASED_METABOLISM;DISEASE:OVARIAN_NEOPLASMS
HYDROCHLOROTHIAZIDE;HSD3B1;rs7553527;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
HYDROCHLOROTHIAZIDE;TTC6;rs177852;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
TENELIGLIPTIN;CYP3A4;rs2242480;CT + TT;LADME_PK;DECREASED_CONCENTRATIONS;
GLATIRAMER ACETATE;IFNAR1;rs1012335;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
DARUNAVIR;SLCO3A1;rs8027174;GT + TT;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
ATORVASTATIN;CYP3A4;rs2740574;CC;EFFICACY;DECREASED_RESPONSE;OTHER:CARDIOVASCULAR_DISEASE,_OTHER:HYPERLIPIDEMIAS
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs121909047;A;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs75961395;AA + AG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
6-HYDROXY S-WARFARIN;;rs368245720;A;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION,_OTHER:VENOUS_THROMBOEMBOLISM,_OTHER:HEART_VALVE_DISEASES
ATORVASTATIN;CYP3A5;rs776746;CC;EFFICACY;INCREASED_RESPONSE;OTHER:CARDIOVASCULAR_DISEASE,_OTHER:HYPERLIPIDEMIAS
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, SERTRALINE;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
6-HYDROXY S-WARFARIN;PARP14;rs10433340;A;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION,_OTHER:VENOUS_THROMBOEMBOLISM,_OTHER:HEART_VALVE_DISEASES
METOPROLOL;ADRB1;rs1801253;C;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs121909019;T;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs121909011;T;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs75549581;A;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
EFAVIRENZ;NR1I3;rs3003596;GG;LADME_PK;INCREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
IMATINIB;ABCG2;rs12505410;G;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
IMATINIB;ABCG2;rs12505410;GG + GT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
TAMOXIFEN;CYP19A1;rs4646;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
6-HYDROXY R-WARFARIN, 6-HYDROXY S-WARFARIN;GRID2;rs558364281;G;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION,_OTHER:VENOUS_THROMBOEMBOLISM,_OTHER:HEART_VALVE_DISEASES
IMATINIB;ABCG2;rs13120400;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
METHOTREXATE;SLCO1B1;rs10841753;CT + TT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
IMATINIB;ABCG2;rs2725252;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
LACIDIPINE, NIFEDIPINE, NITRENDIPINE;CACNA1C;rs2238032;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
LUMEFANTRINE;CYP3A4;rs2740574;C;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MALARIA,_OTHER:PREGNANCY
QUETIAPINE;HTR1A;rs10042486;TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
AMITRIPTYLINE, CLOMIPRAMINE, DULOXETINE, IMIPRAMINE, MILNACIPRAN, VENLAFAXINE;BDNF;rs6265;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
CHLORPROMAZINE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE;EPM2A;rs1415744;C;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
AMLODIPINE, FELODIPINE;CACNA1C;rs2239050;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
WARFARIN;CYP2C18;rs41291550;A;LADME_PK;DECREASED_METABOLISM;OTHER:ATRIAL_FIBRILLATION,_OTHER:VENOUS_THROMBOEMBOLISM,_OTHER:HEART_VALVE_DISEASES
ATORVASTATIN;CYP3A4;rs2740574;TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:CARDIOVASCULAR_DISEASE,_OTHER:HYPERLIPIDEMIAS
CITALOPRAM, FLUOXETINE;GSK3B;rs334558;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;rs9332241;T;LADME_PK;DECREASED_METABOLISM;OTHER:ATRIAL_FIBRILLATION,_OTHER:VENOUS_THROMBOEMBOLISM,_OTHER:HEART_VALVE_DISEASES
LUMEFANTRINE;CYP3A5;rs10264272;T;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MALARIA,_OTHER:PREGNANCY
ATORVASTATIN;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:CARDIOVASCULAR_DISEASE,_OTHER:HYPERLIPIDEMIAS
WARFARIN;FPGS;rs7856096;G;DOSAGE;DECREASED_DOSE;
WARFARIN;FPGS;rs7856096;G;DOSAGE;DECREASED_DOSE;
LUMEFANTRINE;CYP3A5;rs776746;C;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MALARIA,_OTHER:PREGNANCY
INFLIXIMAB;FCGR3A;rs396991;A;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CETUXIMAB;FCGR3A;rs396991;A;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ALCOHOL_ABUSE
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;CG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
AMLODIPINE, FELODIPINE;CACNA1C;rs2239128;C;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:COLORECTAL_NEOPLASMS
SUNITINIB;CYP3A5;rs776746;T;DOSAGE;DECREASED_DOSE;DISEASE:RENAL_CELL_CARCINOMA
N-DESMETHYLCLOZAPINE;UGT2B10;rs61750900;GT;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
LUMEFANTRINE;CYP3A4;rs2740574;T;EFFICACY;DECREASED_RESPONSE;DISEASE:MALARIA,_DISEASE:PREGNANCY
CLOPIDOGREL;N6AMT1;rs2254638;G;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
VALPROIC ACID;UGT1A6;rs6759892;TT;LADME_PK;INCREASED_EXPOSURE;OTHER:EPILEPSY
FENTANYL;ASTN2;rs7858836;CT + TT;DOSAGE;DECREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
BENAZEPRIL, IMIDAPRIL;CYP11B2;rs1799998;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
FENTANYL;ASTN2;rs958804;CC + CT;DOSAGE;DECREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
VALPROIC ACID;UGT1A6;rs1105879;AA;LADME_PK;INCREASED_EXPOSURE;OTHER:EPILEPSY
VALPROIC ACID;UGT1A6;rs2070959;AA;LADME_PK;INCREASED_EXPOSURE;OTHER:EPILEPSY
TACROLIMUS;CYP3A4;rs35599367;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
ETIDRONIC ACID;COL1A1;rs1800012;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE:METABOLIC_BONE_DISORDER
VORICONAZOLE;ABCG2;rs13120400;CC;LADME_PK;INCREASED_TROUGH CONCENTRATION;
MORPHINE, NORTRIPTYLINE;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE;OTHER:PAIN
RISPERIDONE;HTR1A;rs6295;CG + GG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
DULOXETINE;;rs4858478;G;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:COLORECTAL_NEOPLASMS
VALPROIC ACID;UGT1A6;rs6759892;GG;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
DULOXETINE;ZNF385D;rs13093500;T;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
FOLIC ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;SLC19A1;rs1051266;T;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
DULOXETINE;ZNF385D;rs4334661;T;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
FOLIC ACID, HYDROXYCHLOROQUINE, METHOTREXATE, SULFASALAZINE;MTR;rs1805087;A;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
DULOXETINE;;rs7625956;G;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;rs4646453;CC;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TAMOXIFEN;SULT1A1;rs1042028;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
DULOXETINE;ZNF385D;rs7616119;G;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;;rs2933304;T;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;rs9923231;CT;DOSAGE;INCREASED_DOSE;DISEASE:THROMBOEMBOLISM
METHOTREXATE;SLC19A1;rs1051266;T;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
DULOXETINE;NRXN1;rs4971678;T;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TRAMADOL;RGL4;rs184199168;A;LADME_PK;DECREASED_METABOLISM;
DULOXETINE;ZNF385D;rs12630569;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TRAMADOL;;rs72732317;T;LADME_PK;DECREASED_METABOLISM;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:THROMBOEMBOLISM
BEVACIZUMAB, CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN;VEGFA;rs699947;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
TRAMADOL;HCN1;rs79983226;C;LADME_PK;DECREASED_METABOLISM;
TRAMADOL;ICA1;rs62435418;A;LADME_PK;DECREASED_METABOLISM;
ERYTHROPOIETIN;HFE;rs1800562;A;DOSAGE, LADME_PK;DECREASED_DOSE;OTHER:HEMODIALYSIS_TREATMENT
DULOXETINE;;rs6700741;C;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ENALAPRIL;ADRB2;rs1042714;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTROPHY,_LEFT_VENTRICULAR
ATENOLOL, ENALAPRIL;ADRB2;rs1042714;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTROPHY,_LEFT_VENTRICULAR
BEVACIZUMAB, CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN, OXALIPLATIN;VEGFA;rs3025039;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
ERYTHROPOIETIN;HFE;rs1799945;G;DOSAGE, LADME_PK;DECREASED_DOSE;OTHER:HEMODIALYSIS_TREATMENT
TRAMADOL;RFPL4B;rs9384825;T;LADME_PK;DECREASED_METABOLISM;
DULOXETINE;TEX10;rs6479008;C;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;rs15524;AA;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
DULOXETINE;TEX10;rs7035619;A;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;TEX10;rs10989064;T;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DIGOXIN;ABCB1;rs1045642;GG;LADME_PK;INCREASED_METABOLISM;
DULOXETINE;ATP10A;rs12595802;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;TEX10;rs7472;G;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
MYCOPHENOLIC ACID;IMPDH2;rs11706052;G;EFFICACY;DECREASED_RESPONSE;
DULOXETINE;;rs56229625;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DIGOXIN;ABCB1;rs2032582;CC;LADME_PK;INCREASED_METABOLISM;
DULOXETINE;;rs61692318;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;;rs62319299;A;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
DULOXETINE;TEX10;rs10124893;G;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;INVS;rs10123866;G;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ABEMACICLIB, PALBOCICLIB, RIBOCICLIB;ABCB1;rs1045642;A;DOSAGE, TOXICITY;DECREASED_DOSE;OTHER:BREAST_NEOPLASMS
DULOXETINE;;rs10007051;C;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
DULOXETINE;ZNF385D;rs9879065;C;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;;rs55881666;C;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
INFLIXIMAB;;rs2097432;CC + CT;EFFICACY;DECREASED_RESPONSE;OTHER:CROHN_DISEASE
VALPROIC ACID;CYP2C9;rs4918758;CC + CT;LADME_PK;INCREASED_EXPOSURE;OTHER:EPILEPSY
DULOXETINE;;rs11933890;A;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
VALPROIC ACID;CYP2C19;rs4244285;AA + AG;LADME_PK;INCREASED_EXPOSURE;OTHER:EPILEPSY
DULOXETINE;ZNF385D;rs9310658;C;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ZNF385D;rs7653345;A;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
VALPROIC ACID;ABAT;rs1731017;GG;LADME_PK;INCREASED_EXPOSURE;OTHER:EPILEPSY
DULOXETINE;ZNF385D;rs9310657;T;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ZNF385D;rs9824595;G;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ZNF385D;rs9873889;C;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ZNF385D;rs9819548;G;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;
CAPECITABINE;CDA;rs532545;CC;EFFICACY;DECREASED_RESPONSE;OTHER:BREAST_NEOPLASMS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
HYDRALAZINE / ISOSORBIDE DINITRATE;NOS3;rs1799983;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HEART_FAILURE
WARFARIN;CYP2C9;rs56165452;C;DOSAGE;DECREASED_DOSE;
TACROLIMUS;ABCB1;rs1045642;AA;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
ADALIMUMAB;CRP;rs1130864;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
OLANZAPINE;CYP3A43;rs472660;AA;DOSAGE, EFFICACY, TOXICITY, LADME_PK;INCREASED_CLEARANCE;DISEASE:SCHIZOPHRENIA
GLATIRAMER ACETATE;EOMES;rs2371108;T;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
CARVEDILOL;UGT1A1;rs4148323;A;LADME_PK;DECREASED_METABOLISM;DISEASE:ANGINA_PECTORIS
ETOPOSIDE;ABCB1;rs1045642;GG;LADME_PK;INCREASED_METABOLISM;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ADALIMUMAB;ATG5;rs9373839;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
DULOXETINE;MIEF2;rs56355515;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;MIEF2;rs12603700;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
EFAVIRENZ;CYP2B6;rs28399499;C;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
ADALIMUMAB;ATG5;rs510432;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
TACROLIMUS;ABCB1;rs1045642;GG;LADME_PK;INCREASED_DOSE;DISEASE:TRANSPLANTATION
DULOXETINE;MIEF2;rs3889402;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
AZATHIOPRINE;AOX1;rs55754655;G;EFFICACY;DECREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
AZATHIOPRINE;AOX1;rs55754655;AG + GG;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
HYDRALAZINE / ISOSORBIDE DINITRATE;CYP11B2;rs1799998;AA;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HEART_FAILURE
DULOXETINE;;rs58042962;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A4;rs2740574;C;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
DULOXETINE;;rs10771997;T;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
FENOFIBRATE;LPL;rs320;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
DULOXETINE;FCN2;rs3124955;T;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
FENOFIBRATE;APOA1;rs2727786;CG;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
DULOXETINE;FCN2;rs3128624;A;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;;rs7306991;A;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
GLATIRAMER ACETATE;CLEC16A;rs6498169;A;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
TACROLIMUS;CYP3A4;rs2740574;C;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
DIGOXIN;ABCB1;rs1045642;AA;LADME_PK;DECREASED_METABOLISM;
DULOXETINE;;rs10771999;C;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;;rs10771998;A;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;SKIC3;rs12657120;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ETHOSUXIMIDE;CACNA1H;rs61734410;T;EFFICACY;DECREASED_CLINICAL BENEFIT;EFFICACY:EPILEPSY
DULOXETINE;SKIC3;rs4639250;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;;rs4437856;A;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ETHOSUXIMIDE;CACNA1I;rs3747178;T;EFFICACY;DECREASED_CLINICAL BENEFIT;EFFICACY:EPILEPSY
DULOXETINE;TREML4;rs9369266;A;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
AZATHIOPRINE;MOCOS;rs594445;AA + AC;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
DULOXETINE;TREML4;rs13204353;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
LAMOTRIGINE;ABCB1;rs2032582;A;EFFICACY;DECREASED_CLINICAL BENEFIT;EFFICACY:EPILEPSY
CYCLOSPORINE;CALM1;rs12885713;T;EFFICACY;INCREASED_RESPONSE;OTHER:PSORIASIS
IRBESARTAN;AGT;rs699;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTROPHY,_LEFT_VENTRICULAR
DULOXETINE;;rs2419128;C;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METHOTREXATE;SLC19A1;rs1051266;T;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
DULOXETINE;;rs12502866;G;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METHOTREXATE;GGH;rs3758149;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
DULOXETINE;;rs12094644;T;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
CAPECITABINE;CDA;rs2072671;AA + AC;EFFICACY;DECREASED_RESPONSE;OTHER:BREAST_NEOPLASMS
LAMOTRIGINE;CACNA1H;rs2753326;A;EFFICACY;INCREASED_CLINICAL BENEFIT;EFFICACY:EPILEPSY
RIVAROXABAN;ABCB1;rs4728709;GG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
ATENOLOL;ADRA2A;rs1800545;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTROPHY,_LEFT_VENTRICULAR
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
CYCLOSPORINE;;rs2874116;G;EFFICACY;INCREASED_RESPONSE;OTHER:PSORIASIS
IRBESARTAN;APOB;rs1801701;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTROPHY,_LEFT_VENTRICULAR
RIVAROXABAN;ABCB1;rs4148738;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
EFAVIRENZ;CYP2B6;rs28399499;C;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
MEPHENYTOIN;CYP2C19;rs183701923;T;LADME_PK;DECREASED_CLEARANCE;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
MEPHENYTOIN;CYP2C19;rs140278421;A;LADME_PK;DECREASED_CLEARANCE;
EFAVIRENZ;CYP2B6;rs4803419;T;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;rs34067076;A;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
CHLORPROMAZINE;DRD2;rs1799732;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;rs59410695;A;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
WARFARIN;CYP2C9;rs28371686;G;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;rs28371685;T;DOSAGE;DECREASED_DOSE;
METHOTREXATE;AMPD1;rs17602729;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;CYP2C9;rs28371686;G;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;rs56165452;C;DOSAGE;DECREASED_DOSE;
BENAZEPRIL;AGT;rs7079;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
PLATINUM COMPOUNDS;XRCC3;rs861539;A;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;rs200571120;C;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
OMEPRAZOLE;ABCB1;rs1045642;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:GASTROESOPHAGEAL_REFLUX
OPIOIDS;OPRM1;rs1799971;AA;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
NELFINAVIR;CYP2C19;rs4244285;AA;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
TOLBUTAMIDE;CYP2C9;rs771237265;C;LADME_PK;DECREASED_CLEARANCE;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TOLBUTAMIDE;CYP2C9;rs762081829;T;LADME_PK;DECREASED_CLEARANCE;
METFORMIN;SLC22A1;rs628031;A;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
MEPHENYTOIN;CYP2C19;rs145119820;A;LADME_PK;DECREASED_CLEARANCE;
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;
TOLBUTAMIDE;CYP2C9;rs761895497;C;LADME_PK;DECREASED_CLEARANCE;
WARFARIN;F7;rs510317;AA + AG;DOSAGE;INCREASED_DOSE;
FLUOXETINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
MEPHENYTOIN;CYP2C19;rs61311738;T;LADME_PK;DECREASED_CLEARANCE;
SULFONAMIDES, UREA DERIVATIVES;TCF7L2;rs7903146;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
BENAZEPRIL;AGT;rs4762;G;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
BENAZEPRIL;AGT;rs699;A;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
FLUOROURACIL, OXALIPLATIN;GSTP1;rs1695;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;
BENAZEPRIL;AGT;rs7079;T;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;
FENOFIBRATE;APOA5;rs3135506;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
PRAVASTATIN, SIMVASTATIN;RHOA;rs11716445;A;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
SULFONAMIDES, UREA DERIVATIVES;KCNJ11;rs587783672;T;EFFICACY;RESPONSE;
EFAVIRENZ;CYP2B6;rs35303484;AG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;rs72547516;G;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;
CITALOPRAM;;rs585719;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
WARFARIN;GGCX;rs11676382;CG + GG;DOSAGE;DECREASED_DOSE;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
CLOZAPINE, N-DESMETHYLCLOZAPINE;CYP1A2;rs566851431;T;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
WARFARIN;;rs12777823;A;LADME_PK;DECREASED_METABOLISM;OTHER:ATRIAL_FIBRILLATION,_OTHER:VENOUS_THROMBOEMBOLISM,_OTHER:HEART_VALVE_DISEASES
WARFARIN;CYP2C9;rs7900194;A;LADME_PK;DECREASED_METABOLISM;OTHER:ATRIAL_FIBRILLATION,_OTHER:VENOUS_THROMBOEMBOLISM,_OTHER:HEART_VALVE_DISEASES
ISONIAZID;CYP2E1;rs6413432;A;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TUBERCULOSIS
EFAVIRENZ;CYP2B6;rs4803419;TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;
WARFARIN;GATA4;rs2645400;TT;DOSAGE;INCREASED_DOSE;
WARFARIN;CYP2C9;rs28371685;T;LADME_PK;DECREASED_METABOLISM;OTHER:ATRIAL_FIBRILLATION,_OTHER:VENOUS_THROMBOEMBOLISM,_OTHER:HEART_VALVE_DISEASES
WARFARIN;GATA4;rs4841588;TT;DOSAGE;INCREASED_DOSE;
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;rs7662029;GG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
BUPRENORPHINE;UGT2B7;rs7439366;CC;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:OPIOID-RELATED_DISORDERS
METHOTREXATE;SLCO1B1;rs4149056;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;rs7439366;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
METHOTREXATE;SLC19A1;rs2838958;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE, LADME_PK;DECREASED_DOSE;
SILDENAFIL;VEGFA;rs1570360;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:ERECTILE_DYSFUNCTION
SILDENAFIL;VEGFA;rs699947;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE:ERECTILE_DYSFUNCTION
CAPTOPRIL;ACE2;rs2106809;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
CYCLOPHOSPHAMIDE, DOXORUBICIN, PACLITAXEL, TRASTUZUMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
TRASTUZUMAB;FCGR3A;rs396991;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
BUPRENORPHINE;UGT2B7;rs7662029;GG;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:OPIOID-RELATED_DISORDERS
ECULIZUMAB;CR1;rs2274567;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:PAROXYSMAL_NOCTURNAL_HEMOGLOBINURIA
TACROLIMUS;NR1I2;rs3814055;TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;rs2740574;CT;LADME_PK;INCREASED_EXPOSURE;OTHER:KIDNEY_TRANSPLANTATION
MYCOPHENOLIC ACID;UGT1A1;rs4148323;AG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
PHENPROCOUMON;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
CLOZAPINE;DRD1;rs686;G;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
MYCOPHENOLIC ACID ACYL GLUCURONIDE;UGT2B7;rs7438135;AA;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
CLOZAPINE;DRD3;rs6280;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
FOLLITROPIN BETA, MENOTROPINS, THYROTROPIN ALFA, UROFOLLITROPIN;FSHR;rs6166;CT;EFFICACY;DECREASED_RESPONSE;OTHER:INFERTILITY_DISORDER
MERCAPTOPURINE;TPMT;rs12199316;G;DOSAGE;INCREASED_DOSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TICAGRELOR;CYP3A4;rs56324128;CC;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ACUTE_CORONARY_SYNDROME
CANDESARTAN;AGTR1;rs5186;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:HEART_FAILURE
IRBESARTAN;AGTR1;rs5186;AC;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTROPHY,_LEFT_VENTRICULAR
WARFARIN;CYP2C9;rs2256871;G;LADME_PK;DECREASED_METABOLISM;OTHER:ATRIAL_FIBRILLATION,_OTHER:VENOUS_THROMBOEMBOLISM,_OTHER:HEART_VALVE_DISEASES
DOCETAXEL, PACLITAXEL;CYP3A5;rs776746;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
CAPECITABINE, FLUOROURACIL, TEGAFUR / GIMERACIL / OTERACIL;DPYD;rs1801159;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
CANDESARTAN;AGTR1;rs5186;AC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEART_FAILURE
TICAGRELOR;SLCO1B1;rs113681054;C;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ACUTE_CORONARY_SYNDROME
TICAGRELOR;SLCO1B1;rs4149056;T;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ACUTE_CORONARY_SYNDROME
GEMCITABINE, PACLITAXEL;SLC29A1;rs760370;A;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, PAROXETINE, SERTRALINE;BDNF;rs6265;CC;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C19;rs11188082;T;LADME_PK;DECREASED_METABOLISM;OTHER:ATRIAL_FIBRILLATION,_OTHER:VENOUS_THROMBOEMBOLISM,_OTHER:HEART_VALVE_DISEASES
METHYLPHENIDATE;CES1;rs71647871;CT;DOSAGE, LADME_PK;DECREASED_DOSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
TICAGRELOR;UGT2B7;rs61361928;TT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ACUTE_CORONARY_SYNDROME
QUETIAPINE;HTR1A;rs6295;GG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
TICAGRELOR;CYP3A43;rs62471956;G;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ACUTE_CORONARY_SYNDROME
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
SIMVASTATIN;LEPR;rs1137101;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
LAMOTRIGINE;ABCG2;rs2231142;T;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
OPIOIDS;IL2;rs2069762;AA;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_OTHER:NEOPLASMS
OPIOIDS;BDNF;rs6265;CC;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_OTHER:NEOPLASMS
ACENOCOUMAROL, WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
VORICONAZOLE;CYP3A4;rs4646437;AG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:FUNGAL_INFECTIOUS_DISEASE
OPIOIDS;IL6;rs1800795;CC;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_OTHER:NEOPLASMS
ATENOLOL, IRBESARTAN;AGT;rs4762;AG;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTROPHY,_LEFT_VENTRICULAR
TENOFOVIR;ABCC4;rs1059751;AA + AG;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:HEPATITIS_B,_CHRONIC
CAFFEINE;CYP1A1;rs2472297;T;LADME_PK;INCREASED_METABOLISM;
DOCETAXEL;VEGFA;rs1570360;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
OPIOIDS;IL1B;rs1143634;AA + AG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PAIN,_OTHER:NEOPLASMS
FENOFIBRATE;SCARB1;rs4238001;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
TENOFOVIR;SLC22A6;rs4149170;TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HEPATITIS_B,_CHRONIC
NEVIRAPINE;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
OPIOIDS;OPRD1;rs678849;CC;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PAIN,_OTHER:NEOPLASMS
ACENOCOUMAROL, WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
IRBESARTAN;AGT;rs699;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTROPHY,_LEFT_VENTRICULAR
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;CXCL10;rs56061981;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
ATORVASTATIN;ABCB1;rs2032582;T;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
ATORVASTATIN;ABCB1;rs2032582;T;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
ATALUREN;CFTR;rs113993959;T;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
FOLIC ACID;MTHFR;rs1801131;G;LADME_PK;DECREASED_METABOLISM;
ATALUREN;CFTR;rs75039782;T;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
FOLIC ACID;MTHFR;rs1801133;A;LADME_PK;DECREASED_METABOLISM;
ATALUREN;CFTR;rs77010898;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
PLATINUM COMPOUNDS;ERCC2;rs1052555;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
FENOFIBRATE;APOA5;rs3135506;CC + CG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
METHYLPHENIDATE;DRD1;rs5326;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTISM_SPECTRUM_DISORDER
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
FENTANYL;ABCB1;rs1045642;GG;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
FOLIC ACID, METHOTREXATE;ATIC;rs2372536;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CORTICOSTEROIDS, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ADAM33;rs2853209;AA;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
LITHIUM;GADL1;rs17026688;T;EFFICACY;INCREASED_RESPONSE;OTHER:BIPOLAR_DISORDER
TACROLIMUS;POR;rs1057868;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
FOLIC ACID, METHOTREXATE;ITPA;rs1127354;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;ATIC;rs4673993;C;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;VKORC1;rs9923231;TT;DOSAGE, LADME_PK;DECREASED_DOSE;
WARFARIN;GGCX;rs12714145;C;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;
METHOTREXATE;ADA;rs244076;C;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;ADORA2A;rs5751876;T;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
FOLIC ACID, METHOTREXATE;AMPD1;rs17602729;A;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
RITUXIMAB;FCGR3A;rs396991;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;
FLUOROURACIL;EGFR;rs2293347;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;
ANTIDEPRESSANTS;TGFBR3;rs12082710;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
WARFARIN;VKORC1;rs7294;C;DOSAGE;DECREASED_DOSE;
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
ALLOPURINOL;ABCG2;rs2231142;T;DOSAGE;INCREASED_DOSE;DISEASE:GOUT
WARFARIN;VKORC1;rs2884737;C;DOSAGE;DECREASED_DOSE;
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED_DOSE;
RIFAMPIN;AADAC;rs1803155;GG;LADME_PK;DECREASED_EXPOSURE;OTHER:TUBERCULOSIS
CETUXIMAB, PANITUMUMAB;AREG;rs9996584;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
NEVIRAPINE;CYP2B6;rs28399499;CT;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
CETUXIMAB, PANITUMUMAB;AREG;rs1353295;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
NEVIRAPINE;CYP2B6;rs28399499;CT;TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
METHOTREXATE;MTHFR;rs1801133;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BURKITT_LYMPHOMA,_DISEASE:LYMPHOMA,_T-CELL,_DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
RIFAMPIN;ABCB1;rs3842;CC;LADME_PK;INCREASED_EXPOSURE;OTHER:TUBERCULOSIS
NEVIRAPINE;CYP2B6;rs3745274;GT + TT;TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
METHOTREXATE;ABCB1;rs1045642;AA;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BURKITT_LYMPHOMA,_DISEASE:LYMPHOMA,_T-CELL,_DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CLOPIDOGREL;CYP2C19;rs4986893;AG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HYPERTENSION,_OTHER:ACUTE_CORONARY_SYNDROME
FENTANYL;P2RX7;rs1718125;CT + TT;DOSAGE;INCREASED_DOSE;OTHER:LUNG_NEOPLASMS,_OTHER:PAIN,_POSTOPERATIVE
METHYLPHENIDATE;DRD1;rs4867798;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTISM_SPECTRUM_DISORDER
METHYLPHENIDATE;DRD3;rs6280;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTISM_SPECTRUM_DISORDER
METHYLPHENIDATE;DRD4;rs11246226;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTISM_SPECTRUM_DISORDER
PLATINUM COMPOUNDS;XRCC1;rs25487;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
METHYLPHENIDATE;ADRA2A;rs1800544;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTISM_SPECTRUM_DISORDER
METHYLPHENIDATE;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTISM_SPECTRUM_DISORDER
ESTRONE SULFATE;SLCO1B1;rs10841753;C;EFFICACY;DECREASED_CONCENTRATIONS;OTHER:BREAST_NEOPLASMS
ESTRONE SULFATE;SLCO1B1;rs10841753;C;LADME_PK;DECREASED_;OTHER:BREAST_NEOPLASMS
WARFARIN;GGCX;rs12714145;TT;DOSAGE;INCREASED_DOSE;
NEVIRAPINE;CYP2B6;rs3745274;GT + TT;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
CETUXIMAB, PANITUMUMAB;AREG;rs13104811;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
CETUXIMAB, PANITUMUMAB;AREG;rs11942466;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
ANTIDEPRESSANTS;CRHR1;rs28364032;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TOPIRAMATE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs4148324;GG + GT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
CAPECITABINE, FLUOROURACIL;EXO1;rs1047840;A;EFFICACY;INCREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM
CAPECITABINE, FLUOROURACIL;CYP19A1;rs2236722;G;EFFICACY;DECREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM
CAPECITABINE, FLUOROURACIL;PTEN;rs17431184;C;EFFICACY;INCREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM
CYCLOSPORINE;POR;rs1057868;T;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
CAPECITABINE, FLUOROURACIL;DLG5;rs2289310;T;EFFICACY;INCREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;SLC29A1;rs760370;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
METHOTREXATE;MTHFR;rs1801133;AA + AG;LADME_PK;DECREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
TIPIRACIL HYDROCHLORIDE, TRIFLURIDINE;SLC29A1;rs760370;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
ETHANOL;ADH1B;rs2018417;A;TOXICITY, LADME_PK;METABOLISM;
ETHANOL;ADH1B;rs17033;C;TOXICITY, LADME_PK;METABOLISM;
ETHANOL;ADH1B;rs1229985;G;TOXICITY, LADME_PK;METABOLISM;
PHENPROCOUMON;PPARA;rs4253728;A;DOSAGE;INCREASED_DOSE;
ETHANOL;ADH1A;rs931635;A;TOXICITY, LADME_PK;METABOLISM;
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
METHADONE;KCNJ6;rs2070995;TT;;INCREASED_DOSE;DISEASE:SUBSTANCE-RELATED_DISORDERS
ETHANOL;ADH1C;rs283416;A;TOXICITY, LADME_PK;METABOLISM;
CAPECITABINE, FLUOROURACIL;ABCB1;rs17160359;T;EFFICACY;INCREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM
ROSIGLITAZONE;PPARG;rs1801282;CG;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
ETHANOL;ADH1C;rs283411;A;TOXICITY, LADME_PK;METABOLISM;
ETHANOL;ADH1C;rs1662060;C;TOXICITY, LADME_PK;METABOLISM;
TACROLIMUS;SUMO4;rs237025;AA;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
ACENOCOUMAROL;VKORC1;rs17878544;TT;DOSAGE;DECREASED_DOSE;
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;G;EFFICACY;DECREASED_RESPONSE;
ACENOCOUMAROL;VKORC1;rs7200749;AA + AG;DOSAGE;INCREASED_DOSE;
HMG COA REDUCTASE INHIBITORS;ABCG2;rs2231142;G;EFFICACY;DECREASED_RESPONSE;
ACENOCOUMAROL;VKORC1;rs61742245;AA + AC;DOSAGE;INCREASED_DOSE;
WARFARIN;VKORC1;rs7200749;A;DOSAGE;INCREASED_DOSE;
ACENOCOUMAROL;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE;
WARFARIN;VKORC1;rs7294;T;DOSAGE;INCREASED_DOSE;
CITALOPRAM;NEDD4L;rs520210;A;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
HMG COA REDUCTASE INHIBITORS;TOMM40;rs2075650;G;EFFICACY;DECREASED_RESPONSE;
ACENOCOUMAROL;VKORC1;rs55894764;CT + TT;DOSAGE;INCREASED_DOSE;
VALPROIC ACID;UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs28898617;G;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
IVACAFTOR;CFTR;rs78655421;AA + AG;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
METHYLPHENIDATE;PEBP4;rs17685420;T;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
VERAPAMIL;ITGAL;rs2230433;C;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_DISORDER
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HYPERCHOLESTEROLEMIA
PAZOPANIB;KDR;rs34231037;AG;EFFICACY;INCREASED_RESPONSE;DISEASE:RENAL_CELL_CARCINOMA
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
ETHANOL;ADH7;rs1154461;C;TOXICITY, LADME_PK;METABOLISM;
HEPATITIS VACCINES;IL4R;rs1805015;C;EFFICACY;INCREASED_RESPONSE;
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_METABOLISM;OTHER:HIV_INFECTIOUS_DISEASE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
ETHANOL;ADH1A;rs1229967;C;TOXICITY, LADME_PK;METABOLISM;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
ETHANOL;ADH1A;rs2276332;C;TOXICITY, LADME_PK;METABOLISM;
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
BENAZEPRIL, IMIDAPRIL;AGT;rs5051;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
ETHANOL;ADH1A;rs1229976;C;TOXICITY, LADME_PK;METABOLISM;
URSODEOXYCHOLIC ACID;MGAT5;rs661899;TT;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CHOLANGITIS
CLOPIDOGREL THIOL METABOLITE H4;CYP2C19;rs4244285;A;LADME_PK;EXPOSURE;
HEPATITIS VACCINES;IL13;rs1295686;T;EFFICACY;DECREASED_RESPONSE;
PHENPROCOUMON;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;
PHENPROCOUMON;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_DOSE;
TACROLIMUS;ABCB1;rs1045642;AA;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:RHEUMATOID_ARTHRITIS
PEGINTERFERON ALFA-2B, RIBAVIRIN;CYP27B1;rs10877012;GT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
DABIGATRAN;CES1;rs8192935;AA + AG;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
IRINOTECAN;VDR;rs11574077;TT;LADME_PK;INCREASED_METABOLISM;DISEASE:COLORECTAL_NEOPLASMS
METHYLPHENIDATE;ADGRL3;rs1868790;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
METHYLPHENIDATE;SNAP25;rs3746544;GG + GT;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
METHYLPHENIDATE;SLC6A3;rs2550948;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
ATORVASTATIN;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_EXPOSURE;
INTERFERONS, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
MORPHINE;SLC22A1;rs34059508;AA + AG;LADME_PK;DECREASED_CLEARANCE;
METHYLPHENIDATE;ADRA2A;rs1800544;G;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
PLATINUM;XRCC1;rs25487;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;;rs10514475;A;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;PLCB1;rs6108160;A;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
WARFARIN;LRP1;rs1800139;TT;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
METHYLPHENIDATE;ADRA2A;rs1800544;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
WARFARIN;CYP4F2;rs2108622;T;DOSAGE, EFFICACY;INCREASED_DOSE;
WARFARIN;LRP1;rs1800154;CC;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
NICOTINE;CYP2A6;rs56113850;T;LADME_PK;DECREASED_CLEARANCE;
WARFARIN;VKORC1;rs9923231;TT;EFFICACY;INCREASED_RESPONSE;
INTERFERONS, RIBAVIRIN;IFNL3;rs8099917;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
PHENPROCOUMON;VKORC1;rs2359612;AA + AG;EFFICACY;INCREASED_RESPONSE;
METHYLPHENIDATE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
WARFARIN;CYP4F2;rs2108622;T;DOSAGE, EFFICACY;INCREASED_DOSE;
PLATINUM COMPOUNDS;XRCC1;rs1799782;G;EFFICACY;DECREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
MORPHINE;SLC22A1;rs12208357;TT;LADME_PK;DECREASED_CLEARANCE;OTHER:ADENOTONSILLECTOMY
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
METHYLPHENIDATE;ADRA2A;rs1800544;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
FLUOROURACIL;LGR5;rs17109924;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:COLONIC_NEOPLASMS
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;
MORPHINE;SLC22A1;rs34059508;AA;LADME_PK;DECREASED_CLEARANCE;OTHER:ADENOTONSILLECTOMY
METHYLPHENIDATE;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
MORPHINE;SLC22A1;rs34130495;AA;LADME_PK;DECREASED_CLEARANCE;OTHER:ADENOTONSILLECTOMY
ATORVASTATIN, PRAVASTATIN;KIF6;rs9462535;AA + AC;EFFICACY;INCREASED_RESPONSE;
CAPECITABINE, FLUOROURACIL;MTHFR;rs1801133;AA + AG;DOSAGE;DECREASED_DOSE;OTHER:NEOPLASMS
ROSUVASTATIN;ABCG2;rs1481012;AG + GG;EFFICACY;INCREASED_RESPONSE;
SOMATROPIN RECOMBINANT;CDK4;rs2069502;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:TURNER_SYNDROME
ATORVASTATIN, PRAVASTATIN;KIF6;rs9471077;AG + GG;EFFICACY;INCREASED_RESPONSE;
METFORMIN;FMO5;rs7541245;A;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
METHYLPHENIDATE;ADGRL3;rs6858066;A;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
METHYLPHENIDATE;ADGRL3;rs1947274;C;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;DECREASED_RESPONSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ROSUVASTATIN;USP24;rs17111584;CC + CT;EFFICACY;DECREASED_RESPONSE;
METHYLPHENIDATE;ADGRL3;rs6551665;G;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
METHYLPHENIDATE;ADGRL3;rs2345039;G;EFFICACY;DECREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
METHYLPHENIDATE;ADGRL3;rs6858066;G;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
METHYLPHENIDATE;ADGRL3;rs1947274;C;EFFICACY;DECREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
METHYLPHENIDATE;SLC6A2;rs5569;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
INTERFERON BETA-1A;RORA;rs4774388;TT;EFFICACY;INCREASED_RESPONSE;OTHER:MULTIPLE_SCLEROSIS
METHYLPHENIDATE;SLC6A2;rs28386840;AT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
METHYLPHENIDATE;ADGRL3;rs6551665;G;EFFICACY;DECREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
REMIMAZOLAM;CES1;rs71647871;CT + TT;LADME_PK;DECREASED_METABOLISM;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
NICOTINE;;rs113288603;T;LADME_PK;DECREASED_CLEARANCE;
ROSUVASTATIN;APOE;rs71352238;CC + CT;EFFICACY;DECREASED_RESPONSE;
METHYLPHENIDATE;ADRA2A;rs1800544;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
NICOTINE;;rs12461964;A;LADME_PK;DECREASED_CLEARANCE;
ROSUVASTATIN;APOE;rs7412;CT + TT;EFFICACY;INCREASED_RESPONSE;
METHYLPHENIDATE;ADRA2A;rs1800544;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
IDARUBICIN;NCF4;rs1883112;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:ACUTE_MYELOID_LEUKEMIA
SIMVASTATIN;ABCC2;rs717620;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
IDARUBICIN;RAC2;rs13058338;AT;EFFICACY;INCREASED_RESPONSE;DISEASE:ACUTE_MYELOID_LEUKEMIA
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:MYELOPROLIFERATIVE_DISORDER
ROSUVASTATIN;LPA;rs10455872;AG + GG;EFFICACY;DECREASED_RESPONSE;
ATORVASTATIN;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs887829;T;LADME_PK;INCREASED_METABOLISM;
METHYLPHENIDATE;BDNF;rs6265;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
EFAVIRENZ;CYP2B6;rs3745274;GG + GT;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
IVACAFTOR;CFTR;rs78655421;AA + AG;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ATORVASTATIN;CYP3A7;rs45446698;G;LADME_PK;INCREASED_METABOLISM;
ATALUREN;CFTR;rs77010898;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
METHYLPHENIDATE;GRM7;rs3792452;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
CLOZAPINE;CYP1A2;rs762551;AA;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:SCHIZOPHRENIA,_OTHER:TOBACCO_USE_DISORDER
EFAVIRENZ;CYP2B6;rs2279343;G;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;rs2279345;T;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
ATORVASTATIN, PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;INCREASED_RESPONSE;
METHYLPHENIDATE;ADGRL3;rs6551665;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
ATALUREN;CFTR;rs113993959;T;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
METHYLPHENIDATE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
EFAVIRENZ;ABCB1;rs1045642;AG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
SOMATROPIN RECOMBINANT;CDK4;rs2270777;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:GROWTH_HORMONE_DEFICIENCY
IVACAFTOR;CFTR;rs78655421;AG;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
METHYLPHENIDATE;ADRA2A;rs1800544;G;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
ATALUREN;CFTR;rs75039782;T;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ACENOCOUMAROL;VKORC1;rs9923231;CT;DOSAGE;DECREASED_DOSE;
METFORMIN;PRPF31;rs254271;C;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
GABAPENTIN;SLC7A5;rs4240803;AG;DOSAGE;INCREASED_DOSE;OTHER:NEUROPATHIC_PAIN
ATALUREN;CFTR;rs77010898;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
METFORMIN;NBEA;rs57081354;C;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
METFORMIN;SLC22A1;rs628031;AA + AG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GT + TT;EFFICACY;INCREASED_RESPONSE;OTHER:LUPUS_NEPHRITIS
DRUGS USED IN DIABETES;IRS1;rs1801278;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC1;rs25487;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
METHOTREXATE;MTRR;rs1801394;A;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
SALBUTAMOL;DUSP1;rs881152;G;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC1;rs11615;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
HYDROCHLOROTHIAZIDE;NEDD4L;rs4149601;A;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
METFORMIN;SLC22A1;rs622342;AC + CC;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
WARFARIN;CYP4F2;rs2108622;CT;DOSAGE;INCREASED_DOSE;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3;rs12980275;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:MYELOPROLIFERATIVE_DISORDER
EMTRICITABINE;ABCC2;rs2273897;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE,_OTHER:PREGNANCY
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
ATALUREN;CFTR;rs113993959;T;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
GABAPENTIN, PREGABALIN;SLC7A5;rs4240803;AG;EFFICACY;DECREASED_RESPONSE;OTHER:NEUROPATHIC_PAIN
METHOTREXATE;SLC19A1;rs1051266;CT + TT;TOXICITY;DECREASED_DISCONTINUATION;DISEASE:RHEUMATOID_ARTHRITIS
MORPHINE;COMT;rs4680;AA;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
METFORMIN;CPA6;rs2162145;T;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
SALBUTAMOL;DUSP1;rs881152;G;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
MIGALASTAT;GLA;rs372966991;T;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
TACROLIMUS;CYP3A4;rs2242480;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LUNG_TRANSPLANTATION
MIGALASTAT;GLA;rs869312146;T;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
WARFARIN;VKORC1;rs61742245;AA + AC;DOSAGE;INCREASED_DOSE;
TRAMADOL;SLC22A1;rs34059508;A;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
TACROLIMUS;SLCO1B3;rs4149117;GG + GT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LUNG_TRANSPLANTATION
MIGALASTAT;GLA;rs397515870;G;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
ESCITALOPRAM;IL11;rs1126757;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;
CLOPIDOGREL;CES1;rs2307240;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
MIGALASTAT;GLA;rs398123223;G;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
MIGALASTAT;GLA;rs190347120;A;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
TACROLIMUS;SLC2A2;rs1499821;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LUNG_TRANSPLANTATION
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;
MIGALASTAT;GLA;rs28935490;T;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
ABIRATERONE;YBX1;rs10493112;AC + CC;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PROSTATIC_NEOPLASMS
TACROLIMUS;NFATC4;rs1955915;CC + CT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LUNG_TRANSPLANTATION
GRAZOPREVIR;SLCO1B1;rs4149056;C;LADME_PD;INCREASED_EXPOSURE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
BISOPROLOL;CYP2D6;rs1080985;CC;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:CARDIOVASCULAR_DISEASE
GRAZOPREVIR;SLCO1B1;rs11045819;A;LADME_PD;INCREASED_EXPOSURE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;
WARFARIN;VKORC1;rs9923231;C;LADME_PK;INCREASED_STEADY_STATE CONCENTRATION;
WARFARIN;VKORC1;rs9923231;C;LADME_PK;INCREASED_DOSE;
MIGALASTAT;GLA;rs398123212;T;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
WARFARIN;;rs12777823;AA + AG;DOSAGE;DECREASED_DOSE;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
MIGALASTAT;GLA;rs398123217;C;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
METHADONE;BDNF, BDNF-AS;rs7127507;C;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
O-DESMETHYLTRAMADOL;SLC22A1;rs12208357;T;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:PAIN
MIGALASTAT;GLA;rs397515874;G;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
MIGALASTAT;GLA;rs727505292;G;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
ENALAPRIL;NOS3;rs2070744;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
METHADONE;BDNF, BDNF-AS;rs11030118;G;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
MIGALASTAT;GLA;rs869312399;C;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
WARFARIN;VKORC1;rs2359612;AG + GG;DOSAGE;INCREASED_DOSE;
WARFARIN;CYP2C9;rs7089580;T;DOSAGE;DECREASED_DOSE;
MIGALASTAT;GLA;rs104894828;T;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;
METHADONE;BDNF, BDNF-AS;rs1967554;C;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
WARFARIN;VKORC1;rs8050894;CG + GG;DOSAGE;DECREASED_DOSE;
BISOPROLOL;CYP2D6;rs1080985;G;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_CORONARY_SYNDROME
MIGALASTAT;GLA;rs398123226;T;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
MIGALASTAT;GLA;rs398123226;C;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_DOSE;
METHADONE;BDNF;rs2030324;G;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
MIGALASTAT;GLA;rs727504348;T;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
BISOPROLOL;CYP2D6;rs3892097;CT + TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_CORONARY_SYNDROME
BUSULFAN;GSTA1;rs3957357;AA;LADME_PK;INCREASED_CLEARANCE;DISEASE:TRANSPLANTATION
O-DESMETHYLTRAMADOL;SLC22A1;rs34130495;A;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:PAIN
O-DESMETHYLTRAMADOL;SLC22A1;rs34059508;A;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:PAIN
ENALAPRIL;BDKRB2;rs1799722;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
METHADONE;BDNF;rs988748;C;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
O-DESMETHYLTRAMADOL;SLC22A1;rs55918055;C;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:PAIN
WARFARIN;VKORC1;rs61742245;A;DOSAGE;INCREASED_DOSE;
MIGALASTAT;GLA;rs869312136;C;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
TRAMADOL;SLC22A1;rs55918055;C;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
MIGALASTAT;GLA;rs28935195;T;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
METHADONE;BDNF;rs11030119;G;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LUNG_TRANSPLANTATION
TRAMADOL;SLC22A1;rs12208357;T;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
MIGALASTAT;GLA;rs104894827;A;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
FENTANYL;CYP3A4;rs2242480;T;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
MIGALASTAT;GLA;rs869312138;C;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
CELECOXIB;CYP2C9;rs1057910;CC;LADME_PK;DECREASED_METABOLISM;
BISOPROLOL;CYP3A5;rs776746;TT;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ACUTE_CORONARY_SYNDROME
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;
TRAMADOL;SLC22A1;rs34130495;A;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
MIGALASTAT;GLA;rs1569304898;T;EFFICACY;INCREASED_RESPONSE;OTHER:FABRY_DISEASE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;rs4149570;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:CROHN_DISEASE,_DISEASE:INFLAMMATORY_BOWEL_DISEASES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR4;rs5030728;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
METFORMIN;SLC47A1;rs8065082;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER:GLUCOSE_INTOLERANCE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs4696480;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;rs2430561;AA + AT;EFFICACY;INCREASED_RESPONSE;DISEASE:CROHN_DISEASE,_DISEASE:INFLAMMATORY_BOWEL_DISEASES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;rs352139;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:CROHN_DISEASE,_DISEASE:INFLAMMATORY_BOWEL_DISEASES
WARFARIN;VKORC1L1;rs4072879;AA;DOSAGE;DECREASED_DOSE;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs3804099;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs1816702;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CROHN_DISEASE
TACROLIMUS;CYP3A4;rs35599367;A;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
SUFENTANIL;OPRM1;rs1799971;G;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
OPIOIDS;ENPP2;rs2249015;AA;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;APOE;rs429358;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
ROSIGLITAZONE;PAX4;rs6467136;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
ROSIGLITAZONE;PAX4;rs6467136;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
ATORVASTATIN;APOE;rs429358;CT;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
OPIOIDS;ABCB1;rs1045642;AA;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;rs10499563;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS,_DISEASE:INFLAMMATORY_BOWEL_DISEASES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17A;rs2275913;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS,_DISEASE:INFLAMMATORY_BOWEL_DISEASES
LATANOPROST;ABCC4;rs11568658;AC;EFFICACY;DECREASED_RESPONSE;DISEASE:OPEN-ANGLE_GLAUCOMA
ADALIMUMAB, ETANERCEPT, INFLIXIMAB, USTEKINUMAB;TNFRSF1B;rs1061622;GG + GT;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CNPY4;rs1554973;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
BOTULINUM TOXIN TYPE A;CALCA;rs3781719;G;EFFICACY;DECREASED_RESPONSE;OTHER:MIGRAINE_DISORDER
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CD14;rs2569190;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs11938228;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS,_DISEASE:INFLAMMATORY_BOWEL_DISEASES
BOTULINUM TOXIN TYPE A;TRPV1;rs222749;A;EFFICACY;DECREASED_RESPONSE;OTHER:MIGRAINE_DISORDER
OPIOIDS;ENPP2;rs7832704;AA;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1B;rs4848306;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS,_DISEASE:INFLAMMATORY_BOWEL_DISEASES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL1RN;rs4251961;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;rs6927172;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS,_DISEASE:INFLAMMATORY_BOWEL_DISEASES
HMG COA REDUCTASE INHIBITORS;APOE;rs429358;CC;EFFICACY;INCREASED_RESPONSE;OTHER:ALZHEIMER_DISEASE
LOSARTAN;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
PEMETREXED;FOLR3;rs61734430;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA,_DISEASE:MESOTHELIOMA
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs4803217;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
METOPROLOL;GRK4;rs1801058;CT;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSIVE_NEPHROSCLEROSIS
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART);IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE
FLUOXETINE;HTR2A;rs7997012;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:INFLAMMATION
DIRECT ACTING ANTIVIRALS, ELBASVIR / GRAZOPREVIR, LEDIPASVIR / SOFOSBUVIR;IFNL3, IFNL4;rs8099917;GG + GT;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
METOPROLOL;GRK4;rs2960306;GT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSIVE_NEPHROSCLEROSIS
TACROLIMUS;ABCC2;rs3740066;CT + TT;LADME_PK;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;ABCC2;rs3740066;CT + TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
METHOTREXATE;ABCC2;rs717620;CT + TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:LYMPHOMA
TACROLIMUS;ABCC2;rs717620;CT + TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
METOPROLOL;GRK4;rs1024323;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSIVE_NEPHROSCLEROSIS
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:INFLAMMATION
WARFARIN;CYP2C19;rs3814637;T;OTHER, LADME_PK;DECREASED_CLEARANCE;
METHADONE;GAD1;rs3762556;G;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
WARFARIN;CYP3A4;rs2242480;CT;OTHER, LADME_PK;INCREASED_CLEARANCE;
INFLIXIMAB;IL1B;rs1143634;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:CROHN_DISEASE
METHADONE;GAD1;rs769404;TT;DOSAGE;DECREASED_DOSE;OTHER:HEROIN_DEPENDENCE
CLOZAPINE;CYP1A2;rs762551;AA + AC;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
ACENOCOUMAROL;VKORC1;rs9934438;GG;DOSAGE;INCREASED_DOSE;
CAPECITABINE;DPYD;rs67376798;AT;DOSAGE;DECREASED_DOSE;DISEASE:COLORECTAL_NEOPLASMS
CLOZAPINE;UGT1A4;rs2011404;C;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA,_OTHER:PSYCHOTIC_DISORDER
CAPECITABINE;DPYD;rs3918290;CT;DOSAGE;DECREASED_DOSE;DISEASE:COLORECTAL_NEOPLASMS
URIC ACID;VEGFC;rs1002976;C;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HYPERTENSION
LETERMOVIR;SLCO1B1;rs4149032;TT;LADME_PK;DECREASED_EXPOSURE;
CLOZAPINE;UGT1A1;rs34946978;T;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA,_OTHER:PSYCHOTIC_DISORDER
METFORMIN;CAPN10;rs3792269;G;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
LETERMOVIR;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_EXPOSURE;
LETERMOVIR;UGT1A1;rs4148323;AA + AG;LADME_PK;INCREASED_EXPOSURE;
INTERFERON BETA-1A, INTERFERON BETA-1B;FHIT;rs760316;C;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
GLYBURIDE;FMO2;rs7512785;T;EFFICACY;INCREASED_RESPONSE;
METHOTREXATE;MTRR;rs1801394;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS
PROPRANOLOL;ADRB2;rs1042713;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:LIVER_CIRRHOSIS
METHOTREXATE;ABCB1;rs1128503;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS
METHOTREXATE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS
CLOZAPINE;ABCB1;rs10248420;G;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA,_OTHER:PSYCHOTIC_DISORDER
METHOTREXATE;SLC16A7;rs3763980;A;EFFICACY;DECREASED_RESPONSE;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;rs12979860;C;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_B,_CHRONIC
METHOTREXATE;SLC16A7;rs12231740;T;EFFICACY;DECREASED_RESPONSE;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS
METHOTREXATE;ARID5B;rs4948496;CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CLOZAPINE;UGT1A1;rs4148323;A;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA,_OTHER:PSYCHOTIC_DISORDER
FENOFIBRATE;APOE;rs7412;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
METHOTREXATE;SLCO1B1;rs4149056;TT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;rs8099917;T;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_B,_CHRONIC
METHADONE;GAD1;rs3762555;G;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:JUVENILE_RHEUMATOID_ARTHRITIS
METHADONE;GAD1;rs3749034;G;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
CLOZAPINE;ABCB1;rs7787082;A;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA,_OTHER:PSYCHOTIC_DISORDER
IGURATIMOD;NAT2;rs1495741;AG + GG;EFFICACY;DECREASED_CLINICAL BENEFIT;DISEASE:RHEUMATOID_ARTHRITIS
INTERFERON BETA-1A, INTERFERON BETA-1B;;rs4278350;T;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
SITAGLIPTIN, VILDAGLIPTIN;KCNQ1;rs163184;GG + GT;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
IGURATIMOD;ABCG2;rs2231142;GT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT;DISEASE:RHEUMATOID_ARTHRITIS
INTERFERON BETA-1A, INTERFERON BETA-1B;GAPVD1;rs2291858;G;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
METHADONE;OPRD1;rs204047;GG;DOSAGE;INCREASED_DOSE;
METHADONE;OPRD1;rs797397;AA;LADME_PK;INCREASED_CONCENTRATIONS;
METHADONE;OPRD1;rs204047;GG;LADME_PK;INCREASED_CONCENTRATIONS;
ANTIPSYCHOTICS;ZNF804A;rs1344706;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
PLATINUM COMPOUNDS;XRCC1;rs25487;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
INTERFERON BETA-1A, INTERFERON BETA-1B;GAPVD1;rs10819043;T;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
INTERFERON BETA-1A, INTERFERON BETA-1B;;rs3133084;A;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
CAPECITABINE, DOCETAXEL;CYP1A1;rs1048943;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
GLYBURIDE;CYP51A1;rs7793861;G;EFFICACY;INCREASED_RESPONSE;
INTERFERON BETA-1A, INTERFERON BETA-1B;;rs1448673;G;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
GLYBURIDE;FMO2;rs7515157;T;EFFICACY;INCREASED_RESPONSE;
ANASTROZOLE;ABCB1;rs2032582;AA;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
AMISULPRIDE, ANTIPSYCHOTICS, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR1A;rs10042486;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
URIC ACID;BRINP3;rs950569;T;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HYPERTENSION
GLYBURIDE;UGT2B15;rs4148269;G;EFFICACY;INCREASED_RESPONSE;
INTERFERON BETA-1A, INTERFERON BETA-1B;GAPVD1;rs10760397;C;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
URIC ACID;PADI4;rs2477134;G;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HYPERTENSION
INTERFERON BETA-1A, INTERFERON BETA-1B;ZNF697;rs10494227;A;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
DOXORUBICIN;ABCC5;rs1533682;TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:BREAST_NEOPLASMS
PLATINUM COMPOUNDS;XRCC3;rs861539;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
GLYBURIDE;MAPK1;rs1803545;A;EFFICACY;INCREASED_RESPONSE;
GLYBURIDE;ABCC5;rs3749442;A;EFFICACY;INCREASED_RESPONSE;
GLYBURIDE;SPINK5;rs2303070;T;EFFICACY;INCREASED_RESPONSE;
GLYBURIDE;BDKRB2;rs5224;A;EFFICACY;INCREASED_RESPONSE;
GLYBURIDE;MAPK1;rs3729910;G;EFFICACY;INCREASED_RESPONSE;
IGURATIMOD;ABCB1;rs2032582;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;
ETHANOL;KLB;rs11940694;A;TOXICITY;DECREASED_DOSE;
PLATINUM COMPOUNDS;XRCC1;rs1799782;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
GLYBURIDE;ESR1;rs2077647;T;EFFICACY;INCREASED_RESPONSE;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;G;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS,_OTHER:AUTOIMMUNE_DISEASES,_OTHER:PSORIASIS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
ANTIDEPRESSANTS;BDNF;rs6265;C;EFFICACY;INCREASED_RESISTANCE;
FLUNISOLIDE;TBXT;rs2305089;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
GRANISETRON, PALONOSETRON;ERCC1;rs3212986;AC + CC;EFFICACY;INCREASED_RESPONSE;SIDE_EFFECT:NAUSEA,_SIDE_EFFECT:VOMITING
TACROLIMUS;IL6;rs1800795;GG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:KIDNEY_TRANSPLANTATION
VALPROIC ACID;CYP2D6;rs3892097;CT + TT;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs1061622;T;EFFICACY;INCREASED_RESPONSE;OTHER:PSORIASIS
TACROLIMUS;IL6;rs1800795;GG;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;C;EFFICACY;INCREASED_RESPONSE;OTHER:PSORIASIS
TACROLIMUS;CYP3A4;rs4646437;GG;LADME_PK;INCREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
RASAGILINE;DRD2;rs1076560;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:PARKINSON_DISEASE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;rs2242480;CC;LADME_PK;INCREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
RASAGILINE;DRD2;rs2283265;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:PARKINSON_DISEASE
TACROLIMUS;CYP3A4;rs4646437;GG;LADME_PK;INCREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CTLA4;rs4553808;AG + GG;LADME_PK;INCREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
ANTIDEPRESSANTS;BDNF-AS;rs10501087;T;EFFICACY;INCREASED_RESISTANCE;
TACROLIMUS;IL3;rs181781;AA;LADME_PK;INCREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
LAMOTRIGINE;UGT1A4;rs6755571;CC;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:EPILEPSY
WARFARIN;CYP2C9;rs4917639;C;DOSAGE;DECREASED_DOSE;
TELAPREVIR;CYP24A1;rs2585428;C;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:HEPATITIS_C_VIRUS_INFECTION
TACROLIMUS;CTLA4;rs4553808;AA;LADME_PK;INCREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;rs2242480;CC;LADME_PK;INCREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
VARENICLINE;CHRNA4;rs1044396;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
ESCITALOPRAM;CYP1A2;rs4646425;T;LADME_PK;INCREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ESCITALOPRAM;CYP1A2;rs2069526;G;LADME_PK;INCREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ESCITALOPRAM;CYP1A2;rs4646427;C;LADME_PK;INCREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PLATINUM COMPOUNDS;HSPA5;rs430397;TT;EFFICACY;INCREASED_RESISTANCE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;A;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;rs396991;C;EFFICACY;INCREASED_RESPONSE;OTHER:SPONDYLARTHROPATHIES
EFAVIRENZ;CYP2B6;rs2279343;GG;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
MORPHINE;ABCB1;rs1045642;AA;LADME_PK;INCREASED_METABOLISM;
CLOPIDOGREL;P2RY12;rs6785930;AA + AG;EFFICACY;INCREASED_RESISTANCE;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
CLOPIDOGREL;P2RY12;rs6809699;AA + AC;EFFICACY;INCREASED_RESISTANCE;
EFAVIRENZ;CYP2B6;rs2279343;AG;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs361525;G;EFFICACY;INCREASED_RESPONSE;OTHER:PSORIASIS
FLUTICASONE PROPIONATE;ORMDL3;rs2872507;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
RITUXIMAB;FCGR3A;rs396991;AC + CC;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
ABATACEPT, RITUXIMAB, TOCILIZUMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
VALPROIC ACID;CYP2C9;rs1057910;AC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:EPILEPSY
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME_PK;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CALU;rs339097;G;DOSAGE;INCREASED_DOSE;
ATAZANAVIR / RITONAVIR;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
DEFERASIROX;ABCG2;rs13120400;CT + TT;LADME_PK;INCREASED_EXPOSURE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
ATAZANAVIR / RITONAVIR;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;rs10509680;T;DOSAGE;DECREASED_DOSE;
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GOLIMUMAB, INFLIXIMAB;VDR;rs7975232;AA + AC;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
ANTIEPILEPTICS;NR3C1;rs41423247;GG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
TACROLIMUS;CYP3A5;rs776746;CT;EFFICACY, LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
DEFERASIROX;ABCC2;rs2273697;AG;LADME_PK;INCREASED_EXPOSURE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_METABOLISM;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
FLUVASTATIN;APOE;rs7412;CT;EFFICACY;INCREASED_RESPONSE;
METFORMIN;SLC47A1;rs2289669;A;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
LAMOTRIGINE;UGT2B7;rs7439366;TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:EPILEPSY
TACROLIMUS;CYP3A4;rs2740574;CC + CT;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
RITODRINE;PDE4B;rs598961;AA;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PREMATURE_BIRTH
TACROLIMUS;CYP3A4;rs4986910;G;DOSAGE, LADME_PK;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ACENOCOUMAROL, WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;
LAMOTRIGINE;UGT2B15;rs1902023;AA;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:EPILEPSY
PLATINUM COMPOUNDS;XPA;rs1800975;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;ABCB1;rs2032582;CC;LADME_PK;INCREASED_CONCENTRATIONS;
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;ABCB1;rs1045642;GG;LADME_PK;INCREASED_CONCENTRATIONS;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
ARIPIPRAZOLE, DEHYDROARIPIPRAZOLE;ABCB1;rs1128503;GG;LADME_PK;INCREASED_CONCENTRATIONS;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
TACROLIMUS;IL10;rs1800871;AA;LADME_PK;DECREASED_METABOLISM;OTHER:KIDNEY_TRANSPLANTATION
ANTIHYPERTENSIVES, HYDRALAZINE, METHYLDOPA, NIFEDIPINE;MMP9;rs3918242;CT;EFFICACY;DECREASED_RESPONSE;DISEASE:GESTATIONAL_HYPERTENSION
WARFARIN;CYP2C9;rs1799853;T;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DOSE;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;DOSE;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE, EFFICACY, TOXICITY;DECREASED_DOSE;
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;OTHER:RHEUMATIC_HEART_DISEASE,_OTHER:ATRIAL_FIBRILLATION,_OTHER:HEART_VALVE_DISEASES,_OTHER:CORONARY_ARTERY_DISEASE
DACLATASVIR;VDR;rs11568820;TT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:HEPATITIS_C_VIRUS_INFECTION
MORPHINE;COMT;rs4680;AG + GG;EFFICACY;INCREASED_DOSE;
CLOMIPRAMINE;CYP2D6;rs1080985;CG;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
METHYLDOPA;MMP9;rs3918242;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:GESTATIONAL_HYPERTENSION
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DOSE;
DACLATASVIR;CYP24A1;rs2248359;CT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEPATITIS_C_VIRUS_INFECTION
WARFARIN;VKORC1;rs9923231;A;DOSAGE;DOSE;
TACROLIMUS;ABCB1;rs1045642;AG + GG;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
CARBAMAZEPINE, OXCARBAZEPINE;SCN1A;rs3812718;TT;EFFICACY;RESISTANCE;DISEASE:EPILEPSY
METOPROLOL;ADRB1;rs1801252;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
METOPROLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs139304906;C;EFFICACY;INCREASED_CLINICAL BENEFIT;
CALCIUM CHANNEL BLOCKERS;NUMA1;rs10898815;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
CARBAMAZEPINE, OXCARBAZEPINE;SCN1A;rs3812718;TT;EFFICACY;RESISTANCE;DISEASE:EPILEPSY
CALCIUM CHANNEL BLOCKERS;TANC2;rs2429427;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
SIBUTRAMINE;GNB3;rs5443;CC;EFFICACY;INCREASED_RESPONSE;OTHER:OBESITY
CARBAMAZEPINE, OXCARBAZEPINE;ABCC2;rs2273697;AG;EFFICACY;RESISTANCE;DISEASE:EPILEPSY
METHOTREXATE;ABCC2;rs765027508;AG;LADME_PK;INCREASED_EXPOSURE;OTHER:LYMPHOMA,_B-CELL
BUSULFAN;GSTA1;rs3957356;T;LADME_PK;DECREASED_CLEARANCE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
S-EDDP;CYP2B6;rs8192709;CT;LADME_PK;INCREASED_CONCENTRATIONS;
BUSULFAN;GSTA1;rs3957357;A;LADME_PK;DECREASED_CLEARANCE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
SIMVASTATIN;UGT1A9;rs12052787;T;EFFICACY;INCREASED_RESPONSE;
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY, LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
SIMVASTATIN;UGT1A9;rs2003569;A;EFFICACY;INCREASED_RESPONSE;
PLATINUM COMPOUNDS;ERCC4;rs1799801;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
PLATINUM COMPOUNDS;ERCC1;rs11615;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY, LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;rs3892097;TT;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:DEPRESSION
PLATINUM COMPOUNDS;ERCC3;rs3738948;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
TEGAFUR;CYP2A6;rs8192720;AA + AG;LADME_PK;INCREASED_METABOLISM;
ANTIPSYCHOTICS, CHLORPROMAZINE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;MTHFR;rs1801133;AG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA
OXYCODONE;UGT2B7;rs7439366;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:NEOPLASMS,_DISEASE:PAIN
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;
BUPROPION;CYP2B6;rs3745274;T;LADME_PK;INCREASED_EXPOSURE;OTHER:MAJOR_DEPRESSIVE_DISORDER
RISPERIDONE;HRH4;rs4483927;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ATENOLOL;GRK4;rs2960306;T;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
ATENOLOL;GRK4;rs1024323;T;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
CALCIUM CHANNEL BLOCKERS;PICALM;rs588076;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
DELEOBUVIR, FALDAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
WARFARIN;CYP2C9;rs9332131;del;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:PULMONARY_EMBOLISM
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;rs28371686;G;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:PULMONARY_EMBOLISM
PROPOFOL;GABRA2;rs11503014;CC;OTHER;DECREASED_RESPONSE;
WARFARIN;HNF4A;rs3212198;T;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
CODEINE, TRAMADOL;CYP1B1;rs1056836;C;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PAIN
ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
WARFARIN;NR1I3;rs2501873;TT;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
VERAPAMIL;PCDHB8;rs3733694;G;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_DISORDER
RIVAROXABAN;POR;rs1057868;TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
VERAPAMIL;PCDHB6;rs17844444;A;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_DISORDER
WARFARIN;VKORC1;rs72547529;T;DOSAGE;INCREASED_DOSE;
WARFARIN;VKORC1;rs72547529;T;DOSAGE;INCREASED_DOSE;
WARFARIN;VKORC1;rs72547529;T;DOSAGE;INCREASED_DOSE;
CAPECITABINE, CETUXIMAB, OXALIPLATIN;KRAS;rs61764370;AC;EFFICACY;INCREASED_RESPONSE;DISEASE:RECTAL_NEOPLASMS
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
SIMVASTATIN ACID;SLCO1B1;rs4149056;CT;LADME_PK;INCREASED_EXPOSURE;
LOSARTAN;AGTR1;rs5186;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:LIVER_CIRRHOSIS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
HEROIN;OPRM1;rs9479757;AG;DOSAGE;INCREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
5-HYDROXYINDOLE-3-ACETIC ACID, SEROTONIN;MAOB;rs1799836;T;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:MAJOR_DEPRESSIVE_DISORDER
ANTIDEPRESSANTS;GRIK4;rs1954787;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
RIVAROXABAN;ABCB1;rs4148738;CT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
5-HYDROXYINDOLE-3-ACETIC ACID, SEROTONIN;MAOB;rs1799836;TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:MAJOR_DEPRESSIVE_DISORDER
APIXABAN;POR;rs1057868;T;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
OXCARBAZEPINE;UGT1A9;rs2741049;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:SEIZURES
CODEINE, TRAMADOL;CYP1B1;rs1056837;A;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PAIN
CANDESARTAN;CYP11B2;rs1799998;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
3-HYDROXYCOTININE;;rs4105144;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TOBACCO_USE_DISORDER
HYDROCODONE, OXYCODONE;CYP2D6;rs35742686;DELT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PAIN
3-HYDROXYCOTININE;EGLN2;rs3733829;AA + AG;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:TOBACCO_USE_DISORDER
HYDROCODONE, OXYCODONE;MACROD2;rs76026520;G;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PAIN
MERCAPTOPURINE;NUDT15;rs116855232;CT;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
BENAZEPRIL;MTHFR;rs1801133;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
DEFERASIROX;CYP1A1;rs2606345;AC + CC;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
PITRAKINRA;IL4R;rs1029489;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM;DISEASE:LIVER_TRANSPLANTATION
CIPROFLOXACIN;CYP1A2;rs762551;AA + AC;;INCREASED_CLEARANCE;OTHER:INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
RADIOTHERAPY;CACNA2D3;rs11130424;AG + GG;EFFICACY;INCREASED_RESISTANCE;OTHER:NASOPHARYNGEAL_NEOPLASMS
HYDROXYUREA;MAP3K5;rs9483947;CC;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
ANTIHYPERTENSIVES;CLNK;rs13144136;G;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
HYDROXYUREA;MAP3K5;rs9376230;CC;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
IMATINIB;ABCB1;rs1128503;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
IMATINIB;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
ATORVASTATIN;ABCC2;rs717620;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
LENALIDOMIDE, THALIDOMIDE;FGF2;rs308395;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
METHOTREXATE;ABCC2;rs717620;CT + TT;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ANTIDEPRESSANTS;MAOA;rs979605;AA;LADME_PK;DECREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
METHOTREXATE;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ANTIDEPRESSANTS;GRIK4;rs1954787;C;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ETHANOL;ALDH2;rs671;AG;OTHER;INCREASED_EXPOSURE;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
HYDROCHLOROTHIAZIDE;NEDD4L;rs292449;CC + CG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
PITRAKINRA;IL4R;rs8832;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
TACROLIMUS;CYP3A5;rs776746;T;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
PITRAKINRA;IL4R;rs3024530;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
PITRAKINRA;IL4R;rs1110470;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
PITRAKINRA;IL4R;rs2239347;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
BENAZEPRIL;MTR;rs1805087;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
PITRAKINRA;IL4R;rs1805010;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
VORICONAZOLE;ABCC2;rs717620;CT + TT;LADME_PK;INCREASED_TROUGH CONCENTRATION;
ACENOCOUMAROL, PHENPROCOUMON;VKORC1;rs9934438;GG;DOSAGE, TOXICITY;INCREASED_DOSE;
MYCOPHENOLATE MOFETIL;SLCO1B3;rs7311358;A;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
MORPHINE;ABCC3;rs4793665;CC;LADME_PK;INCREASED_METABOLISM;
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8105790;C;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
ATORVASTATIN;SLCO1B1;rs4149056;CT;LADME_PK;INCREASED_EXPOSURE;
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8103142;C;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
MEMANTINE;NR1I2;rs1523130;CT + TT;LADME_PK;DECREASED_CLEARANCE;DISEASE:DEMENTIA
BENAZEPRIL;ADRB2;rs1042713;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs11881222;G;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs7248668;A;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
AMISULPRIDE;ANKS1B;rs7968606;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs28416813;C;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs4803219;C;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
MORPHINE;OPRM1;rs1799971;AG;DOSAGE;INCREASED_DOSE;DISEASE:NEOPLASMS
ESCITALOPRAM;;rs2069521;A;LADME_PK;INCREASED_METABOLISM;DISEASE:MAJOR_DEPRESSIVE_DISORDER
IMATINIB;CYP3A5;rs776746;CC;LADME_PK;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
ROSUVASTATIN;SCARB1;rs4238001;CC;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MYOCARDIAL_ISCHEMIA
IMATINIB;ABCB1;rs1045642;AA;LADME_PK;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
IMATINIB;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
LACOSAMIDE;ABCC2;rs2273697;GG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:EPILEPSY
IMATINIB;ABCB1;rs1045642;AA;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE:DYSLIPIDAEMIA
OLANZAPINE;SV2C;rs11960832;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CORTICOSTEROIDS;TBX21;rs2240017;CG;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
METHOTREXATE;ABCC1;rs2238476;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
ANTIDEPRESSANTS;HTR2A;rs6314;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP2D6;rs1065852;A;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP2C9;rs9332120;C;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
TACROLIMUS;CYP3A5;rs776746;C;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP2D6;rs3892097;C;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP3A4;rs2740574;C;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN, PRIMIDONE, VALPROIC ACID;CYP3A4;rs2687116;C;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
DULOXETINE;ANO2;rs61908411;C;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;rs61908409;C;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;rs61908410;T;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;rs78615940;A;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;rs78482393;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;rs61908405;C;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;rs61908406;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ARG1;rs2781659;A;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
DULOXETINE;ANO2;rs61908404;C;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;rs61908408;A;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;rs61908407;A;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;rs17786412;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
DULOXETINE;ANO2;rs17786400;A;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METHADONE;ABCB1;rs9282564;C;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
DULOXETINE;ANO2;rs61908403;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;rs61908402;T;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;rs17724452;C;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
GLATIRAMER ACETATE;PVT1;rs2114358;A;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
DULOXETINE;;rs7316769;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;rs17724494;C;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;rs56165452;CT;DOSAGE;DECREASED_DOSE;
METHADONE;ABCB1;rs1045642;A;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
DULOXETINE;ANO2;rs17786394;T;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DULOXETINE;ANO2;rs17724464;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METHADONE;UGT2B7;rs7439366;CT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
TENOFOVIR;ABCC4;rs1751034;TT;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;
PEMETREXED, PLATINUM COMPOUNDS;CCND1;rs9344;A;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:LUNG_NEOPLASMS
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED_DOSE;
METOPROLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEART_FAILURE
WARFARIN;VKORC1;rs7294;T;DOSAGE;INCREASED_DOSE;
LIRAGLUTIDE;GLP1R;rs10305420;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:OBESITY,_DISEASE:POLYCYSTIC_OVARY_SYNDROME
LAMOTRIGINE;CACNA1H;rs2753325;A;EFFICACY;INCREASED_CLINICAL BENEFIT;EFFICACY:EPILEPSY
AZATHIOPRINE;TPMT;TPMT low activity;;LADME_PK;DECREASED_DOSE;
FLUOROURACIL;DPYD;rs3918290;CT;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
FLUOROURACIL;DPYD;rs2297595;CC + CT;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
ASPIRIN;GP1BA;rs6065;CT + TT;EFFICACY;INCREASED_RESPONSE;
FLUOROURACIL;DPYD;rs1801160;CT + TT;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
FLUOROURACIL;DPYD;rs1801265;GG;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
LACOSAMIDE;ABCC2;rs717620;CC;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:EPILEPSY
ANASTROZOLE;;rs11648166;G;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
LACOSAMIDE;ABCC2;rs2273697;A;EFFICACY;INCREASED_RESISTANCE;OTHER:EPILEPSY
LACOSAMIDE;ABCC2;rs717620;T;EFFICACY;INCREASED_RESISTANCE;OTHER:EPILEPSY
ANASTROZOLE;;rs28845026;T;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
CYCLOPHOSPHAMIDE;CYP2B6;rs4802101;C;LADME_PK;DECREASED_METABOLISM;DISEASE:LUPUS_ERYTHEMATOSUS
APIXABAN;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:ATRIAL_FIBRILLATION
METHOTREXATE;ARID5B;rs10994982;A;LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
OXYCODONE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_RESPONSE;OTHER:PAIN,_POSTOPERATIVE
CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;A;LADME_PK;DECREASED_METABOLISM;DISEASE:LUPUS_ERYTHEMATOSUS
IMATINIB;ABCB1;rs1045642;AG + GG;LADME_PK;INCREASED_TROUGH CONCENTRATION;OTHER:GASTROINTESTINAL_STROMAL_TUMORS
FENOFIBRATE;PPARA;rs4253778;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
METHOTREXATE;SLC22A11;rs11231809;AT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;ABCC1;rs246240;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
HMG COA REDUCTASE INHIBITORS;HMGCR;rs3846662;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:FAMILIAL_HYPERCHOLESTEROLEMIA
METHOTREXATE;ABCC1;rs3784864;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:LUPUS_NEPHRITIS
4-HYDROXYCYCLOPHOSPHAMIDE;CYP3A5;rs776746;CC + CT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:LUPUS_NEPHRITIS
CYCLOPHOSPHAMIDE;CYP2B6;rs7254579;C;LADME_PK;METABOLISM;DISEASE:LUPUS_ERYTHEMATOSUS
HMG COA REDUCTASE INHIBITORS;;rs445925;A;EFFICACY;INCREASED_RESPONSE;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;G;EFFICACY;DECREASED_RESPONSE;
FENOFIBRATE;IL6;rs1800795;CC + CG;EFFICACY;INCREASED_RESPONSE;OTHER:PATIENTS_WITH_A_HIGH_RISK_OF_CARDIOVASCULAR_DISEASE
RANIBIZUMAB;NRP1;rs2070296;T;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
ATORVASTATIN;CETP;rs708272;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;MICB;rs3828913;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
METHOTREXATE;ABCG2;rs13120400;CC;EFFICACY;INCREASED_RESPONSE;SIDE_EFFECT:PSORIASIS
NICOTINE;DBH;rs77905;GG;DOSAGE;DECREASED_DOSE;DISEASE:TOBACCO_USE_DISORDER
WARFARIN;VKORC1;rs9923231;CC + CT;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
NICOTINE;MAOA;rs1137070;TT;DOSAGE;INCREASED_DOSE;DISEASE:TOBACCO_USE_DISORDER
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_DOSE;
OMEPRAZOLE, PANTOPRAZOLE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:HELICOBACTER_INFECTIONS
DEFERASIROX;CYP24A1;rs2248359;TT;LADME_PK;METABOLISM;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
DEFERASIROX;VDR;rs7975232;AA;LADME_PK;METABOLISM;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;HTR1A;rs1364043;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DEFERASIROX;VDR;rs2228570;G;LADME_PK;METABOLISM;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
ANTIPSYCHOTICS;GRM3;rs6465084;AA;TOXICITY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
METFORMIN;SLC47A1;rs2289669;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
WARFARIN;CYP4F2;rs2108622;CC + CT;DOSAGE;DECREASED_DOSE;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
METFORMIN;SLC47A1;rs2289669;AA;LADME_PK;DECREASED_CLEARANCE;DISEASE:DIABETES_MELLITUS_TYPE2
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
BETA BLOCKING AGENTS;GRK5;rs2230345;AA + AT;EFFICACY;RESPONSE;DISEASE:HEART_FAILURE
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;NR1I3;rs2307424;G;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;NR1I3;rs2307424;AG;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
ANTIHYPERTENSIVES;ATP2B1;rs12817819;CT + TT;EFFICACY;INCREASED_RESISTANCE;DISEASE:CORONARY_ARTERY_DISEASE,_DISEASE:HYPERTENSION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
WARFARIN;EPHX1;rs1051741;CT;DOSAGE;DECREASED_DOSE;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8103142;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs11881222;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;
ISONIAZID;NAT2;rs1799930;AA;LADME_PK;INCREASED_EXPOSURE;DISEASE:HIV_INFECTIOUS_DISEASE,_DISEASE:TUBERCULOSIS
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;
MERCAPTOPURINE;NUDT15;rs73189762;T;DOSAGE;DECREASED_DOSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;PRSS53, VKORC1;rs7294;CT;DOSAGE;INCREASED_DOSE;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
ISONIAZID;NR1I2;rs2472677;TT;LADME_PK;INCREASED_EXPOSURE;DISEASE:HIV_INFECTIOUS_DISEASE,_DISEASE:TUBERCULOSIS
AMLODIPINE, FELODIPINE;CACNA1C;rs2238032;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
ISONIAZID;SLCO1B1;rs4149032;CC;LADME_PK;DECREASED_EXPOSURE;DISEASE:HIV_INFECTIOUS_DISEASE,_DISEASE:TUBERCULOSIS
CALCIUM CHANNEL BLOCKERS;CACNA1C;rs2239128;C;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
MORPHINE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_DOSE;
GEFITINIB;EGFR;rs121434568;G;EFFICACY;RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs2900478;A;EFFICACY;DECREASED_RESPONSE;
CALCIUM CHANNEL BLOCKERS;CACNA1C;rs2239050;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
HMG COA REDUCTASE INHIBITORS;CELSR2;rs646776;C;EFFICACY;INCREASED_RESPONSE;
VALPROIC ACID;UGT2B7;rs12233719;GG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
EFAVIRENZ;CYP2A6;rs28399454;T;LADME_PK;METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;rs28399499;C;LADME_PK;METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
CALCIUM CHANNEL BLOCKERS;CACNA1C;rs2238032;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;DISEASE:VENOUS_THROMBOEMBOLISM
PHENPROCOUMON, WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
EFAVIRENZ;CYP2B6;rs2279343;GG;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
ATAZANAVIR;ABCB1;rs1045642;GG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;rs7900194;A;DOSAGE;DECREASED_DOSE;
EFAVIRENZ;CYP2B6;rs2279343;AG;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
VALPROIC ACID;UGT2B7;rs7668258;CT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;rs28371686;G;DOSAGE;DECREASED_DOSE;
WARFARIN;APOC1, APOE;rs429358;T;DOSAGE;DECREASED_DOSE;OTHER:HAPLOTYPE_EPSILON2
VALPROIC ACID;UGT2B7;rs7668258;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
WARFARIN;APOC1, APOE;rs7412;T;DOSAGE;DECREASED_DOSE;OTHER:HAPLOTYPE_EPSILON2
INFLIXIMAB;;rs2097432;CC + CT;EFFICACY;INCREASED_DISCONTINUATION;EFFICACY:CROHN_DISEASE
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;
PHOTODYNAMIC THERAPY;CFH;rs1061170;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
VALPROIC ACID;UGT2B7;rs7439366;TT;LADME_PK;CONCENTRATIONS;DISEASE:EPILEPSY
RISPERIDONE;ABCG2;rs2231142;GT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;
FLUOXETINE;HTR1B;rs9361233;CC + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
EFAVIRENZ;CYP2B6;rs8192709;CC;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
INFLIXIMAB;;rs73277969;T;EFFICACY;INCREASED_DISCONTINUATION;EFFICACY:CROHN_DISEASE
IVACAFTOR;CFTR;rs121908757;C;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;rs121909005;G;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
ASPIRIN, CLOPIDOGREL;CYP2C19;rs12248560;T;;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
IVACAFTOR;CFTR;rs121908755;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ASPIRIN, PRASUGREL;PEAR1;rs2768759;AC + CC;EFFICACY;DECREASED_RESPONSE;
CYCLOSPORINE;ABCB1;rs2032582;AC + CC;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ASPIRIN, CLOPIDOGREL, PRASUGREL;PEAR1;rs12041331;AA + AG;EFFICACY;INCREASED_RESPONSE;
CYCLOSPORINE;CYP3A4;rs4646437;AG + GG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
HYDRALAZINE / ISOSORBIDE DINITRATE;GNB3;rs5443;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEART_FAILURE
IVACAFTOR;CFTR;rs397508453;C;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
WARFARIN;VKORC1;rs72547529;T;EFFICACY;DECREASED_RESPONSE;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;INCREASED_CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
IVACAFTOR;CFTR;rs121909013;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;rs121909041;C;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
TACROLIMUS;CYP3A4;rs2242480;T;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
IVACAFTOR;CFTR;rs74503330;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
NEVIRAPINE;CYP1A2;rs762551;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE
FENTANYL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:PAIN
ANASTROZOLE, LETROZOLE, TAMOXIFEN;CYP19A1;rs4646;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS,_DISEASE:MENOPAUSE
IVACAFTOR;CFTR;rs267606723;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
SEROTONIN;ERICH3;rs696692;T;OTHER;DECREASED_CONCENTRATIONS;DISEASE:DEPRESSIVE_DISORDER
IVACAFTOR;CFTR;rs80282562;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
TACROLIMUS;ABCB1;rs1045642;AG + GG;DOSAGE;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
CYCLOSPORINE;CYP3A4;rs4646437;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:KIDNEY_TRANSPLANTATION
ANASTROZOLE, LETROZOLE, TAMOXIFEN;CYP19A1;rs4646;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
PLATINUM COMPOUNDS;ERCC2;rs1799793;CT + TT;EFFICACY;INCREASED_RESISTANCE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA
SEROTONIN;TSPAN5;rs11947402;G;OTHER;DECREASED_CONCENTRATIONS;DISEASE:DEPRESSIVE_DISORDER
NEVIRAPINE;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TRAF1;rs3761847;G;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
THALIDOMIDE;CTNNB1;rs4533622;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
WARFARIN;VKORC1;rs9934438;AG;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION,_DISEASE:CARDIOMYOPATHIES,_DISEASE:HEART_VALVE_REPLACEMENT,_DISEASE:PERIPHERAL_VASCULAR_DISEASES,_DISEASE:PULMONARY_EMBOLISM,_DISEASE:VENOUS_THROMBOSIS
FENTANYL;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED_DOSE;DISEASE:PAIN
IVACAFTOR;CFTR;rs193922525;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
CYCLOPHOSPHAMIDE, DEXAMETHASONE, THALIDOMIDE;CTNNB1;rs4135385;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
OPIOIDS;IL17A;rs2275913;A;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
PLATINUM COMPOUNDS;CYP1A1;rs1048943;CC + CT;EFFICACY;INCREASED_RESISTANCE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA
WARFARIN;CYP4F2;rs2108622;C;DOSAGE;DECREASED_DOSE;DISEASE:VENOUS_THROMBOEMBOLISM
TACROLIMUS;ABCB1;rs2032582;AC + CC;DOSAGE;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;DISEASE:VENOUS_THROMBOEMBOLISM
ANTIDEPRESSANTS, CITALOPRAM, ESCITALOPRAM;ERICH3;rs11580409;C;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
ETHANOL;OPRM1;rs1799971;AG + GG;OTHER;DECREASED_DOSE;
CYCLOSPORINE;ABCB1;rs2032582;AC + CC;DOSAGE;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A7;rs10211;TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER
WARFARIN;VKORC1;rs9923231;C;DOSAGE, EFFICACY;INCREASED_DOSE;
WARFARIN;VKORC1;rs9923231;T;DOSAGE, EFFICACY;INCREASED_RESPONSE;
TACROLIMUS;ABCB1;rs1045642;GG;LADME_PK;INCREASED_DOSE;OTHER:LIVER_TRANSPLANTATION
ACETAMINOPHEN, TRAMADOL;OPRM1;rs1799971;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:NEUROPATHIC_PAIN
RITUXIMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHADONE;CYP2B6;rs3745274;T;LADME_PK;DECREASED_CLEARANCE;DISEASE:OPIOID-RELATED_DISORDERS
COTININE;UGT2B10;rs2942857;CC;LADME_PK;DECREASED_CLEARANCE;DISEASE:TOBACCO_USE_DISORDER
FENTANYL;;rs6961071;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:PAIN,_POSTOPERATIVE
RITUXIMAB;FCGR3A;rs396991;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;VKORC1;rs2359612;G;DOSAGE;INCREASED_DOSE;
CYCLOPHOSPHAMIDE, DOXORUBICIN, FEC100, FLUOROURACIL;ALDH1A1;rs13959;AG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BREAST_NEOPLASMS
TACROLIMUS;POR;rs1057868;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
COUMARIN;CYP2A6;rs1801272;TT;OTHER, LADME_PK;DECREASED_METABOLISM;
COUMARIN;CYP2A6;rs1801272;TT;LADME_PK;DECREASED_METABOLISM;
METHADONE;ABCB1;rs2032582;CC;LADME_PK;DECREASED_CLEARANCE;DISEASE:OPIOID-RELATED_DISORDERS
NICOTINE;CYP2A6;rs5031016;G;LADME_PK;DECREASED_METABOLISM;
TOCILIZUMAB;FCGR3A;rs396991;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CARVEDILOL;ADRB2;rs1042714;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HEART_FAILURE
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
FENTANYL;;rs13093031;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:PAIN,_POSTOPERATIVE
ATORVASTATIN, LOVASTATIN, SIMVASTATIN;CYP3A5;rs776746;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:ARTERIOSCLEROSIS
COTININE;UGT2B10;rs2942857;CC;LADME_PK;INCREASED_EXPOSURE;DISEASE:TOBACCO_USE_DISORDER
CLOPIDOGREL;ABCB1;rs1045642;A;EFFICACY;INCREASED_RESPONSE;OTHER:ACUTE_CORONARY_SYNDROME
CISPLATIN;ERCC1;rs11615;A;EFFICACY;DECREASED_RESPONSE;OTHER:OVARIAN_NEOPLASMS
WARFARIN;VKORC1;rs2884737;C;DOSAGE;DECREASED_DOSE;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
WARFARIN;PRSS53, VKORC1;rs7294;TT;DOSAGE;INCREASED_DOSE;
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED_DOSE;
PHENOBARBITAL;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESISTANCE;DISEASE:EPILEPSY
TACROLIMUS;FMO3;rs1800822;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
FENOFIBRATE;CRP;rs1417938;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:METABOLIC_SYNDROME
PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE:DYSLIPIDAEMIA
IVACAFTOR;CFTR;rs397508442;T;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
FLUOXETINE;HTR1B;rs9361235;CC + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
N-DESMETHYLCLOZAPINE;UGT2B10;rs61750900;T;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
WARFARIN;NQO1;rs10517;GG;DOSAGE;DECREASED_DOSE;
FENOFIBRATE;CRP;rs3091244;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:METABOLIC_SYNDROME
PRAVASTATIN;MMP3;rs35068180;A/del + AA;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
N-DESMETHYLCLOZAPINE;UGT1A4;rs2011425;G;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
FENOFIBRATE;CRP;rs3091244;GG + GT;EFFICACY;INCREASED_RESPONSE;DISEASE:METABOLIC_SYNDROME
FENTANYL;ABCB1;rs1128503;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:NEOPLASMS,_DISEASE:PAIN
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
CLOZAPINE;CYP2C18;rs1126545;T;LADME_PK;DECREASED_METABOLISM;OTHER:SCHIZOPHRENIA
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;
SIMVASTATIN;SLCO1B1;rs4149056;C;EFFICACY;DECREASED_RESPONSE;
DESLORATADINE, MIZOLASTINE;FCER1A;rs2298805;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:URTICARIA
ATORVASTATIN;CYP3A5;rs17161788;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;G;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;SELE;rs3917412;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:COLONIC_NEOPLASMS
ATORVASTATIN;CYP3A5;rs776746;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
OPIOIDS;;rs2952768;CC;EFFICACY;DECREASED_RESPONSE;OTHER:PAIN,_POSTOPERATIVE
HMG COA REDUCTASE INHIBITORS;PCSK9;rs11591147;T;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
IMATINIB;CYP3A4;rs28371759;AG;EFFICACY;INCREASED_RESPONSE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
DIGOXIN;ABCB1;rs2032582;CC;LADME_PK;INCREASED_CLEARANCE;DISEASE:HEART_FAILURE
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:COLONIC_NEOPLASMS
PLATINUM;ERCC5;rs17655;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR, IVACAFTOR / TEZACAFTOR;CFTR;rs75389940;AG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
CARVEDILOL;UGT2B7;rs12233719;T;LADME_PK;DECREASED_CLEARANCE;DISEASE:HEART_DISEASES
BUPROPION, NICOTINE, VARENICLINE;CHRNA5;rs2036527;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
BUPROPION, NICOTINE, VARENICLINE;CHRNA5;rs16969968;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
CARVEDILOL;UGT2B7;rs28365063;G;LADME_PK;DECREASED_CLEARANCE;DISEASE:HEART_DISEASES
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;FMO3;rs909530;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
DIGOXIN;ABCB1;rs2032582;AA + AT;LADME_PK;DECREASED_CLEARANCE;DISEASE:HEART_FAILURE
LUMACAFTOR;CFTR;rs121909047;AA;EFFICACY;RESPONSE;
METHADONE;CDH2;rs8094439;AA;EFFICACY;INCREASED_RESPONSE;
PERTUSSIS VACCINES;TLR4;rs4986790;AA;EFFICACY;INCREASED_RESPONSE;
TACROLIMUS;POR;rs1057868;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;
METHADONE;CDH2;rs17446819;CC;EFFICACY;INCREASED_RESPONSE;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;
SORAFENIB;ABCG2;rs2231137;CT;LADME_PK;CONCENTRATIONS;DISEASE:HEPATOCELLULAR_CARCINOMA
NICOTINE;CYP2A6;rs376817657;CT + TT;LADME_PK;DECREASED_METABOLISM;
SORAFENIB;ABCG2;rs2231142;GT;LADME_PK;CONCENTRATIONS;DISEASE:HEPATOCELLULAR_CARCINOMA
IVACAFTOR;CFTR;rs397508602;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
IMATINIB;SLC22A1;rs683369;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
FENOFIBRATE;GCKR;rs780094;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
IVACAFTOR / LUMACAFTOR;CFTR;rs121909011;T;EFFICACY;RESPONSE;
IMATINIB;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;
FENTANYL;OPRM1;rs1799971;GG;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
IVACAFTOR / LUMACAFTOR;CFTR;rs74551128;A;EFFICACY;RESPONSE;
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;
BILIRUBIN;UGT1A1;rs887829;TT;LADME_PK;INCREASED_CONCENTRATIONS;
WARFARIN;CYP2C9;rs1799853;CT;DOSAGE;DECREASED_DOSE;
METHOTREXATE;GGH;rs3758149;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MERCAPTOPURINE;NUDT15;rs186364861;A;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
FENOFIBRATE;APOA5;rs662799;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
IMIQUIMOD;TLR7;rs179008;A;EFFICACY;INCREASED_RESPONSE;DISEASE:BASAL_CELL_CARCINOMA
MERCAPTOPURINE;NUDT15;rs116855232;T;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
METHOTREXATE;GGH;rs11545077;CC + CT;EFFICACY;INCREASED_RESPONSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;VKORC1;rs9923231;T;DOSAGE, OTHER;DECREASED_DOSE;
FENOFIBRATE;APOA5;rs3135506;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
CLONIDINE;GNB3;rs5443;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:LIVER_CIRRHOSIS
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
CLOZAPINE;UGT2B10;rs61750900;T;LADME_PK;DECREASED_METABOLISM;OTHER:SCHIZOPHRENIA
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
OPIOIDS;TAOK3;rs1277441;AG + GG;DOSAGE;INCREASED_DOSE;OTHER:NEOPLASMS,_OTHER:PAIN
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
OPIOIDS;TAOK3;rs795484;TT;DOSAGE;DECREASED_RESPONSE;OTHER:NEOPLASMS,_OTHER:PAIN
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
FENTANYL;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
WARFARIN;CYP2C9;rs1799853;T;LADME_PK;DECREASED_METABOLISM;
IVACAFTOR;CFTR;rs121909005;G;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
OPIOIDS;TAOK3;rs795484;CT + TT;DOSAGE;INCREASED_DOSE;OTHER:NEOPLASMS,_OTHER:PAIN
FENTANYL;ABCB1;rs1128503;AA;DOSAGE;INCREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
IVACAFTOR;CFTR;rs121908757;C;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
TENOFOVIR;ABCC4;rs3742106;AC + CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
VITAMIN B12 AND FOLIC ACID;MTHFR;rs1801133;A;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:HYPERHOMOCYSTEINEMIA,_OTHER:STROKE
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY, LADME_PK;INCREASED_EXPOSURE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CAPTOPRIL;AGTR1;rs5186;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTP1;rs1695;A;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;
DAUNORUBICIN;CBR1;rs25678;CC;LADME_PK;DECREASED_EXPOSURE;DISEASE:ACUTE_MYELOID_LEUKEMIA
IVACAFTOR;CFTR;rs78655421;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
MERCAPTOPURINE;TPMT;rs1142345;CC;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CITALOPRAM;CYP2C19;rs4244285;AG;EFFICACY;DECREASED_RESPONSE;OTHER:ALCOHOL_ABUSE,_OTHER:MAJOR_DEPRESSIVE_DISORDER
BILIRUBIN;SLCO1B1, SLCO1B3, SLCO1B7;rs1910167;C;LADME_PK;INCREASED_CONCENTRATIONS;
CITALOPRAM;CYP2C19;rs4244285;AG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ALCOHOL_ABUSE,_OTHER:MAJOR_DEPRESSIVE_DISORDER
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ATENOLOL;GNB3;rs5443;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
ETANERCEPT;PSORS1C1;rs2233945;C;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TACROLIMUS;POR;rs1057868;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
MERCAPTOPURINE;ABCC4;rs2274407;AA;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE,_DISEASE:TUBERCULOSIS
DISULFIRAM;TPH2;rs4290270;AA + AT;EFFICACY;INCREASED_RESPONSE;OTHER:COCAINE_DEPENDENCE
ATENOLOL;GNB3;rs11064426;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
ENALAPRIL;NR3C2;rs5522;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
ATENOLOL;GNB3;rs2301339;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
ATENOLOL;GNB3;rs5443;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
MERCAPTOPURINE;NUDT15;rs116855232;TT;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ATENOLOL;GNB3;rs11064426;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
ACENOCOUMAROL;CYP2C9;rs4086116;T;DOSAGE;DECREASED_DOSE;
ATENOLOL;GNB3;rs11064426;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
ETANERCEPT;STAT4;rs7574865;T;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ATENOLOL;GNB3;rs2301339;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
METHOTREXATE;GGH;rs11545076;AC + CC;EFFICACY;INCREASED_RESPONSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ALLOPURINOL;ABCG2;rs2231142;T;EFFICACY;DECREASED_RESPONSE;DISEASE:GOUT
PRAVASTATIN;SLCO1B1;rs4149015;AG;EFFICACY, LADME_PK;DECREASED_RESPONSE;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
IVACAFTOR, TEZACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ATORVASTATIN, HMG COA REDUCTASE INHIBITORS, PRAVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERLIPIDEMIAS
FENOFIBRATE;ABCA1;rs2230806;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
SERTRALINE;HTR2A;rs6313;AA + AG;DOSAGE;INCREASED_DOSE;OTHER:DEPRESSION,_OTHER:ANXIETY_DISORDERS
FENOFIBRATE;ABCA1;rs2230808;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
PLATINUM COMPOUNDS;NUP107;rs79419059;C;EFFICACY;INCREASED_RESISTANCE;DISEASE:OVARIAN_NEOPLASMS
FENOFIBRATE;ABCA1;rs2230806;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
VENLAFAXINE;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:ANXIETY_DISORDERS
WARFARIN;NQO1;rs1800566;AA;DOSAGE;DECREASED_DOSE;
KETOPROFEN;CYP2C9;rs1799853;CC;EFFICACY;INCREASED_RESPONSE;OTHER:PAIN,_POSTOPERATIVE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
ETANERCEPT;TNF;rs1800629;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ANTIDEPRESSANTS;CHL1;rs1516338;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER,_DISEASE:DEPRESSIVE_DISORDER,_DISEASE:MAJOR_DEPRESSIVE_DISORDER
ADALIMUMAB;TANK;rs1267067;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;rs15524;AA;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
ADALIMUMAB;VEGFA;rs25648;T;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
DACLATASVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
CARVEDILOL;ADRB1;rs1801253;GG;DOSAGE;INCREASED_DOSE;DISEASE:HEART_FAILURE
TACROLIMUS;CYP3A5;rs4646450;GG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
INFLIXIMAB;TNF;rs361525;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;SLCO1B1;rs11045879;CC + CT;LADME_PK;INCREASED_EXPOSURE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A4;rs4646437;GG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
HYDROCHLOROTHIAZIDE;VASP;rs10995;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
ADALIMUMAB;TNFAIP3;rs2230926;T;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
METHOTREXATE;SLC19A1;rs2838958;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
SIMVASTATIN, SIMVASTATIN ACID;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HYPERCHOLESTEROLEMIA
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;
IVACAFTOR;CFTR;rs121908757;C;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
METHOTREXATE;SLC19A1;rs3788200;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
LITHIUM;NR1D1, THRA;rs2314339;T;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;
NALTREXONE;OPRM1;rs1799971;AG;EFFICACY;INCREASED_RESPONSE;OTHER:AMPLIFICATION_OF_SEXUAL_BEHAVIOR,_OTHER:PARKINSON_DISEASE
TACROLIMUS;CYP3A5;rs776746;CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;DISEASE:VENOUS_THROMBOEMBOLISM
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
ATENOLOL;GNB3;rs2301339;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;ERCC2;rs13181;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
ACENOCOUMAROL;APOE;rs429358;C;DOSAGE;DECREASED_DOSE;DISEASE:VENOUS_THROMBOEMBOLISM
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;
WARFARIN;VKORC1;rs8050894;CG + GG;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_DOSE;
WARFARIN;VKORC1;rs2359612;AA + AG;DOSAGE;DECREASED_DOSE;
ATAZANAVIR;SORCS2;rs73208473;A;LADME_PK;DECREASED_EXPOSURE;DISEASE:HIV_INFECTIOUS_DISEASE
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;ERCC1;rs11615;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
METHADONE;CNR1;rs806368;CT + TT;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
METHADONE;TPH2;rs1386493;GG;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
MORPHINE;UGT2B7;rs7439366;CT + TT;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:NEOPLASMS,_OTHER:PAIN
ATORVASTATIN, SIMVASTATIN;KIF6;rs20455;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
EFAVIRENZ;CYP2B6;rs35303484;GG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
METHADONE;CYP2B6;rs16974799;CT;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
LAMIVUDINE, NEVIRAPINE;ABCB1;rs1045642;A;EFFICACY;RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE
METHADONE;OPRL1;rs2229205;CT;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
ROSUVASTATIN;KIF6;rs20455;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
ADRENERGICS, INHALANTS;;rs34548976;T;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
TOPIRAMATE;GRIK1;rs2832407;AA + AC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ALCOHOL-RELATED_DISORDERS
CISPLATIN, GEMCITABINE;CDA;rs2072671;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
TOPIRAMATE;GRIK1;rs2832407;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE:ALCOHOL-RELATED_DISORDERS
LAMIVUDINE, NEVIRAPINE, ZIDOVUDINE;ABCB1;rs2032582;A;EFFICACY;RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE
ATORVASTATIN;KIF6;rs20455;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
CISPLATIN, GEMCITABINE;ERCC1;rs11615;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
FLUVASTATIN;ABCB1;rs1922242;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
GLICLAZIDE;KCNQ1;rs2237897;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
WARFARIN;CYP4F11;rs1060467;G;DOSAGE;DECREASED_DOSE;
CARBOPLATIN, TAXANES;VEGFA;rs9369421;CC + CT;EFFICACY;INCREASED_RESPONSE;
TACROLIMUS;CYP3A4;rs35599367;AA + AG;LADME_PK;DECREASED_CLEARANCE;OTHER:KIDNEY_TRANSPLANTATION
EFAVIRENZ;CYP2A6;rs28399433;AC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
FLUVASTATIN;CETP;rs4783961;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;ABCB1;rs9282564;CC + CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
METHOTREXATE;MTRR;rs1801394;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
TENOFOVIR;IFNL3, IFNL4;rs12979860;C;LADME_PK;INCREASED_CLEARANCE;OTHER:HIV_INFECTIOUS_DISEASE
GLUCOCORTICOIDS;ABCB1;rs1128503;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:CROHN_DISEASE
METFORMIN;SLC22A1;rs622342;A;EFFICACY;INCREASED_RESPONSE;EFFICACY:DIABETES_MELLITUS
GLUCOCORTICOIDS;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:CROHN_DISEASE
HYDROXYUREA;BCL11A;rs1427407;T;EFFICACY;INCREASED_RESPONSE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
HYDROXYUREA;BCL11A;rs766432;C;EFFICACY;INCREASED_RESPONSE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
WARFARIN;CYP2C9;rs2860905;A;DOSAGE;DECREASED_DOSE;
FENTANYL;UGT2B7;rs7439366;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:PAIN,_POSTOPERATIVE
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE, EFFICACY;DECREASED_DOSE;
TIOTROPIUM;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
LUMEFANTRINE;ABCC2;rs8187710;AA;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:MALARIA
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;G;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
ATORVASTATIN;APOE;rs7412;CT;EFFICACY;INCREASED_RESPONSE;
METHADONE;ABCB1;rs1045642;AG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;
CLOPIDOGREL;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESISTANCE;DISEASE:HYPERTENSION
MORPHINE;UGT2B7;rs7439366;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER:NEOPLASMS,_OTHER:PAIN
VALPROIC ACID;UGT1A6;rs2070959;AG + GG;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:EPILEPSY
VALPROIC ACID;UGT1A6;rs1105879;AC + CC;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:EPILEPSY
CLOZAPINE;HTR2A;rs6314;AA + AG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA
FLUVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE;
PRAVASTATIN;ACE;rs4341;CG + GG;EFFICACY;INCREASED_RESPONSE;
PRAVASTATIN;LPL;rs328;GG;EFFICACY;INCREASED_RESPONSE;
LOVASTATIN;CETP;rs708272;AG;EFFICACY;INCREASED_RESPONSE;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
FENTANYL;UGT2B7;rs10028494;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:PAIN,_POSTOPERATIVE
METHOTREXATE;MTHFR;rs1801133;AA;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
NICOTINE;CHRNA3;rs1051730;A;LADME_PK;INCREASED_DOSE;
FLUVASTATIN;LIPC;rs1800588;CC + CT;EFFICACY;INCREASED_RESPONSE;
CLOZAPINE;CYP1A1;rs2472297;T;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
METHYLPHENIDATE;CES1;rs114119971;CG;DOSAGE;DECREASED_DOSE;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
SIMVASTATIN;LIPC;rs1800588;CT;EFFICACY;INCREASED_RESPONSE;
CISPLATIN, FLUOROURACIL, OXALIPLATIN;VEGFA;rs25648;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
ATORVASTATIN;ABCB1;rs2032582;CC;EFFICACY;INCREASED_RESPONSE;
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ATORVASTATIN;SLCO1B1;rs4149036;AC + CC;EFFICACY;INCREASED_RESPONSE;
ATORVASTATIN;CYP3A5;rs776746;CC + CT;EFFICACY;INCREASED_RESPONSE;
PERTUSSIS VACCINES;TLR4;rs2770150;GG;EFFICACY;DECREASED_RESPONSE;
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs6025211;CC + TT;EFFICACY;INCREASED_RESPONSE;OTHER:LIVER_CANCER
TACROLIMUS;ABCB1;rs2032582;AA + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:NEPHROTIC_SYNDROME
LOVASTATIN;SLCO1B1;rs2291073;GT + TT;EFFICACY;INCREASED_RESPONSE;
SUFENTANIL;CYP3A4;rs2242480;CT + TT;DOSAGE;DECREASED_DOSE;OTHER:PAIN
TACROLIMUS;ABCB1;rs1128503;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:NEPHROTIC_SYNDROME
CATECHOLAMINES, METFORMIN;SLC22A3;rs8187725;T;OTHER, LADME_PK;DECREASED_METABOLISM;
LOVASTATIN;LDLR;rs688;TT;EFFICACY;INCREASED_RESPONSE;
AMLODIPINE;CACNA1C;rs2239050;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HYPERTENSION
FLUVASTATIN;CYP3A4;rs4986910;AG;EFFICACY;INCREASED_RESPONSE;
NALTREXONE;ADH1C;rs698;C;EFFICACY;INCREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
NALTREXONE;ADH1B;rs2066702;A;EFFICACY;DECREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
LOVASTATIN;LDLR;rs5925;CC;EFFICACY;INCREASED_RESPONSE;
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs9679162;TT;EFFICACY;INCREASED_RESPONSE;OTHER:LIVER_CANCER
FLUOXETINE;HTR2A;rs6313;GG;EFFICACY;DECREASED_TIME TO RESPONSE;OTHER:DEPRESSION,_OTHER:ANXIETY_DISORDERS
NALTREXONE;ALDH2;rs671;G;EFFICACY;INCREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
VARENICLINE;CYP2B6;rs8109525;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
TACROLIMUS;ABCB1;rs1128503;AG;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;rs7089580;T;DOSAGE;INCREASED_DOSE;
CLOPIDOGREL;P2RY12;rs2046934;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_DISEASE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS;OTHER
TACROLIMUS;ABCB1;rs1045642;AA;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C19;rs3814637;C;DOSAGE;DOSE;
TACROLIMUS;ABCB1;rs2032582;AA;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;rs4917639;A;DOSAGE;DOSE;
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DOSE;
TACROLIMUS;CYP3A7;rs2257401;CG + GG;LADME_PK;DECREASED_CONCENTRATIONS;OTHER
CLOPIDOGREL;P2RY12;rs3732759;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_DISEASE
ANTIBIOTICS, ESOMEPRAZOLE;ABCB1;rs1045642;AA;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:HELICOBACTER_INFECTIONS
CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;VEGFA;rs833061;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
DOLUTEGRAVIR;ABCG2;rs2231142;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CLOPIDOGREL;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_RESISTANCE;
CISPLATIN, FLUOROURACIL;GALNT14;rs9679162;GG;EFFICACY;INCREASED_RESPONSE;OTHER:LIVER_CANCER
CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;KDR;rs2305948;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
CARFILZOMIB, DEXAMETHASONE, LENALIDOMIDE;KDR;rs1870377;AT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:MULTIPLE_MYELOMA
MORPHINE;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER:LIVER_CANCER,_OTHER:PAIN
SORAFENIB;GALNT14;rs9679162;GG;EFFICACY;INCREASED_RESPONSE;OTHER:HEPATITIS_C_VIRUS_INFECTION,_OTHER:LIVER_CANCER
MYCOPHENOLIC ACID;ABCC2;rs2273697;A;LADME_PK;DECREASED_EXPOSURE;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;OTHER:LIVER_TRANSPLANTATION
MYCOPHENOLIC ACID;ABCC2;rs717620;T;LADME_PK;EXPOSURE;OTHER:KIDNEY_TRANSPLANTATION
FENTANYL;ATF2;rs7583431;A;EFFICACY;INCREASED_RESPONSE;DISEASE:PAIN,_POSTOPERATIVE
MYCOPHENOLIC ACID;ABCC2;rs717620;T;LADME_PK;EXPOSURE;OTHER:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
TACROLIMUS;NR1I2;rs3814055;CT + TT;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
AFLIBERCEPT, RANIBIZUMAB;ANO2;rs2110166;TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MACULAR_DEGENERATION
TACROLIMUS;NR1I2;rs3814055;CT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
VENLAFAXINE;SLC6A2;rs2242446;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
MYCOPHENOLIC ACID;ABCC2;rs2273697;A;LADME_PK;DECREASED_EXPOSURE;OTHER:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
BOCEPREVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;C;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;CHRNA7;rs6494223;T;EFFICACY;INCREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
ADALIMUMAB;FCGR2A;rs1801274;A;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
FLUOROURACIL;ENOSF1;rs2612091;CC;EFFICACY;INCREASED_RESPONSE;OTHER:STOMACH_NEOPLASMS
ALLOPURINOL;SLC22A12;rs505802;T;DOSAGE;INCREASED_DOSE;OTHER:GOUT
ALLOPURINOL;PDZK1;rs12129861;C;DOSAGE;INCREASED_DOSE;OTHER:GOUT
DACLATASVIR, SOFOSBUVIR;HINT1;rs7728773;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;IL6;rs1800795;G;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
LITHIUM;;rs78015114;T;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
BUPRENORPHINE;OPRD1;rs678849;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
CARBAMAZEPINE, PHENOBARBITAL, PHENYTOIN, VALPROIC ACID;SCN2A;rs17183814;A;EFFICACY;RESISTANCE;
LITHIUM;;rs79663003;T;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
APREMILAST;CYP3A4, TMEM130;rs1203844;C;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
APREMILAST;CYP3A4;rs35599367;A;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
ATORVASTATIN;MYLIP;rs9370867;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
LITHIUM;;rs75222709;T;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;;rs74795342;G;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
APREMILAST;PDE4D;rs295943;T;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
METHYLPHENIDATE;ADRA2A;rs1800544;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
SIMVASTATIN;SCAP;rs12487736;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY
CAFFEINE;CYP1A2;rs2069514;AA + AG;OTHER, LADME_PK;DECREASED_METABOLISM;
APREMILAST;CDKN2B, CDKN2B-AS1;rs1063192;G;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
PRAVASTATIN;LIPC;rs1800588;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
WARFARIN;CYP2C9;rs1799853;T;DOSAGE;DECREASED_DOSE;OTHER:TOTAL_KNEE_OR_HIP_ARTHROPLASTY
EFAVIRENZ;CYP2B6;rs28399499;CT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
(R)-METHADONE;NR1I3;rs2307424;GG;LADME_PK;INCREASED_CLEARANCE;OTHER:HIV_INFECTIOUS_DISEASE
OLANZAPINE;HTR2A;rs6314;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
(S)-METHADONE;CYP2B6;rs2279343;G;LADME_PK;DECREASED_CLEARANCE;OTHER:HIV_INFECTIOUS_DISEASE
SIMVASTATIN;ABCB1;rs1128503;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED_DISCONTINUATION;DISEASE:INFLAMMATORY_BOWEL_DISEASES
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
(R)-METHADONE;NR1I3;rs3003596;GG;LADME_PK;INCREASED_CLEARANCE;OTHER:HIV_INFECTIOUS_DISEASE
BEVACIZUMAB;CFH;rs1061170;CT;DOSAGE;INCREASED_DOSE;DISEASE:MACULAR_DEGENERATION
METHADONE;OPRD1;rs678849;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;CT;DOSAGE;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
BEVACIZUMAB;ARMS2;rs10490924;GT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
SIMVASTATIN;ABCB1;rs2032582;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
WARFARIN;NQO1;rs1800566;AA + AG;DOSAGE;INCREASED_DOSE;
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;
DEFERASIROX;ABCC2;rs2273697;AG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
BUDESONIDE;;rs2392165;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER:ASTHMA
THIORIDAZINE;CYP2D6;rs1080985;CC + CG;LADME_PK;DECREASED_METABOLISM;
DEFERASIROX;CYP1A2;rs2470890;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
DEFERASIROX;CYP1A2;rs762551;AC + CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
OLANZAPINE;DRD2;rs1076560;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
DEFERASIROX;CYP1A1;rs2606345;AC + CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
DEFERASIROX;UGT1A1;rs887829;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
CARBAMAZEPINE;ABCB1;rs1128503;A;LADME_PK;INCREASED_CLEARANCE;OTHER:EPILEPSY
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;FCGR2A;rs1801274;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
CAPECITABINE;MTHFR;rs1801133;GG;LADME_PK;INCREASED_EXPOSURE;DISEASE:NEOPLASMS
DACLATASVIR, SOFOSBUVIR;IFNL3;rs12979860;CC;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
BUPRENORPHINE;;rs6973474;T;EFFICACY;INCREASED_RESPONSE;OTHER:OPIOID-RELATED_DISORDERS
CARBAMAZEPINE;ABCB1;rs2032582;A;LADME_PK;INCREASED_CLEARANCE;OTHER:EPILEPSY
METHOTREXATE;SLC19A1;rs2838958;A;LADME_PK;DECREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
BUPRENORPHINE;;rs13169373;T;EFFICACY;INCREASED_RESPONSE;OTHER:OPIOID-RELATED_DISORDERS
HALOPERIDOL;CYP2D6;rs3892097;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:ALCOHOLIC_PSYCHOSIS,_DISEASE:ALCOHOL_ABUSE,_DISEASE:ALCOHOL-RELATED_DISORDERS
CARBAMAZEPINE;ABCB1;rs1045642;A;LADME_PK;INCREASED_CLEARANCE;OTHER:EPILEPSY
NEVIRAPINE;CYP2B6;rs28399499;C;LADME_PK;INCREASED_CONCENTRATIONS;
IMATINIB;SLC22A1;rs628031;GG;LADME_PK;DECREASED_CLEARANCE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
NICOTINE;CHRNA5;rs16969968;A;DOSAGE;INCREASED_DOSE;DISEASE:TOBACCO_USE_DISORDER
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
BUPRENORPHINE;;rs62368105;G;EFFICACY;INCREASED_RESPONSE;OTHER:OPIOID-RELATED_DISORDERS
BUPRENORPHINE;;rs11782370;T;EFFICACY;INCREASED_RESPONSE;OTHER:OPIOID-RELATED_DISORDERS
METHOTREXATE;ABCC4;rs7317112;G;LADME_PK;DECREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;FCGR3A;rs396991;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
METHOTREXATE;SLCO1B1;rs2306283;G;LADME_PK;INCREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
BUPRENORPHINE;;rs7205113;T;EFFICACY;INCREASED_RESPONSE;OTHER:OPIOID-RELATED_DISORDERS
ETANERCEPT;IL10;rs1800896;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
BUPRENORPHINE;ADAMTSL2;rs756770;A;EFFICACY;INCREASED_RESPONSE;OTHER:OPIOID-RELATED_DISORDERS
(R)-METHADONE;ABCB1;rs2032582;AA;LADME_PK;DECREASED_CLEARANCE;OTHER:HIV_INFECTIOUS_DISEASE
ETANERCEPT;TGFB1;rs1800471;CG;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ATORVASTATIN;SLCO1B1;rs2306283;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
EFAVIRENZ, NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS;CYP2B6;rs3745274;T;EFFICACY;INCREASED_RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;rs2279345;CC + CT;LADME_PK;INCREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;rs3745274;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HIV_INFECTIOUS_DISEASE,_DISEASE:TUBERCULOSIS
METHOTREXATE;SLCO1B1;rs4149056;TT;LADME_PK;INCREASED_EXPOSURE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
XK469;AOX1;rs10931910;G;LADME_PK;DECREASED_CLEARANCE;DISEASE:NEOPLASMS
SIMVASTATIN;PON1;rs662;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_DISEASE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE,_DISEASE:TUBERCULOSIS
MERCAPTOPURINE;NUDT15;rs116855232;T;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ETANERCEPT;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
MERCAPTOPURINE;TPMT;rs1142345;CT;DOSAGE;DECREASED_DOSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
NEVIRAPINE;CYP2B6;rs3745274;T;LADME_PK;INCREASED_CONCENTRATIONS;
BUCINDOLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEART_FAILURE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A4;rs4986907;CT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
NEVIRAPINE;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
PHENPROCOUMON;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE;
WARFARIN;CYP4F2;rs2189784;AG + GG;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
PHENPROCOUMON;EPHX1;rs1051740;CC;DOSAGE, LADME_PK;DECREASED_DOSE;
ASPIRIN, DICLOFENAC, IBUPROFEN, INDOMETHACIN, KETOROLAC, NAPROXEN;TNF;rs1800629;A;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_WITHOUT_AURA
PHENPROCOUMON;PROC;rs1799808;CC;DOSAGE, LADME_PK;INCREASED_DOSE;
LAMOTRIGINE;UGT2B7;rs7668258;CT + TT;LADME_PK;INCREASED_STEADY_STATE CONCENTRATION;DISEASE:EPILEPSY
INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
IMATINIB;SLC22A4;rs1050152;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
IMATINIB;SLC22A5;rs2631367;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS
IMATINIB;SLC22A5;rs2631372;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS
ETANERCEPT;TNF;rs1799724;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;EPHX1;rs2260863;CG;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
WARFARIN;APOE;rs7412;CC;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
CYCLOPHOSPHAMIDE;CYP2B6;rs2279343;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-HODGKIN_LYMPHOMA
WARFARIN;CYP3A4;rs28371759;AA;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;DECREASED_RESPONSE;
WARFARIN;CYP1A2;rs2069514;GG;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
IMATINIB;ABCC4;rs9561765;AG;EFFICACY;INCREASED_RESPONSE;DISEASE:GASTROINTESTINAL_STROMAL_TUMORS
WARFARIN;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE;
WARFARIN;SLC15A2;rs1143671;TT;DOSAGE;DECREASED_DOSE;
LAMOTRIGINE;UGT1A4;rs2011425;GG + GT;LADME_PK;DECREASED_STEADY_STATE CONCENTRATION;DISEASE:EPILEPSY
WARFARIN;EPHX1;rs2260863;CC;DOSAGE;DECREASED_DOSE;OTHER:ATRIAL_FIBRILLATION
RITONAVIR;NR1I2;rs1523130;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
L-TRYPTOPHAN;SLC22A2;rs316019;CC;LADME_PK;INCREASED_CLEARANCE;
WARFARIN;VKORC1;rs9923231;AA;DOSAGE;INCREASED_DOSE;OTHER:ATRIAL_FIBRILLATION
PHENPROCOUMON;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;
RITONAVIR;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
RITONAVIR;ABCB1;rs2032582;AC + CC;LADME_PK;CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
ERENUMAB;RAMP1;rs13386048;A;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_WITH_AURA,_OTHER:MIGRAINE_WITHOUT_AURA
ADALIMUMAB, INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;OTHER:SPONDYLITIS,_ANKYLOSING
SIROLIMUS;POR;rs1057868;CT + TT;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;OTHER:ATRIAL_FIBRILLATION
OLANZAPINE;BDNF;rs6265;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RITONAVIR;NR1I2;rs6785049;AA + AG;LADME_PK;CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
ERENUMAB;RAMP1;rs6431564;G;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_WITH_AURA,_OTHER:MIGRAINE_WITHOUT_AURA
INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
LOSARTAN;SLC22A12;rs1529909;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION,_DISEASE:HYPERURICEMIA
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;
ERENUMAB;RAMP1;rs12465864;G;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_WITH_AURA,_OTHER:MIGRAINE_WITHOUT_AURA
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
LOSARTAN;SLC22A12;rs3825016;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION,_DISEASE:HYPERURICEMIA
ADALIMUMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
SIROLIMUS;IL10;rs1800896;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
CYCLOSPORINE;ABCB1;rs9282564;CT;TOXICITY, LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HEART_TRANSPLANTATION
CLADRIBINE, CYTARABINE;RRM1;rs1042919;AT;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_MYELOID_LEUKEMIA
CLADRIBINE, CYTARABINE;RRM2B;rs1265138;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:ACUTE_MYELOID_LEUKEMIA
FLUOROURACIL;DPYD;rs1801265;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_EXPOSURE;DISEASE:COLONIC_NEOPLASMS
CLADRIBINE, CYTARABINE;RRM1;rs2898950;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE:ACUTE_MYELOID_LEUKEMIA
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
BUPROPION;CYP2B6;rs2279343;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
CLADRIBINE, CYTARABINE;RRM1;rs1561876;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_MYELOID_LEUKEMIA
COTININE;PSMA4;rs57064725;A;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:TOBACCO_USE_DISORDER
METHOTREXATE;ATIC;rs16853826;GG;TOXICITY;INCREASED_DISCONTINUATION;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;ABCC1;rs35592;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
COTININE;CHRNA5;rs16969968;A;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:TOBACCO_USE_DISORDER
INFLIXIMAB;TNFRSF10A;rs20575;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CLADRIBINE, CYTARABINE;RRM2;rs1130609;GT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_MYELOID_LEUKEMIA
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, RIBAVIRIN;FTO;rs9939609;AA + AT;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION,_DISEASE:HIV_INFECTIOUS_DISEASE
VITAMIN K AND ANALOGUES;CYP4F2;rs2108622;T;LADME_PK;DECREASED_METABOLISM;
COTININE;;rs77107237;G;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:TOBACCO_USE_DISORDER
CLOZAPINE;DTNBP1;rs742105;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CLADRIBINE, CYTARABINE;RRM2;rs5030743;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_MYELOID_LEUKEMIA
COTININE;CHRNB4;rs10851907;A;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:TOBACCO_USE_DISORDER
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
SIROLIMUS;ABCB1;rs1045642;AA + AG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;SLCO1B3;rs7311358;AA;DOSAGE;DECREASED_DOSE;
WARFARIN;SLC15A2;rs1143672;AA;DOSAGE;DECREASED_DOSE;
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
WARFARIN;SLCO1B3;rs4149117;GG;DOSAGE;DECREASED_DOSE;
ETANERCEPT;TNF;rs1800629;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
COTININE;CHRNA3;rs7170068;A;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:TOBACCO_USE_DISORDER
SUNITINIB;ABCB1;rs1045642;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:RENAL_CELL_CARCINOMA
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE, EFFICACY;DECREASED_DOSE;
INTERFERON ALFA-2A, RECOMBINANT, INTERFERON ALFA-2B, RECOMBINANT, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
FLUPENTHIXOL;NFKB1;rs230504;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
MONTELUKAST;SLCO2B1;rs12422149;AG;EFFICACY, LADME_PK;DECREASED_RESPONSE;DISEASE:ASTHMA
DEFERASIROX;CYP24A1;rs927650;CT + TT;LADME_PK;DECREASED_METABOLISM;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;
DEFERASIROX;CYP24A1;rs2585428;CT + TT;LADME_PK;DECREASED_METABOLISM;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
FLUPENTHIXOL;NFKB1;rs3774959;AG;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ANTIDEPRESSANTS;TPH2;rs10879346;C;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METHOTREXATE POLYGLUTAMATE;IMPDH1;rs4731448;GG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CARBOPLATIN, CISPLATIN;EIF3A;rs3740556;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
METHOTREXATE POLYGLUTAMATE;CEP72;rs924607;TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TACROLIMUS;IL10;rs1800896;TT;DOSAGE;DECREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
MIRTAZAPINE, VENLAFAXINE;TPH2;rs1487278;C;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
TACROLIMUS;ABCB1;rs1045642;GG;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
BILIRUBIN;UGT1A1;rs4124874;GG + GT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:NEOPLASMS
CARBOPLATIN, CISPLATIN;EIF3A;rs3740556;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
DEFERASIROX;CYP24A1;rs2248359;CT + TT;LADME_PK;DECREASED_METABOLISM;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
FLUPENTHIXOL;NFKB1;rs230493;AT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
METHOTREXATE POLYGLUTAMATE;SLCO1B3;rs7311358;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
NICOTINE;FMO3;rs2266780;AA;LADME_PK;INCREASED_METABOLISM;
PAZOPANIB;VEGFA;rs699947;A;EFFICACY;DECREASED_RESPONSE;DISEASE:RENAL_CELL_CARCINOMA
METHOTREXATE POLYGLUTAMATE;FSTL5;rs3749598;AA + AC;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE POLYGLUTAMATE;ATG16L1;rs2241880;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
FLUOROURACIL;DPYD;rs3918290;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TACROLIMUS;CYP3A5;rs776746;CT;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
THEOPHYLLINE;CYP1A2;rs2069514;AA + AG;OTHER, LADME_PK;DECREASED_METABOLISM;DISEASE:ASTHMA
INFLIXIMAB;TNFRSF10A;rs20575;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:ARTHRITIS,_PSORIATIC
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNFRSF1A;rs767455;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:ARTHRITIS,_PSORIATIC
PAZOPANIB;VEGFA;rs2010963;G;EFFICACY;DECREASED_RESPONSE;DISEASE:RENAL_CELL_CARCINOMA
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNFRSF10A;rs20575;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNFRSF1A;rs767455;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
PAZOPANIB;VEGFA;rs833061;T;EFFICACY;DECREASED_RESPONSE;DISEASE:RENAL_CELL_CARCINOMA
ETANERCEPT;PTTG1;rs2431697;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
CISPLATIN, GEMCITABINE;CMPK1;rs4492666;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
BUPROPION, NICOTINE, VARENICLINE;CHRNA5;rs503464;A;EFFICACY;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
VORICONAZOLE;NR1I2;rs6785049;GG;LADME_PK;INCREASED_CONCENTRATIONS;
ETANERCEPT;HLA-B;rs13437088;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
ETANERCEPT;MAP3K1;rs96844;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
CLOZAPINE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CLOZAPINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ETANERCEPT;GBP6;rs928655;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
ATORVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;DECREASED_RESPONSE;
ETANERCEPT;IL12B;rs2546890;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
TEMOZOLOMIDE;ABCB1;rs1128503;AA + AG;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:GLIOMA
IVACAFTOR;SLC26A9;rs7512462;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
GEMCITABINE;DCK;rs66878317;AG + GG;LADME_PK;INCREASED_CLEARANCE;
VORICONAZOLE;NR1I2;rs3814057;CC;LADME_PK;INCREASED_CONCENTRATIONS;
NICOTINE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
MILNACIPRAN;ADRA2A;rs1800544;CC + CG;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
PLATINUM COMPOUNDS;IGF2, IGF2-AS, INS-IGF2;rs4244809;GG;EFFICACY;DECREASED_RESISTANCE;DISEASE:OVARIAN_NEOPLASMS
VORICONAZOLE;FMO3;rs2266780;AA;LADME_PK;INCREASED_CONCENTRATIONS;
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs2306283;GG;EFFICACY;INCREASED_RESPONSE;
FLUVOXAMINE;FGF2;rs1449683;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
VORICONAZOLE;POR;rs10954732;GG;LADME_PK;INCREASED_CONCENTRATIONS;
PLATINUM COMPOUNDS;INS-IGF2;rs3842761;GG;EFFICACY;DECREASED_RESISTANCE;DISEASE:OVARIAN_NEOPLASMS
MILNACIPRAN;HTR1A;rs6295;CC + CG;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
VALPROIC ACID;SCN2A;rs17183814;AA + AG;EFFICACY;INCREASED_RESISTANCE;OTHER:EPILEPSY
VALPROIC ACID;SCN1A;rs2298771;TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
VORICONAZOLE;NR1I2;rs2461817;AA;LADME_PK;DECREASED_CONCENTRATIONS;
VORICONAZOLE;NR1I2;rs3732359;GG;LADME_PK;INCREASED_CONCENTRATIONS;
METHOTREXATE;ABCC2;rs3740066;TT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:OSTEOSARCOMA
CISPLATIN, GEMCITABINE;RRM1;rs720106;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
VORICONAZOLE;NR1I2;rs7643645;AA;LADME_PK;INCREASED_CONCENTRATIONS;
SIMVASTATIN;SLCO1B1;rs2306283;AA;EFFICACY;INCREASED_RESPONSE;
CISPLATIN, GEMCITABINE;RRM1;rs232043;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
CISPLATIN, GEMCITABINE;CMPK1;rs11211524;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
SIMVASTATIN;SLCO1B1;rs2306283;GG;EFFICACY;INCREASED_RESPONSE;
CISPLATIN, GEMCITABINE;RRM1;rs2284449;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
ACENOCOUMAROL;GGCX;rs11676382;G;DOSAGE;DECREASED_DOSE;
ACENOCOUMAROL;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;
ACENOCOUMAROL;VKORC1;rs7294;T;DOSAGE;INCREASED_DOSE;
METHOTREXATE;NR1I2;rs6785049;G;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OSTEOSARCOMA
RITUXIMAB;TGFB1;rs1800470;AG;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
RITUXIMAB;TGFB1;rs1800471;CG;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;A;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;T;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
SIMVASTATIN;CYP3A4;rs35599367;A;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERCHOLESTEROLEMIA
PIOGLITAZONE;ADIPOQ;rs2241766;GT;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
MORPHINE;OPRM1;rs1799971;GG;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
MORPHINE;OPRM1;rs1799971;GG;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
ROSUVASTATIN;CYP3A5;rs776746;C;EFFICACY;INCREASED_RESPONSE;DISEASE:MYOCARDIAL_INFARCTION
METHOTREXATE;GSK3B;rs3732361;A;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OSTEOSARCOMA
NALOXONE;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_RESPONSE;
TIPIFARNIB;ABCB1;rs1128503;AA;OTHER, LADME_PK;DECREASED_METABOLISM;
ETANERCEPT;ZNF816;rs9304742;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
ROSUVASTATIN;ABCG2;rs2231142;T;EFFICACY;INCREASED_RESPONSE;DISEASE:MYOCARDIAL_INFARCTION
EFAVIRENZ;CYP2B6;rs3745274;GG;DOSAGE;INCREASED_DOSE;DISEASE:HIV_INFECTIOUS_DISEASE
NALTREXONE;OPRM1;rs1799971;G;EFFICACY;INCREASED_RESPONSE;DISEASE:ALCOHOL_ABUSE
ANTIPSYCHOTICS;NRG1;rs13250975;G;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;DISEASE:HEART_DISEASES
METHOTREXATE;SLCO1A2;rs4149009;CC + CT;LADME_PK;DECREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ANTIPSYCHOTICS;;rs2513265;A;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;ADCY2;rs1544938;C;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;NRG1;rs17716295;A;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
NICOTINE;CHRNA5;rs16969968;GG;OTHER;DECREASED_DOSE;DISEASE:TOBACCO_USE_DISORDER
METHADONE;DAO;rs55944529;TT;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
ANTIPSYCHOTICS;CCL2;rs4795893;G;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;CCL2;rs4586;T;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
METHADONE;DAO;rs55944529;TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HEROIN_DEPENDENCE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, SERTRALINE;HTR2A;rs3803189;GG + GT;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE,_OTHER:MALARIA
IVACAFTOR;CFTR;rs121908755;A;EFFICACY;INCREASED_RESPONSE;
METHADONE;DRD1;rs5326;TT;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
IVACAFTOR;CFTR;rs121908757;C;EFFICACY;INCREASED_RESPONSE;
IVACAFTOR;CFTR;rs80282562;A;EFFICACY;INCREASED_RESPONSE;
RIFAMPIN;SLCO1B1;rs4149056;CT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:TUBERCULOSIS
METHYLPHENIDATE;CYP2D6;rs1065852;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs11045819;CC;EFFICACY;DECREASED_RESPONSE;
METHYLPHENIDATE;CYP2D6;rs1135840;CG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
IVACAFTOR;CFTR;rs121909041;C;EFFICACY;INCREASED_RESPONSE;
PRAVASTATIN;SLCO1B1;rs2306283;GG;EFFICACY;DECREASED_RESPONSE;
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_DOSE;
IVACAFTOR;CFTR;rs193922525;A;EFFICACY;INCREASED_RESPONSE;
WARFARIN;VKORC1;rs7196161;AA + AG;DOSAGE;INCREASED_DOSE;
IVACAFTOR;CFTR;rs267606723;A;EFFICACY;INCREASED_RESPONSE;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;
IVACAFTOR;CFTR;rs74503330;A;EFFICACY;INCREASED_RESPONSE;
IVACAFTOR;CFTR;rs121909005;G;EFFICACY;INCREASED_RESPONSE;
IVACAFTOR;CFTR;rs121909013;A;EFFICACY;INCREASED_RESPONSE;
SUNITINIB;GLP1R;rs6923761;A;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:RENAL_CELL_CARCINOMA,_OTHER:GASTROINTESTINAL_STROMAL_TUMORS
DOXORUBICIN;ABCB1;rs1128503;AA;LADME_PK;DECREASED_METABOLISM;DISEASE:BREAST_NEOPLASMS
ATOMOXETINE;CYP2D6;rs1135840;CC;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
BETA BLOCKING AGENTS;GRK5;rs3740563;A;EFFICACY;DECREASED_RESPONSE;OTHER:CORONARY_ARTERY_DISEASE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNG;rs2069705;G;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
MONTELUKAST;MLLT3;rs6475448;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
BETA BLOCKING AGENTS;GRK5;rs10787959;A;EFFICACY;DECREASED_RESPONSE;OTHER:CORONARY_ARTERY_DISEASE
BUPROPION;;rs1908557;C;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
BETA BLOCKING AGENTS;GRK5;rs11198893;A;EFFICACY;DECREASED_RESPONSE;OTHER:CORONARY_ARTERY_DISEASE
RIFAMPIN;CYP27B1;rs4646536;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:TUBERCULOSIS
CORTICOSTEROIDS;ST13;rs138335;G;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
RIFAMPIN;VDR;rs1544410;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:TUBERCULOSIS
DOCETAXEL;CYP3A4;rs2740574;C;LADME_PK;INCREASED_CLEARANCE;DISEASE:NEOPLASMS
BETA BLOCKING AGENTS;ADRB1;rs1801253;GG;EFFICACY;DECREASED_RESPONSE;OTHER:HEART_FAILURE
METHADONE;CYP2B6;rs3745274;GG + GT;DOSAGE;INCREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
DOCETAXEL;CYP3A5;rs776746;T;LADME_PK;INCREASED_CLEARANCE;DISEASE:NEOPLASMS
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;EFFICACY;DECREASED_RESPONSE;DISEASE:CARDIOVASCULAR_DISEASE
RAMIPRIL;ADRB2;rs2053044;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
OPIOIDS;COMT;rs4680;GG;DOSAGE;INCREASED_DOSE;OTHER:BREAST_NEOPLASMS,_OTHER:PAIN,_POSTOPERATIVE
METHADONE;NGF;rs2239622;AA;DOSAGE;DECREASED_DOSE;DISEASE:OPIOID-RELATED_DISORDERS
NICOTINE;CYP1A2;rs35694136;T/del + del/del;EFFICACY;INCREASED_EXPOSURE;OTHER:URINARY_BLADDER_NEOPLASMS
METHADONE;CYP2B6;rs2279343;AA + AG;DOSAGE;INCREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
GEMCITABINE;NT5C3A;rs3750117;AA;OTHER, LADME_PK;INCREASED_CLEARANCE;DISEASE:NEOPLASMS
GEMCITABINE;NT5C2;rs11598702;TT;OTHER, LADME_PK;DECREASED_CLEARANCE;DISEASE:NEOPLASMS
FENTANYL, REMIFENTANIL;PGAP6;rs199670311;T;EFFICACY;INCREASED_DOSE;DISEASE:PAIN
OLANZAPINE;UGT1A4;rs2011425;GT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:SCHIZOPHRENIA
ANTIDEPRESSANTS;ADCY9;rs2230739;CC;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
DABIGATRAN;CES1;rs2244613;GG + GT;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:STROKE
ANTIPSYCHOTICS;PI4KA;rs165854;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;GRM3;rs1468412;AA + AT;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
BUDESONIDE, CORTICOSTEROIDS, FLUTICASONE / SALMETEROL, FLUTICASONE PROPIONATE;ZNF432;rs3752120;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
AZATHIOPRINE;ITPA;rs1127354;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;ERBB2;rs1136201;G;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
ANTIPSYCHOTICS;SLC1A3;rs1529461;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;GRM3;rs2299214;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;RNF8;rs2284922;A;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
ANTIPSYCHOTICS;GRM3;rs6465084;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;BARD1;rs2070096;A;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
GEMCITABINE;CDA;rs1048977;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;ERBB3;rs2229046;C;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
CORTICOSTEROIDS;ST13;rs138337;G;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
CARBOPLATIN, DOCETAXEL, TRASTUZUMAB;ERBB3;rs773123;A;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
ANTIPSYCHOTICS;SLC1A4;rs10211524;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RISPERIDONE;GRM3;rs2299214;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME_PK;INCREASED_CONCENTRATIONS;
PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;
SUFENTANIL;COMT;rs4680;AA;DOSAGE, EFFICACY;DECREASED_DOSE;
FLUINDIONE;VKORC1;rs9923231;TT;LADME_PK;DOSE;
APREMILAST;LEPR, LEPROT;rs1045895;AA + AG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;
OPIOIDS;ABCB1;rs1045642;AA;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:NEOPLASMS,_DISEASE:PAIN
CARBOPLATIN, CISPLATIN;AKT1;rs2494752;AG;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
QUINAPRIL;AGT;rs699;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
OPIOIDS;KCNJ6;rs6517442;CC;DOSAGE;INCREASED_DOSE;OTHER:LOW_BACK_PAIN
OLANZAPINE;CYP1A2;rs35694136;T/del;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:SCHIZOPHRENIA
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE:NEOPLASMS,_DISEASE:PAIN
OLANZAPINE;CYP1A2;rs762551;AA;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:SCHIZOPHRENIA
FENTANYL;OPRM1;rs1799971;GG;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
PHENPROCOUMON;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;
CAPECITABINE, FLUOROURACIL, TEGAFUR;TYMS;rs183205964;C;TOXICITY;INCREASED_DISCONTINUATION;DISEASE:NEOPLASMS
KETOPROFEN;CYP2C9;rs1057910;AC;EFFICACY;INCREASED_RESPONSE;OTHER:PAIN,_POSTOPERATIVE
ATORVASTATIN;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_ARTERY_DISEASE
IMATINIB;SLC22A1;rs683369;CC;LADME_PK;INCREASED_CLEARANCE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
CAFFEINE;CYP1A2;rs762551;AA;OTHER, LADME_PK;INCREASED_METABOLISM;
IMATINIB;SLC22A1;rs683369;CC;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
ETANERCEPT;TNFRSF1B;rs1061622;GT;EFFICACY;DECREASED_RESPONSE;DISEASE:SPONDYLITIS,_ANKYLOSING
FENTANYL, REMIFENTANIL;SLC9A9;rs4839603;GG;EFFICACY;DECREASED_DOSE;DISEASE:PAIN
EFAVIRENZ;ABCB1;rs1045642;GG;EFFICACY, LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;rs3745274;T;EFFICACY;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;ABCB1;rs1045642;AA;EFFICACY, LADME_PK;INCREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
APREMILAST;PDE4B;rs12745871;T;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
ATORVASTATIN;SCARB1;rs5888;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
APREMILAST;TSPAN16;rs322144;C;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
PRAVASTATIN;FCAR;rs11666735;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:MYOCARDIAL_INFARCTION
CYCLOPHOSPHAMIDE, EPIRUBICIN;GSTP1;rs1695;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
FENOFIBRATE;APOA1;rs964184;G;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTRIGLYCERIDEMIA
ANTIEPILEPTICS;SCN1A;rs10188577;CT;EFFICACY;INCREASED_RESISTANCE;DISEASE:EPILEPSY
APREMILAST;DOCK6;rs12979813;G;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
DAPTOMYCIN;ABCB1;rs1045642;AA;LADME_PK;INCREASED_CONCENTRATIONS;
DAPTOMYCIN;ABCB1;rs1045642;AA;LADME_PK;DECREASED_CLEARANCE;
NALTREXONE;DBH;rs1611115;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:ALCOHOL_ABUSE
GEMCITABINE;SLC28A2;rs11854484;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
ANTINEOPLASTIC AGENTS;ABCG2;rs2231142;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
GEMCITABINE;SLC28A2;rs1060896;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
APREMILAST;EIF3G, P2RY11, PPAN-P2RY11;rs2305795;G;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1A;rs767455;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OSTEOSARCOMA
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL3;rs1139130;GG;EFFICACY;INCREASED_RESISTANCE;OTHER:TUBERCULOSIS
METHOTREXATE;SLCO1B1;rs11045879;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OSTEOSARCOMA
SUFENTANIL;OPRM1;rs1799971;AG;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
APREMILAST;ILF3;rs76966440;T;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:PSORIASIS
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;GSTP1;rs1695;A;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
SULFASALAZINE;ABCG2;rs2231142;GT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;T;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
WARFARIN;VKORC1;rs9923231;CC + CT;DOSAGE;INCREASED_DOSE;
TACROLIMUS;ABCB1;rs1128503;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
WARFARIN;PRSS53, VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;T;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;VDR;rs2228570;A;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
NORTRIPTYLINE;NOS3;rs1799983;TT;EFFICACY;INCREASED_RESPONSE;OTHER:MIGRAINE_WITHOUT_AURA,_OTHER:MIGRAINE_WITH_AURA
ALLOPURINOL;GREM2;rs1934341;T;EFFICACY;INCREASED_RESPONSE;
COTININE;NAT1;rs13253389;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS;
ALLOPURINOL;GREM2;rs77567654;G;EFFICACY;INCREASED_RESPONSE;
TACROLIMUS;ABCB1;rs2032582;CC;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ALLOPURINOL;ABCG2;rs45499402;C;EFFICACY;DECREASED_RESPONSE;
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
ALLOPURINOL;ABCG2;rs2231142;T;EFFICACY;DECREASED_RESPONSE;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
EXENATIDE;GLP1R;rs10305420;T;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
TOPIRAMATE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE;OTHER:MIGRAINE_WITHOUT_AURA,_OTHER:MIGRAINE_WITH_AURA
LAMOTRIGINE;UGT2B7;rs7668258;TT;LADME_PK;DECREASED_CLEARANCE;DISEASE:EPILEPSY
WARFARIN;VKORC1;rs7294;TT;DOSAGE;INCREASED_DOSE;
BENAZEPRIL;AGT;rs4762;GG;EFFICACY;RESPONSE;DISEASE:HYPERTENSION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION,_DISEASE:HIV_INFECTIOUS_DISEASE
IMATINIB;ABCB1;rs1128503;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
LAMOTRIGINE;UGT2B7;rs28365063;GG;LADME_PK;INCREASED_CLEARANCE;DISEASE:EPILEPSY
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
METHOTREXATE;ABCC4;rs7317112;GG;LADME_PK;INCREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
BENAZEPRIL;AGTR1;rs2640543;GG;EFFICACY;RESPONSE;DISEASE:HYPERTENSION
ALENDRONATE;MVK;rs10161126;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:BONE_DISEASES
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;A;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;G;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
SARILUMAB;IL6R;rs11265618;CC;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;LDLR;rs14158;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION,_DISEASE:HIV_INFECTIOUS_DISEASE
BENAZEPRIL;SPTA1;rs2106089;G;EFFICACY;RESPONSE;DISEASE:HYPERTENSION
IMATINIB;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
TACROLIMUS;CYP3A5;rs776746;TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
SARILUMAB;IL6R;rs4329505;TT;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
IMATINIB;ABCB1;rs2032582;C;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
BUPRENORPHINE;OPRD1;rs678849;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;NCR3;rs1052248;AT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
SALBUTAMOL;COL2A1;rs3809324;GT + TT;LADME_PD;DECREASED_RESPONSE;OTHER:ASTHMA
ANTIPSYCHOTICS;CACNA1C;rs2238087;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
DIURETICS, HYDROCHLOROTHIAZIDE, THIAZIDES, PLAIN;PRKCA;rs4791040;T;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
ANTIPSYCHOTICS;CACNA1B;rs2229949;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ACENOCOUMAROL;STX4;rs10871454;T;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;
WARFARIN;;rs12777823;AA + AG;DOSAGE;DECREASED_DOSE;
CORTICOSTEROIDS;GLCCI1;rs37973;GG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:RHINITIS
DEFERASIROX;GC;rs7041;AA;EFFICACY;INCREASED_RESPONSE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
ASPIRIN, CLOPIDOGREL;CYP4F2;rs2108622;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
ACENOCOUMAROL;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
INTERFERON BETA-1A, INTERFERON BETA-1B;CD58;rs12044852;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:MULTIPLE_SCLEROSIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;rs610604;GG + GT;EFFICACY;INCREASED_RESPONSE;OTHER:ARTHRITIS,_PSORIATIC,_OTHER:PSORIASIS
MORPHINE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_RESPONSE;
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFAIP3;rs6920220;AA;EFFICACY;DECREASED_RESPONSE;OTHER:ARTHRITIS,_PSORIATIC,_OTHER:PSORIASIS
WARFARIN;CYP4F2;rs2108622;CC + CT;DOSAGE;DECREASED_DOSE;DISEASE:CARDIOVASCULAR_DISEASE
ANTIPSYCHOTICS;CACNB2;rs12245847;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A7;rs2257401;C;LADME_PK;TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION,_DISEASE:TRANSPLANTATION
DEFERASIROX;UGT1A1;rs887829;CC;EFFICACY;DECREASED_RESPONSE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
ANTIPSYCHOTICS;CACNG3;rs1859204;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A5;rs776746;C;LADME_PK;TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION,_DISEASE:TRANSPLANTATION
DEFERASIROX;UGT1A3;rs1983023;TT;EFFICACY;INCREASED_RESPONSE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
DEFERASIROX;CYP27B1;rs10877012;GG;EFFICACY;INCREASED_RESPONSE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
TACROLIMUS;CYP3A4;rs4646437;A;LADME_PK;TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION,_DISEASE:TRANSPLANTATION
ADALIMUMAB;ATG16L1;rs10210302;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CROHN_DISEASE
ANTIPSYCHOTICS;CACNB2;rs982003;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
TACROLIMUS;CYP3A4;rs2242480;T;LADME_PK;TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION,_DISEASE:TRANSPLANTATION
DEFERASIROX;VDR;rs731236;GG;EFFICACY;INCREASED_RESPONSE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
DEFERASIROX;VDR;rs1544410;TT;EFFICACY;INCREASED_RESPONSE;OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
TACROLIMUS;CYP3A5;rs41303343;A;LADME_PK;TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION,_DISEASE:TRANSPLANTATION
CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SLC19A1;rs1051266;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
CAPECITABINE, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SLCO1B1;rs2306283;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
TACROLIMUS;CYP3A5;rs4646450;A;LADME_PK;TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION,_DISEASE:TRANSPLANTATION
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
SIMVASTATIN ACID;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;
DIURETICS, HYDROCHLOROTHIAZIDE, THIAZIDES, PLAIN;;rs2776546;A;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
WARFARIN;CYP2C9;rs28371686;CG;DOSAGE;DECREASED_DOSE;
ANTIPSYCHOTICS;CACNB2;rs10741058;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ATAZANAVIR;UGT1A1;rs887829;TT;TOXICITY;INCREASED_DISCONTINUATION;DISEASE:HIV_INFECTIOUS_DISEASE
DIURETICS, HYDROCHLOROTHIAZIDE, THIAZIDES, PLAIN;;rs238;A;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
ANTIPSYCHOTICS;CACNA2D3;rs4505744;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
DIURETICS, HYDROCHLOROTHIAZIDE, THIAZIDES, PLAIN;;rs4815273;T;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
IBUPROFEN;CYP2C9;rs1057910;AC;EFFICACY;DECREASED_TIME TO RESPONSE;OTHER:PATENT_DUCTUS_ARTERIOSUS
ANTIPSYCHOTICS;CACNA1E;rs12060765;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CORTICOSTEROIDS;TAAR6;rs7772821;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
SALBUTAMOL;VEGFA;rs3025039;CT + TT;LADME_PD;DECREASED_RESPONSE;OTHER:ASTHMA
BEVACIZUMAB, RANIBIZUMAB;CFH;rs1061170;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;
MORPHINE;TAOK3;rs795484;TT;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
PREDNISONE;NR3C1;rs6196;G;EFFICACY;DECREASED_RESISTANCE;DISEASE:NEPHROTIC_SYNDROME
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
SN-38;UGT1A1;rs4148323;AA;LADME_PK;DECREASED_METABOLISM;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
DOCETAXEL;;rs4842198;G;LADME_PK;INCREASED_METABOLISM;DISEASE:NASOPHARYNGEAL_NEOPLASMS
FLUVOXAMINE;HTR2A;rs6311;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;rs3794271;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;DOSAGE, EFFICACY;DECREASED_DOSE;
PREDNISONE;NR3C1;rs258751;A;EFFICACY;DECREASED_RESISTANCE;DISEASE:NEPHROTIC_SYNDROME
LEDIPASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
SN-38;UGT1A9;rs3832043;del/del;LADME_PK;DECREASED_METABOLISM;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
PHENYTOIN;CYP2C9;rs28371686;G;OTHER, LADME_PK;DECREASED_METABOLISM;OTHER:NO_DISEASE
IMATINIB;ABCG2;rs2231137;CT + TT;DOSAGE;DECREASED_DOSE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS
PREDNISONE;NR3C1;rs10052957;A;EFFICACY;DECREASED_RESISTANCE;DISEASE:NEPHROTIC_SYNDROME
IMATINIB;CYP1A2;rs762551;CC;DOSAGE;DECREASED_DOSE;OTHER:GASTROINTESTINAL_STROMAL_TUMORS
PHENYTOIN;CYP2C9;rs7900194;A;OTHER, LADME_PK;DECREASED_METABOLISM;OTHER:NO_DISEASE
LURASIDONE;HTR1A;rs6295;CG + GG;EFFICACY;DECREASED_RESPONSE;OTHER:SCHIZOPHRENIA
PHENYTOIN;CYP2C9;rs28371685;T;OTHER, LADME_PK;INCREASED_METABOLISM;PK:NO_DISEASE
PHENYTOIN;CYP2C9;rs9332131;del;OTHER, LADME_PK;DECREASED_METABOLISM;PK:NO_DISEASE
DOCETAXEL;RXRA;rs3132291;A;LADME_PK;INCREASED_METABOLISM;DISEASE:NASOPHARYNGEAL_NEOPLASMS
INFLIXIMAB;TNFRSF1B;rs1061622;G;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
CODEINE;OPRM1;rs1799971;AA;DOSAGE;DECREASED_DOSE;
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
CODEINE;UGT2B7;rs7439366;TT;DOSAGE;DECREASED_DOSE;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2B;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
ANTIPSYCHOTICS;CACNB2;rs4237348;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A4;rs2740574;T;LADME_PK;TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION,_DISEASE:TRANSPLANTATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
ANTIPSYCHOTICS;CACNB4;rs3768652;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A4;rs35599367;A;LADME_PK;TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION,_DISEASE:TRANSPLANTATION
ANTIPSYCHOTICS;CACNA2D3;rs7427395;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;CACNB2;rs1277733;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
SOFOSBUVIR;CES1;rs4513095;A;EFFICACY;DECREASED_RESPONSE;OTHER:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
TACROLIMUS;CYP3A5;rs776746;CT;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
PROPOFOL;SCN9A;rs6746030;AA + AG;OTHER;INCREASED_RESPONSE;
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;DISEASE:TRANSPLANTATION
SALBUTAMOL;PRKG1;rs7081864;A;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
TACROLIMUS;CYP3A5;rs776746;C;DOSAGE;DECREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
TOCILIZUMAB;IL6R;rs12083537;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ANTIPSYCHOTICS;BDNF;rs11030104;AG + GG;EFFICACY;INCREASED_RESISTANCE;DISEASE:SCHIZOPHRENIA
SUNITINIB;ABCB1;rs1045642;GG;LADME_PK;INCREASED_EXPOSURE;DISEASE:RENAL_CELL_CARCINOMA
PROPOFOL;HTR2A;rs6313;AA;DOSAGE;DECREASED_DOSE;
ANTIPSYCHOTICS;BDNF-AS;rs10501087;CC + CT;EFFICACY;INCREASED_RESISTANCE;DISEASE:SCHIZOPHRENIA
PROPOFOL;GABRA1;rs2279020;GG;OTHER;INCREASED_RESPONSE;
SUNITINIB;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:RENAL_CELL_CARCINOMA
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
OPIOIDS;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE;
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;ABCB1;rs1045642;AA;EFFICACY;DECREASED_RESISTANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ANTIPSYCHOTICS;BDNF;rs6265;CT + TT;EFFICACY;INCREASED_RESISTANCE;DISEASE:SCHIZOPHRENIA
OPIOIDS;COMT;rs4680;AG;DOSAGE;DECREASED_DOSE;
METFORMIN, SULFONAMIDES, UREA DERIVATIVES;ABCC8, KCNJ11;rs5219;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
PALIPERIDONE, RISPERIDONE;NFIB;rs28379954;CT;LADME_PK;INCREASED_CONCENTRATIONS;
REMIFENTANIL, SEVOFLURANE;ABCB1;rs1128503;GG;EFFICACY;INCREASED_RESPONSE;OTHER:TONSILLECTOMY
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
MORPHINE;TAOK3;rs1277441;GG;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;ABCB1;rs2229109;CT;EFFICACY;INCREASED_RESISTANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
HYDROXYUREA;KLF4;rs2236599;C;EFFICACY;INCREASED_RESPONSE;OTHER:ANEMIA,_SICKLE_CELL,_OTHER:BETA-THALASSEMIA_AND_RELATED_DISEASES
OXYCODONE;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
TACROLIMUS;CYP3A4;rs2242480;CT + TT;LADME_PK;INCREASED_CLEARANCE;OTHER:HEART_TRANSPLANTATION
METHOTREXATE;SLCO1B1;rs11045821;A;EFFICACY, TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHYLPHENIDATE;SLC6A2;rs28386840;AT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
BILIRUBIN;UGT1A;rs11563250;AG + GG;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:COLORECTAL_NEOPLASMS
DEFERASIROX;UGT1A3;rs1983023;CT + TT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CERS6;rs13393173;A;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
MORPHINE;SLC22A1;rs12208357;CT + TT;LADME_PK;DECREASED_CLEARANCE;
MIDAZOLAM;CYP3A4;rs35599367;AG;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
MORPHINE;SLC22A1;rs55918055;CC + CT;LADME_PK;DECREASED_CLEARANCE;
BUPROPION, DRUGS USED IN NICOTINE DEPENDENCE;CYP2A6;rs4803381;T;EFFICACY;INCREASED_RESPONSE;DISEASE:TOBACCO_USE_DISORDER
METFORMIN;SRR;rs391300;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
METHYLPHENIDATE;SLC6A2;rs5569;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
ERYTHROMYCIN;CYP3A4;rs35599367;AG;LADME_PK;DECREASED_METABOLISM;DISEASE:NEOPLASMS
NICOTINE;CYP2A6;rs4803381;T;LADME_PK;DECREASED_METABOLISM;
CLOZAPINE;ABCB1;rs7787082;G;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CAFFEINE;CYP1A2;rs762551;AA + AC;LADME_PK;INCREASED_METABOLISM;
ATENOLOL;;rs12346562;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
HYDROCHLOROTHIAZIDE;;rs12346562;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
ATENOLOL;;rs1104514;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
IVACAFTOR;CFTR;rs121908755;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
MORPHINE;SLC22A1;rs34130495;AA + AG;LADME_PK;DECREASED_CLEARANCE;
ATENOLOL;;rs10739150;GG + GT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
CLOZAPINE;ABCB1;rs10248420;A;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
DEFERASIROX;UGT1A3;rs3806596;CC;EFFICACY, LADME_PK;INCREASED_RESPONSE;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
TRANDOLAPRIL, VERAPAMIL;PTPRD;rs4742610;T;EFFICACY;RESISTANCE;DISEASE:HYPERTENSION
DEFERASIROX;ABCG2;rs13120400;CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
EFAVIRENZ;ABCB1;rs3842;CC + CT;LADME_PK;INCREASED_TROUGH CONCENTRATION;DISEASE:HIV_INFECTIOUS_DISEASE,_DISEASE:TUBERCULOSIS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
METFORMIN, SULFONAMIDES, UREA DERIVATIVES;SLC47A1;rs2289669;A;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
SUNITINIB;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_EXPOSURE;DISEASE:NEOPLASMS
WARFARIN;VDR;rs11168292;GG;DOSAGE;INCREASED_DOSE;
4-HYDROXYTAMOXIFEN, ENDOXIFEN;SULT1A2;rs1136703;AA;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
ARA-CTP;SLC28A3;rs17343066;AA;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ACUTE_MYELOID_LEUKEMIA
WARFARIN;VDR;rs4760658;GG;DOSAGE;INCREASED_DOSE;
WARFARIN;VDR;rs11168293;TT;DOSAGE;INCREASED_DOSE;
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;ALPL;rs885814;T;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
ETOPOSIDE;SLIT1;rs2784917;AA;LADME_PK;DECREASED_INHIBITION;
METHOTREXATE;SLCO1B1;rs4149056;C;EFFICACY, TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHYLPHENIDATE;SLC6A2;rs5569;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
METHOTREXATE;SLCO1B1;rs2306283;A;EFFICACY, TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;rs1350948;A;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
4-HYDROXYTAMOXIFEN, ENDOXIFEN;SULT1A2;rs1059491;TT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
METHYLPHENIDATE;SLC6A2;rs28386840;AT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
METHOTREXATE;SLCO1B1;rs4149081;A;EFFICACY, TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;EYA4;rs17301249;C;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
METHYLPHENIDATE;SLC6A2;rs28386840;AT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;rs12081765;G;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
METHOTREXATE;SLCO1B1;rs11045879;C;EFFICACY, TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
PHENYLEPHRINE;ADRB2;rs1042713;AA;DOSAGE;INCREASED_DOSE;
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT
ANASTROZOLE;CSMD1;rs6990851;G;EFFICACY;INCREASED_RESPONSE;OTHER:BREAST_NEOPLASMS
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;ABCC2;rs2273697;AA;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs6806020;C;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
NICOTINE;CYP2A6;rs28399433;C;LADME_PK;DECREASED_METABOLISM;
ATORVASTATIN;ABCB1;rs2032582;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
WARFARIN;VKORC1;rs7294;CT + TT;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs1931704;A;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
ACAMPROSATE;CHDH, IL17RB;rs6801605;A;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:ALCOHOL_ABUSE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE, EFFICACY;DECREASED_DOSE;OTHER:MECHANICAL_HEART_VALVE_REPLACEMENT
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:B-CELL_CHRONIC_LYMPHOCYTIC_LEUKEMIA
PRAVASTATIN;MTTP;rs1800591;GT + TT;EFFICACY;RESPONSE;
TACROLIMUS;CYP3A5;rs776746;CT;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;
COUMARIN;CYP2A6;rs28399433;C;LADME_PK;DECREASED_METABOLISM;
PEGINTERFERON ALFA-2B, RIBAVIRIN;IL21R;rs3093390;C;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
BEVACIZUMAB, IRINOTECAN;VEGFA;rs1570360;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs7512595;A;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;CARD16;rs1792774;C;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
WARFARIN;CYP2C19;rs3814637;CC;DOSAGE;INCREASED_DOSE;
WARFARIN;CYP2C9;rs1057910;AA + AC;DOSAGE;INCREASED_DOSE;
N-DESMETHYLTRAMADOL;ABCC2;rs3740066;TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEATH
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs7750468;G;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
WARFARIN;GGCX;rs699664;CT + TT;DOSAGE;INCREASED_DOSE;
IVACAFTOR;CFTR;rs75527207;AG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CYSTIC_FIBROSIS
ATORVASTATIN;SLCO1B1;rs2306283;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
FENTANYL;ABCC3;rs11079921;C;LADME_PK;INCREASED_CLEARANCE;OTHER:PAIN,_OTHER:PREMATURE_BIRTH
PEGINTERFERON ALFA-2B, RIBAVIRIN;CARD16;rs1503391;A;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;CASP1;rs557905;T;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs2066911;A;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
HMG COA REDUCTASE INHIBITORS;CFAP44;rs13064411;G;EFFICACY;DECREASED_RESPONSE;
ATORVASTATIN;CYP7A1;rs3808607;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
PEGINTERFERON ALFA-2B, RIBAVIRIN;CASP1;rs568910;A;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
CODEINE;CYP2D6;rs3892097;TT;LADME_PK;DECREASED_METABOLISM;DISEASE:CHRONIC_KIDNEY_FAILURE
NICOTINE;CHRNB2;rs2072658;AG;OTHER;INCREASED_RESPONSE;OTHER:DAILY_SMOKING
METFORMIN;SLC22A1;rs622342;AC + CC;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
N-DESMETHYLTRAMADOL;UGT1A8;rs8330;CC;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:DEATH
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
NICOTINE;CHRNA4;rs2229959;C;OTHER;INCREASED_RESPONSE;OTHER:DAILY_SMOKING
PEGINTERFERON ALFA-2B, RIBAVIRIN;TUT7;rs17461620;C;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
ACETYLCYSTEINE;TOLLIP;rs3750920;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:PULMONARY_FIBROSIS
OXCARBAZEPINE;ABCB1;rs1045642;A;EFFICACY;DECREASED_RESPONSE;DISEASE:EPILEPSY
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
OXCARBAZEPINE;UGT2B7;rs7439366;C;EFFICACY;DECREASED_RESPONSE;DISEASE:EPILEPSY
ARA-CTP;CDA;rs12404655;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ACUTE_MYELOID_LEUKEMIA
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
ARA-CTP;RRM1;rs11030918;CT + TT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ACUTE_MYELOID_LEUKEMIA
CLOZAPINE;CYP1A2;rs762551;AA;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
CLOPIDOGREL;CYP3A5;rs776746;CC + CT;EFFICACY;INCREASED_RESISTANCE;DISEASE:STROKE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
ARA-CTP;CTPS1;rs11577910;AG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ACUTE_MYELOID_LEUKEMIA
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
ARA-CTP;CTPS1;rs12067645;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ACUTE_MYELOID_LEUKEMIA
ARA-CTP;CTPS1;rs4364871;CT + TT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ACUTE_MYELOID_LEUKEMIA
N-DESMETHYLTRAMADOL;UGT1A8;rs10929303;CC;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:DEATH
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;UGT1A8;rs34650714;CC;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:DEATH
ARA-CTP;SLC28A1;rs11853372;TT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ACUTE_MYELOID_LEUKEMIA
ARA-CTP;DCTD;rs4742;GG;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ACUTE_MYELOID_LEUKEMIA
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
ALLOPURINOL;ABCG2;rs2231142;GT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:GOUT
OXCARBAZEPINE;ABCB1;rs1045642;GG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
AMANTADINE, ANTICHOLINERGICS, LEVODOPA, SELEGILINE;SLC22A1;rs622342;C;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE:PARKINSON_DISEASE
ARA-CTP;DCK;rs4643786;CC + CT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ACUTE_MYELOID_LEUKEMIA
CLOZAPINE;CYP1A2;rs762551;AA;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA,_OTHER:TOBACCO_USE_DISORDER
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
MORPHINE-3-GLUCURONIDE, MORPHINE-6-GLUCURONIDE;ABCC3;rs4793665;CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:SCOLIOSIS,_DISEASE:TONSILLECTOMY
TACROLIMUS;ABCB1;rs1128503;GG;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
MORPHINE-3-GLUCURONIDE;ABCC3;rs4148412;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:TONSILLECTOMY
GLUCOSE;CRTC2;rs8450;AA + AG;TOXICITY;INCREASED_CONCENTRATIONS;DISEASE:TRANSPLANTATION
ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLCO1C1;rs3794271;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:ARTHRITIS,_PSORIATIC
TACROLIMUS;ABCB1;rs1128503;GG;LADME_PK;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
SERTRALINE;GNB3;rs5441;GG;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
FENTANYL;CYP3A4;rs2242480;TT;EFFICACY;INCREASED_RESPONSE;OTHER:PAIN,_POSTOPERATIVE
SUFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER:LUNG_NEOPLASMS,_OTHER:PAIN,_POSTOPERATIVE
SUFENTANIL;OPRM1;rs1323040;AG + GG;DOSAGE;INCREASED_DOSE;OTHER:LUNG_NEOPLASMS,_OTHER:PAIN,_POSTOPERATIVE
SUFENTANIL;ABCB1;rs1128503;AA + AG;DOSAGE;INCREASED_DOSE;OTHER:LUNG_NEOPLASMS,_OTHER:PAIN,_POSTOPERATIVE
CYCLOSPORINE;ABCB1;rs1045642;A;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
SUFENTANIL;ABCB1;rs2032582;AA + AC;DOSAGE;INCREASED_DOSE;OTHER:LUNG_NEOPLASMS,_OTHER:PAIN,_POSTOPERATIVE
MORPHINE;OPRM1;rs1799971;GG;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
HDL CHOLESTEROL;CRTC2;rs8450;AA;TOXICITY;DECREASED_CONCENTRATIONS;DISEASE:TRANSPLANTATION
O-DESMETHYLTRAMADOL;SLC22A1;rs34130495;GG;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:DEATH
MYCOPHENOLIC ACID;ABCC2;rs717620;TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
METHYLPHENIDATE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
METHYLPHENIDATE;COMT;rs4680;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
N-DESMETHYLTRAMADOL, O-DESMETHYLTRAMADOL;SLC22A1;rs1867351;TT;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:DEATH
PHENYTOIN;CYP2C9;rs12782374;AA + AG;DOSAGE, LADME_PK;DECREASED_DOSE;DISEASE:EPILEPSY
WARFARIN;CYP2C9;rs1057910;C;DOSAGE, LADME_PK;DECREASED_DOSE;
FENTANYL;ABCC3;rs8077268;T;LADME_PK;INCREASED_CLEARANCE;OTHER:PAIN,_OTHER:PREMATURE_BIRTH
METHYLPHENIDATE;COMT;rs4680;G;EFFICACY;INCREASED_CLEARANCE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
WARFARIN;CYP2C9;rs1799853;T;DOSAGE, LADME_PK;DECREASED_DOSE;
PLATINUM COMPOUNDS;XRCC1;rs25487;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;
CYCLOSPORINE;ABCB1;rs1045642;GG;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
NICOTINE;CYP1A2;rs35694136;T/del + del/del;EFFICACY;DECREASED_EXPOSURE;
SIROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME_PK;DECREASED_METABOLISM;DISEASE:TRANSPLANTATION
PLATINUM COMPOUNDS;ERCC1;rs3212986;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
MYCOPHENOLIC ACID;UGT2B7;rs7662029;G;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
METHYLPHENIDATE;TH;rs2070762;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
TACROLIMUS;IL18;rs5744247;CC + CG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
SIROLIMUS;CYP3A4;rs2740574;CC + CT;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
SIROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
CETUXIMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
CARBAMAZEPINE;CYP3A4;rs2242480;CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
RISPERIDONE;HTR2C;rs518147;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CARBAMAZEPINE;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
SITAGLIPTIN, VILDAGLIPTIN;GLP1R;rs6923761;AA;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;CYP2C8;rs7910936;C;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS
CARBAMAZEPINE;ABCB1;rs1045642;GG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
CARBAMAZEPINE;EPHX1;rs3738046;CG;LADME_PK;CONCENTRATIONS;DISEASE:EPILEPSY
ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HYPERCHOLESTEROLEMIA
PHENYTOIN;CYP2C9;rs1057910;AC;OTHER, LADME_PK;DECREASED_METABOLISM;DISEASE:EPILEPSY
PHENYTOIN;CYP2C9;rs1799853;CT;LADME_PK;DECREASED_METABOLISM;DISEASE:EPILEPSY
PHENYTOIN;CYP2C19;rs4244285;AG;OTHER, LADME_PK;DECREASED_METABOLISM;DISEASE:EPILEPSY
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION,_DISEASE:HIV_INFECTIOUS_DISEASE
CLOZAPINE;HTR2C;rs6318;C;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CARBAMAZEPINE;EPHX1;rs2234922;AG + GG;LADME_PK;CONCENTRATIONS;DISEASE:EPILEPSY
CARBAMAZEPINE;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
SULFONAMIDES, UREA DERIVATIVES;TCF7L2;rs12255372;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
SIMVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERCHOLESTEROLEMIA
CARBOPLATIN, CISPLATIN, FLUOROURACIL;XRCC1;rs25487;T;EFFICACY;DECREASED_RESPONSE;DISEASE:UTERINE_CERVICAL_NEOPLASM
TRAMADOL;ABCB1;rs2032582;AA;LADME_PK;INCREASED_EXPOSURE;
TRAMADOL;ABCB1;rs1045642;AA;LADME_PK;INCREASED_EXPOSURE;
CARBOPLATIN, CISPLATIN, FLUOROURACIL;SLC19A1;rs12659;A;EFFICACY;DECREASED_RESPONSE;DISEASE:UTERINE_CERVICAL_NEOPLASM
TRAMADOL;ABCB1;rs1128503;AA;LADME_PK;INCREASED_EXPOSURE;
TOCILIZUMAB;IL6R;rs12083537;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CAFFEINE;ADORA1;rs16851030;CC;EFFICACY;INCREASED_RESPONSE;OTHER:APNEA_OF_PREMATURITY
TOCILIZUMAB;IL6R;rs4329505;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
RISPERIDONE;HTR2C;rs1023574;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RISPERIDONE;HTR2C;rs9698290;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
DIURETICS, HYDROCHLOROTHIAZIDE, THIAZIDES, PLAIN;PRKCA;rs16960228;A;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
ANTIDEPRESSANTS;RGS17;rs672170;A;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
LITHIUM;NTRK2;rs1387923;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
WARFARIN;CYP2C9;rs7089580;AT;DOSAGE;INCREASED_DOSE;
WARFARIN;CYP2C9;rs7089580;AT;DOSAGE;INCREASED_CLEARANCE;
VORICONAZOLE;SLCO1B3;rs4149117;GT + TT;LADME_PK;DECREASED_TROUGH CONCENTRATION;
LITHIUM;GSK3B;rs334558;G;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
OXALIPLATIN;TP53;rs1042522;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
ANTIDEPRESSANTS;NBEA;rs9315310;T;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ANTIDEPRESSANTS;CRH;rs4737771;C;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
ANTIDEPRESSANTS;FHIT;rs49411;C;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ANTIDEPRESSANTS;PARP11;rs2532560;G;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ANTIDEPRESSANTS;;rs2831440;T;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
SILDENAFIL;GNB3;rs5443;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:ERECTILE_DYSFUNCTION
ANTIDEPRESSANTS;MTRF1L;rs766127;G;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ATORVASTATIN;POR;rs1057868;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:FAMILIAL_HYPERCHOLESTEROLEMIA
TACROLIMUS;HSD11B1;rs846908;AA;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
SARILUMAB;IL6R;rs4845625;CC;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
SALVIANOLIC ACID B;NOS3;rs1799983;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:CORONARY_DISEASE
BUPROPION;COMT;rs165599;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER:SMOKERS
LITHIUM;TPH1;rs1799913;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
BUPROPION;COMT;rs737865;AA;EFFICACY;DECREASED_RESPONSE;OTHER:SMOKERS
LITHIUM;TPH1;rs1800532;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;CACNG2;rs2284017;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
SALBUTAMOL;CRHR2;rs2267715;G;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;CYP2C8;rs10882521;T;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS
LITHIUM;BCR;rs140504;A;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
WARFARIN;STX1B;rs4889606;AG + GG;DOSAGE;INCREASED_DOSE;
ADALIMUMAB;HFE;rs2071303;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:CROHN_DISEASE
ROSIGLITAZONE;LPIN1;rs10192566;G;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
TACROLIMUS;HSD11B1;rs4844880;AA;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
DESETHYLCHLOROQUINE, HYDROXYCHLOROQUINE;CYP2D6;rs1065852;AA;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS
TACROLIMUS;HSD11B1;rs846910;AA;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
ACENOCOUMAROL;GATA4;rs3735814;AG + GG;DOSAGE;DECREASED_DOSE;
BETA BLOCKING AGENTS, SELECTIVE, DIURETICS;NEDD4L;rs4149601;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
ANTIDEPRESSANTS;CTNNA3;rs10997242;C;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ALDOSTERONE ANTAGONISTS, AMILORIDE;NEDD4L;rs4149601;G;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
LITHIUM;DRD1;rs4532;C;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
ANTIDEPRESSANTS;HTR2A;rs7997012;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
SALBUTAMOL;CRHR2;rs255100;A;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
ANTIDEPRESSANTS;HTR2A;rs6313;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ANTIDEPRESSANTS;CACNA1A;rs2112460;A;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
SALBUTAMOL;CRHR2;rs2284220;G;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
WARFARIN;ORM1;rs17650;AG + GG;DOSAGE;DECREASED_DOSE;
ANTIDEPRESSANTS;;rs521093;T;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
MORPHINE;UGT2B7;rs7439366;CC;DOSAGE;DECREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
WARFARIN;VKORC1;rs7294;C;DOSAGE;DECREASED_DOSE;
ANTIDEPRESSANTS;RAPGEF5;rs16873129;C;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
VALPROIC ACID;ABCB1;rs1128503;AA;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
ANTIDEPRESSANTS;PON2;rs2299267;G;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;rs776746;C;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;C;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
CISPLATIN;GALNT18;rs7937567;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:URINARY_BLADDER_NEOPLASMS
EFAVIRENZ;CYP2B6;rs2279343;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
RITUXIMAB;;rs3759467;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:VASCULITIS
ANTIPSYCHOTICS, ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;CYP3A43;rs680055;CG;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOAFFECTIVE_DISORDER,_DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_STEADY_STATE CONCENTRATION;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;A;DOSAGE;DOSE;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
CORTICOSTEROIDS;HDAC1;rs1741981;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
VINCRISTINE;MTNR1B;rs8192552;AG;LADME_PK;INCREASED_EXPOSURE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA,_OTHER:HODGKIN_DISEASE,_OTHER:RHABDOMYOSARCOMA,_OTHER:MEDULLOBLASTOMA,_OTHER:GLIOMA
MORPHINE;TLR2;rs3804100;CC + CT;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;rs776746;CT;OTHER, LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
DOCETAXEL, THALIDOMIDE;CHST3;rs4148947;T;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
MORPHINE;IL1B;rs1143634;A;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CISPLATIN;MLLT3;rs10964552;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE:URINARY_BLADDER_NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;T;DOSAGE, LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
MORPHINE;IL1B;rs1143634;A;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
EFAVIRENZ;CYP2B6;rs28399499;CT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
DOCETAXEL, THALIDOMIDE;CHST3;rs4148950;A;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE, LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
ATORVASTATIN;MTTP;rs1800591;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERLIPOPROTEINEMIA_TYPE_II
NITROGLYCERIN;ALDH2;rs671;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:CONGENITAL_HEART_DEFECTS
TOCILIZUMAB;GALNT18;rs4910008;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CISPLATIN;RARS1;rs244898;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:URINARY_BLADDER_NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE, LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DOSE;DISEASE:STROKE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
RISPERIDONE;ABCB1;rs2235048;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A5;rs776746;CT;LADME_PK;INCREASED_DOSE;OTHER:HEART_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME_PK;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
NITROGLYCERIN;ALDH2;rs671;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:CONGENITAL_HEART_DEFECTS,_DISEASE:PULMONARY_HYPERTENSION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TOCILIZUMAB;CD69;rs11052877;A;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
PHENAZEPAM;CYP2C19;rs12248560;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:ALCOHOL-RELATED_DISORDERS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
VINCRISTINE;SNU13;rs6519270;G;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA,_OTHER:HODGKIN_DISEASE,_OTHER:RHABDOMYOSARCOMA,_OTHER:MEDULLOBLASTOMA,_OTHER:GLIOMA
ATENOLOL;;rs7184292;A;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
ATENOLOL;XIRP2;rs7606603;C;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
CYCLOSPORINE;CYP3A7;rs10211;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DOSE;
CYCLOSPORINE;CYP3A7;rs2257401;CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;JAK2;rs12343867;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS
NILOTINIB;GSTP1;rs1695;A;EFFICACY;INCREASED_RESPONSE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
HYDROCHLOROTHIAZIDE;;rs16872401;C;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;rs3212217;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
CYCLOSPORINE;CYP3A4;rs4646437;GG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
PAROXETINE;ABCB1;rs2032582;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
NILOTINIB;CYP1A1;rs1048943;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;NLRP3;rs10754558;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
ATENOLOL;;rs7184292;GG;DOSAGE;DECREASED_DOSE;OTHER:HYPERTENSION
ATORVASTATIN;SLCO1B1;rs2306283;GG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:HYPERLIPIDEMIAS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL18;rs1946518;GT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS
RISPERIDONE;AKT1;rs3803300;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RISPERIDONE;AKT1;rs2494732;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR1;rs2234711;AG;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS
IMATINIB;CYP2B6;rs3745274;GG + TT;EFFICACY;INCREASED_RESISTANCE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
WARFARIN;CYP2C19;rs4986893;AA + AG;DOSAGE;DECREASED_DOSE;
CYCLOSPORINE;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C19;rs3814637;CT + TT;DOSAGE;DECREASED_DOSE;
CANNABIDIOL;AOC1;rs12539;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER:EPILEPSY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TBX21;rs17250932;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:ULCERATIVE_COLITIS
VINCRISTINE;RAB7A;rs4548;CT;LADME_PK;INCREASED_EXPOSURE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA,_OTHER:HODGKIN_DISEASE,_OTHER:RHABDOMYOSARCOMA,_OTHER:MEDULLOBLASTOMA,_OTHER:GLIOMA
DOCETAXEL, THALIDOMIDE;CHST3;rs730720;C;EFFICACY;INCREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR2;rs8126756;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:CROHN_DISEASE
CANNABIDIOL;SLC15A1;rs1339067;TT;EFFICACY;DECREASED_RESPONSE;OTHER:EPILEPSY
WARFARIN;;rs12772169;T;DOSAGE;DOSE;
ROSIGLITAZONE;SLCO1B1;rs4149056;C;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL12B;rs3212217;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:CROHN_DISEASE
CORTICOSTEROIDS FOR SYSTEMIC USE;HDAC1;rs1741981;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
WARFARIN;NQO1;rs1800566;A;EFFICACY;DECREASED_RESPONSE;DISEASE:THROMBOTIC_DISEASE
RISPERIDONE;COMT;rs165599;G;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
WARFARIN;VKORC1;rs9923231;A;DOSAGE;DOSE;
RISPERIDONE;GRM3;rs724226;G;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;DOSE;
ATENOLOL, BISOPROLOL, CELIPROLOL, DOXAZOSIN;KCNH2;rs1137617;GG;EFFICACY;RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR5;rs5744174;AG;EFFICACY;DECREASED_RESPONSE;DISEASE:CROHN_DISEASE
MORPHINE;KCNJ6;rs6517442;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:PAIN
METHOTREXATE;ABCG2;rs2231142;GT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;POR;rs1057868;CT + TT;LADME_PK;DECREASED_TROUGH CONCENTRATION;DISEASE:KIDNEY_TRANSPLANTATION
MORPHINE, REMIFENTANIL;KCNJ6;rs6517442;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:PAIN
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
LOW DENSITY LIPOPROTEIN;SH2B1;rs3888190;CC;OTHER;INCREASED_CONCENTRATIONS;DISEASE:BIPOLAR_DISORDER,_DISEASE:DEPRESSIVE_DISORDER,_DISEASE:PSYCHOTIC_DISORDER,_DISEASE:SCHIZOAFFECTIVE_DISORDER
TACROLIMUS;CYP3A5;rs776746;T;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
ENALAPRIL;VEGFA;rs699947;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
LITHIUM;CACNG2;rs2284018;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
EFAVIRENZ;ABCB1;rs1045642;GG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;
ANASTROZOLE;;rs1437153;T;EFFICACY;DECREASED_RESPONSE;OTHER:BREAST_NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
DOCETAXEL;ORM2;rs2250242;AA;LADME_PK;INCREASED_CLEARANCE;DISEASE:PROSTATIC_NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ETANERCEPT, INFLIXIMAB;CARD8;rs2043211;TT;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
METHOTREXATE;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IFNGR1;rs2234711;AG;EFFICACY;DECREASED_RESPONSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
ETANERCEPT, INFLIXIMAB;NLRP3;rs4612666;TT;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ANASTROZOLE;DLG2;rs2449598;T;EFFICACY;DECREASED_RESPONSE;OTHER:BREAST_NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;rs776746;T;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:NEPHROTIC_SYNDROME
EFAVIRENZ;CYP2B6;rs2279343;GG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;rs2242480;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:NEPHROTIC_SYNDROME
METHOTREXATE;MTHFR;rs1801133;AA;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
PEGINTERFERON ALFA-2B;HLA-DPA1;rs3077;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_B,_CHRONIC
RIVASTIGMINE;BCHE;rs1803274;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_DOSE;
METHOTREXATE;ABCB1;rs1045642;AG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ADALIMUMAB, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;A;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
PRAVASTATIN;LDLR;rs1433099;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:VASCULAR_DISEASES
PRAVASTATIN;LDLR;rs2738466;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:VASCULAR_DISEASES
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
CANNABIDIOL;ABCC5;rs3749442;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER:EPILEPSY
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs4803217;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION,_DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
SUFENTANIL;NFKBIA;rs696;TT;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs11881222;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION,_DISEASE:HIV_INFECTIOUS_DISEASE
GLUCOSE;RABEP1;rs1000940;AG + GG;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BIPOLAR_DISORDER,_DISEASE:DEPRESSIVE_DISORDER,_DISEASE:PSYCHOTIC_DISORDER,_DISEASE:SCHIZOAFFECTIVE_DISORDER
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
PAROXETINE;BDNF;rs6265;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
REMIFENTANIL;COMT;rs4680;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:PAIN
TACROLIMUS;CYP3A5;rs776746;CT;LADME_PK;INCREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
MORPHINE;COMT;rs4680;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:PAIN
MORPHINE, REMIFENTANIL;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:PAIN
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE, LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
ANTIPSYCHOTICS;ABCB1;rs2032582;CC;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:SCHIZOPHRENIA
ADALIMUMAB, INFLIXIMAB;TLR2;rs3804099;T;EFFICACY;DECREASED_RESPONSE;OTHER:CROHN_DISEASE
ANTIPSYCHOTICS;ABCB1;rs2032582;C;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
MORPHINE;COMT;rs4680;G;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER:CORONARY_ARTERY_DISEASE,_EFFICACY:PAIN,_POSTOPERATIVE
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_EXPOSURE;DISEASE:HIV_INFECTIOUS_DISEASE
INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8103142;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION,_DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;rs776746;T;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE;OTHER:HSCT
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs28416813;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION,_DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM;OTHER:KIDNEY_DISEASE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
IMATINIB;ABCG2;rs2231142;GT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs8113007;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION,_DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION,_DISEASE:HIV_INFECTIOUS_DISEASE
CLOZAPINE;CHRM1;rs2075748;CC;DOSAGE;DECREASED_DOSE;OTHER:SCHIZOPHRENIA
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CYP1B1;rs1056836;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_EXPOSURE;DISEASE:HIV_INFECTIOUS_DISEASE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs28416813;G;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
INTERFERON ALFA-N1, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
ERENUMAB, FREMANEZUMAB, GALCANEZUMAB;;rs12615320;G;EFFICACY;DECREASED_RESPONSE;OTHER:MIGRAINE_WITHOUT_AURA,_OTHER:MIGRAINE_WITH_AURA
ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_RESPONSE;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;
HYDROXYUREA;ASS1;rs10901080;T;EFFICACY;INCREASED_RESPONSE;DISEASE:ANEMIA,_SICKLE_CELL,_DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
ANASTROZOLE;CSMD1;rs6981827;T;EFFICACY;DECREASED_RESPONSE;OTHER:BREAST_NEOPLASMS
HYDROXYUREA;ASS1;rs10793902;T;EFFICACY;INCREASED_RESPONSE;DISEASE:ANEMIA,_SICKLE_CELL,_DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
DOXORUBICIN;ABCB1;rs2032582;AA;LADME_PK;DECREASED_METABOLISM;DISEASE:BREAST_NEOPLASMS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8103142;T;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
EPIRUBICIN;NQO1;rs1800566;AA;EFFICACY, TOXICITY;DECREASED_RESPONSE;OTHER:BREAST_CANCER_CELL_LINES
DOCETAXEL, EPIRUBICIN;MDM4;rs1563828;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
GEMCITABINE;CDA;rs2072671;C;LADME_PK;DECREASED_CLEARANCE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
HYDROCHLOROTHIAZIDE;NEDD4L;rs75982813;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
GLICLAZIDE;KCNJ11;rs5219;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
WARFARIN;;rs12777823;AA + AG;DOSAGE;DECREASED_DOSE;
DOXORUBICIN;ABCB1;rs1045642;AA;LADME_PK;DECREASED_METABOLISM;DISEASE:BREAST_NEOPLASMS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
ARIPIPRAZOLE;DRD2;rs6277;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
CAPECITABINE, RADIOTHERAPY;AREG;rs11942466;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE:RECTAL_NEOPLASMS
(S)-METHADONE;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
(R)-METHADONE;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
CAPECITABINE, RADIOTHERAPY;ERCC1;rs11615;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:RECTAL_NEOPLASMS
CAPECITABINE, OXALIPLATIN;VEGFA;rs2010963;CG;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
ARIPIPRAZOLE;ANKK1;rs1800497;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
MORPHINE;COMT;rs4633;C;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER:CORONARY_ARTERY_DISEASE,_EFFICACY:PAIN,_POSTOPERATIVE
CLOZAPINE;HTR3A;rs1150226;G;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RISPERIDONE;GRM7;rs2069062;CC;EFFICACY;INCREASED_RESPONSE;
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
CLOZAPINE;HTR3A;rs2276302;A;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
GLUCOSE;COMT;rs4680;AA + AG;TOXICITY;INCREASED_CONCENTRATIONS;
CLOZAPINE;HTR3A;rs1062613;C;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;LADME_PK;DECREASED_METABOLISM;DISEASE:ACUTE_CORONARY_SYNDROME
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;PTPRC;rs10919563;G;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_DISCONTINUATION;DISEASE:KIDNEY_DISORDER
RISPERIDONE;GRID2;rs1875705;GG;EFFICACY;INCREASED_RESPONSE;
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:ACUTE_CORONARY_SYNDROME
PACLITAXEL;ABCB1;rs2032582;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
TACROLIMUS;NR1I2;rs2276707;CC;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT;DOSAGE, LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
CAPECITABINE, OXALIPLATIN;VEGFA;rs699947;AC;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
WARFARIN;PRSS53, VKORC1;rs17886199;A;DOSAGE;DECREASED_DOSE;
4-HYDROXYATORVASTATIN, 4-HYDROXYATORVASTATIN LACTONE;SLCO2B1;rs12422149;AG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:CORONARY_DISEASE
PACLITAXEL;ABCB1;rs2032582;AA + AT;EFFICACY;INCREASED_RESPONSE;DISEASE:OVARIAN_NEOPLASMS
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs11881222;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
2-HYDROXYATORVASTATIN LACTONE, 4-HYDROXYATORVASTATIN LACTONE, ATORVASTATIN LACTONE;UGT1A1;rs887829;CC;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:CORONARY_DISEASE
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;RGS5;rs1056515;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
SN-38;UGT1A1;rs4148323;AA;DOSAGE;DECREASED_METABOLISM;DISEASE:NEOPLASMS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8105790;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
VALPROIC ACID;GABRA1;rs10068980;AA + AG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
CLOZAPINE;CHRM1;rs1942499;GG;DOSAGE;DECREASED_DOSE;OTHER:SCHIZOPHRENIA
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
ROSUVASTATIN;SCAP;rs12487736;C;EFFICACY;INCREASED_RESPONSE;DISEASE:METABOLIC_SYNDROME
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs4803219;CT;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;RALBP1;rs329007;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ROCURONIUM;ABCB1;rs1128503;AA;EFFICACY;DECREASED_RESPONSE;
MYCOPHENOLIC ACID;UGT1A9;rs6714486;AA + AT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
ROCURONIUM;SLCO1B1;rs2306283;AA;EFFICACY;DECREASED_RESPONSE;
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;G;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PERAMPANEL;CYP3A5, ZSCAN25;rs776746;C;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:EPILEPSY
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
MORPHINE;UGT2B7;rs7438135;AA + AG;LADME_PK;DECREASED_CONCENTRATIONS;
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_CLEARANCE;DISEASE:LIVER_TRANSPLANTATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GT;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs7248668;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs10853728;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HYPERCHOLESTEROLEMIA
PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs10853728;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
ACENOCOUMAROL;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;
IMATINIB;ABCG2;rs2725252;C;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
PHENPROCOUMON;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;OTHER:MAINTENANCE_DOSAGE_BY_1.5_MG/WEEK
ATENOLOL, IRBESARTAN;EDN1;rs5370;GT;EFFICACY;INCREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
PAROXETINE;HTR2A;rs6311;CC;EFFICACY;INCREASED_RESPONSE;OTHER:OBSESSIVE-COMPULSIVE_DISORDER
PHENPROCOUMON;CYP2C9;rs4086116;T;DOSAGE;DECREASED_DOSE;OTHER:MAINTENANCE_DOSAGE_BY_2.2_MG/WEEK
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;APOE;rs7412;C;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
IMATINIB;ABCG2;rs2725252;C;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
ATAZANAVIR;NR1I2;rs2472677;CT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
PRAVASTATIN;SLCO1B1;rs4149015;AG;LADME_PK;INCREASED_METABOLISM;DISEASE:HYPERLIPOPROTEINEMIA_TYPE_II
APIXABAN;CYP3A5;rs776746;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ATRIAL_FIBRILLATION
IMATINIB;ABCG2;rs12505410;G;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
NIACIN;HCAR2;rs2454727;CT + TT;EFFICACY;DECREASED_RESPONSE;
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;ABCA1;rs12003906;C;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERLIPIDEMIAS
CEFTRIAXONE;ABCG2;rs13120400;TT;LADME_PK;CONCENTRATIONS;DISEASE:CENTRAL_NERVOUS_SYSTEM_INFECTIOUS_DISORDER
RIBAVIRIN;ITPA;rs1127354;CC;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;rs776746;CT;LADME_PK;DECREASED_EXPOSURE;DISEASE:KIDNEY_TRANSPLANTATION
PRAVASTATIN;SLCO1B1;rs4149015;AG;LADME_PK;INCREASED_RESPONSE;DISEASE:HYPERLIPOPROTEINEMIA_TYPE_II
CREATINE;MOBP;rs616147;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER:AMYOTROPHIC_LATERAL_SCLEROSIS
PEMETREXED;EXO1;rs1047840;AA + AG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:LUNG_NEOPLASMS
PRAVASTATIN;SLCO1B1;rs4149056;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:TRANSPLANTATION
PHENPROCOUMON;STX4;rs10871454;T;DOSAGE;DECREASED_DOSE;OTHER:MAINTENANCE_DOSAGE_BY_4.8_MG/WEEK
PRAVASTATIN;SLCO1B1;rs4149056;CT;LADME_PK;INCREASED_METABOLISM;DISEASE:TRANSPLANTATION
PROPOFOL;CYP2B6;rs3745274;GT + TT;DOSAGE;DECREASED_DOSE;
ADALIMUMAB, ETANERCEPT, INFLIXIMAB, TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;rs352139;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
VALPROIC ACID;CYP2C19;rs4244285;AA + AG;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:MYELODYSPLASTIC_SYNDROMES
APIXABAN;ABCG2;rs2231142;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ATRIAL_FIBRILLATION
IVACAFTOR;CFTR;rs121908755;A;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
3,4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;rs2242446;TT;OTHER;DECREASED_RESPONSE;
ATENOLOL;AGT;rs699;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
3,4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;rs1861647;GG;OTHER;INCREASED_RESPONSE;
3,4-METHYLENEDIOXYMETHAMPHETAMINE;SLC6A2;rs36029;AA;OTHER;INCREASED_RESPONSE;
ATENOLOL;AGT;rs5051;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
TEMOZOLOMIDE;ABCB1;rs2229109;CT;EFFICACY;DECREASED_RESPONSE;OTHER:GLIOMA
FOLLITROPIN BETA, UROFOLLITROPIN;FSHR;rs6166;T;TOXICITY;INCREASED_RESPONSE;
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;HLA-E;rs1264457;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
REPAGLINIDE;SLC30A8;rs13266634;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
DISULFIRAM;ADRA1A;rs1048101;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER:COCAINE_DEPENDENCE
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;ATP5F1E;rs1059150;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
SIROLIMUS;ABCB1;rs1045642;AG;LADME_PK;INCREASED_CONCENTRATIONS;
MERCAPTOPURINE;NUDT15;rs116855232;TT;DOSAGE;DECREASED_DOSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
DEXMEDETOMIDINE;CYP2A6;rs28399433;C;LADME_PK;DECREASED_CLEARANCE;
IRBESARTAN;CYP2C9;rs1799853;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
FENTANYL;CALCA;rs145837941;GG;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
NITRIC OXIDE;NAMPT;rs1319501;TT;EFFICACY;INCREASED_CONCENTRATIONS;OTHER:PRE-ECLAMPSIA
TOCILIZUMAB;GALNT18;rs4910008;CC + CT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
BUPRENORPHINE;OPRD1;rs529520;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
NICOTINE;;rs12459249;C;LADME_PK;DECREASED_METABOLISM;
WARFARIN;GGCX;rs2592551;AA + AG;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
ESCITALOPRAM;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
ATOMOXETINE, DESVENLAFAXINE, DULOXETINE, SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
TOCILIZUMAB;IL6;rs2069840;CC;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
ANTIDEPRESSANTS;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
BENAZEPRIL;MTHFR;rs1801131;G;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
FLUOXETINE, PAROXETINE;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
BENAZEPRIL;MTHFR;rs1801133;G;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
IRBESARTAN;CYP2C9;rs1057910;AC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ESSENTIAL_HYPERTENSION
PAROXETINE;HTR7;rs7905446;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
FENTANYL;CALCA;rs145837941;AG + GG;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE,_OTHER:CAESARIAN_SECTION
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
PEMETREXED;CAMKK2;rs1653586;GT;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:LUNG_NEOPLASMS
ABIRATERONE;SRD5A2;rs523349;CC;EFFICACY;INCREASED_RESPONSE;OTHER:PROSTATIC_NEOPLASMS
BUPRENORPHINE;OPRD1;rs581111;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
CARBOPLATIN, LONAFARNIB, PACLITAXEL;FNTB;rs11623866;GG;EFFICACY;RESPONSE;DISEASE:OVARIAN_NEOPLASMS
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
METHOTREXATE;ABCG2;rs12505410;GG;LADME_PK;INCREASED_CLEARANCE;DISEASE:OSTEOSARCOMA
ESCITALOPRAM;BMP5;rs41271330;A;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ESCITALOPRAM;BMP5;rs41271330;AA + AG;EFFICACY;INCREASED_DOSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METHOTREXATE;ABCG2;rs13137622;GT + TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:OSTEOSARCOMA
METHOTREXATE;ABCG2;rs13120400;CC;LADME_PK;INCREASED_CLEARANCE;DISEASE:OSTEOSARCOMA
AMLODIPINE;CYP3A4;rs2740574;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
TACROLIMUS;IL18;rs1946518;GG + GT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LUNG_TRANSPLANTATION
TACROLIMUS;IL10;rs1800896;TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LUNG_TRANSPLANTATION
RIVASTIGMINE;BCHE;rs1803274;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;rs35303484;G;LADME_PK;CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
VALPROIC ACID;CYP2C9;rs1057910;C;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:EPILEPSY
METHOTREXATE;MTHFR;rs1801133;AG + GG;LADME_PK;INCREASED_STEADY_STATE CONCENTRATION;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
AZATHIOPRINE;NUDT15;rs116855232;TT;TOXICITY;DECREASED_DOSE;DISEASE:LEUKOPENIA
CLOZAPINE;NFIB;rs28379954;CT;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LUNG_TRANSPLANTATION
METFORMIN;SLC22A1;rs594709;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
IRINOTECAN;TDP1;rs2401863;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
METFORMIN;SLC47A1;rs2289669;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
TACROLIMUS;IL18;rs5744247;CC + CG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LUNG_TRANSPLANTATION
METHOTREXATE;SLC19A1;rs1051266;TT;LADME_PK;INCREASED_STEADY_STATE CONCENTRATION;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
DEXMEDETOMIDINE;CYP2D6;rs16947;GG;DOSAGE;INCREASED_DOSE;OTHER:SURGERY
CARBAMAZEPINE;CYP1A2;rs762551;AA;LADME_PK;INCREASED_CLEARANCE;DISEASE:EPILEPSY
RIVAROXABAN;CYP3A4;rs2242480;T;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
CYCLOSPORINE, TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME_PK;INCREASED_CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
METHOTREXATE;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs4148324;GG + GT;LADME_PK;DECREASED_CLEARANCE;DISEASE:OSTEOSARCOMA
EFAVIRENZ;ABCB1;rs3842;C;LADME_PK;CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CYCLOSPORINE, TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE, LADME_PK;DECREASED_DOSE;OTHER:LIVER_TRANSPLANTATION
DEXMEDETOMIDINE;WBP2NL;rs5758550;AG + GG;TOXICITY;INCREASED_RESPONSE;OTHER:SURGERY
MEMANTINE, RIVASTIGMINE;BCHE;rs1803274;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
IVACAFTOR;CFTR;rs75527207;AA;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_DOSE;
WARFARIN;GGCX;rs699664;CC;DOSAGE;INCREASED_DOSE;
METHOTREXATE;MTHFR;rs1801131;GT;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CLOPIDOGREL;ABCB1;rs1045642;AA;LADME_PK;DECREASED_EXPOSURE;
TACROLIMUS;POR;rs1057868;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;rs9934438;GG;DOSAGE;INCREASED_DOSE;
RIVASTIGMINE;BCHE;rs1803274;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:LEWY_BODY_DISEASE
FENTANYL;CALCA;rs145837941;GG;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
APIXABAN;ABCG2;rs2231142;G;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs1061622;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
DEXMEDETOMIDINE;CYP1A2;rs762551;AC + CC;LADME_PK;INCREASED_CLEARANCE;OTHER:SEDATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs3397;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
LATANOPROST;PTGFR;rs3766355;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:GLAUCOMA,_DISEASE:OCULAR_HYPERTENSION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs1061631;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;MTHFR;rs1801133;AG;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNFRSF1B;rs3397;C;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHADONE;NECTIN4;rs11265549;AA;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:OPIOID-RELATED_DISORDERS
OPIOID ANESTHETICS, OTHER GENERAL ANESTHETICS, VOLATILE ANESTHETICS;OPRM1;rs1799971;GG;EFFICACY;INCREASED_RESPONSE;
OPIOID ANESTHETICS, OTHER GENERAL ANESTHETICS, VOLATILE ANESTHETICS;ABCG2;rs2231142;TT;EFFICACY;INCREASED_RESPONSE;
METHADONE;NECTIN4;rs11265549;AA;DOSAGE;DECREASED_DOSE;OTHER:OPIOID-RELATED_DISORDERS
DEXMEDETOMIDINE;KCNMA1;rs16934182;AA + AG;DOSAGE;DECREASED_DOSE;OTHER:SURGERY
DABIGATRAN;CES1;rs2244613;GG + GT;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
ATORVASTATIN;ABCG8;rs11887534;CC + CG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
CAPECITABINE;DPYD;rs3918290;CT;DOSAGE;DOSE;DISEASE:NEOPLASMS
CAPECITABINE;DPYD;rs56038477;CT;DOSAGE;DOSE;DISEASE:NEOPLASMS
CAPECITABINE;DPYD;rs67376798;AT;DOSAGE;DOSE;DISEASE:NEOPLASMS
DEXMEDETOMIDINE;ADRA2A;rs1800544;GG;DOSAGE;DECREASED_DOSE;OTHER:SURGERY
TAMOXIFEN-N-GLUCURONIDE;UGT1A4;rs2011425;GG + GT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
IMATINIB;CYP2B6;rs3745274;GG + GT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
ATORVASTATIN;CYP7A1;rs3808607;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
METHOTREXATE;ATIC;rs4673993;CC;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
BENAZEPRIL;AGT;rs7079;GG;EFFICACY;RESPONSE;DISEASE:HYPERTENSION
WARFARIN;CYP2C9;rs9332098;GG;DOSAGE;INCREASED_DOSE;
CANNABIDIOL;;rs6729738;CC;EFFICACY;INCREASED_RESPONSE;OTHER:EPILEPSY
METHOTREXATE;MTHFR;rs1801133;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
DEXMEDETOMIDINE;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RESPONSE;OTHER:SURGERY
WARFARIN;CYP2C9;rs9332092;TT;DOSAGE;INCREASED_DOSE;
HYDROCHLOROTHIAZIDE;TXNDC11;rs3784921;G;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
WARFARIN;CYP2C9;rs1057910;CC;LADME_PK;DECREASED_CLEARANCE;
PAROXETINE;CYP1A2;rs762551;A;LADME_PK;INCREASED_DOSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
WARFARIN;CYP2C9;rs1799853;TT;LADME_PK;DECREASED_CLEARANCE;
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
DEXMEDETOMIDINE;KCNMA1;rs16934182;AA + AG;TOXICITY;INCREASED_RESPONSE;OTHER:SURGERY
TOPOTECAN;ABCG2;rs4148157;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BRAIN_NEOPLASMS
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
RIVAROXABAN;CYP3A4;rs2246709;G;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
DULOXETINE;KMT2E;rs117986340;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
RIVASTIGMINE;ACHE;rs2571598;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
MORPHINE;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
DULOXETINE;NCAM1;rs2303377;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
RIVAROXABAN;CYP3A5;rs776746;T;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:HEART_TRANSPLANTATION
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
DULOXETINE;ZNF385D;rs4261893;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
EFAVIRENZ;CYP2B6;rs2279343;AG + GG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
RIVAROXABAN;CYP3A4;rs3735451;C;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
WARFARIN;VKORC1;rs2359612;GG;DOSAGE;INCREASED_DOSE;
WARFARIN;VKORC1;rs7294;TT;DOSAGE;INCREASED_DOSE;
DEXMEDETOMIDINE;;rs141294036;CC;TOXICITY;INCREASED_RESPONSE;OTHER:SURGERY
AMPHETAMINE;CDH13;rs3784943;AG + GG;EFFICACY;INCREASED_RESPONSE;
EVEROLIMUS;CYP3A4;rs35599367;AG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
PRAVASTATIN;SLCO1B1;rs4149056;CT;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_STENOSIS
DEXMEDETOMIDINE;KCNMB1;rs11739136;CC + CT;EFFICACY;INCREASED_RESPONSE;OTHER:SURGERY
MORPHINE;UGT2B7;rs7668282;CC + CT;LADME_PK;DECREASED_METABOLISM;DISEASE:ANEMIA,_SICKLE_CELL
MIVACURIUM;BCHE;rs755648929;AG;EFFICACY;INCREASED_RESPONSE;
SUCCINYLCHOLINE;BCHE;rs772583466;CT;EFFICACY;INCREASED_RESPONSE;
EFAVIRENZ;CYP2A7P1, CYP2B6;rs3745274;T;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:PREGNANCY
DABIGATRAN;CES1;rs8192935;GG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
ETHANOL;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED_DOSE;
METHOTREXATE;CLCN6, MTHFR;rs1801133;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;C1orf167, CLCN6, MTHFR;rs1801131;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;MTR;rs1805087;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
RANIBIZUMAB;CXCL8;rs4073;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
ETHANOL;OPRM1;rs10485057;AA;DOSAGE;INCREASED_DOSE;
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_DOSE;
OPIOIDS;COMT;rs4680;AA + AG;DOSAGE;DECREASED_DOSE;OTHER:PAIN,_OTHER:NEOPLASMS
METHOTREXATE;BIRC5;rs9904341;CG;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ACENOCOUMAROL;VKORC1;rs9934438;GG;EFFICACY;DECREASED_RESPONSE;
SALBUTAMOL;;rs17834628;A;EFFICACY;INCREASED_RESPONSE;
NICOTINE;CHRNA3;rs1051730;A;DOSAGE;DECREASED_DOSE;OTHER:TOBACCO_USE_DISORDER
ABIRATERONE, PREDNISOLONE;TSPYL1;rs3828743;A;EFFICACY;DECREASED_RESPONSE;DISEASE:PROSTATIC_NEOPLASMS
PLATINUM;RICTOR;rs6878291;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
CLOZAPINE;DRD2;rs2514218;T;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
METHOTREXATE;FASTKD3, MTRR;rs1801394;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
RANIBIZUMAB;KDR;rs2071559;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
ETHANOL;OPRM1;rs1799971;AG;OTHER;INCREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
BUSULFAN;GSTA1;rs3957356;CT;LADME_PK;DECREASED_CLEARANCE;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
METHOTREXATE;ATIC;rs12995526;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CLOZAPINE;HTR3A;rs1062613;T;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
METHOTREXATE;ATIC;rs7563206;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
WARFARIN;CYP4F2;rs2108622;CC;DOSAGE;DECREASED_DOSE;
METHOTREXATE;ATIC;rs2372536;CC + CG;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;ATIC;rs4673993;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CANDESARTAN;KCNK3;rs1275988;C;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
RISPERIDONE;NR1I2;rs1523130;CC;LADME_PK;DECREASED_CLEARANCE;DISEASE:BIPOLAR_DISORDER,_DISEASE:DEPRESSION,_DISEASE:SUBSTANCE-RELATED_DISORDERS
SUFENTANIL;ABCB1;rs1045642;GG;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
ADALIMUMAB;IL17F;rs763780;TT;EFFICACY;INCREASED_RESPONSE;
IMMUNOGLOBULINS;CASP3, PRIMPOL;rs113420705;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:MUCOCUTANEOUS_LYMPH_NODE_SYNDROME
SUFENTANIL;COMT;rs4680;AA;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
WARFARIN;VKORC1;rs7294;CC;DOSAGE;DECREASED_CONCENTRATIONS;OTHER:HEART_VALVE_REPLACEMENT
IMMUNOGLOBULINS;COQ8B, ITPKC;rs28493229;CC + CG;EFFICACY;DECREASED_RESPONSE;DISEASE:MUCOCUTANEOUS_LYMPH_NODE_SYNDROME
USTEKINUMAB;IL17F;rs763780;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
INFLIXIMAB;IL17F;rs763780;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
EFAVIRENZ;CYP2B6;rs3745274;TT;DOSAGE, LADME_PK;DECREASED_DOSE;DISEASE:HIV_INFECTIOUS_DISEASE
HYDROCHLOROTHIAZIDE;CSK;rs1378942;C;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
SALBUTAMOL;;rs35661809;G;EFFICACY;INCREASED_RESPONSE;
ANTIPSYCHOTICS;DRD3;rs6280;CT + TT;EFFICACY;INCREASED_RESISTANCE;OTHER:MOOD_DISORDER,_OTHER:SCHIZOPHRENIA
HYDROCHLOROTHIAZIDE;PDE3A;rs12579720;C;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
CANDESARTAN;SULT1C3;rs6722745;T;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
ATENOLOL;STN1;rs4387287;A;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
METFORMIN;;rs10783050;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
METFORMIN;IL1B;rs1143623;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
WARFARIN;VKORC1;rs9923231;TT;LADME_PK;DECREASED_CONCENTRATIONS;
CISPLATIN, PACLITAXEL;TP53;rs1042522;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
RIFAPENTINE;ABCB1;rs1045642;AA + AG;LADME_PK;INCREASED_CLEARANCE;
BEVACIZUMAB, PEGAPTANIB, RANIBIZUMAB;VEGFA;rs2010963;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:CHOROIDAL_NEOVASCULARIZATION
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM,_DISEASE:STOMACH_NEOPLASMS
WARFARIN;VKORC1;rs9923231;CT;EFFICACY;INCREASED_DOSE;OTHER:LEFT_VENTRICULAR_DYSFUNCTION
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;PON1;rs662;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:METASTATIC_NEOPLASM,_DISEASE:STOMACH_NEOPLASMS
RISPERIDONE;NR1I2;rs2276707;CC;LADME_PK;DECREASED_CLEARANCE;DISEASE:BIPOLAR_DISORDER,_DISEASE:DEPRESSION,_DISEASE:SUBSTANCE-RELATED_DISORDERS
EFAVIRENZ;CYP2B6;rs28399499;C;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;rs9923231;CT;EFFICACY;DECREASED_RESPONSE;OTHER:LEFT_VENTRICULAR_DYSFUNCTION
RITUXIMAB;FCGR3A;rs396991;C;EFFICACY;INCREASED_RESPONSE;OTHER:AUTOIMMUNE_DISEASES
NICOTINE;CHRNA3, CHRNA5;rs16969968;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
CLOZAPINE;HTR3A;rs2276302;G;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
IMATINIB;ABCB1;rs2032582;AT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
IMATINIB;ABCG2;rs2231142;T;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
TELMISARTAN;GNB3;rs5443;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
EFAVIRENZ;CYP2B6;rs8192719;T;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
LITHIUM, VALPROIC ACID;;rs2769605;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
CISPLATIN, FLUOROURACIL;GNAS;rs7121;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:NEOPLASM_OF_ESOPHAGUS
ATENOLOL, METOPROLOL;ZMAT4;rs1367094;T;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
ATENOLOL, HYDROCHLOROTHIAZIDE, METOPROLOL;LRRC15;rs11313667;del;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
ONDANSETRON;CYP3A5;rs776746;CC;LADME_PK;DECREASED_METABOLISM;
LITHIUM, OLANZAPINE;DRD2;rs1800497;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BIPOLAR_DISORDER
HMG COA REDUCTASE INHIBITORS;;rs247616;T;EFFICACY;INCREASED_RESPONSE;
BOCEPREVIR, PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;KLRC1;rs7301582;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
HYDROCHLOROTHIAZIDE;PRKAG2;rs10224002;A;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
AGOMELATINE, MELATONIN RECEPTOR AGONISTS, SELECTIVE SEROTONIN REUPTAKE INHIBITORS, VENLAFAXINE;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSIVE_DISORDER
ADALIMUMAB, CERTOLIZUMAB PEGOL, ETANERCEPT, GLUCOCORTICOIDS, INFLIXIMAB, METHOTREXATE;KLRD1;rs2302489;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
HYDROCHLOROTHIAZIDE;PLCE1;rs932764;A;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
METOPROLOL;;rs1446468;T;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
ATENOLOL;RRP1B;rs9306160;T;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
ATENOLOL;TBX2;rs8068318;C;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
AMISULPRIDE;DRD2;rs1079597;C;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
USTEKINUMAB;NFKBIA;rs2145623;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
HYDROCHLOROTHIAZIDE;ADO;rs10995311;C;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
PLATINUM COMPOUNDS;XBP1;rs2269577;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
CANDESARTAN;DOT1L, PLEKHJ1;rs740406;A;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
USTEKINUMAB;ADAM33;rs2787094;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
HYDROCHLOROTHIAZIDE;NUCB2;rs757081;C;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
USTEKINUMAB;;rs1975974;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
EXENATIDE;KCNQ1;rs163184;G;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE,_DISEASE:TUBERCULOSIS
USTEKINUMAB;AGBL4;rs191190;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
NORTRIPTYLINE;SLC39A14;rs17060812;C;EFFICACY;INCREASED_RESPONSE;DISEASE:DEPRESSION
ACENOCOUMAROL;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE;
USTEKINUMAB;CHUK;rs11591741;CC + CG;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
USTEKINUMAB;HTR2A;rs6311;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
WARFARIN;VKORC1;rs9923231;CC + CT;DOSAGE;INCREASED_DOSE;
HYDROCHLOROTHIAZIDE;C5orf56;rs12521868;G;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
CANDESARTAN;SH2B3;rs3184504;T;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
CARBAMAZEPINE;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
APIXABAN;ABCG2;rs2231142;GG + GT;LADME_PK;INCREASED_CLEARANCE;DISEASE:ATRIAL_FIBRILLATION
CARBAMAZEPINE;CYP3A5;rs15524;AA;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
PAROXETINE;COMT;rs4680;A;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
CAPECITABINE, PACLITAXEL;TP53;rs1042522;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
SUFENTANIL;CYP3A4;rs2242480;CC;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
TRIGLYCERIDES;CYP19A1;rs749292;A;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS,_DISEASE:MENOPAUSE
HDL CHOLESTEROL;CYP19A1;rs1062033;G;OTHER;INCREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS,_DISEASE:MENOPAUSE
EFAVIRENZ;CYP2B6;rs28399499;C;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
CLOBAZAM;POR;rs1057868;TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:EPILEPSY
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_DISEASES
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;OTHER:HEART_VALVE_REPLACEMENT
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
NORTRIPTYLINE;PPM1A;rs2273623;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:DEPRESSION
AMILORIDE, SPIRONOLACTONE;CYP4A11;rs1126742;GG;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;TT;DOSAGE;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES
DEFERASIROX;UGT1A3;rs3806596;CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
LOPINAVIR;CYP3A5;rs776746;C;LADME_PK;INCREASED_TROUGH CONCENTRATION;OTHER:HIV_INFECTIOUS_DISEASE
PROPOFOL;CYP2B6;rs2279343;AA + AG;LADME_PK;DECREASED_CLEARANCE;
SPIRONOLACTONE;CYP4A11;rs3890011;CC;EFFICACY;DECREASED_RESPONSE;OTHER:HYPERTENSION
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
ATAZANAVIR;NR1I2;rs2472677;TT;LADME_PK;INCREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
RIFAMPIN;AADAC;rs1803155;AA;LADME_PK;DECREASED_CLEARANCE;OTHER:TUBERCULOSIS
APATINIB, APATINIB METABOLITE M1-1;CYP2C9;rs1934968;GG;LADME_PK;INCREASED_EXPOSURE;OTHER:NEOPLASMS
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;rs11075995;AT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:NEOPLASMS
AMPRENAVIR;SLCO1B1;rs4149056;C;LADME_PK;DECREASED_TROUGH CONCENTRATION;OTHER:HIV_INFECTIOUS_DISEASE
ACAMPROSATE;;rs77583603;G;EFFICACY;DECREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
EVEROLIMUS;CYP3A5;rs776746;CC + CT;LADME_PK;DECREASED_CLEARANCE;DISEASE:HEART_TRANSPLANTATION
NALTREXONE;;rs12749274;A;EFFICACY;DECREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
DEFERASIROX;ABCG2;rs13120400;CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:BETA-THALASSEMIA_AND_RELATED_DISEASES
FLUVASTATIN;SLCO1B1;rs4149056;CC + CT;EFFICACY;INCREASED_CLINICAL BENEFIT;
FLUVASTATIN;APOE;rs429358;CC;EFFICACY;INCREASED_CLINICAL BENEFIT;
DOXORUBICIN;CBR1;rs20572;CC;LADME_PK;INCREASED_CLEARANCE;DISEASE:BREAST_NEOPLASMS
DEHYDROARIPIPRAZOLE;CYP1A2;rs762551;AA;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
CLOZAPINE;CYP1A2;rs762551;AA;LADME_PK;DECREASED_EXPOSURE;OTHER:SCHIZOPHRENIA,_OTHER:TOBACCO_USE_DISORDER
ETHANOL;OPRM1;rs1799971;AA;DOSAGE;INCREASED_DOSE;
PREDNISOLONE;GATA3;rs3824662;AA;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TACROLIMUS;GSTM3;rs7483;TT;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:LIVER_TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;rs1051792;AG;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
ADALIMUMAB;TNF;rs1799724;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MICA;rs1051792;GG;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
FLUOXETINE;HTR1B;rs130058;AA + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:MENTAL_DISORDERS
ADALIMUMAB;TNF;rs1800629;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CLOZAPINE;CYP1A2;rs762551;AA;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA
FLUVASTATIN;APOE;rs7412;TT;EFFICACY;INCREASED_CLINICAL BENEFIT;
ADALIMUMAB;TNF;rs361525;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CARBAMAZEPINE;CYP1A2;rs762551;AA;LADME_PK;INCREASED_CLEARANCE;OTHER:EPILEPSY
MORPHINE;SLC6A4;rs1042173;CC;DOSAGE;DECREASED_DOSE;OTHER:LUNG_NEOPLASMS,_OTHER:PAIN
FLUOROURACIL;ABCA2;rs2271862;G;LADME_PK;INCREASED_CLEARANCE;OTHER:COLORECTAL_NEOPLASMS
FLUOXETINE;TPH2;rs4570625;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:MENTAL_DISORDERS
5'-DEOXY-5-FLUOROURIDINE;ABCG5;rs6720173;C;LADME_PK;INCREASED_CLEARANCE;OTHER:COLORECTAL_NEOPLASMS
METHOTREXATE;ADORA2A-AS1;rs17004921;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
ANTIEPILEPTICS;ABCB1;rs2032582;AA;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
ANTIEPILEPTICS;ABCB1;rs1045642;AA;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
ATENOLOL, HYDROCHLOROTHIAZIDE;;rs35123024;C;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
ATENOLOL, HYDROCHLOROTHIAZIDE;ALDH1A2;rs261316;T;EFFICACY;DECREASED_RESPONSE;DISEASE:HYPERTENSION
CISPLATIN;REV3L;rs462779;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:OSTEOSARCOMA
CISPLATIN;REV1;rs3087403;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:OSTEOSARCOMA
ANTIEPILEPTICS;SCN1A;rs2298771;CC + CT;EFFICACY;INCREASED_RESISTANCE;OTHER:EPILEPSY
LOPINAVIR;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_TROUGH CONCENTRATION;OTHER:HIV_INFECTIOUS_DISEASE
FENTANYL;OPRM1;rs9384179;AA;DOSAGE, EFFICACY;INCREASED_DOSE;SIDE_EFFECT:PAIN,_POSTOPERATIVE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
FLUVASTATIN;CYP2C9;rs1057910;AC;LADME_PK;INCREASED_CONCENTRATIONS;
FENTANYL;KCNJ6;rs2835859;TT;DOSAGE, EFFICACY;INCREASED_DOSE;SIDE_EFFECT:PAIN,_POSTOPERATIVE
ABIRATERONE;HSD3B1;rs1047303;AC;LADME_PK;INCREASED_METABOLISM;OTHER:PROSTATIC_NEOPLASMS
FENTANYL;;rs2952768;CC;DOSAGE, EFFICACY;INCREASED_DOSE;SIDE_EFFECT:PAIN,_POSTOPERATIVE
FENTANYL;;rs11959113;AA;DOSAGE, EFFICACY;INCREASED_DOSE;SIDE_EFFECT:PAIN,_POSTOPERATIVE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:HEART_TRANSPLANTATION
CYCLOPHOSPHAMIDE;GSTA1;rs3957356;CT;EFFICACY, TOXICITY, LADME_PK;DECREASED_RESPONSE;DISEASE:LUPUS_NEPHRITIS
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
BILIRUBIN;SOD2;rs4880;GG;TOXICITY;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:HEART_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
METHYLPHENIDATE;SLC6A2;rs5569;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
TACROLIMUS;POR;rs1057868;CT + TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:HEART_TRANSPLANTATION
IVACAFTOR;CFTR;rs77010898;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:CYSTIC_FIBROSIS
DOCETAXEL, DOXORUBICIN;AKR1C3;rs1937840;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS
ANTIDEPRESSANTS;GRIK4;rs1954787;TT;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
ANTIDEPRESSANTS;GRIK4;rs1954787;C;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_DOSE;OTHER:AN_INTERNATIONAL_NORMALIZED_RATIO_(INR)_OF_2.0-3.0
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;rs7294;T;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
WARFARIN;CYP2C9;rs1057910;A;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_DOSE;
BUPRENORPHINE;OPRM1;rs2075572;CC + CG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:OPIOID-RELATED_DISORDERS
SELECTIVE SEROTONIN (5HT1) AGONISTS;PRDM16;rs2651899;C;EFFICACY;INCREASED_RESPONSE;OTHER:MIGRAINE_WITH_AURA,_OTHER:MIGRAINE_WITHOUT_AURA
AFATINIB;NR1I2;rs6785049;AA + AG;LADME_PK;DECREASED_CLEARANCE;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA
WARFARIN;CYP2C9;rs4917639;C;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
LOPINAVIR;SLCO1B1;rs4149056;CT;LADME_PK;INCREASED_EXPOSURE;OTHER:HIV_INFECTIOUS_DISEASE
NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ALCOHOL_ABUSE
ANTIDEPRESSANTS;ABCB1;rs1128503;A;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
METHADONE;COMT;rs933271;CC + CT;EFFICACY;INCREASED_RESPONSE;OTHER:OPIOID-RELATED_DISORDERS
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs2070959;AG;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
METHOTREXATE;MTHFR;rs1801131;GT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
VALPROIC ACID;GRIN2B;rs1019385;AC;DOSAGE, LADME_PK;DECREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;GRIN2B;rs1019385;CC;DOSAGE, LADME_PK;DECREASED_DOSE;DISEASE:EPILEPSY
METHOTREXATE;SLC19A1;rs1051266;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
CARBAMAZEPINE, CLOBAZAM, ETHOSUXIMIDE, LAMOTRIGINE, LEVETIRACETAM, OXCARBAZEPINE, VALPROIC ACID;SCN1A;rs2298771;C;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
LOPINAVIR;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_TROUGH CONCENTRATION;OTHER:HIV_INFECTIOUS_DISEASE
VALPROIC ACID;UGT1A6;rs1105879;AC;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
FLUVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE;
EVEROLIMUS;CYP3A5;rs776746;CT;LADME_PK;DECREASED_TROUGH CONCENTRATION;OTHER:BREAST_NEOPLASMS,_OTHER:KIDNEY_NEOPLASMS,_OTHER:NEUROENDOCRINE_TUMORS
WARFARIN;CYP4F2;rs2108622;C;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
AMISULPRIDE;SNAP25;rs8636;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CLOPIDOGREL;ABCA1;rs2487032;A;LADME_PK;INCREASED_METABOLISM;
CLOPIDOGREL;N6AMT1;rs2254638;G;LADME_PK;DECREASED_METABOLISM;
TENOFOVIR;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
SIROLIMUS;ABCB1;rs2032582;A;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEMATOPOIETIC_STEM_CELL_TRANSPLANTATION
ANTIPSYCHOTICS;NRXN1;rs12467557;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;NRXN1;rs10490162;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
CLOPIDOGREL;CYP2C19;rs4986893;AA;EFFICACY;DECREASED_RESPONSE;
DABIGATRAN;CES1;rs8192935;GG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:ATRIAL_FIBRILLATION
ADALIMUMAB, CERTOLIZUMAB PEGOL, GOLIMUMAB, INFLIXIMAB;TNF;rs1800629;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:BEHCET_SYNDROME
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY;DECREASED_RESPONSE;
TACROLIMUS;CYP3A5;rs776746;CC;OTHER, LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
BEVACIZUMAB;CFH;rs1061170;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs2070959;GG;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
CISPLATIN, FLUOROURACIL;DPYD;rs3918290;CT;EFFICACY;DECREASED_RESPONSE;DISEASE:HEAD_AND_NECK_NEOPLASMS
CISPLATIN, DOCETAXEL, IRINOTECAN;XRCC3;rs861539;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs6759892;GG;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs6759892;GT;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
VALPROIC ACID;UGT1A6;rs1105879;CC;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
10-MONOHYDROXY OXCARBAZEPINE;INSR;rs2396185;C;LADME_PK;DECREASED_CLEARANCE;OTHER:EPILEPSY
ETHANOL;OPRM1;rs1799971;AG;EFFICACY;INCREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
RISPERIDONE;HTR1A;rs6295;GG;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
FENTANYL;CACNA1E;rs3845446;CC + CT;DOSAGE;DECREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
FENTANYL;LAMB3;rs2076222;G;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE:PAIN,_POSTOPERATIVE
CETUXIMAB;VEGFA;rs833061;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
CETUXIMAB;VEGFA;rs1570360;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
CISPLATIN, FLUOROURACIL, MITOXANTRONE;MECP2;rs1734791;A;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;MECP2;rs1734787;A;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;MECP2;rs17435;A;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs5906072;T;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
PROCHLORPERAZINE;ANKK1, DRD2;rs1800497;AA + AG;EFFICACY;DECREASED_RESPONSE;OTHER:NAUSEA
PROCHLORPERAZINE;DRD2;rs1079597;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER:NAUSEA
METFORMIN;ATM;rs11212617;AC;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
MORPHINE;OPRK1;rs1051660;A;DOSAGE, EFFICACY;DECREASED_DOSE;DISEASE:PAIN
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs12613732;G;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs5009910;C;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
ATORVASTATIN;HMGCR;rs17671591;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
ESCITALOPRAM;TPH1;rs1800532;GT + TT;EFFICACY;DECREASED_RESPONSE;OTHER:DEPRESSION
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs6752303;C;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs10209881;C;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
DABIGATRAN;CES1;rs2244613;GG;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:ATRIAL_FIBRILLATION
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs12999804;A;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
TACROLIMUS;CYP3A4;rs2740574;TT;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
APATINIB, APATINIB METABOLITE M1-1;CYP2C9;rs34532201;TT;LADME_PK;INCREASED_EXPOSURE;OTHER:NEOPLASMS
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs5934731;C;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs715171;C;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs4932551;C;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs7170769;T;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;;rs6458232;C;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs7608731;C;EFFICACY;RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs758900656;A;LADME_PD;INCREASED_CLINICAL BENEFIT;
ALLOPURINOL, FEBUXOSTAT;AOX1;rs3731722;G;DOSAGE;DOSE;DISEASE:GOUT
PAZOPANIB;CYP3A4;rs35599367;AG;LADME_PK;DECREASED_CLEARANCE;OTHER:NEOPLASMS
RITUXIMAB;IL2;rs6822844;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:AUTOIMMUNE_DISEASES
TACROLIMUS;CYP3A5;rs776746;TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
RITUXIMAB;IL2;rs6822844;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:SYSTEMIC_LUPUS_ERYTHEMATOSUS
ALLOPURINOL, FEBUXOSTAT;AOX1;rs11678615;T;DOSAGE;DOSE;DISEASE:GOUT
METHOTREXATE;MTHFR;rs1801131;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ALLOPURINOL, FEBUXOSTAT;UGT1A1, UGT1A10, UGT1A3, UGT1A4, UGT1A5, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs34650714;T;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
ALLOPURINOL, FEBUXOSTAT;XDH;rs1884725;G;DOSAGE;DECREASED_DOSE;DISEASE:GOUT
ALLOPURINOL, FEBUXOSTAT;AOX1;rs75995567;T;DOSAGE;INCREASED_DOSE;DISEASE:GOUT
WARFARIN;CYP4F2;rs2108622;T;DOSAGE, LADME_PK;DOSE;
WARFARIN;VKORC1;rs9923231;T;DOSAGE, LADME_PK;DOSE;
WARFARIN;GGCX;rs699664;T;DOSAGE, LADME_PK;DOSE;
METFORMIN;SLC22A1;rs622342;AC;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
PROPOFOL, REMIFENTANIL;ABCB1;rs1128503;GG;EFFICACY;INCREASED_RESPONSE;
METHOTREXATE;ABCC3;rs4148416;TT;LADME_PK;INCREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TACROLIMUS;CYP3A4;rs2740574;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
METHOTREXATE;SLC19A1;rs17004785;CG;LADME_PK;INCREASED_CLEARANCE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
DONEPEZIL;BCHE;rs1803274;T;EFFICACY;INCREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
CISPLATIN, DOXORUBICIN, METHOTREXATE;MTHFD1;rs2236225;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER:OSTEOSARCOMA
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs9679162;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATOCELLULAR_CARCINOMA
PAROXETINE;GDNF;rs2973049;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
PAROXETINE;GDNF;rs2216711;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL17RA;rs4819554;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
ATOMOXETINE;SLC6A2;rs3785143;T;EFFICACY;DECREASED_RESPONSE;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
PAROXETINE;BDNF;rs6265;CC + CT;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR3A;rs396991;AC + CC;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
ROSUVASTATIN;CETP;rs5882;G;EFFICACY;INCREASED_RESPONSE;
DISULFIRAM;DBH;rs1611115;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:ALCOHOL_ABUSE
RIVAROXABAN;CYP3A5;rs776746;TT;LADME_PK;INCREASED_STEADY_STATE CONCENTRATION;OTHER:ATRIAL_FIBRILLATION
RISPERIDONE;COMT;rs9606186;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RIVAROXABAN;ABCB1;rs1045642;AA + AG;LADME_PK;INCREASED_CLEARANCE;OTHER:ATRIAL_FIBRILLATION
TACROLIMUS;C6;rs10052999;CC + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
WARFARIN;VKORC1;rs9934438;GG;DOSAGE;INCREASED_DOSE;
TACROLIMUS;C6;rs9200;CC + CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
CISPLATIN, DOXORUBICIN, METHOTREXATE;ABCC2;rs717620;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER:OSTEOSARCOMA
RISPERIDONE;RGS4;rs2661319;C;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
LAMOTRIGINE;SLC22A1;rs628031;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
RISPERIDONE;ANKK1;rs1800497;A;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
TACROLIMUS;CYP3A4;rs2740574;CT;LADME_PK;INCREASED_DOSE;OTHER:TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
CISPLATIN, DOXORUBICIN, METHOTREXATE;GSTP1;rs1695;AG + GG;EFFICACY;DECREASED_RESPONSE;OTHER:OSTEOSARCOMA
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
PHENYTOIN;CYP2C9;rs1057910;C;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
CARBAMAZEPINE;SCN1A;rs3812718;TT;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
PHENYTOIN;SCN1A;rs3812718;T;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
INDINAVIR;CYP3A4;rs2740574;CC;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;ABCB1;rs2032582;T;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
ALPHA-HYDROXYMETOPROLOL;CYP2D6;rs28371738;A;LADME_PK;INCREASED_CONCENTRATIONS;
RIVAROXABAN;ABCB1;rs1128503;AG + GG;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
LANSOPRAZOLE;ABCB1;rs1045642;G;OTHER, LADME_PK;INCREASED_METABOLISM;
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;HTR1A;rs10042486;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
LAMOTRIGINE;ABCG2;rs2231142;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
RIVAROXABAN;ABCB1;rs1045642;AG + GG;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
RIVAROXABAN;ABCB1;rs4148738;T;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ATRIAL_FIBRILLATION
PHENYTOIN;CYP2C9;rs1934969;AT + TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:EPILEPSY
DEXAMETHASONE, DIPHENHYDRAMINE, PACLITAXEL, RANITIDINE;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:HEAD_AND_NECK_NEOPLASMS
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION,_DISEASE:HEART_VALVE_REPLACEMENT,_DISEASE:PULMONARY_HYPERTENSION,_DISEASE:PULMONARY_EMBOLISM,_DISEASE:VENOUS_THROMBOSIS
HMG COA REDUCTASE INHIBITORS;APOC1;rs4420638;G;EFFICACY;DECREASED_RESPONSE;DISEASE:CARDIOVASCULAR_DISEASE,_DISEASE:HYPERCHOLESTEROLEMIA
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE;DECREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION,_DISEASE:HEART_VALVE_REPLACEMENT,_DISEASE:PULMONARY_HYPERTENSION,_DISEASE:PULMONARY_EMBOLISM,_DISEASE:VENOUS_THROMBOSIS
PHOTODYNAMIC THERAPY;F13A1;rs5985;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE:CHOROIDAL_NEOVASCULARIZATION
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION,_DISEASE:HEART_VALVE_REPLACEMENT,_DISEASE:PULMONARY_HYPERTENSION,_DISEASE:PULMONARY_EMBOLISM,_DISEASE:VENOUS_THROMBOSIS
CITALOPRAM;TPH1;rs1800532;GT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
HMG COA REDUCTASE INHIBITORS;NPC1L1;rs2072183;G;EFFICACY;DECREASED_RESPONSE;DISEASE:CARDIOVASCULAR_DISEASE,_DISEASE:HYPERCHOLESTEROLEMIA
HMG COA REDUCTASE INHIBITORS;SORT1;rs629301;T;EFFICACY;DECREASED_RESPONSE;DISEASE:CARDIOVASCULAR_DISEASE,_DISEASE:HYPERCHOLESTEROLEMIA
MERCAPTOPURINE;NUDT15;rs116855232;CT;DOSAGE;DECREASED_DOSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
MYCOPHENOLIC ACID;UGT1A9;rs3832043;del;LADME_PK;DECREASED_METABOLISM;DISEASE:KIDNEY_TRANSPLANTATION
BISOPROLOL;ACY3;rs2514036;T;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
MYCOPHENOLIC ACID;SLCO1B1;rs2306283;AA + AG;LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
IMATINIB;BCL2L11;rs724710;T;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
FLUOROURACIL;DPYD;rs3918290;CT;LADME_PK;DECREASED_CLEARANCE;DISEASE:COLORECTAL_NEOPLASMS
METOPROLOL;SEPTIN3;rs56234624;G;LADME_PK;INCREASED_CONCENTRATIONS;
ALEMTUZUMAB, CHLORAMBUCIL, CYCLOPHOSPHAMIDE, FLUDARABINE, PREDNISONE, RITUXIMAB, VINCRISTINE;CXCL12;rs1801157;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:B-CELL_CHRONIC_LYMPHOCYTIC_LEUKEMIA
MYCOPHENOLIC ACID;ABCC2;rs3740066;CT;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:LUNG_TRANSPLANTATION
GEMCITABINE;RRM1;rs9937;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
TACROLIMUS;ABCB1;rs1045642;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:LUNG_TRANSPLANTATION
BEVACIZUMAB;CXCL8;rs4073;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
GEMCITABINE;RRM1;rs183484;AC;EFFICACY, TOXICITY;DECREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
HYDROCHLOROTHIAZIDE;NEDD4L;rs4149601;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
SN-38;UGT1A1;rs4148323;AA;DOSAGE;INCREASED_CONCENTRATIONS;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA
COTININE GLUCURONIDE;UGT1A9;rs12471326;CT;LADME_PK;INCREASED_CONCENTRATIONS;
NICOTINE;CYP2A6;rs145014075;GT;LADME_PK;INCREASED_CONCENTRATIONS;
BEVACIZUMAB, RANIBIZUMAB;VEGFA;rs3025000;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
GRANISETRON;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESPONSE;SIDE_EFFECT:NAUSEA,_SIDE_EFFECT:VOMITING
WARFARIN;VKORC1;rs9923231;CC + CT;DOSAGE;INCREASED_DOSE;OTHER:HEART_FAILURE
CARBAMAZEPINE;SCN1A;rs3812718;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
BEVACIZUMAB, RANIBIZUMAB;VEGFA;rs3025000;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:MACULAR_DEGENERATION
CARBAMAZEPINE;SCN1A;rs3812718;TT;DOSAGE;INCREASED_DOSE;DISEASE:EPILEPSY
ETANERCEPT;CD84;rs6427528;AG;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
LOPINAVIR;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_TROUGH CONCENTRATION;OTHER:HIV_INFECTIOUS_DISEASE
CARBAMAZEPINE;SCN1A;rs2298771;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
METHADONE;OPRM1;rs10485058;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
CARBAMAZEPINE;GABRA1;rs2290732;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_DOSE;
USTEKINUMAB;IL12B;rs3213094;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
GEMCITABINE;CDA;rs2072671;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:PANCREATIC_NEOPLASMS
TOCILIZUMAB;IL6R;rs11265618;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
TOCILIZUMAB;IL6R;rs12083537;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
EFAVIRENZ;ABCB1;rs2032582;AA;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
ALFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;DISEASE:PAIN
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;ABCB1;rs1045642;AA;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CETUXIMAB;FCGR3A;rs396991;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:HEAD_AND_NECK_NEOPLASMS
CETUXIMAB;FCGR2A;rs1801274;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HEAD_AND_NECK_NEOPLASMS
EFAVIRENZ;HNF4A;rs1884613;CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
METHADONE;ALDH5A1;rs2760118;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:OPIOID-RELATED_DISORDERS
ATAZANAVIR;UGT1A1;rs887829;TT;TOXICITY;INCREASED_DISCONTINUATION;
PLATINUM COMPOUNDS;XRCC1;rs25487;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS,_DISEASE:STOMACH_NEOPLASMS
OLANZAPINE;CHAT;rs1880676;A;DOSAGE, EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RAMIPRIL;ACE;rs4359;CC + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
RAMIPRIL;ACE;rs4344;AA + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERTENSION
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;DOSE;
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:GLOMERULONEPHRITIS,_MEMBRANOUS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
OXYCODONE;OPRD1;rs581111;AA + AG;EFFICACY;DECREASED_RESPONSE;
PEGINTERFERON ALFA-2B, RIBAVIRIN;KLRK1;rs1049174;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
CITALOPRAM;CRHR2;rs2270007;CC + CG;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
RIFAMPIN;NR1I2;rs3732357;AA + AG;LADME_PK;DECREASED_EXPOSURE;OTHER:TUBERCULOSIS
METHOTREXATE;SLC19A1;rs1051266;CT + TT;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:OSTEOSARCOMA
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
OXYCODONE;;rs6848893;CT;EFFICACY;DECREASED_RESPONSE;
PLATINUM COMPOUNDS;ATP7B;rs9535826;G;EFFICACY;INCREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
DEXAMETHASONE;NR3C1;rs6198;CC;EFFICACY;INCREASED_TIME TO RESPONSE;OTHER:COVID-19
ANTIDEPRESSANTS;HTR2A;rs6313;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER:BIPOLAR_DISORDER,_OTHER:DEPRESSION,_OTHER:MAJOR_DEPRESSIVE_DISORDER
PLATINUM COMPOUNDS;ATP7B;rs9535828;A;EFFICACY;INCREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
DEXAMETHASONE;NR3C1;rs33388;AA;EFFICACY;INCREASED_TIME TO RESPONSE;OTHER:COVID-19
RISPERIDONE;CCL2;rs4795893;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
RISPERIDONE;CCL2;rs4586;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
METHOTREXATE;FPGS;rs1544105;TT;EFFICACY;INCREASED_RESPONSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
METHOTREXATE;FPGS;rs1544105;TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
DEXAMETHASONE;NR3C1;rs33389;TT;EFFICACY;INCREASED_TIME TO RESPONSE;OTHER:COVID-19
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
ATORVASTATIN, ROSUVASTATIN, SIMVASTATIN;ABCA1;rs769705621;AAAA;EFFICACY;DECREASED_RESPONSE;OTHER:FAMILIAL_HYPERCHOLESTEROLEMIA
CORTICOSTEROIDS, SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS;ADRB2;rs1042713;A;EFFICACY;DECREASED_RESPONSE;DISEASE:ASTHMA
RISPERIDONE;CCL2;rs2857657;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
LAMOTRIGINE;UGT1A4;rs2011425;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:EPILEPSY
MERCAPTOPURINE;ITPA;rs1127354;A;LADME_PK;METABOLISM;DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
LAMOTRIGINE;UGT1A4;rs2011425;TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:EPILEPSY
WARFARIN;CYP2C9;rs1057910;C;DOSAGE;DECREASED_DOSE;
EFAVIRENZ;CYP2B6;rs28399499;CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
NICOTINE;CHRNB3;rs4950;G;EFFICACY, OTHER;INCREASED_RESPONSE;OTHER:SMOKERS
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
PLATINUM COMPOUNDS;HMGB1;rs1412125;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR9;rs352139;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
NICOTINE;CHRNB3;rs13280604;G;EFFICACY, OTHER;INCREASED_RESPONSE;OTHER:SMOKERS
WARFARIN;VKORC1;rs749671;G;DOSAGE;INCREASED_DOSE;
DEXAMETHASONE;CYP3A4;rs35599367;AG;EFFICACY;INCREASED_TIME TO RESPONSE;OTHER:COVID-19
PLATINUM COMPOUNDS;HMGB1;rs2249825;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
EFAVIRENZ;CYP2B6;rs2279343;G;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
CISPLATIN, RADIOTHERAPY;XRCC1;rs25487;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:NASOPHARYNGEAL_NEOPLASMS,_DISEASE:TOBACCO_USE_DISORDER
LOSARTAN;ACE;rs4291;AT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HYPERTENSION
VEGF/VEGFR (VASCULAR ENDOTHELIAL GROWTH FACTOR) INHIBITORS;VEGFA;rs699947;AC + CC;EFFICACY;INCREASED_RESPONSE;OTHER:MACULAR_DEGENERATION
ACENOCOUMAROL;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
OXYCODONE;COMT;rs4680;AA + AG;EFFICACY;INCREASED_RESPONSE;
ADALIMUMAB, INFLIXIMAB;IL12B;rs2546890;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
TACROLIMUS;CYP3A4;rs2740574;T;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ADALIMUMAB, INFLIXIMAB;IVL;rs6661932;CT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
OPIOIDS;COMT;rs4680;AA + AG;DOSAGE;INCREASED_DOSE;OTHER:PAIN
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
USTEKINUMAB;TIRAP;rs8177374;CT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
NICOTINE;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_EXPOSURE;OTHER:SCHIZOPHRENIA
USTEKINUMAB;TLR5;rs5744174;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs11938228;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;LY96;rs11465996;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TLR2;rs4696480;AT + TT;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
TACROLIMUS;CYP3A5;rs776746;C;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS, USTEKINUMAB;IL1B;rs1143623;CG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
WARFARIN;ABCB1;rs1045642;A;DOSAGE;INCREASED_DOSE;
WARFARIN;APOE;rs429358;CC + CT;DOSAGE;DECREASED_DOSE;
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS, USTEKINUMAB;IL1B;rs1143627;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
REPAGLINIDE;NR1I2;rs2276706;GG;LADME_PK;DECREASED_METABOLISM;
COTININE;OPRM1;rs510769;T;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
RISPERIDONE;COMT;rs9606186;C;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
REPAGLINIDE;NR1I2;rs3814058;CC;LADME_PK;DECREASED_METABOLISM;
ATEZOLIZUMAB, BEVACIZUMAB;IL7;rs16906115;AA;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:HEPATOCELLULAR_CARCINOMA
COTININE;OPRM1;rs12209447;T;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
RISPERIDONE;COMT;rs2020917;C;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
COTININE;OPRM1;rs3798676;T;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED_DOSE;
FENTANYL;ABCB1;rs1045642;AA;DOSAGE;DECREASED_DOSE;
RISPERIDONE;COMT;rs933271;C;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
COTININE;OPRM1;rs553202;T;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
COTININE;OPRM1;rs1074287;G;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
METHADONE;OPRD1;rs529520;AA + AC;DOSAGE;INCREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION
COTININE;OPRM1;rs1799971;A;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
COTININE;OPRM1;rs6912029;T;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
PREDNISONE;EDNRA;rs5333;CC + CT;EFFICACY;INCREASED_RESISTANCE;DISEASE:NEPHROTIC_SYNDROME
REPAGLINIDE;NR1I2;rs3814058;CC;LADME_PK;INCREASED_METABOLISM;
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;TLR4;rs1927907;CC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:LIVER_TRANSPLANTATION
PAZOPANIB;NR1I2;rs3814055;T;EFFICACY;DECREASED_RESPONSE;DISEASE:RENAL_CELL_CARCINOMA
ACENOCOUMAROL;CYP4F2;rs2108622;T;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
ADALIMUMAB, INFLIXIMAB;ZNF816;rs9304742;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
ACENOCOUMAROL;CALU;rs1043550;G;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HIV_INFECTIOUS_DISEASE
TACROLIMUS;IL18;rs1946518;GG + GT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
ADALIMUMAB, INFLIXIMAB;NFKBIA;rs2145623;CC + CG;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
ADALIMUMAB, INFLIXIMAB;TNFRSF1B;rs1061624;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
REPAGLINIDE;NR1I2;rs2276706;GG;LADME_PK;INCREASED_METABOLISM;
ADALIMUMAB, INFLIXIMAB;SLC9A8;rs645544;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
FLUOROURACIL, PLATINUM COMPOUNDS, RADIOTHERAPY;XRCC4;rs10040363;G;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
FENTANYL, REMIFENTANIL;OPRM1;rs79910351;TT;EFFICACY;DECREASED_RESPONSE;
FLUOROURACIL, PLATINUM COMPOUNDS, RADIOTHERAPY;XRCC4;rs2075685;T;EFFICACY;DECREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
MYCOPHENOLIC ACID;SLCO1B1;rs4149056;TT;LADME_PK;INCREASED_EXPOSURE;OTHER:KIDNEY_TRANSPLANTATION
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE;
SIMVASTATIN;PPARA;rs4253728;AA + AG;LADME_PK;DECREASED_CLEARANCE;
FLUOROURACIL, PLATINUM COMPOUNDS, RADIOTHERAPY;ERCC1;rs2298881;A;EFFICACY;INCREASED_RESPONSE;DISEASE:STOMACH_NEOPLASMS
COTININE;OPRM1;rs563649;T;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
COTININE;OPRM1;rs2075572;G;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
SIMVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE;
COTININE;OPRM1;rs7748401;G;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
COTININE;OPRM1;rs495491;G;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
COTININE;OPRM1;rs10457090;G;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
COTININE;OPRM1;rs3778152;G;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
PRAVASTATIN;SLCO1B1;rs4149056;TT;EFFICACY;INCREASED_RESPONSE;
COTININE;OPRM1;rs589046;T;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:HEROIN_DEPENDENCE
METHOTREXATE;NR1I2;rs3814055;T;LADME_PK;DECREASED_METABOLISM;DISEASE:OSTEOSARCOMA
METHOTREXATE;SLCO1B1;rs2306283;AA + AG;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHOTREXATE;ABCC3;rs4793665;C;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:OSTEOSARCOMA
METHOTREXATE;NR1I2;rs7643038;G;LADME_PK;DECREASED_METABOLISM;DISEASE:OSTEOSARCOMA
METHOTREXATE;ABCB1;rs9282564;C;LADME_PK;INCREASED_CONCENTRATIONS;
METHOTREXATE;ABCG2;rs2231142;T;LADME_PK;DECREASED_METABOLISM;DISEASE:OSTEOSARCOMA
GLUCOCORTICOIDS;;rs17446593;AA;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:THROMBOCYTOPENIA
SUNITINIB;CYP3A5;rs776746;CC;LADME_PK;DECREASED_CLEARANCE;
CLOZAPINE;NTRK2;rs10465180;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:SCHIZOPHRENIA
SIMVASTATIN;CYP3A5;rs776746;TT;LADME_PK;INCREASED_CLEARANCE;
SIMVASTATIN ACID;SLCO1B1;rs4149056;CT;LADME_PK;DECREASED_CLEARANCE;
SIMVASTATIN;SLCO2B1;rs12422149;AA;LADME_PK;INCREASED_CLEARANCE;
WARFARIN;CYP2C9;rs9332238;G;DOSAGE;INCREASED_DOSE;
CLOPIDOGREL;P2RY12;rs6809699;AA + AC;EFFICACY;INCREASED_RESISTANCE;OTHER:CORONARY_DISEASE
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
DOXORUBICIN;CBR1;rs20572;CC;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;ADRA2A;rs1800544;CG;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ERLOTINIB;ABCB1;rs1045642;AA;TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
ERLOTINIB;ABCB1;rs1128503;AA;TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
NICOTINE;CYP2A6;rs28399468;A;LADME_PK;DECREASED_METABOLISM;
METHOTREXATE;ABCC1;rs28364006;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
DOLUTEGRAVIR;NR1I2;rs2472677;TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
ERLOTINIB;ABCB1;rs2032582;AA;TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:NON-SMALL_CELL_LUNG_CARCINOMA
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
LOSARTAN;AGTR1;rs5186;CC;EFFICACY;DECREASED_RESPONSE;DISEASE:ESSENTIAL_HYPERTENSION
CLOPIDOGREL;KDR;rs2305948;T;EFFICACY;DECREASED_RESPONSE;DISEASE:CORONARY_DISEASE
LAMOTRIGINE;UGT2B7;rs7668258;CT + TT;DOSAGE;INCREASED_DOSE;OTHER:EPILEPSY
MERCAPTOPURINE;NUDT15;rs73189762;T;DOSAGE;DECREASED_DOSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METFORMIN;ARFGEF3;rs143276236;AC;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
TRASTUZUMAB;ERBB2;rs1136201;G;TOXICITY;RESPONSE;
DOXORUBICIN;CBR1;rs9024;GG;LADME_PK;INCREASED_CLEARANCE;DISEASE:BREAST_NEOPLASMS
METFORMIN;PRKAB2;rs7541245;A;EFFICACY;DECREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;DOSAGE;DECREASED_DOSE;DISEASE:INFLAMMATORY_BOWEL_DISEASES,_DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
TACROLIMUS;POR;rs1057868;CT + TT;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
DOXORUBICIN;CBR1;rs9024;GG;LADME_PK;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS
DOXORUBICIN;CBR1;rs9024;GG;LADME_PK;DECREASED_EXPOSURE;DISEASE:BREAST_NEOPLASMS
PRAMIPEXOLE;DRD3;rs6280;T;EFFICACY;INCREASED_RESPONSE;
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;
WARFARIN;VKORC1;rs7196161;GG;DOSAGE;DECREASED_DOSE;
ANTIDEPRESSANTS, BENZODIAZEPINE DERIVATIVES, MIRTAZAPINE, SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GAL;rs948854;C;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;rs9934438;GG;DOSAGE;INCREASED_DOSE;
SUFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER:PREGNANCY
WARFARIN;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE;
TACROLIMUS;CYP3A5;rs41303343;A;DOSAGE, LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
METFORMIN;SLC22A1;rs628031;GG;EFFICACY;INCREASED_RESPONSE;OTHER:DIABETES_MELLITUS_TYPE2
TACROLIMUS;CYP3A5;rs10264272;T;DOSAGE, LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
WARFARIN;VKORC1;rs2884737;AA;DOSAGE;INCREASED_DOSE;
WARFARIN;VKORC1;rs61742245;A;DOSAGE;INCREASED_DOSE;
TACROLIMUS;CYP3A5;rs776746;C;DOSAGE, LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
MYCOPHENOLIC ACID;ABCC2;rs717620;CC;LADME_PK;INCREASED_EXPOSURE;OTHER:KIDNEY_TRANSPLANTATION
WARFARIN;PRSS53, VKORC1;rs2359612;A;DOSAGE;DECREASED_DOSE;
CAFFEINE;CYP1A2;rs762551;AA;OTHER, LADME_PK;INCREASED_METABOLISM;DISEASE:TOBACCO_USE_DISORDER
DOXORUBICIN;CBR1;rs20572;CC;LADME_PK;DECREASED_EXPOSURE;DISEASE:BREAST_NEOPLASMS
WARFARIN;GGCX;rs11676382;CG;DOSAGE;DECREASED_DOSE;
CAFFEINE;CYP1A2;rs762551;AA;OTHER, LADME_PK;INCREASED_METABOLISM;OTHER:HEAVY_COFFEE_CONSUMPTION
METHOTREXATE;ATIC;rs2372536;GG;EFFICACY;DECREASED_RESPONSE;OTHER:RHEUMATOID_ARTHRITIS
TACROLIMUS;CYP3A4;rs35599367;AA + AG;LADME_PK;DECREASED_CLEARANCE;OTHER:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A4;rs2740574;C;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;rs35599367;A;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_CLEARANCE;OTHER:LIVER_TRANSPLANTATION
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
WARFARIN;PRSS53, VKORC1;rs7294;T;DOSAGE;INCREASED_DOSE;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL9;rs2069885;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER:SPONDYLITIS,_ANKYLOSING
RITUXIMAB;FCGR3A;rs396991;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:NEUROMYELITIS_OPTICA
PREDNISOLONE;CD40;rs1883832;CC;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:THROMBOCYTOPENIA
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_METABOLISM;OTHER:LIVER_TRANSPLANTATION
METFORMIN;SLC47A1;rs2289669;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
ERENUMAB;CALCRL;rs6710852;G;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:MIGRAINE_WITH_AURA,_OTHER:MIGRAINE_WITHOUT_AURA
TACROLIMUS;ABCB1;rs2032582;AA + TT;DOSAGE, LADME_PK;DECREASED_CLEARANCE;OTHER:LIVER_TRANSPLANTATION
WARFARIN;VKORC1;rs7294;CC;DOSAGE;DECREASED_DOSE;
HALOTHANE;RYR1;rs118192161;T;OTHER;INCREASED_RESPONSE;
WARFARIN;VKORC1;rs8050894;CC;DOSAGE;INCREASED_DOSE;
WARFARIN;VKORC1;rs2359612;GG;DOSAGE;INCREASED_DOSE;
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL5;rs2069812;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER:SPONDYLITIS,_ANKYLOSING
BETA BLOCKING AGENTS, SELECTIVE;BST1;rs28404156;A;EFFICACY;INCREASED_RESPONSE;OTHER:HYPERTENSION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:HEPATITIS_C_VIRUS_INFECTION,_DISEASE:HIV_INFECTIOUS_DISEASE
TAMOXIFEN;CYP19A1;rs4646;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:BREAST_NEOPLASMS,_DISEASE:MENOPAUSE
BISPHOSPHONATES;FDPS;rs2297480;T;EFFICACY;INCREASED_RESPONSE;DISEASE:OSTEOPOROSIS
SIMVASTATIN;CETP;rs5882;A;EFFICACY;INCREASED_RESPONSE;DISEASE:HYPERCHOLESTEROLEMIA
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;APOE;rs405509;TT;EFFICACY;INCREASED_RESPONSE;OTHER:MAJOR_DEPRESSIVE_DISORDER
METHOTREXATE;ABCG2;rs17731538;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1799724;C;EFFICACY;INCREASED_RESPONSE;DISEASE:CROHN_DISEASE,_DISEASE:INFLAMMATORY_BOWEL_DISEASES,_DISEASE:PSORIASIS,_DISEASE:SPONDYLARTHROPATHIES
CYCLOSPORINE;UMOD;rs12917707;GT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:KIDNEY_TRANSPLANTATION
MODAFINIL;ABCB1;rs2032582;AC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:NARCOLEPSY
MODAFINIL;ABCB1;rs1045642;AG;EFFICACY;INCREASED_RESPONSE;DISEASE:NARCOLEPSY
WARFARIN;MYC;rs4645962;CT;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
WARFARIN;MYC;rs4645943;CT + TT;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
CARBAMAZEPINE;EPHX1;rs2234922;G;DOSAGE, LADME_PK;DECREASED_METABOLISM;DISEASE:EPILEPSY
MODAFINIL;ABCB1;rs1128503;AG;EFFICACY;INCREASED_RESPONSE;DISEASE:NARCOLEPSY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs361525;G;EFFICACY;INCREASED_RESPONSE;DISEASE:CROHN_DISEASE,_DISEASE:INFLAMMATORY_BOWEL_DISEASES,_DISEASE:PSORIASIS,_DISEASE:SPONDYLARTHROPATHIES
BISPHOSPHONATES;FDPS;rs11264359;A;EFFICACY;INCREASED_RESPONSE;DISEASE:OSTEOPOROSIS
WARFARIN;MYC;rs4645974;CC;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TNF;rs1800629;G;EFFICACY;INCREASED_RESPONSE;DISEASE:CROHN_DISEASE,_DISEASE:INFLAMMATORY_BOWEL_DISEASES,_DISEASE:PSORIASIS,_DISEASE:SPONDYLARTHROPATHIES
ATORVASTATIN, SIMVASTATIN;ABCC2;rs717620;T;EFFICACY;DECREASED_DOSE;
LEFLUNOMIDE;DHODH;rs3213422;CC;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
ANTIPSYCHOTICS;DRD2;rs1799732;G;EFFICACY;INCREASED_RESISTANCE;OTHER:MOOD_DISORDER,_OTHER:SCHIZOPHRENIA
IMATINIB;SLC22A4;rs1050152;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
RISPERIDONE;HTR2A;rs6313;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
ANTIPSYCHOTICS;HTR2A;rs7997012;AG;EFFICACY;INCREASED_RESISTANCE;OTHER:MOOD_DISORDER,_OTHER:SCHIZOPHRENIA
METHADONE;CYP2B6;rs3745274;TT;DOSAGE, LADME_PK;DECREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
METHADONE;ABCB1;rs1045642;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:OPIOID-RELATED_DISORDERS
OLANZAPINE;HTR2A;rs6313;AG + GG;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DOSE;
OLANZAPINE;HTR2A;rs6313;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
CARBAMAZEPINE;EPHX1;rs1051740;CC;LADME_PK;INCREASED_METABOLISM;DISEASE:EPILEPSY
EFAVIRENZ;CYP2B6;rs3745274;GG;LADME_PK;INCREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
CARBAMAZEPINE;EPHX1;rs2234922;GG;LADME_PK;INCREASED_METABOLISM;DISEASE:EPILEPSY
AZATHIOPRINE, MERCAPTOPURINE;ITPA;rs7270101;AC + CC;TOXICITY, LADME_PK;INCREASED_METABOLISM;DISEASE:INFLAMMATORY_BOWEL_DISEASES,_DISEASE:ACUTE_LYMPHOBLASTIC_LEUKEMIA
IMATINIB;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
IMATINIB;SLC22A4;rs1050152;TT;EFFICACY;DECREASED_RESPONSE;DISEASE:CHRONIC_MYELOGENOUS_LEUKEMIA,_BCR-ABL1_POSITIVE
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
ETHANOL;OPRM1;rs3778150;CC + CT;;DECREASED_RESPONSE;
CARBAMAZEPINE;ABCB1;rs1045642;AG;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
ANTIEPILEPTICS;ABCB1;rs1045642;AG;EFFICACY;INCREASED_RESISTANCE;DISEASE:EPILEPSY
RALOXIFENE;COMT;rs737865;AG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA,_OTHER:SCHIZOAFFECTIVE_DISORDER
PACLITAXEL;ABCC2;rs717620;CT;TOXICITY;DECREASED_DOSE;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
RALOXIFENE;COMT;rs737865;AA;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA,_OTHER:SCHIZOAFFECTIVE_DISORDER
BUPRENORPHINE;OPRD1;rs678849;CT + TT;EFFICACY;INCREASED_RESPONSE;OTHER:OPIOID-RELATED_DISORDERS
METHADONE;ABCB1;rs2032582;AC;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
ETHANOL;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_EXPOSURE;
ANTIEPILEPTICS;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RESISTANCE;DISEASE:EPILEPSY
RISPERIDONE;TNIK;rs7627954;CC;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
RALOXIFENE;COMT;rs4818;CG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA,_OTHER:SCHIZOAFFECTIVE_DISORDER
METHADONE;CYP3A4;rs35599367;AG;LADME_PK;DECREASED_CLEARANCE;DISEASE:OPIOID-RELATED_DISORDERS
SUNITINIB;ABCB1;rs2032582;AA + AT;DOSAGE, TOXICITY;INCREASED_DOSE;DISEASE:RENAL_CELL_CARCINOMA
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_DOSE;OTHER:SYSTEMIC_LUPUS_ERYTHEMATOSUS
ADALIMUMAB, ETANERCEPT, INFLIXIMAB;TNF;rs1800629;AG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
SUNITINIB;ABCB1;rs1128503;AA;DOSAGE, TOXICITY;INCREASED_DOSE;DISEASE:RENAL_CELL_CARCINOMA
METHADONE;ABCB1;rs1045642;AA;LADME_PK;INCREASED_CLEARANCE;DISEASE:OPIOID-RELATED_DISORDERS
METHADONE;ABCB1;rs1128503;AG;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:OPIOID-RELATED_DISORDERS
METHADONE;POR;rs1057868;CT + TT;LADME_PK;INCREASED_CLEARANCE;DISEASE:OPIOID-RELATED_DISORDERS
METHADONE;CYP2B6;rs2279343;AA;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
DOLUTEGRAVIR;ABCG2;rs2231142;TT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE
METHADONE;CYP2B6;rs3745274;GG;DOSAGE;INCREASED_DOSE;OTHER:HEROIN_DEPENDENCE
PREDNISOLONE;TLR4;rs4986791;T;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:THROMBOCYTOPENIA
PERAMPANEL;CYP3A4;rs4986908;CG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
TELBIVUDINE;TK2;rs3826160;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:HEPATITIS_B,_CHRONIC
WARFARIN;EPHX1;rs1877724;TT;DOSAGE;DECREASED_DOSE;
NEVIRAPINE;CYP2B6;rs3745274;TT;TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
ETHANOL;OPRM1;rs3778150;CC + CT;DOSAGE;INCREASED_DOSE;
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;RESPONSE;DISEASE:CYSTIC_FIBROSIS
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_RESPONSE;
NEVIRAPINE;CYP2B6;rs3745274;T;OTHER, LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
NEVIRAPINE;CYP2C19;rs12768009;AA;OTHER, LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
ESCITALOPRAM;CYP2C18;rs11188059;G;LADME_PK;DECREASED_CONCENTRATIONS;
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;PRKCE;rs6720975;T;EFFICACY;INCREASED_RESPONSE;OTHER:ALZHEIMER_DISEASE
ESCITALOPRAM;CYP2C18;rs2860840;T;LADME_PK;DECREASED_CONCENTRATIONS;
EFAVIRENZ;CYP2B6;rs2279345;TT;LADME_PK;DECREASED_METABOLISM;DISEASE:HIV_INFECTIOUS_DISEASE
PERAMPANEL;CYP3A4;rs2242480;CT + TT;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;;rs17798800;T;EFFICACY;DECREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_DOSE;
PREDNISOLONE;TLR4;rs4986790;G;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:THROMBOCYTOPENIA
METHADONE;ABCB1;rs2032582;CC;DOSAGE;DECREASED_DOSE;OTHER:HEROIN_DEPENDENCE
METHADONE;ABCB1;rs1045642;AA;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
SN-38;ABCB1;rs12720066;AC + CC;LADME_PK;DECREASED_EXPOSURE;DISEASE:COLORECTAL_NEOPLASMS
ANTIPSYCHOTICS;GABRB1;rs4627835;T;DOSAGE;INCREASED_DOSE;DISEASE:SCHIZOAFFECTIVE_DISORDER,_DISEASE:SCHIZOPHRENIA
ANTIPSYCHOTICS;GABRB1;rs16860087;A;DOSAGE;INCREASED_DOSE;DISEASE:SCHIZOAFFECTIVE_DISORDER,_DISEASE:SCHIZOPHRENIA
WARFARIN;VKORC1;rs9923231;CC;DOSAGE;INCREASED_DOSE;OTHER:A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_OF_BETWEEN_TWO_AND_THREE
SN-38;ABCC1;rs35621;CT + TT;LADME_PK;INCREASED_EXPOSURE;DISEASE:COLORECTAL_NEOPLASMS
CARBAMAZEPINE;ABCB1;rs1045642;AA;DOSAGE;INCREASED_DOSE;OTHER:EPILEPSY
LITHIUM;ASIC2;rs11869731;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
SN-38;ABCC1;rs6498588;AT + TT;LADME_PK;INCREASED_EXPOSURE;DISEASE:COLORECTAL_NEOPLASMS
CAPECITABINE, FLUOROURACIL;HLA-G;rs9380142;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
ANTIDEPRESSANTS;MAPK1;rs8136867;AG;EFFICACY;INCREASED_RESPONSE;DISEASE:MENTAL_DISORDERS
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED_DOSE;
CAPECITABINE, FLUOROURACIL;HLA-G;rs17179108;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
WARFARIN;VKORC1;rs9923231;CC;DOSAGE, EFFICACY;INCREASED_DOSE;DISEASE:HEART_DISEASES
PHENYTOIN;CYP2C9;rs9332238;A;LADME_PK;INCREASED_CONCENTRATIONS;
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;CHAT;rs3793790;G;EFFICACY;INCREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
FLUVOXAMINE;COMT;rs4680;GG;EFFICACY;DECREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
LITHIUM;OR52E2;rs16909440;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
LITHIUM;OR52J3;rs2499984;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_RESPONSE;
ANTIDEPRESSANTS;CREB1;rs889895;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:MAJOR_DEPRESSIVE_DISORDER
DOLUTEGRAVIR;UGT1A1;rs887829;CT + TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE,_OTHER:TUBERCULOSIS
LITHIUM;;rs16973410;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:BIPOLAR_DISORDER
MERCAPTOPURINE;TPMT;rs1142345;C;EFFICACY;EXPOSURE;DISEASE:LEUKEMIA
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_RESPONSE;
DOLUTEGRAVIR;AADAC;rs1803155;AG + GG;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE,_OTHER:TUBERCULOSIS
DONEPEZIL, GALANTAMINE, RIVASTIGMINE;CHAT;rs2177370;A;EFFICACY;INCREASED_RESPONSE;DISEASE:ALZHEIMER_DISEASE
METHOTREXATE;ATIC;rs2372536;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
ZIDOVUDINE;UGT2B7;rs28365062;G;LADME_PK;INCREASED_METABOLISM;
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DOSE;DISEASE:ATRIAL_FIBRILLATION,_DISEASE:VENOUS_THROMBOEMBOLISM
CHOLESTEROL;APOE;rs429358;TT;TOXICITY;INCREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
METHADONE;DRD2;rs6275;AA;DOSAGE, LADME_PK;DECREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
METFORMIN;SLC47A2;rs12943590;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
ATENOLOL, CARVEDILOL, DILTIAZEM, METOPROLOL, VERAPAMIL;ADRB1;rs1801253;CG + GG;EFFICACY;INCREASED_RESPONSE;DISEASE:ATRIAL_FIBRILLATION
METHADONE;DRD2;rs1799978;CC;DOSAGE, LADME_PK;DECREASED_DOSE;DISEASE:HEROIN_DEPENDENCE
METFORMIN;SLC22A2;rs316019;AA + AC;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
CARBAMAZEPINE;ABCB1;rs1128503;AA + AG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
CARBAMAZEPINE;ABCB1;rs2032582;AA + AC;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
ERYTHROMYCIN;ABCC2;rs717620;TT;OTHER, LADME_PK;INCREASED_METABOLISM;
WARFARIN;GGCX;rs11676382;CG + GG;DOSAGE;DECREASED_DOSE;
CARBAMAZEPINE;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:EPILEPSY
ABIRATERONE, DUTASTERIDE;HSD3B1;rs1047303;AC;EFFICACY;DECREASED_RESPONSE;OTHER:PROSTATIC_NEOPLASMS
AZATHIOPRINE;PACSIN2;rs2413739;CT + TT;EFFICACY;DECREASED_RESPONSE;OTHER:IRRITABLE_BOWEL_SYNDROME
SILDENAFIL;NOS3;rs2070744;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:ERECTILE_DYSFUNCTION
NEVIRAPINE;CYP2B6;rs3745274;TT;TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
ABIRATERONE;SRD5A2;rs523349;CC;LADME_PK;INCREASED_METABOLISM;OTHER:PROSTATIC_NEOPLASMS
TRIGLYCERIDES;CYP19A1;rs10046;A;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS,_DISEASE:MENOPAUSE
TRIGLYCERIDES;CYP19A1;rs3759811;C;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS,_DISEASE:MENOPAUSE
WARFARIN;VKORC1;rs7196161;A;DOSAGE;DOSE;DISEASE:ATRIAL_FIBRILLATION,_DISEASE:PULMONARY_EMBOLISM,_DISEASE:STROKE,_DISEASE:VENOUS_THROMBOSIS
HDL CHOLESTEROL;CYP19A1;rs1008805;G;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS,_DISEASE:MENOPAUSE
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
TRIGLYCERIDES;CYP19A1;rs2289105;C;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS,_DISEASE:MENOPAUSE
WARFARIN;VKORC1;rs7196161;G;DOSAGE;DOSE;
METHOTREXATE;SLC19A1;rs1051296;AC + CC;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
HDL CHOLESTEROL;CYP19A1;rs10046;G;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS,_DISEASE:MENOPAUSE
FENTANYL;CYP3A4;rs2242480;T;DOSAGE;DECREASED_DOSE;OTHER:PAIN,_POSTOPERATIVE
HDL CHOLESTEROL;CYP19A1;rs2289105;T;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS,_DISEASE:MENOPAUSE
LEFLUNOMIDE;ESR1;rs2234693;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
NEVIRAPINE;CYP2B6;rs3745274;GT;TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
LEFLUNOMIDE;ESR1;rs9340799;AA;EFFICACY;INCREASED_RESPONSE;DISEASE:RHEUMATOID_ARTHRITIS
USTEKINUMAB;C9orf72;rs774359;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
METHOTREXATE;GGH;rs3758149;GG;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
HDL CHOLESTEROL;CYP19A1;rs4646;A;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS,_DISEASE:MENOPAUSE
USTEKINUMAB;IL13;rs848;AA + AC;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
TRIGLYCERIDES;CYP19A1;rs700518;C;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS,_DISEASE:MENOPAUSE
USTEKINUMAB;ZNF816;rs9304742;CC + CT;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
TRIGLYCERIDES;CYP19A1;rs4775936;C;OTHER;DECREASED_CONCENTRATIONS;DISEASE:BREAST_NEOPLASMS,_DISEASE:MENOPAUSE
WARFARIN;GGCX;rs11676382;CG + GG;DOSAGE;DECREASED_DOSE;
USTEKINUMAB;STAT4;rs7574865;GT + TT;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
USTEKINUMAB;SLC22A4;rs1050152;CT;EFFICACY;INCREASED_RESPONSE;DISEASE:PSORIASIS
ETHANOL;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_RESPONSE;OTHER:ALCOHOL_ABUSE
NICOTINE;CHRNA5;rs16969968;GG;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
WARFARIN;STX1B;rs72800847;AA + AG;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
WARFARIN;CYP1A1;rs3826041;CC;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
VARENICLINE;CHRNA5;rs16969968;AA + AG;EFFICACY;INCREASED_RESPONSE;OTHER:TOBACCO_USE_DISORDER
WARFARIN;DNMT3A;rs2304429;TT;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
WARFARIN;NQO1;rs10517;AA;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
RALOXIFENE;ESR1;rs2234693;TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:SCHIZOPHRENIA,_OTHER:SCHIZOAFFECTIVE_DISORDER
ACENOCOUMAROL, PHENPROCOUMON;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_DOSE;
FENTANYL;DRD1;rs966775;AG + GG;EFFICACY;INCREASED_CONCENTRATIONS;OTHER:PAIN,_POSTOPERATIVE
FLUTICASONE / SALMETEROL;CHRM2;rs8191992;A;EFFICACY;RESPONSE;DISEASE:ASTHMA
METHOTREXATE;MTHFR;rs1801133;AA + AG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:NON-HODGKIN_LYMPHOMA
WARFARIN;VKORC1;rs9923231;A;DOSAGE;DOSE;
PHENPROCOUMON;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;
WARFARIN;CYP2C9;rs1057910;AA;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
ARIPIPRAZOLE, RISPERIDONE;DRD2;rs2514218;CC;EFFICACY;INCREASED_RESPONSE;OTHER:PSYCHOTIC_DISORDER,_OTHER:SCHIZOAFFECTIVE_DISORDER,_OTHER:SCHIZOPHRENIA
VORICONAZOLE;ABCG2;rs2231142;GT + TT;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LEUKEMIA,_OTHER:LYMPHOMA,_OTHER:MYELODYSPLASTIC_SYNDROMES
WARFARIN;STX1B;rs4889606;AG + GG;DOSAGE;DECREASED_DOSE;
WARFARIN;UGT1A1;rs887829;CC;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
WARFARIN;CYP4F2;rs2108622;CC + CT;DOSAGE;DECREASED_DOSE;DISEASE:HEART_VALVE_REPLACEMENT
AZATHIOPRINE, MERCAPTOPURINE;ITPA;rs1127354;AA + AC;LADME_PK;DECREASED_METABOLISM;DISEASE:INFLAMMATORY_BOWEL_DISEASES
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_DOSE;OTHER:ATRIAL_FIBRILLATION,_OTHER:HEART_VALVE_REPLACEMENT,_OTHER:PULMONARY_EMBOLISM
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SHMT1;rs1979277;A;EFFICACY;INCREASED_RESPONSE;DISEASE:COLORECTAL_NEOPLASMS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL6;rs1800795;G;EFFICACY;DECREASED_RESPONSE;DISEASE:PSORIASIS
WARFARIN;CYP2C9;rs1057910;AC + CC;DOSAGE;INCREASED_DOSE;OTHER:ATRIAL_FIBRILLATION,_OTHER:HEART_VALVE_REPLACEMENT,_OTHER:PULMONARY_EMBOLISM
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;INCREASED_DOSE;OTHER:ATRIAL_FIBRILLATION,_OTHER:HEART_VALVE_REPLACEMENT,_OTHER:PULMONARY_EMBOLISM
PLATINUM COMPOUNDS;;rs6983267;GG + GT;EFFICACY;INCREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
METFORMIN;SLC22A2;rs316009;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;INCREASED_DOSE;OTHER:PAIN,_OTHER:PAIN,_POSTOPERATIVE
ATORVASTATIN;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:HYPERCHOLESTEROLEMIA
CYCLOSPORINE;CYP3A4;rs35599367;AA + AG;TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:KIDNEY_TRANSPLANTATION
PLATINUM COMPOUNDS;MALAT1;rs619586;AG + GG;EFFICACY;DECREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
PLATINUM COMPOUNDS;HOTAIR;rs7958904;CC + CG;EFFICACY;DECREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
PLATINUM COMPOUNDS;H19;rs2839698;AA + AG;EFFICACY;INCREASED_RESPONSE;DISEASE:LUNG_NEOPLASMS
TACROLIMUS;CYP3A4;rs35599367;AG;DOSAGE;DECREASED_DOSE;DISEASE:KIDNEY_TRANSPLANTATION
CARBAMAZEPINE;EPHX1;rs1051740;C;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_DOSE;
FLUTICASONE / SALMETEROL;CHRM2;rs6962027;A;EFFICACY;RESPONSE;DISEASE:ASTHMA
NICOTINE;OPRM1;rs1799971;AG + GG;OTHER;INCREASED_EXPOSURE;
BETA BLOCKING AGENTS;ADRB1;rs1801253;C;EFFICACY;INCREASED_RESPONSE;OTHER:CARDIOMYOPATHY,_DILATED
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_DOSE;DISEASE:STROKE
BETA BLOCKING AGENTS;ADRB2;rs1042713;A;EFFICACY;INCREASED_RESPONSE;OTHER:CARDIOMYOPATHY,_DILATED
FLUTICASONE / SALMETEROL;CHRM2;rs6962027;A;EFFICACY;RESPONSE;DISEASE:ASTHMA
CARBAMAZEPINE;EPHX1;rs2234922;G;DOSAGE, LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
FLUTICASONE PROPIONATE;CRHR1;rs1876831;T;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
RISPERIDONE;TNIK;rs2088885;AA;EFFICACY;INCREASED_RESPONSE;OTHER:SCHIZOPHRENIA
FLUTICASONE PROPIONATE;CRHR1;rs1876828;T;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
METFORMIN;CSMD1;rs2617102;AC + CC;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
FLUTICASONE PROPIONATE;CRHR1;rs1876829;C;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
FLUTICASONE PROPIONATE;CRHR1;rs739645;G;EFFICACY;INCREASED_RESPONSE;DISEASE:ASTHMA
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DOSE;
NEVIRAPINE;CYP2B6;rs3745274;T;TOXICITY, LADME_PK;DECREASED_CLEARANCE;DISEASE:HIV_INFECTIOUS_DISEASE
NICOTINE;POR;rs1057868;CT + TT;LADME_PK;INCREASED_METABOLISM;PK:CYP2A6_NORMAL,_BUT_NOT_REDUCED,_METABOLIZERS
CARBAMAZEPINE;SCN1A;rs3812718;TT;LADME_PK;INCREASED_METABOLISM;DISEASE:EPILEPSY
WARFARIN;CYP4F2;rs2108622;TT;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
VORICONAZOLE;CYP2C18;rs2860840;T;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LEUKEMIA,_OTHER:LYMPHOMA,_OTHER:MYELODYSPLASTIC_SYNDROMES
VORICONAZOLE;CYP2C18;rs11188059;G;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:LEUKEMIA,_OTHER:LYMPHOMA,_OTHER:MYELODYSPLASTIC_SYNDROMES
REMIFENTANIL;ABCB1;rs1045642;GG;DOSAGE;INCREASED_DOSE;
WARFARIN;GGCX;rs12714145;CT + TT;DOSAGE;DECREASED_DOSE;OTHER:ATRIAL_FIBRILLATION,_OTHER:HEART_VALVE_REPLACEMENT,_OTHER:PULMONARY_EMBOLISM
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
REMIFENTANIL;ABCB1;rs1045642;GG;EFFICACY;DECREASED_RESPONSE;
FLUOROURACIL;DPYD;rs1801159;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:COLORECTAL_NEOPLASMS
WARFARIN;VKORC1;rs9934438;AA;DOSAGE;DECREASED_DOSE;DISEASE:ATRIAL_FIBRILLATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_RESPONSE;DISEASE:CHRONIC_HEPATITIS_C_VIRUS_INFECTION
CARBAMAZEPINE;SCN1A;rs3812718;TT;LADME_PK;INCREASED_DOSE;DISEASE:EPILEPSY
NALTREXONE;OPRM1;rs1799971;AA;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:OPIOID-RELATED_DISORDERS
ASPIRIN;P2RY1;rs1371097;T;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:STROKE
GEMCITABINE;CMPK1;rs1044457;TT;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA
TACROLIMUS;SLC7A8;rs7141505;AC + CC;LADME_PK;DECREASED_METABOLISM;OTHER:LIVER_TRANSPLANTATION
MERCAPTOPURINE;NUDT15;rs55713253;CC;DOSAGE;INCREASED_DOSE;OTHER:ACUTE_LYMPHOBLASTIC_LEUKEMIA
CYCLOPHOSPHAMIDE, DOXORUBICIN, PACLITAXEL;ABCC2;rs145008610;AA;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:BREAST_NEOPLASMS
DEOXY-THIOGUANOSINE TRIPHOSPHATE, THIOGUANOSINE TRIPHOSPHATE;TPMT;rs1142345;CT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:INFLAMMATORY_BOWEL_DISEASES
AZATHIOPRINE;PACSIN2;rs2413739;CC + CT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:INFLAMMATORY_BOWEL_DISEASES
CLOPIDOGREL CARBOXYLIC ACID;ABCB1;rs1045642;AA + AG;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:CARDIOVASCULAR_DISEASE
BREXPIPRAZOLE;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;DECREASED_METABOLISM;OTHER:SCHIZOPHRENIA
BREXPIPRAZOLE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
THIORIDAZINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3/*4 + *4/*4 + *4/*5 + *4/*6;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:MENTAL_DISORDERS
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*9, CYP2D6*17, CYP2D6*29, CYP2D6*34, CYP2D6*39, CYP2D6*41;*4/*4 + *4/*5 + *4/*9 + *2/*4 + *1/*4 + *1/*5 + *9/*9;EFFICACY;INCREASED_CONCENTRATIONS;OTHER:MALARIA,_VIVAX
CYCLOSPORINE;CYP3A5;rs776746;CT;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;OTHER:KIDNEY_TRANSPLANTATION
RISPERIDONE;CYP2D6;CYP2D6*17;*17;LADME_PK;INCREASED_METABOLISM;OTHER:SCHIZOPHRENIA,_OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY,_OTHER:AUTISM,_OTHER:BIPOLAR_DISORDER
RISPERIDONE;CYP2D6;CYP2D6*29;*29;LADME_PK;DECREASED_METABOLISM;OTHER:SCHIZOPHRENIA,_OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY,_OTHER:AUTISM,_OTHER:BIPOLAR_DISORDER
DULAGLUTIDE, LIRAGLUTIDE, SEMAGLUTIDE;GLP1R;rs6923761;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:DIABETES_MELLITUS_TYPE2
N-DESMETHYLCLOZAPINE;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:SCHIZOPHRENIA
NORCLOBAZAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;LADME_PK;DECREASED_CLEARANCE;OTHER:EPILEPSY
ARTEMETHER, LUMEFANTRINE;CYP2B6;rs3745274;GT;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:MALARIA
4-ENE VALPROIC ACID;CPT1A;rs2228502;GG;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:EPILEPSY
TACROLIMUS;SULT1E1;rs3775770;CC;LADME_PK;DECREASED_METABOLISM;OTHER:LIVER_TRANSPLANTATION
DEXTROMETHORPHAN;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_METABOLISM;
METHOTREXATE;ATIC;rs4673991;CC + CT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
QUETIAPINE;CYP3A4;CYP3A4*22;*22;LADME_PK;INCREASED_EXPOSURE;OTHER:LIVER_CIRRHOSIS
METHOTREXATE;ATIC;rs4673993;CT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
METHOTREXATE;ADA;rs2057638;GT + TT;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
METHOTREXATE;ATIC;rs2372536;CC + CG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
METHOTREXATE;ADA;rs6017375;CG + GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
METHOTREXATE;ADA;rs371927;AA;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:RHEUMATOID_ARTHRITIS
PROPOFOL;UGT1A9;rs72551330;CT;LADME_PK;DECREASED_CLEARANCE;
PROPOFOL;UGT1A9;rs2741045;CC;LADME_PK;INCREASED_CLEARANCE;
LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*1;;INCREASED_CLINICAL BENEFIT;
CODEINE, HYDROCODONE, OXYCODONE, TRAMADOL;CYP2D6;CYP2D6;poor_metabolizer;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:PAIN
ZUCLOPENTHIXOL;CYP2D6;CYP2D6 normal metabolizer;;LADME_PK;DECREASED_DOSE_ADJUSTED TROUGH CONCENTRATIONS;
SITAGLIPTIN;GLP1R;rs6923761;GG;EFFICACY;INCREASED_CLINICAL BENEFIT;OTHER:HYPERTENSION,_OTHER:DIABETES_MELLITUS
SALBUTAMOL;ADRB2;rs1042717;AA;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
SALBUTAMOL;ADRB2;rs1042714;GG;EFFICACY;DECREASED_CLINICAL BENEFIT;OTHER:ASTHMA
THIORIDAZINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:DEPRESSION
ZUCLOPENTHIXOL;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:MENTAL_DISORDERS
PERPHENAZINE;CYP2D6;CYP2D6;intermediate_metabolizer;LADME_PK;INCREASED_CONCENTRATIONS;OTHER:MENTAL_DISORDERS
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CDKAL1;rs7754840;CC;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;CDKAL1;rs7756992;GG;EFFICACY;INCREASED_RESPONSE;DISEASE:DIABETES_MELLITUS
SITAGLIPTIN, VILDAGLIPTIN;GLP1R;rs6923761;AA;EFFICACY;DECREASED_RESPONSE;DISEASE:DIABETES_MELLITUS_TYPE2
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2C19;CYP2C19*17;*17;EFFICACY;INCREASED_RESISTANCE;OTHER:SCHIZOPHRENIA,_OTHER:MENTAL_DISORDERS,_OTHER:NEUROTIC_DISORDER,_OTHER:PERSONALITY_DISORDER
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME_PK;INCREASED_CONCENTRATIONS;DISEASE:MAJOR_DEPRESSIVE_DISORDER
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2D6;CYP2D6*3;*3;EFFICACY;INCREASED_RESISTANCE;OTHER:SCHIZOPHRENIA,_OTHER:MENTAL_DISORDERS,_OTHER:NEUROTIC_DISORDER,_OTHER:PERSONALITY_DISORDER
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP1A2;CYP1A2*30;*30;EFFICACY;INCREASED_RESISTANCE;OTHER:SCHIZOPHRENIA,_OTHER:MENTAL_DISORDERS,_OTHER:NEUROTIC_DISORDER,_OTHER:PERSONALITY_DISORDER
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;DOSAGE;INCREASED_DOSE;OTHER:LIVER_TRANSPLANTATION
TACROLIMUS;CYP3A4;rs35599367;AG;DOSAGE;DECREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
TACROLIMUS;CYP3A4;rs2740574;CC + CT;DOSAGE;INCREASED_DOSE;OTHER:KIDNEY_TRANSPLANTATION
EFAVIRENZ;CYP2B6;rs4803419;C;LADME_PK;DECREASED_CONCENTRATIONS;OTHER:HIV_INFECTIOUS_DISEASE,_OTHER:MISSED_DOSE
ANTIDEPRESSANTS;SLC22A3;rs2292334;AG + GG;DOSAGE;INCREASED_DOSE;OTHER:DEPRESSION
KETANSERIN;HTR1B;rs130060;C;LADME_PD;DECREASED_AFFINITY;HTR1B
THIOXANTHINE;XDH;rs2295474;T;LADME_PK;DECREASED_CLEARANCE;XDH
PAROMOMYCIN;MT-RNR1;rs267606617;G;LADME_PD;DECREASED_ACTIVITY;MT-RNR1
THIOXANTHINE;XDH;rs45442092;T;LADME_PK;DECREASED_CLEARANCE;XDH
DIHYDROERGOTAMINE, METHYSERGIDE, SUMATRIPTAN;HTR1B;rs130060;C;LADME_PD;INCREASED_AFFINITY;HTR1B
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;LADME_PK;INCREASED_EXPRESSION;TYMS
CISPLATIN, IRINOTECAN;UBE2I;rs9597;CG;LADME_PK;INCREASED_EXPRESSION;SAE1
METHOTREXATE;SHMT1;rs1979277;AA;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;TYMS
IVACAFTOR;CFTR;rs113993960;del;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs397508139;A;EFFICACY;ACTIVITY;CFTR
FLUOROURACIL;DPYD;rs1335150891;C;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;DPYD
IVACAFTOR;CFTR;rs141033578;T;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs121909011;T;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs77409459;T;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs397508510;C;EFFICACY;ACTIVITY;CFTR
PHENYTOIN;CYP2C9;rs12782374;A;;DECREASED_EXPRESSION;CYP2C9
IVACAFTOR;CFTR;rs397508435;C;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs77010898;A;EFFICACY;INCREASED_ACTIVITY;CFTR
ESTRADIOL;TCL1A;rs7158782;G;OTHER;INCREASED_EXPRESSION;IL17RA
IVACAFTOR;CFTR;rs397508328;G;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs77932196;A;EFFICACY;ACTIVITY;CFTR
NIMESULIDE;PTGS2;rs5272;C;LADME_PK;INCREASED_ENZYME_ACTIVITY;PTGS2
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;ASSOCIATED_PROTEIN_STABILITY;CFTR
IVACAFTOR;CFTR;rs1800111;C;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs74551128;A;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs186045772;A;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs78769542;A;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs397508537;A;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs397508256;A;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs121908751;A;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;ACTIVITY;CFTR
CISPLATIN;TPMT;TPMT*1, TPMT*3A;*3A;OTHER;INCREASED_EXPRESSION;TLR4
IVACAFTOR;CFTR;rs368505753;T;EFFICACY;ACTIVITY;CFTR
NIMESULIDE;PTGS2;rs5273;G;LADME_PK;INCREASED_ENZYME_ACTIVITY;PTGS2
IVACAFTOR;CFTR;rs115545701;T;EFFICACY;ACTIVITY;CFTR
SACUBITRIL;CES1;rs71647871;CT;EFFICACY;DECREASED_CATALYTIC_ACTIVITY;CES1
IVACAFTOR;CFTR;rs1800100;T;EFFICACY;ACTIVITY;CFTR
ESTRADIOL;TCL1A;rs7158782;A;OTHER;INCREASED_EXPRESSION;IL12RB2
ESTRADIOL;TCL1A;rs7158782;G;OTHER;INCREASED_EXPRESSION;TCL1A
ANASTROZOLE, EXEMESTANE, LETROZOLE;CYP19A1;rs6493497;AG;OTHER;ACTIVITY;CYP19A1
ANASTROZOLE, EXEMESTANE, LETROZOLE;CYP19A1;rs7176005;CT;OTHER;ACTIVITY;CYP19A1
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*32, TPMT*33, TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*32 + *1/*33 + *1/*34;LADME_PK;DECREASED_ACTIVITY;TPMT
SITAGLIPTIN;DPP4;rs759717;CC;LADME_PD;INCREASED_ACTIVITY;DPP4
SITAGLIPTIN;DPP4;rs2909451;TT;LADME_PD;INCREASED_ACTIVITY;DPP4
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*18, CYP2D6*21, CYP2D6*41;*5/*10 + *5/*21 + *41/*41 + *10/*10 + *10/*41;EFFICACY;INCREASED_EXPRESSION;MKI67
ESTRADIOL;TCL1A;rs7158782;A;OTHER;INCREASED_EXPRESSION;IL1R2
ESTRADIOL;TCL1A;rs7158782;A;OTHER;INCREASED_EXPRESSION;IL17A
ESTRADIOL;TCL1A;rs7159713;A;OTHER;INCREASED_EXPRESSION;IL1R2
ESTRADIOL;TCL1A;rs7159713;A;OTHER;INCREASED_EXPRESSION;IL12RB2
ESTRADIOL;TCL1A;rs7159713;A;OTHER;INCREASED_EXPRESSION;IL17A
ESTRADIOL;TCL1A;rs7159713;G;OTHER;INCREASED_EXPRESSION;TCL1A
IVACAFTOR;CFTR;rs78655421;A;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs397508759;A;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs150212784;G;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs34911792;G;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs397508513;C;EFFICACY;ACTIVITY;CFTR
ESTRADIOL;TCL1A;rs7159713;G;OTHER;INCREASED_EXPRESSION;IL17RA
METHOXSALEN;CYP2A6;CYP2A6*15, CYP2A6*21, CYP2A6*22;*15 + *21 + *22;OTHER;DECREASED_ENZYME_ACTIVITY;CYP2A6
ATORVASTATIN;SCAP;rs12487736;TT;OTHER;DECREASED_TRANSCRIPTION;SCAP
IVACAFTOR;CFTR;rs202179988;T;EFFICACY;ACTIVITY;CFTR
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2;*2;OTHER;DECREASED_ACTIVITY;CYP2D6
VITAMIN E;CYP4F2;rs3093105;C;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;CYP4F2
ESTRADIOL;;rs11849538;C;OTHER;INCREASED_EXPRESSION;IL17A
ESTRADIOL;;rs11849538;C;OTHER;INCREASED_EXPRESSION;IL1R2
IVACAFTOR / LUMACAFTOR;CFTR;rs78655421;A;EFFICACY;INCREASED_ACTIVITY;CFTR
IVACAFTOR, NPPB;CFTR;rs75527207;A;EFFICACY;INCREASED_ACTIVITY;CFTR
EFAVIRENZ;CYP2B6;CYP2B6*6;*6;LADME_PK;INCREASED_ACTIVITY;CYP3A4
FLUOROURACIL;DPYD;rs56005131;T;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;DPYD
ESTRADIOL;;rs2369049;G;OTHER;INCREASED_EXPRESSION;IL17RA
ESTRADIOL;;rs2369049;A;OTHER;INCREASED_EXPRESSION;IL12RB2
ESTRADIOL;;rs2369049;A;OTHER;INCREASED_EXPRESSION;IL17A
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs80034486;CG;LADME_PD;INCREASED_ACTIVITY;CFTR
CORR-4A, IVACAFTOR, LUMACAFTOR;CFTR;rs113993960;del/del;EFFICACY;INCREASED_ACTIVITY;CFTR
ESTRADIOL;;rs2369049;A;OTHER;INCREASED_EXPRESSION;IL1R2
IVACAFTOR;CFTR;rs397508288;G;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs75541969;C;EFFICACY;ACTIVITY;CFTR
ESCITALOPRAM;IL11;rs1126757;CT + TT;OTHER;DECREASED_EXPRESSION;IL11
ESTRADIOL;;rs11849538;G;OTHER;INCREASED_EXPRESSION;TCL1A
METHOTREXATE;FASTKD3, MTRR;rs1801394;AG + GG;;INCREASED_CATALYTIC_ACTIVITY;TYMS
ESTRADIOL;;rs11849538;G;OTHER;INCREASED_EXPRESSION;IL17RA
ESTRADIOL;;rs11849538;C;OTHER;INCREASED_EXPRESSION;IL12RB2
IVACAFTOR;CFTR;rs11971167;T;EFFICACY;ACTIVITY;CFTR
ESTRADIOL;;rs2369049;G;OTHER;INCREASED_EXPRESSION;TCL1A
IVACAFTOR;CFTR;rs121909019;A;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs121908753;A;EFFICACY;ACTIVITY;CFTR
PHENYTOIN;CYP2C9;rs71486745;del;;DECREASED_EXPRESSION;CYP2C9
METHOTREXATE;MTHFR;rs1801131;GT;;INCREASED_CATALYTIC_ACTIVITY;TYMS
IVACAFTOR;CFTR;rs77834169;T;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs397508442;T;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs121909047;A;EFFICACY;ACTIVITY;CFTR
GLYBURIDE;KCNJ11;rs5219;T;LADME_PK;DECREASED_ACTIVITY;KCNJ11
HYDROCHLOROTHIAZIDE;YEATS4;rs7297610;CC;LADME_PK;DECREASED_EXPRESSION;YEATS4
IVACAFTOR;CFTR;rs121908752;G;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;INCREASED_ACTIVITY;CFTR
VITAMIN E;CYP4F2;rs2108622;T;OTHER;DECREASED_ENZYME_ACTIVITY;CYP4F2
IVACAFTOR;CFTR;rs121909020;A;EFFICACY;ACTIVITY;CFTR
IVACAFTOR;CFTR;rs113993958;C;EFFICACY;ACTIVITY;CFTR
DISOPYRAMIDE;KCNH2;rs104894021;T;EFFICACY;DECREASED_INHIBITION;KCNH2
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C19
QUINIDINE;KCNH2;rs104894021;T;EFFICACY;DECREASED_INHIBITION;KCNH2
CHLOROCRESOL;RYR1;rs193922803;T;OTHER;INCREASED_ACTIVITY;RYR1
TAMOXIFEN;NCOA1;rs1804645;T;;DECREASED_ACTIVITY;NCOA1
CYTARABINE;CDA;rs60369023;AA + AG;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CDA
GENTAMICIN;MT-RNR1;rs267606619;T;LADME_PD;DECREASED_ACTIVITY;MT-RNR1
QUINIDINE;KCNH2;rs104894021;C;EFFICACY;DECREASED_INHIBITION;KCNH2
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*30;*1/*30;OTHER;DECREASED_ACTIVITY;CYP2B6
GEMCITABINE;DCTD;rs35932500;C;LADME_PK;DECREASED_ENZYME_ACTIVITY;DCTD
BUPROPION;POR;rs2868177;AG + GG;LADME_PK;INCREASED_ACTIVITY;CYP2B6
GEMCITABINE;CDA;rs2072671;C;LADME_PK;DECREASED_ENZYME_ACTIVITY;CDA
ADALIMUMAB;TNF;rs1800629;AG;LADME_PK;DECREASED_STEADY_STATE_LEVEL;TNF
PAROMOMYCIN;MT-RNR1;rs267606617;G;LADME_PD;DECREASED_ACTIVITY;MT-RNR1
SIMVASTATIN;HLA-G;rs1063320;GG;OTHER;INCREASED_EXPRESSION;HLA-G
ACETAMINOPHEN;CYP2E1;rs2515641;T;OTHER;INCREASED_EXPRESSION;CYP2E1
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*19;*19;OTHER;DECREASED_CATALYTIC_ACTIVITY;CYP2C19
BUPRENORPHINE;OPRM1;rs1799971;G;EFFICACY;DECREASED_ACTIVITY;OPRM1
TAMOXIFEN;UGT1A4;rs8330;CC;LADME_PK;DECREASED_ACTIVITY;UGT1A4
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;CYP2C19
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*28;*28;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;CYP2C19
GEMCITABINE;FKBP5;rs73748206;CT;OTHER;INCREASED_EXPRESSION;FKBP5
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*25, CYP2C19*26;*10 + *14 + *19 + *25 + *26;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C19
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*13, CYP2C19*14, CYP2C19*15, CYP2C19*18, CYP2C19*19, CYP2C19*23, CYP2C19*25, CYP2C19*26;*10 + *13 + *14 + *15 + *18 + *19 + *23 + *25 + *26;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C19
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*26;*26;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C19
ACETAMINOPHEN;UGT1A;rs8330;CC;LADME_PK;DECREASED_ACTIVITY;UGT1A
ETHANOL;ADH1B;rs1229984;CT + TT;LADME_PK;INCREASED_ENZYME_ACTIVITY;ADH1B
ELEXACAFTOR, IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;del/del;OTHER;INCREASED_TRANSPORT;CFTR
ACETAMINOPHEN;UGT1A;rs10929303;CC;LADME_PK;DECREASED_ACTIVITY;UGT1A
XENOBIOTICS;AHR;rs2066853;A;LADME_PK;INCREASED_EXPRESSION;CYP1A1
OMEPRAZOLE, XENOBIOTICS;AHR;rs75519181;G;LADME_PK;DECREASED_EXPRESSION;CYP1A1
ACETAMINOPHEN;UGT1A;rs1042640;CC;LADME_PK;DECREASED_ACTIVITY;UGT1A
GEMCITABINE;FKBP5;rs73748206;CT;OTHER;INCREASED_EXPRESSION;NR3C1
ESTRADIOL;;rs3802201;GG;OTHER;INCREASED_EXPRESSION;MIR2052
ALDOSTERONE, INSULIN RECOMBINANT;SCNN1B;rs34241435;A;OTHER;INCREASED_TRANSCRIPTION;SCNN1B
ESTRADIOL;;rs4476990;CC;OTHER;INCREASED_EXPRESSION;MIR2052
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*9;*9;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME_PK;DECREASED_ACTIVITY;CYP2C19
BERBERINE, COPTISINE;CYP2D6;CYP2D6*1;*1/*1;LADME_PK;INCREASED_INHIBITION;CYP2D6
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;CYP2C19*1, CYP2C19*8, CYP2C19*10;*8 + *10;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C19
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*23;*23;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;CYP2C19
BERBERINE, COPTISINE;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10;LADME_PK;INCREASED_INHIBITION;CYP2D6
DISOPYRAMIDE;KCNH2;rs104894021;C;EFFICACY;DECREASED_INHIBITION;KCNH2
IVACAFTOR;CFTR;rs74503330;A;OTHER;INCREASED_ACTIVITY;CFTR
FLUOROURACIL;DPYD;rs372307932;T;LADME_PK;DECREASED_ACTIVITY;DPYD
MIDAZOLAM;CYP3A4;rs35599367;AG;LADME_PK;DECREASED_ACTIVITY;CYP3A4
DEXTROMETHORPHAN;CYP3A4;rs35599367;AG;LADME_PK;DECREASED_ACTIVITY;CYP3A4
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*16;*16;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*19;*19;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*18;*18;LADME_PK;DECREASED_ACTIVITY;CYP2C19
FLUOROURACIL;DPYD;rs376073289;T;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs374527058;G;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs538336580;A;LADME_PK;DECREASED_ACTIVITY;DPYD
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*9;*9;LADME_PK;DECREASED_ACTIVITY;CYP2C19
FLUOROURACIL;DPYD;rs568367673;A;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs558354142;A;LADME_PK;DECREASED_ACTIVITY;DPYD
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs770829708;A;LADME_PK;DECREASED_ACTIVITY;CYP2C19
FLUOROURACIL;DPYD;rs374825099;T;LADME_PK;DECREASED_ACTIVITY;DPYD
ESTRONE SULFATE, ROSUVASTATIN;SLCO2B1;rs199654337;T;LADME_PK;DECREASED_TRANSPORT;SLCO2B1
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*9, CYP2C19*10, CYP2C19*16;*9 + *10 + *16;LADME_PK;DECREASED_CLEARANCE;CYP2C19
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;LADME_PK;DECREASED_CLEARANCE;CYP2C19
ESTRONE SULFATE, ROSUVASTATIN;SLCO2B1;rs1009122956;C;LADME_PK;DECREASED_TRANSPORT;SLCO2B1
ESTRONE SULFATE, ROSUVASTATIN;SLCO2B1;rs1621378;T;LADME_PK;DECREASED_TRANSPORT;SLCO2B1
ESTRONE SULFATE;SLCO2B1;rs2306168;T;LADME_PK;DECREASED_TRANSPORT;SLCO2B1
FLUOROURACIL;DPYD;rs548783838;T;LADME_PK;DECREASED_ACTIVITY;DPYD
;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*1;EFFICACY;INCREASED_ACTIVITY;CYP2B6
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*1;EFFICACY;INCREASED_ACTIVITY;CYP2B6
FLUOROURACIL;DPYD;rs140989814;G;LADME_PK;DECREASED_ACTIVITY;DPYD
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*8;*8;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*13;*13;LADME_PK;DECREASED_ACTIVITY;CYP2C19
BLONANSERIN;CYP3A4;CYP3A4*1, CYP3A4*29;*29;LADME_PK;INCREASED_ACTIVITY;CYP3A4
TESTOSTERONE;CYP3A4;rs35599367;AG;LADME_PK;DECREASED_ACTIVITY;CYP3A4
ACALABRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*11, CYP3A4*29, CYP3A4*33;*2 + *3 + *11 + *29 + *33;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;CYP3A4
ACALABRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*9, CYP3A4*14, CYP3A4*16, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*32;*9 + *14 + *16 + *19 + *23 + *24 + *28 + *32;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP3A4
VANDETANIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*9, CYP3A4*15, CYP3A4*16, CYP3A4*29, CYP3A4*32, CYP3A4*33;*2 + *3 + *9 + *15 + *16 + *29 + *32 + *33;LADME_PK;INCREASED_CLEARANCE;CYP3A4
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME_PK;DECREASED_ACTIVITY;CYP2C19
FLUOROURACIL;DPYD;rs1801266;A;LADME_PK;DECREASED_ACTIVITY;DPYD
DEXTROMETHORPHAN;SEPTIN3, WBP2NL;rs1062753;G;LADME_PK;INCREASED_ENZYME_ACTIVITY;CYP2D6
BUMETANIDE;SLC17A3;rs34376145;A;LADME_PK;DECREASED_TRANSPORT;SLC17A3
BUMETANIDE;SLC17A3;rs34902660;A;LADME_PK;DECREASED_TRANSPORT;SLC17A3
BUMETANIDE;SLC17A3;rs11966370;A;LADME_PK;DECREASED_TRANSPORT;SLC17A3
BUMETANIDE;SLC17A3;rs56027330;T;LADME_PK;DECREASED_TRANSPORT;SLC17A3
OMEPRAZOLE;CYP2C19;rs148247410;G;LADME_PK;DECREASED_ACTIVITY;CYP2C19
FLUOROURACIL;DPYD;rs528152707;A;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs570122671;A;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs201268750;T;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs527580106;C;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs55886062;C;LADME_PK;DECREASED_ACTIVITY;DPYD
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs550527959;T;LADME_PK;DECREASED_ACTIVITY;CYP2C19
FLUOROURACIL;DPYD;rs538703919;A;LADME_PK;DECREASED_ACTIVITY;DPYD
IBUPROFEN;CYP3A4;CYP3A4*1, CYP3A4*4, CYP3A4*5, CYP3A4*18, CYP3A4*23, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*4 + *5 + *18 + *23 +  *32 + *34 + *28 + *29 + *31 + *33;OTHER;DECREASED_CLEARANCE;CYP3A4
BLONANSERIN;CYP3A4;CYP3A4*1, CYP3A4*20;*20;LADME_PK;DECREASED_ACTIVITY;CYP3A4
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs763625282;A;LADME_PK;DECREASED_ACTIVITY;CYP2C19
BLONANSERIN;CYP3A4;CYP3A4*1, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*31, CYP3A4*33, CYP3A4*34;*4 + *5 + *7 + *8 + *9 + *10 + *12 + *13 + *14 + *16 + *17 + *18 + *23 + *24 + *28 + *31 + *33 + *34;LADME_PK;DECREASED_ACTIVITY;CYP3A4
REGORAFENIB;CYP3A4;CYP3A4*1, CYP3A4*20;*20;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP3A4
FLUOROURACIL;DPYD;rs72549307;C;LADME_PK;DECREASED_ACTIVITY;DPYD
OMEPRAZOLE;CYP2C19;rs1431015009;T;LADME_PK;DECREASED_ACTIVITY;CYP2C19
BUFURALOL;CYP2D6;rs1058171;T;LADME_PK;DECREASED_ACTIVITY;CYP2D6
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*72;*72;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
SUMATRIPTAN;HTR1B;rs130060;C;LADME_PD;INCREASED_CONCENTRATIONS;AMPc
BUFURALOL;CYP2D6;rs1230912765;A;LADME_PK;DECREASED_ACTIVITY;CYP2D6
PURINE ANALOGUES;PACSIN2;rs2413739;C;OTHER, LADME_PK;INCREASED_ACTIVITY;TPMT
L-PHENYLALANINE;PAH;rs76394784;A;LADME_PK;DECREASED_ACTIVITY;PAH
CARBOCISTEINE;PAH;rs62516101;T;LADME_PK;DECREASED_ACTIVITY;PAH
CARBOCISTEINE;PAH;rs75193786;G;LADME_PK;DECREASED_ACTIVITY;PAH
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*75;*75;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
L-PHENYLALANINE;PAH;rs62516101;T;LADME_PK;DECREASED_ACTIVITY;PAH
CARBOCISTEINE;PAH;rs5030860;C;LADME_PK;DECREASED_ACTIVITY;PAH
L-PHENYLALANINE;PAH;rs5030849;T;LADME_PK;DECREASED_ACTIVITY;PAH
CARBOCISTEINE;PAH;rs76394784;A;LADME_PK;DECREASED_ACTIVITY;PAH
DICLOFENAC;CYP2C9;CYP2C9*3;*3;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C9
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*60;*60;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*37;*37;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*46;*46;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C9
CARBOCISTEINE;PAH;rs5030849;T;LADME_PK;DECREASED_ACTIVITY;PAH
L-PHENYLALANINE;PAH;rs5030860;C;LADME_PK;DECREASED_ACTIVITY;PAH
DICLOFENAC;CYP2C9;CYP2C9*54;*54;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;CYP2C9
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*74;*74;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
TOLBUTAMIDE;CYP2C9;rs9332239;T;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C9
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*49, CYP2D6*55;*49 + *55;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
TOLTERODINE;CYP2D6;CYP2D6*92, CYP2D6*96;*92 + *96;LADME_PK;DECREASED_ACTIVITY;CYP2D6
GEFITINIB;CYP2D6;CYP2D6*92, CYP2D6*96;*92 + *96;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2D6
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*18, CYP2D6*36, CYP2D6*47, CYP2D6*49, CYP2D6*50, CYP2D6*51, CYP2D6*54, CYP2D6*55, CYP2D6*114;*10 + *18 + *36 + *47 + *49 + *50 + *51 + *54 + *55 + *114;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*18;*18;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
HYDRALAZINE;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7;*4/*5 + *4/*6;OTHER;INCREASED_ACTIVITY;NAT2
HYDRALAZINE;NAT2;NAT2*4, NAT2*5, NAT2*6;*4/*4;OTHER;INCREASED_ACTIVITY;NAT2
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*36;*36;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
DICLOFENAC, LOSARTAN;CYP2C9;CYP2C9*1, CYP2C9*73;*73;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*36;*36;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
FLUOXETINE;CYP2D6;CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*92, CYP2D6*93, CYP2D6*96;*10 + *92 + *93 + *96 + *87 + *2;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2D6
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*89, CYP2D6*92, CYP2D6*93, CYP2D6*96;*2 + *10 + *89 + *92 + *93 + *96;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2D6
TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*60;*60;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*1, CYP2C9*60;*60;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2D6
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2C9
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*50;*50;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
DICLOFENAC;CYP2C9;CYP2C9*44;*44;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*42;*42;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*40;*40;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;CYP2C9
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs200346442;A;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs200150287;G;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs150152656;T;LADME_PK;DECREASED_ACTIVITY;CYP2C19
BUPROPION;POR;rs2868177;AA;OTHER, LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2B6
BUPROPION;POR;rs2868177;GG;OTHER, LADME_PK;INCREASED_ACTIVITY;CYP2B6
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*51;*51;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*32;*32;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*29, CYP2C19*30, CYP2C19*31, CYP2C19*33;*29 + *30 + *31 + *33;LADME_PK;DECREASED_ACTIVITY;CYP2C19
;POR;rs2868177;AA;OTHER, LADME_PK;DECREASED_ACTIVITY;CYP2B6
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;rs140278421;A;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;rs1361528097;G;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*3;*3;LADME_PK;DECREASED_ACTIVITY;CYP2C19
FLUOROURACIL;DPYD;rs536577604;C;LADME_PK;DECREASED_ACTIVITY;DPYD
DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2D6
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs1267723490;C;LADME_PK;DECREASED_ACTIVITY;CYP2C19
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*54;*54;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
BUFURALOL, DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*29;*29;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2D6
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*47;*47;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs764137538;T;LADME_PK;DECREASED_ACTIVITY;CYP2C19
IBUPROFEN;CYP2C19;CYP2C19*1, CYP2C19*3, CYP2C19*35;*3 + *35;OTHER;DECREASED_CATALYTIC_ACTIVITY;CYP2C19
IBUPROFEN;CYP2C19;CYP2C19*1, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;*33 + *30 + *31 + *32;OTHER;DECREASED_CATALYTIC_ACTIVITY;CYP2C19
DEXTROMETHORPHAN;PHETA2, SMDT1;rs1807493;G;LADME_PK;INCREASED_ENZYME_ACTIVITY;CYP2D6
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2D6
DICLOFENAC;CYP2C9;CYP2C9*52;*52;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*43;*43;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*45;*45;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*36;*36;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*55;*55;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*39;*39;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*50;*50;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*47;*47;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*53;*53;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*38;*38;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C9
DICLOFENAC;CYP2C9;CYP2C9*48;*48;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2C9
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs1463550071;T;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs1349931378;A;LADME_PK;DECREASED_ACTIVITY;CYP2C19
DEBRISOQUINE;CYP2D6;CYP2D6*1, CYP2D6*75;*75;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2D6
OMEPRAZOLE;CYP2C19;rs1393133490;T;LADME_PK;DECREASED_ACTIVITY;CYP2C19
OMEPRAZOLE;CYP2C19;rs1466428833;G;LADME_PK;DECREASED_ACTIVITY;CYP2C19
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;rs749678783;C;LADME_PK;DECREASED_ACTIVITY;CYP2C19
IBRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*17, CYP3A4*24;*17 + *24;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP3A4
EFAVIRENZ;CYP2B6;rs58871670;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
FLUOROURACIL;DPYD;rs72547601;C;LADME_PK;DECREASED_ACTIVITY;DPYD
BUPROPION;CYP2B6;rs201500445;C;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B;*1/*3A + *1/*3B;LADME_PK;DECREASED_ENZYME_ACTIVITY;TPMT
FLUOROURACIL;DPYD;rs188052243;C;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;DPYD
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A;LADME_PK;DECREASED_ENZYME_ACTIVITY;TPMT
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;LADME_PK;DECREASED_ENZYME_ACTIVITY;TPMT
DAUNORUBICIN, DOXORUBICIN;AKR7A2;rs1043657;T;LADME_PK;DECREASED_ENZYME_ACTIVITY;AKR7A2
DAUNORUBICIN;AKR1C4;rs17134592;G;LADME_PK;DECREASED_ENZYME_ACTIVITY;AKR1C4
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*1;LADME_PK;INCREASED_ENZYME_ACTIVITY;TPMT
MERCAPTOPURINE;TPMT;rs3931660;AT;LADME_PK;DECREASED_ENZYME_ACTIVITY;TPMT
MERCAPTOPURINE;TPMT;rs1142345;CT;LADME_PK;DECREASED_ENZYME_ACTIVITY;TPMT
DAUNORUBICIN;AKR1C3;rs4987102;A;LADME_PK;DECREASED_ENZYME_ACTIVITY;AKR1C3
DAUNORUBICIN, DOXORUBICIN;AKR1C3;rs35575889;T;LADME_PK;DECREASED_ENZYME_ACTIVITY;AKR1C3
DAUNORUBICIN, DOXORUBICIN;AKR1C3;rs34186955;T;LADME_PK;DECREASED_ENZYME_ACTIVITY;AKR1C3
;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*5, TPMT*12, TPMT*14, TPMT*18, TPMT*22;*2 + *3A + *5 + *12 + *14 + *18 + *22;LADME_PK;DECREASED_EXPRESSION;TPMT
FLUOROURACIL;DPYD;rs72549306;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;DPYD
SN-38;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*37;*1/*28 + *28/*28 + *1/*37;LADME_PK;DECREASED_ENZYME_ACTIVITY;UGT1A1
SN-38;UGT1A1;rs4148323;A;LADME_PK;DECREASED_ENZYME_ACTIVITY;UGT1A1
FLUOROURACIL;DPYD;rs137999090;T;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs145773863;T;LADME_PK;DECREASED_ACTIVITY;DPYD
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs200858900;T;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;ABCC4
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;LADME_PK;DECREASED_ACTIVITY;TPMT
FLUOROURACIL;DPYD;rs59086055;A;LADME_PK;DECREASED_ACTIVITY;DPYD
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3B, TPMT*3C;*3B/*3C;LADME_PK;DECREASED_ENZYME_ACTIVITY;TPMT
PURINE ANALOGUES;TPMT;rs1142345;CT;OTHER, LADME_PK;DECREASED_ACTIVITY;TPMT
ELEXACAFTOR, TEZACAFTOR;CFTR;rs1792306355;T;EFFICACY;INCREASED_ACTIVITY;CFTR
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR;CFTR;rs186089140;CT;LADME_PD;INCREASED_ACTIVITY;CFTR
ELEXACAFTOR / TEZACAFTOR / IVACAFTOR, IVACAFTOR / TEZACAFTOR;CFTR;rs35516286;A;LADME_PD;INCREASED_ACTIVITY;CFTR
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs143718310;G;LADME_PK;DECREASED_METABOLISM;
ENALAPRIL;CES1;rs202121317;C;LADME_PK;DECREASED_ENZYME_ACTIVITY;
REMIMAZOLAM;CES1;rs2307240;T;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;CES1
CLOPIDOGREL;CES1;rs202001817;A;LADME_PK;DECREASED_ENZYME_ACTIVITY;
REMIMAZOLAM;CES1;rs71647871;T;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CES1
REMIMAZOLAM;CES1;rs151291296;C;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CES1
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs151291296;C;LADME_PK;DECREASED_ENZYME_ACTIVITY;
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs146456965;A;LADME_PK;DECREASED_METABOLISM;
REMIMAZOLAM;CES1;rs143718310;G;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CES1
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs200707504;C;LADME_PK;DECREASED_ENZYME_ACTIVITY;
ENALAPRIL;CES1;rs2307243;T;LADME_PK;DECREASED_ENZYME_ACTIVITY;
REMIMAZOLAM;CES1;rs200707504;C;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CES1
BUPROPION;CYP2B6;rs58871670;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
FLUOROURACIL;DPYD;rs755692084;G;LADME_PK;DECREASED_ACTIVITY;DPYD
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*5, TPMT*6, TPMT*8, TPMT*10, TPMT*11, TPMT*12, TPMT*13;*2 + *3A + *3B + *3C + *5 + *6 + *8 + *10 + *11 + *12 + *13;LADME_PK;DECREASED_ENZYME_ACTIVITY;TPMT
THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C, TPMT*5, TPMT*6, TPMT*7, TPMT*9, TPMT*10, TPMT*12, TPMT*14, TPMT*17, TPMT*18, TPMT*19, TPMT*20, TPMT*21, TPMT*22, TPMT*23, TPMT*30;*2 + *3A + *3B + *3C + *5 + *6 + *7 + *9 + *10 + *12 + *14 + *17 + *18 + *19 + *20 + *21 + *22 + *23 + *30;LADME_PK;DECREASED_ENZYME_ACTIVITY;TPMT
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C;LADME_PK;DECREASED_ENZYME_ACTIVITY;TPMT
ELEXACAFTOR, TEZACAFTOR;CFTR;rs758900656;T;EFFICACY;INCREASED_ACTIVITY;CFTR
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs11568681;T;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;ABCC4
FLUOROURACIL;DPYD;rs183385770;T;LADME_PK;DECREASED_ACTIVITY;DPYD
ESLICARBAZEPINE ACETATE;AADAC;rs35084477;A;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;AADAC
ESLICARBAZEPINE ACETATE;AADAC;rs1803155;A;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;AADAC
ESLICARBAZEPINE ACETATE;AADAC;rs61733692;C;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;AADAC
FLUOROURACIL;DPYD;rs114096998;T;LADME_PK;INCREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs60139309;C;LADME_PK;INCREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs143986398;C;LADME_PK;DECREASED_ACTIVITY;DPYD
SN-38;UGT1A9;rs11692021;C;LADME_PK;DECREASED_ENZYME_ACTIVITY;UGT1A1
SN-38;UGT1A9;rs72551344;G;LADME_PK;DECREASED_ENZYME_ACTIVITY;UGT1A1
SN-38;UGT1A9;rs34993780;G;LADME_PK;DECREASED_ENZYME_ACTIVITY;UGT1A1
FLUOROURACIL;DPYD;rs72549308;G;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs1184321568;del;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs143879757;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs59086055;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs148994843;T;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;DPYD
DEXTROMETHORPHAN;;rs729559;GG;LADME_PK;INCREASED_ENZYME_ACTIVITY;CYP2D6
FLUOROURACIL;DPYD;rs748620513;G;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;DPYD
DEXTROMETHORPHAN;;rs4073010;TT;LADME_PK;INCREASED_ENZYME_ACTIVITY;CYP2D6
FLUOROURACIL;DPYD;rs72549304;A;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs200687447;T;LADME_PK;INCREASED_ACTIVITY;DPYD
ESLICARBAZEPINE ACETATE;AADAC;rs144650170;G;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;AADAC
FLUOROURACIL;DPYD;rs146356975;C;LADME_PK;DECREASED_ACTIVITY;DPYD
ESLICARBAZEPINE ACETATE;AADAC;rs140197497;G;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;AADAC
FLUOROURACIL;DPYD;rs2297595;C;LADME_PK;INCREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs183105782;G;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs190577302;C;LADME_PK;DECREASED_ACTIVITY;DPYD
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs11568644;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;ABCC4
17BETA-ESTRADIOL GLUCURONIDE;ABCC4;rs142211148;T;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;ABCC4
FLUOROURACIL;DPYD;rs186169810;C;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs143154602;A;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs368146607;G;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs371258350;T;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs575853463;T;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs569661196;G;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs138616379;T;LADME_PK;DECREASED_ACTIVITY;DPYD
AMISULPRIDE, ARIPIPRAZOLE, OLANZAPINE, RISPERIDONE;ABCB1;rs2229109;T;LADME_PK;DECREASED_TRANSPORT;ABCB1
FLUOROURACIL;DPYD;rs115232898;C;LADME_PK;DECREASED_ACTIVITY;DPYD
CLOZAPINE;UGT1A4;rs2011425;G;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;UGT1A4
FLUOROURACIL;DPYD;rs111858276;C;LADME_PK;DECREASED_ACTIVITY;DPYD
ACETAMINOPHEN;UGT1A6;UGT1A6*1a, UGT1A6*2a;*2a;LADME_PK;INCREASED_ACTIVITY;UGT1A6
FLUOROURACIL;DPYD;rs140039091;G;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs187713395;G;LADME_PK;DECREASED_ACTIVITY;DPYD
SN-38;UGT1A9;rs35350960;A;LADME_PK;DECREASED_ENZYME_ACTIVITY;UGT1A1
ESLICARBAZEPINE ACETATE;AADAC;rs186388618;T;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;AADAC
ELEXACAFTOR, TEZACAFTOR;CFTR;rs397508139;A;EFFICACY;INCREASED_ACTIVITY;CFTR
FLUOROURACIL;MIR27A;rs895819;C;LADME_PK;DECREASED_ENZYME_ACTIVITY;DPYD
ELEXACAFTOR, TEZACAFTOR;CFTR;rs397508609;A;EFFICACY;INCREASED_ACTIVITY;CFTR
FLUOROURACIL;DPYD;rs141044036;C;LADME_PK;DECREASED_ACTIVITY;DPYD
ARACHIDONIC ACID;CYP4F2;rs753169154;G;LADME_PD;DECREASED_CATALYTIC_ACTIVITY;CYP4F2
EFAVIRENZ;CYP2B6;rs201500445;C;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
BUPROPION;CYP2B6;rs535039125;T;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
EFAVIRENZ;CYP2B6;rs117872433;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
BUPROPION;CYP2B6;rs200238771;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
ARACHIDONIC ACID;CYP4F2;rs114396708;A;LADME_PD;DECREASED_CATALYTIC_ACTIVITY;CYP4F2
COUMARIN, NICOTINE, TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*7, CYP2A6*19;*7 + *19;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2A6
BUPROPION;CYP2B6;CYP2B6*47;*47;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
NICOTINE;CYP2A6;rs4803381;CC + CT;LADME_PK;INCREASED_ACTIVITY;CYP2A6
EFAVIRENZ;CYP2B6;CYP2B6*47;*47;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
NICOTINE;CYP2A6;rs57837628;AG + GG;LADME_PK;INCREASED_ACTIVITY;CYP2A6
COUMARIN, TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*18;*18;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2A6
FLUOROURACIL;DPYD;rs67376798;A;LADME_PK;DECREASED_ACTIVITY;DPYD
EFAVIRENZ;CYP2B6;CYP2B6*46;*46;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
NICOTINE;CYP2A6;rs72549435;C;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2A6
EFAVIRENZ;CYP2B6;rs535039125;T;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
PREGNENOLONE;SULT2B1;rs746398875;T;LADME_PK;DECREASED_ENZYME_ACTIVITY;SULT2B1
PREGNENOLONE;SULT2B1;rs762765702;A;LADME_PK;DECREASED_ENZYME_ACTIVITY;SULT2B1
COUMARIN;CYP2A6;CYP2A6*4, CYP2A6*9;*4/*9;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2A6
BUPROPION;CYP2B6;rs374099483;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
BUPROPION;CYP2B6;rs764288403;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
BUPROPION;CYP2B6;CYP2B6*46;*46;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
EFAVIRENZ;CYP2B6;rs374099483;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
BUPROPION;CYP2B6;rs117872433;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
FLUOROURACIL;DPYD;rs112766203;A;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs1801158;TT;OTHER;INCREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs188052243;C;LADME_PK;DECREASED_ACTIVITY;DPYD
PREGNENOLONE;SULT2B1;rs527454384;T;LADME_PK;DECREASED_ENZYME_ACTIVITY;SULT2B1
FLUOROURACIL;DPYD;rs61757362;A;LADME_PK;DECREASED_ACTIVITY;DPYD
ARACHIDONIC ACID;CYP4F2;rs2108622;T;LADME_PD;DECREASED_CATALYTIC_ACTIVITY;CYP4F2
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*17, CYP2A6*35;*17 + *35;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2A6
BUPROPION;CYP2B6;rs148009906;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
ELEXACAFTOR, TEZACAFTOR;CFTR;rs397508293;T;EFFICACY;INCREASED_ACTIVITY;CFTR
FLUOROURACIL;DPYD;rs1801268;A;LADME_PK;DECREASED_ACTIVITY;DPYD
BUPROPION;CYP2B6;rs200458614;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
EFAVIRENZ;CYP2B6;rs764288403;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
EFAVIRENZ;CYP2B6;rs200238771;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
FLUOROURACIL;DPYD;rs367619008;C;LADME_PK;DECREASED_ACTIVITY;DPYD
EFAVIRENZ;CYP2B6;rs200458614;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
NICOTINE;CYP2A6;rs56113850;CC + CT;LADME_PK;INCREASED_ACTIVITY;CYP2A6
FLUOROURACIL;DPYD;rs758649719;T;LADME_PK;DECREASED_ACTIVITY;DPYD
NICOTINE;CYP2A6;rs7259706;TT;LADME_PK;INCREASED_ACTIVITY;CYP2A6
FLUOROURACIL;DPYD;rs369103276;G;LADME_PK;DECREASED_ACTIVITY;DPYD
VANDETANIB;CYP3A4;CYP3A4*1, CYP3A4*6, CYP3A4*30;*6 + *30;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP3A4
NICOTINE;CYP2A6;rs28399453;AA + AG;LADME_PK;INCREASED_ACTIVITY;CYP2A6
NICOTINE;CYP2A6;rs8192733;CC + CG;LADME_PK;INCREASED_ACTIVITY;CYP2A6
EFAVIRENZ;CYP2B6;rs148009906;A;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2B6
PREGNENOLONE;SULT2B1;rs777924668;G;LADME_PK;DECREASED_ENZYME_ACTIVITY;SULT2B1
FLUOROURACIL;DPYD;rs55674432;A;LADME_PK;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs55886062;CC;OTHER;DECREASED_ACTIVITY;DPYD
LETROZOLE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*1/*4 + *1/*7 + *4/*4 + *4/*9;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP2A6
NICOTINE;CYP2A6;rs7260629;GG;LADME_PK;INCREASED_ACTIVITY;CYP2A6
FLUOROURACIL;DPYD;rs1801265;GG;OTHER;INCREASED_ACTIVITY;DPYD
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*89, CYP2D6*92, CYP2D6*93, CYP2D6*96;*89 + *92 + *93 + *96;LADME_PK;DECREASED_CATALYTIC_ACTIVITY;CYP2D6
PREGNENOLONE;SULT2B1;rs777140014;A;LADME_PK;DECREASED_ENZYME_ACTIVITY;SULT2B1
TESTOSTERONE;CYP3A5;rs55817950;A;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP3A5
NIFEDIPINE;CYP3A5;rs72552791;C;LADME_PK;DECREASED_ENZYME_ACTIVITY;CYP3A5
PREGNENOLONE;SULT2B1;rs774212320;T;LADME_PK;DECREASED_ENZYME_ACTIVITY;SULT2B1
;CYP2C9;rs762081829;T;OTHER;DECREASED_EXPRESSION;CYP2C9protein
;SLCO1B1;SLCO1B1*1, SLCO1B1*14;*14;OTHER;INCREASED_EXPRESSION;SLCO1B1protein
;VDR;rs11568820;T;OTHER;INCREASED_STEADY_STATE_LEVEL;CYP3A4protein
;A2M;rs669;T;LADME_PK;INCREASED_STEADY_STATE_LEVEL;A2Mprotein
;SLCO1B1;SLCO1B1*1, SLCO1B1*37;*37;OTHER;INCREASED_EXPRESSION;SLCO1B1protein
;NAMPT;rs1319501;CC + CT;OTHER;DECREASED_STEADY_STATE_LEVEL;NAMPcTprotein
;DPYD;rs1801160;T;OTHER;INCREASED_EXPRESSION;DPYDprotein
;NAMPT;rs3801266;CC + CT;OTHER;INCREASED_STEADY_STATE_LEVEL;NAMPcTprotein
;SLCO1B1;SLCO1B1*1, SLCO1B1*20;*20;OTHER;INCREASED_EXPRESSION;SLCO1B1protein
;ABCC11;rs17822471;AA + AG;OTHER;DECREASED_EXPRESSION;ABCC11protein
;CYP2C9;rs771237265;C;OTHER;DECREASED_EXPRESSION;CYP2C9protein
;CYP2C9;rs761895497;C;OTHER;DECREASED_EXPRESSION;CYP2C9protein
;CYP2C19;rs183701923;T;OTHER;DECREASED_EXPRESSION;CYP2C19protein
;DPYD;rs748620513;G;OTHER;INCREASED_EXPRESSION;DPYDprotein
;CYP2C19;rs61311738;T;OTHER;DECREASED_EXPRESSION;CYP2C19protein
;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;;DECREASED_ENZYME_ACTIVITY;TPMTprotein
;DPYD;rs143879757;A;OTHER;INCREASED_EXPRESSION;DPYDprotein
;DPYD;rs1212037891;T;OTHER;INCREASED_EXPRESSION;DPYDprotein
;DPYD;rs72549306;A;OTHER;INCREASED_EXPRESSION;DPYDprotein
;CYP2C19;rs140278421;A;OTHER;DECREASED_EXPRESSION;CYP2C19protein
DOXORUBICIN;CBR1;rs9024;GG;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;CBR1
DOXORUBICIN;CBR1;rs9024;GG;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;CBR1
;ADRB2;rs1042713;G;OTHER;DECREASED_ACTIVITY;ADRB2
;NOS3;rs1799983;GT + TT;;DECREASED_EXPRESSION;NOS3mRNA
;IL18;rs5744247;CC + CG;OTHER;INCREASED_EXPRESSION;IL18mRNA
;IL18;rs1946518;GG + GT;OTHER;INCREASED_EXPRESSION;IL18mRNA
;CYP3A5;rs776746;CC;OTHER;DECREASED_EXPRESSION;CYP3A5mRNA
;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PD;DECREASED_EXPRESSION;HDAC2mRNA
;CYP3A5;rs776746;TT;OTHER;INCREASED_EXPRESSION;CYP3A5mRNA
;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PD;DECREASED_EXPRESSION;FKBP5mRNA
;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PD;DECREASED_EXPRESSION;NR3C1mRNA
;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PD;DECREASED_EXPRESSION;GLCCI1mRNA
;ERCC1;rs2298881;A;OTHER;DECREASED_EXPRESSION;ERCC1mRNA
;HSPA5;rs430397;TT;OTHER;INCREASED_EXPRESSION;HSPA5mRNA
;CCND1;rs9344;AA + AG;OTHER;INCREASED_TRANSCRIPTION;CCND1mRNA
;ABCC2;rs113646094;CG;OTHER;INCREASED_EXPRESSION;ABCC2mRNA
;ABCB1;rs1128503;GG;;INCREASED_EXPRESSION;ABCB1mRNA
;XRCC4;rs2075685;T;OTHER;INCREASED_EXPRESSION;XRCC4mRNA
;XRCC4;rs10040363;G;OTHER;INCREASED_EXPRESSION;ERCC1mRNA
;GCLC;rs761142;CC;OTHER;DECREASED_EXPRESSION;GCLCmRNA
;BCL2L11;rs724710;T;OTHER;DECREASED_EXPRESSION;BCL2L11mRNA
;EPO;rs1617640;AA;OTHER;INCREASED_EXPRESSION;EPOmRNA
;KDR;rs34231037;G;OTHER;DECREASED_STEADY_STATE_LEVEL;KDR
METHOTREXATE;GGH;rs11545078;A;LADME_PK;DECREASED_CLEARANCE;
;DPYD;rs1801265;G;LADME_PK;INCREASED_ACTIVITY;DPYD
;FCER2;rs28364072;GG;;DECREASED_EXPRESSION;FCER2
;DPYD;rs114096998;T;OTHER;DECREASED_CATALYTIC_ACTIVITY;DPYD
;DPYD;rs55886062;AC;OTHER;DECREASED_ACTIVITY;DPYD
;MGMT;rs4751104;G;LADME_PK;INCREASED_TRANSCRIPTION;MGMT
;ERCC2;rs1799793;TT;;INCREASED_EXPRESSION;ERCC2
CISPLATIN;ERCC2;rs13181;GG;TOXICITY;DECREASED_SENSITIVITY;
;ERCC2;rs13181;GG;;INCREASED_EXPRESSION;ERCC2
;GSTT1;rs1007888;T;LADME_PK;INCREASED_TRANSCRIPTION;GSTT1
;KCNQ3;rs7818112;AA;OTHER;INCREASED_TRANSCRIPTION;ABCB1
;GSK3B;rs334558;A;;INCREASED_TRANSCRIPTION;GSK3B
CISPLATIN;GSTP1;rs1695;AG;TOXICITY;DECREASED_SENSITIVITY;
BUSULFAN;GSTM1;rs3754446;C;LADME_PK;INCREASED_CLEARANCE;
;DPYD;rs780025995;A;OTHER;DECREASED_CATALYTIC_ACTIVITY;DPYD
;F12;rs1801020;G;LADME_PK;INCREASED_ENZYME_ACTIVITY;F12
;ERCC1;rs11615;GG;;INCREASED_EXPRESSION;ERCC1
;IL7;rs16906115;AA + AG;OTHER;INCREASED_EXPRESSION;IL7
;F3;rs841698;T;;INCREASED_EXPRESSION;ABCD3
;DPYD;rs56038477;CT + TT;LADME_PK;DECREASED_ACTIVITY;DPYD
;DPYD;rs2297595;C;OTHER;DECREASED_ACTIVITY;DPYD
;DPYD;rs1801160;CT + TT;LADME_PK;DECREASED_ACTIVITY;DPYD
;DPYD;rs2297595;CC + CT;LADME_PK;DECREASED_ACTIVITY;DPYD
;HPR;rs2000999;G;OTHER;INCREASED_EXPRESSION;HP
FLUOROURACIL;DPYD;rs4294451;A;TOXICITY;INCREASED_SENSITIVITY;
;DPYD;rs115232898;CT;OTHER;DECREASED_ACTIVITY;DPYD
;DPYD;rs4294451;T;OTHER;INCREASED_EXPRESSION;DPYD
TAMOXIFEN;E2F7;rs310786;CC;OTHER;INCREASED_SENSITIVITY;
;ECHDC1;rs6569487;AA;OTHER;INCREASED_TRANSCRIPTION;ABCB1
;EGFR;rs712829;TT;;INCREASED_EXPRESSION;EGFR
;HLA-G;rs1063320;C;OTHER;INCREASED_EXPRESSION;HLA-G
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;OTHER;INCREASED_SENSITIVITY;
;DPYD;rs3918290;CT;OTHER;DECREASED_ACTIVITY;DPYD
;IFNL3;rs4803217;C;OTHER;INCREASED_EXPRESSION;IFNL3
;DPYD;rs3918290;CT;OTHER;DECREASED_ACTIVITY;DPYD
CISPLATIN;ERCC1;rs11615;GG;TOXICITY;DECREASED_SENSITIVITY;
;DPYD;rs748639205;G;OTHER;DECREASED_CATALYTIC_ACTIVITY;DPYD
;DPYD;rs75017182;CG;OTHER;DECREASED_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs3918290;CT;OTHER;DECREASED_CLEARANCE;
;IFNL4;rs11322783;TT/TT;OTHER;INCREASED_EXPRESSION;IFNAR1
;DPYD;rs75017182;C;LADME_PK;DECREASED_ACTIVITY;DPYD
;IMPDH2;rs121434586;A;OTHER;DECREASED_ENZYME_ACTIVITY;IMPDH2
;DPYD;rs67376798;A;OTHER;DECREASED_ACTIVITY;DPYD
CALCIUM;RYR1;rs118192167;AG;OTHER;INCREASED_STEADY_STATE_LEVEL;
;MIR6076;rs1463411;G;OTHER;DECREASED_EXPRESSION;P2RY12
DESMETHYLNAPROXEN;SULT1A1;rs28374453;G;LADME_PK;INCREASED_SULFATION;
ACETAMINOPHEN;SULT1A1;rs28374453;G;LADME_PK;INCREASED_SULFATION;
DESMETHYLNAPROXEN;SULT1A1;rs1042008;A;LADME_PK;DECREASED_SULFATION;
ACETAMINOPHEN;SULT1A1;rs1042008;A;LADME_PK;DECREASED_SULFATION;
DESMETHYLNAPROXEN;SULT1A1;rs758145522;T;LADME_PK;DECREASED_SULFATION;
DESMETHYLNAPROXEN;SULT1A1;rs767487725;C;LADME_PK;DECREASED_SULFATION;
ACETAMINOPHEN;SULT1A1;rs72547527;T;LADME_PK;DECREASED_SULFATION;
TAPENTADOL;SULT1A1;rs1042008;A;LADME_PK;DECREASED_SULFATION;
ACETAMINOPHEN;SULT1A1;rs767487725;C;LADME_PK;DECREASED_SULFATION;
DESMETHYLNAPROXEN;SULT1A1;rs1042028;T;LADME_PK;DECREASED_SULFATION;
ACETAMINOPHEN;SULT1A1;rs544820732;A;LADME_PK;DECREASED_SULFATION;
;TBXAS1;rs6962291;AA;OTHER;DECREASED_STEADY_STATE_LEVEL;TBX2
;TBXAS1;rs6962291;AA;OTHER;DECREASED_EXPRESSION;TBXAS1
;TMPRSS11E;rs2168047;T;;INCREASED_EXPRESSION;UGT2B4
;TNF;rs1800629;AA + AG;LADME_PK;INCREASED_ACTIVITY;TNF
;TPH2;rs7305115;AA;OTHER;INCREASED_EXPRESSION;TPH2
;TPH2;rs4290270;T;OTHER;INCREASED_EXPRESSION;TPH2
THIOGUANINE;TPMT;TPMT*1, TPMT*7, TPMT*10, TPMT*12, TPMT*13;*7 + *10 + *12 + *13;LADME_PK;DECREASED_CLEARANCE;
;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*3A + *3C;OTHER;DECREASED_ACTIVITY;TPMT
ACETAMINOPHEN;SULT1A1;rs765399160;T;LADME_PK;INCREASED_SULFATION;
;TPMT;TPMT*1, TPMT*3A, TPMT*3C, TPMT*24;*3A + *3C + *24;OTHER;DECREASED_EXPRESSION;TPMT
ACETAMINOPHEN;SULT1A1;rs552524124;G;LADME_PK;DECREASED_SULFATION;
TAPENTADOL;SULT1A1;rs1042028;T;LADME_PK;DECREASED_SULFATION;
ATORVASTATIN, CERIVASTATIN, PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15;LADME_PK;DECREASED_UPTAKE;
PACLITAXEL;SLCO1B3;rs7311358;A;OTHER;DECREASED_TRANSPORT;
ROSUVASTATIN;SLCO2B1;rs2306168;T;LADME_PK;DECREASED_UPTAKE;
ROSUVASTATIN;SLCO2B1;rs142693902;A;LADME_PK;DECREASED_UPTAKE;
ROSUVASTATIN;SLCO2B1;rs35199625;A;LADME_PK;DECREASED_UPTAKE;
METHOTREXATE;SOD2;rs4880;G;TOXICITY;DECREASED_SENSITIVITY;
;SPAG16;rs35945601;CC;OTHER;INCREASED_TRANSCRIPTION;ABCB1
;SQSTM1;rs10277;C;LADME_PK;INCREASED_TRANSCRIPTION;SQSTM1
;STXBP4;rs9303363;AA;OTHER;INCREASED_TRANSCRIPTION;ABCB1
DESMETHYLNAPROXEN;SULT1A1;rs552524124;G;LADME_PK;DECREASED_SULFATION;
TAPENTADOL;SULT1A1;rs758145522;T;LADME_PK;DECREASED_SULFATION;
TAPENTADOL;SULT1A1;rs72547527;T;LADME_PK;DECREASED_SULFATION;
TAPENTADOL;SULT1A1;rs544820732;A;LADME_PK;DECREASED_SULFATION;
TAPENTADOL;SULT1A1;rs767487725;C;LADME_PK;DECREASED_SULFATION;
DESMETHYLNAPROXEN;SULT1A1;rs544820732;A;LADME_PK;DECREASED_SULFATION;
ACETAMINOPHEN;SULT1A1;rs1042028;T;LADME_PK;DECREASED_SULFATION;
DESMETHYLNAPROXEN;SULT1A1;rs72547527;T;LADME_PK;DECREASED_SULFATION;
TAPENTADOL;SULT1A1;rs552524124;G;LADME_PK;DECREASED_SULFATION;
TAPENTADOL;SULT1A1;rs28374453;G;LADME_PK;INCREASED_SULFATION;
ACETAMINOPHEN;SULT1A1;rs758145522;T;LADME_PK;DECREASED_SULFATION;
ATORVASTATIN, CERIVASTATIN, PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*5;LADME_PK;DECREASED_UPTAKE;
MERCAPTOPURINE;TPMT;TPMT deficiency;;TOXICITY, LADME_PK;INCREASED_CONCENTRATIONS;
CISPLATIN;TPMT;TPMT*1, TPMT*3A;*3A;TOXICITY;INCREASED_SENSITIVITY;
SN-38;UGT1A9;rs2741049;CT + TT;LADME_PK;INCREASED_CLEARANCE;
;UGT1A9;rs3832043;T/del + TT;LADME_PK;INCREASED_FORMATION;UGT1A9
;UGT1A9;rs2741049;TT;LADME_PK;INCREASED_FORMATION;UGT1A1
SN-38;UGT1A9;rs3806598;AA;LADME_PK;INCREASED_CLEARANCE;
;UGT1A9;rs3832043;T/del + TT;LADME_PK;INCREASED_FORMATION;UGT1A1
SN-38;UGT1A9;rs3832043;T/del + TT;LADME_PK;INCREASED_CLEARANCE;
;UGT1A9;rs2741049;CT + TT;LADME_PK;INCREASED_FORMATION;UGT1A9
OLANZAPINE;UGT2B10;rs61750900;GT + TT;LADME_PK;DECREASED_GLUCURONIDATION;
LORAZEPAM;UGT2B15;rs1902023;AA;LADME_PK;DECREASED_CLEARANCE;
OXAZEPAM;UGT2B15;rs1902023;A;OTHER;DECREASED_GLUCURONIDATION;
;UGT2B17;rs6817882;C;OTHER;INCREASED_EXPRESSION;UGT2B17
;UGT2B4;rs4557343;T;;INCREASED_EXPRESSION;UGT2B15
BUPRENORPHINE;UGT2B7;rs7438135;A;LADME_PK;INCREASED_GLUCURONIDATION;
;UMPS;rs1801019;C;LADME_PK;INCREASED_EXPRESSION;UMPS
;VKORC1;rs56314408;C;OTHER;INCREASED_TRANSCRIPTION;VKORC1
;VKORC1;rs9923231;T;;DECREASED_EXPRESSION;VKORC1
;WBP2NL;rs5758550;AG + GG;OTHER;INCREASED_EXPRESSION;CYP2D6
;YAP1;rs1820453;C;;DECREASED_TRANSCRIPTION;YAP1
;YEATS4;rs7297610;CC;LADME_PK;INCREASED_EXPRESSION;YEATS4
RALOXIFENE;UGT1A8;UGT1A8*1a, UGT1A8*2;*2/*2;LADME_PK;INCREASED_CLEARANCE;
THIOGUANINE;TPMT;TPMT*1, TPMT*16;*16;LADME_PK;DECREASED_CLEARANCE;
VALPROIC ACID;UGT1A6;rs1105879;C;LADME_PK;INCREASED_GLUCURONIDATION;
CLOZAPINE 5-N-GLUCURONIDE, DESMETHYLCLOZAPINE GLUCURONIDE;UGT1A4;rs2011425;G;LADME_PK;INCREASED_FORMATION;
CISPLATIN;TPMT;TPMT*1, TPMT*3A;*3A;TOXICITY;INCREASED_SENSITIVITY;
;TXLNB;rs9495425;CC;OTHER;INCREASED_TRANSCRIPTION;ABCB1
;UGT1A1;rs4124874;GG + GT;LADME_PK;DECREASED_FORMATION;UGT1A1
SN-38;UGT1A1;rs4124874;GG + GT;LADME_PK;DECREASED_CLEARANCE;
OXAZEPAM;UGT1A1;rs10929302;A;OTHER;DECREASED_GLUCURONIDATION;
;UGT1A1;rs10929302;A;OTHER;DECREASED_CONCENTRATIONS;UGT1A1
;UGT1A1;rs28967009;A;OTHER;INCREASED_EXPRESSION;UGT1A1
SN-38;UGT1A1;rs4148323;AG;LADME_PK;DECREASED_CLEARANCE;
;UGT1A1;rs4148323;AG;LADME_PK;DECREASED_FORMATION;UGT1A1
OXAZEPAM;UGT1A1;rs887829;T;OTHER;DECREASED_GLUCURONIDATION;
OXAZEPAM;UGT1A1;rs4124874;G;OTHER;ASSOCIATED_GLUCURONIDATION;
;UGT1A1;UGT1A1*1, UGT1A1*28;*28;OTHER;DECREASED_CONCENTRATIONS;UGT1A1
CLOZAPINE;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;LADME_PK;DECREASED_METABOLISM;
BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*28;*28;LADME_PK;DECREASED_METABOLISM;
;UGT1A1;rs887829;T;OTHER;DECREASED_CONCENTRATIONS;UGT1A1
;UGT1A1;rs4124874;G;OTHER;DECREASED_CONCENTRATIONS;UGT1A1
RALOXIFENE 6-GLUCURONIDE;UGT1A1;UGT1A1*1, UGT1A1*28;*28;LADME_PK;DECREASED_FORMATION;
;UGT1A1;rs11568319;CG;LADME_PK;DECREASED_FORMATION;UGT1A1
;UGT1A3;rs7604115;T;OTHER;INCREASED_EXPRESSION;UGT1A3
OLANZAPINE;UGT1A4;UGT1A4*1a, UGT1A4*3a;*3a;LADME_PK;INCREASED_GLUCURONIDATION;
;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15;OTHER;DECREASED_EXPRESSION;SLCO1B1
ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*14, SLCO1B1*37;*14;LADME_PK;DECREASED_TRANSPORT;
ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*9, SLCO1B1*37;*9;LADME_PK;DECREASED_TRANSPORT;
;PACSIN2;rs2413739;CT + TT;LADME_PK;DECREASED_ACTIVITY;TPMT
;PHETA2, SMDT1;rs1807493;G;LADME_PK;INCREASED_EXPRESSION;CYP2D6
;PITPNM2;rs12425009;C;;DECREASED_EXPRESSION;ABCB9
;PKNOX1;rs2839629;A;OTHER;INCREASED_EXPRESSION;PKNOX1
;PKNOX1;rs2839629;A;OTHER;INCREASED_EXPRESSION;CBS
;PLG;rs783145;G;LADME_PK;DECREASED_TRANSCRIPTION;PRSS55
;PLG;rs783145;G;LADME_PK;INCREASED_TRANSCRIPTION;PLG
;PLXNB3;rs4898439;A;;INCREASED_EXPRESSION;ABCD1
;POR;rs2868177;AG;EFFICACY;INCREASED_ENZYME_ACTIVITY;CYP2B6
;PPARA;rs4253728;AA;LADME_PK;DECREASED_CONCENTRATIONS;CYP3A4
;PROM1;rs2286455;CC;;DECREASED_EXPRESSION;PROM1
;PSMB8, TAP1, TAP2;rs2071543;T;;INCREASED_EXPRESSION;TAP2
;PSMB8, TAP2;rs9357155;A;;INCREASED_EXPRESSION;TAP2
;RALGAPA2;rs3827963;GG;OTHER;INCREASED_TRANSCRIPTION;ABCB1
DOXORUBICIN;RARG;rs2229774;A;TOXICITY;INCREASED_SENSITIVITY;
;RARG;rs2229774;A;OTHER;DECREASED_PROTEIN_STABILITY;RARG
;REDIC1;rs10783969;T;;INCREASED_EXPRESSION;ABCD2
;RGMA;rs7165938;GG;OTHER;INCREASED_TRANSCRIPTION;ABCB1
CAFFEINE;RYR1;rs193922753;T;OTHER;INCREASED_SENSITIVITY;
;ORMDL3;rs2872507;AG + GG;LADME_PK;INCREASED_EXPRESSION;ORMDL3
CAFFEINE, CHLOROCRESOL, HALOTHANE;RYR1;rs118204423;C;OTHER;INCREASED_SENSITIVITY;
ETHANOL;OPRM1;rs1799971;GG;EFFICACY;DECREASED_SENSITIVITY;
;NT5C2;rs11191612;GG;LADME_PK;INCREASED_TRANSCRIPTION;NT5C2
PAROMOMYCIN;MT-RNR1;rs267606619;T;LADME_PD;INCREASED_SENSITIVITY;
GEMCITABINE;MTHFR;rs1801131;GG + GT;TOXICITY;INCREASED_SENSITIVITY;
;NAF1;rs17571991;AA;OTHER;INCREASED_TRANSCRIPTION;ABCC1
SOLITHROMYCIN;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*14;*4;LADME_PK;INCREASED_METABOLISM;
;NAT2;rs4646244;A;OTHER;DECREASED_TRANSCRIPTION;NAT2
;NCOA1;rs1804645;T;;INCREASED_HALF_LIFE;NCOA1
;NFATC2;rs6021191;T;OTHER;INCREASED_EXPRESSION;NFATC2
;NHLH1;rs11265375;T;OTHER;INCREASED_LUCIFERASE_ACTIVITY;
;NQO1;rs1800566;AA;;DECREASED_ENZYME_ACTIVITY;NQO1
;NQO1;rs1800566;A;;DECREASED_EXPRESSION;NQO1
MIDAZOLAM;NR1I2;rs1464602;G;LADME_PK;INCREASED_CLEARANCE;
MIDAZOLAM;NR1I2;rs1464603;G;LADME_PK;INCREASED_CLEARANCE;
;NRP2;rs10932125;C;;INCREASED_EXPRESSION;CYP1B1
CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;rs201045130;G;OTHER;DECREASED_SENSITIVITY;
CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;rs370457585;T;OTHER;DECREASED_SENSITIVITY;
CLADRIBINE, FLUOROURACIL, GEMCITABINE;NT5C1A;rs374150125;A;OTHER;DECREASED_SENSITIVITY;
CYTARABINE;NT5C2;rs1163075;G;EFFICACY;DECREASED_SENSITIVITY;
;NT5C2;rs1163075;G;LADME_PK;INCREASED_TRANSCRIPTION;NT5C2
CYTARABINE;NT5C2;rs11191612;GG;EFFICACY;DECREASED_SENSITIVITY;
;NT5E;rs9450278;A;;DECREASED_EXPRESSION;NT5E
CHLOROCRESOL;RYR1;rs121918596;del;OTHER;INCREASED_SENSITIVITY;
CAFFEINE;RYR1;rs193922843;T;DOSAGE;INCREASED_SENSITIVITY;
CAFFEINE;RYR1;rs193922816;T;OTHER;INCREASED_SENSITIVITY;
CAFFEINE;RYR1;rs118192176;A;OTHER;INCREASED_SENSITIVITY;
;SEMA6A;rs3806915;A;OTHER;INCREASED_LUCIFERASE_ACTIVITY;
;SEPTIN3, WBP2NL;rs1062753;G;LADME_PK;INCREASED_EXPRESSION;CYP2D6
RANITIDINE;SLC22A1;rs12208357;T;LADME_PK;DECREASED_TRANSPORT;
RANITIDINE;SLC22A1;rs72552763;del;LADME_PK;DECREASED_TRANSPORT;
RANITIDINE;SLC22A1;rs34130495;A;LADME_PK;DECREASED_TRANSPORT;
;SLC22A3;rs2076828;G;OTHER;DECREASED_EXPRESSION;SLC22A3
;SLC22A3;rs884742;C;LADME_PK;INCREASED_TRANSCRIPTION;SLC22A3
;SLC22A3;rs555754;AA;;INCREASED_EXPRESSION;SLC22A3
ADEFOVIR DIPIVOXIL;SLC22A6;rs11568634;T;OTHER;DECREASED_UPTAKE;
CEFOTAXIME;SLC22A8;rs11568482;A;LADME_PK;DECREASED_TRANSPORT;
GEMCITABINE TRIPHOSPHATE;SLC28A3;rs7867504;CC;LADME_PK;INCREASED_FORMATION;
DOXORUBICIN;SLC28A3;rs11140490;AA;TOXICITY;INCREASED_SENSITIVITY;
;SLC29A1;rs731780;G;OTHER;INCREASED_EXPRESSION;SLC29A1
;SLC29A1;rs70914;A;;INCREASED_EXPRESSION;SLC29A1
;SLCO1A2;rs4148981;T;;DECREASED_EXPRESSION;SLCO1A2
ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*15;LADME_PK;DECREASED_TRANSPORT;
;SLCO1B1;rs4149056;C;OTHER;DECREASED_EXPRESSION;SLCO1B1
ATRASENTAN;SLCO1B1;SLCO1B1*1, SLCO1B1*5, SLCO1B1*37;*5;LADME_PK;DECREASED_TRANSPORT;
CAFFEINE, HALOTHANE;RYR1;rs28933397;CT;OTHER;ASSOCIATED_SENSITIVITY;
CAFFEINE, CHLOROCRESOL;RYR1;rs186983396;T;LADME_PK;INCREASED_SENSITIVITY;
CAFFEINE, CHLOROCRESOL;RYR1;rs118192178;T;OTHER;INCREASED_SENSITIVITY;
CHLOROCRESOL;RYR1;rs118192124;T;OTHER;INCREASED_SENSITIVITY;
CAFFEINE;RYR1;rs118192167;G;OTHER;INCREASED_SENSITIVITY;
CAFFEINE;RYR1;rs193922803;T;DOSAGE;INCREASED_SENSITIVITY;
CAFFEINE;RYR1;rs118192122;A;OTHER;INCREASED_SENSITIVITY;
CAFFEINE;RYR1;rs193922809;A;OTHER;INCREASED_SENSITIVITY;
CAFFEINE;RYR1;rs118192168;A;DOSAGE;INCREASED_SENSITIVITY;
CAFFEINE;RYR1;rs193922832;A;DOSAGE;INCREASED_SENSITIVITY;
CAFFEINE;RYR1;rs112563513;A;DOSAGE;INCREASED_SENSITIVITY;
CAFFEINE, CHLOROCRESOL, HALOTHANE;RYR1;rs121918594;A;OTHER;INCREASED_SENSITIVITY;
CAFFEINE;RYR1;rs193922878;G;OTHER;INCREASED_SENSITIVITY;
;MIR27A;rs895819;CC;OTHER;INCREASED_EXPRESSION;MIR27A
CAFFEINE;RYR1;rs118192161;T;OTHER;INCREASED_SENSITIVITY;
CAFFEINE;RYR1;rs118192177;T;OTHER;INCREASED_SENSITIVITY;
CAFFEINE;RYR1;rs118192167;AG;OTHER;INCREASED_SENSITIVITY;
CAFFEINE, HALOTHANE;RYR1;rs118192172;CT;OTHER;ASSOCIATED_SENSITIVITY;
CAFFEINE, HALOTHANE;RYR1;rs193922772;GT;OTHER;ASSOCIATED_SENSITIVITY;
CAFFEINE, HALOTHANE;RYR1;rs118192175;CT;OTHER;ASSOCIATED_SENSITIVITY;
CAFFEINE, HALOTHANE;RYR1;rs193922747;CT;OTHER;ASSOCIATED_SENSITIVITY;
CAFFEINE, HALOTHANE;RYR1;rs118192176;AG;OTHER;ASSOCIATED_SENSITIVITY;
CHLOROCRESOL;RYR1;rs118192124;T;OTHER;INCREASED_SENSITIVITY;
CAFFEINE, CHLOROCRESOL;RYR1;rs118192178;G;OTHER;INCREASED_SENSITIVITY;
CAFFEINE, CHLOROCRESOL;RYR1;rs193922818;A;OTHER;INCREASED_SENSITIVITY;
;;rs2000068;G;;INCREASED_EXPRESSION;ABCA1
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*17, CYP2D6*18, CYP2D6*35, CYP2D6*39, CYP2D6*53;*17 + *18 + *35 + *39 + *53;LADME_PK;DECREASED_CLEARANCE;
;DPYD;rs1801158;T;OTHER;DECREASED_ACTIVITY;DPYD
EFAVIRENZ;CYP2B6;rs142421637;T;LADME_PK;DECREASED_CLEARANCE;
EFAVIRENZ;CYP2B6;rs373442191;A;LADME_PK;INCREASED_CLEARANCE;
PROPOFOL;CYP2B6;rs752695347;T;LADME_PK;DECREASED_CLEARANCE;
PROPOFOL;CYP2B6;rs142421637;T;LADME_PK;DECREASED_CLEARANCE;
PROPOFOL;CYP2B6;rs1282926098;T;LADME_PK;INCREASED_CLEARANCE;
PROPOFOL;CYP2B6;rs1969136524;C;LADME_PK;DECREASED_CLEARANCE;
EFAVIRENZ;CYP2B6;rs773494867;C;LADME_PK;DECREASED_CLEARANCE;
EFAVIRENZ;CYP2B6;rs1969376664;T;LADME_PK;DECREASED_CLEARANCE;
PROPOFOL;CYP2B6;rs138264188;T;LADME_PK;DECREASED_CLEARANCE;
PROPOFOL;CYP2B6;rs373442191;A;LADME_PK;INCREASED_CLEARANCE;
EFAVIRENZ;CYP2B6;rs1969255598;T;LADME_PK;INCREASED_CLEARANCE;
EFAVIRENZ;CYP2B6;rs1248477767;G;LADME_PK;INCREASED_CLEARANCE;
EFAVIRENZ;CYP2B6;rs750671397;G;LADME_PK;INCREASED_CLEARANCE;
EFAVIRENZ;CYP2B6;rs141666881;A;LADME_PK;INCREASED_CLEARANCE;
EFAVIRENZ;CYP2B6;rs1968919352;G;LADME_PK;INCREASED_CLEARANCE;
EFAVIRENZ;CYP2B6;rs1282926098;T;LADME_PK;INCREASED_CLEARANCE;
R-EDDP, S-EDDP;CYP2B6;CYP2B6*1, CYP2B6*4;*4;LADME_PK;INCREASED_FORMATION;
R-EDDP, S-EDDP;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*6, CYP2B6*7, CYP2B6*9, CYP2B6*17, CYP2B6*18, CYP2B6*19, CYP2B6*26;*5+ *17 + *6+ *7 + *9+ *19 + *26 + *18;LADME_PK;DECREASED_FORMATION;
;CYP2B6;rs70950385;CA/CA;OTHER;DECREASED_ACTIVITY;CYP2B6
EFAVIRENZ;CYP2B6;rs1969136524;C;LADME_PK;DECREASED_CLEARANCE;
EFAVIRENZ;CYP2B6;rs772413158;A;LADME_PK;DECREASED_CLEARANCE;
EFAVIRENZ;CYP2B6;rs752695347;T;LADME_PK;DECREASED_CLEARANCE;
EFAVIRENZ;CYP2B6;rs553968231;T;LADME_PK;DECREASED_CLEARANCE;
;CYP1A2;rs762551;A;;INCREASED_ACTIVITY;CYP1A2
;CYP1A2;rs35694136;del;;DECREASED_ACTIVITY;CYP1A2
DACARBAZINE;CYP1A2;CYP1A2*1, CYP1A2*11;*11;LADME_PK;DECREASED_CLEARANCE;
;CYP1A2;rs762551;AA + AC;LADME_PK;INCREASED_TRANSCRIPTION;CYP1A2
DACARBAZINE;CYP1A2;CYP1A2*1, CYP1A2*3;*3;LADME_PK;DECREASED_CLEARANCE;
;CYP2A6;rs8192720;AA + AG;;INCREASED_EXPRESSION;CYP2A6
;CYP2A6;rs8192725;AG + GG;;INCREASED_EXPRESSION;CYP2A6
;CYP2A6;rs28399433;AC + CC;;DECREASED_EXPRESSION;CYP2A6
;CYP2A6;CYP2A6*4, CYP2A6*9;*4/*9;;DECREASED_EXPRESSION;CYP2A6
;CYP2B6;CYP2B6*1, CYP2B6*27;*27;;DECREASED_EXPRESSION;CYP2B6
COUMARIN;CYP2A6;rs28399454;T;LADME_PK;DECREASED_METABOLISM;
COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*4;*1/*4;LADME_PK;DECREASED_CLEARANCE;
COUMARIN;CYP2A6;CYP2A6*1, CYP2A6*9;*1/*9;LADME_PK;DECREASED_CLEARANCE;
;CYP2A6;CYP2A6*46;*46;;INCREASED_EXPRESSION;CYP2A6
;CYP2A6;CYP2A6*1, CYP2A6*4;*4;;DECREASED_EXPRESSION;CYP2A6
;CYP2A6;CYP2A6*46;*46;;INCREASED_TRANSCRIPTION;CYP2A6
;CYP2B6;rs3745274;TT;OTHER;DECREASED_EXPRESSION;CYP2B6
PROPOFOL;CYP2B6;rs553968231;T;LADME_PK;DECREASED_CLEARANCE;
PROPOFOL;CYP2B6;rs1969376664;T;LADME_PK;DECREASED_CLEARANCE;
PROPOFOL;CYP2B6;rs773494867;C;LADME_PK;DECREASED_CLEARANCE;
;CYP2A6;CYP2A6*46;*46;;INCREASED_EXPRESSION;CYP2A6
3-CYANO-7-ETHOXYCOUMARIN;CYP2C19;CYP2C19*1, CYP2C19*8, CYP2C19*9, CYP2C19*10, CYP2C19*16, CYP2C19*19;*8 + *9 + *10 + *16 + *19;LADME_PK;DECREASED_CLEARANCE;
NEBIVOLOL;CYP2C19;CYP2C19*1, CYP2C19*6, CYP2C19*18, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;*30 + *31 + *32 + *33 + *6 + *18;LADME_PK;DECREASED_CLEARANCE;
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*25, CYP2C19*26;*10 + *14 + *19 + *25 + *26;LADME_PK;DECREASED_CLEARANCE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*6;*6;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;rs550527959;T;LADME_PK;DECREASED_CLEARANCE;
METHADONE;CYP2C19;rs1463550071;T;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;rs200346442;A;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;rs200150287;G;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;rs118203756;C;LADME_PK;DECREASED_CLEARANCE;
FLUVOXAMINE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*15;*15;LADME_PK;INCREASED_SENSITIVITY;
FLUVOXAMINE, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*18;*18;LADME_PK;INCREASED_SENSITIVITY;
CELECOXIB, FLUOXETINE, KETOCONAZOLE, TICLOPIDINE;CYP2C19;CYP2C19*1, CYP2C19*18;*18;LADME_PK;DECREASED_SENSITIVITY;
FLUOXETINE;CYP2C19;rs778258371;A;LADME_PK;DECREASED_CLEARANCE;
CELECOXIB;CYP2C19;CYP2C19*1, CYP2C19*19;*19;LADME_PK;INCREASED_SENSITIVITY;
CELECOXIB, FLUOXETINE, KETOCONAZOLE, SERTRALINE, TICLOPIDINE;CYP2C19;CYP2C19*1, CYP2C19*16;*16;LADME_PK;DECREASED_SENSITIVITY;
FLUOXETINE, FLUVOXAMINE, KETOCONAZOLE, OMEPRAZOLE, SERTRALINE, TICLOPIDINE, TRANYLCYPROMINE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;LADME_PK;DECREASED_SENSITIVITY;
;CYP2C19;CYP2C19*1, CYP2C19*16;*16;OTHER;DECREASED_FORMATION;CYP2C19
FLUCONAZOLE, FLUVOXAMINE, SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*11;*11;LADME_PK;INCREASED_SENSITIVITY;
FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME_PK;DECREASED_SENSITIVITY;
CELECOXIB, FLUOXETINE, KETOCONAZOLE, SERTRALINE, TROGLITAZONE;CYP2C19;CYP2C19*1, CYP2C19*9;*9;LADME_PK;DECREASED_SENSITIVITY;
FLUCONAZOLE, FLUVOXAMINE;CYP2C19;CYP2C19*1, CYP2C19*9;*9;LADME_PK;INCREASED_SENSITIVITY;
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*10;*10;LADME_PK;DECREASED_CLEARANCE;
FLUCONAZOLE, FLUOXETINE, FLUVOXAMINE, KETOCONAZOLE, OMEPRAZOLE, SERTRALINE, TICLOPIDINE, TRANYLCYPROMINE, TROGLITAZONE;CYP2C19;CYP2C19*1, CYP2C19*8;*8;LADME_PK;DECREASED_SENSITIVITY;
FLUOXETINE, TRANYLCYPROMINE;CYP2C19;CYP2C19*1, CYP2C19*15;*15;LADME_PK;DECREASED_SENSITIVITY;
;CYP1A2;rs2069514;A;;DECREASED_ACTIVITY;CYP1A2
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*26;*26;LADME_PK;DECREASED_CLEARANCE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*23;*23;LADME_PK;DECREASED_CLEARANCE;
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*10, CYP2C19*14, CYP2C19*19, CYP2C19*23, CYP2C19*25, CYP2C19*26;*10 + *14 + *19 + *23 + *25 + *26;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;rs370803989;A;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;rs145328984;T;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;rs763625282;A;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;rs147255955;T;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;rs3758581;G;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;rs559628884;A;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;rs764137538;T;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;rs1349931378;A;LADME_PK;DECREASED_CLEARANCE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*33;*33;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;rs1463550071;T;LADME_PK;DECREASED_CLEARANCE;
METHADONE;CYP2C19;rs778258371;A;LADME_PK;DECREASED_CLEARANCE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*18;*18;LADME_PK;DECREASED_CLEARANCE;
METHADONE;CYP2C19;rs72552267;A;LADME_PK;DECREASED_CLEARANCE;
METHADONE;CYP2C19;rs118203756;C;LADME_PK;DECREASED_CLEARANCE;
METHADONE;CYP2C19;rs764137538;T;LADME_PK;DECREASED_CLEARANCE;
METHADONE;CYP2C19;rs550527959;T;LADME_PK;DECREASED_CLEARANCE;
METHADONE;CYP2C19;rs1349931378;A;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;rs770829708;A;LADME_PK;DECREASED_CLEARANCE;
METHADONE;CYP2C19;rs1267723490;C;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;rs1267723490;C;LADME_PK;DECREASED_CLEARANCE;
DACARBAZINE;CYP1A1;CYP1A1*1, CYP1A1*2C;*2C;LADME_PK;DECREASED_CLEARANCE;
DACARBAZINE;CYP1A1;CYP1A1*1, CYP1A1*4;*4;LADME_PK;DECREASED_CLEARANCE;
;CHD2;rs28458425;TT;OTHER;INCREASED_TRANSCRIPTION;ABCB1
OXAZEPAM;;rs1976391;G;OTHER;DECREASED_GLUCURONIDATION;
;;rs247616;T;OTHER;DECREASED_EXPRESSION;CETP
;ABCA1;rs2515629;G;;INCREASED_EXPRESSION;ABCA1
;ABCA1;rs4149297;G;;INCREASED_EXPRESSION;ABCA1
;ABCA1;rs2472507;C;;INCREASED_EXPRESSION;ABCA1
;ABCA12;rs10182702;C;;INCREASED_EXPRESSION;ABCA12
;ABCA12;rs2888327;A;;INCREASED_EXPRESSION;ABCA12
;ABCA8;rs11656365;T;;DECREASED_EXPRESSION;ABCA8
;ABCB1;rs1045642;AG + GG;LADME_PK;INCREASED_ACTIVITY;ABCB1
;;rs1976391;G;OTHER;DECREASED_CONCENTRATIONS;UGT1A1
;ABCB1;rs1128503;AG + GG;LADME_PK;INCREASED_ACTIVITY;ABCB1
;ABCB1;rs1045642;AA;OTHER;DECREASED_EXPRESSION;ABCB1
;ABCB1;rs1128503;AA;OTHER;DECREASED_EXPRESSION;ABCB1
;ABCB1;rs2032582;AA;OTHER;DECREASED_EXPRESSION;ABCB1
;ABCB9;rs4148866;T;;INCREASED_EXPRESSION;ABCB9
;ABCC10;rs2185631;A;;DECREASED_EXPRESSION;ABCC10
DOCETAXEL;ABCC10;rs2125739;TT;TOXICITY;INCREASED_SENSITIVITY;
;ABCC10;rs9394952;G;;DECREASED_EXPRESSION;ABCC10
;ABCC10;rs2487663;A;;DECREASED_EXPRESSION;ABCC10
;ABCC11;rs11861379;C;LADME_PK;INCREASED_TRANSCRIPTION;ABCC11
;ABCB1;rs2032582;AC + CC;LADME_PK;INCREASED_ACTIVITY;ABCB1
;ABCC2;rs717620;T;;INCREASED_TRANSCRIPTION;ABCC2
;;rs6822259;CC;;INCREASED_EXPRESSION;UGT2B17
;;rs729559;GG;LADME_PK;INCREASED_EXPRESSION;CYP2D6
;;rs6539870;GG;OTHER;INCREASED_EXPRESSION;IL1B
;;rs478437;CC;OTHER;INCREASED_EXPRESSION;USP7
;;rs9999111;C;OTHER;DECREASED_EXPRESSION;ABCG2
;;rs149713212;A;OTHER;DECREASED_EXPRESSION;ABCG2
;;rs12508471;G;OTHER;DECREASED_EXPRESSION;ABCG2
ENDOXIFEN;;rs4386686;C;TOXICITY;INCREASED_SENSITIVITY;
;;rs4073010;TT;LADME_PK;INCREASED_EXPRESSION;CYP2D6
;;rs35283911;G;OTHER;INCREASED_EXPRESSION;HP
;;rs4386686;C;TOXICITY, OTHER;INCREASED_EXPRESSION;MIRLET7I
TAMOXIFEN;;rs478437;CC;OTHER;INCREASED_SENSITIVITY;
;;rs2784917;AA;OTHER;INCREASED_EXPRESSION;WNT5B
;;rs9999111;C;OTHER;DECREASED_EXPRESSION;ABCG2
;;rs10242455;AG;LADME_PK;INCREASED_TRANSCRIPTION;CYP3A5
;;rs446112;AA;OTHER;INCREASED_EXPRESSION;AGPAT2
;;rs10871454;C;LADME_PK;INCREASED_TRANSCRIPTION;VKORC1
;;rs2487030;T;;INCREASED_EXPRESSION;ABCA1
;;rs4355801;G;;INCREASED_EXPRESSION;TNFRSF11B
;;rs4285917;G;;DECREASED_EXPRESSION;ABCD2
;;rs12195350;G;;DECREASED_EXPRESSION;ABCC10
;;rs4898437;C;;INCREASED_EXPRESSION;ABCD1
;;rs4386686;C;TOXICITY, OTHER;DECREASED_EXPRESSION;TRAF1
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*28;*28;LADME_PK;INCREASED_CLEARANCE;
;ABCC4;rs11568658;A;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;ABCC4
MERCAPTOPURINE;ABCC4;rs3765534;TT;TOXICITY, LADME_PK;INCREASED_SENSITIVITY;
;CACNA1S;rs1800559;T;OTHER;INCREASED_ACTIVITY;CACNA1S
CAFFEINE;CACNA1S;rs1800559;T;OTHER;INCREASED_SENSITIVITY;
HALOTHANE, ISOFLURANE;CACNA1S;rs772226819;A;OTHER;INCREASED_SENSITIVITY;
;CBR3;rs8133052;A;;DECREASED_EXPRESSION;CBR3
;CBR3;rs1056892;A;;INCREASED_EXPRESSION;CBR3
;CBS;rs915854;C;OTHER;INCREASED_EXPRESSION;PKNOX1
;CD38;rs1130169;T;;DECREASED_EXPRESSION;CD38
;CDA;rs3215400;C/del + del/del;OTHER;INCREASED_EXPRESSION;CDA
;CDA;rs2072671;CC;OTHER;INCREASED_EXPRESSION;CDA
DEXAMETHASONE;BCL2L11;rs2241843;AA;TOXICITY;INCREASED_SENSITIVITY;
;CDA;rs532545;CC;OTHER;DECREASED_ACTIVITY;CDA
;CDA;rs2072671;AA;OTHER;DECREASED_ACTIVITY;CDA
;CDA;rs1048977;TT;OTHER;INCREASED_EXPRESSION;CDA
;CDA;rs602950;AA;OTHER;DECREASED_ACTIVITY;CDA
;CDA;rs602950;GG;OTHER;INCREASED_EXPRESSION;CDA
;CDA;rs3215400;del/del;;INCREASED_EXPRESSION;CDA
PALBOCICLIB;CDKN2A;rs759922342;C;EFFICACY;INCREASED_SENSITIVITY;
REMIMAZOLAM;CES1;rs71647871;T;LADME_PK;DECREASED_METABOLISM;
CLOPIDOGREL, ENALAPRIL, SACUBITRIL;CES1;rs201065375;A;LADME_PK;DECREASED_METABOLISM;
;CETP;rs708272;GG;OTHER;INCREASED_EXPRESSION;CETP
;CDA;rs532545;TT;OTHER;INCREASED_EXPRESSION;CDA
MERCAPTOPURINE;ABCC4;ABCC4 deficiency;;TOXICITY, LADME_PK;INCREASED_CONCENTRATIONS;
DEXAMETHASONE;BCL2L11;rs724710;CC;TOXICITY;INCREASED_SENSITIVITY;
;ARNT;rs2134688;GG;LADME_PK;DECREASED_CONCENTRATIONS;CYP3A4
;ABCC4;rs11568684;C;LADME_PK;INCREASED_CATALYTIC_ACTIVITY;ABCC4
;ABCC4;rs4773866;T;;INCREASED_EXPRESSION;ABCC4
;ABCC9;rs704212;T;OTHER;INCREASED_EXPRESSION;ABCC9
;ABCD1, BCAP31;rs17091297;C;;INCREASED_EXPRESSION;ABCD1
;ABCD2;rs4284427;C;;DECREASED_EXPRESSION;ABCD2
;ABCG2;rs2725263;C;OTHER;INCREASED_EXPRESSION;ABCG2
;ACE;rs1799752;del;;INCREASED_ENZYME_ACTIVITY;ACE
;ADCYAP1;rs304400;AA;OTHER;INCREASED_TRANSCRIPTION;ABCB1
LOSARTAN;AGTR1;rs12721226;A;OTHER;DECREASED_AFFINITY;
;ATP2B1;rs12817819;CT + TT;;DECREASED_EXPRESSION;ATP2B1
DOXORUBICINOL;AKR1A1;rs2229540;G;LADME_PK;DECREASED_FORMATION;
DAUNORUBICINOL;AKR1A1;rs6690497;C;LADME_PK;DECREASED_FORMATION;
DAUNORUBICINOL;AKR1A1;rs2229540;G;LADME_PK;DECREASED_FORMATION;
EXEMESTANE;AKR1C3;rs62621365;T;LADME_PK;DECREASED_AFFINITY;
DOXORUBICIN;AKR1C3;rs62621365;T;LADME_PK;DECREASED_CLEARANCE;
DOXORUBICIN;AKR1C3;rs34186955;T;LADME_PK;DECREASED_CLEARANCE;
DOXORUBICIN;AKR1C3;rs28943579;A;LADME_PK;DECREASED_CLEARANCE;
EXEMESTANE;AKR1C4;rs11253043;A;LADME_PK;DECREASED_AFFINITY;
;ALDH1A2;rs12915901;AA + AG;OTHER;DECREASED_EXPRESSION;ALDH1A2
;AMPH;rs12701634;CC;OTHER;INCREASED_TRANSCRIPTION;ABCB1
DOXORUBICINOL;AKR1A1;rs6690497;C;LADME_PK;DECREASED_FORMATION;
;DPYD;rs2297595;C;LADME_PK;DECREASED_ACTIVITY;DPYD
;CYP2C19;CYP2C19*1, CYP2C19*19;*19;OTHER;DECREASED_EXPRESSION;CYP2C19
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*13;*13;LADME_PK;DECREASED_SENSITIVITY;
EBASTINE, TERFENADINE;CYP2J2;rs201379188;A;LADME_PK;DECREASED_CLEARANCE;
TERFENADINE;CYP2J2;rs199717190;A;LADME_PK;DECREASED_CLEARANCE;
OXYCODONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*2 + *3 + *4+ *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *14 + *15 + *16 + *18 + *19 + *23 + *24 + *28 + *29 + *31 + *32 + *33 + *34;LADME_PK;DECREASED_CLEARANCE;
OXYCODONE;CYP3A4;CYP3A4*1, CYP3A4*6, CYP3A4*17, CYP3A4*20, CYP3A4*21, CYP3A4*26, CYP3A4*30;*6 + *17 + *20 + *21 + *26 + *30;LADME_PK;DECREASED_CLEARANCE;
SIROLIMUS;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22 + *22/*22;LADME_PK;DECREASED_CLEARANCE;
SILDENAFIL;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*10, CYP3A4*14, CYP3A4*32;*3 + *10 + *14 + *32;LADME_PK;INCREASED_CLEARANCE;
IBRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32;*2 + *5 + *14 + *15 + *16 + *28 + *29 + *31+ *32;LADME_PK;DECREASED_CLEARANCE;
;CYP3A4;rs2242480;TT;LADME_PK;DECREASED_ACTIVITY;CYP3A4
TESTOSTERONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*11, CYP3A4*15, CYP3A4*31;*2 + *3 + *11 + *15 + *31;LADME_PK;INCREASED_CLEARANCE;
TESTOSTERONE;CYP3A4;CYP3A4*1, CYP3A4*5, CYP3A4*10, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*32, CYP3A4*33, CYP3A4*34;*5 + *10 + *14 + *16 + *17 + *23 + *24 + *28 +*29 + *32 + *33 + *34;LADME_PK;DECREASED_CLEARANCE;
LIDOCAINE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*9, CYP3A4*16, CYP3A4*24;*2 + *5 + *9 + *16 + *24;LADME_PK;DECREASED_CLEARANCE;
MIDAZOLAM;CYP3A4;rs12721627;C;LADME_PK;DECREASED_CLEARANCE;
FENTANYL;CYP3A4;rs2242480;T/T;LADME_PK;DECREASED_METABOLISM;
REGORAFENIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*17, CYP3A4*18, CYP3A4*23, CYP3A4*32, CYP3A4*33, CYP3A4*34;*2 + *3 + *4 + *7 + *8 + *9 + *10 + *11 + *12 + *13 + *17 + *18 + *23 + *32 + *33 + *34;LADME_PK;DECREASED_CLEARANCE;
TICAGRELOR;CYP3A4;CYP3A4*1, CYP3A4*11, CYP3A4*18, CYP3A4*33;*11 + *18 + *33;LADME_PK;INCREASED_CLEARANCE;
TICAGRELOR;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*9, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*19, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31;*2 + *3 + *4 + *5 + *9 + *14 + *15 + *16 + *17 + *19 + *24 + *28 + *29 + *31;LADME_PK;DECREASED_CLEARANCE;
LURASIDONE;CYP3A4;CYP3A4*1, CYP3A4*12;*12;LADME_PK;DECREASED_CLEARANCE;
LURASIDONE;CYP3A4;CYP3A4*1, CYP3A4*15, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*32, CYP3A4*33;*15 + *19 + *23 + *24 + *28 + *29 + *32 + *33;LADME_PK;INCREASED_CLEARANCE;
SAXAGLIPTIN;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *10 + *11 + *12 + *13 +  *14 + *15 + *16 + *17 + *18 + *19 + *20 + *23 + *24 + *28 + *29 + *31 + *32 + *34;LADME_PK;DECREASED_CLEARANCE;
EBASTINE, TERFENADINE;CYP2J2;rs759510111;A;LADME_PK;INCREASED_CLEARANCE;
EBASTINE;CYP2J2;rs757528200;(CTC)1;LADME_PK;DECREASED_CLEARANCE;
;CYP2E1;CYP2E1*7A, CYP2E1*7B;*7B;LADME_PK;INCREASED_TRANSCRIPTION;CYP2E1
;CYP2E1;CYP2E1*7, CYP2E1*7A;*7A;LADME_PK;INCREASED_TRANSCRIPTION;CYP2E1
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*28, CYP2D6*35;*2 + *28 + *35;LADME_PK;DECREASED_METABOLISM;
BUFURALOL, DEBRISOQUINE, DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*17;*17;LADME_PK;DECREASED_CLEARANCE;
;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;LADME_PK;DECREASED_EXPRESSION;CYP2D6
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*169;*169;LADME_PK;DECREASED_CLEARANCE;
DEXTROMETHORPHAN;CYP2D6;rs76187628;G;LADME_PK;INCREASED_CLEARANCE;
;CYP2D6;CYP2D6*1, CYP2D6*169;*169;LADME_PK;DECREASED_EXPRESSION;CYP2D6
;CYP2D6;rs76187628;G;LADME_PK;INCREASED_EXPRESSION;CYP2D6
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*2;*2;LADME_PK;DECREASED_CLEARANCE;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10;LADME_PK;DECREASED_CLEARANCE;
IBRUTINIB;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*9, CYP3A4*19, CYP3A4*34;*3 + *4 + *9 + *19 +*34;LADME_PK;INCREASED_CLEARANCE;
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*28, CYP2D6*35;*2 + *28 + *35;LADME_PK;DECREASED_METABOLISM;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*26;*26;LADME_PK;DECREASED_CLEARANCE;
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs750996195;T;LADME_PK;DECREASED_CLEARANCE;
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*17;*17;LADME_PK;DECREASED_CLEARANCE;
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*14;*14;LADME_PK;DECREASED_CLEARANCE;
N-DESMETHYLTAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*53;*53;LADME_PK;INCREASED_CLEARANCE;
DAPOXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *91 + *93 + *95 + *97 + *98;LADME_PK;DECREASED_CLEARANCE;
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*53;*53;LADME_PK;INCREASED_CLEARANCE;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;LADME_PK;DECREASED_CLEARANCE;
;CYP2E1;rs2515641;T;OTHER;DECREASED_EXPRESSION;CYP2E1
;ZBED5;rs10840501;GG;OTHER;INCREASED_TRANSCRIPTION;ABCB1
REGORAFENIB;CYP3A4;CYP3A4*1, CYP3A4*14, CYP3A4*15, CYP3A4*28, CYP3A4*31;*14 + *15 + *28 + *31;LADME_PK;INCREASED_CLEARANCE;
LIDOCAINE;CYP3A4;CYP3A4*1, CYP3A4*11, CYP3A4*14, CYP3A4*15, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;*11 + *14 + *15 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME_PK;INCREASED_CLEARANCE;
CABOZANTINIB;CYP3A4;CYP3A4*1, CYP3A4*14, CYP3A4*15;*14 + *15;LADME_PK;INCREASED_CLEARANCE;
VITAMIN E;CYP4F2;rs2108622;T;LADME_PK;INCREASED_STEADY_STATE_LEVEL;
;CYP4F2;rs2189784;A;OTHER;INCREASED_EXPRESSION;CYP4F2
;CYP4F2;rs2189784;A;OTHER;DECREASED_EXPRESSION;CYP4F12
;CYP4F2;rs2108622;CT;OTHER;INCREASED_CONCENTRATIONS;CYP4F2
VITAMIN K AND ANALOGUES;CYP4F2;rs2108622;CT + TT;OTHER, LADME_PK;INCREASED_CONCENTRATIONS;
;CYP4F2;rs2108622;T;OTHER;INCREASED_EXPRESSION;CYP4F2
;CYP4F2;rs2108622;T;OTHER;INCREASED_EXPRESSION;CYP4F11
;DCK;rs2306744;T;OTHER;INCREASED_EXPRESSION;DCK
;DHRS4L1;rs10147475;GG;OTHER;INCREASED_TRANSCRIPTION;ABCB1
VITAMIN E;CYP4F2;rs2108622;T;LADME_PK;INCREASED_STEADY_STATE_LEVEL;
;DISP1;rs61840266;TT;OTHER;INCREASED_TRANSCRIPTION;ABCC1
;DPYD;rs568132506;A;OTHER;DECREASED_CATALYTIC_ACTIVITY;DPYD
;DPYD;rs760663364;A;OTHER;DECREASED_CATALYTIC_ACTIVITY;DPYD
FLUOROURACIL;DPYD;rs1801159;CC;TOXICITY, LADME_PK;DECREASED_CLEARANCE;
;DPYD;rs3918290;CT;OTHER;DECREASED_ACTIVITY;DPYD
;DPYD;rs1801158;CT;OTHER;DECREASED_CATALYTIC_ACTIVITY;DPYD
;DPYD;rs547099198;A;OTHER;DECREASED_CATALYTIC_ACTIVITY;DPYD
;DPYD;rs67376798;AT;OTHER;DECREASED_CATALYTIC_ACTIVITY;DPYD
;DPYD;rs1801265;G;OTHER;DECREASED_ACTIVITY;DPYD
;DPYD;rs1801160;T;OTHER;DECREASED_ACTIVITY;DPYD
;DISP1;rs17535305;GG;OTHER;INCREASED_TRANSCRIPTION;ABCB1
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs777560972;A;LADME_PK;DECREASED_CLEARANCE;
;CYP4F11;rs1060467;A;OTHER;INCREASED_EXPRESSION;CYP4F2
;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;OTHER;DECREASED_EXPRESSION;CYP3A5
BREXPIPRAZOLE;CYP3A4;CYP3A4*1, CYP3A4*14, CYP3A4*15;*14 + *15;LADME_PK;INCREASED_CLEARANCE;
ALECTINIB;CYP3A4;CYP3A4*1, CYP3A4*4, CYP3A4*7, CYP3A4*8, CYP3A4*12, CYP3A4*14, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24;*4 + *7 + *8 + *12 + *14 + *16 + *17 + *18 + *19 + *20 + *23 + *24;LADME_PK;DECREASED_METABOLISM;
METHADONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*5, CYP3A4*14, CYP3A4*15, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*24, CYP3A4*29, CYP3A4*31;*2 + *3  + *5  + *14 + *15 + *16 + *17 + *18 + *19 + *24 + *29 + *31;LADME_PK;DECREASED_CLEARANCE;
METHADONE;CYP3A4;CYP3A4*1, CYP3A4*11, CYP3A4*32, CYP3A4*34;*11 + *32 + *34;LADME_PK;INCREASED_CLEARANCE;
;CYP3A4;rs35599367;A;OTHER;DECREASED_EXPRESSION;CYP3A4
MIDAZOLAM;CYP3A4;CYP3A4*1, CYP3A4*39, CYP3A4*40, CYP3A4*41, CYP3A4*42, CYP3A4*43, CYP3A4*44, CYP3A4*46;*39 + *40 + *41 + *42 + *43 + *44 + *46;LADME_PK;DECREASED_CLEARANCE;
MACITENTAN;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*10, CYP3A4*15, CYP3A4*16;*3 + *4 + *5 + *10 +*15 + *16;LADME_PK;INCREASED_CLEARANCE;
;CYP3A4;rs4986909;A;;DECREASED_STEADY_STATE_LEVEL;CYP3A4
VANDETANIB;CYP3A4;CYP3A4*1, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*14, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*31, CYP3A4*34;*5 + *7 + *8 + *10 + *11 + *12 + *13 + *14 + *17 + *18 + *19 + *20 + *23 + *24 + *31 + *34;LADME_PK;DECREASED_CLEARANCE;
;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;OTHER;DECREASED_EXPRESSION;CYP3A5
CABOZANTINIB;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*7, CYP3A4*8, CYP3A4*9, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*16, CYP3A4*17, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*2 + *3 + *4 + *5 + *7 + *8 + *9 + *11 + *12 + *13 + *16 + *17 + *18 + *19 + *23 + *24+ *28 + *29 + *31 + *32 + *33 + *34;LADME_PK;DECREASED_CLEARANCE;
AMIODARONE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*16, CYP3A4*18, CYP3A4*19, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*34;*2 + *9 + *10 + *11 + *16 + *18 + *19 + *23 + *29 + *31 + *32 + *34;LADME_PK;INCREASED_CLEARANCE;
SILDENAFIL;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*5, CYP3A4*24, CYP3A4*28, CYP3A4*29;*2 + *5 + *24 + *28 + *29;LADME_PK;DECREASED_CLEARANCE;
;CYP3A4;CYP3A4*8;*8;;DECREASED_STEADY_STATE_LEVEL;CYP3A4
BREXPIPRAZOLE;CYP3A4;CYP3A4*1, CYP3A4*3, CYP3A4*4, CYP3A4*5, CYP3A4*9, CYP3A4*10, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*16, CYP3A4*18, CYP3A4*23, CYP3A4*29, CYP3A4*31, CYP3A4*32, CYP3A4*33, CYP3A4*34;*3 + *4 + *5 + *9 + *10 + *11 + *12 + *13 + *16 + *18 + *23 + *29 + *31 + *32 + *33 + *34;LADME_PK;DECREASED_CLEARANCE;
;CYP3A4;CYP3A4*12;*12;;DECREASED_ENZYME_ACTIVITY;CYP3A4
BREXPIPRAZOLE;CYP3A4;CYP3A4*1, CYP3A4*2, CYP3A4*7, CYP3A4*8, CYP3A4*17, CYP3A4*20;*2 + *7 + *8 + *17 + *20;LADME_PK;DECREASED_CLEARANCE;
;CYP3A4;CYP3A4*11;*11;;DECREASED_STEADY_STATE_LEVEL;CYP3A4
AMIODARONE;CYP3A4;CYP3A4*1, CYP3A4*17, CYP3A4*24;*17 + *24;LADME_PK;DECREASED_CLEARANCE;
MIDAZOLAM;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME_PK;INCREASED_METABOLISM;
MACITENTAN;CYP3A4;CYP3A4*1, CYP3A4*9, CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*17, CYP3A4*20, CYP3A4*23, CYP3A4*24, CYP3A4*28, CYP3A4*29, CYP3A4*33, CYP3A4*34;*9 + *11 + *12 + *13 +*17 + *20 + *23 + *24 + *28 + *29 + *33 + *34;LADME_PK;DECREASED_CLEARANCE;
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs138417770;T;LADME_PK;DECREASED_CLEARANCE;
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs371793722;G;LADME_PK;DECREASED_CLEARANCE;
;CYP2D6;rs1058164;G;OTHER;DECREASED_EXPRESSION;CYP2D6
METHADONE;CYP2C19;rs181297724;C;LADME_PK;DECREASED_CLEARANCE;
METHADONE;CYP2C19;CYP2C19*1, CYP2C19*29, CYP2C19*30, CYP2C19*31, CYP2C19*32, CYP2C19*33;*29 + *30 + *31 + *32 + *33;LADME_PK;DECREASED_CLEARANCE;
VORICONAZOLE;CYP2C19;rs778258371;A;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*32;*32;LADME_PK;DECREASED_CLEARANCE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;DECREASED_CLEARANCE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*3;*3;LADME_PK;DECREASED_CLEARANCE;
METHADONE;CYP2C19;rs138142612;A;LADME_PK;DECREASED_CLEARANCE;
MEPHENYTOIN, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*24;*24;LADME_PK;DECREASED_CLEARANCE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*32;*32;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*31;*31;LADME_PK;DECREASED_CLEARANCE;
16ALPHA-HYDROXYTESTOSTERONE;CYP2C19;CYP2C19*1, CYP2C19*11, CYP2C19*23;*11 + *23;LADME_PK;INCREASED_FORMATION;
11ALPHA-HYDROXYTESTOSTERONE;CYP2C19;CYP2C19*1, CYP2C19*9, CYP2C19*11, CYP2C19*23;*9 + *11 + *23;LADME_PK;INCREASED_FORMATION;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*29;*29;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*29;*29;LADME_PK;DECREASED_CLEARANCE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*31;*31;LADME_PK;DECREASED_CLEARANCE;
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*30;*30;LADME_PK;DECREASED_CLEARANCE;
SIPONIMOD;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*3/*3 + *2/*2;LADME_PK;DECREASED_METABOLISM;
DICLOFENAC;CYP2C9;CYP2C9*1, CYP2C9*13;*13;LADME_PK;DECREASED_CLEARANCE;
DICLOFENAC;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME_PK;DECREASED_CLEARANCE;
TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;DECREASED_CLEARANCE;
ANDROSTENEDIONE;CYP2C19;CYP2C19*1, CYP2C19*9, CYP2C19*11, CYP2C19*23;*9 + *11 + *23;LADME_PK;INCREASED_FORMATION;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*52;*52;LADME_PK;DECREASED_CLEARANCE;
METHADONE;CYP2C19;rs749678783;C;LADME_PK;DECREASED_CLEARANCE;
METHADONE;CYP2C19;rs770829708;A;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;rs72552267;A;LADME_PK;DECREASED_CLEARANCE;
METHADONE;CYP2C19;rs200150287;G;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;rs749678783;C;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;rs138142612;A;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE;CYP2C19;rs181297724;C;LADME_PK;DECREASED_CLEARANCE;
FLUOXETINE, KETOCONAZOLE, SERTRALINE, TICLOPIDINE;CYP2C19;rs181297724;C;LADME_PK;DECREASED_SENSITIVITY;
FLUVOXAMINE, OMEPRAZOLE;CYP2C19;rs181297724;C;LADME_PK;INCREASED_SENSITIVITY;
FLUOXETINE;CYP2C19;rs17878459;C;LADME_PK;DECREASED_SENSITIVITY;
CELECOXIB, FLUCONAZOLE, FLUVOXAMINE;CYP2C19;rs17878459;C;LADME_PK;INCREASED_SENSITIVITY;
MEPHENYTOIN;CYP2C19;CYP2C19*1, CYP2C19*23;*23;LADME_PK;INCREASED_CLEARANCE;
FLUVOXAMINE;CYP2C19;rs3758581;G;LADME_PK;INCREASED_SENSITIVITY;
VORICONAZOLE;CYP2C19;rs763625282;A;LADME_PK;DECREASED_CLEARANCE;
VORICONAZOLE;CYP2C19;rs3758581;G;LADME_PK;DECREASED_CLEARANCE;
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*19;*19;LADME_PK;DECREASED_AFFINITY;
VORICONAZOLE;CYP2C19;rs770829708;A;LADME_PK;DECREASED_CLEARANCE;
CELECOXIB, FLUCONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*14;*14;LADME_PK;INCREASED_SENSITIVITY;
FLUOXETINE, SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*14;*14;LADME_PK;DECREASED_SENSITIVITY;
FLUCONAZOLE, FLUVOXAMINE;CYP2C19;CYP2C19*1, CYP2C19*13;*13;LADME_PK;INCREASED_SENSITIVITY;
VORICONAZOLE;CYP2C19;rs181297724;C;LADME_PK;DECREASED_CLEARANCE;
METHADONE;CYP2C19;rs200346442;A;LADME_PK;DECREASED_CLEARANCE;
VORICONAZOLE;CYP2C19;rs550527959;T;LADME_PK;DECREASED_CLEARANCE;
;CYP2C19;rs7902257;A;OTHER;DECREASED_EXPRESSION;CYP2C19
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*51;*51;LADME_PK;INCREASED_CLEARANCE;
;CYP2C9;rs4918758;C;OTHER;DECREASED_TRANSCRIPTION;CYP2C9
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*33;*33;LADME_PK;DECREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*13;*13;LADME_PK;DECREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*16;*16;LADME_PK;DECREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*45;*45;LADME_PK;DECREASED_CLEARANCE;
;CYP2D6;rs16947;AA + AG;OTHER;DECREASED_EXPRESSION;CYP2D6
PRIMAQUINE;CYP2D6;CYP2D6*1, CYP2D6*22, CYP2D6*26, CYP2D6*48;*22 + *48;LADME_PK;INCREASED_CLEARANCE;
METHADONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*89, CYP2D6*90, CYP2D6*93, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *89 + *90 + *93 + *95 + *97 + *98;LADME_PK;DECREASED_CLEARANCE;
;CYP2D6;CYP2D6*1, CYP2D6*92, CYP2D6*96;*92 + *96;LADME_PK;DECREASED_ACTIVITY;CYP2D6
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME_PK;DECREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*36;*36;LADME_PK;DECREASED_CLEARANCE;
GEFITINIB;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*87, CYP2D6*90, CYP2D6*93, CYP2D6*95, CYP2D6*98;*10 + *87 + *90 + *93 + *95 + *98;LADME_PK;DECREASED_CLEARANCE;
BUFURALOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98, CYP2D6*134, CYP2D6*153;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME_PK;DECREASED_CLEARANCE;
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME_PK;DECREASED_CLEARANCE;
CITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *98;LADME_PK;DECREASED_CLEARANCE;
ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97;*90 + *91 + *88 + *97 + *2 + *95 + *87 + *93 + *10;LADME_PK;DECREASED_CLEARANCE;
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*98;*2 + *10 + *87 + *90 + *91 + *93 + *95 + *98;LADME_PK;DECREASED_CLEARANCE;
TOLTERODINE;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*93, CYP2D6*94, CYP2D6*95;*10 + *93 + *94 + *95;LADME_PK;DECREASED_CLEARANCE;
DEXTROMETHORPHAN;CYP2D6;CYP2D6*1, CYP2D6*87, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98, CYP2D6*134, CYP2D6*153;*87 + *90 + *91 + *93 + *94 + *95 + *97 + *98 + *134 + *153;LADME_PK;DECREASED_CLEARANCE;
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*89, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*94, CYP2D6*95, CYP2D6*97, CYP2D6*98;*2 + *10 + *87 + *88 + *89 + *90 + *91 + *93 + *94 + *95 + *97 + *98;LADME_PK;DECREASED_CLEARANCE;
BUFURALOL, DEXTROMETHORPHAN;CYP2D6;rs745746329;T;LADME_PK;DECREASED_CLEARANCE;
OLANZAPINE;CYP2D6;CYP2D6*1, CYP2D6*10, CYP2D6*87, CYP2D6*88, CYP2D6*90, CYP2D6*91, CYP2D6*93, CYP2D6*95, CYP2D6*97;*10 + *87 + *88 + *90 + *91 + *93 + *95 + *97;LADME_PK;DECREASED_CLEARANCE;
;CYP2C9;rs9332094;C;OTHER;DECREASED_TRANSCRIPTION;CYP2C9
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*37;*37;LADME_PK;DECREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*42;*42;LADME_PK;DECREASED_CLEARANCE;
;CYP2C9;rs7089580;AT + TT;OTHER;INCREASED_EXPRESSION;CYP2C9
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*55;*55;LADME_PK;DECREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*56;*56;LADME_PK;INCREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*53;*53;LADME_PK;INCREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*50;*50;LADME_PK;DECREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*54;*54;LADME_PK;INCREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*19;*19;LADME_PK;DECREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*31;*31;LADME_PK;DECREASED_CLEARANCE;
LOSARTAN;CYP2C9;rs1057910;C;LADME_PK;DECREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*41;*41;LADME_PK;INCREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*27;*27;LADME_PK;INCREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*14;*14;LADME_PK;DECREASED_CLEARANCE;
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*62;*62;LADME_PK;DECREASED_CLEARANCE;
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*2;*2;LADME_PK;DECREASED_CLEARANCE;
DICLOFENAC, LOSARTAN, TOLBUTAMIDE;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME_PK;DECREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*47;*47;LADME_PK;INCREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*49;*49;LADME_PK;INCREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME_PK;DECREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*43;*43;LADME_PK;DECREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*39;*39;LADME_PK;DECREASED_CLEARANCE;
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*8;*8;LADME_PK;DECREASED_CLEARANCE;
;ZNF890P;rs62442010;AA;OTHER;INCREASED_TRANSCRIPTION;ABCB1
NICOTINE;CYP2A6;rs1801272;AA + AT;TOXICITY;DECREASED_RISK;OTHER:TOBACCO_USE_DISORDER
SACITUZUMAB GOVITECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
TACROLIMUS;CYP3A4;rs2740574;T;LADME_PK;PK;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)
ARIPIPRAZOLE;CYP2D6;CYP2D6;ultrarapid_metabolizer;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;rs1799930;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_REACTIONS
ATORVASTATIN, FLUVASTATIN, HMG COA REDUCTASE INHIBITORS, PITAVASTATIN, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;HLA-DRB1;HLA-DRB1*01:01, HLA-DRB1*04:06;*04:06;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
ETHANOL;CHRNA5;rs615470;T;TOXICITY, OTHER;DECREASED_LIKELIHOOD;DISEASE:ALCOHOL_ABUSE
LIRAGLUTIDE;GLP1R;rs2254336;AT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA,_VOMITING,_DIARRHEA,_GASTROINTESTINAL_TOXICITY
PEGINTERFERON ALFA-2A, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1041983;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799931;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_AUC24
GEFITINIB;ABCG2;rs2231142;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
LIRAGLUTIDE;GLP1R;rs3765467;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA,_VOMITING,_DIARRHEA,_GASTROINTESTINAL_TOXICITY
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS,_STEVENS-JOHNSON_SYNDROME
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:HEMORRHAGE
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;HTR3B;rs2276307;G;TOXICITY;INCREASED_RISK;DISEASE:MYALGIA
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_LIKELIHOODPK;PK:ACHIEVING_OPTIMAL_TROUGH_LEVEL
NORTRIPTYLINE;UST;rs2500535;A;EFFICACY;DECREASED_EFFICACY;EFFICACY:IMPROVEMENT_OF_DEPRESSION_SYMPTOMS
TACROLIMUS;CYP3A4;rs1851426;G;LADME_PK;PK;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT:BLEEDING
OSIMERTINIB;IL6;rs1800796;CG + GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
FLUCLOXACILLIN;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RISPERIDONE;HTR2A;rs6311;CT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
TAMOXIFEN;CYP2D6;CYP2D6*6;*6/*6;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TAMOXIFEN;CYP2D6;CYP2D6*5;*5/*5;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_SEVERITY;OTHER:INTERSTITIAL_INFLAMMATORY_CELL_INFILTRATION
RISPERIDONE;HTR2A;rs6313;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
OXAZEPAM;UGT2B15;rs1902023;AA;LADME_PK;DECREASED_PK;PK:S-OXAZEPAM_GLUCURONIDATION_IN_HUMAN_LIVER_MICROSOMES
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
OXAZEPAM;UGT2B15;rs1902023;AA;LADME_PK;DECREASED_PK;PK:OXAZEPAM_ORAL_CLEARANCE
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
EFAVIRENZ, ISONIAZID;CYP2B6;CYP2B6;poor_metabolizer;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TACROLIMUS;PPARA;rs4823613;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ACUTE_CELLULAR_REJECTION
MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY,_INFECTIOUS_DISEASE,_STOMATITIS,
NITROUS OXIDE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_;SIDE_EFFECT:PLASMA_TOTAL_HOMOCYSTEINE_CONCENTRATIONS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:STROKE,_MYOCARDIAL_INFARCTION,_DEATH,
RISPERIDONE;DRD3;rs167771;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10 + *10/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TARDIVE_DYSKINESIA
FLUCLOXACILLIN;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
FLUCLOXACILLIN;HLA-A;HLA-A*01:01;*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
AMOXICILLIN;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CISPLATIN, PACLITAXEL;GGT1;rs5751901;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA,_LEUKOPENIA
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*27:05;*27:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
FLUCLOXACILLIN;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
BUSULFAN;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*9;*1/*1 + *1/*5 + *1/*9;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TAMOXIFEN;CYP2D6;CYP2D6;poor_metabolizer;TOXICITY;INCREASED_RISK;SIDE_EFFECT:UTERINE_DISORDER,_LEIOMYOMA,_ENDOMETRIAL_HYPERPLASIA,_POLYPS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE
CAPECITABINE, FLUOROURACIL;ABCC11;rs17822471;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*1/*4 + *1/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TARDIVE_DYSKINESIA
FLUVOXAMINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*1/*10 + *1/*5 + *10/*10 + *5/*10;LADME_PK;PK;PK:DIFFERENCES_IN_THE_FLUVOXAMINE_PLASMA_LEVEL_AT_50_MG/DAY
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQA1;HLA-DQA1*05;*05;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BULLOUS_PEMPHIGOID
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IDO1;rs9657182;CC;TOXICITY;INCREASED_;SIDE_EFFECT:DEPRESSION
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;;rs3129763;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BULLOUS_PEMPHIGOID
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;HLA-DQB1*03:01;*03:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BULLOUS_PEMPHIGOID
NITROUS OXIDE;MTHFR;rs1801131;GG;TOXICITY;INCREASED_;SIDE_EFFECT:PLASMA_TOTAL_HOMOCYSTEINE_CONCENTRATIONS
CIPROFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
OMEPRAZOLE;CYP2C19;rs11188072;TT;DOSAGE, LADME_PK;DECREASED_PK;PK:AUC
METHADONE;CYP3A4;rs3735451;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SIDE_EFFECTS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CARBOPLATIN, PACLITAXEL;ABCB1;rs2032582;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*1;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*10;*10;TOXICITY;RISK_;SIDE_EFFECT:TARDIVE_DYSKINESIA
ANTIDEPRESSANTS;CYP2D6;CYP2D6*2, CYP2D6*2xN;*2/*2xN;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
ASPARAGINASE;ATL2;rs59569490;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
AZATHIOPRINE, MERCAPTOPURINE;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCREATITIS
ASPIRIN, CILOSTAZOL, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3;LADME_PK;INCREASED_EFFICACY;EFFICACY:MAXIMAL_PLATELET_AGGREGATION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS_(ST)_AFTER_1_YEAR
ESCITALOPRAM;CYP2C19;rs4986893;A;DOSAGE, LADME_PK;INCREASED_PK;PK:SERUM_CONCENTRATION
PLATINUM COMPOUNDS;RETN;rs1862513;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL,_RECURRENCE_FREE_SURVIVAL
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4 + *1/*4;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL,_RECURRENCE_FREE_SURVIVAL
NILOTINIB;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*27, UGT1A1*28;*6/*6 + *6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
PRIMAQUINE;MAOA;rs1137070;CC + CT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
OMEPRAZOLE;CYP2C19;rs12248560;TT;DOSAGE, LADME_PK;DECREASED_PK;PK:AUC
PRIMAQUINE;CYP2D6;CYP2D6 normal metabolizer;;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs746071566;GGAGTC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA
PRIMAQUINE;CYP2D6;CYP2D6*4;*4;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
ESCITALOPRAM;CYP2C19;rs11188072;TT;DOSAGE, LADME_PK;DECREASED_PK;PK:SERUM_CONCENTRATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK;PK:CONCENTRATION/DOSE_RATIO
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;DECREASED_PK;PK:CONCENTRATION/DOSE_RATIO
TENOFOVIR;ABCC10;rs2125739;C;TOXICITY;INCREASED_;SIDE_EFFECT:KIDNEY_TUBULAR_DYSFUNCTION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;LADME_PK;INCREASED_PK;PK:BLOOD_CONCENTRATION/DOSAGE_RATIO
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK;PK:CONCENTRATION/DOSE_RATIO
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*5;*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
EFAVIRENZ, ISONIAZID;CYP2B6;CYP2B6;poor_metabolizer;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ROSUVASTATIN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAEMATOLOGICAL_TOXICITY_OR_HEPATOTOXICITY
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
TACROLIMUS;CYP3A4;rs2687116;A;LADME_PK;PK;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)
CARBOPLATIN, PACLITAXEL;ABCB1;rs1128503;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
CARBOPLATIN, PACLITAXEL;ABCB1;rs1128503;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
ESCITALOPRAM;CYP2C19;rs4244285;A;DOSAGE, LADME_PK;INCREASED_PK;PK:SERUM_CONCENTRATION
;IFNL4;rs11322783;TT/TT;OTHER;INCREASED_;OTHER:SPONTANEOUS_HCV_CLEARANCE
MERCAPTOPURINE;SLC22A1;rs72552763;del;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:INFECTIOUS_DISEASE
CARBOPLATIN, CISPLATIN;;rs6856089;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;LADME_PK;DECREASED_PK;PK:6-MMPN_LEVELS
;SOD1;rs36232792;GCCCAGTAAAGCATGGGGCCTGGGGCCAGGGACCCCCTTGTTCAGGTGTG/del + del/del;OTHER;DECREASED_LIKELIHOOD;OTHER:OPIOID-RELATED_DISORDERS
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BONE_MARROW_TOXICITY
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*1, NAT2*5, NAT2*6, NAT2*7, NAT2*14;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
LACOSAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;EFFICACY, TOXICITY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DISCONTINUATION
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *3A/*3A + *1/*3C + *3C/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVERALL_ADRS
;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;OTHER;INCREASED_LIKELIHOOD;OTHER:DECREASED_GLOMERULAR_FILTRATION_RATE
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_LIKELIHOOD;OTHER:DISCONTINUATION,_TREATMENT_MODIFICATION
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3 + *3/*3;LADME_PK;INCREASED_LIKELIHOOD;OTHER:DISCONTINUATION,_TREATMENT_MODIFICATION
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C;TOXICITY;DECREASED_;SIDE_EFFECT:HEMATOLOGICAL_INDICES
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CYCLOSPORINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C;TOXICITY;INCREASED_PK;PK:PLASMA_LEVELS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(RAPID_AND_SUSTAINED_VIROLOGICAL_RESPONSE)_FOR_PATIENTS_WITH_HEPATITIS_C_VIRUS_GENOTYPE_1
CISPLATIN, PEMETREXED;MTHFR;rs1801131;GG + GT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ESCITALOPRAM;CYP2C19;rs12248560;TT;DOSAGE, LADME_PK;DECREASED_PK;PK:SERUM_CONCENTRATION
PHENYTOIN;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
SUFENTANIL;ADRB1;rs1801253;GG;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:PAIN,_POSTOPERATIVE
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*35, CYP2D6*36, CYP2D6*41;*10/*5 + *10/*10 + *10/*41;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
TENOFOVIR;ABCC10;rs9349256;G;TOXICITY;INCREASED_;SIDE_EFFECT:KIDNEY_TUBULAR_DYSFUNCTION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MORTALITY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
IMATINIB;ABCB1;rs1045642;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
IMATINIB;NR1I2;rs3814055;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CLINICAL_EVENTS
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR1A;rs6295;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
FLUOROURACIL;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;LADME_PK;DECREASED_PK;PK:AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
METHOTREXATE;MTRR;rs1801394;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;*4 + *7 + *9 + *10;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL,_OVERALL_SURVIVAL
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CLINICAL_EVENTS
CLOPIDOGREL, ROSUVASTATIN;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;OTHER;INCREASED_;OTHER:P2Y12_REACTION_UNIT(PRU)_VALUES
METHADONE;CYP3A4;rs4646437;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SIDE_EFFECTS
TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*1/*4 + *1/*7 + *1/*9 + *4/*4 + *7/*7 + *9/*9;LADME_PK;INCREASED_PK;PK:AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*14;*3 + *4 + *5 + *6 + *7 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TARDIVE_DYSKINESIA
AZATHIOPRINE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
LAMOTRIGINE;HLA-C;HLA-C*07:18;*07:18;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
LAMOTRIGINE;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
RIVAROXABAN;ABCB1;rs4148738;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
LAMOTRIGINE;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
RIVAROXABAN;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT:THROMBOEMBOLISM
TAMOXIFEN;CYP2D6;CYP2D6*10;*10;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ENDOMETRIAL_HYPERPLASIA
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CLOPIDOGREL_RESISTANCE
METHOTREXATE;MTHFD1;rs2236225;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
METHADONE;CYP3A4;rs2242480;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SIDE_EFFECTS
CARBOPLATIN, CISPLATIN;CD274;rs2297136;AG + GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT:BLEEDING_EVENTS
CARBOPLATIN, CISPLATIN;CD274;rs822336;CC + CG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CARBOPLATIN, CISPLATIN;CD274;rs2282055;GT + TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
HYDROMORPHONE, MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PRURITUS
ANTIPSYCHOTICS;CYP2D6;CYP2D6*1, CYP2D6*2;*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_SEVERE_CUTANEOUS_ADVERSE_REACTIONS,_STEVENS-JOHNSON_SYNDROME,
DOXORUBICIN;NCF4;rs1883112;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
AZATHIOPRINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DISCONTINUATION,_MYELOSUPPRESSION
AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*8, TPMT*9, TPMT*12, TPMT*24;*1/*2 + *1/*3A +*1/*3C +*1/*8 +*1/*9 +*1/*12 +*1/*24 +*2/*3A +*3A/*3A +*3C/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DISCONTINUATION,_MYELOSUPPRESSION
DOXORUBICIN;CBR1;rs3787728;CT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL,_OVERALL_SURVIVAL
INFLIXIMAB;HLA-DRB1;HLA-DRB1*04:04;*04:04;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DOXORUBICIN;CBR1;rs1005695;CG + GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL,_OVERALL_SURVIVAL
ATORVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*1/*5 + *5/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DISCONTINUATION,_STATIN-RELATED_MYOPATHY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;OTHER;INCREASED_;OTHER:PLATELET_REACTIVITY_BY_P2Y12_REACTION_UNITS
DABIGATRAN;CES1;rs2244613;GG + GT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
OLANZAPINE, QUETIAPINE, RISPERIDONE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);TOXICITY;INCREASED_RISK;DISEASE:DIZZINESS
RIVAROXABAN;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOEMBOLISM
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
CAPECITABINE, PLATINUM;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ONDANSETRON;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_;OTHER:PERCENTAGE_OF_DAYS_ABSTINENT_AND_LOWER_NUMBER_OF_DRINKS_PER_DRINKING_DAY
CHOP, RITUXIMAB;CBR3;rs8133052;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
CHOP, RITUXIMAB;ABCC2;rs8187710;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*5, CYP2B6*6;*5/*6;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
METHOTREXATE;SLC19A1;rs1051266;T;EFFICACY;EFFICACY;EFFICACY:WORSE_PROGNOSES
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEXUAL_DYSFUNCTION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*11;*1/*11;EFFICACY;INCREASED_EFFICACY;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR)
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3C;*1/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
GEMCITABINE, PLATINUM COMPOUNDS;RRM1;rs1042927;C;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_PROBABILITY
METHOTREXATE;SLC19A1;rs1051266;CC;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;rs6311;CC + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:TREMOR,_DIARRHEA
AMOXICILLIN, CLAVULANATE;HLA-B;HLA-B*15:18;*15:18;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*37;*28/*28 + *28/*37;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ASTHENIA,_DIARRHEA,_NEUTROPENIA,
CAPECITABINE, PACLITAXEL;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
AZATHIOPRINE, MERCAPTOPURINE;PTPN2;rs11664064;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*41;*3/*4 + *4/*4 + *4/*5;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;SHMT1;rs1979277;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_(P=0.00004)_AND_OVERALL_SURVIVAL_(OS)_(P=0.034)
METHOTREXATE;MTHFD1;rs2236225;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
TAMOXIFEN;CYP2D6;rs3892097;CT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;ABCB1;rs1045642;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
METHOTREXATE;GSTP1;rs1695;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
MERCAPTOPURINE, METHOTREXATE;TPMT;rs1142345;C;TOXICITY;INCREASED_;SIDE_EFFECT:GI_TOXICITY
METHOTREXATE;SLCO1B1;rs11045879;T;TOXICITY;INCREASED_RISK;DISEASE:MUCOSITIS
AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
AMOXICILLIN, CLAVULANATE;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
AMOXICILLIN, CLAVULANATE;ERAP1, ERAP2;rs1363907;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CYCLOPHOSPHAMIDE;GSTT1;GSTT1 non-null, GSTT1 null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
AMOXICILLIN, CLAVULANATE;PTPN22;rs2476601;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CYCLOPHOSPHAMIDE;GSTM1;GSTM1 non-null, GSTM1 null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CAPECITABINE;TYMS;rs3786362;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CAPECITABINE;TYMS;rs699517;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CAPECITABINE;ENOSF1, TYMS;rs11280056;TTAAAGTTA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CAPECITABINE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CAPECITABINE;ENOSF1, TYMS;rs2790;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
;NME1, NME1-NME2;rs2302254;TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL,_RECURRENCE_FREE_SURVIVAL
IRINOTECAN;UGT1A7;UGT1A7*1a, UGT1A7*2, UGT1A7*3;*1a/*3 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
RIVAROXABAN;SUSD3;rs76292544;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
;CYP3A5, ZSCAN25;rs776746;CC;;;SIDE_EFFECT:DRUG_TOXICITY
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
IRINOTECAN;UGT1A7;UGT1A7*1a, UGT1A7*2, UGT1A7*3;*1a/*3 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
METHOTREXATE;SLCO1B1;rs4149081;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GI_TOXICITY
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-A;HLA-A*02:07;*02:07;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA,_DRUG_HYPERSENSITIVITY
ASPIRIN;FCER1G;rs11587213;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA
LAPATINIB;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TRANSPLANT_REJECTION
LAPATINIB;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
TACROLIMUS;CYP3A5;rs776746;C;LADME_PK;INCREASED_PK;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
;MS4A2;rs569108;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;OTHER:ATOPY_IN_PATIENTS_WITH_ASPIRIN-INTOLERANT_CHRONIC_URTICARIA
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PACLITAXEL;ABCB1;rs2032582;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:CHANCE_OF_POSITIVE_RESPONSE_TO_PACLITAXEL
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;FECH;rs536560;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
;FCER1G;rs11587213;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;OTHER:ATOPY_IN_PATIENTS_WITH_ASPIRIN-INTOLERANT_CHRONIC_URTICARIA
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
CISPLATIN, RADIOTHERAPY;EPHX1;rs1051740;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY
CISPLATIN, RADIOTHERAPY;ERCC2;rs13181;GG + GT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN, RADIOTHERAPY;ERCC2;rs1799793;CT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
GEMCITABINE, PLATINUM COMPOUNDS;CDA;rs2072671;C;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:NAUSEA
;CYP2A6;CYP2A6*4;*4/*4;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
ANTHRACYCLINES AND RELATED SUBSTANCES;CYP3A5;rs4646450;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*6;*1/*2 + *1/*3 + *1/*6 + *2/*2;TOXICITY;INCREASED_;SIDE_EFFECT:NEUTROPENIA
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;rs7853758;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1 + *1/*2 + *1/*3;EFFICACY;DECREASED_;DISEASE:GASTRIC_PH
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PHENPROCOUMON;VKORC1;rs9923231;TT;DOSAGE, OTHER;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
METHOTREXATE;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CARBOPLATIN, GEMCITABINE;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:THROMBOCYTOPENIA
METHOTREXATE;SLCO1B1;rs4149056;C;OTHER, LADME_PK;DECREASED_PK;PK:CLEARANCE
ASPARAGINASE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ENALAPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_LIKELIHOOD;DISEASE:CHRONIC_KIDNEY_FAILURE
SUCCINYLCHOLINE, VOLATILE ANESTHETICS;RYR1;rs193922752;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MALIGNANT_HYPERTHERMIA
EGFR INHIBITORS;EGFR;rs2227983;GG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:EXANTHEMA
GEMCITABINE, PLATINUM COMPOUNDS;RRM1;rs12806698;A;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:NAUSEA
GEMCITABINE, PLATINUM COMPOUNDS;RRM1;rs11030918;C;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:NAUSEA
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
VERAPAMIL;ADRB1;rs1801252;AA + AG;EFFICACY;INCREASED_RISK;DISEASE:DEATH
HEROIN;DRD2;rs12364283;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEROIN_DEPENDENCE
REPAGLINIDE;CYP2C8;CYP2C8*3;*3;LADME_PK;DECREASED_PK;PK:REPAGLINIDE_AUC
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAEMATOPOIETIC_TOXICITY
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
AZATHIOPRINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
TACROLIMUS;CYP3A7;rs2257401;C;LADME_PK;PK;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)
SIMVASTATIN;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULAR_DISEASES
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
PHENYTOIN;CYP2C19;rs4986893;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*5;*3/*5;DOSAGE, EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;DOSAGE, EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE
TACROLIMUS;CYP3A4;rs4646437;G;LADME_PK;PK;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)
ISONIAZID, RIFAMPIN;NAT2;NAT2*4;*4;TOXICITY, LADME_PK;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ASPARAGINASE;SOD2;rs4880;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
;CYP1A2;rs762551;AC + CC;OTHER;INCREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*39:01;*39:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
TRASTUZUMAB;ERBB2;rs1136201;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
SIMVASTATIN;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PHENYTOIN;CYP2C9;rs1799853;T;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:STEVENS-JOHNSON_SYNDROME
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
BETA BLOCKING AGENTS;ADRA2C;rs61767072;GGGGCGGGGCCG/GGGGCGGGGCCG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
PACLITAXEL;FZD3;rs7001034;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:SENSORY_PERIPHERAL_NEUROPATHY
CAPECITABINE, FLUOROURACIL;TYMS;rs11280056;TTA/TTA;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;RISK_;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
SERTRALINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
CLOZAPINE;HLA-DRB1;HLA-DRB1*04:02;*04:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:AGRANULOCYTOSIS
DIRECT ACTING ANTIVIRALS;IFNL3, IFNL4;rs12979860;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEPATOCELLULAR_CARCINOMA
GLICLAZIDE, GLIMEPIRIDE, GLIPIZIDE, GLIQUIDONE, GLYBURIDE;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;OTHER;INCREASED_RISK;DISEASE:HYPOGLYCEMIA
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*5;*5/*5;DOSAGE, EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE
ASPIRIN, BETA BLOCKING AGENTS, CLOPIDOGREL, HMG COA REDUCTASE INHIBITORS;NOS3;rs1799983;T;OTHER;INCREASED_RISK;OTHER:IN-STENT_RESTENOSIS
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ANTHRACYCLINES AND RELATED SUBSTANCES, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ASPIRIN, CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
TACROLIMUS;CYP3A4;rs6956344;C;LADME_PK;PK;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL,_RECURRENCE_FREE_SURVIVAL
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
CARBAMAZEPINE;HLA-B;HLA-B*15:21;*15:21;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
PACLITAXEL;ABCB1;rs1045642;AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_CONTROL_RATE_AND_LOWER_OVERALL_SURVIVAL_RATE
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;LADME_PK;DECREASED_PK;PK:CLOPIDOGREL_ACTIVE_METABOLITE_LEVEL
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_LIKELIHOODPK;PK:ACHIEVING_TARGET_CONCENTRATIONS
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:POST-TREATMENT_ADP-STIMULATED_PLATELET_AGGREGATION
PACLITAXEL;CYP3A5;rs776746;C;TOXICITY;DECREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HOT_FLASHES
INFLIXIMAB;HLA-DQB1;HLA-DQB1*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
INFLIXIMAB;HLA-DPB1;HLA-DPB1*10:01;*10:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
INFLIXIMAB;HLA-DRB1;HLA-DRB1*03:01;*03:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*10x2, CYP2D6*14, CYP2D6*21, CYP2D6*36, CYP2D6*41;*1/*4 + *1/*5 + *1/*10 + *1/*10x2 + *10/*10x2 + *1/*14 + *1/*21 + *1/*36 + *1/*41 + *1xN/*10 + *5/*5 + *5/*10 + *5/*21 + *5/*41 + *10/*10 + *10/*21 + *10/*36 + *10/*41;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
;HLA-DPB1;HLA-DPB1*03:01;*03:01;TOXICITY;INCREASED_RISK;DISEASE:ASPIRIN-INDUCED_ASTHMA
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10;*4/*4 + *4/*5 + *4/*10;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*6;*6/*6;DOSAGE, EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4/*5;DOSAGE, EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_AND_REQUIRED_HIGHER_DOSE
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:ANTIPLATELET_RESPONSE_AND_REDUCED_CLOPIDOGREL_ACTIVE_METABOLITE_FORMATION
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;CPT1A, IGHMBP2;rs12283870;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
FOLFIRINOX;UGT1A1;UGT1A1*1, UGT1A1*28;*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:THROMBOCYTOPENIA
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*14, CYP2D6*21, CYP2D6*36, CYP2D6*41;*4 + *5 + *10 + *14 + *21 + *36 + *41;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_BLOOD_LEVELS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_PK;PK:TROUGH_CONCENTRATION
TACROLIMUS;CYP3A4;rs2242480;C;LADME_PK;PK;PK:TACROLIMUS_CONCENTRATION_TO_DOSE_RATIO_(C/D_RATIO)
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*2 + *1/*3A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE_TO_PEGIFN-ALPHA/RBV_TREATMENT_AT_WEEK_20/24
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;OTHER;INCREASED_;OTHER:CREATININE_CLEARANCE
FLECAINIDE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*21, CYP2D6*36;*4 + *5 + *10 + *21 + *36;LADME_PK;INCREASED_PK;PK:AGE-RELATED_DECLINE_IN_FLECAINIDE_CLEARANCE_PATIENTS_TREATED_WITH_ORAL_FLECAINIDE_FOR_SUPRAVENTRICULAR_TACHYARRHYTHMIAS
TRANILAST;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*3;*3;LADME_PK;INCREASED_PK;PK:MEAN_NORTRIPTYLINE_CONCENTRATIONS_AND_NORTRIPTYLINE_CONCENTRATIONS_PER_UNIT_DOSE_OF_THE_MEDICATION
FLECAINIDE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*21, CYP2D6*36;*5/*36 + *10/*10 + *10/*36 + *21/*36;LADME_PK;DECREASED_PK;PK:ORAL_CLEARANCE_(CL/F)_OF_FLECAINIDE_IN_PATIENTS_WITH_SUPRAVENTRICULAR_TACHYARRHYTHMIA
ANTITHYROID PREPARATIONS;HLA-DRB1;HLA-DRB1*08:03;*08:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
ANTITHYROID PREPARATIONS;HLA-DQA1;HLA-DQA1*01:03;*01:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
ANTITHYROID PREPARATIONS;HLA-DQB1;HLA-DQB1*06:01;*06:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*20, CYP2D6*35, CYP2D6*41;*4/*4 + *4/*41 + *1/*5 + *2/*5;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CAPECITABINE;DPYD;rs67376798;AT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY,_LEUKOPENIA,_TOXIC_LIVER_DISEASE,
CYTARABINE, IDARUBICIN;ABCB1;rs2032582;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:3_YEAR_EVENT_FREE_SURVIVAL
CLOPIDOGREL;CYP1A2;rs2069514;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
OPIOIDS;OPRM1;rs548646;T;TOXICITY;DECREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK;PK:TROUGH_CONCENTRATIONS
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10;*10;LADME_PK;INCREASED_PK;PK:NORTRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT
TACROLIMUS;CYP3A4;rs2242480;C/T + T/T;TOXICITY;INCREASED_RISK;DISEASE:ACUTE_CELLULAR_REJECTION
RHODAMINE 123;ABCB1;rs1045642;GG;LADME_PK;INCREASED_PK;PK:EFFLUX_OF_RHODAMINE_FROM_CD56+_NATURAL_KILLER_CELLS
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;;SIDE_EFFECT:NEUTROPENIA,_THROMBOCYTOPENIA
ASPIRIN, CLOPIDOGREL, TICAGRELOR;PEAR1;rs2768759;AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
LAMOTRIGINE;HLA-A;HLA-A*68:01;*68:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CELECOXIB;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:PAIN
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5, NUDT15*6;*2 + *3 + *4 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
CARBAMAZEPINE;HLA-A;HLA-A*01:01;*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
TETANUS ANTITOXIN;HLA-A;HLA-A*02:06;*02:06;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
CARBAMAZEPINE;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ACETAMINOPHEN;HLA-A;HLA-A*24:02;*24:02;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME,_TOXIC_EPIDERMAL_NECROLYSIS
CARBAMAZEPINE;HLA-A;HLA-A*24:02;*24:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
INFLIXIMAB;HLA-B;HLA-B*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
VANCOMYCIN;HLA-A;HLA-A*32:01;*32:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
PHENYTOIN;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
NEVIRAPINE;HLA-B;HLA-B*14:02;*14:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
PHENYTOIN;HLA-B;HLA-B*15:01;*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
ANTIEPILEPTICS;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ANTIEPILEPTICS;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PHENYTOIN;HLA-B;HLA-B*15:13;*15:13;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS,_TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME,
AZATHIOPRINE, MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*3A + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA,_NEUTROPENIA
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*6;*1/*2 + *1/*3 + *1/*4 + *1/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CLINDAMYCIN;HLA-B;HLA-B*15:27;*15:27;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
NEVIRAPINE;HLA-B;HLA-B*35:01;*35:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CLOZAPINE;HLA-B;HLA-B*38:01;*38:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
LAMOTRIGINE;HLA-B;HLA-B*38:01;*38:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
INFLIXIMAB;HLA-B;HLA-B*39:01;*39:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;TOXICITY;DECREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
OXCARBAZEPINE;HLA-B;HLA-B*40:02;*40:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*6;*3/*4 + *4/*6;LADME_PK;INCREASED_PK;PK:S-MIRTAZAPINE_PLASMA_LEVELS_IN_NON-SMOKERS_AT_DAY_14_OF_TREATMENT
PHENYTOIN;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
CARBAMAZEPINE;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
NILOTINIB;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
CLINDAMYCIN;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PHENYTOIN;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PHENYTOIN;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
ISONIAZID;HLA-B;HLA-B*52:01;*52:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4 + *5;LADME_PK;INCREASED_PK;PK:SERUM_CONCENTRATIONS_OF_S(+)-MIRTAZAPINE,_MIRTAZAPINE_S(+)/R(-)_RATIOS_AND_S(+)-N-DESMETHYLMIRTAZAPINE
OPIOIDS;OPRM1;rs609148;A;TOXICITY;DECREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
ATAZANAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*1 + *1/*18;LADME_PK;INCREASED_PK;PK:TROUGH_CONCENTRATIONS
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*07:27;*07:27;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
NEVIRAPINE;HLA-C;HLA-C*08:02;*08:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
INFLIXIMAB;HLA-C;HLA-C*12:03;*12:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
;HLA-DPB1;HLA-DPB1*03:01;*03:01;TOXICITY;INCREASED_RISK;DISEASE:ASPIRIN-INDUCED_ASTHMA
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
PHENYTOIN;HLA-C;HLA-C*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
TACROLIMUS;CYP2J2;rs890293;AA + AC;TOXICITY;INCREASED_RISK;DISEASE:NAUSEA,_VOMITING
CARBAMAZEPINE;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ABACAVIR;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
NEVIRAPINE;HLA-DQB1;HLA-DQB1*05:01;*05:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
FLUPIRTINE;HLA-DQB1;HLA-DQB1*05:02;*05:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
AMOXICILLIN, CLAVULANATE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATITIS
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:02;*01:02;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
HYDRALAZINE;HLA-DRB1;HLA-DRB1*04:01;*04:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LUPUS_ERYTHEMATOSUS_DUE_TO_HYDRALAZINE
OXCARBAZEPINE;HLA-DRB1;HLA-DRB1*04:03;*04:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
ABACAVIR;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
ASPARAGINASE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERSENSITIVITY
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs4969170;AA;TOXICITY;DECREASED_RISK;DISEASE:THROMBOCYTOPENIA
PRAVASTATIN;LDLR;rs2738466;G;EFFICACY;INCREASED_RISK;DISEASE:CORONARY_DISEASE
LAMOTRIGINE;HLA-DRB1;HLA-DRB1*13:01;*13:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
FLUPIRTINE;HLA-DRB1;HLA-DRB1*16:01;*16:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
THALIDOMIDE;GSTT1;rs4630;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY
MINOCYCLINE;HLA-B;HLA-B*35:02;*35:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;LADME_PK;DECREASED_PK;PK:DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROTHROMBIN_TIME_(PT)_AT_INDUCTION
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ROSIGLITAZONE;CYP2C8;CYP2C8*1, CYP2C8*3;*3;TOXICITY;DECREASED_;SIDE_EFFECT:WEIGHT_GAIN
TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*3;TOXICITY;INCREASED_RISK;DISEASE:KIDNEY_DISORDER
CALCINEURIN INHIBITORS, CYCLOSPORINE, TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*3;TOXICITY;INCREASED_RISK;DISEASE:KIDNEY_DISORDER
ASPIRIN, CILOSTAZOL, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3;LADME_PK;INCREASED_EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE,_OVER-ANTICOAGULATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
PACLITAXEL, PLATINUM COMPOUNDS;NAT2;rs1799931;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CAFFEINE;CYP1A2;CYP1A2 low activity;;OTHER;INCREASED_;OTHER:INTAKE
HMG COA REDUCTASE INHIBITORS;GNB3;rs5443;CT + TT;EFFICACY;DECREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
;HMGCR;rs3846662;AA;OTHER;DECREASED_;OTHER:HMGCRV_1_EXPRESSION_AND_AN_INCREASE_IN_THE_EXPRESSION_OF_THE_FULL-LENGTH_TRANSCRIPT
ATAZANAVIR, RITONAVIR;UGT1A1;UGT1A1*28;*28;LADME_PK;;DISEASE:HYPERBILIRUBINEMIA
ACYCLOVIR;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4, NUDT15*5;*2/*2 +*2/*3 +*3/*3 + *5/*5;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PRIMARY_GRAFT_FAILURE
METHOTREXATE;SLCO1B1;SLCO1B1*15;*15;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
CAFFEINE;ADORA2A;rs35320474;T/del + TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:BRONCHOPULMONARY_DYSPLASIA
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;EFFICACY;EFFICACY;EFFICACY:HIGHER_MEAN_PEAK_INR_DURING_WEEK_1_OF_WARFARIN_THERAPY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;EFFICACY;EFFICACY;EFFICACY:HIGHER_MEAN_PEAK_INR_DURING_WEEK_1_OF_WARFARIN_THERAPY
;DHFR;rs70991108;del/del;OTHER;INCREASED_;OTHER:SERUM_AND_RED_BLOOD_CELL_FOLATE_CONCENTRATIONS
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA;TOXICITY;INCREASED_;DISEASE:NEUTROPENIA
FLUOXETINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:DEPRESSION
FLUOXETINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ANXIETY_DISORDERS
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*9, CYP2A6*17, CYP2A6*20, CYP2A6*24, CYP2A6*26, CYP2A6*27;*20 + *26 + *24+ *9 + *27 + *17;OTHER, LADME_PK;DECREASED_PK;PK:METABOLISM
COCAINE, ETHANOL, OPIOIDS;OPRM1;rs3823010;A;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE,_COCAINE_DEPENDENCE,_OPIOID-RELATED_DISORDERS,
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CAPECITABINE, FLUOROURACIL, FOLFOX, XELOX;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
COCAINE, ETHANOL, OPIOIDS;OPRM1;rs495491;G;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE,_COCAINE_DEPENDENCE,_OPIOID-RELATED_DISORDERS,
INTERFERON BETA-1A, INTERFERON BETA-1B;HLA-DQA1;rs9272105;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:ANTI-IFN-BETA_ANTIBODIES
CAPECITABINE, FLUOROURACIL, FOLFOX, XELOX;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
REPAGLINIDE;SLCO1B1;SLCO1B1*1, SLCO1B1*5, SLCO1B1*15, SLCO1B1*37;*37/*37;LADME_PK;DECREASED_PK;PK:REPAGLINIDE_EXPOSURE_(DECREASED_AUC_AND_INCREASED_CLEARANCE)
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
EGFR INHIBITORS;EGFR;rs2227983;A;EFFICACY;EFFICACY;EFFICACY:CYTOTOXICITY
ATAZANAVIR, RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
NEVIRAPINE;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
INTERFERON BETA-1A, INTERFERON BETA-1B;;rs4961252;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:ANTI-IFN-BETA_ANTIBODIES
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3 + (CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PEGASPARGASE;HLA-DRB1;HLA-DRB1*16:02;*16:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ASPARAGINASE, CYTARABINE, DAUNORUBICIN, ETOPOSIDE, MERCAPTOPURINE, METHOTREXATE, PREDNISONE, VINCRISTINE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CNS_RELAPSE,_HEMATOLOGIC_RELAPSE
METHOTREXATE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
GEMCITABINE;RRM1;rs9937;G;TOXICITY;DECREASED_RISK;DISEASE:NEUTROPENIA
;ACE;rs1799752;del/del;OTHER;INCREASED_SEVERITY;OTHER:COVID-19
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;PD;DECREASED_LIKELIHOOD;OTHER:TIME_TO_THERAPEUTIC_INR
ETHANOL;OPRM1;rs1381376;T;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE
NEVIRAPINE;HLA-B;HLA-B*35:01;*35:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
PEGASPARGASE;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
PEGASPARGASE;HLA-DQB1;HLA-DQB1*02:02;*02:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
PEGASPARGASE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
METHOTREXATE;DHFR, MSH3;rs70991108;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA
METHOTREXATE;ENOSF1, TYMS;rs11280056;TTA/TTA + TTA/TTAAAGTTA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED_LIKELIHOOD;OTHER:COVID-19
CYCLOSPORINE, TACROLIMUS;ABCB1;rs1128503;GG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TRANSPLANT_REJECTION
;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED_SEVERITY;OTHER:COVID-19
AMITRIPTYLINE, CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*2/*2 + *2/*1 + *2/*17;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_EMERGENT_MANIA
;ACE;rs1799752;del;OTHER;INCREASED_LIKELIHOOD;OTHER:COVID-19
ASPIRIN, BETA BLOCKING AGENTS, CLOPIDOGREL, HMG COA REDUCTASE INHIBITORS;;rs1050450;A;OTHER;INCREASED_RISK;OTHER:IN-STENT_RESTENOSIS
;ACE;rs1799752;del/del;OTHER;INCREASED_RISK;OTHER:DEATH
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*2/*2 + *2/*1 + *2/*17;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_EMERGENT_MANIA
MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;*1/*2 + *1/*3 + *1/*5 + *1/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizers and intermediate metabolizers;;TOXICITY;DECREASED_;SIDE_EFFECT:HEMORRHAGE
LEFLUNOMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
ANAKINRA, CANAKINUMAB, RILONACEPT, TOCILIZUMAB;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;GG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE_TO_PEGYLATED_INTERFERON-ALPHA/RIBAVIRIN_THERAPY_IN_HCV/HIV-1_COINFECTED_PATIENTS
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*3;*3;LADME_PK;INCREASED_PK;PK:APPARENT_TERMINAL_ELIMINATION_HALF-LIFE
FLUCLOXACILLIN;HLA-B;HLA-B*57:03;*57:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CISPLATIN;TPMT;TPMT*1, TPMT*3B, TPMT*3C;*3B + *3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OTOTOXICITY
PREDNISONE, TACROLIMUS;ABCB1;rs1045642;GG;EFFICACY;INCREASED_RISK;OTHER:REMAINING_ON_STEROIDS_AT_1_YEAR_AFTER_TRANSPLANTATION
CARBAMAZEPINE;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
ATAZANAVIR;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *1/*1;LADME_PK;INCREASED_PK;PK:ORAL_CLEARANCE_(CL)_OF_ATAZANAVIR
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FEBRILE_NEUTROPENIA
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_HEMORRHAGE
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
EGFR INHIBITORS;EGFR;rs712829;T;TOXICITY;EFFICACY;EFFICACY:CYTOTOXICITY
ANTINEOPLASTIC AGENTS;TYMS;rs11280056;TTA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
CARBAMAZEPINE;HLA-A;HLA-A*74:01;*74:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;HLA-A;HLA-A*24:07;*24:07;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-A;HLA-A*24:02;*24:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*3A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LOW_LEUKOCYTE_COUNTS
AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A;*1/*1;EFFICACY;INCREASED_EFFICACY;EFFICACY:TREATMENT_DURATION
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*4;*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
ATAZANAVIR;UGT1A1;UGT1A1*28;*28;TOXICITY;INCREASED_RISK;DISEASE:HYPERBILIRUBINEMIA
ATORVASTATIN, PRAVASTATIN;APOE;rs429358;CC + CT;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_C-REACTIVE_PROTEIN_(CRP)
CLOZAPINE;GSTM1;GSTM1 non-null, GSTM1 null;null/null;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3 + *2/*17 + *3/*17;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:THROMBOTIC_DISEASE,_SUDDEN_CARDIAC_DEATH,_MYOCARDIAL_INFARCTION,
OPIOIDS;OPRM1;rs1799971;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
TAMOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*5;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TAMOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*7;*4/*7;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TRAMADOL;CYP2D6;CYP2D6;poor_metabolizer;EFFICACY, LADME_PK;DECREASED_EFFICACY;EFFICACY:METABOLISM_OF_TRAMADOL_AND_DECREASED_RESPONSE_TO_TRAMADOL
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
TAMOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*6;*4/*6;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME,_TOXIC_EPIDERMAL_NECROLYSIS
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*12:02;*12:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME,_TOXIC_EPIDERMAL_NECROLYSIS
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME,_TOXIC_EPIDERMAL_NECROLYSIS
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;INCREASED_;OTHER:INTRAGASTRIC_PH
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
CARBAMAZEPINE;HLA-B;HLA-B*46:01;*46:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*5;*5;LADME_PK;INCREASED_PK;PK:APPARENT_TERMINAL_ELIMINATION_HALF-LIFE
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*09:01;*09:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
CARBAMAZEPINE;HLA-DQA1;HLA-DQA1*03:02;*03:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
TICAGRELOR;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION_INHIBITION
EFAVIRENZ;HLA-DRB1;HLA-DRB1*08:03;*08:03;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
EFAVIRENZ;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
NEVIRAPINE;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
TAMOXIFEN;CYP2D6;CYP2D6*4, CYP2D6*11;*4/*11;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CYCLOSPORINE;ABCB1;rs1128503;AA;DOSAGE, LADME_PK;INCREASED_PK;PK:TROUGH_BLOOD_CONCENTRATION
;TMPRSS2;rs383510;CC;OTHER;INCREASED_LIKELIHOOD;OTHER:COVID-19
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*4;*3/*4;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
FLUVASTATIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;LADME_PK;INCREASED_PK;PK:APPARENT_TERMINAL_ELIMINATION_HALF-LIFE
TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*5;*3/*5;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
CYCLOSPORINE;ABCB1;rs2032582;AA;DOSAGE, LADME_PK;INCREASED_PK;PK:TROUGH_BLOOD_CONCENTRATION
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
SERTRALINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *2/*2 + *2/*3;LADME_PK;INCREASED_PK;PK:MEAN_SERUM_CONCENTRATIONS_OF_SERTRALINE_AND_N-DESMETHYL_SERTRALINE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;DOSAGE, EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
METHADONE;CYP3A4;rs2246709;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SIDE_EFFECTS
FLUVOXAMINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;LADME_PK;INCREASED_PK;PK:FLUVOXAMINE_PLASMA_CONCENTRATIONS
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4;*2/*2 + *2/*4;LADME_PK;INCREASED_PK;PK:AREA_UNDER_THE_TIME-PLASMA_CONCENTRATION_CURVE_(AUC(0-24))
PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;DECREASED_RISK;DISEASE:CORONARY_DISEASE
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
METHAZOLAMIDE;HLA-B;HLA-B*55:02;*55:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
ACETAMINOPHEN, CODEINE, LEVOMEPROMAZINE;CYP2D6;CYP2D6*1;*1/*1;EFFICACY, LADME_PK;PK;PK:INHIBITION_OF_METABOLISM
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME,_TOXIC_EPIDERMAL_NECROLYSIS
METHADONE;CYP3A4;rs2242480;T;OTHER;INCREASED_SEVERITY;SIDE_EFFECT:OPIOID_WITHDRAWAL_SYMPTOMS
DOCETAXEL, THALIDOMIDE;RPL13, SNORD68, SPG7;rs12960;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
DOCETAXEL, THALIDOMIDE;CHST3;rs1871450;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2+ *2/*2+ *1/*3 + *3/*3 + *2/*3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;INCREASED_PK;PK:METABOLIC_RATIO_CIT/DCIT_VALUES_AND_MEAN_CITALOPRAM_DOSE
PEGINTERFERON ALFA-2B, RIBAVIRIN;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);TOXICITY;DECREASED_RISK;DISEASE:DEPRESSION
METHADONE;CYP3A4;rs4646440;A;OTHER;INCREASED_SEVERITY;SIDE_EFFECT:OPIOID_WITHDRAWAL_SYMPTOMS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *1/*17;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:ADVERSE_CARDIOVASCULAR_EVENTS
CARBAMAZEPINE;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ETHANOL, OPIOIDS;OPRM1;rs511435;T;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE,_OPIOID-RELATED_DISORDERS
DOCETAXEL, THALIDOMIDE;NAT2;rs1799931;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME_PK;DECREASED_PK;PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION
DOCETAXEL, THALIDOMIDE;CYP4B1;rs4646487;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*07:02;*07:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:RESPIRATORY_INSUFFICIENCY
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*07:02;*07:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:RESPIRATORY_INSUFFICIENCY
SULFAMETHOXAZOLE / TRIMETHOPRIM;GSTM1;GSTM1 null;null/null;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
OLANZAPINE;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:FATIGUE
FOLFIRINOX;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*6 + *1/*28 + *6/*28 + *6/*6 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FEBRILE_NEUTROPENIA
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
METHOTREXATE;DHFR;rs3045983;GGGAGCTGG/del + del/del;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
OPIOIDS;OPRM1;rs589046;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;INCREASED_PK;PK:METABOLIC_RATIO_(DEFINED_AS_RATIO_OF_OMEPRAZOLE_TO_ITS_METABOLITES)_OF_5-HYDROXYOMEPRAZOLE,_R-5-HYDROXYOMEPRAZOLE_AND_S-5-HYDROXYOMEPRAZOLE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;TOXICITY;DECREASED_;SIDE_EFFECT:LEUKOCYTES_AND_NEUTROPHILS
EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;INCREASED_PK;PK:METABOLIC_RATIO_(DEFINED_AS_RATIO_OF_OMEPRAZOLE_TO_ITS_METABOLITES)_OF_5-HYDROXYOMEPRAZOLE_AND_R-5-HYDROXYOMEPRAZOLE
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME_PK;INCREASED_PK;PK:AMITRIPTYLINE/NORTRIPTYLINE_RATIO_CORRECTED_FOR_DOSE_AND_WEIGHT
ALPRAZOLAM;CYP3A4;CYP3A4 low activity;;EFFICACY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
PACLITAXEL;CYP3A4;CYP3A4*1, CYP3A4*8, CYP3A4*20;*1/*8 + *1/*20;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES,_TREATMENT_MODIFICATION
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CARBAMAZEPINE;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
DOCETAXEL;VEGFA;rs144854329;del/del;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*3/*3 + *3/*2 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;DECREASED_PK;PK:UNBOUND_ORAL_CLEARANCE_FOR_S-WARFARIN
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;TOXICITY;DECREASED_;SIDE_EFFECT:ADVERSE_EFFECT_BURDEN
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;NUDT15*1, NUDT15*3, NUDT15*6;*1/*3 + *3/*3 + *1/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2/*3 + *3/*3 + *2/*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
HALOPERIDOL;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
;HLA-DPB1;HLA-DPB1*04:01;*04:01;TOXICITY;DECREASED_RISK;DISEASE:ASPIRIN-INDUCED_ASTHMA
CARBOPLATIN, CISPLATIN;DPYD;DPYD Reference;Reference;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL,_OVERALL_SURVIVAL
METHAMPHETAMINE;DAOA;rs947267;T;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER
CARBAMAZEPINE, OXCARBAZEPINE, PHENOBARBITAL;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*10x2, CYP2D6*36;*10/*10 + *5/*10 + *36;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;INCREASED_PK;PK:AREA_UNDER_CURVE_(AUC)_OF_OMEPRAZOLE_RACEMATE,_OMEPRAZOLE_SULFONE,_R-OMEPRAZOLE_AND_S-OMEPRAZOLE
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE, LADME_PK;;OTHER:HIGHER_STABLE_DOSE_LEVELS
METHAMPHETAMINE;OPRM1;rs2075572;C;TOXICITY;DECREASED_RISK;OTHER:METHAMPHETAMINE_DEPENDENCE
ACETAMINOPHEN;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME,_TOXIC_EPIDERMAL_NECROLYSIS
ACETAMINOPHEN;HLA-A;HLA-A*02:06;*02:06;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME,_TOXIC_EPIDERMAL_NECROLYSIS
ACETAMINOPHEN;HLA-B;HLA-B*44:03;*44:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME,_TOXIC_EPIDERMAL_NECROLYSIS
EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;INCREASED_PK;PK:AREA_UNDER_CURVE_(AUC)_OF_OMEPRAZOLE_RACEMATE,_OMEPRAZOLE_SULFONE,_R-OMEPRAZOLE_AND_S-OMEPRAZOLE
ACETAMINOPHEN;HLA-C;HLA-C*14:03;*14:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME,_TOXIC_EPIDERMAL_NECROLYSIS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;TOXICITY;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
CARBAMAZEPINE, LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*4/*4 + *4/*5 + *10/*41 + *4/*41 + *1/*4 + *1/*5;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*33, TPMT*34;*1/*2 + *1/*3A + *1/*3C + *1/*9 + *1/*21 + *1/*33 + *1/*34;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA,_THROMBOCYTOPENIA
METHADONE;CYP3A4;rs2246709;A;OTHER;DECREASED_SEVERITY;SIDE_EFFECT:OPIOID_WITHDRAWAL_SYMPTOMS
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_EFFICACY;EFFICACY:CLOPI-H4_CONCENTRATIONS_AFTER_300_OR_900_MG_CLOPIDOGREL_LOADING_DOSE
ATORVASTATIN, PRAVASTATIN;APOE;rs7412;CT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:PERCENT_REDUCTION_IN_LDL-CHOLESTEROL
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*5;*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;UGT1A1;UGT1A1*1, UGT1A1*28;*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
ATENOLOL, HYDROCHLOROTHIAZIDE, TRANDOLAPRIL, VERAPAMIL;GRK5;rs2230345;AT + TT;OTHER;DECREASED_RISK;OTHER:ADVERSE_CARDIOVASCULAR_OUTCOMES
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_CARDIOVASCULAR_EVENTS
METHAMPHETAMINE;BDNF;rs6265;CC;TOXICITY;DECREASED_SEVERITY;OTHER:METHAMPHETAMINE_DEPENDENCE
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
TACROLIMUS;ABCB1;rs1045642;GG;EFFICACY, LADME_PK;INCREASED_LIKELIHOOD;DISEASE:DELAYED_GRAFT_FUNCTION
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ANTICHOLINERGIC AGENTS;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;INCREASED_PK;PK:SERUM_ANTICHOLINERGIC_ACTIVITY
ANTIEPILEPTICS;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_PK;PK:FORMATION_OF_METABOLITES
AZATHIOPRINE;NUDT15;NUDT15*2, NUDT15*3, NUDT15*5, NUDT15*6;*2 + *3 + *5 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA,_DRUG_TOXICITY
;GSTT1;GSTT1 non-null, GSTT1 null;;OTHER;INCREASED_LIKELIHOOD;OTHER:ASTHMA
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
;GSTM1;GSTM1 non-null, GSTM1 null;;OTHER;INCREASED_LIKELIHOOD;OTHER:ASTHMA
METHAMPHETAMINE;DAOA;rs2391191;A;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*22;*1/*6 + *6/*6 + *4/*6 + *5/*6;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
CYCLOPHOSPHAMIDE;CYP2B6;CYP2B6*1, CYP2B6*4, CYP2B6*5, CYP2B6*6, CYP2B6*22;*1/*1 + *1/*5 + *1/*4 + *1/*22;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
IRINOTECAN;HLA-DQB3;rs2859101;C;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
CYCLOSPORINE, METHOTREXATE;MTHFR;rs3737967;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
ANTIDEPRESSANTS;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*1;LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATIONS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs55633228;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
CARBOPLATIN, DEXAMETHASONE, ETOPOSIDE, IRINOTECAN;UGT1A1;UGT1A1*6;*6;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
SULFASALAZINE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
ACENOCOUMAROL, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs746071566;GGAGTC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCYTOPENIA,_THROMBOCYTOPENIA
CYCLOSPORINE, METHOTREXATE;MTHFR;rs2274976;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
;G6PD;rs1050828;T;;INCREASED_;OTHER:PROTECTION_AGAINST_SEVERE_MALARIA
TAMOXIFEN;CYP2D6;CYP2D6*4;*4/*4;EFFICACY;INCREASED_LIKELIHOOD;DISEASE:BREAST_NEOPLASMS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;rs117101815;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*3A + *3B + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
CISPLATIN;ERCC1;rs11615;GG;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:NEPHROTOXICITY
ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:JAUNDICE
PRAVASTATIN;SLCO1B1;SLCO1B1*15, SLCO1B1*37;*15/*15;LADME_PK;INCREASED_PK;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)
CAPECITABINE, FLUOROURACIL;DPYD;DPYD low activity;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY,_TREATMENT_MODIFICATION
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
CISPLATIN, RADIOTHERAPY;GSTM1;GSTM1 non-null, GSTM1 null;null/null;EFFICACY;DECREASED_LIKELIHOOD;OTHER:DEATH,_RECURRENCE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *2/*3 + *1/*3 + *2/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_IN_THERAPEUTIC_RANGE
ANTIDEPRESSANTS, ANTIEPILEPTICS, BETA BLOCKING AGENTS, CALCIUM CHANNEL BLOCKERS;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED_;OTHER:USE
ANTIDEPRESSANTS, ANTIEPILEPTICS, BETA BLOCKING AGENTS, CALCIUM CHANNEL BLOCKERS;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;DECREASED_;OTHER:USE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;LADME_PK;DECREASED_PK;PK:C/D_RATIO
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:ACUTE_CELLULAR_REJECTION
IRINOTECAN;DPYD;rs1042482;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
PAZOPANIB;UGT1A1;UGT1A1*6, UGT1A1*28, UGT1A1*37;*28 + *37 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
METHADONE;CYP3A4;rs4646440;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SIDE_EFFECTS
WARFARIN;VKORC1;rs9923231;CC;OTHER;INCREASED_LIKELIHOOD;OTHER:HAVING_WARFARIN_DOSE_GREATER_THAN_7.5_MG/DAY
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PPP2R5D;rs3805945;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:STROKE
ATAZANAVIR / RITONAVIR, LAMIVUDINE, ZIDOVUDINE;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*36, UGT1A1*37;*1/*36 + *28/*36 + *36/*37 + *1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:HYPERBILIRUBINEMIA
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CCNK;rs77769901;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CARBAMAZEPINE;SCN1A;rs3812718;TT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DISCONTINUATION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_BUT_NOT_MINOR_HEMORRHAGE
;CHRNB2;rs2072661;GG;;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_BUT_NOT_MINOR_HEMORRHAGE
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
ROSIGLITAZONE;PLIN1;rs894160;CT + TT;TOXICITY;DECREASED_;SIDE_EFFECT:WEIGHT_GAIN
PLATINUM;;rs836554;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CYCLOSPORINE, METHOTREXATE;ABCC1;rs17264736;GG + GT;EFFICACY;DECREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHADONE;CYP2B6;CYP2B6*6;*6;TOXICITY;INCREASED_SEVERITY;DISEASE:PAIN
OXCARBAZEPINE;HLA-B;HLA-B*15:01;*15:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
;LRP5;rs3736228;T;;INCREASED_RISK;OTHER:OSTEOPOROTIC_FRACTURE
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs118129530;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;LADME_PK;INCREASED_PK;PK:AUC_OF_CITALOPRAM
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs148013902;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
DRUGS USED IN NICOTINE DEPENDENCE;COMT;rs4680;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:TRANSPLANT_REJECTION
NICOTINE;ANKK1;rs1800497;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
VALGANCICLOVIR;ABCC4;rs11568658;AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs145623321;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CYCLOSPORINE, METHOTREXATE;NFATC1;rs1017860;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CYP2C8;rs117458836;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
PRASUGREL;PEAR1;rs822442;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*3;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:DELAYED_GRAFT_FUNCTION
CARBAMAZEPINE;HLA-B;HLA-B*07:02, HLA-B*15:21;*15:21;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
NICOTINE;COMT;rs4680;G;TOXICITY, OTHER;DECREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;;SIDE_EFFECT:DRUG_TOXICITY
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*3 + *4 + *5 + *10 + *41;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
RISPERIDONE;CYP2D6;CYP2D6*4, CYP2D6*5, CYP2D6*6;*4/*4 + *4/*5 + *4/*6;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_PSYCHOTIC_SYMPTOMS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *1/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
PHENYTOIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA,_STEVENS-JOHNSON_SYNDROME
BOSENTAN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;LADME_PK;DECREASED_PK;PK:BOSENTAN_METABOLISM_IN_VITRO
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *3/*3 + *1/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CLOZAPINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
BOSENTAN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;LADME_PK;DECREASED_PK;PK:BOSENTAN_METABOLISM_IN_VITRO
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_;SIDE_EFFECT:DRUG_TOXICITY
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_;SIDE_EFFECT:NEUTROPENIA
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
ATORVASTATIN;TNF;rs1800629;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:BONE_MARROW_DENSITY_IN_THE_LUMBAR_SPINE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_IN_THERAPEUTIC_RANGE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
LAMOTRIGINE;HLA-B;HLA-B*44:03;*44:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;G/TT + GG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE_IN_JAPANESE_PATIENTS_WITH_WITH_CHRONIC_GENOTYPE_1_HCV_INFECTION
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(SVR_RATE)_TO_HCV_TRIPLE_THERAPY_(TELAPREVIR_(TVR),_PEG-INTERFERON_(PEG-IFN)_PLUS_RIBAVIRIN_(RBV)_COMBINATION_THERAPY)
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
LAMOTRIGINE;HLA-A;HLA-A*02:07;*02:07;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA,_SEVERE_CUTANEOUS_ADVERSE_REACTIONS,_STEVENS-JOHNSON_SYNDROME,
FLUCLOXACILLIN;HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NICOTINE;CYP2A6;CYP2A6 low activity;;TOXICITY;DECREASED_RISK;OTHER:RECURRENCE
FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);EFFICACY;INCREASED_EFFICACY;EFFICACY:IMPROVEMENT_BASED_ON_HAM-D_SCORE_PERCENTAGE_REDUCTION
NICOTINE;CYP2A6;CYP2A6 low activity;;TOXICITY;DECREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA,_SEVERE_CUTANEOUS_ADVERSE_REACTIONS
METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
METHAZOLAMIDE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*6;*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_BUT_NOT_MINOR_HEMORRHAGE
METHOTREXATE;SLCO1B1;rs11045879;T;OTHER, LADME_PK;INCREASED_PK;PK:CLEARANCE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*17/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*11;*11;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_BUT_NOT_MINOR_HEMORRHAGE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*5;*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_BUT_NOT_MINOR_HEMORRHAGE
CODEINE, TRAMADOL;CYP2D6;CYP2D6;poor_metabolizer;EFFICACY;INCREASED_LIKELIHOOD;DISEASE:PAIN
BOSENTAN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;TOXICITY;INCREASED_SEVERITY;OTHER:TUBULAR_VACUOLAR_DEGENERATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_TROUGH_LEVELS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_SEVERITY;DISEASE:INTERSTITIAL_FIBROSIS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK;PK:CONCENTRATION/DOSE_RATIO
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;DECREASED_PK;PK:C/D_RATIO
CLOPIDOGREL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY_AFTER_9MONTH_OF_TREATMENT
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;TOXICITY;INCREASED_RISKPK;PK:ACUTE_REJECTION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*1/*1 + *1/*3 + *1/*6 + *1/*7;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DELAYED_GRAFT_FUNCTION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3 + *3/*3;LADME_PK;INCREASED_PK;PK:BLOOD_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *2/*2 + *2/*3 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
ACE INHIBITORS, PLAIN;BDKRB2;rs71103505;(GGTGGGGAC)2/(GGTGGGGAC)2 + (GGTGGGGAC)2/GGTGGGGACGGTGGGGACGGTGGGGAC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA,_COUGH
CODEINE, TRAMADOL;CYP2D6;CYP2D6 poor and ultrarapid metabolizers;;EFFICACY, TOXICITY, LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
;KCNE1;rs727957;T;OTHER;INCREASED_;OTHER:QT_INTERVAL
AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
OXCARBAZEPINE;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
HYDROCHLOROTHIAZIDE;ACE;rs1799752;del/del;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_SYSTOLIC_BLOOD_PRESSURE
METHOTREXATE;TYMS;rs11280056;del/del;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MUCOSITIS
PERINDOPRIL;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACEI-RELATED_COUGH
METHOTREXATE;TYMS;rs11280056;del/del;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
;RGS2;rs34717272;TC/del + del/del;OTHER;INCREASED_RISK;DISEASE:HYPERTENSION
CARBAMAZEPINE;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
METHOTREXATE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*14:05;*14:05;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CBR3;rs74743371;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CARBAMAZEPINE;HLA-B;HLA-B*58:01;*58:01;TOXICITY;DECREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_RISK;DISEASE:STOMATITIS
LAMOTRIGINE;HLA-A;HLA-A*30:01;*30:01;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
CARBAMAZEPINE;HLA-DRB1;HLA-DRB1*03:01;*03:01;TOXICITY;DECREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
OXCARBAZEPINE;HLA-B;HLA-B*13:02;*13:02;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
OXCARBAZEPINE;HLA-B;HLA-B*15:27;*15:27;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
OXCARBAZEPINE;HLA-B;HLA-B*15:19;*15:19;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
OXCARBAZEPINE;HLA-B;HLA-B*48:04;*48:04;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
RALOXIFENE;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;EFFICACY;INCREASED_EFFICACY;EFFICACY:BONE_MINERAL_DENSITY
ASPIRIN;HLA-DQB1;HLA-DQB1*03:02;*03:02;EFFICACY, TOXICITY;DECREASED_SEVERITY;DISEASE:ASPIRIN-INDUCED_ASTHMA
OXCARBAZEPINE;HLA-B;HLA-B*27:09;*27:09;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
NEVIRAPINE;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
TAMOXIFEN;ABCB1;rs1045642;AG;OTHER;INCREASED_RISK;OTHER:DISEASE_RECURRENCE
NEVIRAPINE;HLA-B;HLA-B*58:02;*58:02;TOXICITY;DECREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12979860;CC;EFFICACY;EFFICACY;EFFICACY:HIGHER_MEAN_BASELINE_HCV_RNA_LEVEL_AND_STEEPER_1ST_PHASE_HCV_RNA_DECLINE_IN_GENOTYPE_2_AND_3_HCV_INFECTED_PATIENTS
PRASUGREL;PEAR1;rs3737224;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
NEVIRAPINE;HLA-C;HLA-C*02:10;*02:10;TOXICITY;DECREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
CYCLOSPORINE, METHOTREXATE;ABCC1;rs4781712;AA + AG;EFFICACY;DECREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
CAPECITABINE, FLUOROURACIL;MIR27A;rs895819;CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
OLANZAPINE;ABCB1;rs4728709;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ASTHENIA
BUPROPION;CYP2B6;rs3211371;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;TP53AIP1;rs118088833;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ASPIRIN, SULFASALAZINE;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5;*3 + *4;DOSAGE, TOXICITY;INCREASED_LIKELIHOOD;DISEASE:BRAIN_NEOPLASMS
PRASUGREL;PEAR1;rs41273215;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_IMPROVE_(BASED_ON_MEAN_REDUCTIONS_FROM_BASELINE_IN_HRSD)
TAMOXIFEN;ABCB1;rs1045642;AG;OTHER;INCREASED_RISK;OTHER:DISEASE_RECURRENCE
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;GNL3;rs112242273;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;DOSAGE;;OTHER:SIGNIFICANTLY_HIGHER_TRAMADOL_CONSUMPTION_IN_CHINESE_GASTRIC_CANCER_PATIENTS_RECOVERING_FROM_GASTRECTOMY
PRASUGREL;PEAR1;rs822441;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY, LADME_PK;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
VORICONAZOLE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;TOXICITY;INCREASED_RISK;DISEASE:CARCINOMA,_SQUAMOUS_CELL
CLOPIDOGREL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CYTARABINE, IDARUBICIN;ABCB1;rs2032582;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:COMPLETE_REMISSION
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY:NON-RESPONSE
CAFFEINE;CYP1A2;CYP1A2 high activity;;TOXICITY;INCREASED_RISK;DISEASE:ABORTION,_SPONTANEOUS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY:NON-RESPONSE
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY:NON-RESPONSE
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;TOP2A;rs181501757;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
LAMOTRIGINE;HLA-B;HLA-B*13:02;*13:02;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION_AFTER_SECOND_TREATMENT_SWITCH
LAMOTRIGINE;HLA-A;HLA-A*33:03;*33:03;TOXICITY;DECREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY:IMPROVED_SECOND_TREATMENT_SWITCH_RESPONSE
BELINOSTAT;UGT1A1;UGT1A1*1, UGT1A1*60;*1/*60 + *60/*60;TOXICITY;INCREASED_RISK;SIDE_EFFECT:THROMBOCYTOPENIA
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;rs9402944;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY:NON-REMISSION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;OAS1;rs2660;AG;TOXICITY;DECREASED_RISK;DISEASE:ANEMIA
ANTIDEPRESSANTS;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR long form (L allele) + HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY:NON-RESPONSE
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
;VDR;rs731236;A;;INCREASED_RISK;DISEASE:ASTHMA
OLANZAPINE;ABCB1;rs3842;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIAC_RHYTHM_DISEASE
IRINOTECAN;UGT1A1;rs10929302;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;CBR3;rs112783657;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
BUPROPION;GALR1;rs2717162;CC + CT;EFFICACY;DECREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
CARBAMAZEPINE;HLA-B;HLA-B*46:01;*46:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
HEROIN;OPRM1;rs1799971;AG;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
CYCLOSPORINE, METHOTREXATE;NFATC1;rs8090560;GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
VINCRISTINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA_AND_VOMITING
RISPERIDONE;LEP;rs7799039;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
BUPROPION;GALR1;rs2717162;CC + CT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;CTLA4;rs231775;AG;TOXICITY;DECREASED_RISK;DISEASE:ANEMIA
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;NOS1;rs149212925;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CYCLOSPORINE, METHOTREXATE;DHFR;rs34965641;GG;EFFICACY;DECREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
ETRAVIRINE;CYP2C19;rs4244285;AA + AG;LADME_PK;DECREASED_PK;PK:ETRAVIRINE_CLEARANCE
CISPLATIN;ERCC1;rs3212986;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL
ROSUVASTATIN;ABCG2;rs2231142;T;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_(LDL-C)_LEVEL,_IN_A_GENE-DOSE-DEPENDENT_MANNER,
FLUOROURACIL;MTHFR;rs1801131;TT;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
FLUOXETINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_EFFICACY;EFFICACY:IMPROVEMENT_BASED_ON_CHANGE_OF_HAM-D_SCORE_AFTER_ANTIDEPRESSANT_MEDICATION
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs58695150;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
PEMETREXED;GGH;rs11545078;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
METFORMIN;SLC22A1;rs72552763;GAT/del;OTHER, LADME_PK;DECREASED_EFFICACY;EFFICACY:TROUGH_METFORMIN_STEADY-STATE_CONCENTRATION
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PHENAZEPAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_;SIDE_EFFECT:DRUG_TOXICITY
CAPECITABINE;CDA;rs602950;AG + GG;TOXICITY;INCREASED_RISK;DISEASE:DEHYDRATION
METHOTREXATE;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;DPYD;DPYD low activity;;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PHENYTOIN;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;;SIDE_EFFECT:DRUG_TOXICITY
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs150688309;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CAPECITABINE;CDA;rs602950;AG + GG;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TAMOXIFEN;CYP2D6;CYP2D6*2;*2;EFFICACY;DECREASED_LIKELIHOOD;DISEASE:BREAST_NEOPLASMS
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
TAMOXIFEN;CYP3A4;CYP3A4*1, CYP3A4*22;*22;TOXICITY;DECREASED_;SIDE_EFFECT:HOT_FLASHES
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-A;HLA-A*74:01;*74:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOTAL_HEMORRHAGE_AND_MAJOR_HEMORRHAGE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:CORONARY_RESTENOSIS
CARBAMAZEPINE;HLA-A;HLA-A*02:01;*02:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CODEINE;SLC22A1;SLC22A1 low activity;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIZZINESS,_DRUG_TOXICITY,_HEADACHE,_NAUSEA
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER_ANTI-COAGULATION
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;TOXICITY;INCREASED_RISK;DISEASE:LEUKOPENIA
OXCARBAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
ETHANOL;OPRM1;rs1799971;G;;INCREASED_;OTHER:ALCOHOL_RESPONSE,_CONSUMPTION,_AND_PREFERENCE
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED_;OTHER:PLATELET_REACTIVITY
AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_RISK;DISEASE:TRANSPLANT_REJECTION
VENLAFAXINE;CYP2D6;CYP2D6*4;*4/*4;LADME_PK;INCREASED_PK;PK:VENLAFAXINE_LEVELS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;HMMR;rs299293;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EXEMESTANE;;rs934635;AA;TOXICITY;;SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_VASOMOTOR_SYMPTOMS_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;rs9389568;C;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED_;OTHER:PLATELET_REACTIVITY
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;FOXO1;rs144991623;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
PRASUGREL;PEAR1;rs12407843;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
DIGOXIN;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SUDDEN_CARDIAC_DEATH
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PRASUGREL;PEAR1;rs77235035;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;INCREASED_PK;PK:VENLAFAXINE_LEVELS
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;LADME_PK;INCREASED_PK;PK:VENLAFAXINE_LEVELS
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2 + *2/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17 + *1/*17;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION_INHIBITION
DIGOXIN;ABCB1;rs2032582;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SUDDEN_CARDIAC_DEATH
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE
IRINOTECAN;UGT1A1;UGT1A1*6, UGT1A1*28;*6 + *28;TOXICITY;RISK_;DISEASE:NEUTROPENIA
DIGOXIN;ABCB1;rs1128503;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SUDDEN_CARDIAC_DEATH
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;LADME_PK;DECREASED_PK;PK:CMAX_AND_AUC_OF_THIOL_METABOLITE
CAPECITABINE;MTHFR;rs1801131;GG;TOXICITY;INCREASED_RISK;DISEASE:HAND-FOOT_SYNDROME
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALL_AND_MINOR_HEMORRHAGE
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs8110364;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
OLANZAPINE;ABCB1;rs10248420;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6/*6 + *28/*28 + *6/*28;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
FLUOROURACIL;DPYD;rs56293913;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
FLUTICASONE PROPIONATE;CD14, TMCO6;rs2569190;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:PC20
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs117341846;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE_REQUIREMENT
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3;EFFICACY;EFFICACY;EFFICACY:SIGNIFICANTLY_DELAYED_TIME_TO_INHIBITION_OF_PLATELET_AGGREGATION_(IPA)
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE
ESCITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;IRS1;rs115457081;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;TOXICITY;DECREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;EFFICACY;EFFICACY;EFFICACY:SIGNIFICANTLY_DELAYED_TIME_TO_INHIBITION_OF_PLATELET_AGGREGATION_(IPA)
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;INSR;rs142244113;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
ASPIRIN, CLOPIDOGREL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_AND_CEREBROVASCULAR_EVENTS
METHOTREXATE;ATIC;rs2372536;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_ACTIVITY_AS_ASSESSED_BY_THE_PHYSICIAN
DOXEPIN;CYP2D6;CYP2D6*4;*4/*4;LADME_PK;DECREASED_PK;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs79430272;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
OLANZAPINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*1/*3 + *1/*4;TOXICITY;INCREASED_;DISEASE:WEIGHT_GAIN
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;TP53;rs4968187;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CITALOPRAM, FLUOXETINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
CISPLATIN;ERCC1;rs3212986;AA;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:NEPHROTOXICITY
PALBOCICLIB;ABCG2;rs2231137;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs117951771;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*4;*2/*2 + *2/*3 + *3/*3 + *4/*4 + *2/*4 + *3/*4;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE
EXEMESTANE;;rs934635;AA;TOXICITY;;SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_MUSCULOSKELETAL_ADVERSE_EVENTS_(MSAES)_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS
PRIMAQUINE;G6PD;G6PD deficiency;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DECREASED_HEMOCRIT_LEVELS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs148235907;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
METHAMPHETAMINE;DAOA;rs3916965;C;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER
;UGT1A1;rs34993780;G;OTHER;INCREASED_LIKELIHOOD;OTHER:GILBERT_SYNDROME,_CRIGLER-NAJJAR_SYNDROME
CYCLOPHOSPHAMIDE;CYP2C9;CYP2C9;poor_metabolizer;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
DESIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;LADME_PK;INCREASED_PK;PK:DESIPRAMINE/2-HYDROXY-DESIPRAMINE_RATIO
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME_PK;INCREASED_PK;PK:THE_INTRINSIC_METABOLIC_ACTIVITY_(V(MAX)/K(M))
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME_PK;INCREASED_PK;PK:THE_MEAN_MAXIMAL_ELIMINATION_RATES_(V(MAX))
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
ATAZANAVIR, RITONAVIR;UGT1A1;UGT1A1*28;*28;OTHER;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
ATAZANAVIR;UGT1A1;UGT1A1*28;*28;OTHER;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PALBOCICLIB;SULT2A1;rs182420;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION,_DISCONTINUATION
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4 + *4/*4;EFFICACY;INCREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
IMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;LADME_PK;DECREASED_PK;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;HMMR;rs299313;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
PRIMAQUINE;G6PD;G6PD deficiency;;OTHER;INCREASED_;OTHER:REDUCTIONS_IN_GLUTATHIONE_LEVELS
SULFANILAMIDE;G6PD;G6PD deficiency;;OTHER;INCREASED_;OTHER:REDUCTIONS_IN_GLUTATHIONE_LEVELS
CHLORAMPHENICOL;G6PD;G6PD deficiency;;OTHER;INCREASED_;OTHER:REDUCTIONS_IN_GLUTATHIONE_LEVELS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6 + *1/*6 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
CODEINE, MORPHINE, TRAMADOL;UGT2B7;rs73823859;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:PAIN
CISPLATIN, DOCETAXEL;ALDH2;rs671;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA,_VOMITING
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;HMMR;rs299314;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*8;*8;LADME_PK;DECREASED_PK;PK:IN_VITRO_INTRINSIC_CLEARANCE_OF_S-WARFARIN_WITH_THE_CDNA-EXPRESSED_R150H_PROTEIN
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;rs1056892;G;TOXICITY;INCREASED_RISK;DISEASE:HEART_FAILURE
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
CISPLATIN;ERCC2;rs13181;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL
ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ALLOPURINOL;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:STEVENS-JOHNSON_SYNDROME
ANTHRACYCLINES AND RELATED SUBSTANCES;CAT;rs10836235;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIAC_DAMAGE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
EXEMESTANE;UGT2B17;UGT2B17 deficiency;;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:FATIGUE
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele) + L allele-rs25531C + L allele-rs25531T;TOXICITY;INCREASED_;SIDE_EFFECT:BLEEDING_TIME
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*3 + *3/*3 + *2/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
VALPROIC ACID;XBP1;rs2269577;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROPHYLACTIC_TREATMENT_RESPONSE
ACE INHIBITORS, PLAIN;ACE;rs1799752;del;TOXICITY;INCREASED_;SIDE_EFFECT:MAJOR_CARDIOVASCULAR_EVENTS_(MACE)_RATE
PACLITAXEL;CYP1B1;rs1056836;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*10;*10/*10 + *4/*10 + *5/*10;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
DOCETAXEL;CYP1B1;rs1056836;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*8;*8;DOSAGE, LADME_PK;DECREASED_PK;PK:UNBOUND_ORAL_CLEARANCE_OF_S-WARFARIN_AND_LOWER_R-_TO_S-WARFARIN_PLASMA_CONCENTRATION_RATIO
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC4;rs9561778;T;TOXICITY, LADME_PK;INCREASED_RISK;SIDE_EFFECT:ADR
CYCLOPHOSPHAMIDE;ABCC4;rs9561778;T;TOXICITY, LADME_PK;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
CYCLOPHOSPHAMIDE;ABCC4;rs9561778;T;TOXICITY, LADME_PK;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION_(PA)
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*1/*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION_(PA)
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION_(PA)
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
HYDROCHLOROTHIAZIDE;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;OTHER;INCREASED_;OTHER:HYDROCHLOROTHIAZIDE_INDUCED_POTASSIUM_EXCRETION
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM
ENALAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_EFFICACY;EFFICACY:BONE_MINERAL_DENSITY_RESPONSE
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
CLOZAPINE;HLA-B;HLA-B*38:01;*38:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME_PK;DECREASED_PK;PK:PAROXETINE_SERUM_CONCENTRATION
FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CAPECITABINE;ANK3;rs143414470;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
GEFITINIB;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10, CYP2D6*14;*10/*10 + *5/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*9;*2 + *3 + *8 + *9;OTHER;INCREASED_RISK;DISEASE:RESPIRATORY_TRACT_INFECTIONS
NEVIRAPINE;CCHCR1;rs130072;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEVIRAPINE-INDUCED_RASH
NEVIRAPINE;HLA-B;HLA-B*35:05;*35:05;TOXICITY;INCREASED_RISK;DISEASE:EXANTHEMA
RITONAVIR;APOC3;rs5128;G;TOXICITY;INCREASED_;SIDE_EFFECT:TRIGLYCERIDE_LEVELS
EFAVIRENZ;CYP2B6;rs3745274;T;TOXICITY, LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
METFORMIN;BDNF;rs6265;C;EFFICACY;INCREASED_LIKELIHOOD;OTHER:WEIGHT_REGAIN_AFTER_INTENTIONAL_WEIGHT_LOSS
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*18;*1/*18;LADME_PK;INCREASED_PK;PK:PLASMA_EFAVIRENZ_LEVELS
LUMIRACOXIB;HLA-DRB1;HLA-DRB1*01:01, HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME_PK;INCREASED_PK;PK:TROUGH_(_R_,_S_)-METHADONE_PLASMA_CONCENTRATIONS
MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT*1, TPMT*12;*12;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
MYCOPHENOLATE MOFETIL;IMPDH1;rs2278293;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:BIOPSY-PROVEN_ACUTE_REJECTION
MITOXANTRONE;ABCB1;rs2032582;AA;OTHER;INCREASED_;OTHER:SENSITIVITY_IN_VITRO
LUMIRACOXIB;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ACENOCOUMAROL;CYP2C9;CYP2C9*3;*3;LADME_PK;INCREASED_RISK;OTHER:OVERANTICOAGULATION
ASPIRIN, CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:RELATIVE_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
ACENOCOUMAROL;CYP2C9;CYP2C9*2;*2;LADME_PK;INCREASED_RISK;OTHER:OVERANTICOAGULATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PROLONGED_QTC
METHADONE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;LADME_PK;INCREASED_PK;PK:(S)-METHADONE_PLASMA_LEVELS
TRIMIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5;*4/*4 + *3/*5 + *3/*3;TOXICITY;INCREASED_;SIDE_EFFECT:SEDATION
CLOPIDOGREL;ABCB1;rs1045642;A;OTHER;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
NEVIRAPINE;HLA-C;rs9461684;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEVIRAPINE-INDUCED_RASH
ASPIRIN;IL1B;rs1143627;A;TOXICITY;;DISEASE:PEPTIC_ULCER_DISEASE
PACLITAXEL;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs714368;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA,_NEUTROPENIA
PHENYTOIN;EPHX1;rs2234922;G;TOXICITY;INCREASED_RISK;DISEASE:DISORDER_OF_FACIAL_SKELETON
PHENYTOIN;EPHX1;rs1051740;T;TOXICITY;INCREASED_RISK;DISEASE:DISORDER_OF_FACIAL_SKELETON
NEVIRAPINE;TCF19;rs2073724;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
CARBOPLATIN, PACLITAXEL;NRG3;rs1649942;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PHENPROCOUMON;EPHX1;rs1051740;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BEING_OVERANTICOAGULATED
;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_PK;PK:STEROL/BILE_ACID_METABOLITES
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;LADME_PK;INCREASED_PK;PK:PLASMA_EFAVIRENZ_LEVELS
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:NON-RESPONSIVENESS
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CAFFEINE;ADORA2A;rs5751876;TT;TOXICITY;INCREASED_;DISEASE:ANXIETY_DISORDERS
PACLITAXEL, PLATINUM COMPOUNDS;NAT2;rs1208;AG + GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;HLA-DQB1*05:01, HLA-DQB1*05:02, HLA-DQB1*05:03;*05:01 + *05:02 + *05:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5, CYP2D6*6;*5/*4 + *6/*6 + *6/*4;TOXICITY, LADME_PK;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
FLUVOXAMINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*1/*5 + *10/*10 + *5/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_SIDE_EFFECTS
NEMONAPRIDE;ANKK1;rs1800497;A;TOXICITY;INCREASED_;SIDE_EFFECT:PROLACTIN_CONCENTRATIONS
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3/*3 + *4/*4;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
METHOTREXATE;SLC19A1;rs1051266;TT;OTHER, LADME_PK;INCREASED_PK;PK:METHOTREXATE_POLYGLUTAMATE_(MTXPG3-5)_LEVELS
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
FLUVOXAMINE;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;INCREASED_PK;PK:AREAS_UNDER_THE_SERUM_CONCENTRATION-TIME_CURVE
METHOTREXATE;GGH;rs3758149;AA;LADME_PK;DECREASED_PK;PK:METHOTREXATE_POLYGLUTAMATE_(MTXPG3-5)_LEVELS
RISPERIDONE;DRD2;rs1799978;C;TOXICITY;INCREASED_RISK;DISEASE:HYPERPROLACTINEMIA
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEATH,_MYOCARDIAL_INFARCTION,_STROKE,
RISPERIDONE;ANKK1;rs1800497;AA + AG;TOXICITY;INCREASED_RISK;DISEASE:HYPERPROLACTINEMIA
MYCOPHENOLATE MOFETIL;IMPDH2;rs11706052;G;OTHER;INCREASED_;OTHER:INOSINE_MONOPHOSPHATE_DEHYDROGENASE_ACTIVITY
MERCAPTOPURINE;XDH;rs2281547;CC + CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:TREATMENT_INTERRUPTION
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2 + *1/*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:ADP-INDUCED_ON_TREATMENT_PLATELET_AGGREGATION_(OTPR)
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;G;LADME_PK;DECREASED_PK;PK:DOSE-NORMALIZED_CMAX_AND_DOSE-NORMALIZED_AUC0TO12_H
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:RELATIVE_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED_EFFICACY;EFFICACY:ON-CLOPIDOGREL_PLATELET_REACTIVITY_(HPR)
INDINAVIR;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
ANASTROZOLE;ABCB1;rs1045642;AA;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT:ARTHRALGIA
METHOTREXATE;MTHFR;rs1801131;GG;EFFICACY;DECREASED_;OTHER:EVENT-FREE_SURVIVAL
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HAVING_INR_ABOVE_TARGET_RANGE_IN_WEEK_1
;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK;OTHER:SUBSTANCE-RELATED_DISORDERS
MERCAPTOPURINE;ITPA;rs1127354;AC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:FEBRILE_NEUTROPENIA
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY,_NEPHROTOXICITY
FLECAINIDE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_PK;PK:SYSTEMIC_EXPOSURE_(AUC)_AND_LOWER_ORAL_CLEARANCE_OF_FLECAINIDE
ETHANOL;ALDH2;rs671;GG;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE
DIDANOSINE;XDH;rs1429376;AA;TOXICITY;INCREASED_RISK;DISEASE:HYPERTENSION,_PORTAL
DAUNORUBICIN;SZRD1;rs6603859;T;OTHER, LADME_PK;DECREASED_PK;PK:IC50
DIDANOSINE;NT5C2;rs11598702;CC + CT;TOXICITY;INCREASED_RISK;DISEASE:HYPERTENSION,_PORTAL
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2;EFFICACY;INCREASED_;OTHER:PLATELET_REACTIVITY
DIDANOSINE;XDH;rs1594160;AA;TOXICITY;INCREASED_RISK;DISEASE:HYPERTENSION,_PORTAL
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*6;*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS
DAUNORUBICIN;;rs7929521;GG;OTHER, LADME_PK;INCREASED_PK;PK:IC50
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28, UGT1A1*37;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
AZACITIDINE;TYMS;rs11280056;del/del;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DAUNORUBICIN;MAN1B1;rs3750518;T;OTHER, LADME_PK;INCREASED_PK;PK:IC50
OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;LADME_PK;DECREASED_PK;PK:MEAN_OXYMORPHONE/OXYCODONE_RATIOS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_;OTHER:PLATELET_REACTIVITY
DIDANOSINE;NT5C2;rs11191561;CG + GG;TOXICITY;INCREASED_RISK;DISEASE:HYPERTENSION,_PORTAL
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQA1;HLA-DQA1*01:02;*01:02;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
IGURATIMOD;CYP2C19;rs4244285;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*22;*1/*22;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TRANSPLANT_REJECTION
PHENYTOIN;HLA-C;HLA-C*14:02;*14:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
PHENYTOIN;HLA-B;HLA-B*56:02;*56:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
NICOTINE;CYP2A6;rs1801272;AT + TT;TOXICITY;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
OLANZAPINE;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*6;*1/*3 + *2/*3 + *3/*6;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:HYPOTENSIVE_DISORDER
DESIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;LADME_PK;INCREASED_PK;PK:STEADY-STATE_PLASMA_CONCENTRATIONS_OF_DESIPRAMINE/DAILY_DOSE_OF_DESIPRAMINE/BODY_WEIGHT
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
OLANZAPINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:FATIGUE
;NAT1;NAT1*4, NAT1*11B;*11B/*4;OTHER;INCREASED_RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C, TPMT*9, TPMT*21, TPMT*32, TPMT*33, TPMT*34;*1/*3C;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
OLANZAPINE;GSTM3;rs1799735;CCT/CCT;LADME_PK;DECREASED_PK;PK:AREA_UNDER_THE_CURVE
OLANZAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_PK;PK:AREA_UNDER_THE_CURVE
MERCAPTOPURINE;XDH;rs2281547;CC + CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
ANASTROZOLE;CYP19A1;rs727479;AA;EFFICACY;INCREASED_;OTHER:RECURRENCE_FREE_SURVIVAL
OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*6;*4/*4 + *4/*6;LADME_PK;DECREASED_PK;PK:SERUM_CONCENTRATIONS_OF_OXYMORPHONE_AND_NOROXYMORPHONE_AND_OXYMORPHONE/OXYCODONE_RATIOS
FLUVASTATIN;SLCO1B1;rs11045819;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:LDL-C_REDUCTION
OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4;*4/*4 + *3/*4;LADME_PK;DECREASED_PK;PK:SERUM_CONCENTRATIONS_OF_OXYMORPHONE_AND_NOROXYMORPHONE_AND_OXYMORPHONE/OXYCODONE_RATIOS
EFAVIRENZ;CYP2B6;CYP2B6*18;*18/*18;LADME_PK;INCREASED_PK;PK:PLASMA_EFAVIRENZ_LEVELS
CYCLOPHOSPHAMIDE, DOXORUBICIN;NQO2;rs1143684;C;EFFICACY;EFFICACY;EFFICACY:WORSE_PROGNOSIS_(OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL)_IN_PATIENTS_WHO_WERE_ER-VE/PR-VE_NEGATIVE
PIOGLITAZONE;CYP2C8;CYP2C8*1, CYP2C8*2;*1/*2 + *2/*2;LADME_PK;DECREASED_PK;PK:M-III,_PIOGLITAZONE_AUC0-48_RATIO_AND_M-III,_M-IV_AUC0-48_RATIO_IN_HEALTHY_AFRICAN-AMERICAN_VOLUNTEERS,
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
DICLOFENAC;UGT2B7;rs7668258;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;TOXICITY;INCREASED_RISK;DISEASE:HEMORRHAGE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17 + *17/*17;EFFICACY;DECREASED_RISK;OTHER:NON-FATAL_MYOCARDIAL_INFARCTION,STROKE,_REVASCULARIZATION_OR_DEATH
IBUPROFEN;CYP2C8;CYP2C8*1, CYP2C8*2;*1/*2;LADME_PK;INCREASED_PK;PK:R-IBUPROFEN_METABOLISM
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs36120609;TCCTC/TCCTC;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;;SIDE_EFFECT:HIGHER_COMPOSITE_HAR_OUTCOME_(CARDIAC_DEATH,_NON_FATAL_MYOCARDIAL_INFARCTION_AND_STENT_THROMBOSIS)_UP_TO_12_MONTHS'_FOLLOW_UP
;IRS1;rs1801123;C;OTHER;;OTHER:LYMPH_NODE_INVOLVEMENT
ESTRADIOL;;rs1864729;A;OTHER;INCREASED_;OTHER:PLASMA_LEVEL
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEDIAN_SURVIVAL_TIME
ACENOCOUMAROL, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE,_STROKE
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE_(RR)
CARBIMAZOLE, METHIMAZOLE, PROPYLTHIOURACIL;HLA-DRB1;HLA-DRB1*08:03;*08:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
ANTHRACYCLINES AND RELATED SUBSTANCES;GSTM1;GSTM1 non-null, GSTM1 null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOMYOPATHIES
;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2;LADME_PK;DECREASED_PK;PK:CITALOPRAM_ORAL_CLEARANCES_OF_CITALOPRAM
DICLOFENAC;ABCC2;rs717620;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ANTIARRHYTHMICS, CLASS I AND III;;rs10033464;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUCCESSFUL_RHYTHM_CONTROL
CARBIMAZOLE, METHIMAZOLE;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED_EFFICACY;EFFICACY:SURVIVAL_TIME
HYDRALAZINE;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;EFFICACY;EFFICACY:MORE_FREQUENT_HIGH_PLATELET_REACTIVITY_IN_JAPANESE_PATIENTS_IN_A_STEADY_STATE_RECEIVING_DUAL_ANTIPLATELET_THERAPY_AFTER_CORONARY_STENT_IMPLANTATION
GEFITINIB;EGFR;rs11568315;(CA)16/(CA)16 + (CA)16/(CA)17;EFFICACY;INCREASED_EFFICACY;EFFICACY:BETTER_CLINICAL_RESPONSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;DECREASED_PK;PK:UNBOUND_ORAL_CLEARANCE_FOR_S-WARFARIN
RIFAMPIN;SLCO1B1;SLCO1B1*15;*15;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;EFFICACY;EFFICACY:MORE_FREQUENT_HIGH_PLATELET_REACTIVITY_IN_JAPANESE_PATIENTS_IN_A_STEADY_STATE_RECEIVING_DUAL_ANTIPLATELET_THERAPY_AFTER_CORONARY_STENT_IMPLANTATION
FLUVOXAMINE, PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele)/HTTLPR short form (S allele) + HTTLPR short form (S allele)/L allele-rs25531C;EFFICACY;DECREASED_EFFICACY;EFFICACY:HAM-D_SCORE_CHANGES_IN_FLUVOXAMINE-TREATED_PATIENTS_COMPARED_TO_PAROXETINE-TREATED_PATIENTS
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*4/*5 + *4/*6 + *3/*4 + *4/*4;OTHER;DECREASED_;OTHER:WAKEFULNESS_ACTIVITY_LEVEL
;IGFBP3;rs2854744;T;OTHER;;OTHER:TUMOR_SIZE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
IRINOTECAN;UGT1A1;UGT1A1*6, UGT1A1*28;*6 + *28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CARBAMAZEPINE;HLA-A;HLA-A*24:02;*24:02;TOXICITY;DECREASED_RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME_AND_TOXIC_EPIDERMAL_NECROLYSIS-BULLOUS_LESIONS
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME_AND_TOXIC_EPIDERMAL_NECROLYSIS-BULLOUS_LESIONS
NEVIRAPINE;GSTM1;GSTM1 non-null, GSTM1 null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs36120609;TCCTC/TCCTC;TOXICITY;DECREASED_RISK;SIDE_EFFECT:THROMBOCYTOPENIA
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME_AND_TOXIC_EPIDERMAL_NECROLYSIS-BULLOUS_LESIONS
CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;TOXICITY;DECREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs36120609;TCCTC/TCCTC;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*4/*5;LADME_PK;INCREASED_PK;PK:PAROXETINE_PLASMA_CONCENTRATION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
;GSTM3;rs36120609;TC/TC + TC/TCCTC;OTHER;INCREASED_LIKELIHOOD;OTHER:METASTATIC_NEOPLASM
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*5/*4 + *1/*3 + *1/*4 + *1/*5 + *1/*6;LADME_PK;INCREASED_PK;PK:FLUOXETINE/(S)-NORFLUOXETINE_RATIO
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;ITPA;rs1127354;CC;OTHER;;SIDE_EFFECT:REQUIREMENT_FOR_EARLIER_DOSE_REDUCTION_OF_RIBAVIRIN
CARBOPLATIN, CYCLOPHOSPHAMIDE, THIOTEPA;ALDH1A1;rs6151031;CTGGTGAGGAGAGAACC/del;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*27:05;*27:05;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:AGRANULOCYTOSIS
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_PLATELET_REACTIVITY
;IFNL3;rs8099917;TT;;INCREASED_;OTHER:BASELINE_VIRAL_LOAD
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*28 + *6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA,_NEUTROPENIA
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*1/*4 + *1/*5;LADME_PK;INCREASED_PK;PK:PAROXETINE_PLASMA_CONCENTRATIONS_INCREASED_DURING_THE_COURSE_OF_PREGNANCY
DICLOFENAC;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3 + *3/*3;LADME_PK;INCREASED_PK;PK:DICLOFENAC/5-HYDROXYDICLOFENAC_URINARY_CONCENTRATION_RATIO
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3/*4;LADME_PK;INCREASED_PK;PK:PAROXETINE_PLASMA_CONCENTRATION
HEPARIN;HLA-DRB3;HLA-DRB3*01:01;*01:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEPARIN-INDUCED_THROMBOCYTOPENIA
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2 + *2/*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
IRINOTECAN;UGT1A1;UGT1A1*6, UGT1A1*28;*6 + *28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL4;rs11322783;TT/TT;TOXICITY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-REMISSION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
IBUPROFEN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;DECREASED_PK;PK:RACEMIC,_S-IBUPROFEN_AND_R-IBUPROFEN_METABOLISM,_WITH_INCREASE_OF_AUC(0-INFINITY)_AND_REDUCTION_OF_CLEARANCE
TENOXICAM;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;LADME_PK;INCREASED_PK;PK:EXPOSURE_(AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_(AUC))_AND_DECREASED_ORAL_CLEARANCE
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
TENOXICAM;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;INCREASED_PK;PK:EXPOSURE_(AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_(AUC))_AND_DECREASED_ORAL_CLEARANCE
EFAVIRENZ, LAMIVUDINE, STAVUDINE, ZIDOVUDINE;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;INCREASED_PK;PK:PLASMA_4BETA-OHC/CHOL_RATIO
TAMOXIFEN;CYP2D6;CYP2D6 low activity;;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
PIROXICAM;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:INHIBITORY_EFFECT_ON_CYCLOOXYGENASE_1_ACTIVITY
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*9, CYP2A6*10;*4 + *10 + *9;LADME_PK;DECREASED_PK;PK:PLASMA_AND_URINARY_RATIO_OF_METABOLITES_TRANS-3'-HYDROXYCOTININE_TO_COTININE_(3HC/COT)
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
LUMIRACOXIB;HLA-DQA1;HLA-DQA1*01:01, HLA-DQA1*01:02;*01:02;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;INCREASED_PK;PK:PAROXETINE_LEVELS
IBUPROFEN;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;OTHER;DECREASED_;OTHER:INOS_EXPRESSION
IRINOTECAN;UGT1A6;rs2070959;A;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
IBUPROFEN;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3;LADME_PK;INCREASED_PK;PK:R-IBUPROFEN_METABOLISM
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IMATINIB;EGFR;rs2072454;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIORBITAL_EDEMA
FLUOROURACIL;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)3;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:SIDE_EFFECTS
KETOPROFEN, TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*41;*1/*3 + *1/*4 + *1/*5 + *1/*6 + *4/*41 + *6/*10 + *10/*10 + *41/*41;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEDATION
PIROXICAM;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:INHIBITORY_EFFECT_ON_CYCLOOXYGENASE_1_ACTIVITY
PIROXICAM;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;INCREASED_PK;PK:PIROXICAM'S_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_AND_DECREASED_ORAL_CLEARANCE
PIROXICAM;CYP2C9;CYP2C9*1, CYP2C9*2;*1/*2;LADME_PK;INCREASED_PK;PK:PIROXICAM'S_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_AND_DECREASED_ORAL_CLEARANCE
GEFITINIB;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10, CYP2D6*114;*10/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;G;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CITALOPRAM, ESCITALOPRAM;CYP2D6;rs1065852;A;OTHER;;OTHER:PLASMA_CONCENTRATION_OF_S-DIDESMETHYL-CITALOPRAM
HYDROCHLOROTHIAZIDE;ACE;rs1799752;del/del;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*1;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;RISK_;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME_PK;INCREASED_PK;PK:CLEARANCE_OF_S(+)_MIRTAZAPINE
TACROLIMUS;CYP3A5;CYP3A5*3;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
;CYP2D6;CYP2D6*2xN;*2xN;OTHER;INCREASED_RISK;DISEASE:SUICIDE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;EFFICACY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_IN_THERAPEUTIC_RANGE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;INCREASED_;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;DECREASED_PK;PK:TOTAL_CLEARANCE_OF_RACEMIC_MIRTAZAPINE
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;OTHER;DECREASED_SEVERITY;DISEASE:DEPRESSION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
IRINOTECAN;UGT1A9;rs11692021;C;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
METOPROLOL;ADRB2;rs1042714;CG;TOXICITY;INCREASED_;SIDE_EFFECT:TRIGLYCERIDES
LAMOTRIGINE;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:MACULOPAPULAR_EXANTHEMA
TAMOXIFEN;IGF1R;rs2016347;GG;EFFICACY;INCREASED_RISK;DISEASE:RECURRENCE
IRINOTECAN, RALTITREXED;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
;CYP2D6;CYP2D6*1xN;*1xN;OTHER;INCREASED_RISK;DISEASE:SUICIDE
ALLOPURINOL;HLA-B;HLA-B*48:01;*48:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
PACLITAXEL;CYP2C8;rs10509681;C;TOXICITY;INCREASED_RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
IRINOTECAN, RALTITREXED;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
PAZOPANIB;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
IRINOTECAN, RALTITREXED;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASTHENIA
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_PK;PK:TROUGH_CONCENTRATIONS
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_;SIDE_EFFECT:INTOLERANCE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
QUETIAPINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4;*1/*2 + *2/*2 + *2/*4;LADME_PK;INCREASED_SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA
CAFFEINE;ADORA2A;rs35060421;TTTTTTT/TTTTTTT;TOXICITY;INCREASED_;SIDE_EFFECT:ANXIETY
ALLOPURINOL;HLA-DRB1;HLA-DRB1*14:01;*14:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
ALLOPURINOL;HLA-DRB1;HLA-DRB1*09:01;*09:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ZONISAMIDE;HLA-A;HLA-A*02:07;*02:07;TOXICITY;;DISEASE:STEVENS-JOHNSON_SYNDROME
PHENOBARBITAL;HLA-B;HLA-B*51:01;*51:01;TOXICITY;;DISEASE:STEVENS-JOHNSON_SYNDROME
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;LADME_PK;DECREASED_PK;PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION_AND_HIGHER_MEAN_METABOLIC_RATIO
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;EFFICACY;INCREASED_SEVERITY;OTHER:PAIN
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK;PK:TROUGH_CONCENTRATIONS
LAMIVUDINE, NEVIRAPINE, STAVUDINE;HLA-B;HLA-B*35:05;*35:05;TOXICITY;;SIDE_EFFECT:EXANTHEMA
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_PK;PK:TIME_TO_ACHIEVE_THERAPEUTIC_WINDOW
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_;SIDE_EFFECT:DEATH
METHOTREXATE;ABCC2;rs3740065;AG + GG;LADME_PK;INCREASED_PK;PK:PLASMA_LEVEL
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
METOPROLOL;ADRB2;rs1042714;CC;TOXICITY;DECREASED_;SIDE_EFFECT:TOTAL_CHOLESTEROL
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
METHOTREXATE;ABCC4;rs9516519;GG + GT;LADME_PK;DECREASED_PK;PK:PLASMA_LEVEL
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
AZATHIOPRINE, MERCAPTOPURINE, THIOGUANINE;NUDT15;rs746071566;del;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;DECREASED_PK;PK:TROUGH_CONCENTRATIONS
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;INCREASED_PK;PK:S-CIT_SERUM_CONCENTRATIONS
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;INCREASED_PK;PK:MEAN_ESCITALOPRAM_CONCENTRATION
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;DECREASED_EFFICACY;EFFICACY:RESPONSE_WHEN_MEASURED_BY_THE_GERIATRIC_DEPRESSION_SCALE_AT_DAY_7_AND_DAY_28
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT:LOWER_FINAL_DAILY_DOSE,_DECREASED_DOSING_COMPLIANCE_AND_LOWER_PLASMA_LEVELS_AT_DAY_28
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17;DOSAGE, LADME_PK;DECREASED_PK;PK:SERUM_CONCENTRATION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE
MIRTAZAPINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*3;*3;DOSAGE, LADME_PK;INCREASED_PK;PK:SERUM_CONCENTRATION
LISINOPRIL;MMP3;rs35068180;del/del;EFFICACY;DECREASED_RISK;SIDE_EFFECT:STROKE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_RISK;DISEASE:INFECTIOUS_DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;EFFICACY;EFFICACY:POSITIVE_CORRELATION_OF_PAROXETINE_CONCENTRATION_WITH_IMPROVEMENT_IN_HAMD_SCORES_AT_WEEK_2
ACENOCOUMAROL, WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE,_STROKE
ESCITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*41;*4/*41;LADME_PK;INCREASED_PK;PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*3 + *2/*3;TOXICITY;INCREASED_EFFICACY;EFFICACY:RISK_OF_RECURRENT_CARDIOVASCULAR_(CV)_EVENTS_1_YEAR_AFTER_PCI_IN_CHINESE_PATIENTS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;TOXICITY;INCREASED_EFFICACY;EFFICACY:RISK_OF_RECURRENT_CARDIOVASCULAR_(CV)_EVENTS_1_YEAR_AFTER_PCI_IN_CHINESE_PATIENTS
FENTANYL;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
DIRECT ACTING ANTIVIRALS, SOFOSBUVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2;DOSAGE, LADME_PK;INCREASED_PK;PK:SERUM_CONCENTRATION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_;OTHER:PLATELET_REACTIVITY
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
CITALOPRAM;CYP2D6;CYP2D6;poor_metabolizer;LADME_PK;DECREASED_PK;PK:DEMETHYLATION_CLEARANCE_OF_DESMETHYLCITALOPRAM
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LONG_QT_SYNDROME
ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:NEUTROPENIA
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*9;*9;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DISCONTINUATION
CAPECITABINE, FLUOROURACIL;DPYD;rs56038477;CT;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A6;UGT1A6*2a;*2a;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:VOMITING
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6/*6 + *28/*28 + *6/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;UGT1A1*28;*28;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FOLFOX;TYMS;rs11280056;TTA/TTA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A1;UGT1A1*60;*60;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ISONIAZID, RIFAMPIN;NAT2;NAT2*4;*4;TOXICITY, LADME_PK;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
METHOTREXATE;TYMS;rs11280056;TTA/TTA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*9;*9/*9 + *1/*9;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DISCONTINUATION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;*2 + *3 + *8;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:STROKE
FOLFOX;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ANEMIA
MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3B;*1/*2 + *1/*3A + *3A/*3B;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
EGFR INHIBITORS;HLA-A;HLA-A*02:01;*02:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:EXANTHEMA
CYCLOPHOSPHAMIDE, FLUDARABINE;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;TOXICITY;DECREASED_RISK;DISEASE:DRUG_TOXICITY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
ANTINEOPLASTIC AGENTS, TAMOXIFEN;UGT2B15;UGT2B15*1, UGT2B15*2;*2/*2 + *1/*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
EGFR INHIBITORS;HLA-A;HLA-A*03:01;*03:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:EXANTHEMA
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_;SIDE_EFFECT:ASTHENIA
DOCETAXEL;SLCO1B3;rs3834935;A;OTHER, LADME_PK;INCREASED_PK;PK:AUC
CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;GABRA1;rs2279020;GG;EFFICACY;EFFICACY;EFFICACY:DRUG-RESISTANT_PHENOTYPE
PACLITAXEL;CYP2C8;CYP2C8*2, CYP2C8*3, CYP2C8*4;*2 + *3 + *4;TOXICITY;INCREASED_RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
AMOXICILLIN, CLAVULANATE;HLA-A;HLA-A*30:02;*30:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CITALOPRAM, ESCITALOPRAM;;rs1074145;A;OTHER;;OTHER:CONCENTRATIONS_OF_S-CITALOPRAM_AND_METABOLIC_RATIO_OF_OF_S-DESMETHYLCITALOPRAM/CITALOPRAM
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:03;*06:03;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NEVIRAPINE;HLA-DRB1;HLA-DRB1*15:03;*15:03;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
NEVIRAPINE;HLA-DQB1;HLA-DQB1*02:01;*02:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
IMATINIB;CYP1A2;rs11636419;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIORBITAL_EDEMA
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_;OTHER:PLATELET_REACTIVITY
NEVIRAPINE;HLA-DQB1;HLA-DQB1*02:01;*02:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
NEVIRAPINE;HLA-DQB1;HLA-DQB1*03:02;*03:02;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
NEVIRAPINE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
NEVIRAPINE;HLA-DQB1;HLA-DQB1*03:02;*03:02;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ETHANOL;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION_INHIBITION
NEVIRAPINE;HLA-DQB1;HLA-DQB1*05:01;*05:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;GABRA1;rs2279020;G;EFFICACY;EFFICACY;EFFICACY:DRUG-RESISTANT_PHENOTYPE
METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*10, CYP2D6*17, CYP2D6*41;*3/*17 + *3/*4 + *4/*10 + *4/*17 + *4/*4 + *4/*41 + *4/*5 + *4/*6 + *5/*10 + *5/*17;OTHER;;OTHER:GREATER_HEART_RATE_(HR)_REDUCTION
BUCILLAMINE;HLA-DRB1;HLA-DRB1*08:02;*08:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PROTEINURIA
MERCAPTOPURINE;TPMT;TPMT deficiency;;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEATH
AZATHIOPRINE, CYCLOSPORINE, PREDNISONE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
BUCILLAMINE;HLA-DQB1;HLA-DQB1*04:02;*04:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PROTEINURIA
CYCLOPHOSPHAMIDE;CYP2B6;rs3211371;CT;EFFICACY;INCREASED_EFFICACY;EFFICACY:RECURRENCE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*2 + *2/*17;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*5, CYP2C9*6, CYP2C9*11;*2 + *3 + *5 + *6 + *11;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
DAPSONE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
LAPATINIB;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
DAPSONE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
LAPATINIB;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_RISK;
MERCAPTOPURINE;ABCC4;ABCC4 deficiency;;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEATH
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;;OTHER:HIGH_PLATELET_REACTIVITY_(HPR)
AMOXICILLIN, CLAVULANATE;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLOZAPINE;HLA-DQB1;HLA-DQB1*05:02;*05:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ASPIRIN;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;INCREASED_RISK;SIDE_EFFECT:URTICARIA
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ASPIRIN;HLA-DRB1;HLA-DRB1*13:02;*13:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:URTICARIA
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
CLOZAPINE;HLA-DQB1;HLA-DQB1*05:02;*05:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
CLOZAPINE;HLA-DPB1;HLA-DPB1*04:01;*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
CLOZAPINE;HLA-DRB5;HLA-DRB5*02:02;*02:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
ASPIRIN, CLOPIDOGREL, PRASUGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17/*17 + *1/*17;EFFICACY;DECREASED_LIKELIHOOD;DISEASE:INFLAMMATION
OXCARBAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:JAUNDICE
PAROXETINE;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;L allele-rs25531T/L allele-rs25531T;OTHER;;OTHER:A_CORRELATION_OF_BRAIN_SERT_OCCUPANCY_WAS_ASSOCIATED_WITH_LARGER_PROPORTIONAL_HDRS17_DECREASES
AMOXICILLIN, CLAVULANATE;HLA-DRB5;HLA-DRB5*01:01;*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATITIS
SORAFENIB;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
SORAFENIB;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION
AMOXICILLIN, CLAVULANATE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATITIS
SUNITINIB;ABCB1;rs1128503;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA,_SEVERE_CUTANEOUS_ADVERSE_REACTIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
TICLOPIDINE;HLA-DRB1;HLA-DRB1*13:02;*13:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:EFFICACY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:EFFICACY
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*41;*41;OTHER, LADME_PK;INCREASED_PK;PK:PLASMA_NORTRIPTYLINE
TICLOPIDINE;HLA-C;HLA-C*14:03;*14:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CYCLOPHOSPHAMIDE;CYP2B6;rs3211371;CT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ATORVASTATIN;LEPR;rs1805094;GG;OTHER;INCREASED_;OTHER:BONE_MARROW_DENSITY_IN_THE_LUMBAR_SPINE
TICLOPIDINE;HLA-DQB1;HLA-DQB1*06:04;*06:04;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
TICLOPIDINE;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
BUSULFAN, CYTARABINE, ETOPOSIDE;ABCC3;rs4148405;G;EFFICACY, TOXICITY;DECREASED_;OTHER:DISEASE-FREE_SURVIVAL
TICLOPIDINE;HLA-B;HLA-B*44:03;*44:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
COCAINE, ETHANOL, NICOTINE;OPRM1;rs1799972;TT;TOXICITY;INCREASED_RISK;DISEASE:SUBSTANCE-RELATED_DISORDERS
NEVIRAPINE;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
ANTIPSYCHOTICS;COMT;rs4680;A;OTHER;INCREASED_;OTHER:METHYLATION_AT_SITES_1_AND_2_IN_THE_COMT_PROMOTER
ISONIAZID;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ASPIRIN;HLA-DRB1;HLA-DRB1*09:01;*09:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:URTICARIA
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ASPIRIN;HLA-DPB1;HLA-DPB1*05:01;*05:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:URTICARIA
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;CYP2E1*1A, CYP2E1*5B;*1A/*5B;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ASPIRIN;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;DECREASED_RISK;SIDE_EFFECT:URTICARIA
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ASPIRIN;HLA-DRB1;HLA-DRB1*13:02;*13:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:URTICARIA
MERCAPTOPURINE, THIOGUANINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;TOXICITY;;SIDE_EFFECT:THROMBOCYTOPENIA
ASPIRIN;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;INCREASED_RISK;SIDE_EFFECT:URTICARIA
FLUTICASONE PROPIONATE;CD14, TMCO6;rs2569190;AA + AG;OTHER;DECREASED_EFFICACY;EFFICACY:FEV1/FVC_RATIO
BLEOMYCIN, DACARBAZINE, DOXORUBICIN, VINBLASTINE;GSTM1;GSTM1 non-null, GSTM1 null;non-null/non-null;TOXICITY;DECREASED_RISK;DISEASE:DRUG_TOXICITY
EFAVIRENZ, NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
NEVIRAPINE;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ETHANOL;ADH1B;rs1229984;T;TOXICITY;DECREASED_RISK;OTHER:ALCOHOL_ABUSE
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
ISONIAZID, RIFAMPIN;GSTT1;GSTT1 null;;LADME_PK;DECREASED_PK;PK:SERUM_HYDRAZINE_CONCENTRATIONS
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs56038477;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ISONIAZID, RIFAMPIN;GSTM1;GSTM1 null;;LADME_PK;INCREASED_PK;PK:SERUM_HYDRAZINE_CONCENTRATIONS
ALLOPURINOL;HLA-DQB1;HLA-DQB1*05:02;*05:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;GSTM1;GSTM1 null;;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMATOLOGIC_DISORDER
NEVIRAPINE;HLA-B;HLA-B*35:01;*35:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA,_SEVERE_CUTANEOUS_ADVERSE_REACTIONS
METHADONE;CYP3A4;rs3735451;C;OTHER;INCREASED_SEVERITY;SIDE_EFFECT:OPIOID_WITHDRAWAL_SYMPTOMS
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*27;*1/*27;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA
CLOZAPINE;CYP2C19;CYP2C19*17;*17/*17;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DIABETES_MELLITUS
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CLOZAPINE;HLA-B;HLA-B*59:01;*59:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA
NEVIRAPINE;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PHENYTOIN;HLA-B;HLA-B*07:02, HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;PK;PK:SIGNIFICANTLY_HIGHER_(S)-FLUOXETINE_AND_LOWER_AND_(S)-NORFLUOXETINE_CONCENTRATIONS
;TRPA1;rs920829;CT + TT;OTHER;INCREASED_LIKELIHOOD;DISEASE:PAIN
ETHANOL;ALDH2;rs671;A;TOXICITY;DECREASED_RISK;OTHER:ALCOHOL_ABUSE
;NAT2;NAT2 deficiency;;OTHER;;DISEASE:INSULIN_RESISTANCE
FLUOXETINE;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;LADME_PK;INCREASED_PK;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS_OF_FLUOXETINE_AND_THE_ACTIVE_MOIETY_IN_PATIENTS_WITH_TWO_FUNCTIONAL_CYP2D6_ALLELES
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*1/*4 + *1/*5;LADME_PK;DECREASED_PK;PK:CONCENTRATIONS_OF_10-OH-NORTRIPTYLINE_AND_HIGHER_NORTRIPTYLINE/10-OH-NORTRIPTYLINE_RATIO
RITODRINE;CACNA1C;rs10774053;AA + AG;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
SPIRONOLACTONE;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC + ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/del;EFFICACY;EFFICACY;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR_EJECTION_FRACTION,_END-SYSTOLIC_AND_END-DIASTOLIC_VOLUME
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
WARFARIN;APOE;rs429358;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
WARFARIN;APOE;rs7412;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DQB1;HLA-DQB1*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ATORVASTATIN, QUINAPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_D-DIMER_LEVELS
TIMOLOL;CYP2D6;CYP2D6;poor_metabolizer;EFFICACY, LADME_PK;INCREASED_PK;PK:PLASMA_TIMOLOL_CONCENTRATION_AND_EXCERICE_HEART_RATE_REDUCTION
LANSOPRAZOLE;CYP2C19;CYP2C19 normal metabolizer;;LADME_PK;DECREASED_;OTHER:GASTRIC_PH
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RABEPRAZOLE;CYP2C19;CYP2C19 normal metabolizer;;EFFICACY;DECREASED_;OTHER:GASTRIC_PH
;AREG;rs1615111;A;OTHER;DECREASED_;OTHER:OVERALL_SURVIVAL
CISPLATIN, EPIRUBICIN, FLUOROURACIL;C18orf56, TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
ATORVASTATIN, QUINAPRIL;ACE;rs1799752;del/del;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_IL-6_LEVELS
ATORVASTATIN, QUINAPRIL;ACE;rs1799752;del/del;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_CRP_LEVELS
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLOPIDOGREL;CYP2C9;CYP2C9*1, CYP2C9*2;*2/*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
VINCRISTINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;TOXICITY;DECREASED_;SIDE_EFFECT:AVERAGE_CUMULATIVE_NEUROTOXICITY_GRADE
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
ETHANOL;CYP2E1;rs2031920;T;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE
CISPLATIN, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;OTHER;INCREASED_LIKELIHOOD;OTHER:BLOOD_COAGULATION_DISORDERS
TOLTERODINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*10/*10 + *5/*10;LADME_PK;INCREASED_PK;PK:TOLTERODINE_EXPOSURE_AND_INCREASED_ACTIVE_METABOLITE_(5-HM)_CONCENTRATIONS
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DQB1;HLA-DQB1*03:03;*03:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PHENYTOIN;CYP2C9;CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ANASTROZOLE;CYP19A1;rs1008805;GG;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT:ARTHRALGIA
ACE INHIBITORS, PLAIN;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
OLANZAPINE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;INSR;rs41412545;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CYCLOSPORINE, METHOTREXATE;ATIC;rs2177735;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
LEVETIRACETAM;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
ALLOPURINOL;HLA-DRB1;HLA-DRB1*03:01;*03:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs56022120;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs6759892;G;DOSAGE, LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs2070959;G;DOSAGE, LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIK3R2;rs138602176;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PHENYTOIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
NEVIRAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
CLOPIDOGREL;MED12L, P2RY12;rs5853517;T/del;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
PHENYTOIN;HLA-A;HLA-A*24:02;*24:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
EXEMESTANE;;rs16964189;TT;TOXICITY;;SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_VASOMOTOR_SYMPTOMS_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PERP;rs78428806;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ASPIRIN, CLOPIDOGREL, PRASUGREL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;EFFICACY;INCREASED_LIKELIHOOD;DISEASE:INFLAMMATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
ANTIPSYCHOTICS;INSIG2;rs11123469;CC;EFFICACY;INCREASED_LIKELIHOOD;DISEASE:METABOLIC_SYNDROME
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS
FENOFIBRATE, SERTRALINE, TERBINAFINE, TICLOPIDINE;HLA-A;HLA-A*33:01;*33:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;ABCB1;rs2032582;T;EFFICACY;EFFICACY;EFFICACY:DRUG-RESISTANT_PHENOTYPE
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2 + (CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/3;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
WARFARIN;CYP4F2;CYP4F2*1, CYP4F2*3;*3;EFFICACY;EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
ASPIRIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTRITIS
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs67376798;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4 + *4/*4;LADME_PK;INCREASED_PK;PK:PLASMA_METOPROLOL_CONCENTRATIONS
FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ATAZANAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*28;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
;ACE2;rs2285666;C;OTHER;INCREASED_SEVERITY;OTHER:COVID-19
"""ACE INHIBITORS, PLAIN"", ""BETA BLOCKING AGENTS"", ""CALCIUM CHANNEL BLOCKERS"", ""DIGOXIN"", ""DIURETICS""";ACE;rs1799752;del;EFFICACY;INCREASED_EFFICACY;EFFICACY:MORTALITY
IVACAFTOR, TEZACAFTOR;CFTR;rs113993960;del/del;OTHER;DECREASED_;SIDE_EFFECT:CYSTIC_FIBROSIS_PULMONARY_EXACERBATION
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3C;*1/*3C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_LEUKOPENIA
DESIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*5;*1/*1;LADME_PK;DECREASED_PK;PK:METABOLIC_RATIOS_OF_DESIPAMINE
PAMAQUINE;G6PD;G6PD deficiency;;TOXICITY;;DISEASE:HEMOLYSIS
METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4 + *4/*4;EFFICACY, OTHER;INCREASED_;OTHER:HEART_RATE_(HR)_AND_DIASTOLIC_BLOOD_PRESSURE_(DBP)_REDUCTIONS_DURING_EARLY_TITRATION
PRIMAQUINE;G6PD;G6PD deficiency;;TOXICITY;;DISEASE:HEMOLYSIS
ITRACONAZOLE, KETOCONAZOLE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;OTHER, LADME_PK;DECREASED_SEVERITY;OTHER:INHIBITION_OF_CYP3A-CATALYZED_METABOLISM_OF_MIDAZOLAM_OR_TESTOSTERONE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
HMG COA REDUCTASE INHIBITORS;;rs3764261;A;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROTECTION_AGAINST_MYOCARDIAL_INFARCTION
CAPECITABINE;TYMS;rs45445694;(CCGCGCCACTTGGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA,_DRUG_TOXICITY,_HAND-FOOT_SYNDROME,
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:ON-TREATMENT_PLATELET_ACTIVITY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;EFFICACY;DECREASED_;SIDE_EFFECT:TIME_BELOW_THERAPEUTIC_RANGE
OSIMERTINIB;CYP2A6;rs28399433;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
AMITRIPTYLINE, FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN;*1/*1xN + *2/*2xN;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
PAZOPANIB, PEMETREXED;VEGFA;rs833061;CC + CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3/*3 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
PENICILLIN G, PENICILLIN V;HLA-B;HLA-B*55:01;*55:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ETHANOL;GHSR;rs2948694;AG;OTHER;;OTHER:WEIGHT
OPIOIDS;OPRM1;rs495491;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*46;*46/*46;;INCREASED_;OTHER:CIGARETTES_PER_DAY
OPIOIDS;OPRM1;rs10457090;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;INCREASED_PK;PK:STEADY_STATE_CONCENTRATION_PER_DOSAGE
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01/*58:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EPIDERMAL_NECROLYSIS,_TOXIC_OR_STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE, PHENYTOIN, VALPROIC ACID;SCN2A;rs17183814;A;EFFICACY;EFFICACY;EFFICACY:NON-RESPONSE
WARFARIN;CYP2C9;CYP2C9*2;*2;EFFICACY;EFFICACY;EFFICACY:SHORTER_TIME_TO_THE_FIRST_INR_OF_MORE_THAN_4
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;HTR7;rs1935349;T;TOXICITY;INCREASED_RISK;DISEASE:MYALGIA
METHOTREXATE;TYMS;rs45445694;CCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTGGCCTGCCTCCGTCCCGCCGCGCCACTTCGCCTGCCTCCGTCCCCC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
NEVIRAPINE;CYP2B6;CYP2B6*1, CYP2B6*6, CYP2B6*18;*6/*18;TOXICITY, LADME_PK;INCREASED_LIKELIHOODPK;PK:ELEVATED_PLASMA_CONCENTRATIONS
DOCETAXEL, TEGAFUR;CYP2A6;CYP2A6*1, CYP2A6*4;*4/*4;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:EFFICACY
CISPLATIN;ERCC2;rs1799793;T;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL
CARBAMAZEPINE;HLA-B;HLA-B*40:01;*40:01;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:STEVENS-JOHNSON_SYNDROME
COCAINE;SLC6A3;rs3836790;CACATACCATGCAACATACACACTCAGACA/CACATACCATGCAACATACACACTCAGACA;TOXICITY;INCREASED_RISK;DISEASE:DEATH
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;DOSAGE;EFFICACY;EFFICACY:LOWER_WARFARIN_DOSE_REQUIREMENT
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS_IN_TAIWANESE_PATIENTS_RECEIVING_CLOPIDOGREL_AFTER_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI)
PHENYTOIN;HLA-DRB1;HLA-DRB1*16:02;*16:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EPIDERMAL_NECROLYSIS,_TOXIC_OR_STEVENS-JOHNSON_SYNDROME
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*41;*1/*4;LADME_PK;INCREASED_PK;PK:PAROXETINE_SERUM_CONCENTRATIONS_(CMIN)
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIPHENYLHYDANTOIN-INDUCED_SKIN_RASH
IBUPROFEN;CYP2C9;CYP2C9*3;*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:DURATION_OF_INHIBITION_OF_PROSTANOIDS
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATION
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME_PK;INCREASED_PK;PK:THE_MAXIMAL_ELIMINATION_RATE_(VMAX)
ACETAMINOPHEN;CYP2E1;CYP2E1*1, CYP2E1*5B;*1/*5B;LADME_PK;INCREASED_PK;PK:ELIMINATION_RATE
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;INCREASED_PK;PK:PLASMA_METHYLMERCAPTOPURINE_NUCLEOTIDES_LEVELS
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE_IN_JAPANESE_PATIENTS
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE, EFFICACY;EFFICACY;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3, CYP2C9*4;*1/*3 + *1/*4;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
MERCAPTOPURINE;CYP2A7;rs73032311;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESPONSE_TO_CLOPIDOGREL_AND_POORER_OUTCOMES_IN_CHINESE_PATIENTS_WITH_ACUTE_ISCHEMIC_STROKE
BUPROPION;CYP2B6;CYP2B6*18;*18;LADME_PK;DECREASED_PK;PK:HYDROXYBUPROPION_CONCENTRATIONS
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATION
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
PHENYTOIN;CYP2C9;CYP2C9*1;*1/*1;LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATION
ANTIEPILEPTICS, CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CUTANEOUS_REACTIONS
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*3;LADME_PK;INCREASED_PK;PK:MEAN_AMITRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT
PHENYTOIN;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EPIDERMAL_NECROLYSIS,_TOXIC_OR_STEVENS-JOHNSON_SYNDROME
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
;NAT1;NAT1*10, NAT1*11A;*10/*11A;OTHER;INCREASED_RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
;NAT1;NAT1*4, NAT1*10;*10/*4;OTHER;INCREASED_RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;GSTT1;GSTT1 null;;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
PACLITAXEL;CYP2C8;CYP2C8*3;*3;LADME_PK;DECREASED_PK;PK:CLERANCE_OF_PACLITAXEL
BUPROPION;CYP2B6;CYP2B6*1, CYP2B6*6;*6;LADME_PK;DECREASED_PK;PK:HYDROXYBUPROPION_CONCENTRATIONS_AND_HYDROXYBUPROPION/BUPROPION_RATIO
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;EFFICACY;EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION_(MPA)_IN_CLOPIDOGREL-TREATED_PATIENTS_UNDERGOING_PE_RCUTANEOUS_CORONARY_INTERVENTION
IRINOTECAN, RALTITREXED;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;TOXICITY;DECREASED_RISK;DISEASE:ASTHENIA
CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;EFFICACY;EFFICACY;EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION_(MPA)_IN_CLOPIDOGREL-TREATED_PATIENTS_UNDERGOING_PE_RCUTANEOUS_CORONARY_INTERVENTION
TEMSIROLIMUS;NR1I2;rs6785049;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
TACROLIMUS;CYP3A4;rs2242480;C/C;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
;NAT1;NAT1*3, NAT1*11B;*11B/*3;OTHER;INCREASED_RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS
;NAT1;NAT1*10;*10/*10;OTHER;INCREASED_RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS
OXCARBAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
CALCINEURIN INHIBITORS, CYCLOSPORINE, TACROLIMUS;CYP2C8;CYP2C8*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALLOGRAFT_DYSFUNCTION_IN_KIDNEY_TRANSPLANT_RECIPIENTS_TREATED_WITH_CALCINEURIN_INHIBITORS
DAUNORUBICIN;NRP2;rs10932125;C;DOSAGE, LADME_PK;INCREASED_PK;PK:IC50
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs1799735;CCT/CCT;TOXICITY, LADME_PK;DECREASED_RISK;DISEASE:THROMBOCYTOPENIA
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs1799735;CCT/CCT;TOXICITY, LADME_PK;DECREASED_RISK;DISEASE:ANEMIA
CISPLATIN, CYCLOPHOSPHAMIDE;GSTM3;rs1799735;CCT/CCT;TOXICITY, LADME_PK;DECREASED_RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
METOPROLOL;CYP2D6;rs5030655;del/del;OTHER;INCREASED_PK;PK:PLASMA_CONCENTRATIONS_OF_METOPROLOL
ANTIDEPRESSANTS;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;;EFFICACY;EFFICACY:LACK_OF_REMISSION_AND_LACK_OF_RESPONSE
ANTIDEPRESSANTS;SLC6A4;rs57098334;(CCCACCCGA)12/(CCCACCCGA)12;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTION_AFTER_THE_SECOND_SWITCH_IN_TREATMENT
VALPROIC ACID;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs1105879;C;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
NEVIRAPINE;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;TOXICITY, LADME_PK;INCREASED_LIKELIHOODPK;PK:ELEVATED_PLASMA_CONCENTRATIONS
ISONIAZID, PYRIDOXAL PHOSPHATE;CYP2E1;CYP2E1*1A;*1A/*1A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ATENOLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;INCREASED_PK;PK:AMITRIPTYLINE/(E)-10-_OH-AT_RATIO
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;INCREASED_PK;PK:NORTRIPTYLINE/(E)-10-OH-NT_RATIO
REPAGLINIDE;SLCO1B1;SLCO1B1*1, SLCO1B1*37;*37/*37;LADME_PK;DECREASED_PK;PK:REPAGLINIDE_EXPOSURE_(DECREASED_AUC_AND_INCREASED_CLEARANCE)
PHENYTOIN;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EPIDERMAL_NECROLYSIS,_TOXIC_OR_STEVENS-JOHNSON_SYNDROME
BENZENE;NQO1;rs1800566;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMATOTOXICITY
ATAZANAVIR, EFAVIRENZ;TPH2;rs4570625;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DEPRESSION
METHOTREXATE;DHFR;rs70991108;TGGCGCGTCCCGCCCAGGT/TGGCGCGTCCCGCCCAGGT;TOXICITY;INCREASED_RISK;DISEASE:THROMBOCYTOPENIA
ALLOPURINOL;HLA-C;HLA-C*03:02;*03:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
EFAVIRENZ;CYP2B6;CYP2B6*1;*1;EFFICACY, LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATION_OF_EFAVIRENZ
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*08:01;*08:01;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:AGRANULOCYTOSIS
TEGAFUR;CYP2A6;CYP2A6*1;*1;OTHER, LADME_PK;INCREASED_PK;PK:PLASMA_FLUOROURACIL
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3;TOXICITY;INCREASED_;SIDE_EFFECT:ADVERSE_DRUG_REACTIONS
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
CYCLOSPORINE;CYP3A4;CYP3A4*1, CYP3A4*18;*1/*1;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LIVER_INJURY
ANTIEPILEPTICS;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;DECREASED_LIKELIHOOD;DISEASE:DRUG_RESISTANCE
ATORVASTATIN;UGT1A3;UGT1A3*1, UGT1A3*2;*2/*2;EFFICACY, LADME_PK;INCREASED_PK;PK:ATORVASTATIN_LACTONIZATION
ATORVASTATIN;UGT1A3;UGT1A3*1, UGT1A3*2;*2;EFFICACY, LADME_PK;DECREASED_EFFICACY;EFFICACY:TOTAL_AND_THE_LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_MAXIMUM_PERCENT_DECREASES_FROM_BASELINE
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
DOXEPIN;CYP2C9;CYP2C9*3;*3/*3;LADME_PK;DECREASED_PK;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN
EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;DECREASED_PK;PK:ORAL_CLEARANCE_(CL/F)_OF_OMEPRAZOLE_RACEMATE,_5-HYDROXYOMEPRAZOLE,_R-OMEPRAZOLE_AND_S-OMEPRAZOLE
TACROLIMUS;CYP2C19;CYP2C19*2;*2/*2;OTHER;INCREASED_;OTHER:HOSPITAL_STAY
MERCAPTOPURINE;COMT;rs4680;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ROSIGLITAZONE;CYP2C8;CYP2C8*3;*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:MEAN_ABSOLUTE_DIFFERENCE_IN_HBA1C
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2xN;*1/*2xN;LADME_PK;INCREASED_PK;PK:MAXIMUM_PLASMA_CONCENTRATION_OF_10-HYDROXY_NORTRIPTYLINE
PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15;LADME_PK;INCREASED_PK;PK:RELATIVE_BIOAVAILABILITY_OF_PRAVASTATIN
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_HYPERSENSITIVITY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*1/*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:ANTIPLATELET_RESPONSE_AND_REDUCED_CLOPIDOGREL_ACTIVE_METABOLITE_FORMATION
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;LADME_PK;INCREASED_PK;PK:MEAN_AMITRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:CLOPIDOGREL_RESPONSE_IN_CHINESE_PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI)
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:CLOPIDOGREL_RESPONSE_IN_CHINESE_PATIENTS_UNDERGOING_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI)
;CYP2C19;CYP2C19*1, CYP2C19*17;*17;OTHER;RISK_;DISEASE:PEPTIC_ULCER_DISEASE
CAFFEINE;ADORA2A;rs5751876;TT;OTHER;INCREASED_;SIDE_EFFECT:ANXIETY
METHOTREXATE;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)3;EFFICACY;INCREASED_SEVERITY;DISEASE:RHEUMATOID_ARTHRITIS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:COMPOSITE_ISCHEMIC_EVENTS
EFAVIRENZ;CYP2B6;CYP2B6*6;*6/*6;TOXICITY, LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:COMPOSITE_ISCHEMIC_EVENTS
ATORVASTATIN;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_;SIDE_EFFECT:SERUM_CREATINE_KINASE_LEVELS_(INCREASED_RISK_OF_MYALGIA_AND_GREATER_DEGREE_OF_MUSCLE_DAMAGE)
NEVIRAPINE;ABCC10;rs2125739;CC;EFFICACY, LADME_PK;INCREASED_LIKELIHOODPK;PK:LOWER_NEVIRAPINE_PLASMA_CONCENTRATIONS
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARBAMAZEPINE-INDUCED_HYPERSENSITIVITY
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARBAMAZEPINE-INDUCED_STEVENS-JOHNSON_SYNDROME_(SJS)_AND_TOXIC_EPIDERMAL_NECROLYSIS_(TEN)
METFORMIN;SLC22A1;rs36056065;GTAAGTTG;TOXICITY, LADME_PK;;SIDE_EFFECT:GASTROINTESTINAL_SIDE_EFFECTS
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:STEVENS-JOHNSON_SYNDROME
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;CYP2E1*1A;*1A/*1A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARBAMAZEPINE-INDUCED_HYPERSENSITIVITY_SYNDROME
CLOPIDOGREL;CYP2C19;CYP2C19*17;*17;EFFICACY;EFFICACY;EFFICACY:ENHANCED_RESPONSE_TO_CLOPIDOGREL_(AS_MEASURED_BY_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION)
PHENYTOIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PHENYTOIN_TOXICITY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:ANTIPLATELET_RESPONSE_AND_REDUCED_CLOPIDOGREL_ACTIVE_METABOLITE_FORMATION
;NAT1;NAT1*10, NAT1*11B;*10/*11B;OTHER;INCREASED_RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS
EFAVIRENZ, OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;LADME_PK;DECREASED_PK;PK:ORAL_CLEARANCE_(CL/F)_OF_OMEPRAZOLE_RACEMATE,_5-HYDROXYOMEPRAZOLE,_R-OMEPRAZOLE_AND_S-OMEPRAZOLE
DRUGS FOR TREATMENT OF TUBERCULOSIS;HLA-DQB1;HLA-DQB1*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
;NAT1;NAT1*4, NAT1*11A;*11A/*4;OTHER;INCREASED_RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS
WARFARIN;CYP2C9;CYP2C9*3;*3;EFFICACY;EFFICACY;EFFICACY:SHORTER_TIME_TO_THE_FIRST_INR_OF_MORE_THAN_4
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A;*1/*3A;TOXICITY;INCREASED_PK;PK:PLASMA_THIOGUANINE_NUCLEOTIDES_METABOLITES
PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*1/*15;LADME_PK;INCREASED_PK;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX
PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*1/*15;LADME_PK;INCREASED_PK;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*13;*1/*13;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;DOSAGE, TOXICITY;INCREASED_RISK;OTHER:COMPLICATIONS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*1/*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:ADP-INDUCED_MAXIMUM_PLATELET_AGGREGATION
METOPROLOL;CYP2D6;CYP2D6*4;*4;DOSAGE, TOXICITY;INCREASED_RISK;DISEASE:BRADYCARDIA
PRAVASTATIN;SLCO1B1;SLCO1B1*1, SLCO1B1*15;*15/*15;LADME_PK;INCREASED_PK;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;GSTM1 null;;TOXICITY;DECREASED_SEVERITY;DISEASE:DRUG_TOXICITY
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*3;*3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE_AFTER_ADJUSTMENT_FOR_VKORC1*1173
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
DOXEPIN;CYP2D6;CYP2D6*3, CYP2D6*5;*3/*5;LADME_PK;DECREASED_PK;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN
HALOPERIDOL;COMT;rs4680;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
ATORVASTATIN;CYP2D6;CYP2D6*4;*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCLE_EFFECTS
DOXEPIN;CYP2D6;CYP2D6*4, CYP2D6*5;*4/*5;LADME_PK;DECREASED_PK;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*13;*1/*13;EFFICACY;EFFICACY;EFFICACY:DELAYED_TIME_TO_REACH_STABLE_DOSE_AND_AND_TENDED_TO_HAVE_HIGH_RISK_FOR_THE_FIRST_INR_GREATER_THAN_3.5
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE, EFFICACY;EFFICACY;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*14;*1/*14;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_INR_VALUES_IN_PATIENTS_WITH_HEART_VALVE_REPLACEMENT
CLOPIDOGREL;CYP2B6;CYP2B6*5;*5;EFFICACY;EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY_IN_CYP2C19*1/*1_CARRIERS
VENLAFAXINE;CYP2D6;CYP2D6*10;*10/*10;LADME_PK;INCREASED_PK;PK:CMAX_AND_AUC_OF_VENLAFAXINE
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2/*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_INR_VALUE
WARFARIN;CYP2C9;CYP2C9*2;*2;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
WARFARIN;CYP2C9;CYP2C9*3;*3;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
VENLAFAXINE;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10;LADME_PK;INCREASED_PK;PK:CMAX_AND_AUC_OF_VENLAFAXINE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*14;*1/*14;EFFICACY;EFFICACY;EFFICACY:DELAYED_TIME_TO_REACH_STABLE_DOSE_AND_AND_TENDED_TO_HAVE_HIGH_RISK_FOR_THE_FIRST_INR_GREATER_THAN_3.5
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;EFFICACY;EFFICACY;EFFICACY:DELAYED_TIME_TO_REACH_STABLE_DOSE_AND_AND_TENDED_TO_HAVE_HIGH_RISK_FOR_THE_FIRST_INR_GREATER_THAN_3.5
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
PHENPROCOUMON;CYP2C9;CYP2C9*3;*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:ACHIEVING_A_STABLE_DOSE
PHENPROCOUMON;CYP2C9;CYP2C9*2;*2;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:ACHIEVING_A_STABLE_DOSE
ESCITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*10;*4/*10;EFFICACY;INCREASED_EFFICACY;EFFICACY:FREQUENCY_OF_REMITTERS
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_;OTHER:INTRAGASTRIC_PH
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;DECREASED_;OTHER:INTRAGASTRIC_PH
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:ON-CLOPIDOGREL_PLATELET_AGGREGATION_(PA)_AND_HIGHER_PLATELET_REACTIVITY_INDEX_(PRI)_IN_PATIENTS_UNDERGOING_ELECTIVE_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI)
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;LADME_PK;DECREASED_PK;PK:TRAMADOL_CLEARANCE_IN_CHINESE_VOLUNTEERS
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY, LADME_PK;DECREASED_EFFICACY;EFFICACY:TRAMADOL_METABOLISM_AND_RESPONSE
OMEPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;INCREASED_;OTHER:MEAL-STIMULATED_PLASMA_GASTRIN_CONCENTRATIONS
PAROXETINE;CYP2D6;CYP2D6*3, CYP2D6*4;*4/*4 + *3/*4;LADME_PK;INCREASED_PK;PK:PAROXETINE_PLASMA_CONCENTRATIONS_INCREASED_DURING_THE_COURSE_OF_PREGNANCY
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;DOSAGE, EFFICACY;DECREASED_EFFICACY;EFFICACY:METABOLISM_AND_DECREASED_RESPONSE_TO_TRAMADOL
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*1/*3 + *3/*3;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESPONSE_TO_CLOPIDOGREL_AND_POORER_OUTCOMES_IN_CHINESE_PATIENTS_WITH_ACUTE_ISCHEMIC_STROKE
TAMOXIFEN;CYP2D6;CYP2D6*6, CYP2D6*7;*6/*7;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
ESCITALOPRAM;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*5/*10;EFFICACY;INCREASED_EFFICACY;EFFICACY:FREQUENCY_OF_REMITTERS
TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*6;*3/*6;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3/*4;DOSAGE, EFFICACY;DECREASED_EFFICACY;EFFICACY:METABOLISM_AND_DECREASED_RESPONSE_TO_TRAMADOL
CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_CLOMIPRAMINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT_AND_HIGHER_METABOLIC_RATIO_OF_CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;LADME_PK;INCREASED_PK;PK:MEAN_NORTRIPTYLINE_CONCENTRATIONS_AND_NORTRIPTYLINE_CONCENTRATIONS_PER_UNIT_DOSE_OF_THE_MEDICATION
OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*4/*4 + *3/*4;LADME_PK;PK;PK:MEAN_PLASMA_CONCENTRATION_OF_OXYMORPHONE_AND_LOWER_MEAN_OXYMORPHONE/OXYCODONE_RATIO
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*41;*1/*1 + *1/*41;LADME_PK;DECREASED_PK;PK:PAROXETINE_PLASMA_CONCENTRATIONS_INCREASED_DURING_THE_COURSE_OF_PREGNANCY
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*5/*10;LADME_PK;INCREASED_PK;PK:MEAN_NORTRIPTYLINE_CONCENTRATIONS_AND_NORTRIPTYLINE_CONCENTRATIONS_PER_UNIT_DOSE_OF_THE_MEDICATION
DESIPRAMINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*1/*1;LADME_PK;DECREASED_PK;PK:METABOLIC_RATIOS_OF_DESIPAMINE
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*10;*2/*10;LADME_PK;DECREASED_PK;PK:TRAMADOL_CLEARANCE_IN_CHINESE_VOLUNTEERS
TRAMADOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*5;*3/*5;DOSAGE, EFFICACY;DECREASED_EFFICACY;EFFICACY:METABOLISM_AND_DECREASED_RESPONSE_TO_TRAMADOL
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5;*5;LADME_PK;INCREASED_PK;PK:NORTRIPTYLINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*5, CYP2D6*10;*1/*10 + *1/*5;LADME_PK;INCREASED_PK;PK:PAROXETINE_PLASMA_CONCENTRATION_AT_AN_ADMINISTERED_DOSE_OF_30MG/DAY
COTININE;CYP2A6;CYP2A6*1, CYP2A6*2, CYP2A6*9, CYP2A6*17, CYP2A6*20;*1/*1;LADME_PK;PK;PK:SHORTER_CONTININ_HALF-LIFE
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;DECREASED_PK;PK:CLEARANCE_OF_S(+)_MIRTAZAPINE
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4;LADME_PK;INCREASED_PK;PK:PAROXETINE_LEVELS
CLOMIPRAMINE;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_CLOMIPRAMINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT_AND_HIGHER_METABOLIC_RATIO_OF_CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;DECREASED_PK;PK:ORAL_CLEARANCE_OF_CITALOPRAM
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10 + *1/*10;LADME_PK;INCREASED_PK;PK:PLASMA_PAROXETINE_CONCENTRATIONS_AT_ADMINISTERED_DOSE_OF_10MG/DAY
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME_PK;INCREASED_PK;PK:TOTAL_CLEARANCE_OF_RACEMIC_MIRTAZAPINE
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*36;*36;LADME_PK;DECREASED_PK;PK:CODEINE_METABOLISM_AND_MORPHINE_AND_GLUCURONIDES_FORMATION
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*1/*1 + *1/*4;LADME_PK;INCREASED_PK;PK:PLASMA_LEVEL_OF_MORPHINE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:ON-TREATMENT_PLATELET_AGGREGATION
WARFARIN;CYP2C9;CYP2C9*2, CYP2C9*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
;UGT1A1;rs34946978;T;OTHER;INCREASED_LIKELIHOOD;OTHER:GILBERT_SYNDROME,_CRIGLER-NAJJAR_SYNDROME
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
FLURBIPROFEN;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3;LADME_PK;INCREASED_PK;PK:AUC,_HIGHER_HALF-LIFE_AND_LOWER_FLURBIPROFEN_CLEARANCE
DICLOFENAC;CYP2C8;CYP2C8*1, CYP2C8*4;*1/*4 + *4/*4;LADME_PK;INCREASED_PK;PK:DICLOFENAC/5-HYDROXYDICLOFENAC_URINARY_CONCENTRATION_RATIO
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_AND_CEREBROVASCULAR_EVENTS
PYRIMIDINE ANALOGUES;MIR27A;rs895819;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_AND_CEREBROVASCULAR_EVENTS
CITALOPRAM;CYP2C19;CYP2C19;poor_metabolizer;LADME_PK;INCREASED_PK;PK:PLASMA_RATIO_CITALOPRAM_(CIT)/N-DESMETHYLCIT_(DCIT)
TIMOLOL;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*3/*3 + *3/*4 + *4/*4 + *5/*4;LADME_PK;INCREASED_PK;PK:EXPOSURE_TO_TIMOLOL_(HIGHER_AREA-UNDER-CURVE,_LONGER_ELIMINATION_HALF-LIVES_)
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
CLOPIDOGREL;PON1;rs662;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOTAL_HEMORRHAGE_AND_MAJOR_HEMORRHAGE
TENOXICAM;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*3;LADME_PK;INCREASED_PK;PK:AUC_AND_HALF-LIFE_TIME_(T1/2)
IBUPROFEN;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*3;TOXICITY;DECREASED_;SIDE_EFFECT:INOS_EXPRESSION_AND_FEWER_ADVERSE_EVENTS
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CLOPIDOGREL;P2RY12;rs2046934;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
ANTIEPILEPTICS;HLA-B;HLA-B*58:01;*58:01;TOXICITY;DECREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
ASPIRIN;HLA-DPB1;HLA-DPB1*03:01;*03:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASTHMA
SULFONAMIDES, UREA DERIVATIVES;TCF7L2;rs7903146;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(REDUCTIONS_IN_HAEMOGLOBIN_A1C_(HBA1C)_AND_FASTING_PLASMA_GLUCOSE_(FPG)_LEVELS)
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
LUMACAFTOR;CFTR;rs113993960;del/del;TOXICITY;INCREASED_EFFICACY;EFFICACY:CHANGE_IN_SWEAT_CHLORIDE
CAFFEINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ABORTION,_SPONTANEOUS
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2/*2 + *2/*3 + *3/*3;DOSAGE;DECREASED_EFFICACY;EFFICACY:ACENOCOUMAROL_DOSE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:ON-CLOPIDOGREL_PLATELET_AGGREGATION_(PA)_AND_HIGHER_PLATELET_REACTIVITY_INDEX_(PRI)_IN_PATIENTS_UNDERGOING_ELECTIVE_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI)
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*10 + *10/*10;LADME_PK;DECREASED_PK;PK:PLASMA_LEVELS_OF_MORPHINE,_M3G_AND_M6G_LEVELS_BUT_NOT_THOSE_OF_CODEINE
AZATHIOPRINE;TPMT;TPMT*1, TPMT*2, TPMT*3A, TPMT*3C;*1/*2 + *1/*3A + *1/*3C;TOXICITY;INCREASED_RISK;DISEASE:TRANSPLANT_REJECTION
BOSENTAN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*1/*1 + *1/*4;OTHER;INCREASED_;OTHER:OROCECCAL_TRANSIT_TIME
;CYP1B1;rs1056836;CC + CG;;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL,_OVERALL_SURVIVAL
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_AND_CEREBROVASCULAR_EVENTS
TETRABENAZINE;CYP2D6;CYP2D6;intermediate_metabolizer;EFFICACY;EFFICACY;EFFICACY:LESS_ROBUST_TREATMENT_RESPONSE
WARFARIN;CYP4F2;CYP4F2*1, CYP4F2*3;*3;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR short form (S allele), SLC6A4 L allele-rs25531C, SLC6A4 L allele-rs25531T;HTTLPR short form (S allele)/L allele-rs25531C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SIDE_EFFECTS
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*17;LADME_PK;DECREASED_PK;PK:METABOLIC_RATIO_CIT/DCIT_VALUES
CLOPIDOGREL;PTGS1;rs1330344;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOMIPRAMINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);TOXICITY;INCREASED_;SIDE_EFFECT:CLOMIPRAMINE-INDUCED_PROLACTIN_RELEASE
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;LADME_PK;INCREASED_PK;PK:AUC_OF_CITALOPRAM
PAROXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele);EFFICACY;INCREASED_EFFICACY;EFFICACY:PRESENTATION_IN_THE_NON-REPONDER_GROUP
PHENOBARBITAL;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_DRUG_REACTIONS
OLANZAPINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIZZINESS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ISCHAEMIC_STROKE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:PRU
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2/*2 + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS
CARBAMAZEPINE;HLA-B;HLA-B*07:02, HLA-B*08:01;*07:02;TOXICITY;DECREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
TRICHLOROETHYLENE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CLINICAL_EVENTS
AZATHIOPRINE, CYCLOSPORINE, PREDNISONE;TPMT;TPMT*3A, TPMT*3C;*3A/*3C;TOXICITY;SEVERITY_;SIDE_EFFECT:LEUKOPENIA
ALLOPURINOL;HLA-A;HLA-A*02:01;*02:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CARDIOVASCULAR_EVENT_OCCURRENCE
ALLOPURINOL;HLA-C;HLA-C*08:01;*08:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
IRINOTECAN, OXALIPLATIN, TEGAFUR / GIMERACIL / OTERACIL;UGT1A7;UGT1A7*3;*3;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:VOMITING
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2 + *2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
OSIMERTINIB;CYP2C9;rs1057910;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS,_EXANTHEMA
CITALOPRAM;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR long form (L allele)/HTTLPR long form (L allele);EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
MYCOPHENOLATE MOFETIL;CYP2C8;rs11572076;CC;TOXICITY;DECREASED_RISK;DISEASE:LEUKOPENIA
ALLOPURINOL;HLA-A;HLA-A*33:03;*33:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CLOZAPINE;HLA-DRB3;HLA-DRB3*02:02;*02:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
MERCAPTOPURINE;TPMT;rs1142345;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
MYCOPHENOLATE MOFETIL;UGT2B7;rs7438135;G;TOXICITY;INCREASED_RISK;DISEASE:ANEMIA
CLOZAPINE;HLA-C;HLA-C*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
CLOZAPINE;HLA-DRB1;HLA-DRB1*01:01;*01:01;TOXICITY;DECREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
AZATHIOPRINE, MERCAPTOPURINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCREATITIS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;EFFICACY;INCREASED_;OTHER:PLATELET_REACTIVITY
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
SULFASALAZINE;HLA-B;HLA-B*39:01;*39:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
METHAZOLAMIDE;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
CARBIMAZOLE, METHIMAZOLE, PROPYLTHIOURACIL;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
PLATINUM COMPOUNDS, PYRIMIDINE ANALOGUES;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CILOSTAZOL, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*3;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_EXANTHEMA,_STEVENS-JOHNSON_SYNDROME,
CAPECITABINE, FLUOROURACIL;DPYD;DPYD deficiency;;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
DOLASETRON;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
CYCLOSPORINE, METHOTREXATE;NFATC2;rs6123048;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;CYP2C8;CYP2C8*1, CYP2C8*4;*4;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
TAMOXIFEN;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ABACAVIR;HLA-B;HLA-B*57:01;*57:01;TOXICITY;;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
IFOSFAMIDE;ALDH1A1;rs3764435;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*17;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
DAPSONE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
CLOZAPINE;GSTT1;GSTT1 non-null, GSTT1 null;null/null;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*3;*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:ACHIEVING_SVR_IN_OLDER_PATIENTS_WITH_GENOTYPE_1B_CHRONIC_HEPATITIS_C
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR),_SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs746071566;del;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCYTOPENIA,_THROMBOCYTOPENIA
HMG COA REDUCTASE INHIBITORS;ADAMTS1;rs402007;CC;EFFICACY;EFFICACY;EFFICACY:THE_MOST_BENEFIT_FROM_STATIN_TREATMENT_IN_REDUCING_THE_RISK_OF_MYOCARDIAL_INFARCTION
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NICOTINE;CYP2B6;CYP2B6*1, CYP2B6*4;*1/*4 + *4/*4;TOXICITY;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*12;*1/*1;TOXICITY;DECREASED_RISK;OTHER:TOBACCO_USE_DISORDER
ANTITHYROID PREPARATIONS;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
ANTITHYROID PREPARATIONS;HLA-DRB1;HLA-DRB1*08:03;*08:03;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;TOXICITY;INCREASED_RISK;DISEASE:VIRUS_DISEASES
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;TOXICITY;INCREASED_RISK;DISEASE:INFECTIOUS_DISEASE
GEFITINIB;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:ALLOGRAFT_REJECTION
CARBOPLATIN, PACLITAXEL;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA,_NEUTROPENIA
LAMOTRIGINE;SCN1A;rs3812718;C;EFFICACY;INCREASED_EFFICACY;EFFICACY:TONIC_BLOCK_OF_NA(V)_1.1_CHANNELS
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;LADME_PK;INCREASED_PK;PK:FORMATION_OF_METABOLITES
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TRANSPLANT_REJECTION
PEMETREXED;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
METHOTREXATE;TYMS;rs11280056;del;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
;SLCO1B1;rs4149056;C;OTHER;DECREASED_;OTHER:ERYTHROMYCIN_TRANSPORT
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME,_TOXIC_EPIDERMAL_NECROLYSIS
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
LEVOFLOXACIN;HLA-B;HLA-B*13:01, HLA-B*13:02;*13:01 + *13:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PHENYTOIN;HLA-A;HLA-A*03:01;*03:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19;intermediate_metabolizer;EFFICACY;INCREASED_RISK;SIDE_EFFECT:THROMBOTIC_DISEASE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS;HLA-DRB1;HLA-DRB1*10:01;*10:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;*2 + *3 + *8;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS
CLOPIDOGREL, PROTON PUMP INHIBITORS;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*1 + *1/*17 + *17/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10  + *1/*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*17;*1/*1 + *1/*17 + *17/*17;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEMORRHAGE
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19;poor_metabolizer;EFFICACY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CYCLOSPORINE, METHOTREXATE;SLC19A1;rs4818789;TT;EFFICACY;DECREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
ATENOLOL, METOPROLOL;ADRB2;rs1042714;GG;TOXICITY;INCREASED_RISK;DISEASE:HYPERTRIGLYCERIDEMIA
ZOLEDRONATE;;rs1152003;CC;TOXICITY;INCREASED_RISK;DISEASE:OSTEONECROSIS
CARBAMAZEPINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2C19;CYP2C19;intermediate_metabolizer;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA,_VOMITING
ATORVASTATIN;HMGCR;rs17671591;T;EFFICACY;EFFICACY;EFFICACY:LDL-C_RESPONSE
ANTIDEPRESSANTS, ANTIPSYCHOTICS;CYP2D6;CYP2D6;intermediate_metabolizer;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DEPRESSION
TACROLIMUS, VORICONAZOLE;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;LADME_PK;INCREASED_SEVERITY;SIDE_EFFECT:DRUG-DRUG_PHARMACOKINETIC_INTERACTION
CARBOPLATIN, PACLITAXEL;LIG3;rs1052536;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
CLOPIDOGREL;CYP1A2;rs2069514;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEATH
CYCLOSPORINE, METHOTREXATE;SLC19A1;rs4819128;TT;EFFICACY;DECREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ATORVASTATIN;HMGCR;rs10474433;T;EFFICACY;EFFICACY;EFFICACY:LDL-C_RESPONSE
VANCOMYCIN;HLA-A;HLA-A*32:01;*32:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS,_DRUG-INDUCED_LIVER_INJURY
MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
ATORVASTATIN;PCSK9;rs11591147;T;EFFICACY;EFFICACY;EFFICACY:LDL-C_RESPONSE
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-A;HLA-A*02:07;*02:07;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-A;HLA-A*01:01;*01:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-C;HLA-C*06:02;*06:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-DRB1;HLA-DRB1*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"""BETA-LACTAM ANTIBACTERIALS, PENICILLINS"", ""OTHER BETA-LACTAM ANTIBACTERIALS""";HLA-DQB1;HLA-DQB1*03:02;*03:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CLOPIDOGREL;CYP2C19;CYP2C19;poor_metabolizer;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
VALPROIC ACID;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ATORVASTATIN;APOE;rs429358;T;EFFICACY;EFFICACY;EFFICACY:LDL-C_RESPONSE
ENALAPRIL;;rs495828;TT;TOXICITY;INCREASED_RISK;DISEASE:COUGH
RIBAVIRIN, SOFOSBUVIR;ITPA;rs1127354;AC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ENALAPRIL;;rs495828;TT;TOXICITY;INCREASED_RISK;DISEASE:COUGH
ATORVASTATIN;APOE;rs7412;T;EFFICACY;EFFICACY;EFFICACY:LDL-C_RESPONSE
;GSTT1;GSTT1 non-null, GSTT1 null;;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TRANSPLANT_REJECTION
SIMVASTATIN;ABCG2;rs2231142;TT;LADME_PK;INCREASED_PK;PK:EXPOSURE_TO_DRUG
CISPLATIN, DOCETAXEL, FLUOROURACIL;TYMS;rs11280056;TTA/TTA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPONATREMIA
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME,_TOXIC_EPIDERMAL_NECROLYSIS,_MACULOPAPULAR_EXANTHEMA,_DRUG_HYPERSENSITIVITY
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME,_TOXIC_EPIDERMAL_NECROLYSIS
;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
EFAVIRENZ;CYP2B6;CYP2B6;poor_metabolizer;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
CAPECITABINE, FLUOROURACIL;DPYS;rs143004875;(T)7/(T)8;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
FLUVASTATIN;ABCG2;rs2231142;TT;LADME_PK;INCREASED_PK;PK:EXPOSURE_TO_DRUG
CAPECITABINE, FLUOROURACIL;DPYD;DPYD c.1129-5923C>G, c.1236G>A (HapB3);c.1129-5923C>G, c.1236G>A (HapB3);TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
OSIMERTINIB;CYP2A6;CYP2A6*4;*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
OSIMERTINIB;ABCG2;rs2622604;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
L-ASPARAGINE, PREDNISONE, VINCRISTINE;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*3/*3 + *3/*6 + *3/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
L-ASPARAGINE, PREDNISONE, VINCRISTINE;ASNS;rs3832526;(GCGGGGCGCAGGGC)3/(GCGGGGCGCAGGGC)3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
PRAVASTATIN;NPC1L1;rs17655652;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_LDL-C
PRAVASTATIN;NPC1L1;rs17655652;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_LDL-C
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;CYP2C19;CYP2C19*17;*17;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
TRAMADOL;CYP2B6;CYP2B6;poor_metabolizer;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:PAIN,_POSTOPERATIVE
TRAMADOL;CYP3A4;CYP3A4;poor_metabolizer;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIZZINESS,_SOMNOLENCE
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19;poor_metabolizer;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
IRINOTECAN;HLA-B;rs9266271;C;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-A;HLA-A*34:01;*34:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-DRB1;HLA-DRB1*16:02;*16:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ATORVASTATIN;HMGCR;rs3846662;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_LEVEL_IN_BASAL_STATE_AND_POSSIBLY_IN_RESPONSE_TO_ATORVASTATIN.
CLOPIDOGREL;ABCB1;rs1128503;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY,_TREMOR,_DIABETES_MELLITUS,
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4, NAT2*6;*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:ACUTE_CELLULAR_REJECTION
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
BETA BLOCKING AGENTS, METOPROLOL;ADRB1;rs1801252;AG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR(LV)_REMODELING
LANSOPRAZOLE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY
FOLFIRI, FOLFOX, XELOX;TYMS;rs11280056;del/del;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;ALOX5;rs1051713;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
ETOPOSIDE;;rs6539870;GG;OTHER;INCREASED_;OTHER:SENSITIVITY_TO_ETOPOSIDE
"""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";ITPA;rs1127354;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:FREQUENCY_OF_PATIENTS_WHO_RECEIVED_AT_LEAST_THE_RECOMMENDED_80%_OF_SCHEDULED_RIBAVIRIN
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2 + *3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:STROKE
"""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";ITPA;rs1127354;CC;EFFICACY;EFFICACY;EFFICACY:CUMULATIVE_REDUCTION_OF_RIBAVIRIN
ASPARAGINASE;F5;rs6025;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM
DABIGATRAN;CES1;rs2244613;GG + GT;LADME_PK;DECREASED_PK;PK:ADJUSTED_TROUGH_CONCENTRATIONS
DESIPRAMINE;MC1R;rs2228478;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
;ABCB1;rs1045642;A;;INCREASED_;OTHER:LEVEL_OF_APOLIPOPROTEIN_A1
ACENOCOUMAROL;VKORC1;rs9934438;AA;DOSAGE, EFFICACY, TOXICITY;DECREASED_EFFICACY;EFFICACY:DOSE_REQUIREMENT
DESIPRAMINE;MC1R;rs2228479;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*7, NAT2*16;*16/*7;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
CARBAMAZEPINE;LTA, TNF;rs1800629;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SERIOUS_HYPERSENSITIVITY
ASPARAGINASE;IL16;rs11556218;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:THROMBOTIC_DISEASE
MERCAPTOPURINE;PACSIN2;rs2413739;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMATOLOGIC_DISORDER
GEMCITABINE;SLC29A1;rs9394992;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
DOCETAXEL, THALIDOMIDE;SPG7;rs2292954;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
ANTINEOPLASTIC AGENTS;CTH;rs648743;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
DOCETAXEL, THALIDOMIDE;ABCC6;rs2238472;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
DOCETAXEL, THALIDOMIDE;ATP7A;rs2227291;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
MERCAPTOPURINE;GNMT;rs10948059;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEMATOLOGIC_DISORDER
ACENOCOUMAROL;CYP4F2;rs2108622;CC;OTHER, LADME_PK;DECREASED_;OTHER:LEVELS_OF_VITAMIN_K-DEPENDENT_PROTEINS
ACENOCOUMAROL;CYP4F2;rs2108622;CT;OTHER, LADME_PK;DECREASED_;OTHER:LEVELS_OF_VITAMIN_K-DEPENDENT_PROTEINS
DABIGATRAN;CES1;rs2244613;GG + GT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:BLEEDING_EVENTS
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENT
ACENOCOUMAROL;CYP4F2;rs2108622;CC;DOSAGE, EFFICACY, TOXICITY;DECREASED_EFFICACY;EFFICACY:DOSAGE_REQUIREMENT
CLOPIDOGREL;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*1/*4 + *1/*10 + *1/*5 + *1/*41 + *1/*3;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
IRINOTECAN;SLCO1B1;rs4149015;AA + AG;TOXICITY;INCREASED_;DISEASE:NEUTROPENIA
;CHRM3;rs2165870;AA + AG;;INCREASED_RISK;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*16;*16/*16;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:A_MILD_INCREASE_OF_LIVER_ENZYMES
SALBUTAMOL, SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:ASTHMA_EXACERBATIONS
IRINOTECAN;UGT1A9;rs3832043;del/del;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
ANTIPSYCHOTICS, ARIPIPRAZOLE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
CISPLATIN;SLC16A5;rs4788863;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY
ISONIAZID, RIFAMPIN;NAT2;NAT2*1, NAT2*4, NAT2*5, NAT2*5G, NAT2*5J, NAT2*6, NAT2*7, NAT2*14, NAT2*16, NAT2*17, NAT2*30, NAT2*34;*5 + *5G + *6 + *17 + *16 + *7 + *34 + *14 + *5J + *30;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_REACTIONS
IRINOTECAN;ABCC2;rs3740066;CC;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ENALAPRIL, IMIDAPRIL, LISINOPRIL;BDKRB2;rs1799722;CT + TT;TOXICITY;INCREASED_RISK;DISEASE:COUGH
IRINOTECAN;ABCG2;rs2231137;CT + TT;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
CLOZAPINE, RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:METABOLIC_SYNDROME
HMG COA REDUCTASE INHIBITORS;SREBF1;rs11868035;AA + AG;OTHER;INCREASED_;OTHER:TOTAL_CHOLESTEROL
OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7;*3/*4 + *4/*4 + *4/*5 + *4/*6 + *4/*7;DOSAGE;INCREASED_PK;PK:OXYCODONE_CONSUMPTION_UP_TO_THE_12(TH)_HOUR_IN_POSTOPERATIVE_PATIENTS
CISPLATIN;GSTP1;rs1695;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY
ACE INHIBITORS, PLAIN;BDKRB2;rs1799722;T;TOXICITY;INCREASED_RISK;DISEASE:COUGH
ATORVASTATIN;ABCG2;rs2231142;TT;DOSAGE, LADME_PK;INCREASED_PK;PK:AUC
LANSOPRAZOLE;CYP2C19;CYP2C19 intermediate metabolizers;;LADME_PK;DECREASED_;OTHER:GASTRIC_PH
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*5, NAT2*6, NAT2*7;*5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY, LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7;*6/*7;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
IRBESARTAN;AGTR1;rs5186;AC + CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:BLOOD_PRESSURE_RESPONSE
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6;*6/*6;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
OPIOIDS;PDE3A;rs12305038;A;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NAUSEA,_VOMITING
ISONIAZID, RIFAMPIN;NAT2;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*7;*5/*7 + *6/*6 + *6/*7;TOXICITY, LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
DEXMEDETOMIDINE;ADRA2A;rs1800544;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:BISPECTRAL_INDEX_AND_RAMSAY_SEDATION_SCORES,_INDICATING_A_LONGER_PERIOD_FOR_FALLING_ASLEEP
PACLITAXEL;CYP2C8;rs1113129;G;TOXICITY;DECREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
OPIOIDS;MUC16;rs11882256;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NAUSEA,_VOMITING
ISONIAZID, RIFAMPIN;NAT2;NAT2*6;*6;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ROSUVASTATIN;ABCG2;rs2231142;TT;DOSAGE, LADME_PK;INCREASED_PK;PK:AUC
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6;*6/*6;TOXICITY, LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;NAT2*5, NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *5 + *6 + *6 + *7 + *7 + *14 + *14;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
IRINOTECAN;UGT1A1;rs4148323;AA;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
ROSUVASTATIN;ABCG2;rs2231142;GG;DOSAGE, LADME_PK;DECREASED_PK;PK:AUC
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*6;*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID, RIFAMPIN;NAT2;NAT2*6, NAT2*7;*6/*7;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
SORAFENIB;TNF;rs1800629;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
OPIOIDS;PDE3A;rs12305038;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NAUSEA,_VOMITING
IRINOTECAN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
ALFENTANIL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_RISK;DISEASE:PAIN
ISONIAZID;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
"""INTERFERON ALFA-2B, RECOMBINANT"", ""RIBAVIRIN""";ITPA;rs1127354;CC;TOXICITY;DECREASED_;SIDE_EFFECT:HEMOGLOBIN_LEVELS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6;*6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ALFENTANIL;OPRM1;rs1799971;AG + GG;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RISK;OTHER:ASTHMA_EXACERBATIONS
PEGINTERFERON ALFA-2B, RIBAVIRIN;DNAAF9, ITPA;rs6051702;C;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANEMIA
CLOPIDOGREL;MIR6076;rs1463411;GG + GT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
LANSOPRAZOLE;CYP2C19;CYP2C19 intermediate metabolizers;;LADME_PK;DECREASED_;OTHER:GASTRIC_PH
TAMOXIFEN;LRMDA;rs10509373;C;EFFICACY;DECREASED_;OTHER:RECURRENCE-FREE_SURVIVAL
OPIOIDS;CRYBG2;rs36024412;T;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NAUSEA,_VOMITING
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799930;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7;*6/*7;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
OPIOIDS;CLCC1;rs168107;T;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NAUSEA,_VOMITING
CAPECITABINE;CDA;rs1048977;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
BOCEPREVIR, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PLATINUM COMPOUNDS;SLC31A1;rs10759637;AC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
OPIOIDS;POM121L2;rs41269255;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NAUSEA,_VOMITING
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""DRUGS FOR TREATMENT OF TUBERCULOSIS""";NAT2;NAT2*1, NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY, LADME_PK;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
DIPYRONE;NAT2;NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *6 + *7 + *14;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *6 + *7 + *14;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
METHOTREXATE;ABCC2;rs3740065;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
IRINOTECAN;NR3C1;rs61754806;A;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
IRINOTECAN;VKORC1;rs7294;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
PLATINUM COMPOUNDS;SLC31A1;rs2233914;AA;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
OPIOIDS;ZNF165;rs9393888;C;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NAUSEA,_VOMITING
CISPLATIN, CYCLOPHOSPHAMIDE;TPMT;rs1142345;CT;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
HMG COA REDUCTASE INHIBITORS;SLCO1B1;SLCO1B1*5;*5;TOXICITY;DECREASED_RISK;SIDE_EFFECT:CATARACT
GEMCITABINE;RRM1;rs9937;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
OLANZAPINE, RISPERIDONE;DRD2;rs1799978;C;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_UNTIL_RESPONSE
PLATINUM COMPOUNDS;SLC31A1;rs2233914;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:BLEEDING_EVENTS
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*5, NAT2*6, NAT2*6J, NAT2*7, NAT2*16;*16/*6 + *16/*7 + *5/*5 + *5/*6 + *6/*6 + *6/*7 + *6/*6J + *6J/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
METHOTREXATE;ABCC4;rs9516519;GG + GT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXICITY
ESCITALOPRAM;CYP2D6;CYP2D6;poor_metabolizer;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PSYCHOMOTOR_AGITATION,_HYPERKINESIS,_IMPULSE_CONTROL_DISORDER,
RISPERIDONE;CYP2D6;CYP2D6 normal metabolizer;;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DISCONTINUATION
PALIPERIDONE;CYP2D6;CYP2D6;poor_metabolizer;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION,_WEIGHT_GAIN
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7;*6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TRAMADOL;CYP2D6;CYP2D6*10;*10/*10;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:MAGNITUDE_OF_PLATELET_REACTIVITY
ISONIAZID;NAT2;NAT2*6, NAT2*7;*6 + *7;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7;*6 + *7;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATOTOXICITY
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*16;*16;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7;*6/*6 + *6/*7;TOXICITY, LADME_PK;INCREASED_RISK;DISEASE:HEPATITIS
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-DRB1;HLA-DRB1*04:03;*04:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:ON-TREATMENT_PLATELET_REACTIVITY
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*16;*16/*4;TOXICITY, LADME_PK;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PLATINUM COMPOUNDS;SLC31A1;rs10759637;AC;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
CAPECITABINE;CDA;rs2072671;AC + CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY,_HAND-FOOT_SYNDROME
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*7 + *6/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATOTOXICITY
ISONIAZID;NAT2;NAT2*16;*16;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
OLANZAPINE, RISPERIDONE;DRD2;rs1799732;del;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_RESPOND
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7;*5/*6 + *5/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
OPIOIDS;CYP2A7P1, CYP2B6;rs3745274;GG;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *6/*7 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-B;HLA-B*35:03;*35:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PLATINUM COMPOUNDS;SLC31A1;rs4979223;AC;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
;CHRNA3;rs1051730;A;OTHER;INCREASED_LIKELIHOOD;OTHER:TOBACCO_USE_DISORDER
RIBAVIRIN, SOFOSBUVIR;ITPA;rs1127354;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMOLYTIC_ANEMIA
PROTON PUMP INHIBITORS;CYP2C19;CYP2C19 rapid and ultrarapid metabolizer genotypes;;TOXICITY;DECREASED_RISK;SIDE_EFFECT:INFECTIOUS_DISEASE
ANTINEOPLASTIC AGENTS;TYMS;rs2853539;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CYCLOPHOSPHAMIDE, DACTINOMYCIN, VINCRISTINE;CYP2B6;rs2279343;AG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
ANTIPSYCHOTICS;CYP2D6;CYP2D6 poor metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TARDIVE_DYSKINESIA
OMEPRAZOLE;CYP2C19;CYP2C19 normal metabolizers;;LADME_PK;DECREASED_;OTHER:GASTRIC_PH
TAMOXIFEN;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT:HOT_FLASHES
ANTINEOPLASTIC AGENTS;AKR1C3;rs1937840;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ANTIHYPERTENSIVES;ADIPOQ;rs266729;CG + GG;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:HYPERTENSION
MYCOPHENOLIC ACID, TACROLIMUS;IMPDH1;rs2278293;T;EFFICACY;DECREASED_LIKELIHOOD;OTHER:SUBCLINICAL_ACUTE_REJECTION
GEMCITABINE;CDA;rs2072671;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ATOMOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*10, CYP2D6*17;*3/*3 + *3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*4xN + *4/*5 + *4/*6 + *5/*5 + *4xN/*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRY_MOUTH,_ERECTILE_DYSFUNCTION,_HYPERHIDROSIS,_INSOMNIA
CODEINE;CYP2D6;CYP2D6 poor metabolizers;;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
NICOTINE;CYP2D6;CYP2D6*2xN, CYP2D6*4, CYP2D6*5;*2xN;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOBACCO_USE_DISORDER
GEMCITABINE;DCK;rs4694362;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;RBX1;rs141084494;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1801280;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PLATINUM COMPOUNDS;SLC31A1;rs4978536;AG + GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
OPIOIDS;BDNF-AS;rs11030096;CC + CT;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
IRINOTECAN, PLATINUM COMPOUNDS;NAT2;rs1799930;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PLATINUM COMPOUNDS;SLC31A1;rs10817464;CC + CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY,_HEMATOLOGIC_DISORDER,_LEUKOPENIA,_THROMBOCYTOPENIA
VORICONAZOLE;CYP2C19;CYP2C19 poor metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
PLATINUM COMPOUNDS;SLC31A1;rs4979223;AC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
COCAINE;SYT1;rs2251214;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:COCAINE_DEPENDENCE
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
VALGANCICLOVIR;ABCB1;rs2229109;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;INCREASED_PK;PK:FLUOXETINE_PLASMA_CONCENTRATION
TETRABENAZINE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;EFFICACY;;OTHER:LONGER_TITRATION_TO_ACHIEVE_OPTIMAL_BENEFIT
MYCOPHENOLATE MOFETIL;UGT1A9;rs3832043;T;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_AREA_UNDER_THE_CONCENTRATION_VERSUS_TIME_CURVE_(AUC6-12)_LEVEL_OF_MYCOPHENOLIC_ACID
OLANZAPINE;CYP2C9;CYP2C9 poor metabolizers;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIZZINESS
"""FOLIC ACID"", ""VITAMIN B-COMPLEX, PLAIN""";MTRR;rs1801394;AA + AG;EFFICACY;DECREASED_SEVERITY;DISEASE:PAIN
NICOTINE;HTR3B;rs3758987;TT;TOXICITY;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
CAPECITABINE;TYMS;rs11280056;TTAAAGTTA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA,_DRUG_TOXICITY,_HAND-FOOT_SYNDROME,
CAPECITABINE;DPYD;rs67376798;AT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
ANTIDEPRESSANTS;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3/*4 + *4/*4 + *4/*5 + *4/*6;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS
ENALAPRIL;PCGF3;rs1044147;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*11;*3/*4 + *3/*5 + *3/*6 + *4/*11 + *4/*4 + *4/*5 + *4/*6 + *4/*7 + *5/*5 + *6/*6 + *6/*7;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
PAROXETINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*3/*4 + *4/*4 + *4/*5;LADME_PK;INCREASED_PK;PK:PAROXETINE_PLASMA_CONCENTRATION
TRAMADOL;COMT;rs4680;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SEDATION
ANTICHOLINERGIC AGENTS;CYP2C19;CYP2C19 poor metabolizers;;LADME_PK;INCREASED_PK;PK:SERUM_ANTICHOLINERGIC_ACTIVITY
VENLAFAXINE;CYP2D6;CYP2D6 normal metabolizers;;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
ANTINEOPLASTIC AGENTS;ABCG2;rs2231164;CC + CT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SURVIVAL
CITALOPRAM, CLOMIPRAMINE, DULOXETINE, ESCITALOPRAM, FLUOXETINE, FLUVOXAMINE, MIRTAZAPINE, PAROXETINE, SERTRALINE, VENLAFAXINE;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;DECREASED_EFFICACY;EFFICACY:NUMBER_OF_FAILED_MEDICATION_TRAILS
MYCOPHENOLATE MOFETIL;UGT1A9;rs3832043;T;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_AREA_UNDER_THE_CONCENTRATION_VERSUS_TIME_CURVE_(AUC6-12)_LEVEL_OF_MYCOPHENOLIC_ACID-7-O-GLUCURONIDE
MYCOPHENOLATE MOFETIL;ABCC2;rs2273697;AG;LADME_PK;INCREASED_PK;PK:AREA_UNDER_THE_CONCENTRATION_VERSUS_TIME_CURVE_(AUC6-12)_LEVEL_OF_THE_ACYL_GLUCURONIDE_OF_MYCOPHENOLIC_ACID
CAPECITABINE;DPYD;rs2297595;CT;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
OPIOIDS;OPRM1;rs1799971;GG;TOXICITY;DECREASED_;SIDE_EFFECT:NAUSEA,_VOMITING
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*3 + *2/*2 + *3/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*17 + *17/*17;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
ATENOLOL;PAH;rs2245360;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:INSULIN_RESISTANCE
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5;*3/*4 + *3/*5 + *4/*4 + *4/*5;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
TAMOXIFEN;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*7;*3/*4 + *3/*5 + *4/*4 + *4/*5 + *4/*7;EFFICACY;INCREASED_LIKELIHOOD;DISEASE:BREAST_NEOPLASMS
ASPIRIN, CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
OPIOIDS;DRD2;rs1125394;CC + CT;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
OPIOIDS;OPRM1;rs1799971;G;TOXICITY;DECREASED_;SIDE_EFFECT:ADVERSE_EVENTS
SORAFENIB;VEGFA;rs3025040;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*5/*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
OPIOIDS;DRD2;rs1079596;CT + TT;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
TRAMADOL;COMT;rs4680;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*5/*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
EFAVIRENZ;CYP2B6;CYP2B6 poor metabolizer and intermediate metabolizer genotypes;;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDE
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;rs3740066;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FEBRILE_NEUTROPENIA
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT intermediate metabolizers;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
FLUOROURACIL;TYMS;rs2847153;AG + GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SURVIVAL
MORPHINE;ABCC3;rs4148412;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPOVENTILATION
SORAFENIB;UGT1A9;rs7574296;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*1 + *1/*28;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
SORAFENIB;KDR;rs2071559;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
TACROLIMUS;CYP3A5;CYP3A5 intermediate metabolizer and normal metabolizer;;DOSAGE;INCREASED_LIKELIHOOD;OTHER:DRUG_DOSAGE_ALTERED
TRAMADOL;COMT;rs4680;GG;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN,_POSTOPERATIVE
"""FOLIC ACID"", ""VITAMIN B-COMPLEX, PLAIN""";MTHFR;rs1801133;AG + GG;EFFICACY;EFFICACY;EFFICACY:GREATER_REDUCTION_IN_HOMOCYSTEINE
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, TRIMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;INCREASED_PK;PK:ANTIDEPRESSANT_SERUM_LEVELS
SORAFENIB;SLC15A2;rs2257212;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
FLUOROURACIL;CCND1;rs9344;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME-TO-TUMOR_RECURRENCE
AZATHIOPRINE;TPMT;TPMT intermediate metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS
CAPECITABINE;UMPS;rs2279199;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA,_VOMITING
METFORMIN;;rs578427;TT;LADME_PK;INCREASED_PK;PK:RENAL_CLEARANCE_AND_SECRETION_CLEARANCE_OF_METFORMIN
CAPECITABINE;TYMS;rs2853741;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
CLOPIDOGREL;CYP2C19;CYP2C19 rapid and ultrarapid metabolizer genotypes;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
CAPECITABINE;SLC22A7;rs4149178;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
CISPLATIN;ABCC3;rs1051640;G;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
GALANTAMINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*41;*3/*4 + *4/*4 + *4/*5;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_PLASMA_LEVELS
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*35;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;CYP2C19 normal metabolizers;;OTHER;DECREASED_RISK;OTHER:MAJOR_ADVERSE_CARDIAC_EVENTS
METHOTREXATE;SLC19A1;rs1051266;T;TOXICITY;INCREASED_;DISEASE:DRUG-INDUCED_LIVER_INJURY
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
ABT-751;UGT1A4;rs6755571;AC;LADME_PK;DECREASED_PK;PK:PLASMA_PREDOSE_CONCENTRATION_(CTROUGH)
CAPECITABINE;UMPS;rs4678145;CC + CG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ASTHENIA
ABT-751;UGT1A8;rs6431558;CC + CT;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION_METABOLIC_RATIOS
IMIPRAMINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;INCREASED_PK;PK:MEAN_AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE_(AUC)_OF_DESIPRAMINE
ANTINEOPLASTIC AGENTS;DPYD;rs1760217;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
AZATHIOPRINE;TPMT;rs1142345;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ANTINEOPLASTIC AGENTS;SERPINA3;rs17091162;AC + CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1/*2 + *2/*17;LADME_PK;DECREASED_PK;PK:MEAN_PEAK_PLASMA_CONCENTRATION_OF_H4
VALPROIC ACID;CYP2C19;CYP2C19 poor metabolizer and intermediate metabolizer genotypes;;TOXICITY;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
ASPIRIN, CLOPIDOGREL;PTGS1;rs10306114;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
METFORMIN;SLC47A2;rs12943590;AA;LADME_PK;INCREASED_PK;PK:RENAL_CLEARANCE_AND_SECRETION_CLEARANCE_OF_METFORMIN
TAMOXIFEN;NCOA1;rs1804645;CT;OTHER;INCREASED_SEVERITY;SIDE_EFFECT:CHANGE_IN_LUMBAR_BONE_MINERAL_DENSITY
CLOPIDOGREL;CYP2C19;CYP2C19 intermediate metabolizer genotype;;EFFICACY;INCREASED_RISK;OTHER:CARDIOVASCULAR_DEATH,MYOCARDIAL_INFARCTION_OR_STROKE
CITALOPRAM, ESCITALOPRAM;;rs352428;A;EFFICACY;EFFICACY;EFFICACY:POOR_RESPONSE_AT_8_WEEK_OF_TREATMENT
CLOPIDOGREL;CYP2C19;CYP2C19 intermediate metabolizer genotype;;EFFICACY;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
CITALOPRAM;;rs352428;A;EFFICACY;EFFICACY;EFFICACY:POOR_RESPONSE_AT_6_WEEK_OF_TREATMENT
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer genotype;;EFFICACY;INCREASED_RISK;OTHER:CARDIOVASCULAR_DEATH,MYOCARDIAL_INFARCTION_OR_STROKE
MIDAZOLAM;POR;rs1057868;CT;LADME_PK;DECREASED_PK;PK:MIDAZOLAM_METABOLIC_RATIOS_BY_45%
CLOPIDOGREL;CYP2C19;CYP2C19 poor metabolizer genotype;;EFFICACY;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
LENVATINIB;ABCG2;rs2231142;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRY_MOUTH,_MUCOSITIS
NICOTINE;CHRNA3;rs578776;G;LADME_PK;INCREASED_PK;PK:PLASMA_LEVEL
GALANTAMINE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*41;*3/*4 + *4/*4 + *4/*5;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_PLASMA_LEVELS
TRAZODONE;CYP2D6;CYP2D6 normal metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIZZINESS
CAPECITABINE;DPYD;rs17376848;AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:STOMATITIS
RISPERIDONE;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
LENVATINIB;CYP3A4;rs2242480;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
LENVATINIB;CYP3A5;rs776746;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
CAPECITABINE;ENOSF1, TYMS;rs699517;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA,_VOMITING
HEROIN;OPRK1;rs6473797;C;TOXICITY;DECREASED_RISK;OTHER:HEROIN_DEPENDENCE
HEROIN;CSNK1E;rs1534891;T;TOXICITY;DECREASED_RISK;OTHER:HEROIN_DEPENDENCE
CAPECITABINE;DPYD;rs12119882;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
ETHANOL;CHRNA5;rs16969968;G;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ALCOHOL_ABUSE
HEROIN;GAL;rs694066;A;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *3/*3 + *2/*3;EFFICACY;INCREASED_;OTHER:PLATELET_REACTIVITY
HEROIN;OPRD1;rs2236861;A;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
CAPECITABINE;SLC22A7;rs2270860;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
HEROIN;OPRD1;rs3766951;C;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
METHADONE;CRHBP;rs1500;G;OTHER;DECREASED_;OTHER:RECURRENCE
METHAMPHETAMINE;FAAH;rs324420;A;OTHER;INCREASED_LIKELIHOOD;OTHER:DEPENDENCE
ETHANOL;CHRNA3;rs1051730;G;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ALCOHOL_ABUSE
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*35;*3/*4 + *3/*5 + *3/*6 + *4/*4 + *4/*5 + *4/*6 + *6/*7;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
HEROIN;OPRD1;rs2236857;C;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
NALOXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PEAK_CORTISOL_RESPONSE
TAMOXIFEN;CYP2D6;CYP2D6 ultrarapid metabolizer phenotype;;TOXICITY;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
CAPECITABINE;ENOSF1, TYMS;rs699517;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ASTHENIA
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*1/*1 + *1/*10;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEIOMYOMA,_LIVER_DISORDER,_OVARIAN_CYSTS,
HEROIN;HTR3B;rs3758987;C;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
METOPROLOL;CYP2D6;CYP2D6 poor metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE
OSIMERTINIB;ABCG2;rs2231142;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
TAMOXIFEN;CYP2D6;CYP2D6 normal metabolizers;;EFFICACY;INCREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ESCITALOPRAM;HTR2C;rs6318;C;EFFICACY;DECREASED_;DISEASE:PAIN
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;LADME_PK;DECREASED_PK;PK:PLASMA_OXYMORPHONE/OXYCODONE_RATIO
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_PAIN_AUC
MERCAPTOPURINE;GNMT;rs10948059;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION
NICOTINE;CHRNA5;rs16969968;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
OXYCODONE;CYP2D6;CYP2D6 poor metabolizer phenotype;;EFFICACY;DECREASED_PK;PK:PLASMA_OXYMORPHONE/OXYCODONE_RATIO
NICOTINE;CHRNA3;rs1051730;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
PAROXETINE;CYP2D6;CYP2D6 normal metabolizers;;OTHER;INCREASED_;OTHER:METABOLIC_RATIO_DEM/DOR
IRINOTECAN, PLATINUM COMPOUNDS;NAT2;rs1799931;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEXUAL_DYSFUNCTION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3;EFFICACY;INCREASED_;OTHER:PLATELET_REACTIVITY
HEROIN;OPRM1;rs3778151;C;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
ESCITALOPRAM;CYP2D6;CYP2D6 intermediate metabolizers;;LADME_PK;INCREASED_PK;PK:MEAN_LOGARITHM_ESCITALOPRAM_CONCENTRATION
PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;LADME_PK;INCREASED_PK;PK:MEDIAN_AUC,_PLASMA_HALF-LIFE_AND_STEADY-STATE_PLASMA_CONCENTRATIONS_OF_PAROXETINE
CAPECITABINE;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED_RISK;DISEASE:HAND-FOOT_SYNDROME
PAROXETINE;CYP2D6;CYP2D6 poor metabolizers;;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEXUAL_DYSFUNCTION
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1;LADME_PK;INCREASED_PK;PK:FLUOXETINE/(S)-NORFLUOXETINE_RATIO
CAPECITABINE;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
ALKYLATING AGENTS, CISPLATIN;ESR1;rs2207396;A;TOXICITY;INCREASED_RISK;DISEASE:OLIGOSPERMIA
HEROIN;OPRM1;rs510769;T;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *3/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE
ANTIDEPRESSANTS;CYP2D6;CYP2D6 poor metabolizers;;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
CITALOPRAM;CYP2C19;CYP2C19 poor metabolizers;;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION_IF_TOLERANT_TO_CITALOPRAM_TREATMENT
TAMOXIFEN;CYP2D6;CYP2D6 normal metabolizers;*1/*1;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL,_OVERALL_SURVIVAL
TAMOXIFEN;CYP2D6;CYP2D6 normal metabolizers;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
ANTIPSYCHOTICS;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PARKINSONIAN_DISORDER,_TARDIVE_DYSKINESIA
OSIMERTINIB;STAT3;rs4796793;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAIL_DISORDER
ESCITALOPRAM;CYP2D6;rs1065852;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESPONSE_AND_REMISSION_RATE
3,4-METHYLENEDIOXYMETHAMPHETAMINE;CYP2C19;CYP2C19 poor metabolizer genotype;;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERTENSION
DRUGS FOR TREATMENT OF TUBERCULOSIS;SLCO1B1;rs4149014;GG + GT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DOCETAXEL, EPIRUBICIN;;poor metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
;;rs6968865;T;DOSAGE;INCREASED_;OTHER:COFFEE_CONSUMPTION
SULFAMETHOXAZOLE;GCLC;rs761142;AA;TOXICITY;DECREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
AZATHIOPRINE, MERCAPTOPURINE;TPMT;TPMT intermediate metabolizer genotype;;EFFICACY, TOXICITY, LADME_PK;INCREASED_PK;PK:6-TG_LEVELS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEATH,_MYOCARDIAL_INFARCTION,_STROKE,
;CYP1A1;rs2472297;T;DOSAGE;INCREASED_;OTHER:COFFEE_CONSUMPTION
SULFAMETHOXAZOLE;GCLC;rs761142;A;TOXICITY;DECREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;CES1;rs2244613;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
TRAMADOL;CYP2D6;CYP2D6 normal metabolizer and ultrarapid metabolizer;;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;rs2273697;AG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
SORAFENIB;KDR;rs1870377;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
TACROLIMUS;CYP3A4;rs35599367;AG;OTHER;INCREASED_PK;PK:CREATININE_CLEARANCE
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCC2;rs3740066;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;PON1;rs662;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:ON-CLOPIDOGREL_PLATELET_REACTIVITY_(PR)_AT_1_MONTH_AND_AT_6_MONTHS_AFTER_PERCUTANEOUS_CORONARY_INTERVENTION_(PCI)
ANTIPSYCHOTICS;CYP2D6;CYP2D6 ultrarapid metabolizer genotype;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TARDIVE_DYSKINESIA
ISONIAZID;ASTN2;rs117491755;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ALECTINIB;PPARA;rs4253728;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
VALPROIC ACID;SCN1A;rs2298771;TT;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME,_TOXIC_EPIDERMAL_NECROLYSIS,_DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS,
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA,_LEUKOPENIA,_DIARRHEA,
ATOMOXETINE;CYP2D6;CYP2D6*10;*10/*10;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
CISPLATIN;GSTT1;GSTT1 non-null, GSTT1 null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY
CISPLATIN;GSTM1;GSTM1 non-null, GSTM1 null;;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY
ARIPIPRAZOLE, OLANZAPINE, RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*4;*1/*4 + *4/*4;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
CODEINE;ABCB1;rs2032582;AA;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION_IN_BREAST-FEEDING_INFANTS
ETHANOL;CRHBP;rs10055255;TT;TOXICITY;INCREASED_SEVERITY;OTHER:ALCOHOL_ABUSE
SUNITINIB;NR1I2;rs2276707;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ANTIPSYCHOTICS;DRD2;rs1799732;del;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SEXUAL_DYSFUNCTION
LAMOTRIGINE;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
OXALIPLATIN;HLA-DRB1;HLA-DRB1*12:01;*12:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
TEGAFUR / GIMERACIL / OTERACIL;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9, CYP2A6*10;*4 + *7 + *9 + *10;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
CEFACLOR;HLA-DRB1;HLA-DRB1*14:54;*14:54;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ETHANOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_SEVERITY;OTHER:ALCOHOL_ABUSE
SULFASALAZINE;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS,_DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
SULFASALAZINE;HLA-B;HLA-B*39:01;*39:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS,_DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
SULFASALAZINE;HLA-B;HLA-B*56:03;*56:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS,_DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
METOPROLOL;CYP2D6;CYP2D6*1, CYP2D6*2;*1/*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:HEART_RATE
METHAMPHETAMINE;DAOA;rs778293;C;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER
CEFACLOR;HLA-DRB1;HLA-DRB1*04:03;*04:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANAPHYLAXIS
CEFACLOR;HLA-DRB1;HLA-DRB1*04:03;*04:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*15;*15;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*20;*20;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*37;*37;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION,_ANGINA_PECTORIS
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*5;*5;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:HYPERCHOLESTEROLEMIA
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*15;*15;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:HYPERCHOLESTEROLEMIA
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*5;*5;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
SORAFENIB;KDR;rs2071559;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*15;*15;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
ATORVASTATIN, SIMVASTATIN;SLCO1B1;SLCO1B1*14;*14;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:HYPERCHOLESTEROLEMIA
TACROLIMUS;ABCB1;rs1045642;AG;EFFICACY;INCREASED_RISK;DISEASE:HYPOKALEMIA
RISPERIDONE;ADRB2;rs1042713;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEXUAL_ADVERSE_EVENTS
BECLOMETHASONE, BUDESONIDE, FLUTICASONE, FLUTICASONE PROPIONATE, MOMETASONE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:STATUS_ASTHMATICUS
NICOTINE;CYP2A6;CYP2A6*1, CYP2A6*1x2;*1/*1x2;TOXICITY;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
CYTARABINE;GLI1;rs2228224;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
CYTARABINE;ARHGAP9, GLI1;rs2229300;GT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL,_OVERALL_SURVIVAL
CODEINE;ABCB1;rs1128503;A;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION_IN_BREAST-FEEDING_INFANTS
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;TYMS;rs45445694;(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2/(CCGCGCCACTTCGCCTGCCTCCGTCCCG)2;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
SORAFENIB;KDR;rs1870377;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
CODEINE;ABCB1;rs2032582;AA;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION
CODEINE;ABCB1;rs1045642;A;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:CNS_DEPRESSION_IN_BREAST-FEEDING_INFANTS
CLOPIDOGREL, RESPIRATORY SYSTEM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
;CELSR2, PSRC1;rs602633;T;LADME_PK;PK;PK:BASELINE_LDL_CHOLESTEROL
COCAINE, ETHANOL, OPIOIDS;OPRM1;rs524731;A;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE,_COCAINE_DEPENDENCE,_OPIOID-RELATED_DISORDERS,
ATAZANAVIR, INDINAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
ATAZANAVIR, RITONAVIR;UGT1A1;UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
PHENPROCOUMON;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*2 + *3/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
METHOTREXATE;SLCO1B1;rs4149081;G;OTHER, LADME_PK;INCREASED_PK;PK:CLEARANCE
BETA BLOCKING AGENTS;GRK5;rs2230345;AA;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:DEATH
VALPROIC ACID;SCN1A;rs10167228;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:GRAFT_VS_HOST_DISEASE
TACROLIMUS;ABCB1;rs1045642;AG;EFFICACY;INCREASED_RISK;DISEASE:TRANSPLANT_REJECTION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*5;*5;TOXICITY;INCREASED_RISK;DISEASE:DEATH
MIRTAZAPINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*6;*4/*4 + *4/*6;LADME_PK;INCREASED_PK;PK:DOSE/WEIGHT_ADJUSTED_AUC_FOR_MIRTAZAPINE
TROGLITAZONE;;rs10811661;C;EFFICACY;INCREASED_EFFICACY;EFFICACY:BETA_CELL_FUNCTION
PLATINUM COMPOUNDS;ERCC2;rs1799793;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
NEVIRAPINE;CYP2B6;rs3745274;T;LADME_PK;INCREASED_;OTHER:PLASMA_LEVEL
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*3;*3;LADME_PK;DECREASED_PK;PK:CITALOPRAM_ORAL_CLEARANCES_OF_CITALOPRAM
METHAMPHETAMINE;PICK1;rs713729;T;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS
IMATINIB;ABCG2;rs2231142;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:EXANTHEMA
CAFFEINE;DRD2;rs1110976;GG;OTHER;DECREASED_;SIDE_EFFECT:ANXIETY
OPIOIDS;;rs4530637;AG + GG;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
NEVIRAPINE;ABCB1;rs1045642;A;TOXICITY;DECREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
COCAINE, ETHANOL, OPIOIDS;OPRM1;rs3778156;G;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE,_COCAINE_DEPENDENCE,_OPIOID-RELATED_DISORDERS,
;;rs1111875;C;LADME_PK;DECREASED_PK;PK:INSULIN_SECRETION_AT_BASELINE
CISPLATIN;COMT;rs9332377;T;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*4, CYP2D6*6;*4 + *6;LADME_PK;INCREASED_PK;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS_OF_FLUOXETINE
OPIOIDS;TACR3;rs1384401;AG + GG;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
CISPLATIN;COMT;rs4646316;C;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
FOLFIRI;ABCC2;rs2273697;GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;INCREASED_PK;PK:CITALOPRAM_AUC_AND_TERMINAL_ELIMINATION_HALF-LIFE
PLATINUM COMPOUNDS;SLC22A2;rs316003;CT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL,_OVERALL_SURVIVAL
METHOTREXATE;ABCC2;rs717620;T;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;EFFICACY;INCREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
METHAMPHETAMINE;PICK1;rs713729;T;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:RECURRENCE
OPIOIDS;CYP2D6;rs1065852;AA;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
FOLFIRI;ABCC2;rs1885301;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NAUSEA
CITALOPRAM, ESCITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;LADME_PK;INCREASED_PK;PK:MEDIAN_CONCENTRATION/DOSE_RATIO_AND_MEDIAN_PARENT_DRUG/METABOLITE_RATIO
OPIOIDS;DRD3;rs6280;CC + CT;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
HYDROCHLOROTHIAZIDE;;rs17137967;CC + CT;TOXICITY;INCREASED_;SIDE_EFFECT:FASTING_GLUCOSE
;CYP2A6;CYP2A6*1, CYP2A6*4, CYP2A6*7, CYP2A6*9;*4/*4 + *4/*7 + *4/*9 + *7/*7 + *7/*9 + *9/*9;OTHER;DECREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
OPIOIDS;DRD3;rs324029;AA + AG;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
TAMOXIFEN;CYP2D6;CYP2D6 poor metabolizers and intermediate metabolizers;;TOXICITY;DECREASED_SEVERITY;DISEASE:BREAST_TENDERNESS,_VAGINAL_DRYNESS,_VOMITING,
OPIOIDS;EXOC4;rs718656;TT;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs4646244;A;TOXICITY, LADME_PK;INCREASED_RISK;DISEASE:HEPATITIS
AMISULPRIDE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE, ZIPRASIDONE, ZUCLOPENTHIXOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
NICOTINE;CHRNB2;rs2072660;T;OTHER;INCREASED_SEVERITY;DISEASE:TOBACCO_USE_DISORDER
DIRECT ACTING ANTIVIRALS;IFNL4;rs11322783;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PLATINUM COMPOUNDS;APLF;rs3213239;CCGG/CCGG + CCGG/del;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs8099917;GG;EFFICACY;EFFICACY;EFFICACY:LACK_OF_TREATMENT_RESPONSE
ATAZANAVIR / RITONAVIR;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PLATINUM COMPOUNDS;ERCC2;rs50872;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PLATINUM COMPOUNDS;ABCG2;rs1448784;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799930;A;TOXICITY, LADME_PK;INCREASED_RISK;DISEASE:HEPATITIS
NICOTINE;CHRNB2;rs2072661;A;OTHER;INCREASED_SEVERITY;DISEASE:TOBACCO_USE_DISORDER
CODEINE, HYDROCODONE, OXYCODONE;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4;*3/*3 + *4/*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*1 + *1/*28;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
BOCEPREVIR, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PLATINUM COMPOUNDS;ERCC1;rs11615;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CARBAMAZEPINE;HLA-B;HLA-B*15:11;*15:11;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
HYDROXYCHLOROQUINE;CYP2C8;rs10882526;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA5;rs660652;GG;TOXICITY;INCREASED_;DISEASE:TOBACCO_USE_DISORDER
METHAMPHETAMINE;;rs1421292;T;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER
ACE INHIBITORS, PLAIN;ABO;rs495828;GT + TT;TOXICITY;;DISEASE:COUGH
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
GLICLAZIDE;KCNJ11;rs5219;CT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:EFFICACY_AS_MEASURED_BY_DECREASE_IN_HBA1C
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*17;*1 + *17;EFFICACY;DECREASED_;OTHER:PLATELET_REACTIVITY
PLATINUM COMPOUNDS;ABCB1;rs1128503;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_DISEASE
OPIOIDS;ZNF804A;rs7597593;CC;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
NORTRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4/*4;LADME_PK;DECREASED_PK;PK:MAXIMUM_PLASMA_CONCENTRATION_OF_10-HYDROXY_NORTRIPTYLINE
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA3;rs1051730;AA;TOXICITY;INCREASED_SEVERITY;DISEASE:SUBSTANCE-RELATED_DISORDERS
HYDROXYCHLOROQUINE;CYP3A5;rs776746;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
PLATINUM COMPOUNDS;IL16;rs7170924;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
INDOMETHACIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
;CHRNA3;rs1051730;AA + AG;OTHER;INCREASED_LIKELIHOOD;OTHER:NON-SMALL_CELL_LUNG_CARCINOMA
NEVIRAPINE;HLA-B;HLA-B*15:10;*15:10;TOXICITY;DECREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*3;*1/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8, CYP2C19*17;*2 + *3 + *8;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:STROKE,_MYOCARDIAL_INFARCTION,_DEATH,
ASPIRIN;TBXA2R;rs1131882;A;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEATH
OPIOIDS;CNR1;rs2023239;TT;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
;NQO1;rs1800566;AA;OTHER;;OTHER:SIGNIFICANTLY_SHORTER_SURVIVAL
BUSULFAN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*2 + *3;LADME_PK;INCREASED_PK;PK:METABOLIC_RATIO
PLATINUM COMPOUNDS;ABCB1;rs1128503;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
METFORMIN;SLC29A4;rs3889348;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
;NQO1;rs1800566;A;TOXICITY;INCREASED_RISK;DISEASE:LEUKEMIA
HYDROCHLOROTHIAZIDE;ACE;rs1799752;ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC/ATACAGTCACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCC;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;GSTM1 null;;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTT1;GSTT1 null;;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
OPIOIDS;CNR1;rs6928499;CC;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*5/*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
NEVIRAPINE;CYP2B6;rs58425034;CC + CG;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
FLUOROURACIL;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;EFFICACY;DECREASED_;DISEASE:EVENT-FREE_SURVIVAL,_OVERALL_SURVIVAL
CLOPIDOGREL;CYP2C19;CYP2C19*2;*2/*2;EFFICACY;INCREASED_RISK;SIDE_EFFECT:DEATH,_MYOCARDIAL_INFARCTION
DOCETAXEL, THALIDOMIDE;CHST3;rs4148945;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
"""FOLIC ACID"", ""VITAMIN B-COMPLEX, PLAIN""";MTHFR;rs1801133;AG + GG;EFFICACY;DECREASED_SEVERITY;DISEASE:PAIN
CARBAMAZEPINE;HLA-B;HLA-B*51:01;*51:01;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
DOCETAXEL, THALIDOMIDE;SLC10A2;rs2301159;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
AXITINIB, SORAFENIB;HIF1A;rs11549465;CT;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;TYMS;rs11280056;TTAAAGTTA/TTAAAGTTA;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DISEASE_PROGRESSION
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*6/*6;TOXICITY, LADME_PK;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
METHOTREXATE;SLC19A1;rs1051266;CC + CT;EFFICACY;INCREASED_SEVERITY;DISEASE:RHEUMATOID_ARTHRITIS
SORAFENIB;KDR;rs2071559;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_IN_THERAPEUTIC_RANGE
NICOTINE;DBH;rs77905;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
METHOTREXATE;ADORA2A;rs2298383;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*2, CYP2D6*5, CYP2D6*10;*5/*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*1/*2;OTHER;INCREASED_;OTHER:PLATELET_AGGREGATION_WITH_ADP
RISPERIDONE;CYP2D6;rs3892097;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS,_TREMOR,_MUSCLE_RIGIDITY,
;CYP2B6;rs3211371;TT;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
;CYP2B6;rs3211371;CT;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*3 + *4 + *5 + *10 + *41;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
FLUOXETINE;SLC6A4;SLC6A4 HTTLPR long form (L allele), SLC6A4 HTTLPR short form (S allele);HTTLPR short form (S allele)/HTTLPR short form (S allele);TOXICITY;INCREASED_RISK;SIDE_EFFECT:PSYCHOMOTOR_AGITATION,_INSOMNIA
IRINOTECAN;UGT1A1;rs4124874;G;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
;CYP24A1;rs2762939;C;OTHER;DECREASED_RISK;DISEASE:CORONARY_ARTERY_DISEASE
OPIUM ALKALOIDS AND DERIVATIVES;CHRNA5;rs16969968;A;TOXICITY;INCREASED_SEVERITY;DISEASE:SUBSTANCE-RELATED_DISORDERS
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2, CYP2C9*3;*1/*2 + *1/*3 + *2/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_OUTCOME
MORPHINE;ABCC3;rs739923;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPOVENTILATION
CITALOPRAM;PAPLN;rs11628713;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
WARFARIN;CYP2C9;CYP2C9*1, CYP2C9*2;*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER_ANTI-COAGULATION
SULFONAMIDES, UREA DERIVATIVES;KCNJ11;rs5219;CT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:EFFICACY_AS_MEASURED_BY_DECREASE_IN_HBA1C_AFTER_6-MONTH_TREATMENT
FLUOXETINE;CYP2D6;CYP2D6*1, CYP2D6*1xN;*1/*1xN;LADME_PK;DECREASED_PK;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS_OF_FLUOXETINE
IMATINIB;SLC22A1;rs1867351;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIORBITAL_EDEMA
FLUOROURACIL, LEUCOVORIN;ERCC2;rs13181;GG + GT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
VERAPAMIL;KCNIP1, KCNMB1;rs11739136;CT + TT;EFFICACY;EFFICACY;EFFICACY:EARLIER_ACHIEVEMENT_OF_BLOOD_PRESSURE_CONTROL
OPIOIDS;DRD3;rs9288993;AG + GG;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL4;rs11322783;TT/TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
OSIMERTINIB;CYP2C9;rs1057910;AC;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
OPIOIDS;DRD3;rs2654754;AG + GG;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
OPIOIDS;ZNF568;rs10405238;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NAUSEA,_VOMITING
ANTIEPILEPTICS;HLA-B;HLA-B*53:01;*53:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME,_TOXIC_EPIDERMAL_NECROLYSIS,_SEVERE_CUTANEOUS_ADVERSE_REACTIONS,
PENICILLIN G;HLA-DPB1;HLA-DPB1*05:01;*05:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
SULFAMETHOXAZOLE, SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*38:02;*38:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME,_TOXIC_EPIDERMAL_NECROLYSIS,_SEVERE_CUTANEOUS_ADVERSE_REACTIONS,
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;ABCB1;rs3842;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:CORONARY_RESTENOSIS,_THROMBOTIC_DISEASE
METFORMIN;AMHR2;rs784892;G;LADME_PK;DECREASED_PK;PK:METFORMIN_SECRETORY_CLEARANCE
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;GG;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_AREA_UNDER_THE_CURVE_(AUC6-12)_OF_MYCOPHENOLIC_ACID_(MPA)
CLOPIDOGREL;CYP2C19;CYP2C19;intermediate_metabolizer;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*9, CYP2C19*13, CYP2C19*17;*1/*2 + *2/*17 + *1/*9 + *2/*13 + *9/*17 + *2/*2;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE),_DEATH,_MYOCARDIAL_INFARCTION,_STROKE
ASPIRIN, CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:THROMBOTIC_DISEASE
OPIOIDS;OPRM1;rs1799971;AA;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4, CYP2C19*17;*2 + *4;OTHER;INCREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*8;*8;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*5;*5;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS
ACENOCOUMAROL;CYP2C9;CYP2C9*1, CYP2C9*2;*2;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR)
ATEZOLIZUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;HLA-A;HLA-A*26:01;*26:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THYROTOXICOSIS,_HYPOTHYROIDISM
CARBOPLATIN, GEMCITABINE;RRM1;rs9937;GG;TOXICITY;RISK_;DISEASE:HEMATOLOGIC_DISORDER
ETHANOL;OPRM1;rs1799971;AA;TOXICITY;INCREASED_SEVERITY;OTHER:ALCOHOL_ABUSE
METFORMIN;SLC22A1;rs628031;A;TOXICITY, LADME_PK;;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
OPIOIDS;GABRB3;rs4906902;AA;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*4;*4;OTHER, LADME_PK;INCREASED_PK;PK:PLASMA_NORTRIPTYLINE
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*10;*10;OTHER, LADME_PK;INCREASED_PK;PK:PLASMA_NORTRIPTYLINE
BECLOMETHASONE DIPROPIONATE, FLUTICASONE PROPIONATE;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:STATUS_ASTHMATICUS,_EMERGENCIES
AMITRIPTYLINE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*3 + *2/*3;LADME_PK;INCREASED_PK;PK:AMITRIPTYLINE/NORTRIPTYLINE_RATIO_CORRECTED_FOR_DOSE_AND_WEIGHT
MYCOPHENOLATE MOFETIL;SLCO1B3;rs7311358;AA;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_AREA_UNDER_THE_CURVE_(AUC6-12)_OF_MYCOPHENOLIC_ACID_(MPA)
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ISONIAZID, RIFAMPIN;HLA-DPB1;HLA-DPB1*05:01;*05:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID, RIFAMPIN;HLA-A;HLA-A*11:01;*11:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ETHANOL;DRD2;rs1799732;GG;TOXICITY;INCREASED_SEVERITY;OTHER:ALCOHOL_ABUSE
SALBUTAMOL;THRB;rs892940;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(BDR)
OPIOIDS;TACR1;rs735668;AA;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6, CYP2D6*7, CYP2D6*9, CYP2D6*10, CYP2D6*35, CYP2D6*41;*3 + *4 + *5 + *6 + *7 + *9 + *10 + *41;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
ASPIRIN, CLOPIDOGREL;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ASPIRIN, CLOPIDOGREL;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:THROMBOTIC_DISEASE
APIXABAN, DABIGATRAN, EDOXABAN, RIVAROXABAN;APOB;rs13306198;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*1/*3 + *1/*4 + *1/*5 + *41/*41 + *4/*4 + *4/*5 + *3/*4 + *3/*3 + *3/*5 + *4/*10 + *4/*41 + *5/*41 + *5/*5;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH,_RECURRENCE
ANTINEOPLASTIC AGENTS, TAMOXIFEN;CYP2D6;CYP2D6*1, CYP2D6*10;*10/*10;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
OPIOIDS;OPRM1;rs510769;CC;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE
FIRST-GENERATION CEPHALOSPORINS, FOURTH-GENERATION CEPHALOSPORINS, OTHER CEPHALOSPORINS, THIRD-GENERATION CEPHALOSPORINS;HLA-B;HLA-B*55:02;*55:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
AMOXICILLIN;HLA-B;HLA-B*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
"""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";SLC22A1;rs72552763;GAT/del;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEPATOTOXICITY
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7, NAT2*16;*16/*16 + *16/*6 + *16/*7 + *6/*6 + *7/*7;TOXICITY, LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
FIRST-GENERATION CEPHALOSPORINS, FOURTH-GENERATION CEPHALOSPORINS, OTHER CEPHALOSPORINS, THIRD-GENERATION CEPHALOSPORINS;HLA-C;HLA-C*01:02;*01:02;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
FIRST-GENERATION CEPHALOSPORINS, FOURTH-GENERATION CEPHALOSPORINS, OTHER CEPHALOSPORINS, THIRD-GENERATION CEPHALOSPORINS;HLA-DQB1;HLA-DQB1*06:09;*06:09;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
INFLIXIMAB;HLA-DQA1;HLA-DQA1*05;*05;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DISCONTINUATION
NICOTINE;CYP2A13;rs72552266;CT;TOXICITY;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*1;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
CYCLOPHOSPHAMIDE;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6;*1/*3 + *1/*6 + *3/*3 + *3/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:CYSTITIS
;UGT1A1;UGT1A1*28;*28;OTHER;INCREASED_LIKELIHOOD;OTHER:GILBERT_SYNDROME,_CRIGLER-NAJJAR_SYNDROME
DOXORUBICIN;GSTT1;GSTT1 non-null, GSTT1 null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS;HLA-DQB1;HLA-DQB1*03:01;*03:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BULLOUS_PEMPHIGOID
IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA,_NEUTROPENIA
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:GRAFT_VS_HOST_DISEASE
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*6;*1/*6 + *6/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:ACUTE_CELLULAR_REJECTION
SACITUZUMAB GOVITECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION,_DRUG_TOXICITY,_NEUTROPENIA,_DIARRHEA
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA,_FEBRILE_NEUTROPENIA,_LEUKOPENIA,
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*1/*28 + *28/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28 + *1/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28/*28 + *1/*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
SUNITINIB;KDR;rs1870377;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;UGT1A1;UGT1A1*6, UGT1A1*28;*28 + *6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*28;*28;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6;*6/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*28 + *28/*28 + *1/*6 + *6/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
MIRABEGRON;CYP2D6;CYP2D6;intermediate_metabolizer;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA,_HEADACHE,_INSOMNIA,_DRUG_TOXICITY
MIRABEGRON;SLCO1B1;SLCO1B1 deficiency;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA,_HEADACHE,_INSOMNIA,_DRUG_TOXICITY
TRAMADOL;CYP2D6;CYP2D6;ultrarapid_metabolizer;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:PAIN
METHOTREXATE;MTR;rs3768142;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS
CARBAMAZEPINE;HLA-B;HLA-B*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
CARBAMAZEPINE;HLA-B;HLA-B*15:01;*15:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME,_TOXIC_EPIDERMAL_NECROLYSIS
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
AZATHIOPRINE, MERCAPTOPURINE, PURINE ANALOGUES;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *3A/*3C;TOXICITY, LADME_PK;INCREASED_PK;PK:LEVELS_OF_ERYTHROCYTE_6-THIOGUANINE_NUCLEOTIDE_METABOLITES
CISPLATIN;GSTT1;GSTT1 non-null, GSTT1 null;non-null;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEARING_LOSS
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*16;*4;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_REACTIONS
MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C + *3A/*3A;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION
ASPIRIN, CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*8;*2 + *3 + *8;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:TRANSIENT_ISCHEMIC_ATTACK,_DEATH,_STROKE,_MYOCARDIAL_INFARCTION
TACROLIMUS;CYP3A4;rs4646437;AG + GG;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
DIHYDROPYRIDINE DERIVATIVES;RYR3;rs877087;TT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HEART_FAILURE,_MYOCARDIAL_INFARCTION,_ANGINA_PECTORIS,
;CYP4A11;rs1126742;AG + GG;LADME_PK;DECREASED_PK;PK:HDL-C_CONCENTRATION
CODEINE;CYP2D6;CYP2D6*1, CYP2D6*1x2, CYP2D6*2, CYP2D6*2x2, CYP2D6*2xN, CYP2D6*4, CYP2D6*9, CYP2D6*10, CYP2D6*41, CYP2D6*41x2;*1/*1x2  + *1/*2x2 + *1x2/*41 + *2/*2x2 + *2xN/*4 + *1/*1 + *1/*10 + *1/*2 + *1/*41 + *1/*41x2 + *1/*9 + *2/*2 + *2/*41 + *2/*9;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
TICAGRELOR;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3, CYP2C19*17;*1/*2 + *1/*3 + *2/*17 + *3/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
PEMETREXED;SLC19A1;rs914232;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*6 + *28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
FLUOROURACIL, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*28 + *28/*28 + *6/*6;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL, IRINOTECAN;DPYD;DPYD c.1627A>G (*5);c.1627A>G (*5);TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
CITALOPRAM;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3;LADME_PK;INCREASED_PK;PK:AUC_OF_THE_S-ENANTIOMER_OF_CITALOPRAM_(NO_EFFECT_ON_R-CT)
PEMETREXED;SLC19A1;rs1051298;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
RISPERIDONE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*4;*1/*1 + *1/*2;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEADACHE,_MUSCLE_SPASM,_SOMNOLENCE,_DIZZINESS
CETUXIMAB;FCGR2A;rs1801274;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
AMOXICILLIN, AMPICILLIN, BACAMPICILLIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
METHAMPHETAMINE;DRD3;rs6280;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:COGNITIVE_DISORDER
NICOTINE;CYP2A6;CYP2A6 low activity;;OTHER;DECREASED_RISK;DISEASE:LUNG_NEOPLASMS
VINCRISTINE;ACTN1;rs2268979;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
CAPECITABINE, FLUOROURACIL;UPB1;rs2070474;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MUCOSITIS
PEMETREXED;MTHFR;rs1801133;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CAPECITABINE, FLUOROURACIL, FOLFIRI, FOLFIRINOX, FOLFOX;DPYD;DPYD c.2194G>A (*6);c.2194G>A (*6);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA,_DIARRHEA,_STOMATITIS,_LEUKOPENIA
VINCRISTINE;PAPPA;rs12235805;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
CAPECITABINE, FLUOROURACIL;UPB1;rs2070474;GG;TOXICITY;DECREASED_SEVERITY;DISEASE:DIARRHEA
CAPECITABINE, FLUOROURACIL;DPYD;rs1801265;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
PEMETREXED;SLC19A1;rs3788189;GG + GT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
NICOTINE;ANKK1, DRD2;rs1800497;AA + AG;TOXICITY;DECREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
CAPECITABINE, FLUOROURACIL, FOLFOX;DPYD;DPYD c.1129-5923C>G, c.1236G>A (HapB3), DPYD c.1679T>G (*13), DPYD c.2846A>T;c.2846A>T + c.1129-5923C>G, c.1236G>A (HapB3) + c.1679T>G (*13);TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEATH
AMITRIPTYLINE, ANTIDEPRESSANTS, CLOMIPRAMINE, DESIPRAMINE, FLUOXETINE, IMIPRAMINE, NORTRIPTYLINE, PAROXETINE, VENLAFAXINE;CYP2D6;CYP2D6*3, CYP2D6*4, CYP2D6*5, CYP2D6*6;*3 + *4 + *5 + *6;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
SIROLIMUS;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_;SIDE_EFFECT:TOTAL_CHOLESTEROL
FOLFIRI, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *1/*28 + *1/*6 + *6/*28;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
FOLFIRI;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*1/*1;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA,_DIARRHEA
ATOMOXETINE;CYP2D6;CYP2D6;poor_metabolizer;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
VINCRISTINE;NRG3;rs12253008;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*6, UGT1A1*28;*28/*28 + *6/*6 + *6/*28;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*1/*3A + *1/*3B + *1/*3C + *3A/*3B;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA,_MYELOSUPPRESSION
MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT;intermediate_metabolizer;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
VINCRISTINE;LRRTM3;rs10997459;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
AZATHIOPRINE;TPMT;TPMT*1, TPMT*3A, TPMT*3C;*1/*3A + *1/*3C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
VINCRISTINE;ARHGAP5;rs8006511;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
MERCAPTOPURINE, METHOTREXATE;TPMT;TPMT normal metabolizer;;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
NICOTINE;CYP2A6;rs28399433;CC;TOXICITY;DECREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
VINCRISTINE;METTL8;rs79802223;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DEATH,_STROKE,_HEART_FAILURE,_MYOCARDIAL_INFARCTION
;UGT1A1;rs4148325;CT;LADME_PK;DECREASED_LIKELIHOOD;OTHER:NEONATAL_HYPERBILIRUBINEMIA
;UGT1A1;rs11888492;G;LADME_PK;DECREASED_LIKELIHOOD;OTHER:NEONATAL_HYPERBILIRUBINEMIA
NALOXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:CORTISOL_RESPONSE
CISPLATIN;CERS6;rs13022792;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY
CISPLATIN;TLR4;rs10759932;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY
VINCRISTINE;NFIB;rs10961381;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
ANTIARRHYTHMICS, CLASS I AND III;;rs10033464;GT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:RECURRENCE
VINCRISTINE;MCM3AP;rs1815857;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
VINCRISTINE;SPDYA;rs12474420;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
VINCRISTINE;PDE4D;rs12658429;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
VINCRISTINE;FBN2;rs12656510;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
VINCRISTINE;VTI1A;rs17129858;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
VINCRISTINE;ZFAND3;rs200858088;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;HLA-DRB1;HLA-DRB1*11:01;*11:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANAPHYLAXIS
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2;*2;TOXICITY;INCREASED_RISKEFFICACY;EFFICACY:PERIPHERAL_VASCULAR_DISEASES
MYCOPHENOLATE MOFETIL, PREDNISONE, TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*1 + *1/*3;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:VIRUS_DISEASES
SIROLIMUS;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_;SIDE_EFFECT:LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL
ACETAMINOPHEN / CODEINE;CYP2D6;CYP2D6;poor_metabolizer;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:CONSTIPATION
RASBURICASE;G6PD;G6PD deficiency;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMOLYTIC_ANEMIA
NEVIRAPINE;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
EFAVIRENZ;CYP2B6;CYP2B6*1, CYP2B6*6;*1/*6 + *6/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
SIROLIMUS;ABCB1;rs1128503;AA;TOXICITY;INCREASED_;SIDE_EFFECT:TRIGLYCERIDES
CLOPIDOGREL;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*1/*2 + *1/*3 + *2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ATRIAL_FIBRILLATION
RISPERIDONE;CYP2D6;CYP2D6;poor_metabolizer;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ISONIAZID;NAT2;NAT2*5, NAT2*6, NAT2*7;*5/*7 + *5/*6 + *6/*6;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*1/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DECREASED_GLOMERULAR_FILTRATION_RATE
ADALIMUMAB, AMIODARONE, BEVACIZUMAB, BICALUTAMIDE, CARBOPLATIN, CYCLOPHOSPHAMIDE, DOCETAXEL, ERLOTINIB, EVEROLIMUS, FLUOROURACIL, GEFITINIB, GEMCITABINE, IRINOTECAN, LEUCOVORIN, METHOTREXATE, OXALIPLATIN, PACLITAXEL, PEMBROLIZUMAB, SITAGLIPTIN, TEGAFUR / GIMERACIL / OTERACIL, TRASTUZUMAB;HLA-DRB1;HLA-DRB1*04:05;*04:05;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
TAMSULOSIN;CYP2D6;CYP2D6;intermediate_metabolizer;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:INTERSTITIAL_LUNG_DISEASES
ANASTROZOLE, EXEMESTANE, LETROZOLE;CCDC148;rs79048288;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN
ALLOPURINOL;HLA-B;HLA-B*58:01;*58:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME,_ERYTHEMA_MULTIFORME
PEMETREXED;DHFR;rs1650697;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3, CYP3A5*6, CYP3A5*7;*3/*3 + *3/*6 + *3/*7 + *6/*6 + *6/*7 + *7/*7;EFFICACY;EFFICACY;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE
TACROLIMUS;CYP2C8;CYP2C8*1, CYP2C8*3;*1/*1;EFFICACY;EFFICACY;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE
FLUOROURACIL, FOLFIRI, FOLFOX;DPYD;DPYD c.85T>C (*9A);c.85T>C (*9A)/c.85T>C (*9A);TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA,_LEUKOPENIA,_THROMBOCYTOPENIA,
LACOSAMIDE;CYP2C19;CYP2C19*1, CYP2C19*2, CYP2C19*3;*2/*2 + *2/*3 + *3/*3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE,_DIZZINESS,_DRUG_TOXICITY,
FLUOROURACIL, FOLFIRI, FOLFOX;DPYD;DPYD c.1627A>G (*5);c.1627A>G (*5)/c.1627A>G (*5);TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA,_LEUKOPENIA,_THROMBOCYTOPENIA,
CARBAMAZEPINE;HLA-A;HLA-A*31:01;*31:01;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ASPIRIN;PTGS2;rs12042763;GG;EFFICACY;DECREASED_RISK;DISEASE:PROSTATIC_NEOPLASMS
METHOTREXATE;SLCO1B1;SLCO1B1*1, SLCO1B1*15, SLCO1B1*37;*37/*37 + *37/*15;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
;CYP2A6;rs56267346;G;OTHER;DECREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
;DBH;rs6479643;C;OTHER;DECREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*6, NAT2*7, NAT2*16;*16 + *6 + *7;TOXICITY, LADME_PK;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;NAT2*4, NAT2*6, NAT2*7, NAT2*16;*16 + *6 + *7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ISONIAZID;NAT2;NAT2*1, NAT2*4, NAT2*5, NAT2*6, NAT2*7, NAT2*14, NAT2*16;*16 + *5 + *6 + *7 + *14;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
FLURBIPROFEN, IRINOTECAN;UGT1A1;UGT1A1*1, UGT1A1*36;*1/*36;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ISONIAZID, RIFAMPIN;NAT2;NAT2*1, NAT2*5, NAT2*6, NAT2*7, NAT2*14;*5/*5 + *5/*6 + *5/*7 + *6/*6 + *6/*7 + *6/*14 + *7/*7;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TACROLIMUS;CYP3A5;CYP3A5*1, CYP3A5*3;*3/*3;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:GRAFT_VS_HOST_DISEASE
IRINOTECAN;UGT1A1;rs4148323;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
;CASP9;rs1052576;T;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:LEUKOCYTOSIS
CAPECITABINE, FLUOROURACIL;DPYD;rs1801265;AA + AG;TOXICITY;DECREASED_;SIDE_EFFECT:DRUG_TOXICITY
IRINOTECAN;UGT1A1;rs4148323;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
CYCLOSPORINE, METHOTREXATE;SLC19A1;rs1051266;CC;EFFICACY;DECREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
CYCLOSPORINE, METHOTREXATE;ATIC;rs17514110;CC;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
CYCLOSPORINE, METHOTREXATE;NFATC2;rs3787186;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
CYCLOSPORINE, METHOTREXATE;ABCC2;rs3740065;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
CETUXIMAB;FCGR3A;rs396991;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:ANTIBODY-DEPENDENT_CELLULAR_CYTOTOXICITY
CYCLOSPORINE, METHOTREXATE;ABCC1;rs8058040;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;HLA-A*24:02;*24:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;HLA-B*15:02;*15:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME,_TOXIC_EPIDERMAL_NECROLYSIS
ATAZANAVIR, EFAVIRENZ;TPH2;rs7305115;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DEPRESSION
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;HLA-A*01:02;*01:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;HLA-B*52:01;*52:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-DRB1;HLA-DRB1*03:01;*03:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS
ATAZANAVIR, EFAVIRENZ;TPH2;rs1386493;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DEPRESSION
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-DRB1;HLA-DRB1*13:01;*13:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
CAPECITABINE;ENOSF1;rs2612091;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-B;HLA-B*40:02;*40:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS
CARBAMAZEPINE, LAMOTRIGINE, PHENYTOIN;HLA-A;HLA-A*31:03;*31:03;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME
CARBOPLATIN, PACLITAXEL;OPRM1;rs544093;GG + GT;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
MYCOPHENOLATE MOFETIL;IMPDH1;rs2228075;T;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GI_INTOLERANCE
CAPECITABINE, FLUOROURACIL;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY,_NEUTROPENIA
ISONIAZID;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ERLOTINIB, GEFITINIB;USP36;rs3744797;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
OSIMERTINIB;HLA-B;HLA-B*51:02;*51:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME,_TOXIC_EPIDERMAL_NECROLYSIS
DEXMEDETOMIDINE;CACNB2;rs10764319;CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA,_HYPOTENSIVE_DISORDER
DEXMEDETOMIDINE;CACNA2D2;rs2236957;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA,_HYPOTENSIVE_DISORDER
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;NAT2;slow_acetylator;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DEXMEDETOMIDINE;UGT2B10;rs1841042;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA,_HYPOTENSIVE_DISORDER
DEXMEDETOMIDINE;ADRA2B;rs3813662;AA + CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA,_HYPOTENSIVE_DISORDER
METHYLPHENIDATE;CES1;rs2307227;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
PURINE ANALOGUES;NUDT15;NUDT15*1, NUDT15*3;*1/*3;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
CLOPIDOGREL;THSD7A;rs7807369;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CLOPIDOGREL;;rs1149515;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY,_MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
ONDANSETRON;CYP2D6;CYP2D6 normal metabolizer;;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:POSTOPERATIVE_NAUSEA_AND_VOMITING
;ERAP2;rs17524572;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
MYCOPHENOLATE MOFETIL;UGT1A8;rs1042597;CC;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
PEMBROLIZUMAB;HLA-DRB1;HLA-DRB1*13:01;*13:01;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PEMBROLIZUMAB;HLA-DPB1;HLA-DPB1*02:02;*02:02;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS
CAPECITABINE, FLUOROURACIL;DPYD;rs1801158;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
MORPHINE;SLC22A1;rs72552763;del/del;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPOVENTILATION
DRUGS FOR TREATMENT OF TUBERCULOSIS;GSTM1;GSTM1 non-null, GSTM1 null;;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
;CASP9;rs4661636;C;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:LEUKOCYTOSIS
;CASP8;rs6736233;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
CLOZAPINE;LEPR;rs6657868;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PNEUMONIA
CLOZAPINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED_RISK;DISEASE:SEIZURES
CISPLATIN, PACLITAXEL;GGT1;rs2017869;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA,_LEUKOPENIA
CISPLATIN;TPMT;rs12201199;T;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
;UGT1A1;rs4148323;A;OTHER;INCREASED_LIKELIHOOD;OTHER:GILBERT_SYNDROME,_CRIGLER-NAJJAR_SYNDROME
CLOZAPINE;LEPR, LEPROT;rs1137101;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PNEUMONIA
DOLUTEGRAVIR;NR1I2;rs2472677;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION,_ADVERSE_EVENTS
CISPLATIN;TPMT;rs1800460;T;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
CLOZAPINE;LEPR;rs1805096;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PNEUMONIA
CLOZAPINE;LEPR;rs9436746;AC + CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PNEUMONIA
RISPERIDONE;DRD2;rs1800497;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
;UGT1A1;rs35350960;A;OTHER;INCREASED_LIKELIHOOD;OTHER:GILBERT_SYNDROME,_CRIGLER-NAJJAR_SYNDROME
CISPLATIN;TPMT;rs1142345;C;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
WARFARIN;ASPH;rs4379440;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_IN_THERAPEUTIC_RANGE
CARBOPLATIN, PACLITAXEL;SLCO1B3;rs7311358;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ASPIRIN, CLOPIDOGREL, TICAGRELOR;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_;SIDE_EFFECT:DRUG_TOXICITY
METHOTREXATE;MTHFR;rs1801131;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_DISTURBANCES_IN_HCV-HIV_COINFECTED_PATIENTS
HMG COA REDUCTASE INHIBITORS;CETP;rs3764261;A;EFFICACY, LADME_PK;INCREASED_;OTHER:HDL_CHOLESTEROL
PYRIMIDINE ANALOGUES;MTHFR;rs1801133;AA + AC;;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
METHOTREXATE;ITPA;rs1127354;A;TOXICITY;;SIDE_EFFECT:GASTROINTESTINAL_TOXICITIES
GEFITINIB;ABCB1;rs1128503;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;CTLA4;rs231775;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)_IN_HCV-HIV_COINFECTED_PATIENTS
CAFFEINE;;rs4410790;T;OTHER;;OTHER:HABITUAL_CONSUMPTION
LIRAGLUTIDE;GLP1R;rs6923761;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:WEIGHT_LOSS
METHAMPHETAMINE;ESR1;rs2234693;CC;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER
;ABCG8;rs11887534;CG;OTHER;INCREASED_RISK;DISEASE:CORONARY_ARTERY_DISEASE
PLATINUM;ERCC5;rs17655;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:SURVIVAL
PLATINUM;ERCC5;rs17655;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
RISPERIDONE;HTR2C;rs3813929;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
PACLITAXEL;FGD4;rs10771973;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SENSORY_PERIPHERAL_NEUROPATHY
CAFFEINE;CYP1A1;rs2470893;T;OTHER;;OTHER:HABITUAL_CONSUMPTION
CITALOPRAM;SLC6A4;rs25531;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SIDE_EFFECTS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;SOCS3;rs4969170;AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA_IN_HCV-HIV_COINFECTED_PATIENTS
MIDAZOLAM;POR;rs1057868;TT;OTHER, LADME_PK;INCREASED_PK;PK:METABOLIC_RATIO_OF_MIDAZOLAM
ENALAPRIL;PNPT1;rs13009649;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
METHOTREXATE;ITPA;rs1127354;A;EFFICACY;EFFICACY;EFFICACY:RESPONSE_TO_METHOTREXATE
NICOTINE;HTR3B;rs11606194;CT + TT;TOXICITY;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
ASPIRIN;SLC6A12;rs499368;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ASTHMA
GEFITINIB;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
WARFARIN;CYP4F2;rs2189784;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
ASPIRIN;SLC6A12;rs557881;G;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ASTHMA
PLATINUM COMPOUNDS;WIF1;rs10878232;GG + GT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ANTIEPILEPTICS;ABCB1;rs1045642;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:NON-RESPONSE
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;rs1056892;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
PLATINUM COMPOUNDS;WNT5B;rs12819505;AG + GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PLATINUM COMPOUNDS;AXIN2;rs4541111;AA + AC;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
MERCAPTOPURINE, METHOTREXATE;PACSIN2;rs2413739;T;TOXICITY;INCREASED_;SIDE_EFFECT:GI_TOXICITY
MERCAPTOPURINE;SLCO1B1;rs11045879;T;TOXICITY;INCREASED_;SIDE_EFFECT:GI_TOXICITY
MERCAPTOPURINE, METHOTREXATE;ITPA;rs1127354;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
PLATINUM COMPOUNDS;CXXC4;rs4413407;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ENALAPRIL;PNPT1;rs13015243;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
AZATHIOPRINE, MERCAPTOPURINE, THIOGUANINE;;rs11969064;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;T;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(SVR_AND_RVR)_IN_HCV-HIV_COINFECTED_PATIENTS
PLATINUM COMPOUNDS;ERCC2;rs13181;GG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PNEUMONITIS
PLATINUM COMPOUNDS;ERCC2;rs1799793;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PNEUMONITIS
DOXORUBICIN;NCF4;rs1883112;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
AMPHETAMINE;DRD2;rs12364283;AA;EFFICACY;DECREASED_;OTHER:STOP_REACTION_TIME
ANTIEPILEPTICS;ABCB1;rs1045642;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DRUG-RESISTANCE
ANTIEPILEPTICS;ABCB1;rs1045642;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DRUG-RESISTANCE
PAROXETINE;HTR2A;rs6313;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DISCONTINUATIONS_DUE_TO_ADVERSE_EVENTS_AND_GREATER_SEVERITY_OF_SIDE_EFFECTS
CLOPIDOGREL;CD80;rs34394661;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
MYCOPHENOLATE MOFETIL;UGT1A9;rs6714486;A;LADME_PK;PK;PK:CHANGES_IN_MYCOPHENOLIC_ACID_EXPOSURE-RELATED_PARAMETERS_ON_DAY_7_AFTER_TRANSPLANTATION_(TREATMENT_WITH_2G_PER_DAY)
CARBAMAZEPINE;;rs1633021;TT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PLATINUM COMPOUNDS;AXIN2;rs11868547;CC + CG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
MYCOPHENOLATE MOFETIL;UGT1A9;rs17868320;T;LADME_PK;PK;PK:CHANGES_IN_MYCOPHENOLIC_ACID_EXPOSURE-RELATED_PARAMETERS_ON_DAY_7_AFTER_TRANSPLANTATION_(TREATMENT_WITH_2G_PER_DAY)
MORPHINE;ABCB1;rs1045642;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA,_VOMITING
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;UGT1A8;rs1042597;CC;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
TACROLIMUS;IL10;rs1800871;AA;LADME_PK;INCREASED_LIKELIHOODPK;PK:ACHIEVING_TARGET_CONCENTRATIONS
METHOTREXATE;ARID5B;rs4948496;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
;CYP2B6;rs3760657;AA;OTHER;DECREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
FOLLITROPIN BETA, THYROTROPIN ALFA, UROFOLLITROPIN;FSHR;rs6166;T;EFFICACY, LADME_PK;EFFICACY;EFFICACY:GOOD_RESPONSE_TO_CONTROLLED_OVARIAN_HYPERSTIMULATION
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY, OTHER;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
;UGT2B10;rs11726322;CC;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM
ASPIRIN, CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;EFFICACY, OTHER;DECREASED_RISK;DISEASE:THROMBOTIC_DISEASE
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;rs1799963;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM
CLOPIDOGREL;ABCB1;rs1045642;AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
CAPECITABINE, FLUOROURACIL;TYMP;rs11479;AA + AG;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
WARFARIN;CYP4F2;rs2108622;CT + TT;LADME_PK;INCREASED_PK;PK:PLASMA_MK-4_CONCENTRATION
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CAPECITABINE, FLUOROURACIL;DPYD;rs75017182;CG;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
ALENDRONATE;VDR;rs1544410;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:BONE_MINERAL_DENSITY
FENOFIBRATE;PPARA;rs135543;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_FASTING_LDL-C
FENOFIBRATE;PPARA;rs9626730;CC + CT;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_FASTING_IL-2
WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;DECREASED_;OTHER:WARFARIN_SENSITIVITY_INDEX_(INR/CPSS)
;VDR;rs1544410;CC;;DECREASED_EFFICACY;EFFICACY:BONE_MINERAL_DENSITY
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK;OTHER:MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK;DISEASE:DEATH
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
FENOFIBRATE;PPARA;rs135550;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_FASTING_LDL-C
ALENDRONATE;VDR;rs1544410;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:URINARY_DPD/CR_LEVELS
EXEMESTANE;CYP19A1;rs7176005;TT;TOXICITY;;SIDE_EFFECT:A_SIGNIFICANTLY_HIGHER_ODDS_OF_VASOMOTOR_SYMPTOMS_IN_POSTMENOPAUSAL_HORMONE_RECEPTOR_(HR)-POSITIVE_BREAST_CANCER_PATIENTS
TACROLIMUS;PPARA;rs4253728;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ACUTE_CELLULAR_REJECTION
VINCRISTINE;SLC5A7;rs1013940;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ETHANOL;ADH1B;rs1229984;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERURICEMIA
VINCRISTINE;NKAIN3;rs10504361;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
SIMVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULAR_DISEASES
ATENOLOL;PROX1;rs340874;C;TOXICITY;INCREASED_;SIDE_EFFECT:GLUCOSE_ELEVATION
TACROLIMUS;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEPSIS,_SEIZURES,_NEPHROTOXICITY,
ABEMACICLIB, PALBOCICLIB, RIBOCICLIB;ABCB1;rs1128503;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
SIMVASTATIN;ABCG2;rs2231142;GT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
VINCRISTINE;ABCC1;rs3784867;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:SIGNIFICANTLY_HIGHER_ON-TREATMENT_PLATELET_REACTIVITY_WITH_A_MAINTENANCE_DOSE_OF_75_MG_DAILY
OPIOIDS;COMT;rs4680;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE,_NAUSEA,_ADVERSE_EVENTS,
OPIOIDS;IL6;rs1800795;CG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE,_NAUSEA,_ADVERSE_EVENTS,
FLUOROURACIL;DPYD;rs67376798;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
SUNITINIB;CYP3A5;rs776746;CT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ABEMACICLIB, PALBOCICLIB, RIBOCICLIB;CYP3A4;rs35599367;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY,_TREATMENT_INTERRUPTION
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
METOPROLOL;CYP2D6;rs1065852;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:HEART_RATE
CONJUGATED ESTROGENS, MEDROXYPROGESTERONE;VDR;rs1544410;TT;EFFICACY;INCREASED_;OTHER:SPINE_BONE_MINERAL_DENSITY
VERAPAMIL;CACNB2;rs2357928;GG;EFFICACY, TOXICITY;INCREASED_RISKEFFICACY;EFFICACY:ADVERSE_OUTCOME
METFORMIN;SLC47A1;rs2252281;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_TO_METFORMIN
TACROLIMUS;CYP3A5;rs4646450;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
METFORMIN;SLC47A1;rs2252281;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_TO_METFORMIN
TRAZODONE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PROLONGED_QTC_INTERVAL
INTERFERONS, RIBAVIRIN;BCL2;rs1800477;T;EFFICACY;INCREASED_EFFICACY;EFFICACY:FREQUENCY_(ABOUT_DOUBLE)_IN_NON-RESPONDER_PATIENTS_COMPARED_WITH_RESPONDER_PATIENTS_(HCV_GENOTYPE_4)
CETUXIMAB, FLUOROURACIL, IRINOTECAN, OXALIPLATIN;KRAS;rs112445441;T;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MSH6;rs3136228;GG;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC3;rs1799794;CC;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
;NR1I2;rs7643645;GG;OTHER;INCREASED_RISK;OTHER:DEATH
PLATINUM COMPOUNDS;CCND1;rs9344;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NAUSEA,_VOMITING
VERAPAMIL;CACNB2;rs11014166;AT + TT;EFFICACY, TOXICITY;INCREASED_RISKEFFICACY;EFFICACY:ADVERSE_OUTCOME
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC1;rs2074087;C;TOXICITY;DECREASED_SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES
FLUOROURACIL;;rs2960436;AA;EFFICACY;;OTHER:BETTER_SURVIVAL_OUTCOME
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;rs1885301;AA;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES
FLUOROURACIL;IGFBP3;rs2854744;TT;EFFICACY;;OTHER:BETTER_SURVIVAL_OUTCOME
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;rs717620;TT;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;rs3740066;TT;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES
COCAINE;DRD2;rs1125394;C;TOXICITY;INCREASED_RISK;DISEASE:COCAINE_DEPENDENCE
COCAINE;DRD2;rs1076560;A;TOXICITY;INCREASED_RISK;DISEASE:COCAINE_DEPENDENCE
COCAINE;DRD2;rs2283265;A;TOXICITY;INCREASED_RISK;DISEASE:COCAINE_DEPENDENCE
MYCOPHENOLATE MOFETIL;SLCO1B1;rs4149015;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTIONS
TACROLIMUS;CYP3A5;rs4646453;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
TACROLIMUS;CYP3A5;rs776746;CC;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TRANSPLANT_REJECTION
MYCOPHENOLATE MOFETIL;SLCO1B1;rs4149056;TT;TOXICITY, LADME_PK;INCREASED_RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTION
OPIOIDS;COMT;rs4633;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
MYCOPHENOLATE MOFETIL;SLCO1B1;rs4149056;C;TOXICITY, LADME_PK;DECREASED_RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTIONS
ACETAMINOPHEN / TRAMADOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CONSTIPATION
;VDR;rs2228570;AA + AG;;DECREASED_EFFICACY;EFFICACY:BONE_MINERAL_DENSITY
OPIOIDS;COMT;rs4633;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIZZINESS
CAPECITABINE;ABCB1;rs1128503;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME,_NEUTROPENIA
OPIOIDS;OPRM1;rs1799971;G;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:OPIOID-RELATED_DISORDERS
CAPECITABINE;ABCB1;rs2032582;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
OPIOIDS;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ERECTILE_DYSFUNCTION,_INSOMNIA,_SEDATION,_PHYSIOLOGICAL_SEXUAL_DISORDER
FLUOROURACIL;ABCB1;rs1045642;GG;TOXICITY;DECREASED_RISK;DISEASE:DIARRHEA
CAPECITABINE;ABCB1;rs1045642;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
WARFARIN;CYP2C9;rs7900194;A;DOSAGE, LADME_PK;;OTHER:WARFARIN_VARIABILITY
SUNITINIB;NR1I2;rs3814055;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
AMPHETAMINE;OPRM1;rs510769;TT;OTHER;DECREASED_;OTHER:STIMULATION_AND_EUPHORIA_SCORES_AFTER_AMPHETAMINE
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;DISEASE:MUSCULAR_DISEASES
SUNITINIB;ABCG2;rs2231137;CT;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
;LRP5;rs3736228;T;;DECREASED_;OTHER:BONE_MINERAL_DENSITY
CISPLATIN;NHLH1;rs11265375;CT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
;;rs4355801;A;;DECREASED_;OTHER:LUMBAR_SPINE_BONE_MINERAL_DENSITY
;;rs4355801;A;;INCREASED_RISK;DISEASE:OSTEOPOROSIS
;LRP5;rs3736228;T;;INCREASED_RISK;DISEASE:OSTEOPOROSIS
BORTEZOMIB;CBS;rs915854;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES,_PAIN,_NEUROPATHIC_PAIN,
;UGT2B15;rs3100;AA;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
AMPHETAMINE;OPRM1;rs2281617;CC;OTHER;INCREASED_;OTHER:EUPHORIC_AND_ENERGETIC_AFTER_AMPHETAMINE_(10_MG)
WARFARIN;HNF4A;rs6130615;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CISPLATIN;SEMA6A;rs3806915;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ASPIRIN, CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY, OTHER;INCREASED_RISK;DISEASE:THROMBOTIC_DISEASE
WARFARIN;HNF4A;rs1884613;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ASPIRIN, CLOPIDOGREL;ITGB3;rs5918;CC + CT;EFFICACY, OTHER;DECREASED_RISK;DISEASE:THROMBOTIC_DISEASE
WARFARIN;HNF4A;rs3212191;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
ONDANSETRON;SLC6A4;rs1042173;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:TREATMENT_RESPONSE_AMONG_PATIENTS_CARRYING_THE_SLC6A4_PROMOTER_LENGTH_POLYMORPHISM_LONG/LONG_GENOTYPE
WARFARIN;;rs61162043;G;OTHER;INCREASED_LIKELIHOOD;OTHER:HAVING_WARFARIN_DOSE_GREATER_THAN_7.5_MG/DAY
RISPERIDONE;HTR2A;rs6313;GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
HEROIN;OPRM1;rs2075572;G;TOXICITY;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
RISPERIDONE;;rs1805054;TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
ANTIHYPERTENSIVES;NEDD4L;rs4149601;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESISTANT_HYPERTENSION
ANTIHYPERTENSIVES;ADRB1;rs1801252;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESISTANT_HYPERTENSION
FLUOROURACIL;MTHFR;rs1801133;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
RISPERIDONE;HTR2C;rs3813929;CT + TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
HEROIN;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
BLEOMYCIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE, VINDESINE;ABCB1;rs2229109;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA,_VOMITING
CYCLOPHOSPHAMIDE;CYP2B6;rs4802101;C;TOXICITY;DECREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY,_LEUKOPENIA
ANTIHYPERTENSIVES;CYP3A5, ZSCAN25;rs776746;CC;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:RESISTANT_HYPERTENSION
CISPLATIN;XPC;rs2228001;GG + GT;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
METHADONE;OPRM1;rs1799971;G;OTHER;DECREASED_LIKELIHOOD;DISEASE:RECURRENCE
;CYP2C9;rs1057910;C;;DECREASED_RISK;DISEASE:CORONARY_ARTERY_DISEASE
;CYP2C9;rs1057910;C;;INCREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
SUFENTANIL;CYP3A4;rs2242480;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPOVENTILATION
;ADRA2A;rs3750625;A;OTHER;INCREASED_LIKELIHOOD;DISEASE:DIABETES,_GESTATIONAL
;ADRA2A;rs11195418;G;OTHER;DECREASED_LIKELIHOOD;DISEASE:DIABETES,_GESTATIONAL
MURAGLITAZAR;REN;rs2368564;TT;TOXICITY;DECREASED_RISK;DISEASE:EDEMA
CHLOROQUINE, PRIMAQUINE;SLCO2B1;rs12422149;GG;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PARASITEMIA
ASPIRIN;IL4;rs2243250;TT;OTHER;DECREASED_;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ANTIPSYCHOTICS;CNR1;rs806374;CC;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TARDIVE_DYSKINESIA
WARFARIN;CYP2C9;rs1057910;AC + CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
METHOTREXATE;SLC16A7;rs3763980;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_TO_METHOTREXATE
METFORMIN;AMHR2;rs784892;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:POST-HBA1C_LEVELS
ACETAMINOPHEN, ASPIRIN, DICLOFENAC, PROPIONIC ACID DERIVATIVES, PYRAZOLONES;PLA2G4A;rs12746200;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:URTICARIA
ANTIPSYCHOTICS;CNR1;rs806374;CC;TOXICITY;INCREASED_SEVERITY;DISEASE:TARDIVE_DYSKINESIA
WARFARIN;VKORC1;rs9923231;TT;EFFICACY;EFFICACY;EFFICACY:SHORTER_TIME_TO_FIRST_THERAPEUTIC_INR_AND_TIME_TO_FIRST_INR>4
FLUOROURACIL;DPYD;rs75017182;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
ETHANOL;OPRM1;rs1799971;AA;TOXICITY;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
NEVIRAPINE;CYCSP5;rs3099844;A;TOXICITY, OTHER;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
ACETAMINOPHEN, ASPIRIN, DICLOFENAC, PROPIONIC ACID DERIVATIVES, PYRAZOLONES;PLCG1;rs2228246;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
ACETAMINOPHEN, ASPIRIN, DICLOFENAC, PROPIONIC ACID DERIVATIVES, PYRAZOLONES;TNFRSF11A;rs1805034;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA,_URTICARIA
ANTIHYPERTENSIVES;NOS3;rs1799983;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE
ANTIHYPERTENSIVES;NOS3;rs2070744;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE
METHOTREXATE;ABCB1;rs1045642;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
;ADRA2A;rs1800038;A;OTHER;INCREASED_LIKELIHOOD;DISEASE:DIABETES,_GESTATIONAL
TACROLIMUS;CYP3A5;rs776746;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
CISPLATIN;SLC22A1;rs683369;CG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NICOTINE;;rs4887074;G;TOXICITY;DECREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCC5;rs10937158;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCC5;rs3749438;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCG1;rs225440;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CLOPIDOGREL;PON1;rs854552;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;;rs2292997;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CISPLATIN;PPARD;rs2038067;AG + GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
TACROLIMUS;CYP3A5;rs6977165;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY,_LEUKOPENIA
WARFARIN;VKORC1;rs9923231;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
WARFARIN;VKORC1;rs9923231;T;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROPERTION_OF_THE_FIRST_6_MONTHS'_TREATMENT_TIME_SPENT_WITHIN_THE_TARGET_INR_RANGE_(PTIR)
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_SEVERITY;DISEASE:MYELOSUPPRESSION
;OPRM1;rs1799971;AA;TOXICITY;INCREASED_SEVERITY;DISEASE:SUBSTANCE-RELATED_DISORDERS
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_SEVERITY;DISEASE:HAND-FOOT_SYNDROME
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA
FLUOROURACIL;DPYD;rs17376848;G;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
OPIOIDS;CYP3A5;rs776746;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
ACETAMINOPHEN / TRAMADOL;MIR107;rs2296616;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
LITHIUM;GSK3B;rs334558;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESPONSE
CYCLOPHOSPHAMIDE, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, METHOTREXATE;NQO1;rs1800566;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA,_DRUG_TOXICITY
ACETAMINOPHEN / TRAMADOL;MIR23B;rs1011784;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
ACETAMINOPHEN / TRAMADOL;MIR23B;rs1011784;CG + GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:NEUROPATHIC_PAIN
OPIOIDS;CYP1A2;rs2069514;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
OPIOIDS;DRD3;rs2654754;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
OPIOIDS;DRD3;rs324029;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
METHAMPHETAMINE;FAAH;rs324420;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:METHAMPHETAMINE_DEPENDENCE
OPIOIDS;CYP3A4;rs2740574;CC + CT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
RISPERIDONE;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
ASPIRIN;UGT1A6;rs1105879;AC + CC;EFFICACY;INCREASED_RISK;DISEASE:COLONIC_NEOPLASMS
ACETAMINOPHEN / TRAMADOL;OPRM1;rs677830;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CONSTIPATION
OPIOIDS;CYP3A5;rs15524;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
REGORAFENIB;KDR;rs4864950;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
EFAVIRENZ, ETHAMBUTOL, ISONIAZID, RIFAMPIN;NR1I2;rs2472677;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DEATH
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE
EFAVIRENZ, ETHAMBUTOL, ISONIAZID, RIFAMPIN;NR1I2;rs2472677;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CYCLOPHOSPHAMIDE, DOXORUBICIN;ABCB1;rs2032582;AA + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
TAXANES;NR1I3;rs11584174;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ATAZANAVIR, RITONAVIR;UGT1A1;rs8330;G;OTHER;INCREASED_RISK;SIDE_EFFECT:NEPHROLITHIASIS
CYCLOPHOSPHAMIDE, DOXORUBICIN;ABCB1;rs2032582;AC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EFAVIRENZ;CYP2B6;rs28399499;TT;TOXICITY;INCREASED_RISK;DISEASE:CENTRAL_NERVOUS_SYSTEM_DISORDER
NEVIRAPINE;ABCB1;rs10276036;TT;TOXICITY;INCREASED_RISK;DISEASE:DRUG_HYPERSENSITIVITY
TAXANES;UGT2B7;rs7438284;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ATAZANAVIR, RITONAVIR;UGT1A1;rs10929303;T;OTHER;INCREASED_RISK;SIDE_EFFECT:NEPHROLITHIASIS
TAXANES;UGT2B7;rs7439366;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ATAZANAVIR, RITONAVIR;UGT1A1;rs1042640;G;OTHER;INCREASED_RISK;SIDE_EFFECT:NEPHROLITHIASIS
TAXANES;UGT2B7;rs7662029;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
TAXANES;UGT2B7;rs7668258;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;INCREASED_RISK;DISEASE:CENTRAL_NERVOUS_SYSTEM_DISORDER
ANTIPSYCHOTICS;GRM3;rs1468412;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MEMORY_IMPAIRMENT
ASPIRIN, CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:NON-RESPONSIVENESS
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
RISPERIDONE;BDNF;rs6265;TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
CORTICOSTEROIDS;FCER2;rs28364072;G;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ASTHMA-RELATED_ER_VISIT_OR_HOSPITALIZATION
FLUOROURACIL, RADIOTHERAPY;CXCL8;rs4073;AA;EFFICACY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
METHOTREXATE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
FLUOROURACIL, RADIOTHERAPY;KDR;rs1870377;AA;TOXICITY;RISK_;SIDE_EFFECT:MUCOSITIS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IL6;rs1800795;CC;TOXICITY;DECREASED_RISK;DISEASE:DEPRESSION
ATORVASTATIN;CYP7A1;rs3808607;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_PERCENTAGE_REDUCTION_OF_TRIGLYCERIDES_LEVEL
CANGRELOR;P2RY12;rs6787801;G;OTHER;;OTHER:5%_LOWER_ADP-INDUCED_PEAK_PLATELET_AGGREGATION_IN-VITRO
;APOC1, APOE;rs445925;A;LADME_PK;PK;PK:BASELINE_LDL_CHOLESTEROL
SUNITINIB;FGFR2;rs2981582;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SULFAMETHOXAZOLE / TRIMETHOPRIM;NAT2;rs1799931;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_REACTIONS
SUNITINIB;FLT4;rs307826;CC + CT;EFFICACY;DECREASED_;DISEASE:OVERALL_SURVIVAL
HEROIN;OPRM1;rs1799971;AG + GG;TOXICITY;DECREASED_RISK;DISEASE:HEROIN_DEPENDENCE
SUNITINIB;NR1I3;rs2307424;AA + AG;EFFICACY;DECREASED_;DISEASE:OVERALL_SURVIVAL
;FADS1, FEN1, MIR611, TMEM258;rs174541;T;LADME_PK;PK;PK:BASELINE_LDL_CHOLESTEROL
;;rs258494;C;LADME_PK;PK;PK:BASELINE_LDL_CHOLESTEROL
;LDLR;rs6511720;T;OTHER;PK;PK:BASELINE_LDL_CHOLESTEROL
;PNMT;rs2934965;T;OTHER;DECREASED_RISK;OTHER:SICKLE_CELL_PAIN_CRISIS
FLUOROURACIL, LEUCOVORIN, LEVAMISOLE, RADIOTHERAPY;GSTP1;rs1695;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DEXAMETHASONE, LENALIDOMIDE;ABCB1;rs2229109;CT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
AZATHIOPRINE;DDRGK1, ITPA;rs1127354;AC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:NON-RESPONSE
;PNMT;rs2941523;GG;OTHER;DECREASED_RISK;OTHER:SICKLE_CELL_PAIN_CRISIS
MYCOPHENOLIC ACID;SLCO1B3;rs4149117;GT + TT;EFFICACY;INCREASED_RISK;OTHER:CHRONIC_LUNG_ALLOGRAFT_DYSFUNCTION
;PNMT;rs876493;AA + AG;OTHER;DECREASED_RISK;OTHER:SICKLE_CELL_PAIN_CRISIS
ATENOLOL, BISOPROLOL;ACY3;rs2514036;C;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE,_ELEVATED_SYSTOLIC_BLOOD_PRESSURE
LOSARTAN;KIRREL2, NPHS1;rs3814995;T;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE
ASPIRIN;ADORA1;rs16851030;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA
ANTINEOPLASTIC AGENTS;FPGS;rs1544105;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
SUNITINIB;NR1I3;rs4073054;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SUNITINIB;FLT4;rs307821;AA + AC;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ALPRAZOLAM;CYP3A4;rs35599367;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
MYCOPHENOLIC ACID;SLCO1B3;rs7311358;AG + GG;EFFICACY;INCREASED_RISK;OTHER:TRANSPLANT_REJECTION
MYCOPHENOLIC ACID;SLCO1B3;rs7311358;AG + GG;EFFICACY;DECREASED_LIKELIHOOD;OTHER:OVERALL_SURVIVAL
SUNITINIB;ABCB1;rs1128503;AG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
OLANZAPINE;CYP1A1;rs2472297;T;LADME_PK;PK;PK:25%_HIGHER_MEAN_4'-DESMETHYL_OLA/OLANZAPINE_(OLA)_RATIO
MYCOPHENOLIC ACID;SLCO1B3;rs4149117;GT + TT;EFFICACY;INCREASED_RISK;OTHER:TRANSPLANT_REJECTION
BEVACIZUMAB, CAPECITABINE, CETUXIMAB, OXALIPLATIN;MGAT4A;rs885036;G;EFFICACY;INCREASED_;DISEASE:PROGRESSION-FREE_SURVIVAL
OPIOIDS;ADGRV1;rs2366929;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
BEVACIZUMAB, CAPECITABINE, OXALIPLATIN;MGAT4A;rs885036;G;EFFICACY;DECREASED_;DISEASE:PROGRESSION-FREE_SURVIVAL
CLOPIDOGREL;FMO3;rs1736557;AA;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
MYCOPHENOLIC ACID;SLCO1B3;rs4149117;GT + TT;EFFICACY;DECREASED_LIKELIHOOD;OTHER:OVERALL_SURVIVAL
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
ASPIRIN, CLOPIDOGREL;PEAR1;rs2644592;G;EFFICACY;EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ASPIRIN, CLOPIDOGREL;PEAR1;rs11264580;C;EFFICACY;EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
BUPROPION, NICOTINE;APOE;rs429358;CC + CT;OTHER;INCREASED_LIKELIHOOD;DISEASE:RECURRENCE
ASPIRIN, CLOPIDOGREL;PEAR1;rs57731889;TT;EFFICACY;EFFICACY;EFFICACY:LOW_ON-TREATMENT_PLATELET_REACTIVITY
ALENDRONATE, IBANDRONATE, RISEDRONATE, ZOLEDRONATE;SIRT1;rs932658;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS_OF_THE_JAW
VALPROIC ACID;LEPR;rs1137101;AG + GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
ANTINEOPLASTIC AGENTS;GSTM5;rs3754446;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
ATORVASTATIN, BEZAFIBRATE;APOE;rs449647;AT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:LIPID-LOWERING_EFFECT
HALOPERIDOL;SLC6A5;rs2298826;AA;TOXICITY;;SIDE_EFFECT:MOTOR_SIDE_EFFECTS
OLANZAPINE;AHR;rs4410790;T;LADME_PK;PK;PK:29%_LOWER_MEAN_4'-DESMETHYL_OLA/OLANZAPINE_(OLA)_RATIO
CLOPIDOGREL;P2RY12;rs6785930;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
ASPIRIN, CLOPIDOGREL;PEAR1;rs3737224;T;EFFICACY;EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ASPIRIN, CLOPIDOGREL;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EPISTAXIS,_GASTROINTESTINAL_HEMORRHAGE,_HEMATOMA,_HEMATURIA
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED_SEVERITY;DISEASE:ALCOHOL_ABUSE
VENLAFAXINE;CYP2D6;rs5030655;del;LADME_PK;PK;PK:IMPAIRED_METABOLIC_ACTIVITY
ASPIRIN, TICAGRELOR;CYP4F2;rs3093135;T;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EPISTAXIS,_GASTROINTESTINAL_HEMORRHAGE,_HEMATOMA,_HEMATURIA
CLOPIDOGREL;P2RY12;rs6809699;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
CISPLATIN, DOXORUBICIN;CASP3;rs2720376;C;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ACE INHIBITORS, PLAIN;XPNPEP2;rs3788853;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs59502379;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
CAPECITABINE;CES1;rs2244613;GG + GT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
NEVIRAPINE;CCHCR1;rs1265112;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEVIRAPINE-INDUCED_RASH
CISPLATIN, DOXORUBICIN;CYP3A4;rs4646437;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
;GLI1;rs2228226;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
NICOTINE;ANKK1, DRD2;rs1800497;AA + AG;TOXICITY;INCREASED_SEVERITY;DISEASE:TOBACCO_USE_DISORDER
VALPROIC ACID;UGT1A6;rs2070959;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TREMOR
ESCITALOPRAM;CYP1A2;rs4646425;T;TOXICITY;INCREASED_;DISEASE:FATIGUE
CLOZAPINE;ACKR1;rs2814778;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
ESCITALOPRAM;;rs2069521;A;TOXICITY;INCREASED_;DISEASE:FATIGUE
ASPIRIN, CLOPIDOGREL;PEAR1;rs41273215;T;EFFICACY;EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ESCITALOPRAM;CYP1A2;rs4646427;C;TOXICITY;INCREASED_;DISEASE:FATIGUE
ESCITALOPRAM;;rs2069521;A;TOXICITY;INCREASED_;SIDE_EFFECT:NAUSEA/VOMITING
ESCITALOPRAM;CYP1A2;rs4646425;T;TOXICITY;INCREASED_;SIDE_EFFECT:NAUSEA/VOMITING
ESCITALOPRAM;CYP1A2;rs4646427;C;TOXICITY;INCREASED_;SIDE_EFFECT:NAUSEA/VOMITING
ALLOPURINOL;CYCSP5;rs3099844;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS,_STEVENS-JOHNSON_SYNDROME
CLOPIDOGREL;CYP1A2;rs762551;AA + AC;EFFICACY, LADME_PK;DECREASED_EFFICACY;EFFICACY:ON-TREATMENT_PLATELET_REACTIVITY
ETHANOL;OPRK1;rs6473797;CC + CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ALCOHOL_ABUSE
CYCLOPHOSPHAMIDE, DOXORUBICIN;NQO1;rs1800566;A;EFFICACY;EFFICACY;EFFICACY:WORSE_OUTCOME_(OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL)
HEROIN;GRM3;rs274618;T;OTHER;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
THIAZOLIDINEDIONES;AQP2;rs296766;T;TOXICITY;INCREASED_RISK;DISEASE:EDEMA
ETHANOL;CHRNA3;rs578776;G;TOXICITY, OTHER;DECREASED_LIKELIHOOD;DISEASE:ALCOHOL_ABUSE
CISPLATIN, DOXORUBICIN;ABCC5;rs939338;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CISPLATIN, DOXORUBICIN;FASLG;rs763110;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CISPLATIN, DOXORUBICIN;MSH2;rs4638843;C;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;SLC1A1;rs3087879;C;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PHARMACOLOGICAL_RESISTANCE
COCAINE;CHRNA5;rs684513;G;OTHER;INCREASED_LIKELIHOOD;DISEASE:COCAINE_DEPENDENCE
ACE INHIBITORS, PLAIN;XPNPEP2;rs3788853;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
ALLOPURINOL;;rs2734583;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS,_STEVENS-JOHNSON_SYNDROME
METHOTREXATE;ABCC2;rs717620;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
ALLOPURINOL;PSORS1C1;rs9263726;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_REACTION_WITH_EOSINOPHILIA_AND_SYSTEMIC_SYMPTOMS,_STEVENS-JOHNSON_SYNDROME
FEXOFENADINE;SLCO2B1;rs2306168;T;LADME_PK;DECREASED_PK;PK:AREA_UNDER_THE_PLASMA_CONCENTRATION-TIME_CURVE
ANTINEOPLASTIC AGENTS;SLC28A3;rs17343066;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION_(P<0.001)
CLOZAPINE;TRAT1;rs116982346;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
MERCAPTOPURINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA,_NEUTROPENIA,_PANCYTOPENIA,_THROMBOCYTOPENIA
EFAVIRENZ;CYP2A6;rs8192726;AC + CC;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION_(P=0.028)
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP3A4;rs2740574;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP3A4;rs2740574;CT;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
;ADH1B;rs1789891;A;OTHER;INCREASED_;DISEASE:ALCOHOL_ABUSE
ANTINEOPLASTIC AGENTS;DCTD;rs12067645;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
EFAVIRENZ;UGT2B7;rs7439366;CC + CT;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
MERCAPTOPURINE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA,_NEUTROPENIA,_PANCYTOPENIA,_THROMBOCYTOPENIA
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC2;rs13181;G;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CLOZAPINE;TRAC;rs377360;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
NEVIRAPINE;CCHCR1;rs746647;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
;FGFBP1;rs2245964;CC;OTHER;INCREASED_;OTHER:BONE_MINERAL_DENSITY
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT:DEATH,_GASTROINTESTINAL_HEMORRHAGE
;FGFBP1;rs16892645;TT;OTHER;INCREASED_;OTHER:BONE_MINERAL_DENSITY
ATORVASTATIN;SLCO1B1;rs2306283;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_LDL
;;rs2824292;G;OTHER;INCREASED_RISK;DISEASE:VENTRICULAR_FIBRILLATION
NEVIRAPINE;;rs6545803;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEVIRAPINE-INDUCED_RASH
NICOTINE;FMO1;rs10912675;C;OTHER;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
NEVIRAPINE;POLR3G;rs2562519;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
NICOTINE;FMO1;rs7877;T;OTHER;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
ASPARAGINASE;GRIA1;rs4958381;T;TOXICITY;INCREASED_RISK;
PACLITAXEL;CYP17A1;rs743572;AG + GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ACENOCOUMAROL;CYP2C9;rs1057910;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT:DEATH,_GASTROINTESTINAL_HEMORRHAGE
CISPLATIN, FLUOROURACIL;ERCC1;rs3212986;AA + AC;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DOXORUBICIN;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NAUSEA,_VOMITING
ANASTROZOLE, LETROZOLE;TNFRSF11B;rs2073618;CC;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:METABOLIC_BONE_DISORDER,_OSTEOPOROSIS
CARBOPLATIN, DOCETAXEL, PACLITAXEL;SOX10;rs139887;CG;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
ANASTROZOLE, LETROZOLE;TNFRSF11B;rs2073618;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN,_ARTHRITIS,_PAIN,
ANASTROZOLE, LETROZOLE;TNFSF11;rs7984870;CC;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:METABOLIC_BONE_DISORDER,_OSTEOPOROSIS
ANTINEOPLASTIC AGENTS;CTPS1;rs12067645;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
DOXORUBICIN;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ANTINEOPLASTIC AGENTS;CTPS1;rs12067645;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
CAPECITABINE;CES2;rs11075646;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
WARFARIN;VKORC1;rs9923231;T;EFFICACY;EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
ANASTROZOLE, LETROZOLE;TNFSF11;rs7984870;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN,_ARTHRITIS,_PAIN,
DRUGS FOR TREATMENT OF TUBERCULOSIS;SOD2;rs4880;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
"""ANALGESICS AND ANESTHETICS"", ""ANTIBIOTICS"", ""ANTIEPILEPTICS"", ""ANTIFUNGALS FOR SYSTEMIC USE"", ""ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS"", ""ANTIMYCOBACTERIALS"", ""ANTITHYROID PREPARATIONS""";SOD2;rs4880;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DOXORUBICIN;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ANEMIA,_THROMBOCYTOPENIA,_NEUTROPENIA,
METFORMIN;PPARG;rs1801282;G;OTHER;INCREASED_LIKELIHOOD;OTHER:SHORT_AND_LONG-TERM_WEIGHT_LOSS
MITOTANE;CYP2B6;rs3745274;GT + TT;LADME_PK;PK;PK:BEING_A_PREDICTOR_OF_MITOTANE_PLASMA_CONCENTRATIONS_OF_AT_LEAST_14_ÃÂ¿Â½G/ML_AFTER_3_MONTHS_OF_TREATMENT
BORTEZOMIB, MELPHALAN, PREDNISONE;CTLA4;rs4553808;GG;TOXICITY;;SIDE_EFFECT:EARLIER_ONSET_OF_BORTEZOMIB-INDUCED_PERIPHERAL_NEUROPATHY
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_PK;PK:PBMC-ASSOCIATED_DRUG_CONCENTRATIONS
;CRHR1;rs1876828;TT;LADME_PK;DECREASED_PK;PK:BASELINE_CORTISOL_LEVELS
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY, LADME_PK;INCREASED_PK;PK:INTRACELLULAR_PBMC_EXPOSURE
VALPROIC ACID;SOD2;rs4880;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ALOPECIA
;ABCB1;rs1045642;AA;OTHER;INCREASED_LIKELIHOOD;OTHER:HELICOBACTER_PYLORI_INFECTION
VALPROIC ACID;LEPR;rs1137101;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ALOPECIA
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_;OTHER:ADP-STIMULATED_PLATELET_AGGREGATION
CAPECITABINE;CDA;rs10916825;AG + GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HAND-FOOT_SYNDROME
ANTINEOPLASTIC AGENTS;ABCB1;rs4148737;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
CLOPIDOGREL, TICAGRELOR;CYP4F2;rs3093135;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION,_RECURRENCE
EFAVIRENZ;CYP2B6;rs28399499;CT;LADME_PK;INCREASED_PK;PK:MINIMUM_PLASMA_CONCENTRATIONS
DEFERASIROX;UGT1A3;rs3806596;CC;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:IRON_OVERLOAD
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;ERCC2;rs13181;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DEFERASIROX;UGT1A1;rs887829;TT;EFFICACY;DECREASED_RISK;DISEASE:IRON_OVERLOAD
METFORMIN;SLC47A2;rs12943590;AA + AG;LADME_PK;INCREASED_PK;PK:RENAL_AND_SECRETORY_CLEARANCE_OF_METFORMIN
METFORMIN;SLC47A2;rs12943590;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESPONSE_TO_METFORMIN
CAPECITABINE;CES1;rs2244613;GG + GT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HAND-FOOT_SYNDROME
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;LADME_PK;DECREASED_PK;PK:ORAL_CLEARANCE_OF_ATORVASTATIN
CAPECITABINE;CES1;rs2244613;GG + GT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
DEFERASIROX;CYP1A2;rs762551;AA;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:IRON_OVERLOAD
ANTINEOPLASTIC AGENTS;CYP3A5;rs776746;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;ERCC2;rs13181;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
DEFERASIROX;CYP1A1;rs2606345;CC;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:IRON_OVERLOAD
HEROIN;GRM3;rs274622;C;OTHER;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
EFAVIRENZ;ABCB1;rs3842;CC + CT;LADME_PK;INCREASED_PK;PK:ACCUMULATION_OF_DRUG_IN_PBMCS
ETHANOL;CHRNA4;rs1044394;G;TOXICITY;DECREASED_RISK;OTHER:ALCOHOL_ABUSE
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;rs1799963;AG;TOXICITY;INCREASED_RISK;DISEASE:VENOUS_THROMBOSIS
OPIOIDS;ENPP2;rs2249015;AA;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;CT;TOXICITY;INCREASED_RISK;DISEASE:VENOUS_THROMBOSIS
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;XRCC1;rs25487;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ASPIRIN;ADORA1;rs2228079;GG + GT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA
LOVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
METHOTREXATE;MTHFR;rs1801131;GG + GT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:SKIN_DISORDER
METHOTREXATE;FASTKD3, MTRR;rs1801394;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
FLUOROURACIL;DPYD;rs56038477;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:THROMBOCYTOPENIA
PROPRANOLOL;CYP2D6;rs1065852;AA;LADME_PK;INCREASED_PK;PK:AREA_UNDER_PLASMA_CONCENTRATION_OF_PROPRANOLOL
CAPECITABINE, FLUOROURACIL;DPYD;rs6668296;T;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
CLOZAPINE;HLA-DQB1;rs113332494;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:AGRANULOCYTOSIS
CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, GEMCITABINE;ERCC2;rs1799793;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
;APOE;rs7412;CT + TT;OTHER;INCREASED_;OTHER:HYPERURICEMIA
CAPECITABINE, FLUOROURACIL;DPYD;rs115349832;C;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
METFORMIN;PPARG;rs1801282;G;OTHER;INCREASED_LIKELIHOOD;OTHER:WEIGHT_REGAIN_AFTER_INTENTIONAL_WEIGHT_LOSS
;APOE;rs429358;CC + CT;OTHER;INCREASED_;OTHER:HYPERTRIGLYCERIDEMIA
CLOZAPINE;HLA-DQB1;rs113332494;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
SIMVASTATIN;APOE;rs429358;C;EFFICACY;INCREASED_RISK;OTHER:MORTALITY_AFTER_MYOCARDIAL_INFARCTION,_HOWEVER_THIS_CAN_BE_ELIMINATED
CLOZAPINE, HALOPERIDOL, OLANZAPINE, RISPERIDONE;HTR2C;rs518147;G;OTHER;INCREASED_LIKELIHOOD;DISEASE:WEIGHT_GAIN
AMISULPRIDE, CLOZAPINE, HALOPERIDOL, ILOPERIDONE, OLANZAPINE, QUETIAPINE, RISPERIDONE, ZIPRASIDONE;HTR2C;rs3813929;C;OTHER;INCREASED_RISK;DISEASE:WEIGHT_GAIN
HEROIN;SOD2;rs5746136;TT;TOXICITY;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
OPIOIDS;ENPP2;rs7832704;A;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
CARBOPLATIN, DOCETAXEL, PACLITAXEL;BCL2;rs2849380;TT;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
CARBOPLATIN, DOCETAXEL, PACLITAXEL;OPRM1;rs544093;TT;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
CARBOPLATIN, DOCETAXEL, PACLITAXEL;;rs879207;AG;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
TOLCAPONE;;rs4680;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:REACTION_TIME
DOLASETRON, GRANISETRON;NOS1AP;rs10494366;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:QTC_PROLONGATION
SUNITINIB;ABCB1;rs2032582;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CAPECITABINE, FLUOROURACIL;DPYD;rs56276561;T;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
CLOZAPINE;ELAVL2;rs73482673;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_PK;PK:MID-DOSE_PLASMA_CONCENTRATIONS
FLUOROURACIL;DPYD;rs2297595;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
DOCETAXEL;SLCO1B3;rs4149118;G;OTHER, LADME_PK;INCREASED_PK;PK:AUC
NEVIRAPINE;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_PK;PK:PLASMA_EXPOSURE
TOLCAPONE;COMT;rs4680;AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:REACTION_TIME
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_PK;PK:PLASMA_EXPOSURE
HEROIN;SOD2;rs2758339;AC + CC;TOXICITY;DECREASED_RISK;DISEASE:HEROIN_DEPENDENCE
DOCETAXEL;SLCO1B3;rs11045585;G;OTHER, LADME_PK;INCREASED_PK;PK:AUC
DOCETAXEL;SLCO1B3;rs7311358;A;OTHER, LADME_PK;INCREASED_PK;PK:AUC
IRINOTECAN;TOP1;rs6072262;GG;TOXICITY;DECREASED_SEVERITY;DISEASE:NEUTROPENIA
WARFARIN;APOB;rs679899;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
ERLOTINIB;EGFR;rs712829;GG;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA
ERLOTINIB;ABCG2;rs2622604;CC;OTHER, LADME_PK;DECREASED_PK;PK:MEAN_AUC
WARFARIN;APOB;rs1367117;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CAPECITABINE, FLUOROURACIL;DPYD;rs56038477;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
MORPHINE;OPRM1;rs1799971;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_PAIN
MORPHINE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_PAIN
PHENYTOIN;ABCB1;rs1045642;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DRUG_RESISTANCE
ATORVASTATIN, FLUVASTATIN, HMG COA REDUCTASE INHIBITORS, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;;SIDE_EFFECT:ALL_STATIN-INDUCED_MYOPATHY_AND_SEVERE_MYOPATHY
ASPIRIN, CLOPIDOGREL;B4GALT2;rs1061781;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
LEFLUNOMIDE;CYB5A;rs1790834;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_ACTIVITY_SCORE_28_IN_RHEUMATOID_ARTHRITIS
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;CT;TOXICITY;INCREASED_RISK;DISEASE:STROKE
NEVIRAPINE;CYP2B6;rs28399499;CT;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
NEVIRAPINE;CYP2B6;rs3745274;T;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
CETUXIMAB, PANITUMUMAB;KRAS;rs61764370;C;EFFICACY;EFFICACY;EFFICACY:NONRESPONSE_TO_ANTI-EGFR-BASED_TREATMENT
EDOXABAN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
CYCLOSPORINE;ABCB1;rs1045642;GG;EFFICACY, LADME_PK;DECREASED_PK;PK:INTRACELLULAR_AND_BLOOD_CONCENTRATION
BLEOMYCIN;BLMH;rs1050565;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
CISPLATIN;GSTP1;rs1695;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_HEARING_IMPAIRMENT
CITALOPRAM;FKBP5;rs4713916;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
OPIOIDS;TH;rs10770141;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
DISULFIRAM;DBH;rs1611115;CC;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:COCAINE_DEPENDENCE
OPIOIDS;COMT;rs4680;AA;TOXICITY;DECREASED_RISK;OTHER:DEATH
;VEGFA;rs2010963;CC + CG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
SOFOSBUVIR, VELPATASVIR, VOXILAPREVIR;IFNL3, IFNL4;rs12979860;CT + TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
OPIOIDS;TH;rs10770140;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
PHENYTOIN;ABCB1;rs1128503;A;OTHER, LADME_PK;INCREASED_PK;PK:PLASMA_DRUG_LEVELS
PHENYTOIN;ABCB1;rs1045642;A;OTHER, LADME_PK;INCREASED_PK;PK:PLASMA_DRUG_LEVELS
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR3;rs1056892;GG;TOXICITY;INCREASED_RISK;DISEASE:CARDIOMYOPATHIES
DEXMEDETOMIDINE;PRKCB;rs9922316;T;OTHER;INCREASED_;OTHER:DEXMEDETOMIDINE_ED50_VALUES_FOR_DRUG-INDUCED_DORSAL_HAND_VEIN_(DHV)_CONSTRICTION
PRASUGREL;CYP2C19;rs12248560;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY_INDEX_(PRI)_VASODILATOR-STIMULATED_PHOSPHOPROTEIN_(VASP)_AT_1_MONTH_OF_TREATMENT
CYCLOSPORINE;ABCB1;rs2229109;CC;EFFICACY, LADME_PK;INCREASED_PK;PK:INTRACELLULAR_AND_BLOOD_CONCENTRATION
PRASUGREL;CYP2C19;rs12248560;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:RATE_OF_HIGH_ON-TREATMENT_PLATELET_REACTIVITY_(HTPR)_AT_1_MONTH_OF_TREATMENT
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CORONARY_DISEASE
EFAVIRENZ;CYP2B6;rs28399499;C;TOXICITY, LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
PRASUGREL;CYP2C19;rs12248560;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:BLEEDING_COMPLICATIONS
NICOTINE;DRD1;rs686;A;EFFICACY, TOXICITY, OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
PRASUGREL;CYP2C19;rs12248560;T;EFFICACY;INCREASED_EFFICACY;EFFICACY:RATE_OF_HYPER-RESPONSE_AT_1_MONTH_OF_TREATMENT
ANTIPSYCHOTICS;DRD2;rs1799732;del;TOXICITY;INCREASED_RISK;DISEASE:WEIGHT_GAIN
MITOTANE;CYP2B6;rs3745274;GT + TT;LADME_PK;INCREASED_PK;PK:MITOTANE_PLASMA_CONCENTRATIONS
NICOTINE;DRD1;rs4532;T;EFFICACY, TOXICITY, OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
REPAGLINIDE;SLC30A8;rs16889462;AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:EFFICACY
ATAZANAVIR, RITONAVIR;UGT1A7;rs17863778;AA;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
BEVACIZUMAB;EDN1;rs5370;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
;G6PD, IKBKG;rs5030868;A;;;OTHER:PROTECTION_FROM_PLASMODIUM_VIVAX_MALARIA_INFECTION
MYCOPHENOLATE MOFETIL;IMPDH1;rs2278294;T;EFFICACY;DECREASED_RISK;DISEASE:TRANSPLANT_REJECTION
ATAZANAVIR, RITONAVIR;UGT1A3;rs3806596;CC;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
GEFITINIB;ABCB1;rs1128503;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA,_EXANTHEMA
MYCOPHENOLATE MOFETIL;IMPDH1;rs2278294;T;TOXICITY;INCREASED_RISK;DISEASE:LEUKOPENIA
ATAZANAVIR, RITONAVIR;UGT1A7;rs7586110;GG;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
OXALIPLATIN;ERCC2, KLC3;rs13181;GG + GT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
APREPITANT, OLANZAPINE;HTR3C;rs6766410;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:NAUSEA,_VOMITING
ATAZANAVIR, RITONAVIR;UGT1A7;rs17868323;GG;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
BEVACIZUMAB;VEGFA;rs3025039;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
APREPITANT, OLANZAPINE;MTHFR;rs1801131;TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:NAUSEA,_VOMITING
APREPITANT, OLANZAPINE;HTR3B;rs7943062;GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:NAUSEA,_VOMITING
TAFENOQUINE;;rs62103056;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
METHOTREXATE;GGH;rs719235;CC;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT:BONE_MARROW_TOXICITY
TIMOLOL;ADRB1;rs1801252;AA;OTHER;INCREASED_;OTHER:SYSTOLIC_(SAP)_AND_DIASTOLIC_(DAP)_ARTERIAL_PRESSURE_RESPONSES_TO_TIMOLOL
CISPLATIN;LRP2;rs2228171;G;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
DISULFIRAM;DBH;rs1611115;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
FENTANYL, PROPOFOL, REMIFENTANIL, SEVOFLURANE;ADRB2;rs1042718;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPOTENSIVE_DISORDER
ROSUVASTATIN;ABCG2;rs2231142;T;EFFICACY;SEVERITY_EFFICACY;EFFICACY:HYPERCHOLESTEROLEMIA
;SLC30A8;rs13266634;C;OTHER;INCREASED_RISK;DISEASE:DIABETES_MELLITUS_TYPE2
THIAZIDES, PLAIN;SLCO2A1;rs34550074;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPONATREMIA
ROSUVASTATIN;FMO3;rs1736557;A;EFFICACY;SEVERITY_EFFICACY;EFFICACY:HYPERCHOLESTEROLEMIA
WARFARIN;GGCX;rs699664;C;EFFICACY;INCREASED_EFFICACY;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR)
CISPLATIN;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
WARFARIN;GGCX;rs11676382;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_IN_THERAPEUTIC_RANGE
METHYLPHENIDATE;COMT;rs4680;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ANTIEPILEPTICS;SCN2A;rs2304016;A;EFFICACY;EFFICACY;EFFICACY:DRUG_RESISTANCE
WARFARIN;GGCX;rs11676382;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR)
WARFARIN;NQO1;rs1800566;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
;G6PD;rs1050828;T;;INCREASED_;OTHER:PROTECTION_AGAINST_SEVERE_(P=0.006)_AND_MILD_MALARIA_(P=0.027)
ANTITHYROID PREPARATIONS, METHIMAZOLE, PROPYLTHIOURACIL;KLRC4;rs2734565;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:AGRANULOCYTOSIS
OXALIPLATIN;ERCC1;rs11615;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
FLUOROURACIL;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA,_MUCOSITIS,_NEUTROPENIA,
ACE INHIBITORS, PLAIN;;rs4267385;CC + CT;OTHER;;OTHER:SAME_PROTECTIVE_PROPERTIES_AGAINST_ANGIOTENSIN-CONVERTING_ENZYME_INHIBITORS-INDUCED_COUGH
ACE INHIBITORS, PLAIN;;rs4459610;AA + AT;OTHER;;OTHER:SAME_PROTECTIVE_PROPERTIES_AGAINST_ANGIOTENSIN-CONVERTING_ENZYME_INHIBITORS-INDUCED_COUGH
;G6PD;rs1050828;T;;INCREASED_;OTHER:PROTECTION_AGAINST_DEVELOPING_SEVERE_MALARIA
METHOTREXATE;MTHFR;rs1801133;AG;TOXICITY;INCREASED_RISK;DISEASE:ALOPECIA
ACE INHIBITORS, PLAIN;BDKRB2;rs8016905;AG;TOXICITY;;DISEASE:COUGH
;F5;rs6025;C;OTHER;INCREASED_LIKELIHOOD;OTHER:RECURRENT_PREGNANCY_LOSS
CARBOPLATIN, PACLITAXEL;TRIM5;rs7950311;C;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
;MTHFR;rs1801131;G;OTHER;INCREASED_LIKELIHOOD;OTHER:RECURRENT_PREGNANCY_LOSS
ANTINEOPLASTIC AGENTS;;rs6674079;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
;MTHFR;rs1801133;G;OTHER;INCREASED_LIKELIHOOD;OTHER:RECURRENT_PREGNANCY_LOSS
CARBOPLATIN, PACLITAXEL;;rs2549714;C;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
;SERPINE1;rs2227631;A;OTHER;INCREASED_LIKELIHOOD;OTHER:RECURRENT_PREGNANCY_LOSS
ANTINEOPLASTIC AGENTS;;rs4910232;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
WARFARIN;CYP4F2;rs2108622;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:INTERNATIONAL_NORMALIZED_RATIO_VARIABILITY_(INR-VAR)
ASPIRIN;PPARG;rs3856806;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN_HYPERSENSITIVITY
CYCLOSPORINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
ANTINEOPLASTIC AGENTS;ZNF100;rs3795247;C;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
WARFARIN;VKORC1;rs9923231;T;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_INR_DURING_3-MONTH_DAILY_OBSERVATION_PERIOD_IN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT
ASPIRIN;PTGIR;rs1126510;AG + GG;OTHER;DECREASED_RISK;OTHER:ASPIRIN-INTOLERANT_ASTHMA
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:NUMBER_OF_EXAMINATIONS_ABOVE_THE_THERAPEUTIC_RANGE_DURING_3-MONTH_DAILY_OBSERVATION_PERIOD_IN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT
ASPIRIN;TBXA2R;rs1131882;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA
ASPIRIN;PTGER3;rs7551789;A;OTHER;INCREASED_RISK;OTHER:ASPIRIN-INTOLERANT_ASTHMA
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR>=2
ASPIRIN;PTGER2;rs1353411;GG;OTHER;INCREASED_RISK;OTHER:ASPIRIN-INTOLERANT_ASTHMA
ASPIRIN;PTGER2;rs2075797;G;OTHER;DECREASED_RISK;OTHER:ASPIRIN-INTOLERANT_ASTHMA
DOCETAXEL, PACLITAXEL;CYP3A4;rs2740574;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
DOXORUBICIN;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NAUSEA,_VOMITING
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_;OTHER:STABLE_WARFARIN_DOSE
CLOPIDOGREL;CYP2C19;rs4244285;AG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:VASP_INDEX
ASPIRIN;PPARG;rs3856806;TT;TOXICITY;INCREASED_;SIDE_EFFECT:DECLINE_IN_FEV_1_AFTER_ASPIRIN_PROVOCATION
CLOPIDOGREL;CYP2C19;rs4986893;AG + GG;EFFICACY;EFFICACY;EFFICACY:HIGH_POST-CLOPIDOGREL_PLATELET_REACTIVITY
ASPIRIN, CLOPIDOGREL;NECAB1;rs74569896;G;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CLOPIDOGREL;CYP2C19;rs4244285;AG + GG;EFFICACY;EFFICACY;EFFICACY:HIGH_POST-CLOPIDOGREL_PLATELET_REACTIVITY
WARFARIN;VKORC1;rs9923231;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ATHEROTHROMBOTIC_EVENTS_DURING_THE_6-YEAR_FOLLOW_UP_IN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT
WARFARIN;CYP2C9;rs1799853;T;EFFICACY, TOXICITY;INCREASED_;SIDE_EFFECT:BLOOD_COAGULATION_DISORDERS
ASPIRIN, CLOPIDOGREL;EFR3A;rs4736529;G;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
DOCETAXEL, PACLITAXEL;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
GEMCITABINE;SLC28A1;rs2242046;GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEMATOLOGIC_TOXICITY
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE_DURING_3-MONTH_DAILY_OBSERVATION_PERIOD_IN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT
WARFARIN;CYP2C9;rs1057910;C;EFFICACY, TOXICITY;INCREASED_;SIDE_EFFECT:BLOOD_COAGULATION_DISORDERS
GEMCITABINE;CDA;rs1048977;CC + CT;OTHER, LADME_PK;INCREASED_PK;PK:ELIMINATION_CLEARANCE_OF_DFDU_AND_FORMATION_CLEARANCE_OF_DFDCTP
PACLITAXEL;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;TOXICITY;INCREASED_RISK;DISEASE:CORONARY_ARTERY_DISEASE
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;TOXICITY;INCREASED_RISK;DISEASE:CORONARY_ARTERY_DISEASE
CYTARABINE;ABCB1;rs1128503;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;EFFICACY;EFFICACY;EFFICACY:POORER_REDUCTION_IN_LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_(LDLC)
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799930;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
HMG COA REDUCTASE INHIBITORS;LPA;rs10455872;AG + GG;EFFICACY;EFFICACY;EFFICACY:POORER_REDUCTION_IN_LOW-DENSITY_LIPOPROTEIN_CHOLESTEROL_(LDLC)
PRAVASTATIN;ABCB1;rs2032582;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:PERCENT_REDUCTION_IN_LDL-CHOLESTEROL
GEMCITABINE;CMPK1;rs1044457;CC;OTHER, LADME_PK;DECREASED_PK;PK:FORMATION_CLEARANCE_OF_DFDCTP
ASPIRIN, CLOPIDOGREL;WDR24;rs11640115;G;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
GEMCITABINE;CDA;rs4655226;CC;OTHER, LADME_PK;INCREASED_PK;PK:ELIMINATION_CLEARANCE_OF_DFDU
CARBOPLATIN, PACLITAXEL;MAD1L1;rs1801368;CT + TT;OTHER;DECREASED_;OTHER:BIOCHEMICAL_RESPONSE,_OPTIMAL_CYTOREDUCTION,_AND_SENSITIVITY_TO_THE_INDUCTION_CHEMOTHERAPY_TREATMENT
VARENICLINE;ICAM5;rs901886;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SLEEP_DISORDERS
METHOTREXATE;ABCC1;rs2238476;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
MITOXANTRONE;ABCB1;rs1128503;AA;OTHER;INCREASED_;OTHER:SENSITIVITY_IN_VITRO
MERCAPTOPURINE, METHOTREXATE;FOLH1;rs61886492;A;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CYTARABINE;ABCB1;rs2032582;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1041983;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NEVIRAPINE;CYP2B6;rs28399499;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STEVENS-JOHNSON_SYNDROME/EPIDERMAL_NECROLYSIS,_TOXIC
;PPARA;rs135561;AA + AG;OTHER;DECREASED_RISK;OTHER:ALL-CAUSE_MORTALITY
CLOZAPINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS,_NEUTROPENIA
DRUGS FOR TREATMENT OF TUBERCULOSIS, ISONIAZID;;rs1495741;AA;TOXICITY;DECREASED_;SIDE_EFFECT:MEAN_CUMULATIVE_DOSES_OF_ISONIAZID_BEFORE_THE_DEVELOPMENT_OF_ABNORMAL_LIVER-FUNCTION_TESTS_(ALFTS)
METHOTREXATE;ATIC;rs4673993;C;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:DISEASE_ACTIVITY
DRUGS FOR TREATMENT OF TUBERCULOSIS, ISONIAZID;;rs1495741;AA;TOXICITY;DECREASED_;SIDE_EFFECT:MEAN_CUMULATIVE_DOSES_OF_ISONIAZID_BEFORE_THE_DEVELOPMENT_OF_ANTITUBERCULOSIS_DRUG-INDUCED_HEPATOTOXICITY_(ATDIH)
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;APOC3;rs5128;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERLIPIDEMIAS
FLUTICASONE PROPIONATE;CYP3A4;rs35599367;AA + AG;EFFICACY;EFFICACY;EFFICACY:IMPROVED_ASTHMA_CONTROL_(AS_MEASURED_BY_DECREASE_IN_AVERAGE_ASTHMA_CONTROL_SCORE)
ALLOPURINOL;CCHCR1;rs9263745;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
LETROZOLE;;rs74418677;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN,_ARTHRITIS,_DISCONTINUATION,
ACE INHIBITORS, PLAIN;AGTR1;rs5186;C;TOXICITY;INCREASED_;SIDE_EFFECT:MAJOR_CARDIOVASCULAR_EVENTS_(MACE)_RATE
CYTARABINE, DAUNORUBICIN, ETOPOSIDE, MITOXANTRONE;SLCO1B1;rs2291075;CT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL,_OVERALL_SURVIVAL
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_PK;PK:TROUGH_BLOOD_CONCENTRATION_NORMALIZED_FOR_THE_DAILY_DOSE_(C)_PER_KILOGRAM_BODY_WEIGHT_(D)_(C/D,_NG/ML/MG/KG/DAY)_RATIO_DURING_THE_FIRST_MONTH_AFTER_TRANSPLANTATION
CYCLOSPORINE;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DELAYED_GRAFT_FUNCTION
ALLOPURINOL;CYCSP5;rs3099844;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
METHOTREXATE;FOXP3;rs3761548;GT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
;CHAT;rs1880676;G;OTHER;INCREASED_RISK;DISEASE:SCHIZOPHRENIA
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;SIK3;rs139961185;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERLIPIDEMIAS
OXALIPLATIN;XRCC1;rs25487;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CYCLOSPORINE;CYP3A4;rs35599367;AA + AG;TOXICITY;DECREASED_;SIDE_EFFECT:RENAL_FUNCTION_(LOWER_CREATININE_CLEARANCE)_AT_3_MONTHS_OF_FOLLOW-UP
METFORMIN;SLC22A1;rs622342;AA;LADME_PK;DECREASED_PK;PK:CL_RENAL_REFERENCE_AND_LOWER_AND_CL_SEC_REFERENCE
ALLOPURINOL;PSORS1C2;rs9263733;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
CYCLOSPORINE;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DELAYED_GRAFT_FUNCTION
METHOTREXATE;ABCG2;rs13120400;CT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
ALLOPURINOL;PSORS1C1, PSORS1C2;rs9263726;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
DRUGS FOR TREATMENT OF TUBERCULOSIS;;rs1495741;AA;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
EXEMESTANE, LETROZOLE;;rs912571;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN,_ARTHRITIS,_DISCONTINUATION,
ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS;APOA5;rs964184;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERLIPIDEMIAS
VALPROIC ACID;POLG;rs2307441;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CISPLATIN, CYCLOPHOSPHAMIDE;ADH1C;rs698;CT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:COMPLETE_RESPONSE
EXEMESTANE, LETROZOLE;CCDC148;rs79048288;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN,_ARTHRITIS,_DISCONTINUATION,
OXALIPLATIN;GSTP1;rs1695;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
;DRD2;rs6277;G;;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
ATORVASTATIN, LOVASTATIN, SIMVASTATIN;CYP3A4;rs35599367;AA + AG;DOSAGE, LADME_PK;DECREASED_;OTHER:STATIN_DOSES_FOR_OPTIMAL_LIPID_CONTROL
;DRD2;rs1799732;G;;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
VALPROIC ACID;POLG;rs3087374;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
EDOXABAN;SLCO1B1;rs2306283;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
EDOXABAN;ABCB1;rs3842;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
HYDROCHLOROTHIAZIDE;ADD1;rs4961;TT;OTHER;INCREASED_;OTHER:HYDROCHLOROTHIAZIDE_INDUCED_CALCIUM_RETENTION
EDOXABAN;SLCO1B1;rs999278;AA + AC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
LEVODOPA;DRD3;rs6280;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
LEVODOPA;DRD2;rs1799732;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
BUSULFAN, CYCLOPHOSPHAMIDE;CTH;rs1021737;TT;TOXICITY;INCREASED_RISK;DISEASE:HEPATIC_VENO-OCCLUSIVE_DISEASE
FUROSEMIDE, SPIRONOLACTONE;CYP11B2;rs1799998;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DIURETIC_UNRESPONSIVENESS
EDOXABAN;SLCO1B1;rs4149057;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
SIMVASTATIN;ABCB1;rs2032582;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL
SIMVASTATIN;ABCB1;rs2032582;AC;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL
FUROSEMIDE, SPIRONOLACTONE;ACE;rs4341;CG + GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DIURETIC_UNRESPONSIVENESS
SIMVASTATIN;ABCB1;rs1045642;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL
ATORVASTATIN;NOS3;rs2070744;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:ANTI-INFLAMMATORY_EFFECTS
ATORVASTATIN;NOS3;rs2070744;CC;OTHER;INCREASED_;OTHER:WHOLE_BLOOD_NITRITE
PAROXETINE;CYP1A2;rs2472304;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
FUROSEMIDE, SPIRONOLACTONE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DIURETIC_UNRESPONSIVENESS
PAROXETINE;CYP1A2;rs4646425;T;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
ATORVASTATIN;ABCB1;rs2032582;AA;OTHER, LADME_PK;INCREASED_PK;PK:AUC
CISPLATIN, DOXORUBICIN;ERCC1;rs11615;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MUCOSITIS
METHAMPHETAMINE;ARRB2;rs4790694;C;OTHER;INCREASED_LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS
METHOTREXATE;ABCG2;rs2231142;GT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PAROXETINE;CYP1A2;rs2470890;T;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
PEGINTERFERON ALFA-2A, RIBAVIRIN;SCARB1;rs10846744;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PLATINUM COMPOUNDS, RADIOTHERAPY;;rs1829346;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DERMATITIS
CISPLATIN, DOXORUBICIN;CYBA;rs4673;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA,_MUCOSITIS
ATORVASTATIN;ABCB1;rs1128503;AA;OTHER, LADME_PK;INCREASED_PK;PK:AUC
CLOZAPINE;CYP2C19;rs4244285;AA;OTHER, LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS
ATORVASTATIN;ABCB1;rs1045642;AA;OTHER, LADME_PK;INCREASED_PK;PK:AUC
PRASUGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
IRINOTECAN;SLCO1B1;rs2306283;GG;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
PLATINUM COMPOUNDS, RADIOTHERAPY;;rs2027701;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
SIMVASTATIN;ABCB1;rs1128503;AA;OTHER, LADME_PK;INCREASED_PK;PK:AUC_SIMVASTATIN_ACID
PRASUGREL;CYP2C19;rs4244285;A;EFFICACY;EFFICACY;EFFICACY:HIGHER_PLATELET_REACTIVITY_INDEX_(PRI)_VASODILATOR-STIMULATED_PHOSPHOPROTEIN_(VASP)_AT_1_MONTH_OF_TREATMENT
ANTIPSYCHOTICS;SLC18A2;rs363341;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PLATINUM COMPOUNDS, RADIOTHERAPY;;rs1059698;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
ANTIPSYCHOTICS;GRIK3;rs1334802;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PLATINUM COMPOUNDS, RADIOTHERAPY;;rs73594404;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA,_NEUTROPENIA
PAROXETINE;CYP1A2;rs4646427;TT;EFFICACY;EFFICACY;EFFICACY:SLOWER_RESPONSE_TIME
METHOTREXATE;SHMT1;rs1979277;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ABDOMINAL_PAIN
PAROXETINE;CYP1A2;rs762551;A;TOXICITY;INCREASED_RISK;DISEASE:FATIGUE
ANTIPSYCHOTICS;HTR2A;rs9567733;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PLATINUM COMPOUNDS, RADIOTHERAPY;;rs36080650;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DERMATITIS
METHOTREXATE;ABCB1;rs1045642;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
ANTIPSYCHOTICS;DRD2;rs1124491;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PLATINUM COMPOUNDS, RADIOTHERAPY;MEG3;rs10132552;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
WARFARIN;CYP4F2;rs2108622;CT + TT;LADME_PK;INCREASED_PK;PK:SERUM_R_-WARFARIN_CONCENTRATION
MYCOPHENOLATE MOFETIL;UGT1A9;rs72551330;C;TOXICITY;;SIDE_EFFECT:DIMINISHED_ESTIMATED_GLOMERULAR_FILTRATION_RATE_(EGFR)_DURING_THE_FIRST_YEAR_AFTER_ENGRAFTMENT
METHOTREXATE;ABCC2;rs17222723;AT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
METHAMPHETAMINE;SLC6A9;rs2486001;T;TOXICITY, OTHER;INCREASED_RISK;DISEASE:SUBSTANCE-RELATED_DISORDERS
MYCOPHENOLATE MOFETIL;UGT1A9;rs72551330;C;TOXICITY;INCREASED_RISK;DISEASE:PROTEINURIA
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
;KCNH2;rs1805123;T;OTHER;INCREASED_LIKELIHOOD;DISEASE:ATRIAL_FIBRILLATION
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR),_SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
METHAMPHETAMINE;ARRB2;rs2036657;A;OTHER;INCREASED_LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS
METHOTREXATE;MTHFR;rs1801133;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
ASPIRIN;P2RY1;rs1065776;CT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:ASPIRIN-RESISTANT_PHENOTYPE
ROSUVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
;CRHR1;rs110402;AA;OTHER;INCREASED_RISK;DISEASE:MAJOR_DEPRESSIVE_DISORDER
NICOTINE;ARRB2;rs4790694;A;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
WARFARIN;CYP2C9;rs7900194;A;DOSAGE;DECREASED_EFFICACY;EFFICACY:MEDIAN_WEEKLY_WARFARIN_DOSE_REQUIREMENTS
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMATOLOGICAL_TOXICITY
ATORVASTATIN;ABCB1;rs1045642;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYALGIA
CAPECITABINE;MTHFR;rs1801133;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION
CARVEDILOL;ADRB2;rs1042714;C;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_RESTING_BLOOD_PRESSURE
CLOPIDOGREL;PON1;rs662;CC + CT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ANTIDEPRESSANTS;NTRK2;rs1439050;G;TOXICITY;INCREASED_RISK;DISEASE:SUICIDE
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
BEVACIZUMAB;;rs1478947;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
ASPIRIN;TBXA2R;rs4523;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN_RESISTANCE
METHAMPHETAMINE;ARRB2;rs1045280;T;OTHER;INCREASED_LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS
ASPIRIN;GP1BA;rs6065;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN_RESISTANCE
OLANZAPINE;PMCH;rs7973796;G;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:OBESITY
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED_;DISEASE:NEUTROPENIA
WARFARIN;VKORC1;rs9934438;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
ASPIRIN;TGFB1;rs1800469;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_CHRONIC_URTICARIA
WARFARIN;F7;rs6046;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:SEN_SITIVITY_TO_WARFARIN_DURING_INDUCTION
WARFARIN;F7;rs6046;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
CARBOPLATIN, CISPLATIN, DOCETAXEL, GEMCITABINE, PACLITAXEL, VINORELBINE;MTHFR;rs1801133;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE_TO_CHEMOTHERAPY
ASPIRIN, CLOPIDOGREL;KRTAP10-4, TSPEAR;rs201441480;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY,_TREATMENT_MODIFICATION
METHOTREXATE;MTHFD1;rs2236225;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
PACLITAXEL;ABCB1;rs1128503;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
METHOTREXATE;MTHFR;rs1801131;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA,_DRUG_TOXICITY
ATORVASTATIN;NOS3;rs2070744;CC;OTHER;DECREASED_;OTHER:ERYTHROCYTE_PLASMA_MEMBRANE_FLUIDITY
WARFARIN;CYP2C9;rs7900194;A;LADME_PK;DECREASED_PK;PK:S-WARFARIN_CLEARANCE
ASPIRIN, CLOPIDOGREL;ECHS1;rs140410716;T;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;PIGB;rs12050587;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA,_NEUTROPENIA
ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PITAVASTATIN, SIMVASTATIN;SLCO1B1;rs4149035;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ASPIRIN, CLOPIDOGREL;AGAP3;rs75750968;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PITAVASTATIN, SIMVASTATIN;SLCO1B1;rs11045818;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
GEMCITABINE;SLC28A2;rs11854484;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEMATOLOGIC_TOXICITY
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DISCONTINUATION
ACETAMINOPHEN;TLR4;rs1927911;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ASTHMA
TIMOLOL;;rs16947;AA + AG;TOXICITY;INCREASED_RISK;DISEASE:BRADYCARDIA
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;;rs11636687;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA,_NEUTROPENIA
GEMCITABINE;SLC28A2;rs1060896;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEMATOLOGIC_TOXICITY
ATORVASTATIN, FLUVASTATIN, LOVASTATIN, PITAVASTATIN, SIMVASTATIN;ABCG2;rs2622629;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PRAVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DISCONTINUATION
ASPIRIN, CLOPIDOGREL;ZDHHC3;rs3749187;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
VENLAFAXINE;CYP2D6;rs3892097;CT + TT;LADME_PK;INCREASED_PK;PK:VENLAFAXINE_CONCENTRATION_PER_UNIT_DOSE
;ADORA2A;rs5996696;AC + CC;OTHER;DECREASED_RISK;DISEASE:PARKINSON_DISEASE
;ADORA2A;rs71651683;CT;OTHER;DECREASED_RISK;DISEASE:PARKINSON_DISEASE
;IFITM3;rs12252;GG;OTHER;INCREASED_SEVERITY;OTHER:COVID-19
METHOTREXATE;ABCB1;rs1128503;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CAFFEINE;CYP1A2;rs762551;CC;OTHER;DECREASED_RISK;DISEASE:PARKINSON_DISEASE
CAFFEINE;CYP1A2;rs2470890;CC;OTHER;DECREASED_RISK;DISEASE:PARKINSON_DISEASE
CLOZAPINE;ABCB1;rs1045642;AA;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
WARFARIN;VKORC1;rs9934438;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_AUC_(AREA_UNDER_CURVE)_PROTHROMBIN_TIME
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;CC;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA
;KCNJ11;rs5219;TT;;INCREASED_LIKELIHOOD;DISEASE:DIABETES_MELLITUS_TYPE2
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ATORVASTATIN, SIMVASTATIN;SLCO1B1;rs374113543;A;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:HYPERCHOLESTEROLEMIA
ATORVASTATIN, SIMVASTATIN;SLCO1B1;rs373327528;A;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:HYPERCHOLESTEROLEMIA
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;DNAAF9;rs6051702;AA;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
DEXAMETHASONE;SERPINE1;rs6092;AA + AG;TOXICITY;INCREASED_RISK;DISEASE:OSTEONECROSIS
GEMCITABINE;CDA;rs2072671;AA + AC;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
NICOTINE;CHRNB2;rs2072661;GG;EFFICACY, TOXICITY, OTHER;INCREASED_;OTHER:ABSTINENCE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;rs7853758;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CLOZAPINE;CYP1A2;rs2069514;A;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_INSULIN_LEVELS
CISPLATIN, DOXORUBICIN, METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
CISPLATIN, DOXORUBICIN, METHOTREXATE;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
EVEROLIMUS;MTOR;rs2024627;C;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CAPECITABINE;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CISPLATIN, DOXORUBICIN, METHOTREXATE;ERCC2;rs13181;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
NICOTINE;CHRM2;rs324650;T;TOXICITY, OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
CETUXIMAB, PANITUMUMAB;EGFR;rs712829;GT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SURVIVAL
;VDR;rs1544410;C;;INCREASED_RISK;DISEASE:ASTHMA
CLOZAPINE;CYP1A2;rs35694136;del;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_INSULIN_LEVELS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CETUXIMAB, PANITUMUMAB;AREG;rs9996584;AA + AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
BEVACIZUMAB, IRINOTECAN;VEGFA;rs1570360;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;PON1;rs662;CT + TT;OTHER;INCREASED_;OTHER:SMALL-DENSE_LDL_LEVELS
PROTON PUMP INHIBITORS;TRPM6;rs3750425;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPOMAGNESEMIA_PRIMARY
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
;FKBP5;rs1360780;CC + CT;EFFICACY;INCREASED_LIKELIHOOD;
CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C, MIR1264, MIR1912;rs12836771;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
METHOTREXATE;GGH;rs3758149;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
HALOTHANE, SUCCINYLCHOLINE;RYR1;rs193922803;T;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
CETUXIMAB, PANITUMUMAB;AREG;rs11942466;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
SIMVASTATIN;ABCB1;rs1045642;AA;OTHER, LADME_PK;INCREASED_PK;PK:AUC_SIMVASTATIN_ACID
PROTON PUMP INHIBITORS;TRPM6;rs2274924;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPOMAGNESEMIA_PRIMARY
DOXORUBICIN;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
DOXORUBICIN;ERCC1;rs3212986;AA + AC;TOXICITY;DECREASED_RISK;SIDE_EFFECT:INFECTIOUS_DISEASE,_LEUKOPENIA
CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs518147;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
SIMVASTATIN;ABCB1;rs2032582;AA;OTHER, LADME_PK;INCREASED_PK;PK:AUC_SIMVASTATIN_ACID
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs118192172;T;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
NEVIRAPINE;CYP2B6;rs2054675;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ASUNAPREVIR, DACLATASVIR, DIRECT ACTING ANTIVIRALS, LEDIPASVIR / SOFOSBUVIR, OMBITASVIR / PARITAPREVIR / RITONAVIR;IFNL3, IFNL4;rs8099917;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERCHOLESTEROLEMIA
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs118192176;A;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs118192177;T;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs121918593;A;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
NEVIRAPINE;CYP2B6;rs3786547;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CAPECITABINE;DPYD;rs1801160;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs121918592;A;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
CAPECITABINE;DPYD;rs1801159;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
METHYLPHENIDATE;DRD3;rs6280;CT + TT;TOXICITY;INCREASED_;SIDE_EFFECT:INTOLERABILITY
CISPLATIN;ACYP2;rs1872328;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OTOTOXICITY
CLOPIDOGREL;PON1;rs662;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS_(COMPOSITE_OF_CARDIAC_DEATH,_MI,_STENT_THROMBOSIS)_IN_KOREAN_PATIENTS_AFTER_PCI
DOXORUBICIN;XPC;rs2228001;GG + GT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:INFECTIOUS_DISEASE
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
HEROIN;OPRM1;rs9479757;GG;TOXICITY;INCREASED_SEVERITY;OTHER:HEROIN_DEPENDENCE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:BLUNTING_OF_ALCOHOL_CRAVING
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;EFFICACY;EFFICACY:HIGHER_RATE_OF_SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;rs1125338;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
BETA-LACTAM ANTIBACTERIALS, PENICILLINS;;rs71542416;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
IRINOTECAN;ABCG1;rs425215;GG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
XELOX;ABCA2;rs2271862;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
IRINOTECAN;ABCC5;rs562;CC;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
OPIOIDS;TACR1;rs6715729;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:OVERDOSE
OPIOIDS;DRD2;rs4436578;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVERDOSE
OPIOIDS;CYP3A5;rs776746;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVERDOSE
IRINOTECAN;SLCO1B1;rs2306283;AG;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
TRAMADOL;ABCB1;rs1045642;AA;TOXICITY;DECREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
;ABCB1;rs2032582;CC + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CARBOPLATIN, PACLITAXEL;SLCO1B3;rs7311358;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
METHOTREXATE;FPGS;rs10106;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ALOPECIA,_LEUKOPENIA
;HIF1A;rs11549467;AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;FTO;rs12596638;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL,_OVERALL_SURVIVAL
COUMARIN, NICOTINE;CYP2A6;rs28399433;C;OTHER, LADME_PK;DECREASED_;OTHER:EXPRESSION_OF_ENZYME_CONTRIBUTING_TO_THE_METABOLISM
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
;PEMT;rs7946;T;;INCREASED_RISK;DISEASE:FATTY_LIVER_DISEASE
ANTIBIOTICS;LGALS3;rs11125;AT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;INCREASED_RISK;DISEASE:THROMBOCYTOPENIA
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;;rs12600192;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;INCREASED_RISK;DISEASE:HAND-FOOT_SYNDROME
METHOTREXATE;DHFR;rs1650723;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MUCOSITIS
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;;rs12600192;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL,_OVERALL_SURVIVAL
METHOTREXATE;ABCG2;rs2231135;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
NICOTINE;HINT1;rs3852209;CC;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:METASTATIC_NEOPLASM
;VDR;rs1544410;CC;OTHER;DECREASED_LIKELIHOOD;OTHER:PRE-ECLAMPSIA
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;ALAS1;rs352139;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
RISPERIDONE;SLC6A4;rs3813034;AA;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ISONIAZID, RIFAMPIN;GSTP1;rs1695;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CYCLOPHOSPHAMIDE, DOXORUBICIN;ALDH1A1;rs3764435;A;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CYCLOPHOSPHAMIDE, DOXORUBICIN;ALDH1A1;rs168351;A;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
METHOTREXATE;MTHFR;rs1801133;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CARBOPLATIN, PACLITAXEL;SLCO1B3;rs4149117;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs117648444;AA + AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ETHANOL, NALTREXONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:INTOXICATION
ISONIAZID, RIFAMPIN;NAT2;rs1799929;TT;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
OPIOIDS;COMT;rs4680;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERALGESIA
ISONIAZID, RIFAMPIN;NAT2;rs1799930;AA;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
METHOTREXATE;SLC19A1;rs1051266;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;DHFR;rs1053129;CC;TOXICITY;INCREASED_RISKEFFICACY;EFFICACY:METASTATIC_NEOPLASM
METHOTREXATE;MTHFR;rs1801133;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
TAMOXIFEN;HS6ST3;rs118042719;A;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
PHENYTOIN;ABCB1;rs2229107;A;OTHER, LADME_PK;INCREASED_PK;PK:PLASMA_DRUG_LEVELS
"""3,4-METHYLENEDIOXYMETHAMPHETAMINE"", ""COCAINE"", ""ETHANOL"", ""OPIOIDS""";OPRM1;rs1799971;AG;TOXICITY;INCREASED_RISK;OTHER:SUBSTANCE-RELATED_DISORDERS
TRASTUZUMAB;FCGR3A;rs396991;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
MYCOPHENOLIC ACID, TACROLIMUS;ABCC2;rs717620;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PRIMARY_GRAFT_FAILURE,_KIDNEY_TUBULAR_NECROSIS,_ACUTE
METHADONE;CYP2B6;rs1038376;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
TRASTUZUMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
METHOTREXATE;SLC19A1;rs1051266;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
SUCCINYLCHOLINE;BCHE;rs1799807;C;LADME_PK;;SIDE_EFFECT:BUTYRYLCHOLINESTERASE_DEFICIENCY
SUCCINYLCHOLINE;BCHE;rs1803274;T;LADME_PK;;SIDE_EFFECT:BUTYRYLCHOLINESTERASE_DEFICIENCY
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:THROMBOCYTOPENIA
CLOPIDOGREL;CYP2C18;rs1042192;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
CLOZAPINE;HNMT;rs2737385;GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:SEDATION
FLUOROURACIL;DPYD;rs1801160;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
METHADONE;CYP2B6;rs2279343;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
CLOPIDOGREL;NOC3L;rs12572897;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
TAMOXIFEN;LPP;rs6790761;A;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799929;T;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
SUNITINIB;ABCB1;rs1128503;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
NICOTINE;CHRNA5;rs16969968;A;TOXICITY, OTHER;INCREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
CLOPIDOGREL;CYP2C8;rs1058932;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
SUNITINIB;ABCB1;rs2032582;AA + AC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
NICOTINE;CHRNA3;rs578776;A;TOXICITY, OTHER;DECREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
TAMOXIFEN;LPP;rs77693286;A;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
ANTHRACYCLINES AND RELATED SUBSTANCES;UGT1A6;rs17863783;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;INCREASED_RISK;DISEASE:TRANSPLANT_REJECTION
RIFAMPIN;RIPOR2;rs10946739;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;rs2229774;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
;EGFR;rs763317;AA;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
;GAL;rs948854;C;OTHER;INCREASED_SEVERITY;DISEASE:ANXIETY_DISORDERS
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
CARBAMAZEPINE;ZNRD1-AS1;rs3869066;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
ATAZANAVIR;ABCB1;rs2032582;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
HMG COA REDUCTASE INHIBITORS;EYS;rs1337512;G;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:RHABDOMYOLYSIS
RIFAMPIN;AGBL4;rs393994;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ATAZANAVIR;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
PHENYTOIN;CYP2C9;rs1799853;T;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
HMG COA REDUCTASE INHIBITORS, OTHER COMBINATIONS;EYS;rs9342288;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:RHABDOMYOLYSIS
ASPIRIN;SLC30A9;rs1047626;A;TOXICITY, OTHER;DECREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ESCITALOPRAM, NORTRIPTYLINE;BDNF;rs962369;C;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SUICIDAL_IDEATION
ACE INHIBITORS, PLAIN;KCNMA1;rs2253201;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
HMG COA REDUCTASE INHIBITORS, OTHER COMBINATIONS;EYS;rs3857532;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:RHABDOMYOLYSIS
ASPIRIN;TSC1;rs7862221;C;TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
RIFAMPIN;AGBL4;rs320003;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ASPIRIN;THRA;rs11819745;G;TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
RIFAMPIN;CUX2;rs7958375;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC28A3;rs7853758;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
HMG COA REDUCTASE INHIBITORS;GATM;rs9806699;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4363657;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
ASPIRIN;CHIA;rs3818822;A;TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ATAZANAVIR;ABCB1;rs1128503;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERBILIRUBINEMIA
ASPIRIN;;rs1074373;C;TOXICITY, OTHER;DECREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
PHENYTOIN;CYP2C9;rs1799853;T;TOXICITY, LADME_PK;INCREASED_PK;PK:PLASMA_FREE_PHENYTOIN_CONCENTRATION
PHENYTOIN;CYP2C9;rs1057910;C;TOXICITY, LADME_PK;INCREASED_PK;PK:PLASMA_FREE_PHENYTOIN_CONCENTRATION
HEROIN;GRM3;rs1990040;A;OTHER;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
ASPIRIN;ZBTB22;rs3130100;C;TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
CYCLOSPORINE, SIROLIMUS, TACROLIMUS;TCF7L2;rs7903146;T;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIABETES_MELLITUS
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:RHABDOMYOLYSIS
PHENYTOIN;CYP2C9;rs1057910;C;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
ASPIRIN;HLA-DPB1;rs3097671;C;TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ASPIRIN;HLA-DPB2;rs3129294;C;TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ASPIRIN;HLA-DPB1;rs1042151;G;TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ASPIRIN;HLA-DPB1;rs1042136;C;TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
ATORVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
RIFAMPIN;RIPOR2;rs10946737;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PREDNISOLONE;GATA3;rs3824662;AA;PD;INCREASED_RISK;SIDE_EFFECT:SEPSIS
RIFAMPIN;AGBL4;rs319952;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NICOTINE;OPRM1;rs10485057;AA;TOXICITY;INCREASED_RISK;OTHER:TOBACCO_USE_DISORDER
ETHANOL;DPP6;rs2533200;C;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CISPLATIN, CYCLOPHOSPHAMIDE;EPHX1;rs1051740;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY_GRADES_1-4
CARBAMAZEPINE;;rs192543598;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ETHANOL;;rs7900002;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;;rs2582405;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CISPLATIN, CYCLOPHOSPHAMIDE;NAT2;rs1801280;CT;TOXICITY;INCREASED_RISK;DISEASE:ANEMIA
ETHANOL;;rs56722963;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CISPLATIN, CYCLOPHOSPHAMIDE;MUTYH;rs3219484;CT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA_GRADE_3-4
CARBAMAZEPINE;ALK;rs187926838;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ETHANOL;MED19, TMX2;rs576859;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
METHOTREXATE;ATIC;rs7563206;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ENZYMES;A2M;rs669;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGIC_TRANSFORMATION
METHOTREXATE;ATIC;rs3821353;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CHOP, RITUXIMAB;NCF4;rs1883112;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL,_OVERALL_SURVIVAL
ENZYMES;F12;rs1801020;GG;TOXICITY;INCREASED_RISK;DISEASE:DEATH
SUNITINIB;ABCB1;rs1128503;A;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
METHOTREXATE;ATIC;rs2372536;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ETHANOL;;rs6589386;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE
ETHANOL;ADH1C;rs13125415;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
METHOTREXATE;ATIC;rs12995526;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CISPLATIN, CYCLOPHOSPHAMIDE;RAD52;rs11226;AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA_GRADE_3-4
ETHANOL;SLC39A8;rs13135092;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CISPLATIN, CYCLOPHOSPHAMIDE;LIG3;rs1052536;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA_GRADE_3-4
ABIRATERONE, PREDNISOLONE;TSPYL1;rs3828743;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
OPIOIDS;COMT;rs4680;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA,_FATIGUE,_DEPRESSION,
CISPLATIN, FLUOROURACIL, RADIOTHERAPY;XRCC1;rs1799782;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
INDINAVIR;UGT1A1;rs4148323;AG;TOXICITY;INCREASED_RISK;DISEASE:HYPERBILIRUBINEMIA
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR),_SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ETHANOL;ADH1B;rs1229984;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
METHOTREXATE;FPGS;rs10760502;AA;EFFICACY, TOXICITY, OTHER;DECREASED_LIKELIHOOD;OTHER:DISCONTINUATION
METHOTREXATE;FPGS;rs10106;TT;EFFICACY, TOXICITY, OTHER;DECREASED_LIKELIHOOD;OTHER:DISCONTINUATION
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs55886062;AC + CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
METHOTREXATE;FPGS;rs10106;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ETHANOL;;rs9679319;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;;rs1402398;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;THSD7B;rs13382553;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
PEGINTERFERON ALFA-2A, RIBAVIRIN;;rs4273729;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR),_SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR),_SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
METHOTREXATE;ABCB1;rs868755;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ETHANOL;;rs2673136;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;;rs13129401;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
METHOTREXATE;ABCB1;rs10280623;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ETHANOL;CADM2;rs62250713;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;ADH1B;rs75967634;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CARBOPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, LOMUSTINE, METHOTREXATE, VINCRISTINE;METTL3;rs1139130;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FEVER,_MUCOSITIS
HEROIN;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_SEVERITY;OTHER:HEROIN_DEPENDENCE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;;rs4273729;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
;CYP2A6;rs56113850;T;OTHER;DECREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
ETHANOL;PDE4B;rs6421482;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;;rs61767420;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;GCKR;rs1260326;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;;rs494904;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
;CHRNA5;rs503464;AA + AT;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
METHOTREXATE;SPATA9;rs72783407;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
METHOTREXATE;BIRC5;rs9904341;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:DISEASE_ACTIVITY_SCORE_28_IN_RHEUMATOID_ARTHRITIS
PROTEIN KINASE INHIBITORS;STAT6;rs324011;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
OPIOIDS;ANKK1, DRD2;rs1800497;AA + AG;TOXICITY;INCREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
TAMOXIFEN;C1QTNF6;rs114557570;C;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
;CHRNA5;rs637137;AA + AT;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
DOCETAXEL;VEGFA;rs833061;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DOCETAXEL;VEGFA;rs13207351;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
DOCETAXEL;VEGFA;rs35864111;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;GATA3;rs3824662;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RELAPSE
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;GATA3;rs3824662;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:MINIMAL_RESIDUAL_DISEASE
DOCETAXEL;VEGFA;rs699947;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
EXEMESTANE;;rs62293499;C;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:RECURRENCE
ASPIRIN, CLOPIDOGREL;CYP4F2;rs2108622;CT;OTHER;INCREASED_;OTHER:PLATELET_AGGREGATION_WITH_EPINEPHRINE
FLUOROURACIL;DPYD;rs4294451;AT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
CITALOPRAM;COL26A1;rs17135437;T;TOXICITY;INCREASED_;SIDE_EFFECT:HEARING_AND_VISION-RELATED_SIDE-EFFECTS
CITALOPRAM;;rs16965962;A;TOXICITY;INCREASED_;SIDE_EFFECT:GENERAL_SIDE-EFFECT_BURDEN
ALLOPURINOL;PSORS1C1, PSORS1C2;rs9263726;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ASPIRIN;ACE;rs4292;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN_INTOLERANCE
CLOPIDOGREL;P2RY12;rs6809699;AA;EFFICACY;EFFICACY;EFFICACY:STRONGER_AGGREAGTION
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC22A17;rs4982753;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
TACROLIMUS;CYP3A5;rs776746;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIABETES_MELLITUS
FLUOROURACIL;DPYD;rs4294451;AT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
;ACE2;rs2074192;T;OTHER;INCREASED_SEVERITY;OTHER:COVID-19
CLOPIDOGREL;P2RY12;rs6809699;AA;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CLOPIDOGREL_RESISTANCE
ASPIRIN, CLOPIDOGREL;F2R;rs168753;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
CLOPIDOGREL;P2RY12;rs6809699;AA;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
ASPIRIN;P2RY1;rs1065776;CT;EFFICACY;INCREASED_EFFICACY;EFFICACY:NET_DECREASE_IN_AA-INDUCED_PLATELET_AGGREGATION_AFTER_ASPIRIN_TREATMENT
MERCAPTOPURINE;ITPA;rs1127354;AC;LADME_PK;INCREASED_PK;PK:6-MMPN_LEVELS
;FGFR2;rs1219648;G;TOXICITY, OTHER;INCREASED_RISK;DISEASE:BREAST_NEOPLASMS
ANASTROZOLE;;rs6735923;T;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
ACENOCOUMAROL;CYP2C9;rs1799853;CT + TT;TOXICITY;INCREASED_RISK;DISEASE:GASTROINTESTINAL_HEMORRHAGE
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
ANTHRACYCLINES AND RELATED SUBSTANCES;SLC10A2;rs7319981;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
;AGT;rs699;AG;OTHER;INCREASED_LIKELIHOOD;OTHER:COVID-19
ANASTROZOLE;;rs1877193;C;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
CAPECITABINE;DPYD;rs2786783;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
;COMT;rs4818;CC + CG;OTHER;INCREASED_SEVERITY;OTHER:PAIN
DRUGS FOR TREATMENT OF TUBERCULOSIS;UGT2B7;rs7662029;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DRUGS FOR TREATMENT OF TUBERCULOSIS;UGT2B7;rs7439366;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY, TOXICITY;INCREASED_;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CEFACLOR;LIMD1;rs62242178;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
WARFARIN;VKORC1;rs9923231;TT;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
CEFACLOR;LIMD1;rs62242177;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
REPAGLINIDE;SLCO1B1;rs4149056;CC;OTHER, LADME_PK;INCREASED_PK;PK:MEAN_PLASMA_AUC
DIHYDROPYRIDINE DERIVATIVES;ADRA1A;rs1048101;AG + GG;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:KIDNEY_DISORDER
THALIDOMIDE;XRCC5;rs1051685;AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
THALIDOMIDE;ERCC1;rs735482;AC + CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOZAPINE, OLANZAPINE;GCG;rs13429709;C;OTHER;INCREASED_;DISEASE:WEIGHT_GAIN
CLOZAPINE, OLANZAPINE;GLP1R;rs2268639;T;OTHER;INCREASED_;DISEASE:WEIGHT_GAIN
NICOTINE;OPRM1;rs1799971;AA + AG;DOSAGE;INCREASED_;OTHER:SMOKING
NICOTINE;OPRM1;rs1799971;AG + GG;DOSAGE;INCREASED_;OTHER:SMOKING
TOLCAPONE;COMT;rs4680;AA;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:ALCOHOL_ABUSE
NICOTINE;UGT2B10;rs112561475;AG + GG;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION_OF_NICOTINE
NICOTINE;UGT2B10;rs61750900;T;LADME_PK;DECREASED_PK;PK:NICOTINE_GLUCURONIDATION
CLOZAPINE, OLANZAPINE;GCG;rs13429709;CC;OTHER;INCREASED_;DISEASE:WEIGHT_GAIN
DIHYDROPYRIDINE DERIVATIVES;CYP3A5;rs776746;TT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:KIDNEY_DISORDER
METHAMPHETAMINE;HTR1A;rs878567;A;TOXICITY, OTHER;;DISEASE:PSYCHOTIC_DISORDER
METHOTREXATE;MTHFR;rs1801133;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
CISPLATIN, FLUOROURACIL, MITOXANTRONE;GALNT14;rs9679162;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
CAPTOPRIL;ACE;rs4291;AA;EFFICACY;DECREASED_SEVERITY;DISEASE:KIDNEY_FAILURE
ANTIEPILEPTICS;;rs4471527;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
ANTIPSYCHOTICS;LEPR;rs1137101;G;OTHER;INCREASED_LIKELIHOOD;DISEASE:OBESITY
ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;rs2232228;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
ETHANOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE
ANTIEPILEPTICS;;rs77542827;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
STAVUDINE;SAMHD1;rs8124728;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CARVEDILOL;ADRB1;rs1801253;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESPONSE_(HEART-RATE_LOWERING)
IRINOTECAN;TGFB1;rs1800469;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;rs2229774;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
CYTARABINE, DAUNORUBICIN, MITOXANTRONE;DCK;rs4643786;CT;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ANTIEPILEPTICS;NIPAL2;rs199755581;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
OXALIPLATIN, PACLITAXEL;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
AMLODIPINE, CHLORTHALIDONE, LISINOPRIL;ACE;rs4291;AA + AT;OTHER;DECREASED_;SIDE_EFFECT:FASTING_GLUCOSE
SORAFENIB;KDR;rs1870377;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
IRINOTECAN;TGFBR2;rs3087465;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
SORAFENIB;KDR;rs1870377;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTENSION
SUNITINIB;FLT4;rs307826;CT;EFFICACY;EFFICACY;EFFICACY:REDUCED_PROGRESSION-FREE_SURVIVAL
SUNITINIB;CYP3A5;rs776746;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DOSE_REDUCTIONS_DUE_TO_TOXICITY
RITODRINE;PDE4B;rs17128809;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
CYCLOPHOSPHAMIDE, DOCETAXEL, EPIRUBICIN;ABCC1;rs246221;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
SUNITINIB;FLT4;rs307821;AC;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
BETA BLOCKING AGENTS;ADRB2;rs1042713;AG + GG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HEART_TRANSPLANTATION,_DEATH
SALBUTAMOL;;rs9552679;C;EFFICACY;DECREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SALBUTAMOL;COL22A1;rs6988229;T;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SALBUTAMOL;;rs17495520;T;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
ASPIRIN, CLOPIDOGREL;CDH15;rs72819363;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:CORONARY_RESTENOSIS,_DISEASE_PROGRESSION
ANTIEPILEPTICS;DDX12P;rs77491650;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
SALBUTAMOL;;rs1663332;T;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SALBUTAMOL;;rs1663330;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SALBUTAMOL;;rs17701271;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SALBUTAMOL;;rs518350;T;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SALBUTAMOL;;rs10511905;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SORAFENIB;ABCC2;rs717620;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
SALBUTAMOL;CLOCK;rs1522113;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SALBUTAMOL;;rs1423515;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SALBUTAMOL;;rs1419555;T;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SALBUTAMOL;;rs6002674;C;EFFICACY;DECREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
;ACE2;rs2106809;A;OTHER;INCREASED_LIKELIHOOD;OTHER:COVID-19
DOXORUBICIN;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
METHOTREXATE;ABCB1;rs1045642;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
ASPIRIN, CLOPIDOGREL;CDH13;rs11859453;AA + AG;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:CORONARY_RESTENOSIS,_DISEASE_PROGRESSION
ALLOPURINOL;CYCSP5;rs3099844;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
ALLOPURINOL;;rs1634776;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
PACLITAXEL;ABCB1;rs1128503;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
SALBUTAMOL;;rs11252394;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:BRONCHODILATOR_RESPONSE_(FEV1)
SORAFENIB;SLCO1B1;rs4149056;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
COCAINE;GABRA2;rs11503014;G;TOXICITY;INCREASED_SEVERITY;OTHER:COCAINE_DEPENDENCE
COCAINE;OPRM1;rs2236256;C;TOXICITY;DECREASED_SEVERITY;OTHER:COCAINE_DEPENDENCE
SORAFENIB;SLCO1B1;rs2306283;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
SORAFENIB;SLCO1B1;rs2306283;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
METHOTREXATE;ABCB1;rs1128503;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
;AGT;rs699;A;OTHER;DECREASED_SEVERITY;OTHER:COVID-19
CANGRELOR;P2RY12;rs9859552;TT;OTHER;;OTHER:20%_AND_17%_LESS_INHIBITION_OF_PLATELET_AGGREGATION_WITH_CRANGRELOR_(0.05_AND_0.25_MICROM)_IN-VITRO
SORAFENIB;NOS3;rs2070744;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
RADIOTHERAPY;TANC1;rs10497203;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK;DISEASE:LEUKOPENIA
SORAFENIB;NOS3;rs1799983;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SORAFENIB;NOS3;rs1799983;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GLUCOCORTICOIDS;GLCCI1;rs37973;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:POOR_RESPONSE
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCG2;rs7699188;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:TUMOR_RESPONSE_RATE
SORAFENIB;NOS3;rs2070744;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;DECREASED_;SIDE_EFFECT:INTERVAL_OF_THERAPY_TO_LEUKOPENIA_ONSET
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CTLA4;rs3087243;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:PSORIASIS
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK;DISEASE:LEUKOPENIA
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FBXL19;rs10782001;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PSORIASIS
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;IL23R;rs11209026;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PSORIASIS
AZATHIOPRINE;NUDT15;rs116855232;TT;TOXICITY;INCREASED_SEVERITY;DISEASE:LEUKOPENIA
METHOTREXATE;MTHFR;rs1801133;A;LADME_PK;INCREASED_RISKPK;PK:PROLONGED_HIGH_CONCENTRATIONS
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
MORPHINE;ABCB1;rs2032582;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA,_VOMITING
COLISTIMETHATE;SLC15A2;rs2257212;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY
HEROIN;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
ASPARAGINASE, DAUNORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:FOLIC_ACID_DEFICIENCY_ANEMIA
ASPARAGINASE, DAUNORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;MTHFR;rs1801131;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
WARFARIN;GGCX;rs699664;CT + TT;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
CETUXIMAB;FCGR3A;rs396991;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL
WARFARIN;CYP2C9;rs28371685;CT;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
CETUXIMAB;CCND1;rs9344;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL
WARFARIN;F7;rs510335;GT + TT;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
TACROLIMUS;IL10;rs1800871;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
ESCITALOPRAM;HTR1B;rs11568817;AC + CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_COGNITIVE_EFFECTS
CETUXIMAB;CCND1;rs9344;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
FLUVOXAMINE, MILNACIPRAN, PAROXETINE;MDGA2;rs1160351;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEXSUAL_DYSFUNCTION
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""RITONAVIR""";APOC1, APOE, TOMM40;rs429358;CC + CT;TOXICITY;INCREASED_;SIDE_EFFECT:NON-HDL_CHOLESTEROL
ESCITALOPRAM;HTR2A;rs6311;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_COGNITIVE_EFFECTS
TACROLIMUS;IL10;rs1800872;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
;;rs17234657;G;;INCREASED_RISK;DISEASE:CROHN_DISEASE
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_;OTHER:WARFARIN_DOSE
LEVODOPA;HOMER1;rs4704559;AG + GG;TOXICITY;DECREASED_RISK;DISEASE:DYSKINESIAS
CYCLOPHOSPHAMIDE, DOCETAXEL, EPIRUBICIN;SOD2;rs4880;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
LEVODOPA;HOMER1;rs4704559;AG + GG;TOXICITY;DECREASED_RISK;DISEASE:HALLUCINATIONS
;;rs2200733;T;;INCREASED_RISK;DISEASE:ATRIAL_FIBRILLATION
ESTRADIOL;NFE2L2;rs6721961;T;TOXICITY;INCREASED_RISK;DISEASE:VENOUS_THROMBOEMBOLISM
HYDROCHLOROTHIAZIDE;YEATS4;rs7297610;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
CAPECITABINE;DPYD;rs3918290;CT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
WARFARIN;F2;rs5896;CT + TT;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
;HLA-DRA;rs3135388;A;;INCREASED_RISK;DISEASE:MULTIPLE_SCLEROSIS
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
;NOD2;rs17221417;G;;INCREASED_RISK;DISEASE:CROHN_DISEASE
CISPLATIN, PACLITAXEL;TP53;rs1042522;CG + GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:ONE_YEAR_PROGRESSION_FREE_SURVIVAL
AZATHIOPRINE;ITPA;rs1127354;AC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FLU-LIKE_SYMPTOMS
CLOPIDOGREL;CES1;rs71647871;CT;PD;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PLATELET_REACTIVITY
;TCF7L2;rs12255372;T;;INCREASED_RISK;DISEASE:DIABETES_MELLITUS_TYPE2
;IL6;rs1800797;AG + GG;OTHER;INCREASED_SEVERITY;OTHER:PAIN
;TCF7L2;rs12243326;C;;INCREASED_RISK;DISEASE:DIABETES_MELLITUS_TYPE2
;TCF7L2;rs4506565;T;;INCREASED_RISK;DISEASE:DIABETES_MELLITUS_TYPE2
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
ETHANOL;ADH1B;rs1229984;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
WARFARIN;VKORC1;rs9934438;AG;DOSAGE;INCREASED_;OTHER:WARFARIN_DOSE
;CDKN2B-AS1;rs10965219;G;OTHER;INCREASED_;OTHER:PLATELET_REACTIVITY
MORPHINE;COMT;rs4680;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:NUMERICAL_RATING_SCALE_(NRS)_SCORE_FOR_PAIN_DURING_PAINFUL_PROCEDURE
ETHANOL;RABGAP1L;rs61826952;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
MORPHINE;COMT;rs4680;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_MEAN_NUMERICAL_RATING_SCALE_(NRS)_SCORE_FOR_PAIN
;CDKN2B-AS1;rs10965219;G;OTHER;INCREASED_RISK;DISEASE:CORONARY_ARTERY_DISEASE
TRAMADOL;CYP2D6;rs1058172;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVERDOSE
CLOZAPINE;CYP2D6;rs16947;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA
TRAMADOL;CYP2B6;rs4803419;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVERDOSE
;ACE2;rs4240157;CC;OTHER;INCREASED_RISK;OTHER:DEATH
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_TROUGH_CONCENTRATIONS
;ACE2;rs4240157;C;OTHER;INCREASED_LIKELIHOOD;OTHER:COVID-19
CLOZAPINE;CYP2D6;rs1065852;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION,_ELEVATED_LIVER_ENZYMES
CLOZAPINE;CYP2D6;rs1065852;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_PK;PK:CONCENTRATION-TO-ADJUSTED_DOSE_RATIO
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS,_NEUTROPENIA,_PANCREATITIS,_VOMITING
CLOZAPINE;CYP2D6;rs16947;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION,_ELEVATED_LIVER_ENZYMES
HMG COA REDUCTASE INHIBITORS;COQ5;rs10849757;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
AZATHIOPRINE;ITPA;rs1127354;AC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
ZOLEDRONATE;FDPS;rs2297480;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS
HMG COA REDUCTASE INHIBITORS;COQ3;rs11548336;TT;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
IMATINIB;CYP2B6;rs3745274;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
HMG COA REDUCTASE INHIBITORS;COQ2;rs4693075;CG + GG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
CYCLOPHOSPHAMIDE, DOXORUBICIN;ABCB1;rs2032582;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs3211371;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY
ATORVASTATIN, PRAVASTATIN, SIMVASTATIN;CLMN;rs8014194;A;EFFICACY;EFFICACY;EFFICACY:CHANGE_IN_TOTAL_CHOLESTEROL
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs12721655;AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
NINTEDANIB;DSP;rs2076295;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs8192709;CT;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_PROGRESSION
FLUOROURACIL, LEUCOVORIN;MTHFR;rs1801133;GG;TOXICITY;DECREASED_SEVERITY;DISEASE:DRUG_TOXICITY
WARFARIN;F2;rs5896;CT + TT;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
BUSULFAN;CYP2C19;rs12248560;CC;LADME_PK;INCREASED_PK;PK:METABOLIC_RATIO
CAPECITABINE;MTHFR;rs1801131;TT;TOXICITY;DECREASED_;DISEASE:DRUG_TOXICITY
WARFARIN;F7;rs510317;GG;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;TAP1;rs1135216;CT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:PSORIASIS
OLANZAPINE, QUETIAPINE, RISPERIDONE;ANKK1;rs1800497;AA;TOXICITY;INCREASED_RISK;DISEASE:HEADACHE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;SLC12A8;rs651630;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT:PSORIASIS
RADIOTHERAPY;TANC1;rs264588;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY, LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
RADIOTHERAPY;TANC1;rs264631;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
BUSULFAN;CYP2C9;rs1799853;CT + TT;LADME_PK;INCREASED_PK;PK:METABOLIC_RATIO
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs714368;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY
RADIOTHERAPY;TANC1;rs7582141;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCG2;rs7699188;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GRADE_3-4_NONHEMATOLOGICAL_TOXICITY
RADIOTHERAPY;TANC1;rs6432512;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
RADIOTHERAPY;TANC1;rs264663;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;ABCB1;rs2032582;CC;EFFICACY;EFFICACY;EFFICACY:OVERALL_SURVIVAL
RADIOTHERAPY;TANC1;rs264651;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs3745274;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION
CYCLOPHOSPHAMIDE, DOXORUBICIN;CYP2B6;rs8192709;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY
PLATINUM COMPOUNDS;XPC;rs2228000;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY,_HEMATOLOGIC_DISORDER,_LEUKOPENIA,
SECUKINUMAB;ERAP2;rs2248374;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs12210538;G;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs723685;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY
CYCLOPHOSPHAMIDE, DOXORUBICIN;SLC22A16;rs6907567;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_DELAY
ASPIRIN;LTC4S;rs730012;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:URTICARIA
ATORVASTATIN, ROSUVASTATIN;COQ2;rs4693075;G;TOXICITY;INCREASED_RISK;DISEASE:MUSCULAR_DISEASES
ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;SEMA5A;rs35719165;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
METHOTREXATE;MTHFD1;rs2236225;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
WARFARIN;VKORC1;rs2884737;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
EFAVIRENZ, NELFINAVIR;ABCB1;rs1045642;AA;EFFICACY, OTHER;INCREASED_EFFICACY;EFFICACY:RISE_IN_CD4-CELL_COUNT
EFAVIRENZ;ABCB1;rs1045642;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:FAVORABLE_VIROLOGIC_RESPONSES
ATEZOLIZUMAB, AVELUMAB, DURVALUMAB, IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;EDIL3;rs1862167;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_PK;PK:TROUGH_CONCENTRATION
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_PK;PK:TROUGH_CONCENTRATIONS
DOXORUBICIN;ABCC2;rs17222723;A;TOXICITY, LADME_PK;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs2032583;AG + GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
AZATHIOPRINE;XDH;rs2295475;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
;ATP8B3;rs10421558;G;TOXICITY;DECREASED_LIKELIHOOD;OTHER:ASPIRIN-INDUCED_ASTHMA
;ABCB1;rs1045642;AA;OTHER;INCREASED_LIKELIHOOD;DISEASE:BREAST_NEOPLASMS
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799929;T;TOXICITY, LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799930;A;TOXICITY, LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ANTHRACYCLINES AND RELATED SUBSTANCES, DOXORUBICIN, EPIRUBICIN;ABCB1;rs1045642;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_PROGRESSION
RITONAVIR;APOC3;rs2854117;T;TOXICITY;INCREASED_RISK;DISEASE:HYPERTRIGLYCERIDEMIA
;AGTR1;rs5186;CC;OTHER;INCREASED_RISK;DISEASE:ISCHEMIA
IMATINIB;ARID5B;rs10821936;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1041983;T;TOXICITY, LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1801280;C;TOXICITY, LADME_PK;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
FEXOFENADINE;ABCB1;rs1045642;AA;DOSAGE, LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATION
EFAVIRENZ;CYP2B6;rs28399499;C;LADME_PK;INCREASED_PK;PK:PLASMA_CMIN_VALUES
EFAVIRENZ;CYP2B6;rs4803419;T;LADME_PK;INCREASED_PK;PK:PLASMA_CMIN_VALUES
IMATINIB;ATIC;rs2372536;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
ATORVASTATIN, SIMVASTATIN;CYP3A4;rs2740574;CC + CT;OTHER;DECREASED_RISK;OTHER:DOSE_DECREASE_OR_DRUG_SWITCHING
FEXOFENADINE;ABCB1;rs2032582;AA;DOSAGE, LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATION
RITODRINE;KCNMB2;rs7625907;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
EFAVIRENZ;CYP2B6;rs3745274;T;LADME_PK;INCREASED_PK;PK:PLASMA_CMIN_VALUES
DOXORUBICIN;ABCC1;rs45511401;T;TOXICITY, LADME_PK;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN;ABCC2;rs8187710;A;TOXICITY, LADME_PK;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
CAPECITABINE, FOLFOX, TEGAFUR;SMAD7;rs4939827;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DOXORUBICIN;NCF4;rs1883112;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
;ATP8B3;rs10403288;A;TOXICITY;DECREASED_LIKELIHOOD;OTHER:ASPIRIN-INDUCED_ASTHMA
SIMVASTATIN;ABCB1;rs1128503;A;EFFICACY;DECREASED_RISK;SIDE_EFFECT:MYALGIA
;ACE2;rs2074192;T;OTHER;INCREASED_SEVERITY;OTHER:COVID-19
DOXORUBICIN;CYBA;rs4673;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
SIMVASTATIN;ABCB1;rs1045642;A;EFFICACY;DECREASED_RISK;SIDE_EFFECT:MYALGIA
DOXORUBICIN;RAC2;rs13058338;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
SIMVASTATIN;ABCB1;rs2032582;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT:MYALGIA
;ABO;rs8176746;T;;INCREASED_;OTHER:ACE_ACTIVITY
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_PK;PK:CONCENTRATION-TO-ADJUSTED_DOSE_RATIO
ATORVASTATIN, SIMVASTATIN;PON1;rs705379;AA + AG;EFFICACY;EFFICACY;EFFICACY:CHANGE_IN_HDL-CHOLESTEROL
ATORVASTATIN, SIMVASTATIN;PON1;rs662;CC + CT;EFFICACY;EFFICACY;EFFICACY:CHANGE_IN_HDL-CHOLESTEROL
ATORVASTATIN;PON1;rs705379;GG;OTHER;DECREASED_;OTHER:OXIDATIVE_STRESS
CLOZAPINE;TACR1;rs58933792;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRY_MOUTH
TACROLIMUS;CYP3A5;rs776746;CT + TT;LADME_PK;DECREASED_PK;PK:CONCENTRATION/DOSE_RATIO
FLUCONAZOLE, TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_PK;PK:TIME_TO_REACH_STABLE_DOSE_OF_TACROLIMUS
FLUCONAZOLE, TACROLIMUS;CYP3A5;rs776746;CC;DOSAGE;DECREASED_PK;PK:DOSE_OF_TACROLIMUS
TACROLIMUS;CYP3A5;rs776746;CT + TT;DOSAGE;INCREASED_PK;PK:TIME_TO_REACH_STABLE_DOSE
TAMOXIFEN;SLCO1A2;rs10841795;AG + GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DIZZINESS
CLOZAPINE;ERBB4;rs3942465;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRY_MOUTH
DIAZEPAM;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS"", ""BETA BLOCKING AGENTS"", ""DIGOXIN"", ""DIURETICS"", ""SPIRONOLACTONE""";ADRB2;rs1042713;GG;OTHER;INCREASED_RISK;OTHER:EMERGENCY_DEPARTMENT_AND_HOSPITAL_UTLIIZATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;AA + AC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
L-ASPARAGINE, PREDNISONE, VINCRISTINE;ASNS;rs1049674;AT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CUSHING_SYNDROME
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS"", ""BETA BLOCKING AGENTS"", ""DIGOXIN"", ""DIURETICS"", ""SPIRONOLACTONE""";NOS3;rs1799983;TT;OTHER;INCREASED_RISK;OTHER:EMERGENCY_DEPARTMENT_UTLIIZATION
EFAVIRENZ, LOPINAVIR, NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS, RITONAVIR;;rs2853826;G;TOXICITY;INCREASED_;SIDE_EFFECT:BASELINE_ADIPONECTIN_AND_WITH_GREATER_ADIPONECTIN_DECLINE
DIAZEPAM;CYP2C19;rs12248560;CT + TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS"", ""BETA BLOCKING AGENTS"", ""DIGOXIN"", ""DIURETICS"", ""SPIRONOLACTONE""";ADRB1;rs1801253;GG;OTHER;DECREASED_RISK;OTHER:EMERGENCIES
L-ASPARAGINE, PREDNISONE, VINCRISTINE;ABCB1;rs9282564;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
OLANZAPINE;UGT1A4;rs2011425;GG + GT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:AUTONOMIC_NERVOUS_SYSTEM_DISORDER
OLANZAPINE;CYP3A4;rs2740574;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRY_MOUTH
CABAZITAXEL;ABCB1;rs17327624;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
SIMVASTATIN;ABCB1;rs1128503;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL
OLANZAPINE;UGT1A4;rs2011425;GG + GT;LADME_PK;INCREASED_PK;PK:GLUCURONIDATED_METABOLITES_OF_OLANZAPINE
;COL1A1;rs1800012;AA + AC;;INCREASED_RISK;DISEASE:FRACTURES,_BONE
CYCLOSPORINE;ABCB1;rs1045642;AG;TOXICITY;INCREASED_SEVERITY;DISEASE:GINGIVAL_HYPERPLASIA
TACROLIMUS;CYP3A5;rs776746;CT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:ACUTE_REJECTION
CLOPIDOGREL;P2RY12;rs6785930;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DRUG_RESISTANCE
CABAZITAXEL;ABCB1;rs2235040;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ASTHENIA
TACROLIMUS;NOD2;rs2066844;CC;OTHER;INCREASED_;OTHER:HOSPITAL_STAY
TACROLIMUS;CYP3A5;rs776746;TT;EFFICACY;INCREASED_RISK;OTHER:ACUTE_REJECTION
TACROLIMUS;CYP3A5;rs776746;CT;EFFICACY;INCREASED_RISK;OTHER:ACUTE_REJECTION
CYCLOSPORINE, TACROLIMUS;CYP3A4;rs2740574;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TRANSPLANT_REJECTION
WARFARIN;VKORC1;rs2359612;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE
AZATHIOPRINE, MERCAPTOPURINE;FTO;rs16952570;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT:LEUKOPENIA,_NEUTROPENIA
OSELTAMIVIR;CES1;rs121912777;CT + TT;LADME_PK;PK;PK:SIGNIFICANTLY_LARGER_MEAN_AUC_OF_OSELTAMIVIR,_LOWER_CMAX_OF_OSELTAMIVIR_CARBOXYLATE,_AND_A_SMALLER_OSELTAMIVIR_CARBOXYLATE-TO-OSELTAMIVIR_AUC_RATIO
AZATHIOPRINE, MERCAPTOPURINE;FTO;rs16952570;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA,_NEUTROPENIA
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_PK;PK:PBMC_CONCENTRATIONS
CABAZITAXEL;CYP2C8;rs11572093;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ASTHENIA
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE
CITALOPRAM;CYP2C19;rs4244285;A;TOXICITY;INCREASED_;SIDE_EFFECT:INTOLERANCE
WARFARIN;VKORC1;rs9934438;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE
NORTRIPTYLINE;GNB3;rs5443;TT;TOXICITY;;DISEASE:WEIGHT_GAIN
WARFARIN;VKORC1;rs8050894;CG + GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE
NORTRIPTYLINE;GNB3;rs5443;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SLEEP_INITIATION_AND_MAINTENANCE_DISORDERS
WARFARIN;VKORC1;rs2884737;AC + CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THE_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE
NORTRIPTYLINE;GNB3;rs5443;TT;EFFICACY;EFFICACY;EFFICACY:IMPROVEMENTS_IN_NEUROVEGETATIVE_SYMPTOMS
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_PK;PK:TROUGH_CONCENTRATION
WARFARIN;VKORC1;rs9934438;A;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
TACROLIMUS;CYP3A5;rs776746;CC;LADME_PK;INCREASED_PK;PK:TROUGH_CONCENTRATION
;SLC19A1;rs1051266;C;OTHER;INCREASED_LIKELIHOOD;OTHER:DOWN_SYNDROME
DIGOXIN;ABCB1;rs1045642;AA;LADME_PK;DECREASED_PK;PK:DUODENAL_ABSORPTION_OF_DIGOXIN_AFTER_DIRECT_DELIVERY_TO_THE_SURFACE_OF_THE_DUODENUM_BY_ENDOSCOPE
OLANZAPINE;HTR2A;rs7997012;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs3918290;T;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CAPECITABINE, FLUOROURACIL, TEGAFUR;DPYD;rs67376798;A;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
OLANZAPINE;ABCB1;rs1045642;A;EFFICACY;EFFICACY;EFFICACY:POSITIVE_RELATIONSHIP_BETWEEN_OLANZAPINE_PLASMA_LEVELS_AND_POSITIVE_SYMPTOM_REDUCTION_COMPARED_TO_SUBJECTS_WITH_THE_GG_GENOTYPE
OLANZAPINE;CYP1A2;rs762551;AA;LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATIONS
NICOTINE;OPRM1;rs1799971;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
OLANZAPINE;DRD2;rs6275;A;OTHER, LADME_PK;INCREASED_;OTHER:PROLACTIN
ANTHRACYCLINES AND RELATED SUBSTANCES;CBR1;rs9024;GG;TOXICITY;INCREASED_RISK;DISEASE:CARDIOMYOPATHIES
OLANZAPINE;DRD2;rs6279;G;OTHER, LADME_PK;INCREASED_;OTHER:PROLACTIN
CEPHALEXIN;;rs34545984;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
OLANZAPINE;DRD2;rs1124493;T;OTHER, LADME_PK;INCREASED_;OTHER:PROLACTIN
OLANZAPINE;DRD2;rs2734841;A;OTHER, LADME_PK;INCREASED_;OTHER:PROLACTIN
ASPIRIN;;rs115346678;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
METHOTREXATE;MTHFD1;rs2236225;A;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
SIMVASTATIN;PPARA;rs4253728;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL_AND_LDL-CHOLESTEROL
METHOTREXATE;MTHFR;rs1801133;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
CODEINE;WBP2NL;rs9620007;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE_IN_KOREAN_PATIENTS_WITH_MECHANICAL_HEART_VALVE_REPLACEMENT_SINCE_DAY_7_OF_WARFARIN_THERAPY
CODEINE, HYDROCODONE, OXYCODONE, TRAMADOL;OPRM1;rs62436463;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
METFORMIN;SLC22A2;rs316009;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
METFORMIN;SLC22A2;rs316019;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
SIMVASTATIN;PPARA;rs4823613;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL_AND_LDL-CHOLESTEROL
;ANKK1;rs1800497;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
NICOTINE;COMT;rs4680;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RELAPSE
ESCITALOPRAM;HTR2A;rs6311;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SUICIDAL_IDEATION,_ADVERSE_EVENTS,_DELIBERATE_SELF-HARM,
NICOTINE;ANKK1;rs1800497;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
AMIODARONE, ANTIBIOTICS, ANTIPSYCHOTICS, DIURETICS, QUINIDINE, SOTALOL;KCNE1;rs1805128;T;TOXICITY;INCREASED_RISK;DISEASE:TORSADES_DE_POINTES
NICOTINE;OPRM1;rs1799971;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
NICOTINE;OPRM1;rs1799971;AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
BUPROPION;ANKK1;rs1800497;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
OLANZAPINE;DRD2;rs2734842;G;OTHER, LADME_PK;INCREASED_;OTHER:PROLACTIN
METHOTREXATE;MTHFR;rs1801133;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
PYRIMIDINE ANALOGUES;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ROSUVASTATIN;ABCG2;rs2231142;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PERCENTAGE_CHANGE_IN_LDL-CHOLESTEROL_LEVELS
AMITRIPTYLINE;CYP2C19;rs4244285;AA;OTHER, LADME_PK;INCREASED_PK;PK:LOG_METABOLIC_RATIO_OF_AMITRIPTYLINE/NORTRIPTYLINE
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CARDIOVASCULAR_DEATH,_MYOCARDIAL_INFARCTION,_OR_STROKE
ROSUVASTATIN;SLCO1B1;rs4149056;TT;LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATIONS_OF_ROSUVASTATIN
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CARDIOVASCULAR_DEATH,_MYOCARDIAL_INFARCTION,_OR_STROKE
ROSUVASTATIN;ABCG2;rs2231142;TT;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS_OF_ROSUVASTATIN
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CARDIOVASCULAR_DEATH,_MYOCARDIAL_INFARCTION,_OR_STROKE
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:CORONARY_RESTENOSIS
CISPLATIN, DOCETAXEL, FLUOROURACIL;CCL2;rs1024611;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ANEMIA
;SERPINE1;rs7242;T;OTHER;INCREASED_LIKELIHOOD;DISEASE:MAJOR_DEPRESSIVE_DISORDER
;SERPINE1;rs2227684;G;OTHER;INCREASED_LIKELIHOOD;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METHOTREXATE;MTHFR;rs1801131;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:CLINICAL_RESPONSE
GEMCITABINE;CDA;rs60369023;A;TOXICITY, LADME_PK;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
METHOTREXATE;GGH;rs3758149;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA
BISPHOSPHONATES;IL1B;rs16944;GG;EFFICACY;INCREASED_LIKELIHOODPK;PK:RESISTANCE
CLODRONATE;VDR;rs1544410;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESISTANCE
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER_ANTI-COAGULATION
CLODRONATE;VDR;rs731236;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESISTANCE
CYTARABINE, IDARUBICIN;NT5C3A;rs3750117;GG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:INDUCTION_FAILURE
ATORVASTATIN, LOVASTATIN, SIMVASTATIN;APOA5;rs662799;AG + GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_LDLC
CITALOPRAM, SERTRALINE;HTR2A;rs6311;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
CISPLATIN, DOCETAXEL, FLUOROURACIL;IL6;rs1800796;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
CITALOPRAM;HTR2A;rs6313;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA,_THROMBOCYTOPENIA,_ANEMIA,
BUPRENORPHINE / NALOXONE;OPRM1;rs648893;AG + GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DEPRESSION
METHOTREXATE;ADORA2A;rs2267076;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
METHOTREXATE;ADORA2A;rs2236624;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
METHOTREXATE;ADORA2A;rs2298383;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
TACROLIMUS;CYP3A5;rs776746;CT + TT;OTHER;INCREASED_PK;PK:BLOOD_PRESSURE
METHOTREXATE;ADORA2A;rs3761422;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
CISPLATIN, DOCETAXEL, FLUOROURACIL;TNF;rs1799964;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DRUG_RESISTANCE
ASPIRIN, CLOPIDOGREL;PEAR1;rs12041331;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CISPLATIN, DOCETAXEL, FLUOROURACIL;ABCC2;rs717620;CT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
HYDROCHLOROTHIAZIDE;NELL1;rs12279250;C;LADME_PK;INCREASED_;SIDE_EFFECT:PLASMA_TRIGLYCERIDES
BUPRENORPHINE / NALOXONE;OPRD1;rs678849;TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANXIETY_DISORDERS
ARIPIPRAZOLE;DAOA;rs2391191;A;EFFICACY;DECREASED_EFFICACY;EFFICACY:BRIEF_PSYCHIATRIC_RATING_SCALE_SCORES
BUPRENORPHINE / NALOXONE;OPRD1;rs569356;A;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:CRAVING
OLANZAPINE;HTR2C;rs6318;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
TACROLIMUS;CYP3A5;rs776746;T;TOXICITY;INCREASED_RISK;OTHER:TACROLIMUS_NEPHROTOXICITY
TACROLIMUS;CYP3A5;rs776746;CC;EFFICACY, TOXICITY;INCREASED_RISK;OTHER:SUBCLINICAL_ALLOGRAFT_NEPHROPATHY
SIMVASTATIN;CYBA;rs4673;AA + AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_DNA_DAMAGE
BUPROPION;CYP2B6;rs3211371;CT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
ASPIRIN;ABCB1;rs1045642;AG + GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DRUG_RESISTANCE
OLANZAPINE;DRD3;rs6280;CC;EFFICACY;EFFICACY;EFFICACY:GREATER_POSITIVE_SYMPTOM_IMPROVEMENT_AND_POSITIVE_SYMPTOM_REMISSION
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA,_NEUTROPENIA
OLANZAPINE;RGS4;rs951439;CT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE
CABAZITAXEL;TUBB1;rs151352;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
RISPERIDONE;RGS4;rs951439;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE
OLANZAPINE, PERPHENAZINE;RGS4;rs951439;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:POSITIVE_RESPONSE
CABAZITAXEL;CYP2C8;rs1341164;C;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
OLANZAPINE;LEP;rs4731426;GG;TOXICITY;INCREASED_RISK;DISEASE:WEIGHT_GAIN
HEROIN;GRM3;rs13242038;T;OTHER;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs2235015;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
;ACE;rs4343;G;LADME_PK;INCREASED_;OTHER:ACE_ACTIVITY
ANTIDEPRESSANTS;HTR1A;rs6295;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:TREATMENT_RESPONSE
OPIOIDS;ABCB1;rs9282564;CC + CT;TOXICITY;DECREASED_RISK;OTHER:DEATH
ANTHRACYCLINES AND RELATED SUBSTANCES, TAXANES;ABCB1;rs1045642;AA;EFFICACY, LADME_PK;INCREASED_LIKELIHOODEFFICACY;EFFICACY:COMPLETE_RESPONSE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PAROXETINE, SERTRALINE;HTR1A;rs6295;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:NON-RESPONSE
OPIOIDS;KCNJ6;rs2070995;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:FREQUENCY_OF_RESCUE_ANALGESIC_ADMINISTRATION
WARFARIN;VKORC1;rs8050894;G;DOSAGE, EFFICACY;EFFICACY;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION
WARFARIN;VKORC1;rs9923231;T;DOSAGE, EFFICACY;EFFICACY;EFFICACY:DECREASED_WARFARIN_DOSE_AND_INCREASED_RISK_OF_OVER-ANTICOAGULATION
NEVIRAPINE;CYP2B6;rs28399499;CT;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
NEVIRAPINE;CYP3A5;rs776746;CC + CT;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;C9orf72;rs3849942;T;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
METHAMPHETAMINE;DTNBP1;rs3213207;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PSYCHOTIC_DISORDER
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;rs2814707;T;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
METHAMPHETAMINE;PICK1;rs2076369;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:RELAPSE_OF_PSYCHOSIS
NEVIRAPINE;CYP2B6;rs12721646;CT + TT;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;GBP6;rs928655;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
FLUOROURACIL;DPYD;rs1801265;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:OVERALL_GASTROINTESTINAL_TOXICITY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;C9orf72;rs774359;C;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CSRP3;rs983332;T;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;rs868856;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
METHOTREXATE;MTHFR;rs1801131;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
METHOTREXATE;MTHFR;rs1801131;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_BASE_ON_DISEASE_ACTIVITY_SCORE_IN_44_JOINTS_IMPROVEMENT_AT_6_MONTHS_OF_TREATMENT
METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_ACTIVITY_AS_ASSESSED_BY_THE_PHYSICIAN,_LESS_PATIENT-ASSESSED_DIFFICULTY_WITH_PHYSICAL_TASKS,_AND_FEWER_SWOLLEN_JOINTS
GEFITINIB;EGFR;rs712829;GT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
ANTIANDROGENS;AKR1C3;rs12529;CC;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:PROSTATE_CANCER-SPECIFIC_MORTALITY
WARFARIN;VKORC1;rs9934438;AA + AG;DOSAGE;DECREASED_;OTHER:MAINTENANCE_DOSE_OF_WARFARIN
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC1;rs11615;AG;TOXICITY;INCREASED_RISK;DISEASE:NEPHROTOXICITY
CISPLATIN, CYCLOPHOSPHAMIDE;TP53;rs1042522;GG;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
PACLITAXEL;CYP2C8;rs11572080;TT;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES
METHOTREXATE;ABCC1;rs2238476;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAFB;rs6028945;T;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
OLANZAPINE;HTR2C;rs3813929;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MAFB;rs6071980;C;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
OLANZAPINE;HTR2C;rs3813929;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CST5;rs6138150;T;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
OLANZAPINE;HTR2C;rs3813929;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
CISPLATIN, CYCLOPHOSPHAMIDE;GSTP1;rs1695;AA;EFFICACY, LADME_PK;INCREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
ANTIPSYCHOTICS;CLCN6, MTHFR;rs1801133;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:METABOLIC_SYNDROME
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PON1;rs854548;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;PON1;rs854555;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;MOB3B;rs7046653;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
BUPRENORPHINE;CYP3A4;rs2740574;CC + CT;EFFICACY;INCREASED_RISK;OTHER:SUBSTANCE_WITHDRAWAL_SYNDROME
WARFARIN;VKORC1;rs9934438;AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_IN_THERAPEUTIC_RANGE_OF_INR_(TTR)
DOCETAXEL;;rs11185648;CT;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE_IN_JAPANESE_PATIENTS
DOCETAXEL;RXRA;rs11185647;AG;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA,_NEUTROPENIA
CISPLATIN;TPMT;rs12201199;T;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
DOCETAXEL;RXRA;rs2234753;AG;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
DOCETAXEL;RXRA;rs6413517;GT;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
DOCETAXEL;RXRA;rs62576288;GG;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
;DRD2;rs1799732;GG;;INCREASED_LIKELIHOOD;DISEASE:SCHIZOPHRENIA
;SCN1A;rs2298771;CT;OTHER;INCREASED_LIKELIHOOD;DISEASE:EPILEPSY
METHOTREXATE;;rs9345389;G;TOXICITY;;SIDE_EFFECT:END-OF-INDUCTION_MINIMAL_RISIDUAL_DISEASE_(MRD)_IN_CHILDHOOD_ACUTE_LYMPHOBLASTIC_LEUKEMIA_(ALL)_AND_IS_ALSO_ASSOCIATED_WITH_GREATER_METHOTREXATE_CLEARANCE.
DOCETAXEL;HNF4A;rs6130615;TT;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
ANTIPSYCHOTICS;HTR2A;rs7997012;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DRUG_RESISTANCE
SIMVASTATIN;;rs76103438;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
DIAZEPAM;CYP3A4;rs35599367;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS
ANTIPSYCHOTICS;HTR2A;rs6314;AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DRUG_RESISTANCE
DOCETAXEL;HNF4A;rs2273618;CT;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
DOCETAXEL;HNF4A;rs3746574;CT;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
WARFARIN;VKORC1;rs9934438;A;DOSAGE, EFFICACY;;OTHER:A_MORE_RAPID_ATTAINMENT_OF_TARGET_INR_AND_HIGHER_FREQUENCY_OF_DOSE_ADJUSTMENTS
DOCETAXEL;NR1I2;rs3732360;TT;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
;NRXN1;rs985919;C;OTHER;INCREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
"""BETA BLOCKING AGENTS, SELECTIVE"", ""DIURETICS""";NEDD4L;rs4149601;AG + GG;EFFICACY;DECREASED_RISK;OTHER:CARDIOVASCULAR_EVENTS
MEPERIDINE;SERINC5;rs185462714;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
CISPLATIN, CYCLOPHOSPHAMIDE;GSTA1;rs3957357;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DOCETAXEL;NR1I2;rs3732359;AA;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
;CHRNA5;rs17408276;C;OTHER;INCREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
BETA BLOCKING AGENTS;;rs139945292;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_EVENTS
NICOTINE;COMT;rs4680;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;DISEASE:MUSCULAR_DISEASES
PENICILLIN G, PENICILLIN V;;rs115200108;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
NICOTINE;COMT;rs4680;AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RELAPSE
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
DOCETAXEL;NR1I2;rs3814058;CC + TT;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
;CHRNA5;rs16969968;A;OTHER;INCREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
;NRXN1;rs1882296;C;OTHER;INCREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
DOCETAXEL;NR1I3;rs10538494;TT;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
CODEINE, HYDROCODONE, OXYCODONE, TRAMADOL;SEPTIN3, WBP2NL;rs739296;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
MEPERIDINE;FIP1L1;rs113100019;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
DOCETAXEL;NR1I3;rs75114882;AG;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
;NRXN1;rs10865246;C;OTHER;INCREASED_SEVERITY;DISEASE:TOBACCO_USE_DISORDER
CISPLATIN;COMT;rs9332377;T;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
DOCETAXEL;NR1I3;rs2501873;CC;TOXICITY;DECREASED_SEVERITY;DISEASE:ANEMIA
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC2;rs1799793;CT;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC1;rs3212986;AC;TOXICITY;INCREASED_RISK;DISEASE:NEPHROTOXICITY
CISPLATIN, CYCLOPHOSPHAMIDE;XRCC1;rs25487;CC;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
MEPERIDINE;;rs11049274;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
DOCETAXEL;RXRA;rs1536475;AG;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
CISPLATIN;XPC;rs2228001;G;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
DOCETAXEL;NR1I3;rs2502815;GG;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
DOCETAXEL;NR1I3;rs9725457;AA;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA
CISPLATIN;ERCC2, KLC3;rs13181;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
ETHANOL;ACSS2;rs6088638;T;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE
CAPECITABINE, FLUOROURACIL;DPYD;rs17376848;AG;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
ETHANOL;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs1058164;C;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE
CISPLATIN;ERCC1;rs11615;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_AND_PROGRESSION-FREE_SURVIVAL
;APOE;rs429358;CC;OTHER;INCREASED_SEVERITY;OTHER:COVID-19
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs1985842;T;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE
;NAT2;rs1801280;T;OTHER;INCREASED_SEVERITY;DISEASE:INSULIN_RESISTANCE
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs1135840;G;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE
CLOPIDOGREL;CYP2C19;rs28399504;G;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs28371713;G;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE
;NAT2;rs1208;A;OTHER;INCREASED_SEVERITY;DISEASE:INSULIN_RESISTANCE
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;;rs72631546;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
GEFITINIB;ABCG2;rs2231142;GT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs112568578;G;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE
CAPECITABINE, FLUOROURACIL;MIR23A, MIR24-2, MIR27A;rs895819;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;;DISEASE:NEUTROPENIA
AMOXICILLIN, CLAVULANATE;PTPN22;rs2476601;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SLEEP_APNEA_SYNDROMES
COCAINE;CNR1;rs6454674;GT + TT;OTHER;INCREASED_RISK;DISEASE:COCAINE_DEPENDENCE
;PTGS2;rs20417;G;;INCREASED_RISK;DISEASE:STROKE
ATENOLOL, BETA BLOCKING AGENTS, CARVEDILOL, METOPROLOL;PPARA;rs4253778;GG;EFFICACY;DECREASED_;OTHER:CARDIAC_REHOSPITALIZATION
DOXORUBICIN;RARG;rs2229774;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
FLUVASTATIN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ASPIRIN;TMEM196;rs9886152;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
PAZOPANIB;HIF1A;rs11549467;AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
;CLOCK;rs1801260;AA + AG;OTHER;INCREASED_LIKELIHOOD;OTHER:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
MERCAPTOPURINE, METHOTREXATE;ITPA;rs7270101;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA,_NEUTROPENIA
COCAINE;CNR1;rs6454674;GT + TT;OTHER;INCREASED_RISK;DISEASE:COCAINE_DEPENDENCE
RITUXIMAB;FCGR3A;rs396991;C;EFFICACY;INCREASED_EFFICACY;EFFICACY:COMPLETE_RESPONSE_RATE
MERCAPTOPURINE, METHOTREXATE;IMPDH1;rs2278293;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
RITUXIMAB;FCGR3A;rs396991;AA;;DECREASED_;OTHER:LEVELS_OF_IGG
COCAINE;CNR1;rs806368;C;OTHER;DECREASED_RISK;DISEASE:COCAINE_DEPENDENCE
MERCAPTOPURINE, METHOTREXATE;ITPA;rs1127354;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
ALENDRONATE, RALOXIFENE;VDR;rs1544410;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:IMPROVEMENT_IN_BONE_MINERAL_DENSITY
ASPARAGINASE, DEXAMETHASONE, METHOTREXATE;PYGL;rs7142143;CC + CT;DOSAGE;INCREASED_RISKEFFICACY;EFFICACY:RELAPSE
INTERFERONS;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PAZOPANIB;CXCL8;rs4073;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ERLOTINIB;EGFR;rs121434569;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
ERLOTINIB, GEFITINIB;EGFR;rs121434569;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
INTERFERONS;IFNL3;rs8099917;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(SVR)_TO_INTERFERON_MONOTHERAPY_IN_HCV_GENOTYPE_1_PATIENTS
CAPECITABINE, IRINOTECAN, OXALIPLATIN;DPYD;rs17376848;AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
METHOTREXATE;;rs4888024;G;TOXICITY;;SIDE_EFFECT:END-OF-INDUCTION_MINIMAL_RISIDUAL_DISEASE_(MRD)_IN_CHILDHOOD_ACUTE_LYMPHOBLASTIC_LEUKEMIA_(ALL)_AND_IS_ALSO_ASSOCIATED_WITH_GREATER_METHOTREXATE_CLEARANCE
TACROLIMUS;ABCB1;rs1128503;AG;LADME_PK;INCREASED_PK;PK:TROUGH_CONCENTRATIONS
TACROLIMUS;ABCB1;rs2032582;AC + CT;LADME_PK;INCREASED_PK;PK:TROUGH_CONCENTRATIONS
METHOTREXATE;ABCC1;rs3784862;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXICITY
ETHANOL;OPRM1;rs1799971;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CAPECITABINE;DPYD;rs2297595;CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
CLOPIDOGREL;ABCB1;rs1045642;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;CTBP2;rs945665113;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(SVR)_IN_HCV_GENOTYPE_1_PATIENTS
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801133;AG;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
ANTIDEPRESSANTS;HTR2A;rs6313;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SUNITINIB;SLC22A5;rs2631367;C;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT:PRIMARY_CLINICAL_ENDPOINT_OF_DEATH_DUE_TO_CARDIOVASCULAR_CAUSES,_NON-FATAL_MI_OR_STENT_THROMBOSIS
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
SUNITINIB;SLC22A5;rs2631370;C;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
;PTGS2;rs20417;CG + GG;;DECREASED_RISK;DISEASE:STROKE
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;CTBP2;rs376695472;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ANTIDEPRESSANTS;HTR2A;rs6311;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
BETA BLOCKING AGENTS;ADRB2;rs1042713;GG;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:DEATH
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
FLUOROURACIL;DPYS;rs2959023;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
SUNITINIB;IL4R;rs1805015;C;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
OMEGA-3 POLYUNSATURATED FATTY ACIDS;PTGS2;rs20417;CG + GG;OTHER;INCREASED_RISK;DISEASE:COLONIC_NEOPLASMS
;PTGS2;rs20417;CG + GG;OTHER;DECREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
FLUOROURACIL;DPYS;rs2669429;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
METHOTREXATE;CLCN6, MTHFR;rs1801133;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
SUNITINIB;SLC22A5;rs2631372;C;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CAPECITABINE, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801131;GG;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
SUNITINIB;IL4R;rs1801275;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
HEROIN;BDNF;rs16917234;TT;TOXICITY;DECREASED_AGE AT ONSET;SIDE_EFFECT:HEROIN_DEPENDENCE
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;rs267606619;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OTOTOXICITY
TENOFOVIR;ABCC4;rs1751034;CC + CT;LADME_PK;INCREASED_PK;PK:INTRACELLULAR_TENOFOVIR_DIPHOSPHATE_(TFV-DP)_CONCENTRATIONS
AZITHROMYCIN, ERYTHROMYCIN;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PAIN,_DIARRHEA
CORTICOSTEROIDS;DTNBP1;rs35514893;T;EFFICACY;DECREASED_SEVERITY;DISEASE:ASTHMA
;CYP1B1;rs1056836;CC + CG;OTHER;INCREASED_RISK;DISEASE:BREAST_NEOPLASMS
THIOTEPA;GSTP1;rs1138272;T;OTHER;INCREASED_PK;PK:NON-INDUCIBLE_THIOTEPA_CLEARANCE_AND_DECREASED_TEPA_CLEARANCE
TENOFOVIR;ABCC4;rs1751034;TT;OTHER;INCREASED_PK;PK:TENOFOVIR_RENAL_CLEARANCE,_AND_LOWER_AUC
FLUOROURACIL;DPYD;rs2786783;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
;G6PD;rs72554664;T;OTHER;INCREASED_LIKELIHOOD;OTHER:DIABETES_MELLITUS_TYPE2
OPIOIDS;;rs12442183;T;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:OPIOID-RELATED_DISORDERS
CORTICOSTEROIDS;KL;rs450789;G;EFFICACY;DECREASED_SEVERITY;DISEASE:ASTHMA
INTERFERON BETA-1A, INTERFERON BETA-1B;IRF6;rs2205986;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
METHOTREXATE;NR1I2;rs3814058;C;TOXICITY;DECREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
METHOTREXATE;ABCC2;rs2273697;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:BONE_MARROW_DISORDER
FLUOROURACIL;WNT5B;rs2010851;CC;EFFICACY;DECREASED_;OTHER:TIME_TO_TUMOR_RECURRENCE_(TTR)
CORTICOSTEROIDS;ME3;rs2125362;A;EFFICACY;INCREASED_SEVERITY;DISEASE:ASTHMA
HEROIN;OPRD1;rs508448;GG;TOXICITY;DECREASED_AGE AT ONSET;SIDE_EFFECT:HEROIN_DEPENDENCE
METHOTREXATE;NR1I2;rs6785049;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CORTICOSTEROIDS;LHX2;rs7851998;A;EFFICACY;DECREASED_SEVERITY;DISEASE:ASTHMA
FLUOROURACIL;DPYD;rs2811178;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CORTICOSTEROIDS;LHFPL3;rs61585310;G;EFFICACY;DECREASED_SEVERITY;DISEASE:ASTHMA
ASPARAGINASE, CORTICOSTEROIDS, CYCLOPHOSPHAMIDE, CYTARABINE, MERCAPTOPURINE, METHOTREXATE, VINCRISTINE;IL10;rs1800896;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;GSK3B;rs3732361;A;LADME_PK;DECREASED_RISK;SIDE_EFFECT:BONE_MARROW_DISORDER,_TOXIC_LIVER_DISEASE
HEROIN;BDNF;rs6265;TT;TOXICITY;DECREASED_AGE AT ONSET;SIDE_EFFECT:HEROIN_DEPENDENCE
MORPHINE;SLC22A1;rs12208357;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
CORTICOSTEROIDS;TRDN;rs4897302;T;EFFICACY;INCREASED_SEVERITY;DISEASE:ASTHMA
NICOTINE;CHRNA5;rs55781567;G;TOXICITY;INCREASED_;DISEASE:TOBACCO_USE_DISORDER
HEROIN;OPRD1;rs4654327;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEROIN_DEPENDENCE
OLANZAPINE;GIPR;rs10423928;AA + AT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
NICOTINE;CHRNA5;rs16969968;A;TOXICITY;INCREASED_;DISEASE:TOBACCO_USE_DISORDER
NICOTINE;CHRNA5;rs503464;A;TOXICITY;INCREASED_;DISEASE:TOBACCO_USE_DISORDER
ALLOPURINOL;CYCSP5;rs9469003;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
FLUOROURACIL;DPYD;rs1801265;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
DAUNORUBICIN, DOXORUBICIN;SLC22A17;rs4982753;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
WARFARIN;VKORC1;rs9923231;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_IN_THERAPEUTIC_RANGE
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;CYCSP5;rs9469003;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
NICOTINE;CHRNA5;rs55853698;G;TOXICITY;INCREASED_;DISEASE:TOBACCO_USE_DISORDER
AMANTADINE, ANTICHOLINERGICS, DOPAMINE AGONISTS, LEVODOPA, SELEGILINE;SLC22A1;rs622342;C;DOSAGE, EFFICACY, TOXICITY;INCREASED_RISK;DISEASE:DEATH
MELPHALAN;POLR1G;rs967591;A;EFFICACY, TOXICITY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_AND_TIME-TO-TREAT_FAILURE
CORTICOSTEROIDS;ACOT7;rs11121611;G;EFFICACY;DECREASED_SEVERITY;DISEASE:ASTHMA
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;ITPA;rs1127354;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
MORPHINE;TLR2;rs3804100;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA,_FATIGUE,_COGNITIVE_DISORDER,_CONSTIPATION
DAUNORUBICIN, DOXORUBICIN;SLC22A7;rs4149178;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
ROSUVASTATIN;SCAP;rs12487736;CC + CT;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:HYPERLIPIDEMIAS
ALLOPURINOL;PSORS1C3;rs3094188;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
CORTICOSTEROIDS;APOBEC3B;rs5995653;A;EFFICACY;DECREASED_SEVERITY;DISEASE:ASTHMA
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;PSORS1C3;rs3094188;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
MORPHINE;COMT;rs4680;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA,_FATIGUE,_DEPRESSION,
GEMCITABINE, PACLITAXEL;CDA;rs2072671;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
MONTELUKAST;ABCC1;rs119774;CT;EFFICACY;INCREASED_EFFICACY;EFFICACY:CHANGES_IN_FEV1
TRIAMCINOLONE;HCG22;rs2523864;T;TOXICITY;INCREASED_;SIDE_EFFECT:OCULAR_HYPERTENSION
ANTIDEPRESSANTS;CREB1, METTL21A;rs7569963;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
MORPHINE;IL6;rs10499563;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA,_FATIGUE,_DEPRESSION,
ALLOPURINOL;POU5F1;rs3130501;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;POU5F1;rs3130501;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;rs184278615;A;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CITALOPRAM;;rs4675690;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT-EMERGENT_SUICIDALITY
CITALOPRAM;CREB1, METTL21A;rs7569963;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT-EMERGENT_SUICIDALITY
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;rs201469165;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""RITONAVIR""";APOE;rs7412;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTRIGLYCERIDEMIA
ALLOPURINOL;POU5F1;rs3130931;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
TRIAMCINOLONE;HCG22;rs3873352;G;TOXICITY;INCREASED_;SIDE_EFFECT:OCULAR_HYPERTENSION
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;PSORS1C1;rs3815087;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
MORPHINE;IL6R;rs2228145;AC + CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA,_FATIGUE,_DEPRESSION,
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;POU5F1;rs3130931;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
MORPHINE;BDNF;rs6265;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA,_FATIGUE,_DEPRESSION,
ALLOPURINOL;PSORS1C1;rs3815087;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
MORPHINE;IL2;rs2069762;AC + CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA,_FATIGUE,_DEPRESSION,
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;HLA-DRB5;rs1071748;C;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ASPIRIN, CLOPIDOGREL;B4GALT2;rs1061781;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
METHOTREXATE;ABCB1;rs1128503;AA + AG;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
ALLOPURINOL;;rs2844665;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
MERCAPTOPURINE, METHOTREXATE;SLC28A2;rs2413775;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CHLORTHALIDONE;NPPA;rs5065;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
METHOTREXATE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
MERCAPTOPURINE, METHOTREXATE;SLC28A2;rs2413775;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CYCLOPHOSPHAMIDE;SOD2;rs4880;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
CYCLOPHOSPHAMIDE;CYP3A4;rs2740574;C;TOXICITY;DECREASED_RISK;SIDE_EFFECT:PRIMARY_OVARIAN_FAILURE
DOXORUBICIN;SLC22A16;rs714368;CC;TOXICITY, LADME_PK;INCREASED_PK;PK:DOXORUBICINOL_AUC
MERCAPTOPURINE, METHOTREXATE;SLC29A1;rs747199;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT:AGRANULOCYTOSIS,_LEUKOPENIA
ALLOPURINOL, CARBAMAZEPINE, PHENYTOIN;;rs2844665;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
CYCLOPHOSPHAMIDE;CYP2B6;rs2279343;AG + GG;TOXICITY, LADME_PK;INCREASED_RISK;SIDE_EFFECT:ORAL_MUCOSITIS
CYCLOPHOSPHAMIDE;CYP2B6;rs8192709;CT + TT;TOXICITY, LADME_PK;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGIC_CYSTITIS
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS;KIR3DL2;rs973541788;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
AMOXICILLIN, CLAVULANATE, FLUCLOXACILLIN;HLA-DRA;rs3129880;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GT + TT;TOXICITY, LADME_PK;DECREASED_RISK;SIDE_EFFECT:VENOOCCLUSIVE_DISEASE_OF_THE_LIVER
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs28371725;C;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE
OPIOIDS;OPRM1;rs1799971;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SLEEP_DISORDERS
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CYCLOSPORINE, METHOTREXATE;MTHFR;rs1801133;A;OTHER;;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
CARBOPLATIN, CISPLATIN, GEMCITABINE;GSTP1;rs1695;AG + GG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs2004511;T;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE
MERCAPTOPURINE, METHOTREXATE;ABCC4;rs2274407;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA,_NEUTROPENIA
DOXORUBICIN;CBR3;rs8133052;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:TUMOR_RESPONSE
DOXORUBICIN;CBR3;rs8133052;G;TOXICITY, LADME_PK;DECREASED_SEVERITY;DISEASE:NEUTROPENIA
DOXORUBICIN;CBR3;rs1056892;A;DOSAGE, LADME_PK;INCREASED_PK;PK:DOXORUBICINOL_AUC
ANTIHYPERTENSIVES;ATP2B1;rs1401982;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESISTANT_HYPERTENSION
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs28371702;A;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE
MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PRURITUS
MERCAPTOPURINE, METHOTREXATE;SLC28A3;rs10868138;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
HEROIN;GRM3;rs724226;A;OTHER;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
ACENOCOUMAROL;VKORC1;rs7294;T;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESIDUAL_PLATELET_REACTIVITY
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
CORTICOSTEROIDS;CRHR1;rs242941;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:PERCENT_CHANGE_IN_FEV
METHOTREXATE;CLCN6, MTHFR;rs1801133;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
CORTICOSTEROIDS;FKBP5;rs4713916;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:GLUCOCORTICOID_RESPONSIVENESS
BUDESONIDE, FLUTICASONE PROPIONATE;CRHR1;rs242941;AA;EFFICACY;PK;PK:DELAYED_CORTISOL_RESPONSE_TO_STRESS
OPIOIDS;ABCB1;rs1045642;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
CORTICOSTEROIDS;CRHR1;rs1876828;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:PERCENT_CHANGE_IN_FEV
GEMCITABINE;;rs1155463;C;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CENTRAL_NERVOUS_SYSTEM_DISORDER
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs212090;AA + AT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA,_LEUKOPENIA,_THROMBOCYTOPENIA,_ANEMIA
BUDESONIDE, FLUTICASONE PROPIONATE;CRHR1;rs1876828;TT;EFFICACY;PK;PK:DELAYED_CORTISOL_RESPONSE_TO_STRESS
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;rs4149171;CC + CT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA,_LEUKOPENIA,_THROMBOCYTOPENIA,_ANEMIA
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;;rs955434;AA + AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA,_LEUKOPENIA,_THROMBOCYTOPENIA,_ANEMIA
CHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE;;rs61824877;A;EFFICACY, TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERGLYCEMIA
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;SLC22A6;rs4149170;CT + TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA,_LEUKOPENIA,_THROMBOCYTOPENIA,_ANEMIA
TRAMADOL;OPRM1;rs1799971;GG;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:NAUSEA
CHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE;HMGCS2;rs9943291;G;EFFICACY, TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERGLYCEMIA
METHOTREXATE;CLCN6, MTHFR;rs1801133;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
METHADONE;DAO;rs55944529;TT;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:SUBSTANCE_WITHDRAWAL_SYNDROME
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148579;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA,_LEUKOPENIA,_THROMBOCYTOPENIA,_ANEMIA
;KCNIP1, KCNMB1;rs11739136;CT + TT;OTHER;DECREASED_RISK;DISEASE:HYPERTENSION
INFLIXIMAB;IL1B;rs1143634;GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA,_VOMITING
ATAZANAVIR;ABCB1;rs2032582;AT;TOXICITY;INCREASED_RISK;DISEASE:HYPERBILIRUBINEMIA
DABIGATRAN;ABCB1;rs4148738;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
NICOTINE;CHRNA5;rs16969968;A;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs212087;AA + AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA,_LEUKOPENIA,_THROMBOCYTOPENIA,_ANEMIA
INFLIXIMAB;IL23R;rs10489629;TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
IRINOTECAN;UGT1A1;rs10929302;AA;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148580;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA,_LEUKOPENIA,_THROMBOCYTOPENIA,_ANEMIA
INFLIXIMAB;SLCO1C1;rs3794271;GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
NICOTINE;CHRNA3;rs578776;A;OTHER;DECREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
CARVEDILOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR_FUNCTION_(LVEF)
PEGINTERFERON ALFA-2A;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:CRYOGLOBULINEMIA
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IL7;rs16906115;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
IRINOTECAN;ABCC1;rs3743527;CT + TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
NICOTINE;CHRNA3;rs1051730;A;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
IRINOTECAN;ABCB1;rs12720066;AC + CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
NICOTINE;CHRNA3;rs3743078;C;OTHER;DECREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs4148575;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA,_LEUKOPENIA,_THROMBOCYTOPENIA,_ANEMIA
NICOTINE;CHRNB4;rs3813567;G;OTHER;DECREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
IRINOTECAN;ABCC1;rs17501331;AG + GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
CARVEDILOL;ADRB1;rs1801253;CC;EFFICACY;EFFICACY;EFFICACY:SIGNIFICANTLY_GREATER_IMPROVEMENT_IN_LEFT_VENTRICULAR_EJECTION_FRACTION_(LVEF)
PEGINTERFERON ALFA-2A;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:CRYOGLOBULINEMIA
PEGINTERFERON ALFA-2A;IFNL4;rs8099917;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:CRYOGLOBULINEMIA
;UGT1A1;rs4148323;AA;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS,_CEREBRAL_PALSY,_HEARING_LOSS,
PEGINTERFERON ALFA-2A;NT5C2;rs10883841;CT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:CRYOGLOBULINEMIA
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
INFLIXIMAB;ADAM17;rs10929587;TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
CLOPIDOGREL;MED12L, P2RY12;rs10935838;AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
;ago-02;rs4961280;AA + AC;OTHER;DECREASED_;OTHER:PROGRESSION-FREE_SURVIVAL
STAVUDINE;TNF;rs1799964;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROPATHY
CLOPIDOGREL;MED12L, P2RY12;rs2046934;AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CLOPIDOGREL;MED12L, P2RY12;rs6809699;AC;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs3749442;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA,_LEUKOPENIA,_THROMBOCYTOPENIA,_ANEMIA
NICOTINE;CHRNA5;rs684513;G;OTHER;DECREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;rs267606618;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OTOTOXICITY
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs1132776;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA,_LEUKOPENIA,_THROMBOCYTOPENIA,_ANEMIA
NICOTINE;CHRNA5;rs637137;A;OTHER;DECREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
;IL1A;rs1800587;A;OTHER;INCREASED_SEVERITY;DISEASE:PAIN
FLUTICASONE / SALMETEROL;CRHR1;rs242941;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_CHANGE_IN_FEV
PROPRANOLOL;COMT;rs4680;G;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC5;rs939338;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA,_LEUKOPENIA,_THROMBOCYTOPENIA,_ANEMIA
PEGINTERFERON ALFA-2A;CYP27B1, METTL1;rs10877012;GT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PROPRANOLOL;COMT;rs4818;G;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
CORTICOSTEROIDS;APOBEC3B;rs6001366;T;EFFICACY;DECREASED_SEVERITY;DISEASE:ASTHMA
PEGINTERFERON ALFA-2A;IFNL3;rs12979860;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CORTICOSTEROIDS;KCNN1;rs2278992;C;EFFICACY;DECREASED_SEVERITY;DISEASE:ASTHMA
PEGINTERFERON ALFA-2A;VDR;rs7975232;AA;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CORTICOSTEROIDS;ANKRD30B;rs12959468;A;EFFICACY;DECREASED_SEVERITY;DISEASE:ASTHMA
ROSUVASTATIN;CRP;rs1205;CT + TT;EFFICACY, OTHER, LADME_PK;DECREASED_;OTHER:PLASMA_LEVEL_OF_HIGH-SENSITIVITY_C-REACTIVE_PROTEIN
PROPRANOLOL;COMT;rs6269;G;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS;ABCC1;rs129081;CC + CG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA,_LEUKOPENIA,_THROMBOCYTOPENIA,_ANEMIA
RISPERIDONE;HTR2A;rs6311;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
HEROIN;GRM3;rs2189814;T;OTHER;INCREASED_RISK;DISEASE:HEROIN_DEPENDENCE
ROSUVASTATIN;;rs2808630;CC + CT;EFFICACY, OTHER, LADME_PK;DECREASED_;OTHER:PLASMA_LEVEL_OF_HIGH-SENSITIVITY_C-REACTIVE_PROTEIN
METHADONE;OPRD1;rs204076;AT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ROSUVASTATIN;HNF1A;rs1169288;AC + CC;EFFICACY, OTHER, LADME_PK;DECREASED_;OTHER:PLASMA_LEVEL_OF_HIGH-SENSITIVITY_C-REACTIVE_PROTEIN
METOPROLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR(LV)_REMODELING_AND_GREATER_INCREASE_IN_LVEF_(LEFT_VENTRICULAR_EJECTION_FRACTION)
PROPRANOLOL;COMT;rs4633;C;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
BUCINDOLOL;ADRB1;rs1801253;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE
ERYTHROMYCIN;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ASPIRIN;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
;KCNIP1, KCNMB1;rs11739136;CT + TT;OTHER;DECREASED_;OTHER:BLOOD_PRESSURE
TACROLIMUS;ABCB1;rs2032582;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
CAFFEINE, ISOFLURANE;RYR1;rs118192162;AC;TOXICITY;;DISEASE:MALIGNANT_HYPERTHERMIA
RISPERIDONE;NR1I2;rs7643645;GG;LADME_PK;DECREASED_PK;PK:9-HYDROXY-RISPERIDONE_LEVELS
REPAGLINIDE;SLCO1B1;rs2306283;GG;OTHER, LADME_PK;DECREASED_PK;PK:REPAGLINIDE_PLASMA_CONCENTRATION_(AUC)_AND_CMAX
HALOTHANE;RYR1;rs118192161;CT;TOXICITY;;DISEASE:MALIGNANT_HYPERTHERMIA
RISPERIDONE;NR1I2;rs7643645;GG;LADME_PK;DECREASED_PK;PK:ACTIVE_MOIETY_LEVELS
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
TACROLIMUS;ABCB1;rs1045642;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
GEFITINIB;CYP2D6;rs1065852;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
DALCETRAPIB;ADCY9;rs1967309;AA;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
EGFR INHIBITORS;PIK3CA;rs6443624;C;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:EXANTHEMA
EGFR INHIBITORS;PIK3CA;rs2677760;T;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:EXANTHEMA
MISOPROSTOL;SLCO1B1;rs4149087;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FEVER
MISOPROSTOL;ABCC4;rs11568658;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FEVER
ASPIRIN, CLOPIDOGREL;PEAR1;rs12041331;A;EFFICACY;DECREASED_EFFICACY;EFFICACY:COLLAGEN_INDUCED_PLATELET_AGGREGATION_AFTER_ASPIRIN_OR_DUAL_ANTIPLATELET_THERAPY_(DAPT)_ADMINISTRATION
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs2031920;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CARBOPLATIN, CISPLATIN, DOCETAXEL, GEMCITABINE, PACLITAXEL;RAF1;rs11710163;AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;CYP2C19;rs12248560;T;TOXICITY;DECREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
ASPIRIN, CLOPIDOGREL;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED_;SIDE_EFFECT:CARDIOVASCULAR_EVENTS_IN_PATIENTS_UNDERGOING_PCI
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
OLANZAPINE;GSTP1;rs1695;AG + GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
ASPIRIN, CLOPIDOGREL;PEAR1;rs12041331;AA + AG;TOXICITY;INCREASED_;SIDE_EFFECT:CARDIOVASCULAR_EVENTS_IN_PATIENTS_UNDERGOING_PCI
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;ALOX15;rs3892408;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
METHADONE;CCL11;rs1129844;A;TOXICITY;INCREASED_;SIDE_EFFECT:INSOMNIA
EGFR INHIBITORS;PIK3CA;rs2699905;C;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:EXANTHEMA
FLUOXETINE;;rs2433320;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:HAMD_SCORES
ANTIPSYCHOTICS;MTHFR;rs1801133;G;TOXICITY;INCREASED_;SIDE_EFFECT:WEIGHT_GAIN
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, MERCAPTOPURINE, PREDNISOLONE, VINCRISTINE;PNPLA3;rs738409;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;rs5789;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
CLOZAPINE, OLANZAPINE;MTHFR;rs1801131;GG;TOXICITY;INCREASED_;SIDE_EFFECT:WEIGHT_GAIN
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799929;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;PNPLA3;rs738409;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
LEUCOVORIN, TEGAFUR;UMPS;rs1801019;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA,_DRUG_TOXICITY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
GEFITINIB;EGFR;rs121434568;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
CARBOPLATIN, CISPLATIN, DOCETAXEL, PACLITAXEL;MAP3K1;rs726501;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C9;rs9332096;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:MACULOPAPULAR_EXANTHEMA
ANTHRACYCLINES AND RELATED SUBSTANCES, CYCLOPHOSPHAMIDE, FLUOROURACIL, TAXANES;CYP4X1;rs17102977;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;TPMT;rs1142345;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C19;rs4986893;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:MACULOPAPULAR_EXANTHEMA
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DOSE_DECREASE_OR_SWITCH_TO_ANOTHER_CHOLESTEROL-LOWERING_DRUG
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;rs10306135;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ASPIRIN-INDUCED_ASTHMA
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
IMATINIB;SLC22A1;rs683369;CG + GG;EFFICACY;DECREASED_;DISEASE:EVENT-FREE_SURVIVAL
ANTIPSYCHOTICS;GABRG3;rs2061051;A;TOXICITY;INCREASED_SEVERITY;DISEASE:TARDIVE_DYSKINESIA
GEMCITABINE;;rs642990;CT + TT;TOXICITY;DECREASED_RISK;DISEASE:NEUTROPENIA
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:LONGER_MEDIAN_PROGRESSION-FREE_SURVIVAL_TIME
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
CARBOPLATIN, CISPLATIN, DOCETAXEL, PACLITAXEL;MAP3K1;rs16886403;CC + CT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GEMCITABINE;RRM1;rs1042858;A;DOSAGE;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CARBOPLATIN, CISPLATIN, DOCETAXEL, PACLITAXEL;;rs17661089;AG + GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CARBOPLATIN, CISPLATIN, DOCETAXEL, GEMCITABINE, PACLITAXEL;ACSS2;rs17309872;AT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;ABCC1;rs246240;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ONSET_OF_TOXICITY
BUPROPION, NICOTINE;EPB41;rs6702335;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:ABSTINENCE
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL14;rs62328061;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT:LEUKOPENIA
;IL17F;rs763780;CC;OTHER;INCREASED_LIKELIHOOD;OTHER:RECURRENT_PREGNANCY_LOSS
DAUNORUBICIN;NOS3;rs1799983;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
;IL17A;rs2275913;AA;OTHER;INCREASED_LIKELIHOOD;OTHER:RECURRENT_PREGNANCY_LOSS
ACE INHIBITORS, PLAIN;KCNIP4;rs145489027;A;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
PEMETREXED;ATIC;rs12995526;C;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
OPIOIDS;PDYN;rs910080;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
ACE INHIBITORS, PLAIN;KCNIP4;rs1495509;C;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
FOLFIRI, FOLFOX, XELOX;MTHFR;rs1801131;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GEMCITABINE;ALG10;rs1705772;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXICITY
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DOXORUBICIN, MERCAPTOPURINE, METHOTREXATE, PEGASPARGASE, THIOGUANINE, VINCRISTINE;UGT1A1;rs887829;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
RITONAVIR;APOC3;rs2854116;C;OTHER;INCREASED_RISK;DISEASE:HYPERTRIGLYCERIDEMIA
PEMETREXED;GGH;rs16930092;CT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ANASTROZOLE;UGT1A4;rs3732218;GG;LADME_PK;INCREASED_PK;PK:GLUCURONIDATION
HALOPERIDOL;CYP2D6;rs3892097;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
FOLFIRI, FOLFOX, XELOX;ABCB1;rs1045642;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ACE INHIBITORS, PLAIN;KCNIP4;rs7675300;A;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
CYCLOPHOSPHAMIDE;VEGFA;rs2010963;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
NICOTINE;CHRNA3;rs1051730;A;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING
NEVIRAPINE;TRAF3IP2;rs76228616;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
GEMCITABINE;ALOX5AP;rs4769060;AG + GG;LADME_PK;DECREASED_PK;PK:CMAX_AND_A_LOWER_MEAN_AUC
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
SUFENTANIL;OPRM1;rs1799971;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
IPILIMUMAB, NIVOLUMAB, PEMBROLIZUMAB;IL7;rs16906115;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
GEMTUZUMAB OZOGAMICIN;CD33;rs1803254;CC + CG;TOXICITY;INCREASED_;SIDE_EFFECT:DEATH
FOLFIRI, FOLFOX, XELOX;BRAF;rs113488022;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;CLCN6, MTHFR;rs1801133;AG + GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA
OPIOIDS;TH;rs2070762;G;TOXICITY;INCREASED_RISK;DISEASE:OPIOID-RELATED_DISORDERS
GEMTUZUMAB OZOGAMICIN;CD33;rs35112940;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ISONIAZID, RIFAMPIN;CYP2E1, DUX1;rs6413432;AT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CISPLATIN;SLC22A2;rs316019;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OTOTOXICITY
ANTINEOPLASTIC AGENTS, FLUOROURACIL, LEUCOVORIN;SPARC;rs1059829;AG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_TUMOR_RECURRENCE
OPIOIDS;DBH;rs1611131;G;TOXICITY;DECREASED_RISK;DISEASE:OPIOID-RELATED_DISORDERS
ANTIPSYCHOTICS;HSPG2;rs2445142;C;TOXICITY;INCREASED_SEVERITY;DISEASE:TARDIVE_DYSKINESIA
FOLFIRI, FOLFOX, XELOX;DPYD;rs1801265;AG + GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ANTIPSYCHOTICS;HSPG2;rs878949;T;TOXICITY;INCREASED_RISK;DISEASE:TARDIVE_DYSKINESIA
QUETIAPINE;RIMS1;rs502046;CC + CT;EFFICACY, TOXICITY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:DISCONTINUATION
ETHANOL;TAS2R16;rs846664;C;OTHER;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
DRUGS FOR TREATMENT OF TUBERCULOSIS;METTL3;rs1139130;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
METHOTREXATE;C1orf167, CLCN6, MTHFR;rs1801131;GG + GT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F5;rs6025;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOSIS
SORAFENIB;KDR;rs2239702;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
FLUOROURACIL;SCN1A;rs3812718;CC;OTHER;DECREASED_;OTHER:TIME_TO_TUMOR_RECURRENCE_(TTR)
EFAVIRENZ;CYP2B6;rs3745274;GT + TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DISCONTINUATION
"""ACETAMINOPHEN"", ""ANTIEPILEPTICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""OPIOIDS""";OPRM1;rs510769;CT + TT;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:PAIN
WARFARIN;VKORC1;rs9934438;A;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_IN_THERAPEUTIC_RANGE
OPIOIDS;DRD2;rs1076560;A;TOXICITY;INCREASED_RISK;DISEASE:OPIOID-RELATED_DISORDERS
EFAVIRENZ;NR1I2;rs2472677;TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:DISCONTINUATION
EFAVIRENZ;CYP2B6;rs3745274;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:VIROLOGICAL_RESPONSE
CETUXIMAB;KRAS;rs112445441;T;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN, CYCLOPHOSPHAMIDE, DACTINOMYCIN, DOXORUBICIN, METHOTREXATE, VINCRISTINE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
SORAFENIB;VEGFA;rs2010963;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
CISPLATIN, CYCLOPHOSPHAMIDE, DACTINOMYCIN, DOXORUBICIN, METHOTREXATE, VINCRISTINE;MTR;rs1805087;GG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
SORAFENIB;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTENSION
SORAFENIB;VEGFA;rs1570360;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ATORVASTATIN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY,_MUSCULAR_DISEASES,_RHABDOMYOLYSIS,_TOXIC_LIVER_DISEASE
COCAINE, HEROIN;OPRM1;rs62638690;T;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:COCAINE_DEPENDENCE,_HEROIN_DEPENDENCE
SORAFENIB;KDR;rs2239702;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
EFAVIRENZ;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CENTRAL_NERVOUS_SYSTEM_DISORDER
CETUXIMAB, PANITUMUMAB;KRAS;rs112445441;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;CYP2C9;rs1799853;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOSIS
;MTR;rs1805087;GG;OTHER;INCREASED_LIKELIHOOD;DISEASE:RHEUMATOID_ARTHRITIS
METHOTREXATE;MTR;rs1805087;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METHOTREXATE-INDUCED_NODULOSIS
"""ACETAMINOPHEN"", ""ANTIEPILEPTICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""OPIOIDS""";OPRD1;rs2236861;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
PRAVASTATIN;SLCO1B1;rs4149056;CT;LADME_PK;INCREASED_PK;PK:AUC0-12
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F2;rs1799963;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOSIS
EFAVIRENZ;CYP2B6;rs3745274;TT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DISCONTINUATION
FLUOROURACIL;SCN1A;rs3812718;TT;OTHER;DECREASED_;OTHER:TIME_TO_TUMOR_RECURRENCE_(TTR)
ATAZANAVIR;UGT1A1;rs887829;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
SIMVASTATIN;SLCO1B1;rs4363657;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULAR_DISEASES
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:CENTRAL_NERVOUS_SYSTEM_DISORDER
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
TACROLIMUS;CYP3A5;rs776746;CT;TOXICITY;INCREASED_RISK;DISEASE:NEPHROTOXICITY
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:MUSCULAR_DISEASES
EFAVIRENZ;CYP2B6;rs4803419;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CENTRAL_NERVOUS_SYSTEM_DISORDER
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
FLUOROURACIL;DPYD;rs1801160;CT;LADME_PK;DECREASED_PK;PK:DPD_ACTIVITY
ALLOPURINOL;PSORS1C1;rs3131003;AG + GG;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
FLUOROURACIL;MTHFR;rs1801133;GG;EFFICACY;INCREASED_;DISEASE:EVENT-FREE_SURVIVAL,_OVERALL_SURVIVAL
OPIOIDS;PDYN;rs1997794;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:OPIOID-RELATED_DISORDERS
ONDANSETRON;ABCB1;rs1045642;GG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
DEXMEDETOMIDINE;CYP2A6;rs8192733;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA,_HYPOTENSIVE_DISORDER
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
"""ACETAMINOPHEN"", ""ANTIEPILEPTICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""OPIOIDS""";OPRM1;rs1799971;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PAIN
OPIOIDS;PDYN;rs1022563;CC;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:OPIOID-RELATED_DISORDERS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
RISPERIDONE;LEP;rs7799039;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OBESITY
PERINDOPRIL;AGTR1;rs5182;TT;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:CARDIAC_EVENTS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)_AND_CHANGES_IN_VIRAL_LOAD_AFTER_4_WEEKS_OF_TREATMENT
GEMCITABINE;CDA;rs2072671;AC + CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_NEUTROPENIA
CYTARABINE;CDA;rs602950;GG;EFFICACY, LADME_PK;INCREASED_EFFICACY;EFFICACY:CYTOTOXICITY
HALOPERIDOL;CYP2D6;rs3892097;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
CYTARABINE;CDA;rs532545;TT;EFFICACY, LADME_PK;INCREASED_EFFICACY;EFFICACY:CYTOTOXICITY
ALLOPURINOL;CYCSP5;rs3099844;AA + AC;TOXICITY;INCREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
BISPHOSPHONATES;RBMS3;rs17024608;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:OSTEONECROSIS
;NEDD4L;rs4149601;AG;OTHER;INCREASED_RISK;DISEASE:CARDIOVASCULAR_DISEASE
FLUOROURACIL;DPYD;rs55886062;AC;LADME_PK;DECREASED_PK;PK:DPD_ACTIVITY
ANTIPSYCHOTICS;INSIG2;rs17587100;C;OTHER;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
ONDANSETRON;ABCB1;rs2032582;CC;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
;CTLA4;rs3087243;A;OTHER;DECREASED_RISK;DISEASE:RHEUMATOID_ARTHRITIS
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;GCKR;rs780094;CC + CT;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FLUOROURACIL;DPYD;rs115232898;CT;LADME_PK;DECREASED_PK;PK:DPD_ACTIVITY
RIBAVIRIN, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
TENOFOVIR;ABCC4;rs1059751;G;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:KIDNEY_DISORDER
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;IGF2BP2;rs6769511;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:DISEASE_PROGRESSION
WARFARIN;VKORC1;rs9934438;A;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
CYTARABINE;CDA;rs2072671;CC;EFFICACY, LADME_PK;INCREASED_EFFICACY;EFFICACY:CYTOTOXICITY
WARFARIN;VKORC1;rs9934438;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
ALLOPURINOL;NOTCH4;rs367398;AA + AG;TOXICITY;DECREASED_RISK;DISEASE:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;KCNQ1;rs163182;CC + GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:DISEASE_PROGRESSION
;NQO1;rs1800566;AA;OTHER;DECREASED_LIKELIHOOD;OTHER:SURVIVAL
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;EFFICACY;EFFICACY:RAPID_VIRAL_RESPONSE_(RVR)_TO_PEG-IFN/RIBAVIRIN_THERAPY_AT_4_WEEKS_IN_HCV_GENOTYPE_3_PATIENTS
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;IGF2BP2;rs4402960;G;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:DISEASE_PROGRESSION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
EFAVIRENZ;CYP2B6;rs3745274;GG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:IMMUNOLOGICAL_FAILURE
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CYCLOPHOSPHAMIDE, EPIRUBICIN, FLUOROURACIL;NQO1;rs1800566;AA;TOXICITY;DECREASED_LIKELIHOOD;OTHER:SURVIVAL
METHOTREXATE;SLCO1B1;rs2306283;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY,_GASTROINTESTINAL_TOXICITY,_TOXIC_LIVER_DISEASE,
EFAVIRENZ;CYP2B6;rs3745274;GT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:SLEEP_DISORDERS
SUNITINIB;ABCB1;rs1045642;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
VERAPAMIL;CACNA1C;rs1051375;AA;EFFICACY;DECREASED_RISK;OTHER:PRIMARY_OUTCOME
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEDIAN_SURVIVAL_TIME_(MST)
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED_SEVERITY;DISEASE:THROMBOCYTOPENIA
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME
SUNITINIB;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
EFAVIRENZ;CYP2B6;rs3745274;GT;LADME_PK;INCREASED_PK;PK:PLASMA_LEVEL
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME
EFAVIRENZ;CYP2A6;rs28399433;AC + CC;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
;DRD2;rs1800497;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DEATH
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
VERAPAMIL;CACNA1C;rs1051375;GG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:PRIMARY_OUTCOME
EPIRUBICIN, FLUOROURACIL, OXALIPLATIN;GCKR;rs780093;CC + CT;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
SIMVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DOSE_DECREASE_OR_SWITCH_TO_ANOTHER_CHOLESTEROL-LOWERING_DRUG
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DOSE_DECREASE_OR_SWITCH_TO_ANOTHER_CHOLESTEROL-LOWERING_DRUG_IN_USERS_WITH_A_STARTING_DOSE_OF_MORE_THAN_20_MG
CARBOPLATIN, CISPLATIN, GEMCITABINE;;rs12118636;AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CISPLATIN, IRINOTECAN;UGT1A1;rs4148323;AA + AG;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;TT;TOXICITY;;SIDE_EFFECT:ALOPECIA
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
ANTINEOPLASTIC AGENTS;ABCB1;rs1045642;AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NAUSEA
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEDIAN_SURVIAL_TIME
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
CARBOPLATIN, CISPLATIN, GEMCITABINE;NRAS;rs1065634;CT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
CARBOPLATIN, CISPLATIN, GEMCITABINE;GPX5;rs451774;AG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
VINCRISTINE;ACTG1;rs1135989;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
METHADONE;CYP2B6;rs3745274;GG;TOXICITY;INCREASED_SEVERITY;OTHER:NEONATAL_ABSTINENCE_SYNDROME
CARBOPLATIN, TAXANES;ATP7B;rs1801249;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
VINCRISTINE;CAPG;rs3770102;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
VALPROIC ACID;COL1A1;rs1800012;AA + AC;TOXICITY;DECREASED_;SIDE_EFFECT:BONE_DENSITY
VINCRISTINE;ABCB1;rs4728709;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
DOXORUBICIN;AKR1C3;rs1937840;GG;OTHER;DECREASED_;OTHER:ABSOLUTE_LEUCOCYTE_AND_NEUTROPHIL_COUNTS_ON_DAY_15
METHADONE;CYP2B6;rs2279343;AA;TOXICITY;INCREASED_SEVERITY;OTHER:NEONATAL_ABSTINENCE_SYNDROME
KETOPROFEN;CYP2C9;rs1799853;CC;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DYSPEPSIA
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;T;EFFICACY;INCREASED_;OTHER:TIME_TO_THERAPEUTIC_INR
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
REMIFENTANIL;OPRM1;rs1799971;GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
WARFARIN;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
MERCAPTOPURINE;ITPA;rs1127354;AA + AC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
CARBOPLATIN, TAXANES;GSR;rs3594;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
ACENOCOUMAROL, WARFARIN;APOE;rs429358;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
ETHANOL;SLC6A4;rs4251417;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CARBOPLATIN, TAXANES;VEGFA;rs6900017;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
ACENOCOUMAROL, WARFARIN;CYP2C9;rs1057910;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
METHYLPHENIDATE;COMT;rs4680;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
NALOXONE;OPRM1;rs1799971;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:CORTISOL_RESPONSE
ETHANOL;SLC6A4;rs25531;C;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
INTERFERONS, RIBAVIRIN;VDR;rs2228570;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:CRYOGLOBULINEMIA
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
EGFR INHIBITORS;PIK3CA;rs2677760;C;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIARRHEA
CETUXIMAB;EGFR;rs2227983;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
EGFR INHIBITORS;PIK3CA;rs2459693;T;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIARRHEA
IRINOTECAN;CES1;rs7187684;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
METHOTREXATE;ATIC;rs2372536;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ETHANOL;SLC6A4;rs2066713;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CORTICOSTEROIDS, SALMETEROL;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:EXACERBATIONS
ANTIPSYCHOTICS;IL1B;rs4849127;AA + AG;TOXICITY;INCREASED_;SIDE_EFFECT:WEIGHT_GAIN
BETA BLOCKING AGENTS;CYP2D6;rs1065852;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA
FLUOROURACIL;DPYD;rs1801265;GG;LADME_PK;INCREASED_PK;PK:DPD_ACTIVITY
EGFR INHIBITORS;PIK3CA;rs6443624;C;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ANTIPSYCHOTICS;IL1B;rs16944;AG;TOXICITY;INCREASED_;SIDE_EFFECT:WEIGHT_GAIN
DAUNORUBICIN, DOXORUBICIN;SLC28A3;rs885004;A;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:CARDIOTOXICITY
CYCLOSPORINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GINGIVAL_OVERGROWTH
EGFR INHIBITORS;PIK3CA;rs2677760;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CORTICOSTEROIDS;ADRB2;rs1042713;AA;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:UNCONTROLLED_ASTHMA
IRINOTECAN;CES1;rs2244614;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
EXEMESTANE, LETROZOLE;CYP19A1;rs6493497;AA;TOXICITY;DECREASED_;SIDE_EFFECT:BONE_DENSITY
ANTIPSYCHOTICS;IL1B;rs1143634;AA;TOXICITY;DECREASED_;SIDE_EFFECT:WEIGHT_GAIN
ANTIPSYCHOTICS;BDNF;rs6265;CT + TT;TOXICITY;DECREASED_;SIDE_EFFECT:WEIGHT_GAIN
METHYLPHENIDATE;ADGRL3;rs2345039;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
DAUNORUBICIN, DOXORUBICIN;SLC28A3;rs7853758;A;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:CARDIOTOXICITY
MERCAPTOPURINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
WARFARIN;CYP2C9;rs1799853;T;EFFICACY;EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
CARBOPLATIN, TAXANES;ATP7B;rs1061472;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
IRINOTECAN;UGT1A1;rs4148323;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;SUGCT;rs4379368;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOSIS
;FMO3;rs2266780;AG + GG;OTHER;DECREASED_SEVERITY;DISEASE:TOBACCO_USE_DISORDER
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;KNG1;rs710446;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOSIS
FLUOROURACIL;DPYD;rs1801265;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
IRINOTECAN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
ASPIRIN;LPA;rs3798220;CT;EFFICACY;DECREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
BOCEPREVIR, PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
WARFARIN;CYP2C19;rs3814637;T;TOXICITY;RISK_;SIDE_EFFECT:OVER-ANTICOAGULATION
FLUOROURACIL;DPYD;rs72728438;CT;LADME_PK;DECREASED_PK;PK:DPD_ACTIVITY
FLUOROURACIL;ABCC11;rs7194667;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
EGFR INHIBITORS;PIK3CA;rs2699905;C;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FLUOROURACIL;DPYD;rs115632870;CT;LADME_PK;DECREASED_PK;PK:DPD_ACTIVITY
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ABO;rs56392308;del;TOXICITY;DECREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOSIS
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
ETHANOL;SLC6A3;rs6350;AG;TOXICITY;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;ABO;rs8176719;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOSIS
METHOTREXATE;SLCO1B1;rs4149056;TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;PROCR;rs9574;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOSIS
HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE;F11;rs2289252;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOSIS
METHOTREXATE;SLCO1B1;rs2306283;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_;SIDE_EFFECT:INFECTIOUS_DISEASE,_TOXIC_LIVER_DISEASE
DEXMEDETOMIDINE;NR1I2;rs3814057;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:BRADYCARDIA,_HYPOTENSIVE_DISORDER
;MAOA;rs1137070;TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOBACCO_USE_DISORDER
;MAOB;rs1799836;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOBACCO_USE_DISORDER
CAPECITABINE;;rs9936750;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
FLUOROURACIL;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED_;SIDE_EFFECT:INFECTIOUS_DISEASE,_NEPHROTOXICITY,_TOXIC_LIVER_DISEASE,
DOXORUBICIN;ABCB1;rs1045642;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN;CBR3;rs1056892;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
CAPECITABINE;DPYD;rs3918290;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
FOLFIRI;UGT1A1;rs4124874;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MYELOSUPPRESSION
CAPECITABINE;DPYD;rs67376798;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CETUXIMAB;EGF;rs4444903;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:COMPLETE_PATHOLOGIC_RESPONSE
AFATINIB, ERLOTINIB, GEFITINIB;UHRF1;rs2261988;TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
;HAVCR2;rs10515746;AA + AC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
;HAVCR2;rs1036199;AC + CC;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
AFATINIB, ERLOTINIB, GEFITINIB;DVL2;rs2074216;AA;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
GLATIRAMER ACETATE;;rs12459996;T;TOXICITY;INCREASED_RISK;DISEASE:CORONARY_ARTERY_DISEASE
WARFARIN;VKORC1;rs9923231;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
WARFARIN;VKORC1;rs9923231;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
FLUOROURACIL;OR10AE3P, PSMB3P;rs10876844;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIARRHEA
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
HEROIN;BDNF;rs6265;TT;OTHER;INCREASED_RISK;OTHER:ADDICTION
METHAMPHETAMINE;BDNF;rs6265;T;OTHER;INCREASED_RISK;OTHER:ADDICTION
DOXORUBICIN, PACLITAXEL, TRASTUZUMAB;ABCB1;rs2235047;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
DOXORUBICIN, PACLITAXEL, TRASTUZUMAB;CBR3;rs1056892;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
FENTANYL;OPRM1;rs540825;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
ASPIRIN, TICAGRELOR;CYP4F2;rs3093135;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
CLOPIDOGREL;ABCB1;rs2032582;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
AFATINIB, ERLOTINIB, GEFITINIB;NUP62;rs9523;CC;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
;;rs2207418;GG;OTHER;INCREASED_RISK;DISEASE:DEATH
ALFENTANIL;OPRM1;rs1799971;GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:RESPIRATORY_INSUFFICIENCY
WARFARIN;CYP2C9;rs9332197;C;EFFICACY;EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
WARFARIN;CYP2C9;rs1057910;C;TOXICITY;RISK_;SIDE_EFFECT:OVER-ANTICOAGULATION
WARFARIN;CYP2C18;rs2901783;AG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
WARFARIN;F5;rs6018;G;TOXICITY;RISK_;SIDE_EFFECT:HEMORRHAGE
WARFARIN;PROS1;rs8178607;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
;CHRM3;rs2165870;GG;TOXICITY;INCREASED_RISK;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
CISPLATIN, GEMCITABINE;CDA;rs2072671;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
CAPECITABINE;DPYD;rs1801265;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
DOXORUBICIN;GSTP1;rs1695;GG;TOXICITY;INCREASED_;SIDE_EFFECT:MICRONUCLEATED_BINUCLEATED_CELLS
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
METHOTREXATE;MTHFR;rs1801131;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
METHOTREXATE;MTHFR;rs1801133;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;FCGR2A;rs1801274;AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_ACTIVITY_SCORE_28_IN_RHEUMATOID_ARTHRITIS
;SCN5A;rs7626962;GT + TT;OTHER;INCREASED_LIKELIHOOD;DISEASE:CARDIAC_RHYTHM_DISEASE
CARBOPLATIN, TAXANES;VEGFA;rs879825;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
EXEMESTANE, LETROZOLE;ESR1;rs4870061;CT + TT;TOXICITY;DECREASED_;SIDE_EFFECT:BONE_DENSITY
METHOTREXATE;MTRR;rs1801394;AG + GG;LADME_PK;DECREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CARBOPLATIN, TAXANES;SCN10A;rs9825762;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
CARBOPLATIN, TAXANES;VEGFA;rs9369421;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
LETROZOLE;ESR1;rs4870061;TT;TOXICITY;DECREASED_;SIDE_EFFECT:BONE_DENSITY
WARFARIN;CYP2C9;rs1057910;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
METHOTREXATE;ABCC2;rs2273697;AA + AG;LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
EXEMESTANE, LETROZOLE;ESR1;rs9322335;TT;TOXICITY;DECREASED_;SIDE_EFFECT:BONE_DENSITY
LETROZOLE;ESR1;rs9322335;TT;TOXICITY;DECREASED_;SIDE_EFFECT:BONE_DENSITY
CISPLATIN, ETOPOSIDE;NQO1;rs1800566;AA;OTHER;DECREASED_;OTHER:OVERALL_SURVIVAL
CISPLATIN;SLC22A2;rs316019;AC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEPHROTOXICITY
LETROZOLE;ESR2;rs10140457;CC;TOXICITY;DECREASED_;SIDE_EFFECT:BONE_DENSITY
EXEMESTANE;ESR1;rs2813543;AA;TOXICITY;DECREASED_;SIDE_EFFECT:BONE_DENSITY
EXEMESTANE;CYP19A1;rs6493497;AA;TOXICITY;DECREASED_;SIDE_EFFECT:BONE_DENSITY
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
BISPHOSPHONATES;;rs2736308;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS_OF_THE_JAW
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
BISPHOSPHONATES;;rs2736308;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS_OF_THE_JAW
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;rs10306135;TT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
BEVACIZUMAB, CAPECITABINE, CISPLATIN, DOCETAXEL, EPIRUBICIN, OXALIPLATIN, TRASTUZUMAB;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
CARBOPLATIN, GEMCITABINE;TNF;rs1800629;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
SORAFENIB;KDR;rs2305948;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
;COMT;rs4680;AG + GG;OTHER;DECREASED_;OTHER:LENGTH_OF_HOSPITAL_STAY
CARBOPLATIN, GEMCITABINE;PRRC2A;rs11229;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
CARBOPLATIN, GEMCITABINE;PRRC2A;rs10885;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
METHADONE, MORPHINE;COMT;rs4680;AG + GG;OTHER;DECREASED_LIKELIHOOD;OTHER:TREATMENT
SORAFENIB;FLT1;rs664393;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
SORAFENIB;KDR;rs2071559;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
CARBOPLATIN, GEMCITABINE;MSH5;rs3115672;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
CYCLOPHOSPHAMIDE, DOXORUBICIN, FEC100, FLUOROURACIL;ALDH1A1;rs13959;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA
HMG COA REDUCTASE INHIBITORS;ATP2B1;rs17381194;T;TOXICITY;INCREASED_RISK;DISEASE:MYALGIA
CARBOPLATIN, GEMCITABINE;DOCK8;rs10491684;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
HMG COA REDUCTASE INHIBITORS;;rs4693570;C;TOXICITY;INCREASED_RISK;DISEASE:MYALGIA
;EPO;rs1617640;A;OTHER;INCREASED_;OTHER:ENDOGENOUS_LEVELS_OF_EPO
HMG COA REDUCTASE INHIBITORS;DMPK;rs672348;G;TOXICITY;INCREASED_RISK;DISEASE:MYALGIA
ASPIRIN;EYA1;rs12678747;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PEPTIC_ULCER_DISEASE
CARBOPLATIN, GEMCITABINE;CYP2C8;rs1058932;A;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
CARBOPLATIN, GEMCITABINE;CYP2C8;rs11572078;A;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
AZITHROMYCIN, CHLORPROMAZINE, CILOSTAZOL, CIPROFLOXACIN, CITALOPRAM, CLARITHROMYCIN, DOFETILIDE, DONEPEZIL, DRONEDARONE, ERYTHROMYCIN, ESCITALOPRAM, FLECAINIDE, FLUCONAZOLE, HALOPERIDOL, HYDROXYCHLOROQUINE, LEVOFLOXACIN, METHADONE, MOXIFLOXACIN, ONDANSETRON, OXALIPLATIN, PAPAVERINE, PENTAMIDINE, PROCAINAMIDE, PROPOFOL, QUINIDINE, SOTALOL;KCNE1;rs1805128;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
CARBOPLATIN, GEMCITABINE;C6orf15;rs2233980;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
CARBOPLATIN, GEMCITABINE;CDSN;rs3130985;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
ETOPOSIDE, PLATINUM COMPOUNDS;DYNC2H1;rs716274;AG + GG;EFFICACY;INCREASED_RISK;DISEASE:DEATH
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
METHADONE, MORPHINE;OPRM1;rs1799971;AG + GG;OTHER;DECREASED_LIKELIHOOD;OTHER:TREATMENT
CYCLOPHOSPHAMIDE, DOXORUBICIN, FEC100, FLUOROURACIL;NQO1;rs1800566;AA + AG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA,_NEUTROPENIA,_GASTROINTESTINAL_TOXICITY,
ETOPOSIDE, PLATINUM COMPOUNDS;YAP1;rs10895256;GT + TT;EFFICACY;INCREASED_RISK;DISEASE:DEATH
HMG COA REDUCTASE INHIBITORS;COQ2;rs6535454;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN_INTOLERANCE,_DEFINED_PRIMARILY_THROUGH_MUSCLE_SYMPTOMATOLOGY
HMG COA REDUCTASE INHIBITORS;COQ2;rs4693075;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN_INTOLERANCE,_DEFINED_PRIMARILY_THROUGH_MUSCLE_SYMPTOMATOLOGY
CARBOPLATIN, GEMCITABINE;HLA-C;rs1049709;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
CARBOPLATIN, GEMCITABINE;HCP5;rs3130907;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
LENALIDOMIDE;CTNNB1;rs4135385;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CARBOPLATIN, ERLOTINIB, PACLITAXEL;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
CARBOPLATIN, GEMCITABINE;SERPINC1;rs5877;C;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
IBRUTINIB;KCNQ1;rs2237895;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIAC_RHYTHM_DISEASE,_CARDIOTOXICITY
TAMOXIFEN;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;SLC19A1;rs1051266;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MUCOSITIS
;SCN5A;rs7626962;GG;OTHER;INCREASED_LIKELIHOOD;DISEASE:SUDDEN_INFANT_DEATH
LENALIDOMIDE;CTNNB1;rs4533622;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CARBOPLATIN, GEMCITABINE;;rs886423;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
CARBOPLATIN, GEMCITABINE;;rs886424;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
BETA BLOCKING AGENTS;ADRB1;rs1801252;AG + GG;EFFICACY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
CARBOPLATIN, GEMCITABINE;ATAT1;rs9262132;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
SORAFENIB;VEGFA;rs2010963;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SORAFENIB;VEGFA;rs2010963;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
;ABO;rs495828;GG;LADME_PK;INCREASED_;OTHER:ACE_ACTIVITY
CARBOPLATIN, GEMCITABINE;PPP1R18;rs9262143;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
;OPRM1;rs1799971;AG + GG;OTHER;DECREASED_;OTHER:LENGTH_OF_HOSPITAL_STAY
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE
SORAFENIB;;rs4604006;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
IBRUTINIB;KCNQ1;rs163182;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIAC_RHYTHM_DISEASE,_CARDIOTOXICITY
CARBOPLATIN, GEMCITABINE;MUCL3;rs3094086;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
OLANZAPINE;GIPR;rs10423928;AA;TOXICITY;INCREASED_;SIDE_EFFECT:PLASMA_INSULIN_LEVELS
SORAFENIB;;rs4604006;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
SORAFENIB;VEGFA;rs25648;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ANTHRACYCLINES AND RELATED SUBSTANCES;;rs28714259;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
CYCLOSPORINE;CTLA4;rs231775;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GINGIVAL_OVERGROWTH
SORAFENIB;VEGFA;rs833061;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
SORAFENIB;VEGFA;rs699947;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
SORAFENIB;VEGFA;rs25648;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FENTANYL;OPRM1;rs9397685;AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NAUSEA,_VOMITING
SORAFENIB;VEGFA;rs833061;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;EFFICACY;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE
;ABCC4;rs2274407;AA + AC;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PHYSICAL_AND_LIFE_WELL-BEING_QUALITY_OF_LIFE_(QOL)_SCALES
ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME
WARFARIN;VKORC1;rs9923231;TT;DOSAGE, EFFICACY, TOXICITY;INCREASED_RISKEFFICACY;EFFICACY:OVER-ANTICOAGULATION
PAZOPANIB;HFE;rs2858996;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PACLITAXEL;ABCB1;rs1128503;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA,_NEUTROPENIA
;;rs2207418;GG;OTHER;INCREASED_RISK;DISEASE:HEART_FAILURE
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY, LADME_PK;DECREASED_PK;PK:TROUGH_CONCENTRATIONS
GLATIRAMER ACETATE;;rs75041078;A;TOXICITY;INCREASED_RISK;DISEASE:CORONARY_ARTERY_DISEASE
GLATIRAMER ACETATE;;rs1056854;A;TOXICITY;INCREASED_RISK;DISEASE:CORONARY_ARTERY_DISEASE
METHAMPHETAMINE;GAD2;rs2236418;AG + GG;OTHER;INCREASED_LIKELIHOOD;DISEASE:METHAMPHETAMINE_DEPENDENCE,_PSYCHOTIC_DISORDER,_SUBSTANCE-RELATED_DISORDERS,
GLICLAZIDE, GLYBURIDE;ABCC8, KCNJ11;rs757110;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
ERLOTINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs4803217;AA + AC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
TACROLIMUS;ABCB1;rs2229109;CT + TT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RENAL_TRANSPLANT_FAILURE
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs4803217;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TRANSPLANT_REJECTION
FENTANYL;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPOVENTILATION
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY, LADME_PK;DECREASED_PK;PK:TROUGH_LEVELS
AFATINIB, ERLOTINIB, GEFITINIB;ARF1;rs11541557;GT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
DRUGS FOR TREATMENT OF TUBERCULOSIS;CYP2E1;rs2031920;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
OSELTAMIVIR;ABCB1;rs1045642;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEPRESSION,_GASTRITIS,_HYPERSENSITIVITY,
METHOTREXATE;ABCC3;rs9895420;AA + AT;TOXICITY, LADME_PK;INCREASED_;SIDE_EFFECT:PLASMA_LEVELS
METHOTREXATE;ABCC3;rs9895420;AA + AT;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
COCAINE;OPRD1;rs678849;T;TOXICITY;DECREASED_RISK;OTHER:COCAINE_DEPENDENCE
CERIVASTATIN;RYR2;rs2819742;AA;TOXICITY;DECREASED_RISK;DISEASE:RHABDOMYOLYSIS
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;;rs1891059;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
ANTIEPILEPTICS;ABCC2;rs2273697;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROBABILITY_OF_ANTIEPILEPTIC_DRUG_RESPONSE
METHOTREXATE;ABCC3;rs9895420;AA + AT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RELAPSE_IN_THE_CENTRAL_NERVOUS_SYSTEM
;CYP1A2;rs35694136;T;OTHER;INCREASED_LIKELIHOOD;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE
ANTITHYMOCYTE GLOBULIN;FCGR3A;rs396991;AC + CC;OTHER;INCREASED_;OTHER:SENSITIVE_TO_ANTILYMPHOCYTE_SERUM
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;LINC00251;rs141059755;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;;rs17021408;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
PEGASPARGASE;ARHGAP28;rs9958628;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;DOK5;rs117532069;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;;rs80223967;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE;ABCG2;rs3114020;CT + TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT:DEATH
THEOPHYLLINE;CYP1A2;rs35694136;T/del + TT;EFFICACY;INCREASED_SEVERITY;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE
THEOPHYLLINE;CYP1A2;rs35694136;T;EFFICACY, LADME_PK;DECREASED_PK;PK:PLASMA_DRUG_LEVELS
;CYP1A2;rs762551;C;OTHER;INCREASED_LIKELIHOOD;DISEASE:CHRONIC_OBSTRUCTIVE_PULMONARY_DISEASE
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;ATP7B;rs1061472;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
VERAPAMIL;NR1H3;rs2279238;T;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION,_STROKE
VERAPAMIL;NR1H3;rs12221497;A;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION,_STROKE
;DDC;rs921451;T;;SEVERITY_;DISEASE:TOBACCO_USE_DISORDER
ATENOLOL, VERAPAMIL;NR1H3;rs11039149;G;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION,_STROKE
;DDC;rs3735273;C;;SEVERITY_;DISEASE:TOBACCO_USE_DISORDER
SEVOFLURANE;KCNK2;rs6686529;CC + CG;EFFICACY;INCREASED_EFFICACY;EFFICACY:SEDATION
;DDC;rs1451371;T;;SEVERITY_;DISEASE:TOBACCO_USE_DISORDER
CHOP, RITUXIMAB;SLC35F4;rs74832512;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PROTEASE INHIBITORS;APOC3;rs2854116;CC + CT;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT:HYPERTRIGLYCERIDEMIA
VARENICLINE;CHRNB1, ZBTB4;rs2302764;C;TOXICITY;INCREASED_SEVERITY;DISEASE:NAUSEA
PROTEASE INHIBITORS;APOC3;rs2854117;CT + TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:HYPERTRIGLYCERIDEMIA
VARENICLINE;CHRNB2;rs2072661;A;TOXICITY;INCREASED_SEVERITY;DISEASE:NAUSEA
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, DEXAMETHASONE, DOXORUBICIN, METHOTREXATE, PEGASPARGASE, PREDNISONE, THIOGUANINE, VINCRISTINE;BMP7;rs79085477;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
VARENICLINE;CHRNB2;rs4292956;T;TOXICITY;INCREASED_SEVERITY;DISEASE:NAUSEA
VARENICLINE;CHRNB2;rs2072660;C;TOXICITY;INCREASED_SEVERITY;DISEASE:NAUSEA
CARBOPLATIN, ETOPOSIDE, IFOSFAMIDE;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_RISK;SIDE_EFFECT:DEATH
AZATHIOPRINE;DDRGK1, ITPA;rs1127354;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
MORPHINE;FAAH;rs324420;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:RESPIRATORY_INSUFFICIENCY
CHOP, RITUXIMAB;OXNAD1;rs11721010;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
MORPHINE;FAAH;rs11576941;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
PROTEASE INHIBITORS;APOC3;rs5128;CG + GG;TOXICITY;DECREASED_;SIDE_EFFECT:HYPERTRIGLYCERIDEMIA
SUNITINIB;ABCB1;rs2032582;AC;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
DOCETAXEL;SLCO1B3;rs11045585;G;TOXICITY;INCREASED_RISK;DISEASE:LEUKOPENIA
APIXABAN;ABCB1;rs4148738;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEMORRHAGE
DOCETAXEL;ABCC2;rs12762549;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
;DTNBP1;rs3213207;T;;DECREASED_RISK;DISEASE:BIPOLAR_DISORDER
ASPIRIN;ITGB3;rs5918;CT;OTHER;INCREASED_;OTHER:SENSITIVITY_TO_ASPIRIN
CHOP, RITUXIMAB;CIDEA;rs75614943;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CYTARABINE;CDA;rs3215400;C/del + del/del;TOXICITY;INCREASED_;DISEASE:DRUG_TOXICITY
METHAMPHETAMINE;BDNF;rs6265;CC;OTHER;INCREASED_LIKELIHOOD;DISEASE:SUBSTANCE-RELATED_DISORDERS
CHOP, RITUXIMAB;NOS1;rs77241831;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
METHAMPHETAMINE;BDNF;rs6265;CC;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT:PSYCHOTIC_DISORDER
CYTARABINE;CDA;rs2072671;AC + CC;TOXICITY;INCREASED_;DISEASE:DRUG_TOXICITY
ANTIPSYCHOTICS;;rs9346455;GG + GT;TOXICITY;INCREASED_;SIDE_EFFECT:WEIGHT_GAIN
;DTNBP1;rs3213207;T;;DECREASED_SEVERITY;OTHER:MANIC_SYMPTOMS_IN_PSYCHOSIS
SUFENTANIL;ABCB1;rs1045642;GG;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN,_POSTOPERATIVE
;DTNBP1;rs2619539;C;;DECREASED_SEVERITY;OTHER:MANIC_SYMPTOMS_IN_PSYCHOSIS
CYTARABINE;CDA;rs602950;AG + GG;TOXICITY;INCREASED_;DISEASE:DRUG_TOXICITY
HEROIN;OPRD1;rs2236857;C;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
CYTARABINE;CDA;rs532545;CT + TT;TOXICITY;INCREASED_;DISEASE:DRUG_TOXICITY
HEROIN;OPRD1;rs2236855;A;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
SUNITINIB;ABCB1;rs1128503;AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
RIVAROXABAN;ABCB1;rs1045642;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:THROMBOEMBOLISM
HEROIN;OPRD1;rs3766951;C;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
NICOTINE;NRXN1;rs2193225;C;OTHER;;OTHER:SMOKING_QUANTITY
HEROIN;OPRD1;rs2298897;C;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
NICOTINE;NRXN1;rs2193225;C;OTHER;;OTHER:SMOKING_QUANTITY,_HEAVINESS_OF_SMOKING_INDEX_AND_FAGERSTROM_TEST_FOR_NICOTINE_DEPENDENCE
NICOTINE;NRXN1;rs6721498;A;OTHER;;OTHER:SMOKING_QUANTITY,_HEAVINESS_OF_SMOKING_INDEX_AND_FAGERSTROM_TEST_FOR_NICOTINE_DEPENDENCE
SUNITINIB;ABCB1;rs1045642;AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CHOP, RITUXIMAB;;rs1607795;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SUFENTANIL;COMT;rs4680;AA;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN,_POSTOPERATIVE
;DTNBP1;rs2619538;T;;DECREASED_SEVERITY;OTHER:MANIC_SYMPTOMS_IN_PSYCHOSIS
ETHANOL;FUT2;rs492602;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;FTO;rs9937709;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
PLATINUM;RICTOR;rs6878291;GG;TOXICITY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ANTIDEPRESSANTS;NR3C1;rs852977;G;EFFICACY;INCREASED_PK;PK:ANTIDEPRESSANT_RESPONSE
CERIVASTATIN;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_RISK;DISEASE:RHABDOMYOLYSIS
PAROXETINE;HTR3B;rs1176744;AA;TOXICITY;INCREASED_RISK;DISEASE:NAUSEA
ETHANOL;;rs1783835;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
CHOP, RITUXIMAB;TNIP3;rs116665727;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CISPLATIN, FLUOROURACIL, RADIOTHERAPY;APEX1;rs1760944;GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
CHOP, RITUXIMAB;IL10;rs1800871;AG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL,_OVERALL_SURVIVAL
SUNITINIB;ABCB1;rs2032582;A;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CISPLATIN, FLUOROURACIL, RADIOTHERAPY;MUTYH;rs3219489;CG + GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ETHANOL;SLC4A8;rs12296477;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ASPIRIN;ITGB3;rs5918;CC + CT;OTHER;;OTHER:SHORTER_BLEEDING_TIME
;NR3C1;rs10482633;G;;INCREASED_EFFICACY;EFFICACY:ANTIDEPRESSANT_RESPONSE
ESCITALOPRAM;HTR2A;rs9316233;C;EFFICACY;INCREASED_EFFICACY;EFFICACY:ANTIDEPRESSANT_RESPONSE
ETHANOL;ARID4A;rs61974485;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
ETHANOL;;rs8008020;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
NICOTINE;OPRM1;rs1799971;AG;TOXICITY;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
ETHANOL;TNRC6A;rs72768626;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
GLIMEPIRIDE, GLIPIZIDE, GLYBURIDE;NOS1AP;rs10494366;T;TOXICITY;INCREASED_RISK;OTHER:HYPOGLYCEMIA
KETOROLAC;;rs2562456;CC;EFFICACY;EFFICACY;EFFICACY:SLOWER_ANALGESIC_ONSET_IN_EUROPEAN_AMERICANS_UNDERGOING_ORAL_SURGERY
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
AZATHIOPRINE;ABCC1;rs2074087;CC + CG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LYMPHOPENIA
FLUVASTATIN;SREBF1;rs60282872;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:APOLIPOPROTEIN_A1_AND_C3
BEVACIZUMAB, PEMETREXED;SLC19A1;rs1051298;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CISPLATIN, RADIOTHERAPY;TP53;rs1042522;CG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
;SLC30A8;rs13266634;C;OTHER, LADME_PK;INCREASED_;OTHER:BASELINE_PROINSULIN_LEVELS_AFTER_ADJUSTING_FOR_INSULIN_LEVELS
OPIOIDS;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED_LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;AGT;rs943580;GG;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;MMP1, MMP10;rs2071230;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
LEVONORGESTREL;ADAMTS10;rs7255721;CG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;MMP1, MMP10;rs7945189;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
CITALOPRAM;HTR2A;rs6313;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEART_PALPITATIONS
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;PTGS1;rs12353214;TT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;KL;rs211247;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CRP;rs1205;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
NICOTINE;CHRNA4;rs1044396;AG;OTHER;INCREASED_LIKELIHOOD;OTHER:SMOKING_INITIATION
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CDKN2B-AS1;rs10757274;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
NICOTINE;CHRNA4;rs1044396;GG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;AGT;rs699;GG;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
NICOTINE;CHRNA4;rs1044397;CC;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOBACCO_USE_DISORDER
COXIBS;PTGS2;rs20417;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
COXIBS;PTGS2;rs4648276;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ACUTE_CORONARY_SYNDROME
SEVOFLURANE;FASTKD3, MTRR;rs3733784;CC + CT;EFFICACY;INCREASED_EFFICACY;EFFICACY:VOL%_END-TIDAL_SEVOFLURANE_CONCENTRATION
HEROIN;OPRM1;rs524731;A;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
HEROIN;OPRM1;rs511435;T;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
HEROIN;OPRM1;rs495491;G;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
AZATHIOPRINE;ADK;rs10824095;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
HEROIN;OPRM1;rs510769;T;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
CISPLATIN;ACYP2;rs1872328;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OTOTOXICITY
AZATHIOPRINE;SLC29A1;rs747199;CG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:ON-TREATMENT_PLATELET_AGGREGATION
AZATHIOPRINE;IMPDH2;rs11706052;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LYMPHOPENIA
HEROIN;OPRM1;rs3778151;C;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
AZATHIOPRINE;IMPDH1;rs2278294;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:LYMPHOPENIA
CLOZAPINE, OLANZAPINE, RISPERIDONE;SLC1A1;rs2228622;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OBSESSIVE-COMPULSIVE_SYMPTOMS
HEROIN;OPRM1;rs3823010;A;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
CLOZAPINE, OLANZAPINE, RISPERIDONE;SLC1A1;rs3780413;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OBSESSIVE-COMPULSIVE_SYMPTOMS
CLOZAPINE, OLANZAPINE, RISPERIDONE;SLC1A1;rs3780412;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OBSESSIVE-COMPULSIVE_SYMPTOMS
HEROIN;;rs9478495;A;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
;;rs9424490;G;;INCREASED_RISK;OTHER:CURRENT_SMOKING
;USH2A;rs12126638;C;;INCREASED_RISK;OTHER:CURRENT_SMOKING
;AK4;rs1109374;C;;INCREASED_RISK;OTHER:CURRENT_SMOKING
ASPIRIN, CLOPIDOGREL;ITGA2;rs1062535;AA + AG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESIDUAL_PLATELET_REACTIVITY
;ITGB1;rs1187075;AA;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
HEROIN;OPRM1;rs562859;C;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
FLUOROURACIL;DPYD;rs3918290;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
LETROZOLE;;rs1324052;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_PAIN,_ARTHRITIS,_DISCONTINUATION,
PLATINUM, VINORELBINE;STMN1;rs182455;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
TEGAFUR;DPYD;rs1801159;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
;ITGB1;rs2230395;GG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
HEROIN;OPRM1;rs3778150;C;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
BEVACIZUMAB, PEMETREXED;GGH;rs3780126;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
;TPH2;rs1843809;TT;OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT:AGGRESSION,_DEPRESSION
ASPIRIN, CLOPIDOGREL;ITGA2;rs1126643;CT + TT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESIDUAL_PLATELET_REACTIVITY
HEROIN;;rs9384169;C;TOXICITY;INCREASED_RISK;OTHER:HEROIN_DEPENDENCE
ANTIPSYCHOTICS;CYP1A2;rs762551;AC + CC;TOXICITY;INCREASED_;SIDE_EFFECT:QT_INTERVAL
PLATINUM COMPOUNDS;SLC22A2;rs316019;AA + AC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
PLATINUM COMPOUNDS;SLC22A2;rs316019;AA + AC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ANTIDEPRESSANTS, ANTIPSYCHOTICS, BENZODIAZEPINE DERIVATIVES, OPIOIDS, SYMPATHOMIMETICS;OPRM1;rs1799971;G;TOXICITY;INCREASED_RISK;OTHER:CARDIAC_ARREST,_RESPIRATORY_INSUFFICIENCY
BEVACIZUMAB, PEMETREXED;GGH;rs11545077;CT;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DIGOXIN;NOS1AP;rs10494366;GG;TOXICITY;INCREASED_;SIDE_EFFECT:SHORTENED_QT_INTERVAL
SUNITINIB;ABCB1;rs2032582;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS,_HAND-FOOT_SYNDROME,_HYPERTENSION,
ASPIRIN, CLOPIDOGREL;ITGA2;rs1126643;CT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION_AFTER_STIMULI_WITH_ADENOSINE_DIPHOSPHATE,_COLLAGEN,_AND_EPINEPHRINE
FENTANYL;OPRM1;rs1799971;GG;DOSAGE;EFFICACY;EFFICACY:HIGHER_FENTANYL_DOSE_REQUIREMENT_TO_ACHIEVE_ADEQUATE_PAIN_RELIEF_IN_CHINESE_WOMEN_UNDERGOING_GYNECOLOGIC_SURGERY
CANNABINOIDS, COCAINE, ETHANOL, NICOTINE, OPIOIDS;OPRM1;rs1799971;G;TOXICITY;DECREASED_RISK;OTHER:SUBSTANCE-RELATED_DISORDERS
CAPECITABINE, FLUOROURACIL;MIR27A;rs895819;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
SUNITINIB;FLT1;rs7993418;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;NFE2L2;rs6721961;GG + GT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OTOTOXICITY
SUNITINIB;FLT1;rs9582036;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
FENTANYL;OPRM1;rs1799971;AG + GG;DOSAGE, EFFICACY;EFFICACY;EFFICACY:HIGHER_RESPONSIVENESS_TO_OPIOIDS_AND_REQUIRED_LESS_ANALGESIC_DRUGS_IN_LABORING_WOMEN
FLUVOXAMINE;HTR2A;rs6311;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_SIDE_EFFECTS
FENTANYL;OPRM1;rs1799971;AG + GG;EFFICACY;EFFICACY;EFFICACY:LESS_PAIN_CONTROL_IN_JAPANESE_PATIENTS_UNDERGOING_PAINFUL_OROFACIAL_COSMETIC_SURGERY
OLANZAPINE;FMO3;rs2266780;GG;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_SERUM_OLANZAPINE_N-OXIDE_CONCENTRATIONS
METOPROLOL;CYP2D6;rs3892097;T;EFFICACY, LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS_OF_METOPROLOL_AND_GREATER_REDUCTIONS_IN_HEART_RATE,_DIASTOLIC_BLOOD_PRESSURE,_AND_MEAN_ARTERIAL_PRESSURE_IN_PMS_THAN_IN_NON-PMS.
SUNITINIB;FLT1;rs9554320;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESIDUAL_PLATELET_REACTIVITY
PLATINUM COMPOUNDS;CCN4;rs10956697;AA + AC;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
ASPIRIN;ITGB3;rs5918;CC + CT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:THE_LACK_OF_ASPIRIN_EFFECT
SUNITINIB;FLT1;rs9554320;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
OLANZAPINE;FMO1;rs12720462;AA + AC;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_SERUM_OLANZAPINE_CONCENTRATIONS
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
PLATINUM COMPOUNDS;ERCC1;rs3212986;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ARIPIPRAZOLE;DRD2;rs2514218;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PSYCHOMOTOR_AGITATION
PLATINUM COMPOUNDS, TAXANES;GSTP1;rs1695;AA;TOXICITY, LADME_PK;INCREASED_RISK;SIDE_EFFECT:HEMATOLOGICAL_TOXICITY
PLATINUM, TAXANES;ABCB1;rs2032582;CC;TOXICITY, LADME_PK;DECREASED_RISK;SIDE_EFFECT:GRADE_3_OR_4_GASTROINTESTINAL_TOXICITY
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
SUNITINIB;FLT1;rs9582036;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
OLANZAPINE;FMO1;rs7877;CT + TT;LADME_PK;INCREASED_PK;PK:DOSE-ADJUSTED_SERUM_OLANZAPINE_CONCENTRATIONS
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESIDUAL_PLATELET_REACTIVITY
BUMETANIDE, FUROSEMIDE, TORASEMIDE;SLC12A3;rs1529927;C;EFFICACY;INCREASED_EFFICACY;EFFICACY:24-H_EXCRETION_OF_CHLORIDE_AND_POTASSIUM
AMPHETAMINE, CANNABINOIDS, COCAINE, OPIOIDS;KAT2B;rs9829896;C;TOXICITY;DECREASED_RISK;OTHER:SUBSTANCE-RELATED_DISORDERS
PACLITAXEL;EPHA5;rs7349683;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
IMATINIB;ABCG2;rs2231142;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ASPIRIN;NAT2;rs4271002;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INTOLERANCE
OPIOIDS;OPRM1;rs1799971;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
METHADONE;ARRB2;rs3786047;AA;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NONRESPONSE_TO_METHADONE_MAINTENANCE_TREATMENT
BUMETANIDE, FUROSEMIDE, TORASEMIDE;SCNN1G;rs5723;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:24-H_EXCRETION_OF_CALCIUM_AND_DECREASED_URINARY_VOLUME
PLATINUM COMPOUNDS;CCN4;rs2929973;GG + GT;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ENALAPRIL;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
ANTIPSYCHOTICS;HTR2A;rs6311;TT;TOXICITY;INCREASED_RISK;DISEASE:TARDIVE_DYSKINESIA
METHADONE;ARRB2;rs1045280;CC;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NONRESPONSE_TO_METHADONE_MAINTENANCE_TREATMENT
METHADONE;MYOCD;rs1714984;AA + AG;EFFICACY;EFFICACY;EFFICACY:INCREASED_RISK_OF_BEING_NONRESPONDERS
METHADONE;ARRB2;rs2036657;GG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NONRESPONSE_TO_METHADONE_MAINTENANCE_TREATMENT
BUMETANIDE, FUROSEMIDE, TORASEMIDE;SCNN1G;rs5729;A;EFFICACY;DECREASED_EFFICACY;EFFICACY:24-H_EXCRETION_OF_CALCIUM_AND_DECREASED_URINARY_VOLUME
ANTIPSYCHOTICS;CYP1A2;rs762551;CC;TOXICITY;INCREASED_RISK;DISEASE:TARDIVE_DYSKINESIA
ANTIPSYCHOTICS;CYP2D6;rs1065852;A;TOXICITY;INCREASED_RISK;DISEASE:TARDIVE_DYSKINESIA
OLANZAPINE;HTR2C;rs518147;C;TOXICITY;DECREASED_RISK;DISEASE:WEIGHT_GAIN
PRAVASTATIN;CETP;rs708272;AG;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:CORONARY_ARTERY_DISEASE
ATORVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:BENEFIT
ASPIRIN;ITGB3;rs5918;TT;EFFICACY;EFFICACY;EFFICACY:ASPIRIN-DEPRESSED_THROMBIN_GENERATION_AND_PROLONGED_BLEEDING_TIME_AFTER_ASPIRIN
ASPIRIN;F13A1;rs5985;AA + AC;EFFICACY;INCREASED_EFFICACY;EFFICACY:INHIBITION_OF_FXIII_ACTIVATION_BY_ASPIRIN
VERAPAMIL;ADRB1;rs1801253;CC + CG;EFFICACY;INCREASED_RISK;DISEASE:DEATH
AZATHIOPRINE;ITPA;rs1127354;C;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
CHOP, RITUXIMAB;NCF4;rs1883112;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
IVACAFTOR;CFTR;rs75527207;AA + AG;EFFICACY;DECREASED_SEVERITY;SIDE_EFFECT:BONE_DENSITY
CHOP, RITUXIMAB;ABCG2;rs2231137;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PRAVASTATIN;CETP;rs708272;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_LUMINAL_DIAMETER
AMIODARONE, DIURETICS, SOTALOL;NOS1AP;rs10800397;T;TOXICITY;;SIDE_EFFECT:DRUG-INDUCED_VENTRICULAR_ARRHYTHMIA_AND_QT_PROLONGATION
ANTIPSYCHOTICS;;rs6977820;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TARDIVE_DYSKINESIA
AMIODARONE;NOS1AP;rs10800397;T;TOXICITY;;SIDE_EFFECT:AMIODARONE-INDUCED_VENTRICULAR_ARRHYTHMIA_AND_QT_PROLONGATION
WARFARIN;VKORC1;rs17880887;T;DOSAGE;EFFICACY;EFFICACY:LOWER_LEVELS_OF_TRANSTHYRETIN_PRECUROR
AMIODARONE;NOS1AP;rs10919035;T;TOXICITY;;SIDE_EFFECT:AMIODARONE-INDUCED_VENTRICULAR_ARRHYTHMIA_AND_QT_PROLONGATION
ASPIRIN;HNMT;rs1050891;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ACETYLSALICYLIC_ACID-INTOLERANT_CHRONIC_URTICARIA
AMIODARONE;NOS1AP;rs10919035;T;TOXICITY;;SIDE_EFFECT:AMIODARONE-INDUCED_VENTRICULAR_ARRHYTHMIA_AND_QT_PROLONGATION
ASPIRIN;LTC4S;rs730012;AC + CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SENSITIVITY_TO_ASPIRIN
ANTIPSYCHOTICS;SMYD3;rs2485914;T;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TARDIVE_DYSKINESIA
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799929;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATOTOXICTY
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799929;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEPATOTOXICTY
CYTARABINE, IDARUBICIN;ABCB1;rs1045642;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:COMPLETE_REMISSION
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14
LEVONORGESTREL;TP53;rs1042522;CG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ASPIRIN;GP6;rs1613662;AG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_TO_ASPIRIN
CISPLATIN, DOXORUBICIN, IFOSFAMIDE, METHOTREXATE;ERCC2;rs1799793;CT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
CYTARABINE, IDARUBICIN;ABCB1;rs1045642;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:3-YEAR_EVENT_FREE_SURVIVAL
CISPLATIN, DOXORUBICIN, IFOSFAMIDE, METHOTREXATE;ERCC2, KLC3;rs13181;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
ACENOCOUMAROL, PHENPROCOUMON, WARFARIN;CYP4F2;rs2108622;CT + TT;DOSAGE;EFFICACY;EFFICACY:8.3%_HIGHER_MEAN_DAILY_COUMARIN_DOSE_TO_REACH_A_STABLE_INTERNATIONAL_NORMALIZED_RATIO_(INR)
ASPIRIN;ITGB3;rs5918;CT;TOXICITY;INCREASED_;SIDE_EFFECT:BLOOD_LOSS
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA,_THROMBOCYTOPENIA
SUNITINIB;KDR;rs2305948;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
CAPECITABINE, EPIRUBICIN, PLATINUM;GSTP1;rs1695;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:ON-CLOPIDOGREL_PLATELET_REACTIVITY_(HPR)
;ITGB3;rs5918;CC + CT;OTHER;;OTHER:SHORTER_BLEEDING_TIME
BETA BLOCKING AGENTS;GRK5;rs2230345;AA;OTHER;INCREASED_RISK;OTHER:DEATH
FENTANYL, HYDROMORPHONE, OXYCODONE;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PAIN
CLOPIDOGREL;PON1;rs662;CT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION
BEVACIZUMAB;CXCR4;rs2228014;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
BETA BLOCKING AGENTS;ADRB1;rs1801253;CC;OTHER;DECREASED_RISK;OTHER:DEATH
DOCETAXEL, FEC100, GEMCITABINE, TRASTUZUMAB, ZOLEDRONATE;PPCDC;rs147451859;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:AMENORRHEA
SUNITINIB;FLT4;rs6877011;GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:DISEASE_PROGRESSION
HALOPERIDOL;ABCB5;rs17143212;CT;TOXICITY;INCREASED_;SIDE_EFFECT:DRUG_TOXICITY
DOCETAXEL, FEC100, GEMCITABINE, TRASTUZUMAB, ZOLEDRONATE;;rs17587029;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:AMENORRHEA
SUNITINIB;ABCG2;rs2231142;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
OPIOIDS;CNIH3;rs10799590;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
AZATHIOPRINE, MERCAPTOPURINE;ITPA;rs7270101;AC + CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
SUNITINIB;VEGFA;rs3025039;CT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
ANTIPSYCHOTICS;CYP1A2;rs762551;CC;TOXICITY;INCREASED_SEVERITY;DISEASE:TARDIVE_DYSKINESIA
METHOTREXATE;MTHFR;rs1801133;A;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CISPLATIN;SLC22A2;rs316019;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OTOTOXICITY
SUNITINIB;CYP3A4;rs4646437;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERTENSION
ATORVASTATIN;ABCB1;rs2032582;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs6025;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
CISPLATIN;NFE2L2;rs6721961;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OTOTOXICITY
CARVEDILOL;ADRB2;rs1042714;CC;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:IMPROVED_LEFT_VENTRICULAR_EJECTION_FRACTION
TACROLIMUS;FOXP3;rs3761548;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
TACROLIMUS;CYP3A4;rs2740574;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DIABETES_MELLITUS
METHOTREXATE;RAVER2;rs72675408;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
PHENYTOIN;CYP2C9;rs1057910;C;EFFICACY;INCREASED_RISK;SIDE_EFFECT:ATAXIA,_DIPLOPIA,_DIZZINESS,_DYSARTHRIA
PHENYTOIN;CYP2C9;rs1799853;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT:ATAXIA,_DIPLOPIA,_DIZZINESS,_DYSARTHRIA
CAPECITABINE, FLUOROURACIL;PPARD;rs2016520;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
EFAVIRENZ;CYP2B6;rs8192719;CT + TT;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
;SULT1A1, SULT1A2;rs1801030;CC + CT;OTHER;INCREASED_LIKELIHOOD;DISEASE:HOT_FLASHES
OPIOIDS;MCOLN1;rs116181528;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:OVERDOSE
CERIVASTATIN, HMG COA REDUCTASE INHIBITORS, ROSUVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
;AKT1;rs2494732;CC;OTHER;INCREASED_LIKELIHOOD;DISEASE:PSYCHOTIC_DISORDER
CAPECITABINE;MTHFR;rs1801131;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14
BEVACIZUMAB;KCNAB1;rs6770663;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTENSION
WARFARIN;VKORC1;rs9934438;A;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14
CYCLOPHOSPHAMIDE, EPIRUBICIN;GSTP1;rs1695;AA + AG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:TOXICITY
ASPIRIN;CEP68;rs7572857;AA;TOXICITY;INCREASED_;SIDE_EFFECT:DECLINE_OF_FORCED_EXPIRATORY_VOLUME_IN_1S_(FEV(1))_BY_ASPIRIN_PROVOCATION
OPIOIDS;MCOLN1;rs114077267;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:OVERDOSE
ACENOCOUMAROL;VKORC1;rs9923231;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
PLATINUM COMPOUNDS;MDM2;rs2279744;GT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
SUNITINIB;FLT3;rs1933437;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
ASPIRIN;ITGB3;rs5918;CT;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_INHIBITION_BY_ASPIRIN
;SLC2A9;rs62293298;AG;OTHER;DECREASED_LIKELIHOOD;OTHER:HYPERURICEMIA
EFAVIRENZ;CYP2B6;rs2279343;GG;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATION
ASPIRIN;TLR3;rs3775291;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-EXACERBATED_RESPIRATORY_DISEASE
EFAVIRENZ;CYP2B6;rs2279345;CC + CT;LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATION
OPIOIDS;MCOLN1;rs115208233;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:OVERDOSE
TACROLIMUS;CYP3A4;rs2740574;CC + CT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:ACUTE_CELLULAR_REJECTION
NICOTINE;DRD2;rs1800497;AA + AG;TOXICITY;INCREASED_;SIDE_EFFECT:CRAVING
NICOTINE;DRD2;rs1800497;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:CRAVING
WARFARIN;VKORC1;rs2884737;CC;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IL6;rs1800795;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
;ABCG2;rs2231142;GT + TT;OTHER;INCREASED_LIKELIHOOD;OTHER:HYPERURICEMIA
ACENOCOUMAROL, WARFARIN;CYP2C9;rs72558189;AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
TELBIVUDINE;TK2;rs3826160;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION
SUNITINIB;FLT1;rs9582036;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE_REQUIREMENTS_ON_DAY_14
;SLC22A12;rs3825017;CT;OTHER;INCREASED_LIKELIHOOD;OTHER:HYPERURICEMIA
ACENOCOUMAROL, WARFARIN;CYP4F2;rs2108622;CT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
SUNITINIB;CYP1A1;rs1048943;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA,_MUCOSITIS
OLANZAPINE;DRD2;rs2440390;T;TOXICITY;INCREASED_;DISEASE:WEIGHT_GAIN
PRAVASTATIN;ADAMTS1;rs428785;GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:FATAL_CORONARY_DISEASE_OR_NONFATAL_MYOCARDIAL_INFARCTION
OLANZAPINE;HTR2C;rs6318;G;TOXICITY;INCREASED_;DISEASE:WEIGHT_GAIN
CAFFEINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:NEURAL_TUBE_DEFECTS
OLANZAPINE;HTR2C;rs2497538;C;TOXICITY;INCREASED_;DISEASE:WEIGHT_GAIN
OLANZAPINE;HTR2C;rs1414334;G;TOXICITY;INCREASED_;DISEASE:WEIGHT_GAIN
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
PIOGLITAZONE;LPL;rs328;CG + GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESPONSE_RATE_AFTER_10_WEEKS_OF_PIOGLITAZONE_TREATMENT
PACLITAXEL;EPHA5;rs7349683;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
;SCN1A;rs3812718;T;OTHER;INCREASED_RISK;DISEASE:SEIZURES,_FEBRILE
;UGT1A1;rs4148323;AA + AG;OTHER;INCREASED_SEVERITY;OTHER:NEONATAL_HYPERBILIRUBINEMIA,_HYPERBILIRUBINEMIA
;CHRNA5;rs16969968;A;OTHER;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
PACLITAXEL;ABCB1;rs3213619;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
VERAPAMIL;NOS1AP;rs10494366;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:QTC_PROLONGATION
MERCAPTOPURINE;PACSIN2;rs2413739;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
;;rs1051730;A;OTHER;INCREASED_SEVERITY;OTHER:TOBACCO_USE_DISORDER
;CYP2R1;rs12794714;A;OTHER;INCREASED_LIKELIHOOD;OTHER:VITAMIN_D_DEFICIENCY
OLANZAPINE;ABCB1;rs1045642;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:SOCIAL_AND_CLINICAL_NEEDS
PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799930;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
;CYP2R1;rs10741657;A;OTHER;DECREASED_LIKELIHOOD;OTHER:VITAMIN_D_DEFICIENCY
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;NAT2;rs1799929;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
PAROXETINE;HTR1A;rs6295;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_AT_4_WEEKS_AFTER_THE_INITIATION_OF_TREATMENT
TAMOXIFEN;E2F7;rs310786;CC;TOXICITY;INCREASED_;SIDE_EFFECT:LUMBAR_BONE_LOSS
ALENDRONATE;DKK1;rs2241529;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:BONE_DENSITY
CLOPIDOGREL;CES1;rs8192950;G;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:TRANSIENT_ISCHEMIC_ATTACK,_STROKE
ANTIPSYCHOTICS;DRD2;rs1799732;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SIDE_EFFECTS
SUNITINIB;KDR;rs2305948;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
WARFARIN;CYP2C9;rs4918758;C;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE_REQUIREMENT_IN_MECHANICAL_HEART_VALVE_REPLACEMENT_PATIENTS
SUNITINIB;VEGFA;rs3025039;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
OLANZAPINE;ANKK1;rs1800497;GG;OTHER;DECREASED_PK;PK:AREA_UNDER_THE_CURVE_FROM_BASELINE_TO_THE_LAST_MEASURED_CONCENTRATION
EXEMESTANE;ESR1;rs9322336;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULOSKELETAL_TOXICITY
WARFARIN;CYP2C9;rs9332096;T;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE_REQUIREMENT_IN_MECHANICAL_HEART_VALVE_REPLACEMENT_PATIENTS
OLANZAPINE;ANKK1;rs1800497;GG;OTHER;DECREASED_;OTHER:PEAK_PLASMA_CONCENTRATION_OF_INCREASED_PROLACTIN
SUNITINIB;VEGFA;rs2010963;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERTENSION
SUNITINIB;FLT4;rs6877011;C;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
OLANZAPINE;GSTP1;rs1695;AA;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:SYNCOPE
SUNITINIB;NR1I2;rs2276707;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_;OTHER:WARFARIN_DOSE
ANTHRACYCLINES AND RELATED SUBSTANCES;HAS3;rs2232228;AA;TOXICITY;INCREASED_RISK;DISEASE:CARDIOMYOPATHIES
WARFARIN;VKORC1;rs9923231;T;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
SUNITINIB;FLT3;rs1933437;AG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
NORTRIPTYLINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ORTHOSTATIC_HYPOTENSION
WARFARIN;VKORC1;rs2359612;A;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
MORPHINE, OXYCODONE;OPRM1;rs1799971;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE
MORPHINE, OXYCODONE;COMT;rs4680;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE
CARBAMAZEPINE;HNF4A;rs2071197;GG;EFFICACY;INCREASED_PK;PK:CONCENTRATION-TO-DOSE_RATIOS
WARFARIN;VKORC1;rs8050894;G;DOSAGE;DECREASED_;OTHER:WARFARIN_DOSE
PRAVASTATIN;MTHFR;rs1801133;GG;EFFICACY;DECREASED_LIKELIHOOD;DISEASE:CORONARY_ARTERY_DISEASE,_MYOCARDIAL_INFARCTION
SUNITINIB;ABCB1;rs1128503;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
SUNITINIB;VEGFA;rs833061;CC + CT;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;IMPDH2;rs11706052;AG + GG;EFFICACY;INCREASED_RISK;DISEASE:TRANSPLANT_REJECTION
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;TNF;rs1800629;AA + AG;EFFICACY;INCREASED_RISK;DISEASE:TRANSPLANT_REJECTION
METHOTREXATE;MTHFR;rs1801131;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;IL10;rs1800872;TT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TRANSPLANT_REJECTION
SUNITINIB;ABCB1;rs2032582;AA + AT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TRANSIENT_ISCHEMIC_ATTACK,_STROKE
SUNITINIB;VEGFA;rs2010963;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
NICOTINE;CHRNA5;rs16969968;A;OTHER;INCREASED_SEVERITY;OTHER:SMOKING
NICOTINE;CHRNA5;rs16969968;A;OTHER;INCREASED_SEVERITY;OTHER:SMOKING
;CHRNA5;rs16969968;A;OTHER;INCREASED_LIKELIHOOD;DISEASE:SCHIZOPHRENIA
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
CLOPIDOGREL;N6AMT1;rs2254638;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:THROMBOCYTOPENIA,_TOXIC_LIVER_DISEASE
NICOTINE;GALR1;rs2717162;CT + TT;OTHER;INCREASED_SEVERITY;OTHER:CRAVING
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;T;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
ERYTHROMYCIN;SLCO1B1;rs4149056;C;LADME_PK;DECREASED_PK;PK:ERYTHROMYCIN_METABOLISM
PAZOPANIB, SIMVASTATIN;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
GENTAMICIN;MT-RNR1;rs267606617;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OTOTOXICITY
CYCLOSPORINE, TACROLIMUS;LEP;rs2167270;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIABETES_MELLITUS
ERLOTINIB;ABCB1;rs1045642;AA;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
MERCAPTOPURINE;NUDT15;rs73189762;GT;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
ETHANOL;HTR3B;rs1176744;C;OTHER;INCREASED_LIKELIHOOD;DISEASE:ALCOHOL_ABUSE
CLOPIDOGREL;CYP2C19;rs12248560;T;TOXICITY;DECREASED_;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MUCOSITIS
METHOTREXATE;ADORA2A, SPECC1L;rs5760410;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
CALCIUM CHANNEL BLOCKERS, NITRENDIPINE;KCNH2;rs1137617;AA + AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
CLOPIDOGREL;KDR;rs7667298;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ANGINA_PECTORIS
METHOTREXATE;MTHFR;rs1801131;G;EFFICACY;INCREASED_RISK;DISEASE:GRAFT_VS_HOST_DISEASE
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;DECREASED_RISK;DISEASE:GRAFT_VS_HOST_DISEASE
NICOTINE;GALR1;rs2717162;CT + TT;OTHER;INCREASED_SEVERITY;OTHER:CRAVING
ANTINEOPLASTIC AGENTS;CLCN6, MTHFR;rs1801133;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
IRINOTECAN;UGT1A1;rs4148323;AG;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
;MTHFR;rs1801131;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
BUSULFAN, CYCLOPHOSPHAMIDE, METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
ERLOTINIB;ABCB1;rs1128503;AA;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
METHOTREXATE;MTHFR;rs1801131;GG;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:RELAPSE
CLOPIDOGREL;KDR;rs2305948;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGINA_PECTORIS,_MYOCARDIAL_INFARCTION
METHOTREXATE;ABCB1;rs1128503;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:MUCOSITIS
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
METHOTREXATE;MTHFR;rs1801131;GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ORAL_MUCOSITIS
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
ERLOTINIB;ABCB1;rs2032582;AA;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
PACLITAXEL;ARHGEF10;rs9657362;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
;FKBP5;rs1360780;CC + CT;;INCREASED_RISK;OTHER:POST-TRAUMATIC_STRESS_DISORDER_(PTSD)
;FKBP5;rs3800373;AA + AC;OTHER;INCREASED_RISK;DISEASE:ATTENTION_DEFICIT_DISORDER_WITH_HYPERACTIVITY
PACLITAXEL;ARHGEF10;rs9657362;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
;TBX21;rs17244587;A;;INCREASED_RISK;DISEASE:MAJOR_DEPRESSIVE_DISORDER
;PSMB4;rs2296840;T;OTHER;INCREASED_RISK;DISEASE:MAJOR_DEPRESSIVE_DISORDER
METFORMIN;SLC22A1;rs34059508;A;DOSAGE, LADME_PK;INCREASED_PK;PK:BIOAVAILABILITY
METFORMIN;SLC22A1;rs12208357;C;DOSAGE, LADME_PK;INCREASED_PK;PK:BIOAVAILABILITY_(AUC,_CL_&_AUC/CL_RATIO)
CLOPIDOGREL;CYP2C19;rs12248560;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:BLEEDING_EVENTS
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DEATH
;CHRNA5;rs680244;C;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
METHOTREXATE;PTPN22;rs2476601;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
;CHRNA3;rs1051730;G;;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
METHOTREXATE;TNFAIP3;rs6920220;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
;CHRNA3, CHRNA5;rs578776;G;;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
SUNITINIB;ABCG2;rs2231142;TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
;CHRNA5;rs16969968;A;;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
RISPERIDONE;ABCB1;rs1045642;AA;LADME_PK;INCREASED_SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA
;CHRNA5;rs569207;C;;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
CARBAMAZEPINE, PHENOBARBITAL, PHENYTOIN, VALPROIC ACID;CYP1A1;rs2606345;A;EFFICACY, LADME_PK;INCREASED_RISK;DISEASE:SEIZURES
;SLCO1B3;rs2417940;C;OTHER;INCREASED_SEVERITY;OTHER:NEONATAL_HYPERBILIRUBINEMIA,_HYPERBILIRUBINEMIA
SERTRALINE;;rs13432159;G;TOXICITY;INCREASED_;SIDE_EFFECT:GENERAL_SIDE-EFFECTS
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
TAMOXIFEN;CYP2D6;rs3892097;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
TAMOXIFEN;CYP2D6;rs3892097;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
TAMOXIFEN;CYP2D6;rs3892097;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:RELAPSE_FREE_TIME
;KIF6;rs20455;AG + GG;OTHER;INCREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;A;TOXICITY;DECREASED_;SIDE_EFFECT:ANEMIA
ROSUVASTATIN;GATM;rs9806699;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
TAMOXIFEN;CYP2D6;rs3892097;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4363657;CC + CT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs7270101;C;TOXICITY;DECREASED_;SIDE_EFFECT:ANEMIA
IRINOTECAN;UGT1A1;rs4148323;AA;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
FLUOROURACIL, IRINOTECAN, OXALIPLATIN;GSTP1;rs1695;AA;TOXICITY;INCREASED_RISK;DISEASE:NEUROTOXICITY_SYNDROMES,_NEUTROPENIA
PRAVASTATIN;IL1B;rs16944;GG;OTHER;INCREASED_;OTHER:CORONARY_FLOW_RESERVE
HMG COA REDUCTASE INHIBITORS;;rs116561224;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
;KCNH2;rs3815459;T;OTHER;INCREASED_;OTHER:QT_INTERVAL
FENOFIBRATE, SERTRALINE, TERBINAFINE, TICLOPIDINE;;rs114577328;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ANTIDEPRESSANTS;HTR2A;rs17288723;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
;KCNH2;rs3807375;CT + TT;OTHER;INCREASED_;OTHER:QT_INTERVAL
CITALOPRAM;GRIK4;rs1954787;C;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:NON-RESPONSE
;KCNH2;rs1805123;GT + TT;OTHER;INCREASED_;OTHER:QT_INTERVAL
CYCLOSPORINE;NR1I2;rs2276707;C;DOSAGE, LADME_PK;DECREASED_PK;PK:BIOAVAILABILITY
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799929;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799930;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
PLATINUM COMPOUNDS;GSTP1;rs1695;G;TOXICITY, LADME_PK;DECREASED_RISK;DISEASE:NEUTROPENIA
CLOZAPINE;;rs149104283;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
DRUGS FOR TREATMENT OF TUBERCULOSIS;NAT2;rs1799931;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
;KCNH2;rs1805123;G;OTHER;DECREASED_;OTHER:QT_INTERVAL
ASPARAGINASE, CYCLOPHOSPHAMIDE, DAUNORUBICIN, PREDNISOLONE, VINCRISTINE;PNPLA3;rs738409;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
;KCNH2;rs3807375;T;OTHER;INCREASED_;OTHER:QT_INTERVAL
OXALIPLATIN;GSTP1;rs1695;GG;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUROTOXICITY_SYNDROMES
;KCNQ1;rs757092;G;OTHER;INCREASED_;OTHER:QT_INTERVAL
;KCNH2;rs3815459;T;OTHER;INCREASED_;OTHER:QT_INTERVAL
PRAVASTATIN;IL1B;rs16944;GG;OTHER;INCREASED_;OTHER:ADENOSINE-STIMULATED_MYOCARDIAL_FLOW
;VEGFA;rs2010963;CG + GG;OTHER;INCREASED_RISK;OTHER:PREMATURE_BIRTH
;KCNH2;rs1805123;GG;OTHER;DECREASED_;OTHER:QT_INTERVAL
;KCNQ1;rs757092;G;OTHER;INCREASED_;OTHER:QT_INTERVAL
OXALIPLATIN;GSTP1;rs1695;AA;TOXICITY, LADME_PK;INCREASED_SEVERITY;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
METHOTREXATE;SLCO1B1;rs4149056;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:INFECTIOUS_DISEASE
CYCLOSPORINE;NR1I2;rs2276707;T;DOSAGE, LADME_PK;INCREASED_PK;PK:BIOAVAILABILITY
RIFAMPIN;NR1I2;rs3814055;TT;OTHER;INCREASED_PK;PK:ERYTHROMYCIN_BREATH_TEST
PLATINUM COMPOUNDS;CCN4;rs2977549;CC + CT;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CITALOPRAM;HTR2A;rs7997012;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE
TACROLIMUS;CYP3A4;rs2740574;CC + TT;TOXICITY, LADME_PK;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
CITALOPRAM;HTR2A;rs7997012;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE
TACROLIMUS;CYP3A5;rs776746;T;TOXICITY, LADME_PK;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
CYCLOSPORINE;NR1I2;rs3814055;C;DOSAGE, LADME_PK;DECREASED_PK;PK:BIOAVAILABILTY
ASPIRIN, CLOPIDOGREL;MYOM2;rs17064642;CC + CT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
ANTIDEPRESSANTS;HTR2A;rs7997012;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
CITALOPRAM;HTR2A;rs7997012;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE
SUFENTANIL;COMT;rs4680;AA + AG;DOSAGE;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
ANTIDEPRESSANTS;GRIK4;rs1954787;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
SUFENTANIL;OPRM1;rs1799971;AG + GG;DOSAGE;DECREASED_SEVERITYEFFICACY;EFFICACY:PAIN
ANTIDEPRESSANTS;GRIK4;rs12800734;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;DECREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
;KIF6;rs20455;AG + GG;OTHER;INCREASED_RISK;DISEASE:CORONARY_DISEASE
PRAVASTATIN;SLCO1B1;rs2306283;G;LADME_PK;DECREASED_PK;PK:PLASMA_AUC
PRAVASTATIN;SLCO1B1;rs4149015;AG;OTHER, LADME_PK;INCREASED_PK;PK:AUC0-12
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
PLATINUM COMPOUNDS;CCN4;rs2977551;CC + CT;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
FLUOROURACIL;TP53;rs1042522;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PEGINTERFERON ALFA-2A, RIBAVIRIN;ITPA;rs6051702;AC + CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA
NICOTINE;CHRNA3, CHRNA5;rs578776;GG;TOXICITY;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
NICOTINE;CHRNA4;rs1044396;AA;TOXICITY;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
NICOTINE;CHRNA4;rs2229959;CC;TOXICITY;INCREASED_LIKELIHOOD;OTHER:SMOKING_CESSATION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;COMT, TXNRD2;rs13306278;T;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
PRAVASTATIN;TLR4;rs4986790;AG + GG;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:CARDIOVASCULAR_EVENTS
PHENPROCOUMON;VKORC1;rs9923231;TT;EFFICACY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
AMINOGLYCOSIDE ANTIBACTERIALS;MT-RNR1;rs267606617;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OTOTOXICITY
PEGINTERFERON ALFA-2A, RIBAVIRIN;VDR;rs1544410;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
PHENPROCOUMON;VKORC1;rs9923231;TT;TOXICITY;INCREASED_;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE
FLUOROURACIL;IGFBP3;rs2854746;CC;EFFICACY;;OTHER:BETTER_SURVIVAL_OUTCOME
PHENPROCOUMON;VKORC1;rs9923231;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_ACHIEVE_STABLE_DOSE
PLATINUM COMPOUNDS;GSTP1;rs1695;AA;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DYING
PLATINUM COMPOUNDS;ERCC2, KLC3;rs13181;GG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DYING
PHENPROCOUMON;EPHX1;rs1051740;CC;TOXICITY;INCREASED_;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE
PLATINUM COMPOUNDS;ERCC1;rs11615;AA;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DYING
CLOPIDOGREL;ABCB1;rs2032582;AA;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
PLATINUM COMPOUNDS;GSTP1;rs1695;AA;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DISEASE_PROGRESSION
CARBOPLATIN, PACLITAXEL;NR1I2;rs1523130;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CETUXIMAB;EGF;rs4444903;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:SURVIVAL
CARBOPLATIN, PACLITAXEL;NR1I2;rs1523127;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
IRINOTECAN;UGT1A1;rs10929302;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
CARBOPLATIN, PACLITAXEL;SLCO1B3;rs4149117;GT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:THROMBOCYTOPENIA
NICOTINE;CHRNA4;rs1044396;G;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
CISPLATIN;LRP2;rs2075252;T;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
CETUXIMAB;EGF;rs4444903;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CAPECITABINE;CDA;rs3215400;C/del + CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CLOPIDOGREL;POR;rs2286823;GG;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
SUNITINIB;POR;rs1057868;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SUNITINIB;SLCO1B3;rs4149117;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;SLC19A1;rs1051266;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
PHENPROCOUMON;VKORC1;rs9923231;TT;TOXICITY;INCREASED_;SIDE_EFFECT:TIME_ABOVE_THERAPEUTIC_RANGE
CAPECITABINE;CDA;rs532545;T;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:HAND-FOOT_SYNDROME
CLOPIDOGREL;CES1P1;rs3785161;AC + CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:ON-TREATMENT_PLATELET_ACTIVITY
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
METHOTREXATE;ATIC;rs2372536;G;;SEVERITY_;DISEASE:RHEUMATOID_ARTHRITIS
LEUCOVORIN, TEGAFUR;FASTKD3, MTRR;rs1801394;GG;TOXICITY;INCREASED_SEVERITY;DISEASE:STOMATITIS
CAPECITABINE;DPYD;rs67376798;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
LEUCOVORIN, TEGAFUR;UMPS;rs1801019;CC;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA
LEUCOVORIN, TEGAFUR;UMPS;rs1801019;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANY_GRADE_3_ADVERSE_EVENT
ASPIRIN, CLOPIDOGREL;F13A1;rs5985;AA + AC;EFFICACY;INCREASED_RISK;DISEASE:DEATH
PAZOPANIB;CXCL8;rs1126647;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
NICOTINE;CHRNA4;rs2236196;G;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
ANGIOTENSIN II ANTAGONISTS;CYP2D6;rs111564371;CT;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_DIASTOLIC_BLOOD_PRESSURE,_ELEVATED_SYSTOLIC_BLOOD_PRESSURE
METHOTREXATE;SLC19A1;rs1051266;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MUCOSITIS
NICOTINE;CHRNA3;rs1051730;AA + AG;TOXICITY;DECREASED_;SIDE_EFFECT:LUNG_FUNCTION
CYCLOPHOSPHAMIDE, FLUOROURACIL;MTHFR;rs1801133;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
LEDIPASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
CARBAMAZEPINE;HSPA1A;rs1043620;T;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:HYPERSENSITIVITY
ASPIRIN, CLOPIDOGREL;F13A1;rs5985;AA + AC;EFFICACY;INCREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
LEDIPASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CARBAMAZEPINE;HSPA1A;rs506770;G;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:HYPERSENSITIVITY
ASPIRIN, CLOPIDOGREL;F13A1;rs5985;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:FIBRIN_CLOT_FORMATION_TIME
CYCLOPHOSPHAMIDE, FLUOROURACIL;TP53;rs1042522;G;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
CARBAMAZEPINE;HSPA1L;rs2227956;G;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:HYPERSENSITIVITY
CLOPIDOGREL;P2RY12;rs6787801;AG + GG;EFFICACY;EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY_IN_CYP2C19*1/*1_CARRIERS
CLOZAPINE;ABCB1;rs1045642;AG + GG;TOXICITY;INCREASED_;SIDE_EFFECT:HYPERTENSION
RIBAVIRIN;ITPA;rs1127354;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION,_TREATMENT_INTERRUPTION
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_PK;PK:EXPOSURE
CLOZAPINE;ABCC1;rs212090;AT + TT;TOXICITY;INCREASED_;SIDE_EFFECT:HYPERTENSION
CARBAMAZEPINE;MLN;rs2894342;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY_SYNDROME
EFAVIRENZ;CYP2B6;rs28399499;CC + CT;LADME_PK;INCREASED_PK;PK:EXPOSURE
CLOZAPINE;ABCB1;rs1045642;AG + GG;TOXICITY;INCREASED_;SIDE_EFFECT:WEIGHT_GAIN
CLOZAPINE;ABCC1;rs212090;AT + TT;TOXICITY;INCREASED_;SIDE_EFFECT:WEIGHT_GAIN
CAFFEINE;ADORA2A;rs5751876;TT;TOXICITY;INCREASED_;SIDE_EFFECT:ANXIETY
CAFFEINE;ADORA2A;rs2298383;CC;TOXICITY;INCREASED_;SIDE_EFFECT:ANXIETY
CAFFEINE;;rs4822492;CC;TOXICITY;INCREASED_;SIDE_EFFECT:ANXIETY
;MT-RNR1;rs267606617;G;OTHER;INCREASED_LIKELIHOOD;OTHER:HEARING_LOSS,_SENSORINEURAL
CARBAMAZEPINE;;rs3130690;T;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
CAFFEINE;ADORA2A;rs5751876;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:BEING_SENSITIVE_TO_CAFFEINE
CAFFEINE;ADORA2A;rs5751876;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:INSOMNIA
ETHANOL, HEROIN, METHAMPHETAMINE;ANKS1B;rs2133896;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE,_HEROIN_DEPENDENCE,_METHAMPHETAMINE_DEPENDENCE,
CARBAMAZEPINE;MICA;rs2848716;C;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ASPIRIN""";;rs2965667;TT;OTHER;DECREASED_RISK;DISEASE:COLORECTAL_NEOPLASMS
CAFFEINE;ADORA2A;rs5751876;TT;DOSAGE;DECREASED_;OTHER:HABITUAL_CONSUMPTION
CARBAMAZEPINE;BAG6, PRRC2A;rs750332;C;TOXICITY;INCREASED_RISK;DISEASE:STEVENS-JOHNSON_SYNDROME
"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ASPIRIN""";;rs16973225;AA;OTHER;DECREASED_LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS
;CHRNA5;rs588765;T;EFFICACY;EFFICACY;EFFICACY:DECREASED_CHANCE_OF_ACHIEVING_6_MONTH_ABSTINENCE_IN_THE_PLACEBO_GROUP
WARFARIN;VKORC1;rs9934438;AG + GG;DOSAGE;INCREASED_;OTHER:WARFARIN_DOSE
RIBAVIRIN;ITPA;rs7270101;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMOLYTIC_ANEMIA
SIMVASTATIN;LEPR;rs1137101;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PERCENTAGE_CHANGE_IN_HDL-C_LEVELS
ALENDRONATE;SOST;rs1234612;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:BONE_DENSITY
CYTARABINE, DAUNORUBICIN;ABCB1;rs1128503;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
CYTARABINE, DAUNORUBICIN;CDA;rs532545;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:COLITIS
CYTARABINE, DAUNORUBICIN;ABCB1;rs1045642;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;EFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
ALENDRONATE;SOST;rs865429;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:BONE_DENSITY
RIBAVIRIN;ITPA;rs1127354;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMOLYTIC_ANEMIA
CYTARABINE;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;MED12L, P2RY12;rs6801273;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESIDUAL_ON-CLOPIDOGREL_PLATELET_REACTIVITY
CYTARABINE;ABCB1;rs2032582;AA + AC;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;MED12L;rs6798347;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESIDUAL_ON-CLOPIDOGREL_PLATELET_REACTIVITY
ERLOTINIB, GEFITINIB;EGFR;rs121434569;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL_(PFS)_TIME
CYTARABINE;ABCB1;rs1045642;AA + AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
SEVOFLURANE;ABCB1;rs1128503;GG;OTHER;DECREASED_LIKELIHOOD;OTHER:ADVERSE_EVENTS
TACROLIMUS;KCNJ11;rs5219;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIABETES_MELLITUS_TYPE2
ACE INHIBITORS, PLAIN;ETV6;rs2724635;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
ERLOTINIB, GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
SUNITINIB;ABCB1;rs1128503;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ASPIRIN;TAPBP;rs2071888;CC + CG;TOXICITY;INCREASED_;SIDE_EFFECT:FEV1_DECREASE_AFTER_ASPIRIN_CHALLENGE
DRUGS FOR TREATMENT OF TUBERCULOSIS;ABCC2;rs3740065;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ESCITALOPRAM;HTR2A;rs6311;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:COMPOSITE_OUTCOME_OF_NON-FATAL_MI,_ALL_CAUSE_DEATH_AND_STENT_THROMBOSIS
HYDROCHLOROTHIAZIDE;KCNJ1;rs12795437;C;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIABETES_MELLITUS
PHENPROCOUMON;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
VALPROIC ACID;LEPR;rs1137101;AA + AG;TOXICITY;INCREASED_;SIDE_EFFECT:WEIGHT_GAIN
PHENYTOIN;CFHR4;rs78239784;G;TOXICITY;INCREASED_RISK;DISEASE:MACULOPAPULAR_EXANTHEMA
HYDROCHLOROTHIAZIDE;KCNJ1;rs11600347;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIABETES_MELLITUS
CABAZITAXEL;ABCB1;rs2032582;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
VALPROIC ACID;ANKK1;rs1800497;AG + GG;TOXICITY;INCREASED_;SIDE_EFFECT:WEIGHT_GAIN
HYDROCHLOROTHIAZIDE;KCNJ1;rs658903;A;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:DIABETES_MELLITUS
CABAZITAXEL;ABCB1;rs1045642;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
CLOPIDOGREL;P2RY12;rs6787801;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESIDUAL_ON-CLOPIDOGREL_PLATELET_REACTIVITY
CABAZITAXEL;CYP3A5;rs776746;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
ACE INHIBITORS, PLAIN;PRKCQ;rs500766;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
HYDROCHLOROTHIAZIDE;KCNJ1;rs675388;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DIABETES_MELLITUS
DOXORUBICIN;GSTP1;rs1695;GG;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:CHEMORESISTANCE
CABAZITAXEL;ABCB1;rs1128503;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
PROPOFOL;DRD2;rs2283265;AA + AC;OTHER;DECREASED_;OTHER:HEART_RATE
NICOTINE;CHRNA4;rs2236196;A;OTHER;INCREASED_LIKELIHOOD;OTHER:NICOTINE_DEPENDENCE
ACETAMINOPHEN;UGT1A;rs1042640;CG + GG;TOXICITY;DECREASED_RISK;DISEASE:LIVER_FAILURE,_ACUTE
CLOPIDOGREL;ABCB1;rs1045642;AA;TOXICITY;DECREASED_;SIDE_EFFECT:BLEEDING_EVENTS
ACETAMINOPHEN;UGT1A;rs8330;CG + GG;TOXICITY;DECREASED_RISK;DISEASE:LIVER_FAILURE,_ACUTE
GEFITINIB;EGFR;rs121434569;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:RESPONSE_RATE_(RR)
HYDROCHLOROTHIAZIDE;KCNJ1;rs59172778;AG;TOXICITY;INCREASED_;SIDE_EFFECT:SERUM_POTASSIUM
ETHANOL;CACNA1C;rs1034936;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALCOHOL_ABUSE
DOXORUBICIN, METHOTREXATE, PREDNISOLONE, VINCRISTINE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA,_THROMBOCYTOPENIA
CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
WARFARIN;EPHA7;rs114504854;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
ACETAMINOPHEN;UGT1A;rs10929303;CT + TT;TOXICITY;DECREASED_RISK;DISEASE:LIVER_FAILURE,_ACUTE
ACE INHIBITORS, PLAIN;XPNPEP2;rs2050011;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;TNF;rs1800629;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
NICOTINE;ADGRL3;rs2271339;AG;TOXICITY;INCREASED_RISK;OTHER:TOBACCO_USE_DISORDER
NICOTINE;ADGRL3;rs1456862;AT;TOXICITY;INCREASED_RISK;OTHER:TOBACCO_USE_DISORDER
GEFITINIB;EGFR;rs2293347;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE_(RR)
GEFITINIB;EGFR;rs2293347;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
ETHANOL;MAP2K4;rs2159140;CT;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE
SUNITINIB;ABCB1;rs1045642;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA,_MUCOSITIS
SORAFENIB;UGT1A9;rs17868320;T;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL_(OS)_TIME
GEFITINIB;EGFR;rs712829;GT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE_(RR)
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
MORPHINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPOVENTILATION
ACE INHIBITORS, PLAIN;XPNPEP2;rs3788853;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS_(MACE)_(MORE_THAN_ONE_YEAR)_WHEN_RECEIVING_A_LOADING_DOSE_OF_300_MG
DOCETAXEL;ABCC10;rs2125739;CT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
;ARNT;rs2228099;CG + GG;OTHER;DECREASED_LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs3813867;GG;TOXICITY;INCREASED_SEVERITY;DISEASE:TOXIC_LIVER_DISEASE
CLOPIDOGREL;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EARLY_MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS_(MACE)
;DEPTOR;rs4871827;AA + AG;OTHER;INCREASED_;OTHER:HDL_CHOLESTEROL
CISPLATIN, IRINOTECAN;SYNE3;rs8020368;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
;DEPTOR;rs4871827;AG;OTHER;DECREASED_LIKELIHOOD;OTHER:BRAIN_ISCHEMIA,_MYOCARDIAL_INFARCTION,_PERIPHERAL_VASCULAR_DISEASES,
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""DRUGS FOR TREATMENT OF TUBERCULOSIS""";CYP2B6;rs3745274;TT;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
;DEPTOR;rs4871827;AG;OTHER;DECREASED_LIKELIHOOD;OTHER:DIABETIC_RETINOPATHY,_CHRONIC_KIDNEY_FAILURE
LOSARTAN;STK39;rs6749447;GG + GT;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_AMBULATORY_BLOOD_PRESSURE
CLOPIDOGREL;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EARLY_MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS_(MACE)
;AHR;rs2066853;AA + AG;OTHER;INCREASED_RISK;OTHER:ADENOMATOUS_AND_HYPERPLASTIC_POLYPS
RISPERIDONE;HTR6;rs9659997;CC + CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA
CISPLATIN, IRINOTECAN;DCBLD1;rs17574269;AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN, IRINOTECAN;;rs7186128;AG + GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
RISPERIDONE;TYMS;rs3786362;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERPROLACTINEMIA
;TNF;rs1800630;C;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:LEUKOCYTOSIS
CISPLATIN, IRINOTECAN;;rs2166219;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
RISPERIDONE;HTR2A;rs6311;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA
CISPLATIN, IRINOTECAN;;rs4655567;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ANTINEOPLASTIC AGENTS, CORTICOSTEROIDS;ITPA;rs1127354;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY,_NEUROTOXICITY_SYNDROMES
CISPLATIN, IRINOTECAN;;rs2018683;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
RISPERIDONE;BDNF;rs6265;CT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA
ANTINEOPLASTIC AGENTS, CORTICOSTEROIDS;ADORA2A;rs2236624;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
LEUCOVORIN, METHOTREXATE;ABCC2;rs717620;CT + TT;LADME_PK;INCREASED_PK;PK:DISTRIBUTION_VOLUME
CISPLATIN, IRINOTECAN;;rs2018683;TT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESISTANT_RELAPSE
;OPRM1;rs1799971;G;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:HEROIN_DEPENDENCE
CISPLATIN, IRINOTECAN;SYNE3;rs8020368;CC;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESISTANT_RELAPSE
CISPLATIN, IRINOTECAN;;rs4655567;CC;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESISTANT_RELAPSE
METHOTREXATE;ABCC4;rs7317112;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
RISPERIDONE;UGT1A1;rs1976391;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERPROLACTINEMIA
RISPERIDONE;HTR2C;rs6318;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERPROLACTINEMIA
CYCLOSPORINE;;rs2275913;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
LENALIDOMIDE;ABCB1;rs2032582;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
HEROIN;DBH;rs1611114;TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MEMORY_IMPAIRMENT
DILTIAZEM;PLCD3;rs12946454;T;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
CAPECITABINE, FLUOROURACIL, OXALIPLATIN;MTHFR;rs1801131;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL,_OVERALL_SURVIVAL
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;AC;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANEMIA
DOCETAXEL;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
"""BETA BLOCKING AGENTS"", ""THIAZIDES, PLAIN""";;rs11191548;C;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_DIASTOLIC_BLOOD_PRESSURE
NICOTINE;COMT;rs4680;GG;OTHER;INCREASED_SEVERITY;SIDE_EFFECT:WITHDRAWAL
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_PK;PK:MINIMUM_PLASMA_CONCENTRATIONS
MORPHINE;ABCB1;rs9282564;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPOVENTILATION
ANTINEOPLASTIC AGENTS, CORTICOSTEROIDS;ABCC1;rs246240;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
LENALIDOMIDE;NCF4;rs1883112;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
NICOTINE;COMT;rs4680;GG;OTHER;INCREASED_;OTHER:BLOOD_PRESSURE
LENALIDOMIDE;GSTP1;rs1695;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
CISPLATIN, IRINOTECAN;ABCC4;rs16950650;CT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ASPIRIN, CLOPIDOGREL;ITGA2;rs1126643;CT + TT;OTHER;INCREASED_;OTHER:COLLAGEN-INDUCED_PLATELET_AGGREGATION
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;TT;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
EFAVIRENZ, LAMIVUDINE, TENOFOVIR;ABCB1;rs1045642;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA
GEMCITABINE;SLC29A3;rs780668;CT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;A;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANEMIA
MYCOPHENOLATE MOFETIL;SLCO1B3;rs4149117;TT;TOXICITY;INCREASED_RISK;DISEASE:DIARRHEA
ATORVASTATIN;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs7270101;C;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANEMIA
CAFFEINE;CYP1A2;rs762551;AC + CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ALBUMINURIA,_HYPERTENSION
GEMCITABINE;ABCG2;rs2231142;GT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
PLATINUM COMPOUNDS;ERCC1;rs11615;AA;EFFICACY;INCREASED_RISK;DISEASE:DEATH
CAPECITABINE;CDA;rs1048977;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
CLOPIDOGREL;CYP2C9;rs1799853;CT + TT;LADME_PK;DECREASED_PK;PK:EXPOSURE_TO_CLOPIDOGREL_ACTIVE_METABOLITE
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY,_MUSCULAR_DISEASES,_RHABDOMYOLYSIS,_TOXIC_LIVER_DISEASE
ALLOPURINOL;CFLAR;rs1594;A;TOXICITY;;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
OXYCODONE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
CAPECITABINE;CES2;rs11075646;CG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:TIME_TO_PROGRESSION
PLATINUM COMPOUNDS;ERCC1;rs11615;AA;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE_OF_DISEASE
CLOPIDOGREL;CYP2C9;rs1799853;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:INHIBITION_OF_PLATELET_AGGREGATION_AND_POOR-RESPONDER_STATUS
PLATINUM COMPOUNDS;HSPA5;rs430397;TT;EFFICACY;DECREASED_;OTHER:PROGRESSION-FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_EFFICACY;EFFICACY:INHIBITION_OF_PLATELET_AGGREGATION_AND_POOR-RESPONDER_STATUS
ASPIRIN;AGT;rs5050;GG;TOXICITY;INCREASED_RISK;DISEASE:PEPTIC_ULCER_HEMORRHAGE
SUNITINIB;NR1I2;rs6785049;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTENSION
BUPROPION;SACM1L;rs2251954;C;TOXICITY;DECREASED_;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS
ROSUVASTATIN;GATM;rs9806699;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
CLOPIDOGREL;CYP2C19;rs4244285;A;LADME_PK;DECREASED_PK;PK:EXPOSURE_TO_CLOPIDOGREL_ACTIVE_METABOLITE
BUPROPION;SACM1L;rs2742421;G;TOXICITY;DECREASED_;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS
ETHAMBUTOL, ISONIAZID / PYRAZINAMIDE / RIFAMPIN;CYP3A4;rs28371759;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ROSUVASTATIN;SLCO1B1;rs4149081;AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:LDL-C_REDUCTION
BUPROPION;SACM1L;rs2742423;G;TOXICITY;DECREASED_;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;;SIDE_EFFECT:EARLY_(<_3_MONTHS)_TERMINATION_OF_EFAVIRENZ_THERAPY
CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;LADME_PK;DECREASED_PK;PK:EXPOSURE_TO_CLOPIDOGREL_ACTIVE_METABOLITE
BUPROPION;SACM1L;rs1969624;T;TOXICITY;DECREASED_;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS
EFAVIRENZ;NR1I3;rs2307424;GG;TOXICITY;;SIDE_EFFECT:EARLY_(<_3_MONTHS)_TERMINATION_OF_EFAVIRENZ_THERAPY
BUPROPION;SACM1L;rs2245705;C;TOXICITY;DECREASED_;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS
BUPROPION;SACM1L;rs2742435;G;TOXICITY;DECREASED_;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS
CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:INHIBITION_OF_PLATELET_AGGREGATION_AND_POOR-RESPONDER_STATUS
BUPROPION;SACM1L;rs2742390;A;TOXICITY;DECREASED_;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS
SIMVASTATIN;SLCO1B1;rs4149081;AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:LDL-C_REDUCTION
PLATINUM COMPOUNDS;HSPA5;rs430397;TT;EFFICACY;INCREASED_LIKELIHOOD;OTHER:EARLY_RELAPSE
SIMVASTATIN;SLCO1B1;rs4149081;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:LDL-C_REDUCTION
PEMETREXED;DHFR;rs442767;GG;TOXICITY;INCREASED_RISK;DISEASE:FATIGUE
FLUOROURACIL;MTHFR;rs1801131;GG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
BUPROPION;SACM1L;rs2742417;T;TOXICITY;DECREASED_;SIDE_EFFECT:SEXUAL_SIDE-EFFECTS
TEMSIROLIMUS;NR1I2;rs3814055;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
PHENPROCOUMON;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
SUNITINIB;FLT3;rs1933437;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA,_NEUTROPENIA
CAPECITABINE;CES1;rs71647871;CT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HAND-FOOT_SYNDROME,_DRUG_TOXICITY
ROSUVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
GEMCITABINE;ABCG2;rs2231142;GT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PLATINUM COMPOUNDS;HSPA5;rs430397;TT;EFFICACY;INCREASED_RISK;DISEASE:DEATH
ROSUVASTATIN;SLCO1B1;rs4149081;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:LDL-C_REDUCTION
NALTREXONE;OPRD1;rs4654327;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:NALTREXONE-INDUCED_BLUNTING_OF_ALCOHOL_STIMULATION_AND_ALCOHOL_CRAVING
IRINOTECAN;UGT1A;rs11563250;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ATORVASTATIN, SIMVASTATIN;RYR2;rs2819742;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:MUSCULAR_DISEASES,_MYALGIA
CAPECITABINE, FLUOROURACIL, GEMCITABINE;SPARC;rs2347128;GG;EFFICACY;INCREASED_;OTHER:PROGRESSION-FREE_SURVIVAL
;MET;rs40239;AG + GG;OTHER;INCREASED_;OTHER:OVERALL_SURVIVAL
AZATHIOPRINE;ITPA;rs7270101;AC + CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION,_DRUG_TOXICITY,_ADVERSE_EVENTS,
CAPECITABINE, FLUOROURACIL, GEMCITABINE;SPARC;rs17718347;TT;EFFICACY;INCREASED_;OTHER:PROGRESSION-FREE_SURVIVAL
;MET;rs40239;AG + GG;OTHER;INCREASED_;OTHER:OVERALL_SURVIVAL
"""ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS"", ""DRUGS FOR TREATMENT OF TUBERCULOSIS""";ABCB1;rs1045642;AA;TOXICITY, LADME_PK;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
EFAVIRENZ;CYP2B6;rs3745274;T;OTHER, LADME_PK;INCREASED_PK;PK:PLASMA_EFAVIRENZ_EXPOSURE_(AUC)_DURING_THE_FIRST_24_WEEKS_OF_ANTIRETROVIRAL_THERAPY
EFAVIRENZ;CYP2B6;rs3745274;T;TOXICITY;INCREASED_RISK;DISEASE:CENTRAL_NERVOUS_SYSTEM_DISORDER
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs112563513;A;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
EFAVIRENZ;CYP3A4;rs2740574;C;OTHER, LADME_PK;INCREASED_PK;PK:PLASMA_EFAVIRENZ_EXPOSURE
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DISCONTINUATION
EFAVIRENZ;CYP3A5;rs776746;C;LADME_PK;DECREASED_PK;PK:PLASMA_EFAVIRENZ_EXPOSURE
CLOPIDOGREL;ABCB1;rs1045642;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS
CLOPIDOGREL;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
CLOPIDOGREL;CYP2C19;rs4986893;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS
ACE INHIBITORS, PLAIN;MME;rs989692;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANGIOEDEMA
HMG COA REDUCTASE INHIBITORS;LILRB5;rs12975366;TT;DOSAGE, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE, VENLAFAXINE;HTR2A;rs6311;TT;TOXICITY;INCREASED_LIKELIHOOD;OTHER:PHYSIOLOGICAL_SEXUAL_DISORDER
CABAZITAXEL;CYP3A5;rs776746;CT;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;rs4986893;AA;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;HTR2A;rs6311;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
CABAZITAXEL;TUBB1;rs463312;AC;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CLOPIDOGREL;CYP2C19;rs28399504;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ISCHAEMIC_EVENTS
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;rs4986893;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
NEVIRAPINE;CYP2B6;rs28399499;C;LADME_PK;INCREASED_;OTHER:PLASMA_LEVEL
;SLC2A9;rs16890979;T;LADME_PK;DECREASED_PK;PK:SERUM_URIC_ACID
CYCLOPHOSPHAMIDE;IKZF3;rs9908694;CC;EFFICACY;INCREASED_;DISEASE:EVENT-FREE_SURVIVAL
METHOTREXATE;ABCB1;rs1045642;AG;TOXICITY;DECREASED_RISK;DISEASE:DRUG_TOXICITY
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs118192122;A;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs193922816;T;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
METHAMPHETAMINE;DRD4;rs1800955;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_PSYCHOSIS
BEVACIZUMAB;GC;rs4588;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CETUXIMAB;GC;rs4588;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs28933397;T;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
ASPIRIN;TAPBP;rs1059288;AG + GG;TOXICITY;INCREASED_;SIDE_EFFECT:FEV1_DECREASE_AFTER_ASPIRIN_CHALLENGE
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs140530655;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
GEFITINIB;IKBKB;rs2272733;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT:EXANTHEMA
"""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";SLC22A1;rs628031;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
DESFLURANE, ENFLURANE, HALOTHANE, ISOFLURANE, SEVOFLURANE, SUCCINYLCHOLINE;RYR1;rs193922772;T;OTHER;INCREASED_RISK;DISEASE:MALIGNANT_HYPERTHERMIA
CLOPIDOGREL;CYP2C19;rs4986893;AG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
FENOTEROL;SLC22A1;rs12208357;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
FENOTEROL;SLC22A1;rs34130495;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
ACE INHIBITORS, PLAIN;AGT;rs699;GG;EFFICACY;DECREASED_RISK;DISEASE:STROKE
;P2RY12;rs2046934;G;OTHER;INCREASED_RISK;DISEASE:PERIPHERAL_VASCULAR_DISEASES
GEFITINIB;RELA;rs11227247;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
FENOTEROL;SLC22A1;rs55918055;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
IRINOTECAN;KCNQ5;rs9351963;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
FENOTEROL;SLC22A1;rs34059508;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
;P2RY12;rs2046934;G;OTHER;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION
GEFITINIB;IKBKE;rs2151222;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
ISONIAZID, PHENYTOIN;NAT2;rs1801280;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ISONIAZID, PHENYTOIN;NAT2;rs1799931;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
TAMOXIFEN;CYP2D6;rs28371725;T;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
TAMOXIFEN;CYP2D6;rs3892097;C;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
TAMOXIFEN;CYP2D6;rs1065852;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
PAROXETINE;HTR2A;rs6314;AG;EFFICACY;EFFICACY;EFFICACY:IMPROVED_RESPONSE
GABAPENTIN, PREGABALIN;SLC7A5;rs4240803;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_EVENTS
BEVACIZUMAB, CYCLOPHOSPHAMIDE;CXCR2;rs2230054;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
PAROXETINE;HTR2A;rs6314;AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
TAMOXIFEN;CYP2C19;rs12248560;T;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:RECURRENCE
GEMCITABINE;SLCO1B1;rs4149086;AG + GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PAROXETINE;HTR2A;rs6313;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_DRUG_REACTION
HYDROCHLOROTHIAZIDE;CDCA3, GNB3, USP5;rs5443;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
BETA BLOCKING AGENTS;GRK5;rs2230345;AT + TT;OTHER;DECREASED_RISK;DISEASE:DEATH
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
;CHRNA3;rs1051730;A;OTHER;INCREASED_RISK;DISEASE:LUNG_NEOPLASMS
CITALOPRAM;GRIK2;rs2518224;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TREATMENT-EMERGENT_SUICIDAL_IDEATION
ACENOCOUMAROL, WARFARIN;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
IRINOTECAN;UGT1A9;rs7586110;G;TOXICITY;INCREASED_RISK;DISEASE:ANEMIA
ACENOCOUMAROL, WARFARIN;CYP4F2;rs2108622;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
;HYKK;rs8034191;C;OTHER;INCREASED_RISK;DISEASE:LUNG_NEOPLASMS
ISONIAZID, PHENYTOIN;NAT2;rs1041983;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
TACROLIMUS;TCF7L2;rs290487;CC + CT;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
ACE INHIBITORS, PLAIN;AGT;rs699;GG;EFFICACY;DECREASED_RISK;DISEASE:STROKE
GEMCITABINE;POLR2A;rs2228130;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
VALPROIC ACID;CYP2C9;rs1057910;AC;OTHER, LADME_PK;INCREASED_PK;PK:MEAN_PLASMA_DRUG_CONCENTRATIONS
CITALOPRAM;GRIA3;rs4825476;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TREATMENT-EMERGENT_SUICIDAL_IDEATION
IMATINIB;SLC22A5;rs274558;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY,_EYE_DISEASES
ISONIAZID, PHENYTOIN;NAT2;rs1208;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ANTIPSYCHOTICS;COMT;rs4818;CC + CG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:TARDIVE_DYSKINESIA
;CHRNA3;rs1051730;A;OTHER;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_VASCULAR_DISEASES
;CHRNA3;rs1051730;A;OTHER;INCREASED_LIKELIHOOD;DISEASE:LUNG_NEOPLASMS
DACARBAZINE, PROCARBAZINE;EPM2AIP1;rs1800734;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:BREAST_NEOPLASMS
ISONIAZID, PHENYTOIN;NAT2;rs1799930;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
;CHRNA3;rs1051730;A;OTHER;INCREASED_;OTHER:NUMBER_OF_CIGARETTES_SMOKED_PER_DAY
ISONIAZID, PHENYTOIN;NAT2;rs1799929;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
IMATINIB;ABCB1;rs2235040;CT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY,_EYE_DISEASES
DEXAMETHASONE, DOXORUBICIN, VINCRISTINE;ABCB1;rs2032582;AA + AC;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DACARBAZINE, PROCARBAZINE;EPM2AIP1;rs1800734;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:THERAPY-RELATED_ACUTE_MYELOID_LEUKEMIA_(T-AML)
IMATINIB;EGFR;rs10258429;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY,_EYE_DISEASES
ANTIPSYCHOTICS;COMT;rs165599;AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:TARDIVE_DYSKINESIA
IMATINIB;SLC22A1;rs683369;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY,_EYE_DISEASES
RISPERIDONE;CYP2D6;rs1065852;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OBESITY
DACLATASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";HTR2A;rs6305;A;OTHER;INCREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS,_SUBSTANCE_WITHDRAWAL_SYNDROME
ASPIRIN;TBXA2R;rs4523;AA;EFFICACY;INCREASED_RISK;OTHER:HIGH_ON-ASPIRIN_RESIDUAL_PLATELET_REACTIVITY
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";DBH;rs1611115;T;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS,_SUBSTANCE_WITHDRAWAL_SYNDROME
RISPERIDONE;DRD2;rs1799978;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:INSULIN_RESISTANCE
PACLITAXEL;ABCB1;rs2032582;AA;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
PACLITAXEL;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";OPRM1;rs1799971;G;OTHER;INCREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS,_SUBSTANCE_WITHDRAWAL_SYNDROME
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";BDNF;rs6265;T;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS,_SUBSTANCE_WITHDRAWAL_SYNDROME
ANTIPSYCHOTICS;COMT;rs4680;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:TARDIVE_DYSKINESIA
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";COMT;rs4680;AA;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS,_SUBSTANCE_WITHDRAWAL_SYNDROME
RISPERIDONE;CYP2D6;rs1065852;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERTENSION
TACROLIMUS;CAPN10;rs5030952;CT;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
WARFARIN;CYP2C18;rs2901783;G;DOSAGE;;OTHER:OUTCOME_TIME_TO_STABLE_DOSE
IDARUBICIN;RAC2;rs13058338;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
"""ANALGESICS"", ""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""ERGOT ALKALOIDS"", ""OPIOIDS"", ""SUMATRIPTAN""";DRD2;rs6275;AA;OTHER;DECREASED_LIKELIHOOD;DISEASE:HEADACHE_DISORDERS,_SUBSTANCE_WITHDRAWAL_SYNDROME
IDARUBICIN;NCF4;rs1883112;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOTOXICITY
OPIOIDS;OPRM1;rs9479757;AG;OTHER;DECREASED_RISK;DISEASE:OPIOID-RELATED_DISORDERS
TACROLIMUS;CYP3A5;rs776746;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
PEGINTERFERON ALFA-2B, PROTEASE INHIBITORS, RIBAVIRIN;ITPA;rs1127354;AA + AC;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA
OPIOIDS;GAL;rs948854;CC;OTHER;INCREASED_RISK;DISEASE:OPIOID-RELATED_DISORDERS
OPIOIDS;ABCB1;rs1045642;GG;OTHER;DECREASED_RISK;DISEASE:OPIOID-RELATED_DISORDERS
OPIOIDS;OPRD1;rs2236861;A;OTHER;DECREASED_RISK;DISEASE:OPIOID-RELATED_DISORDERS
IDARUBICIN;CYBA;rs4673;AG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
HYDROCHLOROTHIAZIDE;NOS3;rs1799983;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_DIASTOLIC_BLOOD_PRESSURE
IDARUBICIN;CYBA;rs4673;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PRAVASTATIN;CETP;rs708272;A;EFFICACY;INCREASED_RISK;DISEASE:DEATH
PEGINTERFERON ALFA-2B, PROTEASE INHIBITORS, RIBAVIRIN;SLC28A2;rs11854484;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
DACLATASVIR, SOFOSBUVIR;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
DIURETICS;PDE4D;rs702553;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:BASELINE_MEAN_ARTERIAL_BLOOD_PRESSURE
CITALOPRAM, FLUVOXAMINE, PAROXETINE, SERTRALINE, VENLAFAXINE;ABCB1;rs2235040;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS
ESCITALOPRAM;KCNE1;rs1805127;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_INHIBITION
ESCITALOPRAM;KCNE1;rs4817668;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK;OTHER:HIGH_PLATELET_REACTIVITY
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA5;rs588765;T;EFFICACY;EFFICACY;EFFICACY:INCREASED_CHANCE_OF_ACHIEVING_6_MONTH_ABSTINENCE_IF_PRESCRIBED_NRT_(NICOTIENE_REPLACEMENT_THERAPY)
;CHRNA3;rs1051730;A;EFFICACY;EFFICACY;EFFICACY:DECREASED_CHANCE_OF_ACHIEVING_6_MONTH_ABSTINENCE_IN_THE_PLACEBO_GROUP
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCYTOPENIA,_THROMBOCYTOPENIA
DRUGS USED IN NICOTINE DEPENDENCE;CHRNA3;rs1051730;A;EFFICACY;EFFICACY;EFFICACY:INCREASED_CHANCE_OF_ACHIEVING_6_MONTH_ABSTINENCE_IF_PRESCRIBED_NRT_(NICOTIENE_REPLACEMENT_THERAPY)
CITALOPRAM, FLUVOXAMINE, PAROXETINE, SERTRALINE, VENLAFAXINE;ABCB1;rs2032583;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EFFECTS
FLUOROURACIL;DPYD;rs1801159;CC;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
FLUOROURACIL;DPYD;rs1801159;CC;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA,_VOMITING
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCB1;rs4148737;C;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCC3;rs4148416;T;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
;FOXO3;rs4946936;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NEVIRAPINE;ABCB1;rs1045642;A;TOXICITY;DECREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
;FOXO3;rs17069665;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
;ARNT;rs3215133;T/del + del/del;OTHER;DECREASED_LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS
METHADONE;ARRB2;rs2036657;GG;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCB1;rs2032582;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ETHANOL;GHSR;rs2232165;AG;OTHER;;OTHER:HEAVY_CONSUMPTION
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCB1;rs1045642;G;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCB1;rs10276036;C;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:OVERALL_SURVIVAL
ANTIPSYCHOTICS;NEFM;rs1379357;G;EFFICACY;EFFICACY;EFFICACY:RESPONSE_TIME
CISPLATIN, CYCLOPHOSPHAMIDE, DOXORUBICIN, METHOTREXATE, VINCRISTINE;ABCB1;rs1128503;G;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DEATH
ANTIPSYCHOTICS;NEFM;rs1457266;G;EFFICACY;EFFICACY;EFFICACY:RESPONSE_TIME
;ARNT;rs12410394;AA + AG;OTHER;DECREASED_LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS
CELECOXIB;IL23R;rs7518660;A;TOXICITY;INCREASED_RISK;DISEASE:ADENOMA
CELECOXIB;ALOX12;rs11078659;A;TOXICITY;INCREASED_RISK;DISEASE:ADENOMA
;CYP1A2;rs2470890;CT + TT;OTHER;DECREASED_LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS
;;rs11072508;CT + TT;OTHER;DECREASED_LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS
CELECOXIB;PTGES;rs2302821;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_TOXICITY_AND_SYMPTOMS
;CSK;rs4886410;CG + GG;OTHER;DECREASED_LIKELIHOOD;DISEASE:COLORECTAL_NEOPLASMS
CELECOXIB;PTGER4;rs4133101;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITIES
CARBOPLATIN, CYCLOPHOSPHAMIDE, THIOTEPA;ALDH3A1;rs2228100;CC + CG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:CYSTITIS
TAMOXIFEN;ABCC2;rs3740065;AA;EFFICACY, LADME_PK;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE_OF_BREAST_CANCER
CAFFEINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:INSOMNIA
DEXAMETHASONE, DOXORUBICIN, VINCRISTINE;ABCB1;rs1045642;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
FARGLITAZAR, INSULINS AND ANALOGUES;SCNN1B;rs34241435;A;TOXICITY;;SIDE_EFFECT:OEDEMA
HYDROCHLOROTHIAZIDE;SCNN1G;rs5723;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_OFFICE_DIASTOLIC_BLOOD_PRESSURE
FARGLITAZAR, GLYBURIDE;SCNN1B;rs889299;A;TOXICITY;;SIDE_EFFECT:OEDEMA
HYDROCHLOROTHIAZIDE;SCNN1G;rs5729;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_OFFICE_DIASTOLIC_BLOOD_PRESSURE
GEFITINIB;IKBKE;rs12142086;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
NICOTINE;CHRNA5;rs680244;C;OTHER;DECREASED_LIKELIHOOD;OTHER:ABSTINENCE
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS,_ORAL_ULCER
METHADONE;ARRB2;rs1045280;CC;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
TACROLIMUS;CYP3A5;rs776746;CT;EFFICACY;DECREASED_EFFICACY;EFFICACY:DOSE-ADJUSTED_TACROLIMUS_BLOOD_CONCENTRATION
LORAZEPAM;UGT2B15;rs1902023;AA;LADME_PK;INCREASED_PK;PK:AREA_UNDER_THE_VISUAL_ANALOG_SCALE-TIME_CURVE_DURING_THE_INDUCED_STATE
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCB1;rs3213619;G;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;TUBB2A;rs9501929;C;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
NALOXONE, OXYCODONE;COMT;rs4680;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ERYTHEMA
TACROLIMUS;CYP3A4;rs2740574;CT;LADME_PK;DECREASED_PK;PK:DOSE-ADJUSTED_TACROLIMUS_BLOOD_CONCENTRATIONS
NICOTINE;CHRNA5;rs16969968;A;OTHER;DECREASED_LIKELIHOOD;OTHER:ABSTINENCE
METHADONE;ARRB2;rs3786047;AA;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_LIVER_ENZYMES
BISOPROLOL;CYP3A5;rs776746;TT;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_SYSTOLIC_BLOOD_PRESSURE,_ELEVATED_DIASTOLIC_BLOOD_PRESSURE
NALOXONE, OXYCODONE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ERYTHEMA
PAZOPANIB;VEGFA;rs2010963;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
HYDROCHLOROTHIAZIDE;WNK1;rs1159744;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_WHOLE_DAY_AMBULATORY_BLOOD_PRESSURE
TAMOXIFEN;CYP2C19;rs12248560;T;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
;SLC22A3;rs2504938;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
NALOXONE, OXYCODONE;COMT;rs4680;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
FLUOROURACIL, LEUCOVORIN;UMPS;rs1801019;CC + CG;TOXICITY, LADME_PK;;DISEASE:DIARRHEA
FLUOROURACIL, LEUCOVORIN;UMPS;rs1801019;CC;TOXICITY, LADME_PK;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
BUPRENORPHINE, METHADONE;COMT;rs4680;AG + GG;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:PAIN
CAPECITABINE, FLUOROURACIL;DPYD;rs56038477;T;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
;SLC22A3;rs512077;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
BUPRENORPHINE, METHADONE;OPRM1;rs1799971;AG + GG;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:PAIN
CAPECITABINE, FLUOROURACIL;DPYD;rs2297595;CC + CT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
GLUCARPIDASE;ABCC4;rs7317112;AG + GG;TOXICITY;INCREASED_RISK;OTHER:NEPHROTOXICITY
HYDROCHLOROTHIAZIDE;ADRB2;rs2400707;AA + AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_WHOLE_DAY_AMBULATORY_BLOOD_PRESSURE
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
NICOTINE;CHRNA5;rs16969968;GG;OTHER;INCREASED_;OTHER:FUNCTIONAL_MRI_REACTIVITY_TO_SMOKING_IMAGES
HYDROCHLOROTHIAZIDE;WNK1;rs1159744;CC;OTHER;INCREASED_;SIDE_EFFECT:URINARY_POTASSIUM_EXCRETION
HEROIN;DRD2;rs1076560;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:HEROIN_DEPENDENCE
SUFENTANIL;ABCB1;rs1128503;GG;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:PAIN,_POSTOPERATIVE
HYDROCHLOROTHIAZIDE;WNK1;rs2107614;CC + CT;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_WHOLE_DAY_AMBULATORY_BLOOD_PRESSURE
HYDROCHLOROTHIAZIDE;RAD52, WNK1;rs2277869;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_WHOLE_DAY_AMBULATORY_BLOOD_PRESSURE
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DOXORUBICIN, MERCAPTOPURINE, PREDNISONE, VINCRISTINE;XRCC1;rs1799782;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MYELOSUPPRESSION
METFORMIN;SLC47A2;rs34399035;T;LADME_PK;DECREASED_PK;PK:METFORMIN_UPTAKE_IN_HEK-293_CELLS_AND_REDUCTION_IN_PROTEIN_EXPRESSION_LEVELS
OXALIPLATIN;ABCB1;rs1128503;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;rs1870377;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERTENSION,_HAND-FOOT_SYNDROME
CYTARABINE, IDARUBICIN;CBR3;rs8133052;GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
WARFARIN;;rs16871327;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
WARFARIN;EPHA7;rs78132896;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
FENOFIBRATE;FABP1;rs2241883;CC + CT;TOXICITY;INCREASED_RISK;DISEASE:HYPERTRIGLYCERIDEMIA
ANTIPSYCHOTICS;SNAP25;rs1051312;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
GEFITINIB;TAB2;rs577001;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFIT1;rs304478;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SVR_(SUSTAINED_VIROLOGICAL_RESPONSE)
PEGINTERFERON ALFA-2B, RIBAVIRIN;OASL;rs12819210;T;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
OXALIPLATIN;ABCB1;rs1045642;AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:RECURRENCE-FREE_SURVIVAL
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PAZOPANIB;VEGFA;rs833061;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
COCAINE;SLC6A3;rs6347;TT;TOXICITY;INCREASED_RISK;DISEASE:DEATH
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE_(RR)
ATORVASTATIN;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCC2;rs8187710;A;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL_(PFS)_TIME
COCAINE;DRD2;rs1076560;A;TOXICITY;INCREASED_RISK;DISEASE:DEATH
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_HEMORRHAGE
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;ABCC2;rs17222723;A;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;CYP1B1;rs1056836;C;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;rs1870377;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
GEFITINIB;EGFR;rs121434568;G;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE_(RR)
GEFITINIB;NFKBIA;rs2233407;AA + AT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;SPIDR;rs6473187;G;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
GEFITINIB;NR1H2;rs2695121;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;SLCO1B1;rs3829306;T;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
SUNITINIB;VEGFA;rs2010963;CG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;EPHA6;rs301927;G;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
WARFARIN;;rs115112393;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
ANTIPSYCHOTICS;HTR2C;rs6318;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ANTIPSYCHOTICS;HTR2C;rs3813929;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ANTIPSYCHOTICS;HTR2C;rs518147;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ATORVASTATIN;ABCB1;rs2032582;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
COCAINE;DRD2;rs2283265;A;TOXICITY;INCREASED_RISK;DISEASE:DEATH
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;rs2305948;CT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
ANTIPSYCHOTICS;DRD2;rs6275;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ANTIPSYCHOTICS;DRD2;rs7131056;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ANTIPSYCHOTICS;INSIG2;rs17047764;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ANTIPSYCHOTICS;GNB3;rs5443;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ANTIPSYCHOTICS;MC4R;rs489693;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
TIANEPTINE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_RISK;OTHER:SUICIDAL_IDEATION
ATORVASTATIN;ABCB1;rs1128503;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
ANTIPSYCHOTICS;BDNF, BDNF-AS;rs6265;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ANTIPSYCHOTICS;ADRA2A;rs1800544;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
ANLOTINIB, APATINIB, AXITINIB, BEVACIZUMAB, SORAFENIB, SUNITINIB;KDR;rs2071559;G;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
THEOPHYLLINE;CYP1A2;rs2069514;GG;LADME_PK;INCREASED_PK;PK:RATIO_OF_1,3_DMU/THEOPHYLLINE
ANTIPSYCHOTICS;DRD2;rs1799732;del;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
GEFITINIB;NFKBIA;rs2233409;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
GEFITINIB;NFKBIA;rs8904;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CLOPIDOGREL_RESISTANCE
GEFITINIB;NFKBIB;rs2053071;CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
LEVODOPA;DRD3;rs6280;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HALLUCINATIONS
GEFITINIB;NFKBIA;rs2233406;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
CLOPIDOGREL;ITGB3;rs5918;C;EFFICACY;EFFICACY;EFFICACY:LESS_DECREASE_IN_THE_PLATELET_REACTIVITY_AFTER_600_MG_OF_CLOPIDOGREL
CLOPIDOGREL;ITGB3;rs5918;CT;EFFICACY;DECREASED_EFFICACY;EFFICACY:ANTIPLATELET_EFFECT_TO_A_300_MG_CLOPIDOGREL_LOADING-DOSE_UP_TO_24_H_FOLLOWING_INTERVENTION
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;CYP2E1;rs2070673;A;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;CYP2E1;rs2515641;T;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
PERINDOPRIL;AGTR1;rs275651;TT;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:CARDIAC_EVENTS
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;SULT2B1;rs2302948;T;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:FEVER
ESCITALOPRAM;KCNH2;rs3807372;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACQUIRED_LONG_QT_SYNDROME_(ALQTS)
HEROIN;OPRM1;rs1799971;AA + AG;OTHER;DECREASED_LIKELIHOOD;OTHER:ADDICTION
GEFITINIB;IKBKB;rs9694958;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
CYTARABINE, FLUDARABINE, GEMTUZUMAB OZOGAMICIN, IDARUBICIN;SLC22A12;rs11231825;TT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:FEVER
GEFITINIB;IKBKE;rs3748022;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXANTHEMA
ASPIRIN;FSIP1;rs7179742;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA
ASPIRIN;PTGS1;rs10306114;G;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_TO_ASPIRIN
DRUGS FOR TREATMENT OF TUBERCULOSIS;XPO1;rs4430924;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ASPIRIN;CEP68;rs7572857;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN-INTOLERANT_ASTHMA
CYCLOSPORINE, MYCOPHENOLATE MOFETIL;ABCB1;rs2032582;A;EFFICACY;INCREASED_RISK;DISEASE:TRANSPLANT_REJECTION
PAROXETINE;HTR2A;rs6311;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NAUSEA
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;;rs10945919;G;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
AMISULPRIDE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE, ZIPRASIDONE, ZUCLOPENTHIXOL;CYP2D6;rs5030655;A/DELA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS
DAUNORUBICIN, DOXORUBICIN, EPIRUBICIN;SLC28A3;rs7853758;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEFT_VENTRICULAR_DYSFUNCTION
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799930;AA;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799931;AG;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
CETUXIMAB, PANITUMUMAB;KRAS;rs61764370;AC + CC;EFFICACY;INCREASED_;DISEASE:PROGRESSION-FREE_SURVIVAL
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1041983;TT;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
CYCLOPHOSPHAMIDE, FLUOROURACIL, METHOTREXATE;FGFR4;rs351855;GG;EFFICACY;INCREASED_LIKELIHOOD;OTHER:DISEASE_FREE_SURVIVAL
TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) INHIBITORS;CERS6;rs13393173;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE
CLOPIDOGREL;CES1;rs71647871;CT;LADME_PK;INCREASED_PK;PK:LEVELS_OF_CLOPIDOGREL_ACTIVE_METABOLITE
CLOPIDOGREL;CES1;rs71647871;CT;EFFICACY;DECREASED_EFFICACY;EFFICACY:ON-TREATMENT_ADP-INDUCED_PLATELET_AGGREGATION
CLOPIDOGREL;CES1;rs71647871;CT;EFFICACY;DECREASED_EFFICACY;EFFICACY:ON-TREATMENT_ADP-INDUCED_PLATELET_AGGREGATION
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;DECREASED_PK;PK:CMAX_OF_THE_ACTIVE_METABOLITE
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_PK;PK:CMAX_OF_THE_ACTIVE_METABOLITE
CARBOPLATIN, PEMETREXED;MTHFR;rs1801133;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
VEMURAFENIB;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
VEMURAFENIB;CYP3A4;rs35599367;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARCINOMA,_SQUAMOUS_CELL,_HYPERBILIRUBINEMIA,_NAUSEA,
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY_INDEX_(PRI)_AT_4_H_AFTER_THE_DOSING
CITALOPRAM, ESCITALOPRAM, FLUOXETINE, PAROXETINE, SERTRALINE;HTR2A;rs7997012;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY_INDEX_(PRI)_AT_4_H_AFTER_THE_DOSING
WARFARIN;VKORC1;rs9923231;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
FLUOROURACIL, IRINOTECAN, LEUCOVORIN;KLC1, XRCC3;rs861539;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
TACROLIMUS;CYP3A5;rs776746;TT;DOSAGE, LADME_PK;PK;PK:RISK_OF_BEING_UNDERDOSED
OPIOIDS;SLC18A2;rs363332;A;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
OPIOIDS;SLC18A2;rs363334;G;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
OPIOIDS;SLC18A2;rs363338;C;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:OPIOID-RELATED_DISORDERS
CYCLOPHOSPHAMIDE, EPIRUBICIN, PACLITAXEL;MISP;rs8110536;G;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CLOPIDOGREL;CYP2C19;rs4986893;AA + AG;EFFICACY;EFFICACY;EFFICACY:HIGHER_P2Y12_REACTION_UNITS_(PRU)_AND_LOWER_PERCENT_INHIBITION
PACLITAXEL;EPHA5;rs7349683;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_TO_CLOPIDOGREL
SUNITINIB;VEGFA;rs699947;AA + AC;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PAZOPANIB;VEGFA;rs699947;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CYTARABINE, IDARUBICIN;NQO2;rs1143684;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
PACLITAXEL;EPHA6;rs301927;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
TACROLIMUS;CYP3A5;rs776746;CC;TOXICITY;INCREASED_RISK;DISEASE:HYPERLIPIDEMIAS
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:NON-RESPONSE_TO_CLOPIDOGREL
WARFARIN;VEGFA;rs35410204;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
PACLITAXEL;EPHA8;rs209709;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
URSODEOXYCHOLIC ACID;MGAT5;rs661899;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
GLUCOCORTICOIDS, METHOTREXATE, RADIOTHERAPY;CDH2;rs1944294;AT + TT;TOXICITY;DECREASED_;SIDE_EFFECT:BONE_DENSITY
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
MYCOPHENOLATE MOFETIL;IMPDH2;rs11706052;AG;TOXICITY;DECREASED_RISK;DISEASE:LYMPHOPENIA
PACLITAXEL;EPHA5;rs7349683;TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;EFFICACY;EFFICACY:HIGHER_P2Y12_REACTION_UNITS_(PRU)_AND_LOWER_PERCENT_INHIBITION
CYTARABINE, IDARUBICIN;NQO1;rs1800566;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
WARFARIN;VEGFA;rs866236;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
PACLITAXEL;ABCG1;rs492338;AA;TOXICITY;INCREASED_RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CISPLATIN;AQP1;rs1049305;CC + CG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
OXALIPLATIN;ABCB1;rs1128503;AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PACLITAXEL;EPHA6;rs301927;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
;SULT1A1;rs1042028;T;OTHER;INCREASED_LIKELIHOOD;DISEASE:BREAST_NEOPLASMS
;SULT1A1;rs1042028;T;OTHER;INCREASED_LIKELIHOOD;DISEASE:LUNG_NEOPLASMS
;SULT1A1;rs1042028;T;OTHER;INCREASED_LIKELIHOOD;OTHER:LYMPH_NODE_METASTASIS
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_RESPONSIVENESS_TO_CLOPIDOGREL
AMITRIPTYLINE, CLOMIPRAMINE, DOXEPIN, IMIPRAMINE, MAPROTILINE, NORTRIPTYLINE, OPIPRAMOL;CYP2D6;rs3892097;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
CALCIUM;VDR;rs731236;G;EFFICACY;INCREASED_RISK;DISEASE:FRACTURES,_BONE
;SULT1A1;rs1042028;T;OTHER;DECREASED_LIKELIHOOD;DISEASE:UROLOGIC_NEOPLASMS
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_RESPONSIVENESS_TO_CLOPIDOGREL
;SULT1A1;rs1042028;T;OTHER;INCREASED_LIKELIHOOD;DISEASE:BREAST_NEOPLASMS
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs2235040;T;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs12720067;T;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
ASPIRIN, CLOPIDOGREL;IRS1;rs13431554;AG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
DOCETAXEL;VAC14;rs875858;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CLOPIDOGREL;CYP3A4;rs2242480;CT + TT;EFFICACY;EFFICACY;EFFICACY:REDUCED_GP_IIB/IIIA_ACTIVATION_AND_LOWER_PLATELET_ACTIVATION
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs10280101;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
DIRECT FACTOR XA INHIBITORS, DIRECT THROMBIN INHIBITORS;FGG;rs1800792;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs7787082;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
OPIOIDS;COMT;rs6269;AG + GG;OTHER;INCREASED_LIKELIHOOD;OTHER:REQUIRING_POSTOPERATIVE_INTERVENTION
FLUINDIONE;VKORC1;rs9934438;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:THE_TIME_TO_ACHIEVE_A_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE
FLUINDIONE;VKORC1;rs9934438;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:THE_TIME_TO_ACHIEVE_A_FIRST_INR_WITHIN_THE_THERAPEUTIC_RANGE
OSIMERTINIB;EGFR;rs121434569;T;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL,_OVERALL_SURVIVAL
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs4148739;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
FLUINDIONE;VKORC1;rs9934438;AA;EFFICACY;EFFICACY;EFFICACY:SHORTER_TIME_TO_HAVE_OVER-ANTICOAGULATION_(INR_>4)_RISK
OPIOIDS;COMT;rs4680;AG + GG;OTHER;INCREASED_LIKELIHOOD;OTHER:REQUIRING_POSTOPERATIVE_INTERVENTION
ETHANOL;ADH1B;rs1229984;TT;LADME_PK;INCREASED_PK;PK:VMAX
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs11983225;C;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
FLUINDIONE;VKORC1;rs9934438;AA;EFFICACY;EFFICACY;EFFICACY:SHORTER_TIME_TO_HAVE_OVER-ANTICOAGULATION_(INR_>4)_RISK
OPIOIDS;COMT;rs4818;CG + GG;OTHER;INCREASED_LIKELIHOOD;OTHER:REQUIRING_POSTOPERATIVE_INTERVENTION
FLUINDIONE;VKORC1;rs9934438;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:AVERAGE_DAILY_DOSE_DURING_THE_FIRST_PERIOD_OF_STABILITY
OPIOIDS;COMT;rs4633;CC + CT;OTHER;INCREASED_LIKELIHOOD;OTHER:REQUIRING_POSTOPERATIVE_INTERVENTION
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs10248420;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;NAT2;rs1799931;A;TOXICITY, LADME_PK;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ANTINEOPLASTIC AGENTS;UGT1A;rs6744284;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
DIRECT FACTOR XA INHIBITORS, DIRECT THROMBIN INHIBITORS;F2;rs5896;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
BORTEZOMIB;PKNOX1;rs2839629;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ANTINEOPLASTIC AGENTS;UGT1A;rs6744284;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERBILIRUBINEMIA
SUNITINIB;VEGFA;rs699947;A;TOXICITY;INCREASED_;SIDE_EFFECT:SYSTOLIC_BLOOD_PRESSURE_AND_INCREASED_RISK_OF_DEVELOPING_GRADE_3_HYPERTENSION
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs2235067;T;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
ATENOLOL;FTO;rs9940629;G;OTHER;;DISEASE:HYPERCHOLESTEROLEMIA
SUNITINIB;VEGFA;rs833061;C;TOXICITY;INCREASED_;SIDE_EFFECT:SYSTOLIC_BLOOD_PRESSURE_AND_INCREASED_RISK_OF_DEVELOPING_GRADE_3_HYPERTENSION
ALFENTANIL, FENTANYL;OPRM1;rs1799971;AG + GG;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:PAIN,_POSTOPERATIVE
SUNITINIB;VEGFA;rs2010963;G;TOXICITY;INCREASED_;SIDE_EFFECT:SYSTOLIC_BLOOD_PRESSURE_AND_INCREASED_RISK_OF_DEVELOPING_GRADE_3_HYPERTENSION
AMITRIPTYLINE, CITALOPRAM, PAROXETINE, VENLAFAXINE;ABCB1;rs4148740;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
ATENOLOL;ABCB1;rs10267099;G;OTHER;INCREASED_RISK;DISEASE:HYPERCHOLESTEROLEMIA
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;OTHER;DECREASED_;OTHER:PLATELET_FUNCTION
ATENOLOL;ABCB1;rs3213619;G;OTHER;INCREASED_RISK;DISEASE:HYPERCHOLESTEROLEMIA
CORTICOSTEROIDS;DCAF4;rs7160796;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:CHANGE_IN_FORCED_EXPIRATORY_VOLUME_IN_1_S_(FEV1)
SUNITINIB;NOS3;rs2070744;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GRADE_3_HYPERTENSION
ATENOLOL;PRKCB;rs11649514;GT + TT;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERGLYCEMIA
ATENOLOL;FTO;rs12595985;AA;OTHER;INCREASED_RISK;DISEASE:HYPERCHOLESTEROLEMIA
CYCLOPHOSPHAMIDE;ALDH1A1;rs8187996;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY,_TREATMENT_MODIFICATION
CLOPIDOGREL;P2RY12;rs2046934;AG + GG;OTHER;DECREASED_;OTHER:PLATELET_FUNCTION
ATENOLOL;GALNT2;rs2144297;T;OTHER;;DISEASE:HYPERCHOLESTEROLEMIA
ATENOLOL;GALNT2;rs2144300;C;OTHER;;DISEASE:HYPERCHOLESTEROLEMIA
ETHANOL;ANKK1, DRD2;rs1800497;A;TOXICITY;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
WARFARIN;CYP2C9;rs1057910;AC;DOSAGE, LADME_PK;DECREASED_PK;PK:IN_VIVO_METABOLISM_OF_(S)-WARFARIN_BUT_NOT_(R)-WARFARIN
ATENOLOL;PLA2G4A;rs10157410;C;OTHER;INCREASED_RISK;DISEASE:HYPERCHOLESTEROLEMIA
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION_VALUES
ATENOLOL;PTGS2;rs4648287;G;OTHER;INCREASED_LIKELIHOOD;DISEASE:HYPERCHOLESTEROLEMIA
ISONIAZID, RIFAMPIN;NOS2;rs11080344;CC;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ENALAPRIL;SLCO1B1;rs2306283;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:COUGH
ISONIAZID, RIFAMPIN;BACH1;rs2070401;GG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
CLOPIDOGREL;CYP2C19;rs12248560;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_AGGREGATION_VALUES
ISONIAZID, RIFAMPIN;MAFK;rs4720833;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
ISONIAZID, RIFAMPIN;XPO1;rs11125883;AC + CC;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
CLOPIDOGREL;CYP2C19;rs12248560;CC;EFFICACY;EFFICACY;EFFICACY:GREATER_PLATELET_INHIBITION_2_H_AFTER_A_600-MG_DOSE
ISONIAZID;NAT2;rs1041983;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
ISONIAZID;NAT2;rs1495741;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CLOPIDOGREL;CYP2C9;rs1057910;C;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_INHIBITION_7H_AFTER_A_CLOPIDOGREL_600-MG_LOADING_DOSE
CAPECITABINE, FLUOROURACIL;DPYD;rs1801158;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PLATELET_AGGREGATION_INHIBITION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs7270101;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
ANASTROZOLE, LETROZOLE;ESR1;rs9340799;A;OTHER;INCREASED_RISK;DISEASE:MUSCULOSKELETAL_PAIN
CLOPIDOGREL;CYP3A5;rs776746;CT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:PLATELET_AGGREGATION_INHIBITION
ANASTROZOLE, LETROZOLE;ESR1;rs2234693;C;OTHER;INCREASED_RISK;DISEASE:MUSCULOSKELETAL_PAIN
CLOPIDOGREL;P2RY12;rs2046934;AG + GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PLATELET_AGGREGATION_INHIBITION
;CYP3A4;rs2740574;CC;OTHER;INCREASED_LIKELIHOOD;OTHER:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION
OPIOIDS;OPRM1;rs1799971;AA + AG;OTHER;DECREASED_LIKELIHOOD;OTHER:ADDICTION
CAPECITABINE, FLUOROURACIL;DPYD;rs75017182;C;DOSAGE, TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
REPAGLINIDE;NEUROD1;rs1801262;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:DIFFERENCE_IN_POSTPRANDIAL_PLASMA_GLUCOSE_(BEFORE_AND_AFTER_DRUG_TREATMENT)
REPAGLINIDE;PAX4;rs114202595;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:DIFFERENCE_IN_POSTPRANDIAL_PLASMA_GLUCOSE_(BEFORE_AND_AFTER_DRUG_TREATMENT)
;CYP3A4;rs2740574;CT;OTHER;INCREASED_RISK;DISEASE:ENDOMETRIAL_NEOPLASMS
VINCRISTINE;COCH;rs1045644;CG + GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CETUXIMAB, IRINOTECAN, LEUCOVORIN, TEGAFUR;EGFR;rs712830;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
TAMOXIFEN;CYP3A4;rs2740574;CT;OTHER;INCREASED_RISK;DISEASE:ENDOMETRIAL_NEOPLASMS
VINCRISTINE;;rs7963521;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
REPAGLINIDE;NEUROD1;rs1801262;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:DIFFERENCE_IN_FASTING_PLASMA_GLUCOSE_(BEFORE_AND_AFTER_DRUG_TREATMENT)
;VDR;rs3782905;G;OTHER;INCREASED_RISK;DISEASE:ASTHMA
OPIOIDS;OPRL1;rs6090043;C;TOXICITY;INCREASED_RISK;DISEASE:OPIOID-RELATED_DISORDERS
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH-ON_CLOPIDOGREL_PLATELET_REACTIVITY
CLOPIDOGREL;P2RY12;rs6785930;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT:NEUROLOGICAL_EVENTS
OPIOIDS;COMT;rs165599;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE
DOCETAXEL, PACLITAXEL;ABCB1;rs2032582;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
;VDR;rs2239185;G;;INCREASED_RISK;DISEASE:ASTHMA
;VDR;rs1540339;T;;INCREASED_RISK;DISEASE:ASTHMA
CISPLATIN;AQP1;rs1049305;CC + CG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALOPECIA
CLOPIDOGREL;CYP2C19;rs4986893;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:ANTIPLATELET_EFFECT
CALCITRIOL;VDR;rs2228570;A;EFFICACY;INCREASED_RISK;DISEASE:FRACTURES,_BONE
CISPLATIN;AQP1;rs1049305;CC + CG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ANEMIA
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_POST-TREATMENT_PLATELET_REACTIVITY
PERINDOPRIL;BDKRB1;rs12050217;AA;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:CARDIAC_EVENTS
CISPLATIN;AQP1;rs1049305;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:THROMBOCYTOPENIA
ATENOLOL, VERAPAMIL;GRK4;rs1801058;TT;EFFICACY, TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT:ADVERSE_CARDIOVASCULAR_OUTCOMES
CLOZAPINE;CYP1A2;rs762551;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
MYCOPHENOLATE MOFETIL;IMPDH1;rs2278294;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:BIOPSY-PROVEN_ACUTE_REJECTION
PLATINUM COMPOUNDS;HLA-DOB;rs2071554;CT + TT;EFFICACY;INCREASED_RISK;DISEASE:DEATH
PLATINUM COMPOUNDS;;rs2900420;AA + AG;EFFICACY;DECREASED_RISK;DISEASE:DEATH
CLOZAPINE;CYP1A2;rs762551;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, MERCAPTOPURINE, METHOTREXATE, PREDNISONE, VINCRISTINE;DROSHA;rs639174;T;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
OPIOIDS;DRD2;rs6275;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE
CISPLATIN;TPMT;rs12201199;T;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs6413432;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
CISPLATIN;;rs3746444;AG + GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ACENOCOUMAROL, WARFARIN;CYP2C9;rs1057910;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE,_ADVERSE_EVENTS
ASPIRIN;PTGS2;rs20417;G;OTHER;DECREASED_RISK;DISEASE:CORONARY_DISEASE
CISPLATIN;AQP1;rs28362731;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:THROMBOCYTOPENIA
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs2031920;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ASPIRIN;PTGS2;rs20417;G;OTHER;INCREASED_RISK;DISEASE:CORONARY_DISEASE
CLOPIDOGREL;CYP2C19;rs4986893;A;EFFICACY;DECREASED_EFFICACY;EFFICACY:CLOPIDOGREL_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
FOLFIRI;ABCC1;rs17501011;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
OPIOIDS;OPRL1;rs6090041;G;TOXICITY;INCREASED_RISK;DISEASE:OPIOID-RELATED_DISORDERS
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:ANTIPLATELET_EFFECT
ANTIDEPRESSANTS;CUX1;rs365836;G;EFFICACY;LIKELIHOOD_EFFICACY;EFFICACY:NON-RESPONSE
;SULT1A1;rs1042028;CC + CT;;INCREASED_RISK;DISEASE:PROSTATIC_NEOPLASMS
;SULT1A1;rs1042028;CT + TT;OTHER;INCREASED_RISK;DISEASE:BREAST_NEOPLASMS
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_EFFICACY;EFFICACY:CLOPIDOGREL_INHIBITION_OF_ADP-INDUCED_PLATELET_AGGREGATION
;SULT1A1;rs1042028;CT + TT;OTHER;DECREASED_LIKELIHOOD;DISEASE:BREAST_NEOPLASMS
CLOZAPINE;LEPR;rs1137101;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE,_ADVERSE_EVENTS
ANTIDEPRESSANTS;CUX1;rs201522;A;EFFICACY;LIKELIHOOD_EFFICACY;EFFICACY:NON-RESPONSE
BORTEZOMIB;PKNOX1;rs2839629;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES,_PAIN,_NEUROPATHIC_PAIN,
CISPLATIN;COMT;rs9332377;T;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
WARFARIN;VKORC1;rs9923231;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
CISPLATIN;COMT;rs4646316;C;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
CAPECITABINE;ENOSF1;rs2741171;T;TOXICITY;INCREASED_RISK;DISEASE:HAND-FOOT_SYNDROME
CAPECITABINE;ENOSF1;rs2612091;C;TOXICITY;INCREASED_RISK;DISEASE:HAND-FOOT_SYNDROME
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_;DISEASE:DRUG_TOXICITY
CISPLATIN;ABCC3;rs1051640;G;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
CAPECITABINE;DPYD;rs12022243;T;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA
FOLFIRI;CES1;rs9921399;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
DEXTROAMPHETAMINE, METHYLPHENIDATE;DRD1;rs4532;CC;TOXICITY;INCREASED_SEVERITY;OTHER:SOCIAL_WITHDRAWAL
CISPLATIN;TPMT;rs1142345;C;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
METHAMPHETAMINE;GRIN1;rs1126442;GG;TOXICITY;INCREASED_RISK;DISEASE:PSYCHOTIC_DISORDER
FOLFIRI;UGT1A10, UGT1A8;rs1113193;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CISPLATIN;TPMT;rs1800460;T;TOXICITY;INCREASED_RISK;DISEASE:OTOTOXICITY
CAPECITABINE;ENOSF1;rs2741171;T;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CAPECITABINE;ENOSF1;rs2612091;C;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CAPECITABINE;DPYD;rs12022243;T;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_RATE_TO_PEGIFN-ALPHA/RBV_TREATMENT_AT_WEEK_20/24
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;rs1800469;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SIALOADENITIS
NICOTINE;CHRNA5;rs588765;CT + TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;GG + GT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE
CAPECITABINE;DPYD;rs76387818;A;TOXICITY;INCREASED_SEVERITY;DISEASE:HAND-FOOT_SYNDROME
CAPECITABINE;DPYD;rs12132152;A;TOXICITY;INCREASED_SEVERITY;DISEASE:HAND-FOOT_SYNDROME
CAPECITABINE;DPYD;rs76387818;A;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
ATENOLOL;DPYS;rs2669429;AG + GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPERGLYCEMIA
LENALIDOMIDE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ADVERSE_EVENTS
CAPECITABINE;DPYD;rs12132152;A;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
;IFNL3, IFNL4;rs12979860;CC;OTHER;INCREASED_;OTHER:SPONTANEOUS_HCV_CLEARANCE
RISPERIDONE;LEP;rs7799039;G;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
WARFARIN;VKORC1;rs9923231;T;EFFICACY, TOXICITY;INCREASED_;SIDE_EFFECT:BLOOD_COAGULATION_DISORDERS
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATG10;rs10514231;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:FATIGUE
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CARBOPLATIN, PACLITAXEL;EIF4E2, TIGD1;rs1656402;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATM;rs11212570;AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:FATIGUE
NICOTINE;;rs2056527;CT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
NICOTINE;;rs2056527;CT + TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_CESSATION
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AA + AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
PIRFENIDONE;TOLLIP;rs5743890;CC + CT;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CAPECITABINE, FLUOROURACIL;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
WARFARIN;VKORC1;rs9923231;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:TIME_TO_THERAPEUTIC_INR
IMATINIB;ABCB1;rs1045642;GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
PLATINUM COMPOUNDS;XBP1;rs2269577;GG;TOXICITY;INCREASED_RISK;DISEASE:NAUSEA
IMATINIB;SLC22A1;rs683369;CC;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
CARBOPLATIN, PACLITAXEL;DSCAM;rs9981861;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
CARBOPLATIN, PACLITAXEL;ETS2;rs1209950;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATG10;rs10514231;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIZZINESS,_HEADACHE
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;rs1800469;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIZZINESS,_HEADACHE
WARFARIN;VKORC1;rs9923231;T;EFFICACY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATG10;rs1864183;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
MERCAPTOPURINE;NUDT15;rs186364861;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
AMISULPRIDE, CLOZAPINE, OLANZAPINE, PALIPERIDONE, QUETIAPINE, RISPERIDONE;MC4R;rs17782313;CC;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
AMISULPRIDE, ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, QUETIAPINE, RISPERIDONE, ZIPRASIDONE;MC4R;rs489693;A;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
AMISULPRIDE, ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, QUETIAPINE, RISPERIDONE, ZIPRASIDONE;MC4R;rs489693;AA;OTHER;INCREASED_LIKELIHOOD;DISEASE:HYPERTRIGLYCERIDEMIA,_WEIGHT_GAIN
ATENOLOL, VERAPAMIL;PLEKHH2;rs11124945;G;TOXICITY;DECREASED_RISK;DISEASE:DIABETES_MELLITUS
CLOPIDOGREL;CYP2C19;rs4244285;AG;EFFICACY;INCREASED_;DISEASE:PLATELET_AGGREGATION
REGADENOSON;AMPD1;rs17602729;AA + AG;EFFICACY;INCREASED_SEVERITY;SIDE_EFFECT:ELEVATED_SYSTOLIC_BLOOD_PRESSURE
EFAVIRENZ;CYP2B6;rs3745274;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SOMNOLENCE
CLOPIDOGREL;CYP2C19;rs4244285;AA;EFFICACY;INCREASED_;OTHER:PLATELET_REACTIVITY
CAPECITABINE, FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
;;rs2952768;CC;EFFICACY;DECREASED_SEVERITY;OTHER:SUBSTANCE-RELATED_DISORDERS
CISPLATIN, CYCLOPHOSPHAMIDE;ERCC2;rs1799793;CT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
ACENOCOUMAROL, WARFARIN;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE,_STROKE
NICOTINE;DBH;rs1541333;CC;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:END_OF_TREATMENT_ABSTINENCE
REGADENOSON;AMPD1;rs17602729;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
RISPERIDONE;CNR1;rs806378;T;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
RISPERIDONE;CNR1;rs1049353;C;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
MERCAPTOPURINE;ABCC4;rs3765534;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
ASPARAGINASE;NFATC2;rs6021191;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
ASPARAGINASE;HLA-DRB1;rs17885382;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERSENSITIVITY
CYCLOPHOSPHAMIDE, EPIRUBICIN;GSTP1;rs1695;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
IVACAFTOR;CFTR;rs75527207;A;EFFICACY;DECREASED_LIKELIHOOD;DISEASE:CYSTIC_FIBROSIS_PULMONARY_EXACERBATION
VANCOMYCIN;;rs2789047;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION
LISINOPRIL;MMP3;rs35068180;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT:STROKE
CARBOPLATIN, GEMCITABINE;SERPINA5;rs6113;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;EFFICACY;EFFICACY:SUBOPTIMAL_REPERFUSION_(POST-PCI_TIMI_FLOW_<3)
CARBOPLATIN, GEMCITABINE;SERPINA5;rs6118;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
CARBOPLATIN, GEMCITABINE;XYLT2;rs6504649;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
CARBOPLATIN, GEMCITABINE;SERPINA5;rs6119;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
ETHANOL;CAT;rs1001179;T;OTHER;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
CARBOPLATIN, GEMCITABINE;ETS2;rs73450548;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
BEVACIZUMAB, PEGAPTANIB, RANIBIZUMAB;VEGFA;rs2010963;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:ANTI-VEGF_INJECTIONS
CLOPIDOGREL;ABCB1;rs1045642;AA;EFFICACY;INCREASED_;OTHER:PLATELET_REACTIVITY
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;INCREASED_LIKELIHOOD;DISEASE:RECURRENCE
DOXORUBICIN;GSTA1;rs3957357;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
AMISULPRIDE, CLOZAPINE, OLANZAPINE, PALIPERIDONE, QUETIAPINE, RISPERIDONE;MC4R;rs489693;AA;OTHER;INCREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
ETHANOL;CAT;rs1001179;T;OTHER;INCREASED_SEVERITY;DISEASE:ALCOHOL_ABUSE
;ERCC1;rs3212986;AC;OTHER;DECREASED_;OTHER:DISEASE-FREE_SURVIVAL_AND_OVERALL_SURVIVAL
DEXMEDETOMIDINE;GABRA2;rs279847;GG;TOXICITY;DECREASED_;SIDE_EFFECT:HEART_RATE
TAMOXIFEN;ESR1;rs9340799;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VENOUS_THROMBOEMBOLISM
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs149389480;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
MORPHINE;FAAH;rs3766246;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
CLOZAPINE, OLANZAPINE;TBC1D1;rs9852;CC;TOXICITY;INCREASED_;DISEASE:WEIGHT_GAIN
FLUOROURACIL;DPYD;rs67376798;AT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
MORPHINE;FAAH;rs4141964;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
;ABCB11;rs2287622;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEPATOCELLULAR_INJURY
HYDROCODONE;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPOVENTILATION
HYDROCODONE;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SIDE_EFFECTS
;DRD2;rs1800497;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ALCOHOL_ABUSE,_SUBSTANCE-RELATED_DISORDERS
OPIOIDS;GNB3;rs5443;CT + TT;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:INCREASED_PULSE_RATE
ARIPIPRAZOLE, CLOZAPINE, HALOPERIDOL, OLANZAPINE, QUETIAPINE, RISPERIDONE;FAAH;rs324420;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:WEIGHT_GAIN
MORPHINE;FAAH;rs2295632;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
CAFFEINE;CYP1A2;rs762551;AC + CC;OTHER;DECREASED_RISK;DISEASE:BREAST_NEOPLASMS
MORPHINE;FAAH;rs324420;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
PEGINTERFERON ALFA-2B, RIBAVIRIN;VDR;rs2228570;AA + AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
;ABCB11;rs2287622;GG;TOXICITY;INCREASED_RISK;DISEASE:DRUG-INDUCED_LIVER_INJURY
PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;ITPA;rs1127354;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
DOCETAXEL;NR1I3;rs3003593;AA;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
ANTITHYROID PREPARATIONS;EHMT2;rs652888;G;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:AGRANULOCYTOSIS
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TNF;rs1800629;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PAIN
HYDROCODONE;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK;DISEASE:CONSTIPATION
HMG COA REDUCTASE INHIBITORS;HLA-G;rs1063320;G;OTHER;DECREASED_LIKELIHOOD;DISEASE:ASTHMA
HYDROCODONE;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_RISK;DISEASE:DRY_MOUTH
DEXMEDETOMIDINE;CYP2A6;rs28399433;C;EFFICACY;INCREASED_EFFICACY;EFFICACY:SEDATION
DEFERIPRONE;UGT1A6;rs6759892;GG;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
DEFERIPRONE;UGT1A6;rs6759892;GG;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
ANTITHYROID PREPARATIONS;;rs111618861;del;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:AGRANULOCYTOSIS
ANTITHYROID PREPARATIONS;HLA-B;rs1071816;C;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:AGRANULOCYTOSIS
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATM;rs11212570;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PAIN
EFAVIRENZ;IL10;rs1800896;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
ETHANOL;ANKK1, DRD2;rs1800497;A;OTHER;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
IODINE (131I) COMPOUNDS, RADIOTHERAPY;NFKB1;rs230493;AT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PAIN
OPIOIDS;OPRM1;rs1799971;G;TOXICITY;DECREASED_RISK;OTHER:OPIOID-RELATED_DISORDERS
ETHANOL;DRD2;rs1800497;A;OTHER;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;rs2241716;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PAIN
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
IODINE (131I) COMPOUNDS, RADIOTHERAPY;TGFB1;rs1800469;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PAIN
ANTITHYROID PREPARATIONS;FOXF2;rs199564443;del;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:AGRANULOCYTOSIS
CAPECITABINE;CES1P1;rs7187684;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;;rs6977967;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
CAPECITABINE;CES1P1;rs11861118;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PLATINUM;XRCC1;rs25487;TT;EFFICACY;;OTHER:WORSE_OVERALL_SURVIVAL_OUTCOME
PLATINUM;ERCC1;rs11615;AG + GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RESPONSE
CAPECITABINE;CES1;rs2244613;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PLATINUM;ERCC1;rs3212986;AA + AC;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOZAPINE, ETHANOL;CYP1A2;rs2069514;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
MERCAPTOPURINE, METHOTREXATE;PACSIN2;rs2413739;CT + TT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RECURRENCE
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;MIR4268;rs4674470;CC + CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
CAPECITABINE;CES1;rs2244614;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CITALOPRAM;CYP2C19;rs4244285;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
IODINE (131I) COMPOUNDS, RADIOTHERAPY;ATM;rs620815;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;TT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TREATMENT_FAILURE_TO_PEGYLATED_INTERFERON-ALPHA/RIBAVIRIN_THERAPY_IN_HCV/HIV-1_COINFECTED_PATIENTS
TENOFOVIR;ABCC2;rs17222723;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:RENAL_PROXIMAL_TUBULOPATHY
TENOFOVIR;ABCC2;rs2273697;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:RENAL_PROXIMAL_TUBULOPATHY
FLUOROURACIL;DPYD;rs1801160;CT;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CYTARABINE, IDARUBICIN;;rs12036333;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;ATF5;rs8667;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
NEVIRAPINE;CYP2B6;rs28399499;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
PEGINTERFERON ALFA-2B, RIBAVIRIN;CYP2R1;rs10741657;AA + AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
ASPARAGINASE, CYCLOPHOSPHAMIDE, CYTARABINE, DAUNORUBICIN, HYDROCORTISONE, METHOTREXATE, PREDNISONE, VINCRISTINE;MIR3117;rs12402181;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
NEVIRAPINE;CYP2B6;rs3745274;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
TENOFOVIR DISOPROXIL FUMARATE;CYP24A1;rs2248359;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEPHROTOXICITY
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
CYCLOPHOSPHAMIDE;CYP2C19;rs4244285;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3;rs8099917;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
TENOFOVIR DISOPROXIL FUMARATE;CYP27B1;rs4646536;GG;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:NEPHROTOXICITY
NICOTINE;DDC;rs2060761;C;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
DRUGS FOR TREATMENT OF TUBERCULOSIS;RIPOR2;rs10946737;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
NICOTINE;DDC;rs12718541;A;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE_(RAPID_AND_SUSTAINED_VIROLOGICAL_RESPONSE)_FOR_PATIENTS_WITH_HEPATITIS_C_VIRUS_GENOTYPE_1
IMIPRAMINE;CYP2C19;rs12248560;CT + TT;LADME_PK;DECREASED_PK;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS
IMIPRAMINE;CYP2C19;rs11188072;CT + TT;LADME_PK;DECREASED_PK;PK:DOSE-CORRECTED_PLASMA_CONCENTRATIONS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR),_SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
;CXCL5;rs352046;GG;OTHER;INCREASED_RISK;DISEASE:DEATH
NEVIRAPINE;CYP2B6;rs28399499;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR),_SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
WARFARIN;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OVER-ANTICOAGULATION
CAPECITABINE;CDA;rs602950;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
CAPECITABINE;CDA;rs532545;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
TENOFOVIR DISOPROXIL FUMARATE;ABCC2;rs717620;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEPHROTOXICITY
CAPECITABINE;CDA;rs6690069;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HAND-FOOT_SYNDROME
TENOFOVIR;ABCC2;rs717620;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:KIDNEY_TUBULAR_DYSFUNCTION
METHYLPHENIDATE;DRD1;rs4532;CC;TOXICITY;INCREASED_SEVERITY;OTHER:SOCIAL_WITHDRAWAL
CAPECITABINE, FLUOROURACIL;DPYD;rs67376798;AA + AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:SUBCLINICAL_INTRA-STENT_THROMBUS
CAPECITABINE;CES1;rs3217164;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CAPECITABINE;CDA;rs10916825;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
CAPECITABINE, FLUOROURACIL;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
TENOFOVIR DISOPROXIL FUMARATE;SLC28A2;rs11854484;CT + TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEPHROTOXICITY
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;rs6311;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DIZZINESS
CAPECITABINE;NSUN3;rs144470777;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CAPECITABINE;PHC1;rs187805828;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
ALENDRONATE;VDR;rs1544410;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:SERUM_OSTEOCALCIN
ASPIRIN;ITGB3;rs5918;TT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:INADEQUATE_INHIBITION_OF_PLATELET_ACTIVITY
CAPECITABINE;FAT1;rs116134453;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CISPLATIN;XPC;rs2228001;GG + GT;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
CAPECITABINE;TENM4;rs141531882;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
TICAGRELOR;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DYSPNEA
WARFARIN;CYP4F2;rs2108622;T;DOSAGE;EFFICACY;EFFICACY:A_22%_INCREASE_IN_THERAPEUTIC_WARFARIN_DOSE_REQUIREMENT_AFTER_ADJUSTMENT_FOR_CLINICAL_AND_GENETIC_COVARIATES_IN_HISPANIC-AMERICANS
AMOXICILLIN, CLAVULANATE;HLA-DQB1;rs9274407;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_INDUCED_LIVER_INJURY
CAPECITABINE;CD96;rs77475703;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
METHOTREXATE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CYCLOPHOSPHAMIDE, DOCETAXEL, DOXORUBICIN, EPIRUBICIN, FLUOROURACIL, GOSERELIN;SLCO1B1;rs4149056;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AMENORRHEA
WARFARIN;NQO1;rs1800566;A;DOSAGE;EFFICACY;EFFICACY:A_34%_INCREASE_IN_THERAPEUTIC_WARFARIN_DOSE_REQUIREMENT_WHILE_HOLDING_CLINICAL_AND_GENETIC_PREDICTORS_CONSTANT_IN_HISPANIC-AMERICANS
CAPECITABINE;ZMIZ1;rs117484357;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CAPECITABINE;VPS13D;rs138385713;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CETUXIMAB;RASSF1;rs2236947;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PAROXETINE;CYP1A2;rs4646425;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SLOWER_RESPONSE_TIME
CAPECITABINE;CCDC77;rs141213385;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
ANTIPSYCHOTICS;RGS2;rs4606;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:EXTRAPYRAMIDAL_SYMPTOMS,_PARKINSONIAN_DISORDER
PRAVASTATIN;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_PK;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)
DEXMEDETOMIDINE;WBP2NL;rs5758550;AA;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:SEDATION
CAPECITABINE;ADGRG7;rs117308378;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CARBOPLATIN, CISPLATIN;AKT1;rs1130214;AA + AC;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:DISEASE_PROGRESSION
CYCLOSPORINE, MYCOPHENOLIC ACID, PREDNISONE;NFATC1;rs2280055;CC;EFFICACY;EFFICACY;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE
ASPIRIN, CLOPIDOGREL;PEAR1;rs41273215;T;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION,_STROKE,_DEATH,
CARBOPLATIN, CISPLATIN;;rs2498804;AA + AC;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:DISEASE_PROGRESSION
CLOZAPINE, OLANZAPINE, RISPERIDONE;DRD2;rs4436578;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:BODY_WEIGHT_GAIN
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
VINCRISTINE;ABCC2;rs12826;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
EFAVIRENZ;CYP2B6;rs3745274;TT;LADME_PK;INCREASED_PK;PK:PLASMA_EXPOSURE
NICOTINE;GRIN3A;rs10121600;C;OTHER;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
ASPIRIN, CLOPIDOGREL;CYP1A2;rs762551;C;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION,_STROKE,_DEATH,
WARFARIN;VKORC1;rs9923231;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_PEAK_INR_DURING_WEEK_1_OF_WARFARIN_THERAPY
ASPIRIN, CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION,_STROKE,_DEATH,
CITALOPRAM;HTR1B;rs6296;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:AGITATION
PRAVASTATIN;ABCA1;rs2230806;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:HDL-CHOLESTEROL
ASPIRIN, CLOPIDOGREL;PON1;rs662;T;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION,_STROKE,_DEATH,
DEXMEDETOMIDINE;ABCG2;rs2231142;GG;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:SEDATION
PEGINTERFERON ALFA-2B, RIBAVIRIN, SIMEPREVIR;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""CELECOXIB"", ""DICLOFENAC"", ""IBUPROFEN"", ""NAPROXEN"", ""PIROXICAM""";CYP2C9;rs1057910;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_BLEEDING
CAPECITABINE;DPYD;rs75267292;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
NICOTINE;GRIN3A;rs11788456;G;OTHER;RISK_;DISEASE:TOBACCO_USE_DISORDER
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:FATIGUE
"""ANTIINFLAMMATORY AGENTS, NON-STEROIDS"", ""CELECOXIB"", ""DICLOFENAC""";CYP2C9;rs1057910;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ACUTE_GASTROINTESTINAL_BLEEDING
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:SLEEP_DISORDERS
PRAVASTATIN;KIF6;rs20455;AG + GG;EFFICACY;DECREASED_RISK;DISEASE:CORONARY_DISEASE
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs368967198;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
CAPECITABINE;SSU72;rs146898897;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
ASPIRIN, CLOPIDOGREL;F2R;rs168753;T;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION,_STROKE,_DEATH,
BETA BLOCKING AGENTS;GNB3;rs5443;CT + TT;OTHER;DECREASED_;OTHER:HEART_RATE
CARBOPLATIN, CISPLATIN;PIK3CA;rs2699887;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
BETA BLOCKING AGENTS;GNB3;rs5443;CT + TT;OTHER;DECREASED_;OTHER:HEART_RATE
CARBOPLATIN, CISPLATIN;PTEN;rs2299939;AC + CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CAPECITABINE;MAN1A1;rs185346775;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CARBOPLATIN, CISPLATIN;AKT1;rs3803304;C;EFFICACY;RISK_EFFICACY;EFFICACY:DISEASE_PROGRESSION
COCAINE;BCHE;rs1803274;TT;OTHER;;DISEASE:COCAINE_DEPENDENCE
PRAVASTATIN;SLCO1B1;rs4149056;CC;LADME_PK;INCREASED_PK;PK:MEAN_PEAK_CONCENTRATION_IN_PLASMA_AND_AREA_UNDER_THE_PLASMA_CONCENTRATION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;EGFR;rs11506105;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR),_SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
CISPLATIN, FLUOROURACIL;ABCB1;rs1045642;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:SURVIVAL_RATE
ASPIRIN, CLOPIDOGREL;P2RY12;rs2046934;AG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_REACTIVITY
HMG COA REDUCTASE INHIBITORS;STAT4;rs7574865;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
CISPLATIN, FLUOROURACIL;ABCB1;rs1045642;AA + AG;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:LYMPH_NODE_METASTASES
MERCAPTOPURINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
HEROIN;ALDH2;rs671;AA + AG;OTHER;INCREASED_;DISEASE:HEROIN_DEPENDENCE
FENTANYL;CALCA;rs145837941;GG;DOSAGE;DECREASED_SEVERITY;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING
"""METFORMIN"", ""SULFONAMIDES, UREA DERIVATIVES""";KCNJ11;rs5219;T;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TREATMENT_FAILURE
ANTIHYPERTENSIVES, BETA BLOCKING AGENTS, DIURETICS;ADRB1;rs1801253;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:STROKE
NICOTINE;GRIN3A;rs17189632;T;OTHER;RISK_;DISEASE:TOBACCO_USE_DISORDER
FLUOROURACIL;DPYD;rs3918290;CT + TT;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
HMG COA REDUCTASE INHIBITORS;SLCO1A2;rs4149000;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:POOR-RESPONSE_TO_CLOPIDOGREL
TRAMADOL;SLC22A1;rs35167514;del;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS_OF_O-DESMETHYLTRAMADOL
EFAVIRENZ;CYP2B6;rs3745274;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
SEVOFLURANE;FASTKD3, MTRR;rs2307116;AA + AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:VOL%_END-TIDAL_SEVOFLURANE_CONCENTRATION
ASPIRIN, CLOPIDOGREL;P2RY12;rs2046934;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
METHOTREXATE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA,_NEUTROPENIA,_MUCOSITIS,
TRAMADOL;SLC22A1;rs34130495;A;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS_OF_O-DESMETHYLTRAMADOL
TRAMADOL;SLC22A1;rs12208357;T;LADME_PK;PK;PK:HIGHER_PLASMA_CONCENTRATIONS_OF_O-DESMETHYLTRAMADOL
METHADONE;KCNJ6;rs2070995;TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:WITHDRAWAL_EFFECTS
IMATINIB;SLCO1A2;rs3764043;CC;LADME_PK;DECREASED_PK;PK:IMATINIB_CLEARANCE
IMATINIB;SLCO1A2;rs4148978;CC;LADME_PK;INCREASED_PK;PK:IMATINIB_CLEARANCE
VINCRISTINE;ABCC2;rs3740066;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
IMATINIB;SLCO1A2;rs4148977;CC;LADME_PK;INCREASED_PK;PK:IMATINIB_CLEARANCE
FLUOROURACIL;DPYD;rs55886062;AC;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
FLUCLOXACILLIN;NR1I2;rs3814055;CC;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
CYCLOSPORINE, MYCOPHENOLIC ACID, PREDNISONE;NFATC1;rs3894049;CC;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
SEVOFLURANE;FASTKD3, MTRR;rs1801394;AG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:VOL%_END-TIDAL_SEVOFLURANE_CONCENTRATION
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
EFAVIRENZ;CYP2B6;rs28399499;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs143509841;GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs8099917;G;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
"""ACE INHIBITORS, PLAIN"", ""ANGIOTENSIN II ANTAGONISTS""";F5;rs200157005;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANGIOEDEMA
PAROXETINE;CYP1A2;rs4646427;TT;EFFICACY;EFFICACY;EFFICACY:SLOWER_RESPONSE_TIME
CARBAMAZEPINE;SCN1A;rs3812718;CC;OTHER;INCREASED_;OTHER:CORTICAL_SILENT_PERIOD_DURATION
METHOTREXATE;MIR1206;rs2114358;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
PAROXETINE;CYP1A2;rs4646425;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SLOWER_RESPONSE_TIME
ATORVASTATIN;SLCO1B1;rs2306283;G;LADME_PK;DECREASED_PK;PK:PLASMA_CONCENTRATIONS
ATORVASTATIN;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS
FOLIC ACID, METHOTREXATE;ABCB1;rs1045642;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_DRUG_EVENT
CYTARABINE, IDARUBICIN;BRD10;rs10758713;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUSCULAR_DISEASES
SORAFENIB;KDR;rs4864950;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;T;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
SORAFENIB;PIK3R5;rs444904;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTENSION
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs17868323;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA_WITHIN_24_HOURS_AND_THROMBOCYTOPENIA
CYTARABINE, IDARUBICIN;;rs2897047;AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;ABCC2;rs2273697;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CYTARABINE, IDARUBICIN;;rs6550826;GG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
METHOTREXATE;ABCB1;rs1128503;AG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
AZATHIOPRINE, MERCAPTOPURINE;ABCC4;rs3765534;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:LEUKOPENIA
METHOTREXATE;ABCC2;rs4148396;CC + CT;TOXICITY;INCREASED_;SIDE_EFFECT:TIME_TO_DISCONTINUATION_OR_DOSE_REDUCTION
METHOTREXATE;ABCC2;rs4148396;CC;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ALOPECIA
CYTARABINE, IDARUBICIN;;rs9883101;CC;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
FOLIC ACID, METHOTREXATE;TLR4;rs4986790;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ADVERSE_DRUG_EVENTS
ROSUVASTATIN;ABCG2;rs2231142;T;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS
ROSUVASTATIN;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS
FLUOROURACIL, LEUCOVORIN;DPYD;rs67376798;AT;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
PRAVASTATIN;SLCO1B1;rs4149056;C;LADME_PK;INCREASED_PK;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR),_SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR),_SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
HYDROCHLOROTHIAZIDE;;rs10792367;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:BLOOD_PRESSURE_(BP)_REDUCTION
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs17868323;G;DOSAGE;INCREASED_LIKELIHOOD;SIDE_EFFECT:NECESSITY_TO_REDUCE_IRINOTECAN_DOSAGE
;HMGCR;rs12654264;AT + TT;OTHER;INCREASED_;OTHER:SERUM_TOTAL_CHOLESTEROL
DOXORUBICIN;SLC28A3;rs7853758;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
HMG COA REDUCTASE INHIBITORS;ABCB1;rs1045642;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION
NICOTINE;CHRNA3;rs3743075;T;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:TOBACCO_USE_DISORDER
NICOTINE;CHRNB4;rs7178270;G;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:TOBACCO_USE_DISORDER
VINCRISTINE;NDRG1;rs2272653;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
NICOTINE;CHRNB4;rs1948;A;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:TOBACCO_USE_DISORDER
PLATINUM COMPOUNDS;ERCC2;rs1052555;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
HMG COA REDUCTASE INHIBITORS, SIMVASTATIN;;rs1719247;T;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:MUSCULAR_DISEASES
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs2306283;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION
HMG COA REDUCTASE INHIBITORS, SIMVASTATIN;;rs1346268;C;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:MUSCULAR_DISEASES
PRAVASTATIN;SLCO1B1;rs4149056;CT;LADME_PK;INCREASED_PK;PK:PRAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC2;rs3740066;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
IMATINIB;UGT2A1;rs11249454;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ANTHRACYCLINES AND RELATED SUBSTANCES;ECT2L;rs11155012;A;EFFICACY;INCREASED_RISK;DISEASE:DEATH
HMG COA REDUCTASE INHIBITORS;ABCB1;rs1128503;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_CIRCULATING_CREATINE_KINASE_CONCENTRATION
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ATM;rs1801516;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
GEMCITABINE;SLC28A1;rs3825876;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
ATORVASTATIN;SLCO1B1;rs4149056;CC;LADME_PK;INCREASED_PK;PK:AUC
GEMCITABINE;CDA;rs2072671;AC + CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
RISPERIDONE;ABCB1;rs1045642;AA + AG;TOXICITY;INCREASED_;SIDE_EFFECT:PROLONGED_QTC_INTERVAL
PITAVASTATIN;SLCO1B1;rs2306283;AG + GG;LADME_PK;INCREASED_PK;PK:PITAVASTATIN_PLASMA_CONCENTRATIONS_(AUC)_AND_CMAX
SORAFENIB;EGFR;rs2330951;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTENSION
ROSUVASTATIN;SLCO1B1;rs4149056;CC;LADME_PK;INCREASED_PK;PK:AUC_(P=0.002)_AND_CMAX_(P=0.003)
HMG COA REDUCTASE INHIBITORS;GATM;rs9806699;A;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:MUSCULAR_DISEASES
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_RISK;OTHER:MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS
EVEROLIMUS;ABCB1;rs2032582;A;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:LYMPHOPENIA
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP1B1;rs1056836;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
AZATHIOPRINE, MERCAPTOPURINE;;rs2647087;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCREATITIS
EVEROLIMUS;RPTOR;rs9906827;T;TOXICITY, OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS
RADIOTHERAPY;XPC;rs2228001;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA
EVEROLIMUS;ABCB1;rs1045642;A;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ATM;rs1801516;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;rs12041331;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION,_MYOCARDIAL_ISCHEMIA,_STROKE,
SUNITINIB;VEGFA;rs833061;CC + CT;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
AZACITIDINE;MTHFR;rs1801133;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CLOPIDOGREL;CYP2C19;rs4986893;AA + AG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_POST-TREATMENT_PLATELET_REACTIVITY
PLATELET AGGREGATION INHIBITORS EXCL. HEPARIN;PEAR1;rs2768759;AA;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:MYOCARDIAL_INFARCTION,_MYOCARDIAL_ISCHEMIA,_STROKE,
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ERCC1;rs3212986;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
IMATINIB;SLC22A1;rs628031;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ACETAMINOPHEN, IBUPROFEN, LOXOPROFEN, SALICYLAMIDE;;rs6500265;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
IMATINIB;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;GRIA1;rs1994862;CC;OTHER;DECREASED_RISK;SIDE_EFFECT:AROUSAL_DYSFUNCTION
EVEROLIMUS;RPTOR;rs9906827;CT + TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
IMATINIB;CHST1;rs9787901;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
IMATINIB;CYP2F1;rs305968;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ACETAMINOPHEN, IBUPROFEN, LOXOPROFEN, SALICYLAMIDE;;rs9933632;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_EPIDERMAL_NECROLYSIS,_STEVENS-JOHNSON_SYNDROME
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CBR1;rs20572;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;TP53;rs1042522;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
SORAFENIB;PRKCE;rs11125039;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTENSION
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;SLC22A16;rs714368;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;IL10;rs1800896;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;XRCC1;rs25487;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
ANTIINFLAMMATORY AGENTS, NON-STEROIDS;CTLA4;rs231775;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
;ADH7;rs971074;CT + TT;OTHER;INCREASED_SEVERITY;OTHER:PAIN
SORAFENIB;ADAMTS18;rs1346563;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERTENSION
PLATINUM COMPOUNDS;XRCC1;rs25487;CT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;GSTP1;rs1695;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
CISPLATIN;SLC31A1;rs10981694;GG + GT;TOXICITY;INCREASED_SEVERITY;DISEASE:OTOTOXICITY
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP2C19;rs12248560;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC2;rs3740066;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
DEXMEDETOMIDINE;ABCC9;rs11046209;AA;EFFICACY;INCREASED_SEVERITYEFFICACY;EFFICACY:SEDATION
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCB1;rs1045642;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
VINCRISTINE;CEP72;rs12522955;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CAPECITABINE;;rs72765700;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCG2;rs2231142;GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
ANTINEOPLASTIC AGENTS, MERCAPTOPURINE, METHOTREXATE;ABCC4;rs2274407;AC;TOXICITY;INCREASED_SEVERITY;DISEASE:THROMBOCYTOPENIA
AZATHIOPRINE, MERCAPTOPURINE;FTO;rs79206939;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ALDH3A1;rs2228100;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA,_LEUKOPENIA
ANTINEOPLASTIC AGENTS, MERCAPTOPURINE, METHOTREXATE;ABCC4;rs2274407;AC;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
PRAVASTATIN;HMGCR;rs17238540;GT;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_POST-TREATMENT_PLATELET_REACTIVITY
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ABCC2;rs2273697;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;SLC22A16;rs6907567;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
EVEROLIMUS;FGFR4;rs351855;A;TOXICITY, OTHER;DECREASED_LIKELIHOOD;OTHER:DISCONTINUATION
VINCRISTINE;CEP72;rs924607;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
AZATHIOPRINE, MERCAPTOPURINE;;rs2834826;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
IMATINIB;SLC19A1;rs12659;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
AZATHIOPRINE, MERCAPTOPURINE;FTO;rs16952570;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
AZACITIDINE;XRCC1;rs25487;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
IMATINIB;NQO1;rs10517;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
EVEROLIMUS;PIK3R1;rs10515074;G;TOXICITY, OTHER;DECREASED_LIKELIHOOD;SIDE_EFFECT:HYPERGLYCEMIA
DESLORATADINE;HRH1;rs901865;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:SEDATION
IMATINIB;ABCC2;rs2273697;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CYTARABINE, DOXORUBICIN, LEUCOVORIN, METHOTREXATE, PREDNISONE, VINCRISTINE;NOS3;rs1799983;TT;TOXICITY;DECREASED_;SIDE_EFFECT:IQ
IMATINIB;ABCB4;rs1202283;AA + AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
EVEROLIMUS;PIK3R1;rs10515074;G;TOXICITY, OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
CAPECITABINE;MIR2054;rs10024471;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
AZATHIOPRINE;NUDT15;rs116855232;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
METHOTREXATE;DHFR;rs1105525;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE;PRKAB2;rs3766522;TT;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
METHADONE;NECTIN4;rs11265549;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PRURITUS
CAPECITABINE;SPRY2;rs117876855;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
AZATHIOPRINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
CAPECITABINE;SPRY2;rs139544515;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
HMG COA REDUCTASE INHIBITORS;HMGCR;rs12654264;AA;EFFICACY;DECREASED_RISK;DISEASE:COLONIC_NEOPLASMS
RIVAROXABAN;CYP3A4;rs2246709;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
METHOTREXATE;GGH;rs11545078;A;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:THROMBOCYTOPENIA
CAPECITABINE;NCOA7;rs185217050;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
CAPECITABINE;CCDC70;rs139368788;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
;HMGCR;rs12654264;AT + TT;OTHER;INCREASED_;OTHER:SERUM_LDL
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL;ERCC1;rs11615;AG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA,_NEPHROTOXICITY
CAPECITABINE;TMEM131L;rs117412990;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
PRAVASTATIN;HMGCR;rs17244841;AT;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_TOTAL_CHOLESTEROL
HMG COA REDUCTASE INHIBITORS;HMGCR;rs12654264;TT;EFFICACY;DECREASED_RISK;DISEASE:COLONIC_NEOPLASMS
CAPECITABINE;SIRPA;rs191934521;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE;PRKAA2;rs10789038;AA;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
RIVAROXABAN;CYP3A4;rs3735451;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
CAPECITABINE;LMNTD1;rs146644707;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME
METHOTREXATE;MTHFR;rs1801133;GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ANTINEOPLASTIC AGENTS;RBFOX1;rs6500843;G;EFFICACY;INCREASED_RISK;DISEASE:DEATH
HMG COA REDUCTASE INHIBITORS;HMGCR;rs12654264;AA;EFFICACY;DECREASED_RISK;DISEASE:COLONIC_NEOPLASMS
PLATINUM;XRCC5;rs1051685;G;TOXICITY;DECREASED_SEVERITY;DISEASE:ANEMIA,_LEUKOPENIA,_NEUTROPENIA,_THROMBOCYTOPENIA
CLOZAPINE, OLANZAPINE, RISPERIDONE;LEP;rs7799039;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
IRINOTECAN;ABCC1;rs17287570;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION
SORAFENIB;EPAS1;rs1868089;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY
PLATINUM;XRCC5;rs6941;A;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA,_LEUKOPENIA,_NEUTROPENIA,_THROMBOCYTOPENIA
CYCLOPHOSPHAMIDE;CYP2A6;rs143731390;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DEATH
IRINOTECAN;ABCG2;rs2622604;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION
FOLIC ACID;MTHFD1;rs2236225;AA;OTHER;DECREASED_LIKELIHOOD;OTHER:DIABETES,_GESTATIONAL
METHOTREXATE;DHFR;rs442767;GG;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
IRINOTECAN;UGT1A10, UGT1A6, UGT1A7, UGT1A8, UGT1A9;rs11692021;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION
PLATINUM;AQP2;rs10875989;T;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA,_LEUKOPENIA,_NEUTROPENIA,_THROMBOCYTOPENIA
APIXABAN, RIVAROXABAN;ABCG2;rs3114018;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
IRINOTECAN;SLCO1B3;rs7977213;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION
METHOTREXATE;DHFR;rs408626;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CYCLOPHOSPHAMIDE;CYP2B6;rs3745274;T;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
PLATINUM;AQP2;rs3759125;AA + AC;TOXICITY;INCREASED_SEVERITY;DISEASE:ANEMIA,_LEUKOPENIA,_NEUTROPENIA,_THROMBOCYTOPENIA
IRINOTECAN;SLCO1B3;rs10841661;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_MYELOSUPPRESSION
METHOTREXATE;DHFR;rs1650697;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
APIXABAN, RIVAROXABAN;ABCG2;rs2622604;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
PLATINUM;AQP2;rs461872;A;TOXICITY;DECREASED_SEVERITY;DISEASE:DIARRHEA,_NAUSEA,_VOMITING,
PLATINUM;AQP2;rs7305534;CC + CT;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA,_NAUSEA,_VOMITING,
MEPHENYTOIN, TOLBUTAMIDE;CYP2C19;rs41291556;C;LADME_PK;PK;PK:DRAMATIC_(APPROXIMATELY_90%_AND_70%)_REDUCTION_IN_THE_METABOLISM_OF_S-MEPHENYTOIN_AND_TOLBUTAMIDE
PLATINUM;CD74;rs2748249;A;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
ASPIRIN;TBXAS1;rs6962291;AA;OTHER;DECREASED_RISK;SIDE_EFFECT:INTOLERANCE
PLATINUM;CD74;rs1560661;C;TOXICITY;DECREASED_SEVERITY;DISEASE:DRUG_TOXICITY
CYTARABINE;CDA;rs2072671;AA;TOXICITY, LADME_PK;DECREASED_RISK;SIDE_EFFECT:GRADE_III/IV_LIVER_TOXICITY
WARFARIN;;rs12777823;A;DOSAGE;EFFICACY;EFFICACY:REDUCED_WARFARIN_DOSE_IN_AFRICAN_AMERICANS,_INDEPENDENT_OF_CYP2C9*2_AND_CYP2C9*3.
WARFARIN;;rs12777823;A;DOSAGE;EFFICACY;EFFICACY:REDUCED_WARFARIN_DOSE_IN_AFRICAN_AMERICANS,_INDEPENDENT_OF_CYP2C9*2_AND_CYP2C9*3.
;ALDH1A2;rs12915901;A;OTHER;INCREASED_LIKELIHOOD;OTHER:OSTEOARTHRITIS
RALOXIFENE, TAMOXIFEN;;rs10030044;G;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:OCCURRENCE_OF_BREAST_CANCER_DURING_SERM_(SELECTIVE_ESTROGEN_RECEPTOR_MODULATORS)_THERAPY
CAPECITABINE, FLUOROURACIL;DPYD;rs2297595;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME,_MUCOSITIS,_PERIPHERAL_NERVOUS_SYSTEM_DISEASES,
;SLC2A1;rs841844;CG + GG;TOXICITY;INCREASED_SEVERITY;DISEASE:DRUG_TOXICITY
CAPECITABINE, FLUOROURACIL;DPYD;rs2297595;TT;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DIARRHEA
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:INSUFFICIENT_ANTIPLATELET_RESPONSE_TO_CLOPIDOGREL
DASATINIB;ABL1;rs121913459;CT;OTHER, LADME_PK;DECREASED_PK;PK:AUC_0-4_HOURS
PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3;rs8099917;TT;EFFICACY;DECREASED_SEVERITY;DISEASE:HEPATITIS_C_VIRUS_INFECTION
HYDROCHLOROTHIAZIDE;AGT;rs5051;T;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
HYDROCHLOROTHIAZIDE;AGTR1;rs5186;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
TAMOXIFEN;ESR2;rs4986938;CC;OTHER;INCREASED_;SIDE_EFFECT:TRIGLYCERIDES_IN_POSTMENOPAUSAL_WOMAN
AZATHIOPRINE, MERCAPTOPURINE;NUDT15;rs116855232;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:LEUKOPENIA,_NEUTROPENIA
ONDANSETRON;ABCB1;rs1045642;AA;EFFICACY;DECREASED_LIKELIHOOD;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING
TAMOXIFEN;ESR1;rs9340799;GG;OTHER;DECREASED_;SIDE_EFFECT:IN_TOTAL_CHOLESTEROL_IN_POSTMENOPAUSAL_WOMAN_AND_INCREASE_IN_TRIGLYCERIDES_AND_DECREASE_IN_HIGH_DENSITY_LIPOPROTEIN_IN_PREMENOPAUSAL_WOMEN
TALINOLOL;ABCC2;rs2273697;A;OTHER;INCREASED_PK;PK:RESIDUAL_CLEARANCE_OF_INTRAVENOUS_TALINOLOL_AND_LOWER_BIOAVAILABLILTY_OF_ORALLY_ADMINISTERED_TALINOLOL
CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
DOXORUBICIN;CBR3;rs8133052;G;TOXICITY, LADME_PK;INCREASED_PK;PK:DOXORUBICINOL_AUC
ONDANSETRON;ABCB1;rs2032582;AA;EFFICACY;DECREASED_LIKELIHOOD;DISEASE:POSTOPERATIVE_NAUSEA_AND_VOMITING
CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;rs518147;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:METABOLIC_SYNDROME
BEVACIZUMAB, CYANOCOBALAMIN, FOLIC ACID, PEMETREXED;MTHFR;rs1801131;GG + GT;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ARTESUNATE, PRIMAQUINE, PYRIMETHAMINE, SULFADOXINE;G6PD, IKBKG;rs1050828;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MODERATE_ANEMIA
RALOXIFENE, TAMOXIFEN;ZNF423;rs8060157;A;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:OCCURRENCE_OF_BREAST_CANCER_DURING_SERM_(SELECTIVE_ESTROGEN_RECEPTOR_MODULATORS)_THERAPY
TACROLIMUS;ABCB1;rs1045642;AA + AG;EFFICACY;EFFICACY;EFFICACY:DECREASED_GLOMERULAR_FILTRATION_RATE
CARBAMAZEPINE;ABCC2;rs2273697;AA + AG;TOXICITY, LADME_PK;INCREASED_RISK;SIDE_EFFECT:NEUROLOGICAL_ADR
ARTESUNATE, PRIMAQUINE, PYRIMETHAMINE, SULFADOXINE;G6PD, IKBKG;rs1050828;TT;OTHER;INCREASED_RISK;SIDE_EFFECT:MODERATE_ANEMIA
SORAFENIB;VEGFB;rs12366035;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY
CYTARABINE;CDA;rs532545;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:5_YEAR_SURVIVAL
CYTARABINE;CDA;rs532545;TT;EFFICACY;INCREASED_RISK;DISEASE:DEATH
VINCRISTINE;CEP72;rs71585289;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CYCLOSPORINE, TACROLIMUS;ABCB1;rs1128503;AA + AG;EFFICACY;INCREASED_RISK;DISEASE:INFECTIOUS_DISEASE
CLOPIDOGREL;P2RY12;rs2046934;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ACUTE_CORONARY_SYNDROME
VINCRISTINE;MIR6076;rs35650931;CC + CG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
SORAFENIB;WWOX;rs9927200;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
DOXEPIN;CYP2C19;rs4244285;AA;LADME_PK;DECREASED_PK;PK:MEDIAN_ORAL_CLEARANCE_OF_DOXEPIN
ANTHRACYCLINES AND RELATED SUBSTANCES;RARG;rs2229774;A;TOXICITY;INCREASED_RISK;DISEASE:CARDIOTOXICITY
VINCRISTINE;MIR4481;rs7896283;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
CLOMIPRAMINE;CYP2C19;rs4244285;AG;LADME_PK;INCREASED_PK;PK:MEAN_CLOMIPRAMINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT_AND_HIGHER_METABOLIC_RATIO_OF_CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE
CAPECITABINE, FLUOROURACIL;DPYD;rs2297595;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
METHOTREXATE;SLC19A1;rs1051266;CT;EFFICACY;INCREASED_RISK;OTHER:TOXIC_LIVER_DISEASE
CORTICOSTEROIDS;ACP1;rs11553746;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS
SORAFENIB;MAP2K6;rs11651488;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
METHOTREXATE;MTHFR;rs1801131;GT;EFFICACY;DECREASED_RISK;OTHER:TOXIC_LIVER_DISEASE
SORAFENIB;CDH13;rs17682789;C;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DIARRHEA
TACROLIMUS;CYP3A5;rs776746;CC;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
CLOMIPRAMINE;CYP2C19;rs4244285;AA;LADME_PK;INCREASED_PK;PK:MEAN_CLOMIPRAMINE_CONCENTRATIONS_CORRECTED_FOR_DOSE_AND_WEIGHT_AND_HIGHER_METABOLIC_RATIO_OF_CLOMIPRAMINE/DESMETHYLCLOMIPRAMINE
PAROXETINE;FKBP5;rs1360780;T;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
CLOMIPRAMINE, LIOTHYRONINE, LITHIUM, NEFAZODONE, PAROXETINE, VENLAFAXINE;FKBP5;rs1360780;T;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
ILOPERIDONE;CYP2D6;rs1065852;GG;OTHER;INCREASED_;SIDE_EFFECT:QTC_INTERVAL
GEMCITABINE;SLC28A1;rs12148896;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
METHOTREXATE;MTHFR;rs1801133;AA;EFFICACY;INCREASED_RISK;SIDE_EFFECT:MYELOSUPPRESSION
CLOMIPRAMINE, LIOTHYRONINE, LITHIUM, NEFAZODONE, VENLAFAXINE;HTR1B;rs130058;A;EFFICACY;DECREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
PAROXETINE;HTR1B;rs130058;A;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
GEMCITABINE;CDA;rs471760;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CANNABIDIOL;ABCC5;rs3749442;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEDATION
CISPLATIN;ACYP2;rs1872328;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OTOTOXICITY
CLOMIPRAMINE, LIOTHYRONINE, LITHIUM, NEFAZODONE, PAROXETINE, VENLAFAXINE;ABCB1;rs2032582;A;OTHER;INCREASED_RISK;SIDE_EFFECT:SUICIDAL_IDEATION
MELPHALAN;SLC7A5;rs4240803;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
ANTIPSYCHOTICS;MC4R;rs17782313;CC + CT;OTHER;INCREASED_RISK;DISEASE:WEIGHT_GAIN
PLATINUM;SLC2A1;rs3738514;T;TOXICITY;DECREASED_SEVERITY;DISEASE:DRUG_TOXICITY
DOXORUBICIN;RARG;rs2229774;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
VINCRISTINE;GARS1;rs1049402;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
SORAFENIB;EGFR;rs917881;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIARRHEA
VINCRISTINE;FGD4;rs12823621;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
CARBOPLATIN, CISPLATIN;SLC31A1;rs7851395;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
VINCRISTINE;MIR3117;rs12402181;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
FLUOROURACIL, OXALIPLATIN;ERCC2, KLC3;rs13181;GT;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PLATINUM;SLC2A1;rs4658;CC;TOXICITY;DECREASED_SEVERITY;DISEASE:DRUG_TOXICITY
PEGINTERFERON ALFA-2B, RIBAVIRIN, TELAPREVIR;ITPA;rs1127354;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:ANEMIA
FLUOROURACIL, OXALIPLATIN;GSTP1;rs1695;AG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
;ADD1;rs4961;GT + TT;OTHER;INCREASED_;OTHER:AMBULATORY_BLOOD_PRESSURE
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC2;rs238406;GT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
ATORVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
CLOPIDOGREL;CYP3A5;rs776746;CC + CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
HMG COA REDUCTASE INHIBITORS;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
;RAD52, WNK1;rs2277869;CC;OTHER;INCREASED_;OTHER:AMBULATORY_BLOOD_PRESSURE
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs13422094;C;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
SUNITINIB;IL13;rs1800925;TT;OTHER;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs12211463;G;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs7757130;A;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
FENTANYL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs2473967;G;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
THIAZIDES, PLAIN;ADD1;rs4961;GG;EFFICACY;DECREASED_RISK;DISEASE:MYOCARDIAL_INFARCTION
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC2;rs1799793;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
SUNITINIB;IL13;rs1800925;TT;OTHER;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
FENTANYL;COMT;rs4680;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SOMNOLENCE
SIMVASTATIN;SLCO1B1;rs4149056;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STATIN-RELATED_MYOPATHY
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;RHBDF2;rs12948783;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:EFFICACT_AS_MEASURED_BY_LOWER_PAIN_RELIEF_TO_OPIOIDS
ACE INHIBITORS, PLAIN;SH2B1;rs192613545;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
RADIOTHERAPY;OSMR;rs1239344;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ESOPHAGITIS
BLEOMYCIN, CISPLATIN, ETOPOSIDE;BLMH;rs1050565;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PAIN
RADIOTHERAPY;CDK1;rs10711;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PNEUMONITIS
BLEOMYCIN, CISPLATIN, ETOPOSIDE;BLMH;rs1050565;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALOPECIA
CELECOXIB;CYP2C9;rs1799853;CT;LADME_PK;PK;PK:HIGHER_PLASMA_CONCENTRATIONS_OF_CELECOXIB
HYDROCHLOROTHIAZIDE;REN;rs11240688;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_SBP
HYDROCHLOROTHIAZIDE;YEATS4;rs7297610;C;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
ACE INHIBITORS, PLAIN;RBFOX3;rs62063838;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_BLOOD_PRESSURE
RADIOTHERAPY;PRKCE;rs940052;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ESOPHAGITIS
ACE INHIBITORS, PLAIN;MBOAT1;rs10946364;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
RADIOTHERAPY;PRKCE;rs11125035;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ESOPHAGITIS
ROFECOXIB;PTGS1;rs3842787;T;EFFICACY;EFFICACY;EFFICACY:REDUCTION_IN_COX-1_INHIBITION_AND_DEPRESSION_OF_THE_URINARY_THROMBOXANE_METABOLITE
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC1;rs11615;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:FEBRILE_NEUTROPENIA
RADIOTHERAPY;RIGI;rs11795343;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PNEUMONITIS
CISPLATIN;TPMT;rs12201199;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OTOTOXICITY
DRUGS FOR TREATMENT OF TUBERCULOSIS;;rs1495741;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ACE INHIBITORS, PLAIN;RBFOX3;rs56044629;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
HYDROCHLOROTHIAZIDE;WNK1;rs880054;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:REDUCTION_IN_SBP
RADIOTHERAPY;;rs7259857;C;TOXICITY;DECREASED_RISK;SIDE_EFFECT:ESOPHAGITIS
CELECOXIB;PTGS1;rs3842787;T;EFFICACY;EFFICACY;EFFICACY:REDUCTION_IN_COX-1_INHIBITION
;COL1A1;rs1800012;AA + AC;;INCREASED_RISK;DISEASE:FRACTURES,_BONE
HYDROCHLOROTHIAZIDE;ADD1;rs4961;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:ABSOLUTE_MEAN_BLOOD_PRESSURE
ACE INHIBITORS, PLAIN;GABRG2;rs77370934;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
;COL1A1;rs1800012;AA + AC;;DECREASED_;OTHER:BONE_MINERAL_DENSITY_(BMD)
VINCRISTINE;BAHD1;rs3803357;AA + AC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
ACE INHIBITORS, PLAIN;RBFOX3;rs56209714;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
CAPECITABINE, FLUOROURACIL;DPYD;rs1801160;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
METHYLPREDNISOLONE, PREDNISOLONE;ABCB1;rs1045642;AA;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
BLEOMYCIN, CISPLATIN, ETOPOSIDE;GSTP1;rs1695;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INFECTIOUS_DISEASE
ANASTROZOLE, LETROZOLE, TAMOXIFEN;ZNF613;rs8113308;C;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
PIRFENIDONE;CYP1A2;rs762551;AA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC2;rs13181;GG + GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALOPECIA
CISPLATIN;OTOS;rs2291767;CC + CT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:OTOTOXICITY
ACE INHIBITORS, PLAIN;RBFOX3;rs2061538;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DISCONTINUATION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS;HTR2A;rs6311;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIMINISHED_ABILITY_TO_CONCENTRATE
CITALOPRAM;HTR2A;rs6311;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA,_VOMITING
TACROLIMUS;CYP3A5;rs776746;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEPHROTOXICITY
MERCAPTOPURINE, METHOTREXATE;MTHFR;rs1801131;GG;TOXICITY;DECREASED_RISK;DISEASE:MYELOSUPPRESSION
SUNITINIB;CXCL8;rs1126647;TT;OTHER;INCREASED_LIKELIHOOD;SIDE_EFFECT:HYPERTENSION
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;PDGFRB;rs2302273;AA + AG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
ETHANOL;PNPLA3;rs738409;GG;TOXICITY;INCREASED_RISK;OTHER:ALCOHOL_ABUSE
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;RGS5;rs2661280;CC + CG;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
SORAFENIB;EPAS1;rs9973653;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
;WT1;rs16754;CC + CT;OTHER;INCREASED_LIKELIHOOD;DISEASE:EVENT-FREE_SURVIVAL
TACROLIMUS;CYP3A5;rs776746;CT + TT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:TRANSPLANT_REJECTION
MERCAPTOPURINE;ITPA;rs1127354;A;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
CANNABINOIDS;FAAH;rs324420;AA;TOXICITY;DECREASED_RISK;DISEASE:SUBSTANCE-RELATED_DISORDERS
SORAFENIB;;rs315498;C;TOXICITY;DECREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
CYCLOPHOSPHAMIDE;GSTA1;rs3957357;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DEATH
VINCRISTINE;MRPL47;rs10513762;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
FLUOROURACIL;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
VINCRISTINE;SYNE2;rs2781377;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
SORAFENIB;EPAS1;rs4035887;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
ANTIPSYCHOTICS;COMT;rs4680;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_DIASTOLIC_BLOOD_PRESSURE,_ELEVATED_SYSTOLIC_BLOOD_PRESSURE
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;INCREASED_EFFICACY;EFFICACY:ON-TREATMENT_PLATELET_REACTIVITY
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
METHOTREXATE;DHFR;rs408626;CC;EFFICACY;DECREASED_;OTHER:EVENT-FREE_SURVIVAL,_OVERALL_SURVIVAL
METHOTREXATE;MTHFR;rs1801131;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ELEVATED_TRANSAMINASES
CYCLOPHOSPHAMIDE;GSTA1;rs1051775;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DEATH
EFAVIRENZ;ABCB1;rs1045642;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXICITY-RELATED_TREATMENT_FAILURE
DOXORUBICIN;GALNT14;rs9679162;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
ASPIRIN;CYP2D6;rs28360521;CC;TOXICITY, OTHER;INCREASED_RISK;SIDE_EFFECT:GASTROINTESTINAL_HEMORRHAGE
DESFLURANE, PROPOFOL;ATP8B3;rs45574836;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:POSTOPERATIVE_NAUSEA_AND_VOMITING,_VOMITING
LOSARTAN;CAMK1D;rs10752271;AG + GG;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_SYSTOLIC_BLOOD_PRESSURE
METHOTREXATE;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;DISEASE:TOXIC_LIVER_DISEASE
METHOTREXATE;DHFR;rs408626;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
LOSARTAN;CAMK1D;rs10737062;AG + GG;EFFICACY;DECREASED_SEVERITYEFFICACY;EFFICACY:ELEVATED_SYSTOLIC_BLOOD_PRESSURE
CYCLOPHOSPHAMIDE;GSTA1;rs1051775;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
METHOTREXATE;MTHFR;rs1801131;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
METHOTREXATE;DHFR;rs442767;GT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:LEUKOPENIA
CELECOXIB;CYP2C9;rs1057910;C;EFFICACY;DECREASED_RISK;DISEASE:ADENOMA
MERCAPTOPURINE;SLC19A1;rs1051266;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTIONS
BLEOMYCIN, CISPLATIN, ETOPOSIDE;CYP3A4;rs2740574;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ALOPECIA
MERCAPTOPURINE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT_INTERRUPTION
EFAVIRENZ;ABCB1;rs1045642;A;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:EMERGING_VIRAL_DRUG_RESISTANCE
BEVACIZUMAB, FLUOROURACIL, IRINOTECAN, LEUCOVORIN;CSPG4;rs1127648;AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SORAFENIB;;rs10958704;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY
METHOTREXATE;SHMT1;rs1979277;AG;TOXICITY;DECREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
METHOTREXATE;FASTKD3, MTRR;rs1801394;AG;TOXICITY;INCREASED_;SIDE_EFFECT:SPEED_OF_PLATELET_RECOVERY
SORAFENIB;EPAS1;rs7557402;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY
METHOTREXATE;MTHFR;rs1801131;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:RED_BLOOD_CELL_TRANSFUSIONS
CYCLOPHOSPHAMIDE;CYP2B6;rs3211371;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GRAFT_VS_HOST_DISEASE
APIXABAN, RIVAROXABAN;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
EFAVIRENZ;ABCB1;rs2032582;A;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:EMERGING_VIRAL_DRUG_RESISTANCE
CYCLOPHOSPHAMIDE, DOCETAXEL;VEGFA;rs1570360;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
CARBOPLATIN, GEMCITABINE;OR4D6;rs1453542;CC;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:NEUTROPENIA
SORAFENIB;MAP2K6;rs12948059;G;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DERMATOLOGIC_TOXICITY
CARBOPLATIN, GEMCITABINE;DDX53;rs5925720;T;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:THROMBOCYTOPENIA
METHOTREXATE;MTHFD1;rs2236225;AA;OTHER;INCREASED_PK;PK:RED_BLOOD_CELL_FOLATE
METHOTREXATE;FASTKD3, MTRR;rs1801394;AA;OTHER;INCREASED_PK;PK:RED_BLOOD_CELL_FOLATE
IRINOTECAN;SEMA3C;rs11979430;T;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
ANTIPSYCHOTICS;DRD2;rs1800497;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
ANTIPSYCHOTICS;COMT;rs4680;AA + AG;TOXICITY;DECREASED_RISK;DISEASE:TARDIVE_DYSKINESIA
IRINOTECAN;SEMA3C;rs7779029;C;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
ANTIEPILEPTICS;ABCB1;rs2032582;C;EFFICACY;EFFICACY;EFFICACY:PROTECTION_FROM_DRUG_RESISTANCE
ANTIPSYCHOTICS;DRD2;rs1800497;G;TOXICITY;INCREASED_RISK;DISEASE:TARDIVE_DYSKINESIA
ANTIEPILEPTICS;ABCB1;rs2032582;C;EFFICACY;EFFICACY;EFFICACY:PROTECTION_FROM_DRUG_RESISTANCE
ANTIPSYCHOTICS;DRD2;rs1800497;G;TOXICITY;INCREASED_RISK;DISEASE:TARDIVE_DYSKINESIA
IRINOTECAN;;rs1661167;G;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA
ANTIEPILEPTICS;ABCB1;rs2032582;C;EFFICACY;EFFICACY;EFFICACY:PROTECTION_FROM_DRUG_RESISTANCE
AMISULPRIDE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs498207;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
CISPLATIN, CYCLOPHOSPHAMIDE;CYP2E1;rs6413432;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
BUDESONIDE;FCER2;rs28364072;G;OTHER;;OTHER:SEVERE_EXACERBATIONS_WITH_ASTHMA
CYCLOPHOSPHAMIDE;NOS3;rs1799983;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
AMISULPRIDE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs3813928;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
MYCOPHENOLATE MOFETIL;IL12A;rs568408;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT
IRINOTECAN;PLCB1;rs2745761;C;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA
CYCLOPHOSPHAMIDE;NOS3;rs2070744;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
AMISULPRIDE, CLOZAPINE, OLANZAPINE, QUETIAPINE, RISPERIDONE;HTR2C;rs3813929;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:WEIGHT_GAIN
CYCLOPHOSPHAMIDE, DOXORUBICIN, FLUOROURACIL, METHOTREXATE;NOS3;rs1799983;GG + GT;EFFICACY;INCREASED_EFFICACY;EFFICACY:DISEASE_FREE_SURVIVAL
IRINOTECAN;PDZRN3;rs11128347;C;TOXICITY;INCREASED_SEVERITY;DISEASE:NEUTROPENIA
METHADONE;UGT2B7;rs4554144;TT;EFFICACY, LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
DAPSONE;HLA-DRB1;rs201929247;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
OLANZAPINE;PPARG;rs1801282;CG;OTHER;INCREASED_;DISEASE:WEIGHT_GAIN
METHADONE;UGT2B7;rs11940316;CC;EFFICACY, LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
CORTICOSTEROIDS;BCL2L11;rs2241843;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
METHADONE;UGT2B7;rs7438135;AA;EFFICACY, LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
METHADONE;UGT2B7;rs7662029;GG;EFFICACY, LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
CISPLATIN, CYCLOPHOSPHAMIDE;GSTA1;rs3957357;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:ANEMIA
OXALIPLATIN;PIN1;rs2233678;CC + CG;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL,_PROGRESSION-FREE_SURVIVAL
METHADONE;UGT2B7;rs7668258;CC;EFFICACY, LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C9;rs9332096;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
METHOTREXATE;ABCG2;rs2231142;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
METHOTREXATE;AMPD1;rs17602729;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CNS_ADVERSE_EVENTS
ANTIEPILEPTICS;ABCB1;rs1045642;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DRUG_RESISTANCE
METHADONE;UGT2B7;rs7439366;CC;EFFICACY, LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
ANTIEPILEPTICS;ABCB1;rs1128503;A;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DRUG_RESISTANCE
ANTIEPILEPTICS;ABCB1;rs3789243;G;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DRUG_RESISTANCE
METHADONE;UGT2B7;rs4292394;GG;EFFICACY, LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2C19;rs4986893;AA + AG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:MACULOPAPULAR_EXANTHEMA
CISPLATIN, CYCLOPHOSPHAMIDE;CYP2E1;rs2070676;CG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:SEVERE_EMESIS
ANTIEPILEPTICS;ABCB1;rs3789243;G;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:DRUG_RESISTANCE
FLUOROURACIL;DPYD;rs3918290;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY,_LEUKOPENIA,_MUCOSITIS,
THIAZIDES, PLAIN;GNB3;rs5443;CC;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
AMLODIPINE;RYR3;rs877087;TT;EFFICACY;INCREASED_RISK;DISEASE:HEART_FAILURE
FLUOROURACIL;GSTP1;rs1695;GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HAEMATOLOGICAL_TOXICITY
;COL1A1;rs1800012;AA;;DECREASED_;OTHER:BONE_MINERAL_DENSITY_AT_FEMORAL_NECK_AND_LUMBAR_SPINE
METHADONE;UGT2B7;rs6600879;GG;EFFICACY, LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
;COL1A1;rs1800012;AA + AC;;DECREASED_;OTHER:BMD_VALUES_AT_THE_LUMBAR_SPINE_AND_FEMORAL_NECK
METHADONE;UGT2B7;rs6600880;AA;EFFICACY, LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
PLATINUM COMPOUNDS;EIF3A;rs10510050;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:THROMBOCYTOPENIA,_TOXIC_LIVER_DISEASE,_VOMITING,
CAPECITABINE;DPYD;rs67376798;AT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
THIAZIDES, PLAIN;AGTR1;rs5186;AA + AC;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
THIAZIDES, PLAIN;ACE;rs4341;GG;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
ATORVASTATIN, RIFAMPIN;SLCO1B1;rs4149056;TT;LADME_PK;PK;PK:A_NEARLY_TRIPLED_INCREASED_PERCENTAGE_OF_ATORVASTATIN_AUC(0_-_48)_VALUES_AFTER_A_SINGLE_ORAL_DOSE_OF_RIFAMPICIN
CAPECITABINE, FLUOROURACIL;MIR27A;rs895819;C;TOXICITY;RISK_;SIDE_EFFECT:DRUG_TOXICITY
ATORVASTATIN;FDPS;rs2297480;TT;TOXICITY;INCREASED_;SIDE_EFFECT:BONE_DENSITY
ETHANOL;OPRM1;rs1799971;G;;INCREASED_;OTHER:SUBJECTIVE_FEELINGS_OF_INTOXICATION,_STIMULATION,_SEDATION,_AND_HAPPINESS
;ABCC2;rs3740066;C;LADME_PK;;OTHER:ALLELIC_IMBALENCE
CISPLATIN;GSTM4;rs560018;CC;EFFICACY, TOXICITY;INCREASED_EFFICACY;EFFICACY:IC-50
ATORVASTATIN;FDPS;rs11264359;AA;TOXICITY;INCREASED_;SIDE_EFFECT:BONE_DENSITY
IRINOTECAN;C8orf34;rs1517114;C;TOXICITY;INCREASED_SEVERITY;DISEASE:DIARRHEA
DICLOXACILLIN, PROBENECID;ABCB1;rs1045642;GG;OTHER, LADME_PK;INCREASED_PK;PK:CLEARANCE_OF_DICLOXACILLIN
ANTIPSYCHOTICS, CLOZAPINE, OLANZAPINE, RISPERIDONE;HTR2C;rs1414334;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OBESITY
ETHANOL;OPRM1;rs1799971;G;OTHER;RISK_;DISEASE:ALCOHOL_ABUSE
CYCLOSPORINE, DICLOXACILLIN;ABCB1;rs2032582;CC;OTHER, LADME_PK;INCREASED_PK;PK:CLEARANCE_OF_DICLOXACILLIN
ETHAMBUTOL, ISONIAZID, PYRAZINAMIDE, RIFAMPIN;CYP2E1;rs2031920;CT + TT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
ATORVASTATIN, FLUVASTATIN, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;SLCO1B1;rs4149056;CC;;INCREASED_;OTHER:CHOLESTEROL_SYNTHESIS_RATE
PLATINUM COMPOUNDS;MDM2;rs1690924;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
METHOTREXATE;SLC19A1;rs1051266;TT;LADME_PK;INCREASED_PK;PK:PLASMA_DRUG_LEVELS
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_INHIBITION_AFTER_A_CLOPIDOGREL_600-MG_LOADING_DOSE
SEVOFLURANE;GRIN2B;rs1806201;AA + AG;OTHER;INCREASED_;OTHER:MEAN_ARTERIAL_PRESSURE
CLOPIDOGREL;CYP2C19;rs28399504;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:PLATELET_INHIBITION_AFTER_A_CLOPIDOGREL_600-MG_LOADING_DOSE
DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES;ADRB2;rs1042714;GG;EFFICACY;INCREASED_;OTHER:STATUS_ASTHMATICUS
METHOTREXATE;CCND1;rs9344;AA;TOXICITY;DECREASED_SEVERITY;DISEASE:DRUG_TOXICITY
RISPERIDONE;ABCB1;rs1045642;A;TOXICITY;INCREASED_;SIDE_EFFECT:WEIGHT_GAIN
METHOTREXATE;MTHFR;rs1801133;AA + AG;TOXICITY;DECREASED_SEVERITY;DISEASE:LEUKOPENIA
PACLITAXEL;SOD2;rs4880;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
MERCAPTOPURINE, METHOTREXATE;SLC19A1;rs1051266;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
METHYLPHENIDATE;ABCB1;rs2032582;AA;TOXICITY;INCREASED_;SIDE_EFFECT:ADVERSE_EVENTS
DOCETAXEL;ERCC2;rs13181;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NEUTROPENIA
CYCLOSPORINE, TACROLIMUS;CRTC2;rs8450;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERLIPIDEMIAS
DOCETAXEL;ERCC1;rs11615;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
CLOPIDOGREL;CYP2C19;rs12248560;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:RATES_OF_TARGET_LESION_REVASCULARIZATION_AND_MAJOR_ADVERSE_CARDIOVASCULAR_EVENTS
METFORMIN;SP1;rs2683511;C;LADME_PK;DECREASED_PK;PK:METFORMIN_SECRETORY_CLEARANCE
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
NICOTINE;CHRNA3, CHRNA5;rs16969968;A;TOXICITY;INCREASED_RISK;DISEASE:TOBACCO_USE_DISORDER
METFORMIN;;rs10747673;G;EFFICACY;DECREASED_EFFICACY;EFFICACY:POST-HBA1C_LEVELS
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:TO_BE_CLASSIFIED_AS_CLOPIDOGREL_POOR_RESPONDERS
METFORMIN;;rs10747673;G;LADME_PK;DECREASED_PK;PK:METFORMIN_SECRETORY_CLEARANCE
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HEMORRHAGE
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
CLOPIDOGREL;ATP10A;rs12913988;AA + AG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MAJOR_ADVERSE_CARDIAC_EVENTS_(MACE)
PLATINUM COMPOUNDS;EIF3A;rs4752220;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA,_LEUKOPENIA,_THROMBOCYTOPENIA,_TOXIC_LIVER_DISEASE
CHOP, RITUXIMAB;NCF4;rs1883112;AG + GG;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TOXICITY
CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:CLOPIDOGREL_POOR_RESPONSE
PLATINUM COMPOUNDS;EIF3A;rs1409314;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA,_LEUKOPENIA,_THROMBOCYTOPENIA,_TOXIC_LIVER_DISEASE
PLATINUM COMPOUNDS;EIF3A;rs4752219;C;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA,_LEUKOPENIA,_THROMBOCYTOPENIA,_TOXIC_LIVER_DISEASE
CLOPIDOGREL;CYP2C9;rs1057910;AC + CC;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:HIGH_ON-TREATMENT_PLATELET_REACTIVITY
MERCAPTOPURINE, METHOTREXATE;GSTP1;rs1695;GG;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:DRUG_TOXICITY
CLOZAPINE;HTR2C;rs3813929;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:WEIGHT_GAIN
ACENOCOUMAROL;ABCB1;rs1045642;GG + GT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
RISPERIDONE;ABCB1;rs2032582;A;TOXICITY;INCREASED_;SIDE_EFFECT:WEIGHT_GAIN
METHOTREXATE;SLC19A1;rs1051266;TT;LADME_PK;INCREASED_PK;PK:PLASMA_DRUG_LEVELS
SEVOFLURANE;KCNK3;rs1275988;CT + TT;OTHER;INCREASED_;OTHER:MEAN_ARTERIAL_PRESSURE
LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE;SLC19A1;rs1051266;CC;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:TOXIC_LIVER_DISEASE
LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_LIKELIHOOD;DISEASE:MYELOSUPPRESSION
DOCETAXEL;CYP3A4;rs2740574;CC + CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:INFUSION_RELATED_REACTION
METFORMIN;SP1;rs784888;G;EFFICACY;DECREASED_SEVERITY;DISEASE:HYPERGLYCEMIA
PLATINUM COMPOUNDS;MTR;rs1805087;AA + AG;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SEVOFLURANE;GABRA2;rs279858;CC + CT;OTHER;DECREASED_;OTHER:MEAN_ARTERIAL_PRESSURE
LEUCOVORIN, MERCAPTOPURINE, METHOTREXATE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:STAYING_IN_REMISSION
ACENOCOUMAROL;VKORC1;rs9923231;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
PLATINUM COMPOUNDS;EIF3A;rs7091672;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA,_LEUKOPENIA,_THROMBOCYTOPENIA,_TOXIC_LIVER_DISEASE
PACLITAXEL;CYP2C8;rs1113129;CG + GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
METFORMIN;PPARA;rs149711321;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:POST-HBA1C_LEVELS
;COL1A1;rs1800012;AA;;INCREASED_RISK;DISEASE:FRACTURES,_BONE
ACENOCOUMAROL;CYP4F2;rs2108622;CT + TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
PLATINUM COMPOUNDS;SLC19A1;rs1051266;TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PACLITAXEL;CYP2C8;rs1934951;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ANEMIA
LENALIDOMIDE;VEGFA;rs699947;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
METFORMIN;SP1;rs2683511;C;EFFICACY;DECREASED_EFFICACY;EFFICACY:POST-HBA1C_LEVELS
SEVOFLURANE;FASTKD3, MTRR;rs1801394;AG + GG;OTHER;DECREASED_;OTHER:MEAN_ARTERIAL_PRESSURE
CLOPIDOGREL;CYP2C19;rs28399504;G;TOXICITY;INCREASED_RISK;DISEASE:DEATH
BUPROPION, NICOTINE;DRD1;rs2168631;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_ABSTINENCE_WITHIN_SLOW_NICOTINE_METABOLIZERS
SIMVASTATIN;HMGCR;rs17238540;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_OF_LDL_CHOLESTEROL
;NR3C1;rs9324918;C;OTHER;INCREASED_;DISEASE:SICKLE_CELL_PAIN_CRISIS
CLOPIDOGREL;CYP2C19;rs4986893;A;TOXICITY;INCREASED_RISK;DISEASE:DEATH
SEVOFLURANE;FASTKD3, MTRR;rs2307116;AA + AG;OTHER;DECREASED_;OTHER:MEAN_ARTERIAL_PRESSURE
PACLITAXEL;ERCC1;rs3212986;AA + AC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
MORPHINE;ABCC3;rs1978153;C;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPOVENTILATION
;P2RY12;rs2046934;G;;INCREASED_RISK;SIDE_EFFECT:CORONARY_ARTERY_DISEASE
CLOPIDOGREL;CYP2C19;rs12248560;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:BLEEDING
BUPROPION, NICOTINE;DRD1;rs11749035;T;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_ABSTINENCE_WITHIN_SLOW_NICOTINE_METABOLIZERS
CLOPIDOGREL;CYP2C19;rs12248560;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:ADP-INDUCED_PLATELET_AGGREGATION
PAZOPANIB, SUNITINIB;CXCL8;rs1126647;T;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
;NR3C1;rs2963155;G;OTHER;INCREASED_;DISEASE:SICKLE_CELL_PAIN_CRISIS
MORPHINE;ABCC3;rs733392;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPOVENTILATION
METHADONE;UGT2B7;rs6600893;CC;EFFICACY, LADME_PK;INCREASED_SEVERITY;OTHER:OPIATE_WITHDRAWAL_SYMPTOMS
FENTANYL;MYD88;rs6853;G;TOXICITY;DECREASED_RISK;SIDE_EFFECT:COGNITIVE_DISORDER
METHOTREXATE, PREDNISONE;SLC19A1;rs1051266;TT;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:REMISSION
BUPROPION, NICOTINE;DRD1;rs11746641;G;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SMOKING_ABSTINENCE_WITHIN_SLOW_NICOTINE_METABOLIZERS
;NR3C1;rs33389;T;OTHER;INCREASED_;DISEASE:SICKLE_CELL_PAIN_CRISIS
SPIRONOLACTONE;ACE;rs4343;AA + AG;EFFICACY;EFFICACY;EFFICACY:IMPROVEMENT_IN_LEFT_VENTRICULAR_EJECTION_FRACTION,_END-SYSTOLIC_AND_END-DIASTOLIC_VOLUME
SIMVASTATIN;HMGCR;rs17244841;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_OF_LDL_CHOLESTEROL
DOCETAXEL;ERCC1;rs3212986;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:MUCOSITIS
SEVOFLURANE;CYP2E1;rs3813867;CC + CG;OTHER;DECREASED_;OTHER:MEAN_ARTERIAL_PRESSURE
CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE;GSTA1;rs3957357;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
SEVOFLURANE;CYP2E1, DUX1;rs2031920;CT + TT;OTHER;DECREASED_;OTHER:MEAN_ARTERIAL_PRESSURE
ANTIHYPERTENSIVES, DIURETICS;NOS3;rs2070744;CC;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESISTANT_HYPERTENSION
CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE, RITUXIMAB, VINCRISTINE;CYBA;rs4673;AA;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
IBUPROFEN;PTGS2;rs20417;CG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PAIN_RELIEF
DIFLOMOTECAN;ABCG2;rs2231142;T;LADME_PK;INCREASED_PK;PK:PLASMA_CONCENTRATIONS_OF_DIFLOMOTECAN
CYCLOSPORINE;ABCB1;rs2032582;AA;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESISTANCE
CYCLOSPORINE, TACROLIMUS;CRTC2;rs8450;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIABETES_MELLITUS
ROFECOXIB;PTGS2;rs20417;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:PAIN_RELIEF
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs2884129;G;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
HMG COA REDUCTASE INHIBITORS;;rs13210472;C;TOXICITY;INCREASED_RISK;OTHER:NEOPLASMS
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs7104613;T;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
PAZOPANIB, SUNITINIB;CXCL8;rs4073;A;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
BLEOMYCIN, CISPLATIN, ETOPOSIDE;GSTP1;rs1695;GG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:NAUSEA
FENTANYL, MORPHINE, OPIOIDS, OXYCODONE;;rs10413396;T;EFFICACY;EFFICACY;EFFICACY:OPIOIDS_RESPONSE
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY;DECREASED_EFFICACY;EFFICACY:PHARMACODYNAMIC_RESPONSE
METHOTREXATE;CCND1;rs9344;AA;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT_FREE_SURVIVAL
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ERCC1;rs3212986;AC + CC;TOXICITY;DECREASED_RISK;SIDE_EFFECT:VOMITING
ASPIRIN;PTGS1;rs10306114;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
FLUOROURACIL;DPYD;rs67376798;A;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:DRUG_TOXICITY
ANTHRACYCLINES AND RELATED SUBSTANCES;ABCB1;rs2032582;CC;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:RESISTANCE
CYCLOSPORINE, TACROLIMUS;CRTC2;rs8450;AA + AG;TOXICITY;INCREASED_;SIDE_EFFECT:WEIGHT_GAIN
CLOPIDOGREL;CYP2C19;rs4244285;A;LADME_PK;DECREASED_PK;PK:PLASMA_EXPOSURE_TO_THE_ACTIVE_METABOLITE_OF_CLOPIDOGREL
ACENOCOUMAROL;VKORC1;rs9923231;TT;DOSAGE;DECREASED_EFFICACY;EFFICACY:ACENOCOUMAROL_DOSE
FLUOROURACIL;DPYD;rs1801160;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
CLOPIDOGREL;CYP2C19;rs4244285;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:STENT_THROMBOSIS
MORPHINE;ABCC3;rs886493;G;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPOVENTILATION
BLEOMYCIN, CISPLATIN, ETOPOSIDE;ABCB1;rs1045642;AA;TOXICITY;INCREASED_RISK;SIDE_EFFECT:VOMITING
MORPHINE;ABCC3;rs7216383;T;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:HYPOVENTILATION
METHOTREXATE;ABCB1;rs1045642;A;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
ETHANOL;;rs10516440;A;TOXICITY;DECREASED_RISK;OTHER:ALCOHOL_ABUSE
TRAMADOL;ABCB1;rs1045642;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:A_DECREASE_IN_VISUAL_ANALOG_SCALE_>30MM_WITHIN_6_HOURS
CITALOPRAM;CYP2C19;rs12248560;TT;LADME_PK;DECREASED_PK;PK:METABOLIC_RATIO_CIT/DCIT_VALUES
TRAMADOL;ABCB1;rs2032582;A;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:A_DECREASE_IN_VISUAL_ANALOG_SCALE_>30MM_WITHIN_6_HOURS
PEGINTERFERON ALFA-2A, PEGINTERFERON ALFA-2B, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2B, RIBAVIRIN;ITPA;rs1127354;A;TOXICITY;DECREASED_SEVERITY;SIDE_EFFECT:ANEMIA
CLOPIDOGREL;CYP2C19;rs4244285;A;EFFICACY, TOXICITY;INCREASED_RISK;SIDE_EFFECT:CARDIOVASCULAR_EVENTS
METHOTREXATE;ABCC2;rs17222723;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUROTOXICITY_SYNDROMES
RISPERIDONE;UGT1A1;rs887829;CT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERPROLACTINEMIA
FLUOXETINE;CRHR1;rs242941;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:RESPONSE
RISPERIDONE;UGT1A1;rs10929302;AG;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HYPERPROLACTINEMIA
SARILUMAB;IL6R;rs11265618;CC;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
CISPLATIN;ERCC2;rs1799793;CT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL
CISPLATIN;GSTP1;rs1138272;CT + TT;EFFICACY;DECREASED_EFFICACY;EFFICACY:EVENT-FREE_SURVIVAL,_OVERALL_SURVIVAL
SARILUMAB;IL6R;rs4845625;TT;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
VITAMIN K ANTAGONISTS;CYP4F2;rs2108622;TT;EFFICACY;INCREASED_RISKEFFICACY;EFFICACY:STROKE
RISPERIDONE;HTR2C;rs6318;GG;TOXICITY;INCREASED_SEVERITY;SIDE_EFFECT:WEIGHT_GAIN
WARFARIN;CRP;rs1205;CT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:HEMORRHAGE
HYDROCHLOROTHIAZIDE;TCF7L2;rs4132670;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DIABETES
HYDROCHLOROTHIAZIDE;TCF7L2;rs7917983;T;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
ATORVASTATIN, CERIVASTATIN, FLUVASTATIN, PRAVASTATIN, ROSUVASTATIN, SIMVASTATIN;HMGCR;rs17238540;GT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:REACHING_TARGET_CHOLESTEROL_LEVELS
HYDROCHLOROTHIAZIDE;TCF7L2;rs4506565;T;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
CLOPIDOGREL;CYP2C19;rs4244285;AA + AG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
CITALOPRAM;CYP2C19;rs4244285;AA;LADME_PK;INCREASED_PK;PK:METABOLIC_RATIO_CIT/DCIT_VALUES_AND_MEAN_CITALOPRAM_DOSE
LENALIDOMIDE;ABCB1;rs2032582;CC;EFFICACY;DECREASED_EFFICACY;EFFICACY:OVERALL_SURVIVAL
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC1;rs25487;CC;OTHER;;OTHER:LATER_ONSET_OF_SENSORY_NEUROPATHY
DOCETAXEL, THALIDOMIDE;CHST3;rs4148950;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXICITY
IRINOTECAN;UGT1A9;rs3832043;T/del + del/del;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;rs4680;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:VOMITING
SARILUMAB;IL6R;rs4537545;CC;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DYSLIPIDAEMIA
CALCIUM, ETIDRONIC ACID;VDR;rs1544410;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:MEAN_SPINAL_BONE_MINERAL_DENSITY_CHANGES
SARILUMAB;IL6R;rs2228145;AA;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DYSLIPIDAEMIA
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRD1;rs2234918;CT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PHYSIOLOGICAL_SEXUAL_DISORDER
VALPROIC ACID;SOD2;rs4880;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
SARILUMAB;IL6R;rs4329505;TT;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE
BUPRENORPHINE, FENTANYL, TRAMADOL;ARRB2;rs1045280;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
PEGINTERFERON ALFA-2A, RIBAVIRIN;;rs4273729;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE
BISPHOSPHONATES;CYP2C8;rs1934951;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS_OF_THE_JAW
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;rs1799971;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;rs4680;AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;rs4680;AA + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS,_PHYSIOLOGICAL_SEXUAL_DISORDER
;IFNL3, IFNL4;rs12979860;CC;OTHER;INCREASED_LIKELIHOOD;DISEASE:JAUNDICE
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NAUSEA
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ABCC2;rs717620;CC;TOXICITY;INCREASED_RISK;DISEASE:DRUG_TOXICITY
BUPRENORPHINE, FENTANYL, TRAMADOL;OPRM1;rs1799971;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
LENALIDOMIDE;CRBN;rs1705814;CC;DOSAGE, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DOSE_REDUCTION,_DISCONTINUATION
BUPRENORPHINE, FENTANYL, TRAMADOL;COMT;rs4680;AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;ERCC1;rs11615;AA;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;XRCC1;rs25487;CC;TOXICITY;DECREASED_RISK;DISEASE:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
RIFAMPIN;NR1I2;rs2472677;T;OTHER, LADME_PK;DECREASED_PK;PK:CYP3A4_ACITVITY
CARBAMAZEPINE, LAMOTRIGINE, OXCARBAZEPINE, PHENYTOIN, TOPIRAMATE;SCN2A;rs2304016;A;EFFICACY;EFFICACY;EFFICACY:DRUG_RESISTANCE
CAPECITABINE, OXALIPLATIN;PTGS2;rs5275;AA;EFFICACY;INCREASED_;OTHER:PROGRESSION-FREE_SURVIVAL_AND_OVERALL_SURVIVAL
;CETP;rs708272;A;;;OTHER:VARIANCE_IN_LDL,_HDL_AND_LDL/HDL
HMG COA REDUCTASE INHIBITORS;CETP;rs708272;A;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:CARDIOVASCULAR_EVENTS
DIURETICS;ADD1;rs4961;GT + TT;EFFICACY;DECREASED_LIKELIHOOD;DISEASE:MYOCARDIAL_INFARCTION
WARFARIN;VKORC1;rs9923231;CT + TT;DOSAGE;EFFICACY;EFFICACY:LOWER_WARFARIN_DOSE_REQUIREMENT
ETHANOL;DRD2;rs1076560;A;OTHER;INCREASED_RISK;DISEASE:ALCOHOL_ABUSE
CLOPIDOGREL;P2RY12;rs2046934;AG + GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PLATELET_ACTIVATION_RESPONSE_TO_ADP
METHOTREXATE;ABCC2;rs717620;CT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_MEAN_BLOOD_PRESSURE
FLUOROURACIL, LEUCOVORIN, OXALIPLATIN;MTHFR;rs1801133;AA;TOXICITY;INCREASED_RISK;DISEASE:NEUTROPENIA
BROMPERIDOL, NEMONAPRIDE;DRD2;rs1799732;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:IMPROVEMENT_IN_ANXIETY-DEPRESSION_SYMPTOMS
THIAZIDES, PLAIN;SLC12A3;rs13306673;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_MEAN_BLOOD_PRESSURE
VALPROIC ACID;ABCB1;rs3789243;GG;EFFICACY;DECREASED_LIKELIHOOD;SIDE_EFFECT:GASTROINTESTINAL_TOXICITY
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs12979860;CC;EFFICACY;INCREASED_EFFICACY;EFFICACY:RAPID_VIROLOGICAL_RESPONSE_(RVR)
AZATHIOPRINE;ITPA;rs1127354;AC;TOXICITY;INCREASED_RISK;DISEASE:LEUKOPENIA
VALPROIC ACID;ABCB1;rs3789243;GG;EFFICACY;INCREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA,_ALOPECIA,_HYPERSENSITIVITY,
ATORVASTATIN, ROSUVASTATIN;CYP3A5;rs776746;CC;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUSCULAR_DISEASES
METHOTREXATE;SLCO1B1;rs4149056;CC + CT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE
THIAZIDES, PLAIN;ADRB3;rs4994;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_MEAN_BLOOD_PRESSURE
TRASTUZUMAB;FCGR2A;rs1801274;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION_FREE_SURVIVAL
IRINOTECAN;UGT1A9;rs3832043;T/del + del/del;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DIARRHEA
ASPARAGINASE;CPA2;rs199695765;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:PANCREATITIS
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3;rs12980275;AA;EFFICACY;INCREASED_EFFICACY;EFFICACY:COMPLETE_EARLY_VIROLOGICAL_RESPONSE
DAPSONE;HLA-DRB1;rs701829;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
TACROLIMUS;POR;rs1057868;CT + TT;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
WARFARIN;THBD;rs1042580;CC + CT;TOXICITY;DECREASED_RISK;SIDE_EFFECT:HEMORRHAGE
PEGINTERFERON ALFA-2A, RIBAVIRIN;IFNL3, IFNL4;rs8099917;TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
METHYLPHENIDATE;CES1;rs3815583;AC + CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:APPETITE_SUPPRESSION
ACE INHIBITORS, PLAIN;BDKRB2;rs8012552;C;TOXICITY;INCREASED_RISK;DISEASE:COUGH
CORTICOSTEROIDS;BCL2L11;rs724710;CC;TOXICITY;INCREASED_RISK;SIDE_EFFECT:OSTEONECROSIS
ACE INHIBITORS, PLAIN;MME;rs2016848;A;TOXICITY;INCREASED_RISK;DISEASE:COUGH
IRINOTECAN;PIN1;rs2233678;CC + CG;EFFICACY;INCREASED_EFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
PEGINTERFERON ALFA-2A, RIBAVIRIN;;rs4273729;GG;EFFICACY;INCREASED_EFFICACY;EFFICACY:SUSTAINED_VIROLOGICAL_RESPONSE_(SVR)
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_MEAN_ARTERIAL_PRESSURE
ACENOCOUMAROL;VKORC1;rs9934438;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OVER-ANTICOAGULATION
ASPIRIN;ACE;rs4291;AT + TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:ASPIRIN_INTOLERANCE
MYCOPHENOLATE MOFETIL;CYP2C8;rs11572103;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT
HYDROCHLOROTHIAZIDE;ADD1;rs4961;GT + TT;EFFICACY;INCREASED_EFFICACY;EFFICACY:REDUCTION_IN_MEAN_BLOOD_PRESSURE
MYCOPHENOLATE MOFETIL;CYP2C8;rs11572076;T;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT
ACE INHIBITORS, PLAIN;PTGER3;rs11209716;C;TOXICITY;DECREASED_RISK;DISEASE:COUGH
MYCOPHENOLATE MOFETIL;HUS1;rs1056663;T;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT
DAPSONE;HLA-DRB1;rs17211071;A;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_HYPERSENSITIVITY
TACROLIMUS;PPARA;rs4253728;AA + AG;TOXICITY;INCREASED_RISK;DISEASE:DIABETES_MELLITUS
MYCOPHENOLATE MOFETIL;HUS1;rs2037483;A;TOXICITY;DECREASED_RISK;SIDE_EFFECT:TIME_TO_ANEMIA_IN_PATIENTS_UNDERGOING_LIVING_OR_DECEASED_DONOR_KIDNEY_TRANSPLANT
;ADD1;rs4961;GT + TT;OTHER;INCREASED_LIKELIHOOD;DISEASE:HYPERTENSION
FLUOROURACIL;ABCB1;rs2032582;C;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:EXANTHEMA
FLUOROURACIL;SLCO1B1;rs2306283;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
;ARG1;rs2781666;TT;OTHER;INCREASED_SEVERITY;OTHER:ASTHMA
TACROLIMUS;CYP3A4;rs2740574;TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
EPIRUBICIN;ABCC1;rs246221;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEFT_VENTRICULAR_DYSFUNCTION
LEVODOPA;COMT;rs4680;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DYSKINESIA,_DRUG-INDUCED
METHOTREXATE;SLC19A1;rs1051266;TT;TOXICITY;INCREASED_RISK;SIDE_EFFECT:TOXIC_LIVER_DISEASE
DAUNORUBICIN, DOXORUBICIN;ABCC2;rs8187710;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
FOLFOX;DPYD;DPYD c.1129-5923C>G, c.1236G>A (HapB3);c.1129-5923C>G, c.1236G>A (HapB3);EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:RECURRENCE_FREE_SURVIVAL
DAUNORUBICIN, DOXORUBICIN;HFE;rs1799945;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DAUNORUBICIN, DOXORUBICIN;GPR35;rs12468485;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DAUNORUBICIN, DOXORUBICIN;UGT1A6;rs17863783;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DAUNORUBICIN, DOXORUBICIN;GSTA2;rs2180314;G;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DAUNORUBICIN, DOXORUBICIN;ETFB;rs79338777;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DAUNORUBICIN, DOXORUBICIN;HNMT;rs17583889;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
DAUNORUBICIN, DOXORUBICIN;ABCC5;rs7627754;AA + AT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:CARDIOTOXICITY
CEFAZOLIN, CEFDINIR, CEFTRIAXONE, CEFUROXIME, CEPHALEXIN;HLA-A;HLA-A*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG-INDUCED_LIVER_INJURY
TACROLIMUS;CYP2B6;rs3745274;GT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
CORTICOSTEROIDS;WNT7B;rs73175102;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS
CORTICOSTEROIDS;POGK;rs115587273;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS
CORTICOSTEROIDS;FAM240C;rs78233573;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS
CORTICOSTEROIDS;ZNF37A;rs376867011;A;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:OSTEONECROSIS
CODEINE, HYDROCODONE, TRAMADOL;CYP2D6;CYP2D6;intermediate_metabolizer;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:EMERGENCIES,_PAIN
GANCICLOVIR, VALGANCICLOVIR;NUDT15;NUDT15*1, NUDT15*2, NUDT15*3, NUDT15*4;*2 + *3 + *4;;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEUTROPENIA
VALPROIC ACID;ACOT1;rs758109;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
TACROLIMUS;SLCO1B1;rs2306283;AA + AG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY
AZATHIOPRINE;MOCOS;rs73430958;GT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
VALPROIC ACID;GABPA;rs59288687;CC;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
VALPROIC ACID;NQO1;rs10517;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
VALPROIC ACID;PPARA;rs881740;G;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TOXIC_LIVER_DISEASE
METHOTREXATE;SLCO1B3;rs7311358;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA
METHOTREXATE;SLCO1B3;rs4149117;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA
METHOTREXATE;SLCO1B1;rs2306283;AA + AG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ANEMIA
APIXABAN;APOE;rs7412;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:INTRACRANIAL_HEMORRHAGES
APIXABAN;APOE;rs429358;C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:INTRACRANIAL_HEMORRHAGES
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;rs8099917;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;rs12980275;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS
PD-1/PDL-1 (PROGRAMMED CELL DEATH PROTEIN 1/DEATH LIGAND 1) INHIBITORS;IFNL3;rs12979860;TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PNEUMONITIS
TACROLIMUS;ABCB1;rs9282564;TT;EFFICACY;DECREASED_RISKEFFICACY;EFFICACY:DEATH
TACROLIMUS;ABCC2;rs2273697;GG;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL
TACROLIMUS;SLCO1B1;rs4149056;TT;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:TRANSPLANT_REJECTION
TACROLIMUS;CYP2C19;rs4244285;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY
AZATHIOPRINE;NUDT15;rs116855232;CT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
AZATHIOPRINE;RRM1;rs1735053;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
AZATHIOPRINE;TPMT;rs9465102;GT + TT;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
CISPLATIN;TRPA1;rs920829;TT;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:NEPHROTOXICITY
FOLFOX, XELOX;DPYD;rs1801265;AG + GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES
FLUOXETINE;CYP2D6;CYP2D6;ultrarapid_metabolizer;EFFICACY, TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:TREATMENT_MODIFICATION
CYCLOSPORINE;SLC29A1;rs693955;AA;EFFICACY;DECREASED_LIKELIHOODEFFICACY;EFFICACY:OVERALL_SURVIVAL,_RECURRENCE_FREE_SURVIVAL
AFATINIB, ERLOTINIB, GEFITINIB;AKT1;rs2494750;CC;EFFICACY;INCREASED_LIKELIHOODEFFICACY;EFFICACY:PROGRESSION-FREE_SURVIVAL
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*44:03;*44:03;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-B;HLA-B*38:01;*38:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
SULFAMETHOXAZOLE / TRIMETHOPRIM;HLA-C;HLA-C*04:01;*04:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:SEVERE_CUTANEOUS_ADVERSE_REACTIONS
FOLFOX, XELOX;GSTP1;rs1695;GG;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES,_MYELOSUPPRESSION
FOLFOX, XELOX;TYMS;rs11280056;TTA/TTA + TTA/TTAAAGTTA;TOXICITY;DECREASED_LIKELIHOOD;SIDE_EFFECT:PERIPHERAL_NERVOUS_SYSTEM_DISEASES,_MYELOSUPPRESSION
FOLFOX, XELOX;TYMS;rs45445694;(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3/(GGCCTGCCTCCGTCCCGCCGCGCCACTT)3;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:HAND-FOOT_SYNDROME,_EXANTHEMA,_DRUG_TOXICITY,
FOLFOX, XELOX;GSTP1;rs1695;GG;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:MUCOSITIS
AZATHIOPRINE;HLA-DQA1;HLA-DQA1*02:01;*02:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PANCREATITIS
AZATHIOPRINE;HLA-DRB1;HLA-DRB1*07:01;*07:01;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:PANCREATITIS
HMG COA REDUCTASE INHIBITORS;ABCG2;rs2231142;T;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:DRUG_TOXICITY,_TOXIC_LIVER_DISEASE
AMITRIPTYLINE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*4, CYP2D6*5, CYP2D6*10, CYP2D6*41;*1/*4 + *2/*4 + *2/*5 + *4/*41 + *4/*10;TOXICITY;INCREASED_RISK;SIDE_EFFECT:DRUG_TOXICITY
AZATHIOPRINE, MERCAPTOPURINE;TPMT;TPMT*1, TPMT*3A, TPMT*3B, TPMT*3C;*3A + *3B + *3C;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:LEUKOPENIA
RISPERIDONE;CYP2D6;CYP2D6*1, CYP2D6*1xN, CYP2D6*2, CYP2D6*2xN, CYP2D6*3, CYP2D6*4, CYP2D6*4xN, CYP2D6*5, CYP2D6*6, CYP2D6*9, CYP2D6*10, CYP2D6*17, CYP2D6*29, CYP2D6*35, CYP2D6*41;*4/*4 + *3/*4 + *3/*5 + *4/*4xN + *4/*6 + *5/*41 + *4/*29 + *4/*17 + *5/*10 + *3/*41 + *4/*9 + *4/*41 + *4/*10 + *5/*17;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:ADVERSE_EVENTS
CODEINE, MORPHINE, OXYCODONE;OPRM1;rs1799971;AA;TOXICITY;INCREASED_LIKELIHOOD;SIDE_EFFECT:URINARY_RETENTION,_CONSTIPATION,_NAUSEA,_VOMITING
